Any feedback?
Information on EC 3.5.1.98 - histone deacetylase
for references in articles please use BRENDA:EC3.5.1.98Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.5.1.98 histone deacetylaseIUBMB Comments
A class of enzymes that remove acetyl groups from N6-acetyl-lysine residues on a histone. The reaction of this enzyme is opposite to that of EC 2.3.1.48, histone acetyltransferase. Histone deacetylases (HDACs) can be organized into three classes, HDAC1, HDAC2 and HDAC3, depending on sequence similarity and domain organization. Histone acetylation plays an important role in regulation of gene expression. In eukaryotes, HDACs play a key role in the regulation of transcription and cell proliferation . May be identical to EC 3.5.1.17, acyl-lysine deacylase.
Specify your search results
Word Map
- 3.5.1.98
- hdacs
- chromatin
- deacetylases
-
trichostatin
-
deacetylation
-
hydroxamic
-
valproic
- saha
- acetyltransferase
- leukemia
- butyrate
-
hyperacetylation
- methyltransferase
- vorinostat
- repressor
- lymphoma
- microtubule
- cyclin
- sirtuins
- nucleosome
- t-cells
-
transactivation
-
caspase
- bcl-2
- metastasis
- myeloid
- proteasome
-
hypermethylation
- tumorigenesis
- cardiac
- sirt1
- neurodegenerative
- hematological
- prostate
-
demethylation
-
antiproliferative
-
corepressors
- sirnas
- cpg
-
non-histone
- 5-aza-2'-deoxycytidine
- valproate
- medicine
-
polycomb
- bortezomib
- dnmt3a
- heterochromatin
-
creb-binding
-
epigenome
- drug development
-
coactivator
-
relapsed
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria, Archaea
Reaction Schemes
hydrolysis of an N6-acetyl-lysine residue of a histone to yield a deacetylated histone
Synonyms
histone deacetylase, hdac1, hdac6, hdac2, hdac3, hdac4, hdac5, hdac8, hdac9, hdac7, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
histone amidohydrolase
A class of enzymes that remove acetyl groups from N6-acetyl-lysine residues on a histone. The reaction of this enzyme is opposite to that of EC 2.3.1.48, histone acetyltransferase. Histone deacetylases (HDACs) can be organized into three classes, HDAC1, HDAC2 and HDAC3, depending on sequence similarity and domain organization. Histone acetylation plays an important role in regulation of gene expression. In eukaryotes, HDACs play a key role in the regulation of transcription and cell proliferation [4]. May be identical to EC 3.5.1.17, acyl-lysine deacylase.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9076-57-7
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
additional information
?
-
enzyme assay using carboxyfluorescein (FAM)-labeled acetylated or trifluoroacetylated peptide substrates in vitro, and in a cell-based assay by measuring H3K9 and H4K12 acetylation changes in primary mouse neuronal culture
-
-
-
additional information
?
-
enzyme assay using carboxyfluorescein (FAM)-labeled acetylated or trifluoroacetylated peptide substrates in vitro, and in a cell-based assay by measuring H3K9 and H4K12 acetylation changes in primary mouse neuronal culture
-
-
-
additional information
?
-
enzyme assay using carboxyfluorescein (FAM)-labeled acetylated or trifluoroacetylated peptide substrates in vitro, and in a cell-based assay by measuring H3K9 and H4K12 acetylation changes in primary mouse neuronal culture
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide
(2R)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide
-
(2S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide
-
N-(4-amino-3'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
-
N-(4-amino-4'-chloro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
-
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-1H-2-benzopyran-3-carboxamide
-
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-2H-1-benzopyran-3-carboxamide
-
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3-oxabicyclo[3.1.0]hexane-6-carboxamide
-
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-3-carboxamide
-
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
inhibition kinetics
N-[4-amino-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxane-4-carboxamide
-
(1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide
-
(1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide
inhibition kinetics
additional information
determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes
-
additional information
determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes
-
additional information
determination of structure-activity and structure-kinetic relationships of a series of selective ortho-aminoanilide inhibitors of histone deacetylase isozymes (HDACs) 1 and 2, overview. Measurements of increases in neuronal histone acetylation in mouse fore-brain primary neuronal cultures induced by HDAC inhibitor compounds. Analysis of the stability of the compounds in murine plasma and liver microsomes
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
abc-type fatty-acyl-coa transporter deficiency
Vorinostat in the acute neuroinflammatory form of X-linked adrenoleukodystrophy.
Aberrant Crypt Foci
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Aberrant Crypt Foci
Potent antitumor activity of Laccaic acid and Phenethyl isothiocyanate combination in colorectal cancer via dual inhibition of DNA methyltransferase-1 and Histone deacetylase-1.
Abortion, Spontaneous
Downregulation of HDAC8 expression decreases CD163 levels and promotes the apoptosis of macrophages by activating the ERK signaling pathway in recurrent spontaneous miscarriage.
Acanthamoeba Keratitis
Application of histone deacetylase inhibitors MPK472 and KSK64 as a potential treatment option for Acanthamoeba keratitis.
Achondroplasia
HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
Acidosis
Sodium butyrate attenuated iE-DAP induced inflammatory response in the mammary glands of dairy goats fed high-concentrate diet.
Acne Vulgaris
Short-Chain Fatty Acids from Cutibacterium acnes Activate Both a Canonical and Epigenetic Inflammatory Response in Human Sebocytes.
Acquired Immunodeficiency Syndrome
Establishment and application of a flow cytometry-based method for detecting histone acetylation levels.
Acquired Immunodeficiency Syndrome
Passport control for foreign integrated DNAs: An unexpected checkpoint by class II HDAC4 revealed by amino acid starvation.
Acrocephalosyndactylia
A contiguous gene deletion neighboring TWIST1 identified in a patient with Saethre-Chotzen syndrome associated with neurodevelopmental delay: possible contribution of HDAC9.
ACTH-Secreting Pituitary Adenoma
HDAC2 Expression and Variable Number of Repeats in Exon 1 of the HDAC2 Gene in Corticotroph Adenomas.
ACTH-Secreting Pituitary Adenoma
Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease.
Acute Coronary Syndrome
Polymorphism of HDAC9 Gene Is Associated with Increased Risk of Acute Coronary Syndrome in Chinese Han Population.
Acute Kidney Injury
2-Methylquinazoline derivative 23BB as a highly selective histone deacetylase 6 inhibitor alleviated cisplatin-induced acute kidney injury.
Acute Kidney Injury
2-methylquinazoline derivative F7 as a potent and selective HDAC6 inhibitor protected against rhabdomyolysis-induced acute kidney injury.
Acute Kidney Injury
A PTBA small molecule enhances recovery and reduces postinjury fibrosis after aristolochic acid-induced kidney injury.
Acute Kidney Injury
Acute Kidney Injury Results in Long-Term Diastolic Dysfunction That Is Prevented by Histone Deacetylase Inhibition.
Acute Kidney Injury
Alpha-2 adrenoceptor agonist-dexmedetomidine protects septic acute kidney injury through increasing BMP-7 and inhibiting HDAC2 and HDAC5.
Acute Kidney Injury
Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.
Acute Kidney Injury
Class I HDAC activity is required for renal protection and regeneration after acute kidney injury.
Acute Kidney Injury
Class IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury.
Acute Kidney Injury
Downregulation of miR-29b-3p aggravates podocyte injury by targeting HDAC4 in LPS-induced acute kidney injury.
Acute Kidney Injury
Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-? and EGFR signaling pathways in obstructive nephropathy.
Acute Kidney Injury
Histone deacetylase inhibitors protect against cisplatin-induced acute kidney injury by activating autophagy in proximal tubular cells.
Acute Kidney Injury
Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury.
Acute Kidney Injury
Selective Histone Deacetylase 6 Inhibitor 23BB Alleviated Rhabdomyolysis-Induced Acute Kidney Injury by Regulating Endoplasmic Reticulum Stress and Apoptosis.
Acute Kidney Injury
Suppression of BMP-7 by histone deacetylase 2 promoted apoptosis of renal tubular epithelial cells in acute kidney injury.
Acute Kidney Injury
The histone deacetylase, SIRT1, contributes to the resistance of young mice to ischemia/reperfusion-induced acute kidney injury.
Acute Kidney Injury
The Nephroprotective Effect of MS-275 on Lipopolysaccharide (LPS)-Induced Acute Kidney Injury by Inhibiting Reactive Oxygen Species (ROS)-Oxidative Stress and Endoplasmic Reticulum Stress.
Acute Kidney Injury
Time-dependent effects of histone deacetylase inhibition in sepsis-associated acute kidney injury.
Acute Lung Injury
Cigarette Smoke Disrupted Lung Endothelial Barrier Integrity and Increased Susceptibility to Acute Lung Injury via Histone Deacetylase 6.
Acute Lung Injury
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
Acute Lung Injury
HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury.
Acute Lung Injury
Histone Deacetylase 7 Inhibition in A Murine Model of Gram-Negative Pneumonia-Induced Acute Lung Injury.
Acute Lung Injury
Histone deacetylase inhibitor, butyrate, attenuates lipopolysaccharide-induced acute lung injury in mice.
Acute Lung Injury
Histone Deacetylase Inhibitors Attenuate Acute Lung Injury During Cecal Ligation and Puncture-Induced Polymicrobial Sepsis.
Acute Lung Injury
Histone deacetylase inhibitors prevent pulmonary endothelial hyperpermeability and acute lung injury by regulating heat shock protein 90 function.
Acute Lung Injury
miR-23b Attenuates LPS-Induced Inflammatory Responses in Acute Lung Injury via Inhibition of HDAC2.
Adenocarcinoma
(-)-Epigallocatechin 3-gallate inhibits invasion by inducing the expression of Raf kinase inhibitor protein in AsPC?1 human pancreatic adenocarcinoma cells through the modulation of histone deacetylase activity.
Adenocarcinoma
2,4?Di?tert?butylphenol, a potential HDAC6 inhibitor, induces senescence and mitotic catastrophe in human gastric adenocarcinoma AGS cells.
Adenocarcinoma
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.
Adenocarcinoma
Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Adenocarcinoma
Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.
Adenocarcinoma
Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors.
Adenocarcinoma
Broccoli Sprouts Delay Prostate Cancer Formation and Decrease Prostate Cancer Severity with a Concurrent Decrease in HDAC3 Protein Expression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) Mice.
Adenocarcinoma
Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas.
Adenocarcinoma
Collecting data through high throughput in vitro early toxicity and off-target liability assays to rapidly identify limitations of novel thyromimetics.
Adenocarcinoma
Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma.
Adenocarcinoma
CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
Adenocarcinoma
Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.
Adenocarcinoma
Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A.
Adenocarcinoma
Effects of histone deacetylase inhibitors on p55CDC/Cdc20 expression in HT29 cell line.
Adenocarcinoma
Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung.
Adenocarcinoma
Epigenetic alterations in TRAMP mice: epigenome DNA methylation profiling using MeDIP-seq.
Adenocarcinoma
Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines.
Adenocarcinoma
Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay.
Adenocarcinoma
Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study.
Adenocarcinoma
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Adenocarcinoma
Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells.
Adenocarcinoma
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.
Adenocarcinoma
HDAC3 overexpression and colon cancer cell proliferation and differentiation.
Adenocarcinoma
HDAC6 is required for invadopodia activity and invasion by breast tumor cells.
Adenocarcinoma
High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma.
Adenocarcinoma
High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas.
Adenocarcinoma
Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.
Adenocarcinoma
Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer.
Adenocarcinoma
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis.
Adenocarcinoma
Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1.
Adenocarcinoma
Histone deacetylase inhibitors FK228, N-(2-aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)amino- methyl]benzamide and m-carboxycinnamic acid bis-hydroxamide augment radiation-induced cell death in gastrointestinal adenocarcinoma cells.
Adenocarcinoma
Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.
Adenocarcinoma
Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines.
Adenocarcinoma
Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.
Adenocarcinoma
Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis.
Adenocarcinoma
Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin.
Adenocarcinoma
Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation, in part, via transcriptional repression of histone H3 lysine 4 demethylases.
Adenocarcinoma
Impact of The Hybrid-Polar Histone Deacetylase Inhibitor M-Carboxycinnamic Acid Bis-Hydroxamide on Human Pancreatic Adenocarcinoma Cells.
Adenocarcinoma
In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs.
Adenocarcinoma
Increased expression of histone deacetylase 2 is found in human gastric cancer.
Adenocarcinoma
Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal Adenocarcinoma.
Adenocarcinoma
Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.
Adenocarcinoma
Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma.
Adenocarcinoma
MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8.
Adenocarcinoma
Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus.
Adenocarcinoma
OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.
Adenocarcinoma
Predicting chemotherapeutic drug combinations through gene network profiling.
Adenocarcinoma
RAR? acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.
Adenocarcinoma
Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells.
Adenocarcinoma
Retraction Note to: MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8.
Adenocarcinoma
SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin.
Adenocarcinoma
Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer.
Adenocarcinoma
Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Adenocarcinoma
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Adenocarcinoma
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Adenocarcinoma
The Anti-Tumor Effect of HDAC Inhibition in a Human Pancreas Cancer Model Is Significantly Improved by the Simultaneous Inhibition of Cyclooxygenase 2.
Adenocarcinoma
The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma.
Adenocarcinoma
Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells.
Adenocarcinoma
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Adenocarcinoma of Lung
AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma.
Adenocarcinoma of Lung
Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model.
Adenocarcinoma of Lung
Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.
Adenocarcinoma of Lung
Esterase-sensitive cleavable histone deacetylase inhibitor-coupled hyaluronic acid nanoparticles for boosting anticancer activities against lung adenocarcinoma.
Adenocarcinoma of Lung
Expression of HDAC9 in lung cancer--potential role in lung carcinogenesis.
Adenocarcinoma of Lung
HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways.
Adenocarcinoma of Lung
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma.
Adenocarcinoma of Lung
Histone deacetylase 1/Sp1/microRNA-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma.
Adenocarcinoma of Lung
Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells.
Adenocarcinoma of Lung
Histone deacetylase 5 promotes the proliferation and invasion of lung cancer cells.
Adenocarcinoma of Lung
HOXA10 promotion of HDAC1 underpins the development of lung adenocarcinoma through the DNMT1-KLF4 axis.
Adenocarcinoma of Lung
Long noncoding RNA MALAT1 regulates HDAC4-mediated proliferation and apoptosis via decoying of miR-140-5p in osteosarcoma cells.
Adenocarcinoma of Lung
MCM5 Aggravates the HDAC1-Mediated Malignant Progression of Lung Cancer.
Adenocarcinoma of Lung
Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1.
Adenocarcinoma of Lung
New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
Adenocarcinoma of Lung
Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Adenocarcinoma of Lung
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC.
Adenocarcinoma of Lung
Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Adenocarcinoma of Lung
SNP rs10248565 in HDAC9 as a novel genomic aberration biomarker of lung adenocarcinoma in non-smoking women.
Adenocarcinoma of Lung
Suppression of phosphatidylinositol 3-kinase/Akt signaling pathway is a determinant of the sensitivity to a novel histone deacetylase inhibitor, FK228, in lung adenocarcinoma cells.
Adenocarcinoma of Lung
Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma.
Adenocarcinoma of Lung
Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma.
Adenocarcinoma of Lung
Targeting histone deacetylase SIRT1 selectively eradicates EGFR TKI-resistant cancer stem cells via regulation of mitochondrial oxidative phosphorylation in lung adenocarcinoma.
Adenocarcinoma of Lung
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.
Adenocarcinoma of Lung
Up-regulation of IRF-3 expression through GATA-1 acetylation by histone deacetylase inhibitor in lung adenocarcinoma A549 cells.
Adenocarcinoma of Lung
Vorinostat combined with brigatinib overcomes acquired resistance in EGFR-C797S-mutated lung cancer.
Adenocarcinoma of Lung
[Relationship between expression of HDAC2, IL-8, TNF-? in lung adenocarcinoma tissues and smoking].
Adenocarcinoma, Follicular
Retinoic acid and tributyrin induce in-vitro radioiodine uptake and inhibition of cell proliferation in a poorly differentiated follicular thyroid carcinoma.
Adenoma
HDAC2 Expression and Variable Number of Repeats in Exon 1 of the HDAC2 Gene in Corticotroph Adenomas.
Adenoma
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.
Adenoma
Histone deacetylase inhibitor-induced cellular apoptosis involves stanniocalcin-1 activation.
Adenoma
Influence of miRNA-106b and miRNA-135a on butyrate-regulated expression of p21 and Cyclin D2 in human colon adenoma cells.
Adenoma
Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer.
Adenomatous Polyposis Coli
Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells.
Adenomatous Polyposis Coli
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Adenomatous Polyposis Coli
Histone deacetylase expression in white matter oligodendrocytes after stroke.
Adenomatous Polyposis Coli
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.
Adenomyosis
Promoter hypermethylation of progesterone receptor isoform B (PR-B) in adenomyosis and its rectification by a histone deacetylase inhibitor and a demethylation agent.
Adenoviridae Infections
Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
Adenoviridae Infections
Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models.
Adenoviridae Infections
Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells.
Adenoviridae Infections
Rejection of adenovirus infection is independent of coxsackie and adenovirus receptor expression in cisplatin-resistant human lung cancer cells.
Adenoviridae Infections
The adenovirus-2 E1B-55K protein interacts with a mSin3A/histone deacetylase 1 complex.
Adenoviridae Infections
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.
Adrenal Gland Neoplasms
Management of patients with adrenal cancer: recommendations of an international consensus conference.
Adrenocortical Carcinoma
Alterations in the glycome after HDAC inhibition impact oncogenic potential in epigenetically plastic SW13 cells.
Adrenoleukodystrophy
HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.
African Swine Fever
Analysis of HDAC6 and BAG3-aggresome pathways in African swine fever viral factory formation.
Agenesis of Corpus Callosum
De novo satellited 2q associated with corpus callosum dysgenesis, short stature, mental retardation and developmental delay.
Albuminuria
HDAC6-mediated ?-tubulin deacetylation suppresses autophagy and enhances motility of podocytes in diabetic nephropathy.
Alexander Disease
Adult-onset Alexander disease, associated with a mutation in an alternative GFAP transcript, may be phenotypically modulated by a non-neutral HDAC6 variant.
Alopecia
Disrupted Ectodermal Organ Morphogenesis in Mice with a Conditional Histone Deacetylase 1, 2 Deletion in the Epidermis.
Alopecia
Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis.
Alopecia
Susceptibility variants on chromosome 7p21.1 suggest HDAC9 as a new candidate gene for male-pattern baldness.
alpha-tubulin n-acetyltransferase deficiency
MEC-17 Deficiency Leads to Reduced ?-Tubulin Acetylation and Impaired Migration of Cortical Neurons.
Alzheimer Disease
(-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression.
Alzheimer Disease
3,4-Dihydroxyphenylethanol Assuages Cognitive Impulsivity in Alzheimer's Disease by Attuning HPA-Axis via Differential Crosstalk of ?7 nAChR with MicroRNA-124 and HDAC6.
Alzheimer Disease
5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes.
Alzheimer Disease
A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.
Alzheimer Disease
Action of trichostatin A on Alzheimer's disease-like pathological changes in SH-SY5Y neuroblastoma cells.
Alzheimer Disease
An epigenetic blockade of cognitive functions in the neurodegenerating brain.
Alzheimer Disease
Beneficial Effects of Sulforaphane Treatment in Alzheimer's Disease May Be Mediated through Reduced HDAC1/3 and Increased P75NTR Expression.
Alzheimer Disease
Biophenols: Enzymes (?-secretase, Cholinesterases, histone deacetylase and tyrosinase) inhibitors from olive (Olea europaea L.).
Alzheimer Disease
Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.
Alzheimer Disease
c-Abl stabilizes HDAC2 levels by tyrosine phosphorylation repressing neuronal gene expression in Alzheimer's disease.
Alzheimer Disease
Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain.
Alzheimer Disease
Co-location of HDAC2 and Insulin Signaling Components in the Adult Mouse Hippocampus.
Alzheimer Disease
Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer's disease.
Alzheimer Disease
Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease.
Alzheimer Disease
Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
Alzheimer Disease
Discovery of in-vivo chemical probes for treating Alzheimer´s disease: Dual phosphodiesterase 5 (PDE5) and class I histone deacetylases-selective inhibitors.
Alzheimer Disease
Effects of velvet antler polypeptides on Alzheimer's disease cell model via miR-613 HDAC6 pathway.
Alzheimer Disease
Epigenetic regulation of HDAC1 SUMOylation as an endogenous neuroprotection against A? toxicity in a mouse model of Alzheimer's disease.
Alzheimer Disease
Evaluation of Class IIa Histone Deacetylases Expression and In Vivo Epigenetic Imaging in a Transgenic Mouse Model of Alzheimer's Disease.
Alzheimer Disease
Exifone Is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration.
Alzheimer Disease
HDAC1 modulates OGG1-initiated oxidative DNA damage repair in the aging brain and Alzheimer's disease.
Alzheimer Disease
HDAC2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease.
Alzheimer Disease
HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease.
Alzheimer Disease
Histone deacetylase 6 interacts with the microtubule-associated protein tau.
Alzheimer Disease
Histone Deacetylase Inhibitor Alleviates the Neurodegenerative Phenotypes and Histone Dysregulation in Presenilins-Deficient Mice.
Alzheimer Disease
Histone Deacetylase Inhibitors as Multitarget Ligands: New Players in Alzheimer's Disease Drug Discovery?
Alzheimer Disease
Histone Deacetylases 1 and 2 Regulate Microglia Function during Development, Homeostasis, and Neurodegeneration in a Context-Dependent Manner.
Alzheimer Disease
How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
Alzheimer Disease
Identification of novel class I and class IIb histone deacetylase inhibitor for Alzheimer's disease therapeutics.
Alzheimer Disease
Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease.
Alzheimer Disease
In silico investigation of traditional Chinese medicine compounds to inhibit human histone deacetylase 2 for patients with Alzheimer's disease.
Alzheimer Disease
Increased acetylation of Peroxiredoxin1 by HDAC6 inhibition leads to recovery of A?-induced impaired axonal transport.
Alzheimer Disease
Inhibition of Amyloid-Beta Production, Associated Neuroinflammation, and Histone Deacetylase 2-Mediated Epigenetic Modifications Prevent Neuropathology in Alzheimer's Disease in vitro Model.
Alzheimer Disease
Jatrorrhizine can improve nerve cell injury induced by A? 25-35, acting through miR-223-3p/HDAC4 axis.
Alzheimer Disease
L1CAM Beneficially Inhibits Histone Deacetylase 2 Expression under Conditions of Alzheimer's Disease.
Alzheimer Disease
Loss of HDAC5 Impairs Memory Function: Implications for Alzheimer's Disease.
Alzheimer Disease
MAPT/Tau accumulation represses autophagy flux by disrupting IST1-regulated ESCRT-III complex formation: a vicious cycle in Alzheimer neurodegeneration.
Alzheimer Disease
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer's Disease Mouse Model.
Alzheimer Disease
MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric A?25-35 -induced anxiety and cognitive deficits in a mouse model.
Alzheimer Disease
Molecular dynamics and quantum chemistry-based approaches to identify isoform selective HDAC2 inhibitor - a novel target to prevent Alzheimer's disease.
Alzheimer Disease
Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles.
Alzheimer Disease
Neuronal susceptibility to beta-amyloid toxicity and ischemic injury involves histone deacetylase-2 regulation of endophilin-B1.
Alzheimer Disease
Novel Histone Deacetylase 6 Inhibitors for Treating Alzheimer's Disease and Cancer.
Alzheimer Disease
Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model.
Alzheimer Disease
Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice.
Alzheimer Disease
Potential of chromatin modifying compounds for the treatment of Alzheimer's disease.
Alzheimer Disease
Protective effect of valproic acid in streptozotocin-induced sporadic Alzheimer's disease mouse model: possible involvement of the cholinergic system.
Alzheimer Disease
PTML Modeling for Alzheimer's Disease: Design and Prediction of Virtual Multi-Target Inhibitors of GSK3B, HDAC1, and HDAC6.
Alzheimer Disease
Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain.
Alzheimer Disease
Re-exploring the core genes and modules in the human frontal cortex during chronological aging: insights from network-based analysis of transcriptomic studies.
Alzheimer Disease
Recent studies on cellular and molecular mechanisms in Alzheimer's disease: focus on epigenetic factors and histone deacetylase.
Alzheimer Disease
Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease.
Alzheimer Disease
Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.
Alzheimer Disease
Sirtuin 3 mRNA Expression is Downregulated in the Brain Tissues of Alzheimer's Disease Patients: A Bioinformatic and Data Mining Approach.
Alzheimer Disease
Small-molecule modulation of HDAC6 activity: The propitious therapeutic strategy to vanquish neurodegenerative disorders.
Alzheimer Disease
Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression.
Alzheimer Disease
Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease.
Alzheimer Disease
Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
Alzheimer Disease
Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.
Alzheimer Disease
The glial-specific hypermethylated 3' untranslated region of histone deacetylase 1 may modulates several signal pathways in Alzheimer's disease.
Alzheimer Disease
The role of ATM and DNA damage in neurons: upstream and downstream connections.
Alzheimer Disease
The Transcription Factor Sp3 Cooperates with HDAC2 to Regulate Synaptic Function and Plasticity in Neurons.
Alzheimer Disease
Translation of HDAC6 PET Imaging Using [18F]EKZ-001-cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates.
Alzheimer Disease
Treatment with Histone Deacetylase Inhibitor Attenuates Peripheral Inflammation-Induced Cognitive Dysfunction and Microglial Activation: The Effect of SAHA as a Peripheral HDAC Inhibitor.
Alzheimer Disease
Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice.
Amyloidosis
Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model.
Amyotrophic Lateral Sclerosis
Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Class I and II histone deacetylase expression is not altered in human amyotrophic lateral sclerosis: Neuropathological and positron emission tomography molecular neuroimaging evidence.
Amyotrophic Lateral Sclerosis
Clinical validation of the novel HDAC6 radiotracer [18F]EKZ-001 in the human brain.
Amyotrophic Lateral Sclerosis
Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Exifone Is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration.
Amyotrophic Lateral Sclerosis
HDAC6 is a Bruchpilot deacetylase that facilitates neurotransmitter release.
Amyotrophic Lateral Sclerosis
HDAC6 maintains mitochondrial connectivity under hypoxic stress by suppressing MARCH5/MITOL dependent MFN2 degradation.
Amyotrophic Lateral Sclerosis
Histone deacetylase 4 protects from denervation and skeletal muscle atrophy in a murine model of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Histone deacetylase 6 delays motor neuron degeneration by ameliorating the autophagic flux defect in a transgenic mouse model of amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression.
Amyotrophic Lateral Sclerosis
Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Peptidylprolyl isomerase A governs TARDBP function and assembly in heterogeneous nuclear ribonucleoprotein complexes.
Amyotrophic Lateral Sclerosis
Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Amyotrophic Lateral Sclerosis
Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Small-molecule modulation of HDAC6 activity: The propitious therapeutic strategy to vanquish neurodegenerative disorders.
Amyotrophic Lateral Sclerosis
The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity.
Amyotrophic Lateral Sclerosis
Therapeutic potential of HDAC6 in amyotrophic lateral sclerosis.
Amyotrophic Lateral Sclerosis
Translation of HDAC6 PET Imaging Using [18F]EKZ-001-cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates.
Anaphylaxis
DNA methyl transferase I acts as a negative regulator of allergic skin inflammation.
Anaphylaxis
Fc?RI-HDAC3-MCP1 Signaling Axis Promotes Passive Anaphylaxis Mediated by Cellular Interactions.
Anaphylaxis
Histone Deacetylase 3 Mediates Allergic Skin Inflammation by Regulating Expression of MCP1 Protein.
Anaphylaxis
Histone deacetylase-3mediates positive feedback relationship between anaphylaxis and tumor metastasis.
Anemia, Hemolytic
Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone.
Anemia, Refractory
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Anemia, Refractory, with Excess of Blasts
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Anemia, Sickle Cell
Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease.
Anemia, Sickle Cell
Mechanisms of human gamma-globin transcriptional induction by apicidin involves p38 signaling to chromatin.
Anemia, Sickle Cell
Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
Anemia, Sickle Cell
Role of stem cell factor in the reactivation of human fetal hemoglobin.
Aneurysm
An HDAC9-MALAT1-BRG1 complex mediates smooth muscle dysfunction in thoracic aortic aneurysm.
Aneurysm, Dissecting
Downregulation of HDAC1 suppresses media degeneration by inhibiting the migration and phenotypic switch of aortic vascular smooth muscle cells in aortic dissection.
Anhedonia
Valproic acid administration exerts protective effects against stress-related anhedonia in rats.
Anthrax
HDAC8 Prevents Anthrax Lethal Toxin-induced Cell Cycle Arrest through Silencing PTEN in Human Monocytic THP-1 Cells.
Anthrax
Inhibition of IL-1? Expression by Anthrax Lethal Toxin is Reversed by HDAC8 Inhibition in Murine Macrophages.
Anthrax
Inhibition of interleukin 1? (IL-1?) expression by anthrax lethal toxin (LeTx) is reversed by histone deacetylase 8 (HDAC8) inhibition in murine macrophages.
Aortic Aneurysm, Abdominal
A Novel Histone Deacetylase Inhibitor Reduces Abdominal Aortic Aneurysm Formation in Angiotensin II-Infused Apolipoprotein E-Deficient Mice.
Aortic Valve Stenosis
Histone deacetylase 6 reduction promotes aortic valve calcification via an endoplasmic reticulum stress-mediated osteogenic pathway.
Apnea
Histone Deacetylase 5 Is an Early Epigenetic Regulator of Intermittent Hypoxia Induced Sympathetic Nerve Activation and Blood Pressure.
Arrhythmias, Cardiac
Changes in cardiac NaV1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors.
Arrhythmias, Cardiac
Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation.
Arrhythmias, Cardiac
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility.
Arrhythmias, Cardiac
The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice.
Arthritis
A novel histone deacetylase 6-selective inhibitor suppresses synovial inflammation and joint destruction in a collagen antibody-induced arthritis mouse model.
Arthritis
Genome-wide expression and methylation profiling reveal candidate genes in osteoarthritis.
Arthritis
Histone Deacetylase 3-Mediated Inhibition of microRNA-19a-3p Facilitates the Development of Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Arthritis
Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice.
Arthritis
Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
Arthritis
Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay.
Arthritis
Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis.
Arthritis
Inhibition of histone deacetylase 6 suppresses inflammatory responses and invasiveness of fibroblast-like-synoviocytes in inflammatory arthritis.
Arthritis
Post-GWAS functional studies reveal an RA-associated CD40-induced NF-kB signal transduction and transcriptional regulation network targeted by class II HDAC inhibitors.
Arthritis
Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis.
Arthritis
Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis.
Arthritis
Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo.
Arthritis
Suberoylanilide Hydroxamic Acid Attenuates Autoimmune Arthritis by Suppressing Th17 Cells through NR1D1 Inhibition.
Arthritis
Therapeutic Effect of Histone Deacetylase Inhibitor, Sodium Butyrate, on Allergic Rhinitis In Vivo.
Arthritis
Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis.
Arthritis
Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model.
Arthritis, Experimental
A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis.
Arthritis, Experimental
Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents.
Arthritis, Experimental
Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis.
Arthritis, Experimental
Histone deacetylase 1 is increased in rheumatoid arthritis synovium and promotes synovial cell hyperplasia and synovial inflammation in the collagen-induced arthritis mouse model via the microRNA-124-dependent MARCKS-JAK/STAT axis.
Arthritis, Experimental
Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis.
Arthritis, Experimental
Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.
Arthritis, Experimental
Therapeutic effects of NK-HDAC-1, a novel histone deacetylase inhibitor, on collagen-induced arthritis through the induction of apoptosis of fibroblast-like synoviocytes.
Arthritis, Juvenile
Post-GWAS functional studies reveal an RA-associated CD40-induced NF-kB signal transduction and transcriptional regulation network targeted by class II HDAC inhibitors.
Arthritis, Juvenile
Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis.
Arthritis, Juvenile
Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis.
Arthritis, Juvenile
Specific inhibition of histone deacetylase 8 reduces gene expression and production of proinflammatory cytokines in vitro and in vivo.
Arthritis, Rheumatoid
A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis.
Arthritis, Rheumatoid
AAA-ATPase p97 suppresses apoptotic and autophagy-associated cell death in rheumatoid arthritis synovial fibroblasts.
Arthritis, Rheumatoid
Control of cytokine mRNA degradation by the histone deacetylase inhibitor ITF2357 in rheumatoid arthritis fibroblast-like synoviocytes: beyond transcriptional regulation.
Arthritis, Rheumatoid
HDAC Inhibition in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis.
Arthritis, Rheumatoid
Histone deacetylase 1 is increased in rheumatoid arthritis synovium and promotes synovial cell hyperplasia and synovial inflammation in the collagen-induced arthritis mouse model via the microRNA-124-dependent MARCKS-JAK/STAT axis.
Arthritis, Rheumatoid
Histone deacetylase 1 regulates tissue destruction in rheumatoid arthritis.
Arthritis, Rheumatoid
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
Arthritis, Rheumatoid
Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes.
Arthritis, Rheumatoid
Histone Deacetylase 3-Mediated Inhibition of microRNA-19a-3p Facilitates the Development of Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Arthritis, Rheumatoid
Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
Arthritis, Rheumatoid
Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-{kappa}B p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells.
Arthritis, Rheumatoid
Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue.
Arthritis, Rheumatoid
Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay.
Arthritis, Rheumatoid
Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients.
Arthritis, Rheumatoid
Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis.
Arthritis, Rheumatoid
Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression.
Arthritis, Rheumatoid
Inhibition of histone deacetylase 6 suppresses inflammatory responses and invasiveness of fibroblast-like-synoviocytes in inflammatory arthritis.
Arthritis, Rheumatoid
Largazole, a class I histone deacetylase inhibitor, enhances TNF-?-induced ICAM-1 and VCAM-1 expression in rheumatoid arthritis synovial fibroblasts.
Arthritis, Rheumatoid
MicroRNA-449 targets histone deacetylase 1 to regulate the proliferation, invasion, and apoptosis of synovial fibroblasts in rheumatoid arthritis.
Arthritis, Rheumatoid
miR-138 activates NF-?B signaling and PGRN to promote rheumatoid arthritis via regulating HDAC4.
Arthritis, Rheumatoid
Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009.
Arthritis, Rheumatoid
Reduced Activity of HDAC3 and Increased Acetylation of Histones H3 in Peripheral Blood Mononuclear Cells of Patients with Rheumatoid Arthritis.
Arthritis, Rheumatoid
Suberoylanilide Hydroxamic Acid, an Inhibitor of Histone Deacetylase, Induces Apoptosis in Rheumatoid Arthritis Fibroblast-Like Synoviocytes.
Arthritis, Rheumatoid
Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?
Arthritis, Rheumatoid
The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis.
Arthritis, Rheumatoid
The histone deacetylase inhibitors MS-275 and SAHA suppress the p38 mitogen-activated protein kinase signaling pathway and chemotaxis in rheumatoid arthritic synovial fibroblastic E11 cells.
Arthritis, Rheumatoid
Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro.
Arthritis, Rheumatoid
Therapeutic effects of NK-HDAC-1, a novel histone deacetylase inhibitor, on collagen-induced arthritis through the induction of apoptosis of fibroblast-like synoviocytes.
Arthritis, Rheumatoid
Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis.
Arthritis, Rheumatoid
Trichostatin A cooperates with fas-mediated signal to induce apoptosis in rheumatoid arthritis synovial fibroblasts.
Arthritis, Rheumatoid
Trichostatin A, an Inhibitor of Histone Deacetylase, Inhibits the Viability and Invasiveness of Hypoxic Rheumatoid Arthritis Fibroblast-Like Synoviocytes via PI3K/Akt Signaling.
Aspergillosis
Histone deacetylase inhibition as an alternative strategy against invasive aspergillosis.
Asthma
Activation of AMPK inhibits TGF-?1-induced airway smooth muscle cells proliferation and its potential mechanisms.
Asthma
Conserved responses to trichostatin A in rodent lungs exposed to endotoxin or stretch.
Asthma
Corticosteroid insensitivity in smokers with asthma : clinical evidence, mechanisms, and management.
Asthma
Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease.
Asthma
CpG oligodeoxynucleotides attenuate ROR?t-mediated Th17 response by restoring histone deacetylase-2 in cigarette smoke-exposure asthma.
Asthma
Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction.
Asthma
Effects of genetic factors to inhaled corticosteroid response in children with asthma: a literature review.
Asthma
Genome-wide interaction study reveals age-dependent determinants of responsiveness to inhaled corticosteroids in individuals with asthma.
Asthma
Glucocorticoid receptor ? and histone deacetylase 1 and 2 expression in the airways of severe asthma.
Asthma
HDAC4 induces the development of asthma by increasing Slug-upregulated CXCL12 expression through KLF5 deacetylation.
Asthma
HDAC8 inhibitor attenuates airway responses to antigen stimulus through synchronously suppressing galectin-3 expression and reducing macrophage-2 polarization.
Asthma
Histone deacetylase 6 (HDAC6) is an essential factor for oocyte maturation and asymmetric division in mice.
Asthma
Histone deacetylase activity and recurrent bacterial bronchitis in severe eosinophilic asthma.
Asthma
Histone deacetylase inhibitor regulates the balance of Th17/Treg in allergic asthma.
Asthma
Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue.
Asthma
Histone deacetylase inhibitors: can we consider potent anti-neoplastic agents for the treatment of asthma?
Asthma
Histone deacetylases and their inhibitors: new implications for asthma and chronic respiratory conditions.
Asthma
Identification of differentially expressed genes associated with asthma in children based on the bioanalysis of the regulatory network.
Asthma
Impact of gene expression associated with glucocorticoid-induced transcript 1 (GLCCI1) on severe asthma and future exacerbation.
Asthma
Increased glucocorticoid receptor-beta expression, but not decreased histone deacetylase 2, in severe asthma.
Asthma
Inhibition of histone deacetylase 2 expression by elevated glucocorticoid receptor beta in steroid-resistant asthma.
Asthma
Low-level laser therapy suppresses the oxidative stress-induced glucocorticoids resistance in U937 cells: relevance to cytokine secretion and histone deacetylase in alveolar macrophages.
Asthma
MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase-mediated suppression of histone deacetylase 2.
Asthma
Outside-in hypothesis revisited: The role of microbial, epithelial, and immune interactions.
Asthma
Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages.
Asthma
PARP inhibition by olaparib alleviates chronic asthma-associated remodeling features via modulating inflammasome signaling in mice.
Asthma
PI3K inhibitor treatment ameliorates the glucocorticoid insensitivity of PBMCs in severe asthma.
Asthma
PM2.5 exposure and cold stress exacerbates asthma in mice by increasing histone acetylation in IL-4 gene promoter in CD4+ T cells.
Asthma
Protective effects of valproic acid against airway hyperresponsiveness and airway remodeling in a mouse model of allergic airways disease.
Asthma
Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma.
Asthma
Simple Fluorogenic Cellular Assay for Histone Deacetylase Inhibitors Based on Split-Yellow Fluorescent Protein and Intrabodies.
Asthma
Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin-induced mouse model of asthma.
Asthma
Soluble fibre supplementation with and without a probiotic in adults with asthma: A 7-day randomised, double blind, three way cross-over trial.
Asthma
Steroid-resistant neutrophilic inflammation in a mouse model of an acute exacerbation of asthma.
Asthma
Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on?
Asthma
Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease.
Asthma
The role of HDAC2 in cigarette smoke-induced airway inflammation in a murine model of asthma and the effect of intervention with roxithromycin.
Asthma
Therapeutic Effect of Histone Deacetylase Inhibitor, Sodium Butyrate, on Allergic Rhinitis In Vivo.
Asthma
Treatment with 1,25(OH)2D3 induced HDAC2 expression and reduced NF-?B p65 expression in a rat model of OVA-induced asthma.
Asthma
Trichostatin A Abrogates Airway Constriction, but not Inflammation in Mouse and Human Asthma Models.
Asthma
Trichostatin A abrogates airway constriction, but not inflammation, in murine and human asthma models.
Asthma
USP17-mediated deubiquitination and stabilization of HDAC2 in cigarette smoke extract-induced inflammation.
Asthma
[Characteristics of histone deacetylase 9 in peripheral blood of patients with bronchial asthma].
Asthma
[Roles of histone acetyltransferase and histone deacetylase in the pathogenesis of bronchial asthma].
Asthma
[Therapeutic effects of histone deacetylase inhibitor givinostat on air inflammation and high airway resistance in a murine asthma model].
Asthma
[Therapeutic effects of Tubastatin A Hcl on airway inflammation in acute mice asthma model].
Astrocytoma
Abnormal methylation of histone deacetylase genes: implications on etiology and epigenetic therapy of astrocytomas.
Astrocytoma
Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas.
Astrocytoma
Elevated and deregulated expression of HDAC3 in human astrocytic glial tumours.
Astrocytoma
Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas.
Astrocytoma
HDAC6 mediates HIV-1 tat-induced proinflammatory responses by regulating MAPK-NF-kappaB/AP-1 pathways in astrocytes.
Astrocytoma
The role of DNA methylation and histone acetylation in the regulation of progesterone receptor isoforms expression in human astrocytoma cell lines.
Ataxia
Sodium valproate increases activity of the sirtuin pathway resulting in beneficial effects for spinocerebellar ataxia-3 in vivo.
Ataxia
The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1.
Ataxia Telangiectasia
ATM modulates transcription in response to histone deacetylase inhibition as part of its DNA damage response.
Ataxia Telangiectasia
DDIT4 gene expression is switched on by a new HDAC4 function in ataxia telangiectasia.
Ataxia Telangiectasia
Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.
Ataxia Telangiectasia
Histone deacetylase 9 (HDAC9) regulates the functions of the ATDC (TRIM29) protein.
Ataxia Telangiectasia
Modulation of chromatin conformation by the histone deacetylase inhibitor trichostatin A promotes the removal of radiation-induced lesions in ataxia telangiectasia cell lines.
Ataxia Telangiectasia
Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia.
Ataxia Telangiectasia
Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated.
Ataxia Telangiectasia
Role of chromatin structure modulation by the histone deacetylase inhibitor trichostatin A on the radio-sensitivity of ataxia telangiectasia.
Atherosclerosis
ApoE-/- PGC-1?-/- Mice Display Reduced IL-18 Levels and Do Not Develop Enhanced Atherosclerosis.
Atherosclerosis
Association between rs2107595 HDAC9 gene polymorphism and advanced carotid atherosclerosis in the Slovenian cohort.
Atherosclerosis
Association Between the Gene Polymorphisms of HDAC9 and the Risk of Atherosclerosis and Ischemic Stroke.
Atherosclerosis
Deficiency of the stroke relevant HDAC9 gene attenuates atherosclerosis in accord with allele-specific effects at 7p21.1.
Atherosclerosis
Endothelial-Specific Overexpression of Histone Deacetylase 2 Protects Mice against Endothelial Dysfunction and Atherosclerosis.
Atherosclerosis
Enhancing PPAR? by HDAC inhibition reduces foam cell formation and atherosclerosis in ApoE deficient mice.
Atherosclerosis
Epigenetic-sensitive pathways in personalized therapy of major cardiovascular diseases.
Atherosclerosis
Estrogen modulates vascular smooth muscle cell function through downregulation of SIRT1.
Atherosclerosis
Estrogen-SIRT1 Axis Plays a Pivotal Role in Protecting Arteries Against Menopause-Induced Senescence and Atherosclerosis.
Atherosclerosis
Evidence HDAC9 Genetic Variant Associated With Ischemic Stroke Increases Risk via Promoting Carotid Atherosclerosis.
Atherosclerosis
Fluid shear stress stimulates phosphorylation-dependent nuclear export of HDAC5 and mediates expression of KLF2 and eNOS.
Atherosclerosis
HDAC1 and 2 regulate endothelial VCAM-1 expression and atherogenesis by suppressing methylation of the GATA6 promoter.
Atherosclerosis
HDAC1-mediated deacetylation of HIF1? prevents atherosclerosis progression by promoting miR-224-3p-mediated inhibition of FOSL2.
Atherosclerosis
HDAC3 inhibitor suppresses endothelial-to-mesenchymal transition via modulating inflammatory response in atherosclerosis.
Atherosclerosis
HDAC3 protects against atherosclerosis through inhibition of inflammation via the microRNA-19b/PPAR?/NF-?B axis.
Atherosclerosis
HDAC9 regulates ox-LDL-induced endothelial cell apoptosis by participating in inflammatory reactions.
Atherosclerosis
Histone deacetylase 3 is critical in endothelial survival and atherosclerosis development in response to disturbed flow.
Atherosclerosis
Histone deacetylase 9 promotes endothelial-mesenchymal transition and an unfavorable atherosclerotic plaque phenotype.
Atherosclerosis
Histone deacetylase 9 represses cholesterol efflux and alternatively activated macrophages in atherosclerosis development.
Atherosclerosis
Inhibition of HDAC6 Activity Protects Against Endothelial Dysfunction and Atherogenesis in vivo: A Role for HDAC6 Neddylation.
Atherosclerosis
Inhibition of miR?34a prevents endothelial cell apoptosis by directly targeting HDAC1 in the setting of atherosclerosis.
Atherosclerosis
Inhibition of myeloid HDAC2 upregulates glutaredoxin 1 expression, improves protein thiol redox state and protects against high-calorie diet-induced monocyte dysfunction and atherosclerosis.
Atherosclerosis
Interactive Effects of a Combination of the HDAC3 and HDAC9 Genes with Diabetes Mellitus on the Risk of Ischemic Stroke.
Atherosclerosis
Interfering microRNA-410 attenuates atherosclerosis via the HDAC1/KLF5/IKB?/NF-?B axis.
Atherosclerosis
Involvement of the Antioxidant Effect and Anti-inflammatory Response in Butyrate-Inhibited Vascular Smooth Muscle Cell Proliferation.
Atherosclerosis
Ketone Body, 3-Hydroxybutyrate: Minor Metabolite - Major Medical Manifestations.
Atherosclerosis
LncRNA NORAD Promotes Vascular Endothelial Cell Injury and Atherosclerosis Through Suppressing VEGF Gene Transcription via Enhancing H3K9 Deacetylation by Recruiting HDAC6.
Atherosclerosis
Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study.
Atherosclerosis
MicroRNA-200b-3p promotes endothelial cell apoptosis by targeting HDAC4 in atherosclerosis.
Atherosclerosis
miR-34a Targets HDAC1-Regulated H3K9 Acetylation on Lipid Accumulation Induced by Homocysteine in Foam Cells.
Atherosclerosis
Pharmacological inhibition of histone deacetylase reduces NADPH oxidase expression, oxidative stress and the progression of atherosclerotic lesions in hypercholesterolemic apolipoprotein E-deficient mice; potential implications for human atherosclerosis.
Atherosclerosis
Protein kinase B mediates insulin-like growth factor 1-induced phosphorylation and nuclear export of histone deacetylase 5 via NADPH oxidase 4 activation in vascular smooth muscle cells.
Atherosclerosis
Role of histone deacetylase Sirt3 in the development and regression of atherosclerosis.
Atherosclerosis
Silencing of Histone Deacetylase 9 Expression in Podocytes Attenuates Kidney Injury in Diabetic Nephropathy.
Atherosclerosis
Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions.
Atherosclerosis
The Atherosclerosis Risk Variant rs2107595 Mediates Allele-Specific Transcriptional Regulation of HDAC9 via E2F3 and Rb1.
Atherosclerosis
The involvement of NFAT transcriptional activity suppression in SIRT1-mediated inhibition of COX-2 expression induced by PMA/Ionomycin.
Atherosclerosis
Trichostatin A exacerbates atherosclerosis in low density lipoprotein receptor-deficient mice.
Atrial Fibrillation
Chronic HDAC6 Activation Induces Atrial Fibrillation Through Atrial Electrical and Structural Remodeling in Transgenic Mice.
Atrial Fibrillation
Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation.
Atrial Fibrillation
Epigenetic regulation of cardiac electrophysiology in atrial fibrillation: HDAC2 determines action potential duration and suppresses NRSF in cardiomyocytes.
Atrial Fibrillation
Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy.
Atrioventricular Block
Relevance of calmodulin/CaMKII activation for arrhythmogenesis in the AV block dog.
Atypical Squamous Cells of the Cervix
MoSnt2-dependent deacetylation of histone H3 mediates MoTor-dependent autophagy and plant infection by the rice blast fungus Magnaporthe oryzae.
Autoimmune Diseases
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
Autoimmune Diseases
CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus.
Autoimmune Diseases
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
Autoimmune Diseases
Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction.
Autoimmune Diseases
Effects of trichostatin A in a rat model of acute graft-versus-host disease after liver transplantation.
Autoimmune Diseases
Epigenetic Alterations and MicroRNA Misexpression in Cancer and Autoimmune Diseases: a Critical Review.
Autoimmune Diseases
Global expression and CpG methylation analysis of primary endothelial cells before and after TNFa stimulation reveals gene modules enriched in inflammatory and infectious diseases and associated DMRs.
Autoimmune Diseases
Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes.
Autoimmune Diseases
Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation.
Autoimmune Diseases
Histone Deacetylase 7 mediates tissue-specific autoimmunity via control of innate effector function in invariant Natural Killer T Cells.
Autoimmune Diseases
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Autoimmune Diseases
Histone deacetylases 6 and 9 and sirtuin-1 control Foxp3+ regulatory T cell function through shared and isoform-specific mechanisms.
Autoimmune Diseases
Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis.
Autoimmune Diseases
Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
Autoimmune Diseases
The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis.
Autoimmune Diseases
Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells.
Autoimmune Diseases
Trichostatin A down-regulates ZAP-70, LAT and SLP-76 content in Jurkat T cells.
Autoimmune Diseases
Trichostatin A, a Histone Deacetylase Inhibitor, Alleviates Eosinophilic Meningitis Induced by Angiostrongylus cantonensis Infection in Mice.
Autoimmune Diseases
Trichostatin Differentially Regulates Th1 and Th2 Responses and Alleviates Rheumatoid Arthritis in Mice.
Autoimmune Diseases
Valproic Acid Ameliorates Graft-versus-Host Disease by Downregulating Th1 and Th17 Cells.
Autoimmune Lymphoproliferative Syndrome
Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS).
Bacteremia
Histone Deacetylase 6 Inhibition Improves Survival in a Swine Model of Lethal Hemorrhage, Polytrauma and Bacteremia.
Bacterial Infections
Augmentation of Cationic Antimicrobial Peptide Production with Histone Deacetylase Inhibitors as a Novel Epigenetic Therapy for Bacterial Infections.
Bacterial Infections
HDAC6 controls innate immune and autophagy responses to TLR-mediated signalling by the intracellular bacteria Listeria monocytogenes.
beta-Thalassemia
Histone deacetylase inhibitors and hemoglobin F induction in beta-thalassemia.
beta-Thalassemia
Mechanisms of human gamma-globin transcriptional induction by apicidin involves p38 signaling to chromatin.
Bicuspid Aortic Valve Disease
Histone Deacetylase 3 Coordinates Deacetylase-independent Epigenetic Silencing of Transforming Growth Factor-?1 (TGF-?1) to Orchestrate Second Heart Field Development.
Biliary Tract Neoplasms
A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.
Biliary Tract Neoplasms
A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Biliary Tract Neoplasms
Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.
Biliary Tract Neoplasms
Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.
Biliary Tract Neoplasms
Loss of RUNX3 expression by histone deacetylation is associated with biliary tract carcinogenesis.
Blast Crisis
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Blast Crisis
Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Blast Crisis
The Long Noncoding RNA MEG3 and its Target miR-147 Regulate JAK/STAT Pathway in Advanced Chronic Myeloid Leukemia.
Blindness
HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness.
Blindness
Selective Histone Deacetylase 6 Inhibitors Restore Cone Photoreceptor Vision or Outer Segment Morphology in Zebrafish and Mouse Models of Retinal Blindness.
Blister
Modulating Ocular Scarring in Glaucoma Filtration Surgery Using the Epigenetic Adjunct Suberoylanilide Hydroxamic Acid.
Bloom Syndrome
Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor.
Bone Diseases
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Bone Diseases
Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.
Bone Diseases
Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL.
Bone Diseases, Metabolic
Hdac3 Deficiency Increases Marrow Adiposity and Induces Lipid Storage and Glucocorticoid Metabolism in Osteochondroprogenitor Cells.
Bone Diseases, Metabolic
Histone deacetylase 3 suppression increases PH domain and leucine-rich repeat phosphatase (Phlpp)1 expression in chondrocytes to suppress Akt signaling and matrix secretion.
Bone Diseases, Metabolic
miR-4286 functions in osteogenesis and angiogenesis via targeting histone deacetylase 3 and alleviates alcohol-induced bone loss in mice.
Bone Marrow Failure Disorders
Histone deacetylase inhibition modulates cell fate decisions during myeloid differentiation.
Bone Marrow Failure Disorders
Sin3a-associated Hdac1 and Hdac2 are essential for hematopoietic stem cell homeostasis and contribute differentially to hematopoiesis.
Bone Marrow Failure Disorders
Transcriptomic and Epigenomic Profiling of Histone Deacetylase Inhibitor Treatment Reveals Distinct Gene Regulation Profiles Leading to Impaired Neutrophil Development.
Bone Neoplasms
HDAC inhibitor TSA ameliorates mechanical hypersensitivity and potentiates analgesic effect of morphine in a rat model of bone cancer pain by restoring ?-opioid receptor in spinal cord.
Bone Neoplasms
Suppression of HDAC2 in Spinal Cord Alleviates Mechanical Hyperalgesia and Restores KCC2 Expression in a Rat Model of Bone Cancer Pain.
Bone Neoplasms
[Early intervention of bone-nearby acupuncture combined with electroacupuncture on morphine tolerance in bone cancer pain rats and its effect on the expression of HDAC and MOR in dorsal root ganglia].
Bone Resorption
Blueberry juice protects osteocytes and bone precursor cells against oxidative stress partly through SIRT1.
Bone Resorption
Compounds that inhibit histone deacetylases in class I and class II effectively suppress human osteoclasts in vitro.
Bone Resorption
Deletion of histone deacetylase 7 in osteoclasts decreases bone mass in mice by interactions with MITF.
Bone Resorption
Hdac3 deletion in myeloid progenitor cells enhances bone healing in females and limits osteoclast fusion via Pmepa1.
Bone Resorption
Hdac3 regulates bone modeling by suppressing osteoclast responsiveness to RANKL.
Bone Resorption
HDAC7 inhibits osteoclastogenesis by reversing RANKL-triggered ?-catenin switch.
Bone Resorption
HDAC9 Inhibits Osteoclastogenesis via Mutual Suppression of PPAR?/RANKL Signaling.
Bone Resorption
Histone deacetylase 3 is required for maintenance of bone mass during aging.
Brachydactyly
Dose dependent expression of HDAC4 causes variable expressivity in a novel inherited case of brachydactyly mental retardation syndrome.
Brachydactyly
Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems.
Brachydactyly
Haploinsufficiency of HDAC4 does not cause intellectual disability in all affected individuals.
Brachydactyly
Phenotypic variant of Brachydactyly-mental retardation syndrome in a family with an inherited interstitial 2q37.3 microdeletion including HDAC4.
Brachydactyly
Primary hyperoxaluria type 1 and brachydactyly mental retardation syndrome caused by a novel mutation in AGXT and a terminal deletion of chromosome 2.
Brachydactyly
The first familial case of inherited 2q37.3 interstitial deletion with isolated skeletal abnormalities including brachydactyly type E and short stature.
Brachydactyly
Transcriptome analysis of genes and gene networks involved in aggressive behavior in mouse and zebrafish.
Brachydactyly
[Analysis of clinical phenotypes and genetic variations in a Chinese family affected with craniofacial and skeletal deformities].
Bradycardia
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility.
Bradycardia
Mitochondrial thioredoxin-2 maintains HCN4 expression and prevents oxidative stress-mediated sick sinus syndrome.
Brain Concussion
Repeated mild traumatic brain injury causes persistent changes in histone deacetylase function in hippocampus: Implications in learning and memory deficits in rats.
Brain Diseases
A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests.
Brain Diseases
Aberrant Expression of Histone Deacetylases 4 in Cognitive Disorders: Molecular Mechanisms and a Potential Target.
Brain Diseases
Class I Histone Deacetylase Inhibitor Valproic Acid Reverses Cognitive Deficits in a Mouse Model of Septic Encephalopathy.
Brain Diseases
HDAC1 Silence Promotes Neuroprotective Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Mouse Model of Traumatic Brain Injury via PI3K/AKT Pathway.
Brain Diseases
Image-guided synthesis reveals potent blood-brain barrier permeable histone deacetylase inhibitors.
Brain Diseases
Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers.
Brain Diseases
Salvianolic acid B attenuates apoptosis and inflammation via SIRT1 activation in experimental stroke rats.
Brain Edema
Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock.
Brain Edema
[Protective effect of the histone deacetylase inhibitor ACY1215 against brain edema in mice with acute liver failure].
Brain Infarction
Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
Brain Infarction
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Brain Infarction
Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of ?-tubulin acetylation and FGF-21 up-regulation.
Brain Injuries
Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies.
Brain Injuries
Early Histone Deacetylase Inhibition Mitigates Ischemia/Reperfusion Brain Injury by Reducing Microglia Activation and Modulating Their Phenotype.
Brain Injuries
HDAC3 inhibition ameliorates ischemia/reperfusion-induced brain injury by regulating the microglial cGAS-STING pathway.
Brain Injuries
HDAC9 Silencing Exerts Neuroprotection Against Ischemic Brain Injury via miR-20a-Dependent Downregulation of NeuroD1.
Brain Injuries
Histone deacetylase 6 interference protects mice against experimental stroke-induced brain injury via activating Nrf2/HO-1 pathway.
Brain Injuries
Inhibition of HDAC4 Attenuated JNK/c-Jun-Dependent Neuronal Apoptosis and Early Brain Injury Following Subarachnoid Hemorrhage by Transcriptionally Suppressing MKK7.
Brain Injuries
Inhibition of HDAC6 expression decreases brain injury induced by APOE4 and A? co?aggregation in rats.
Brain Injuries
Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism.
Brain Injuries
Magnolol attenuates the inflammation and apoptosis through the activation of SIRT1 in experimental stroke rats.
Brain Injuries
Neuroprotection by the histone deacetylase inhibitor trichostatin A in a model of lipopolysaccharide-sensitised neonatal hypoxic-ischaemic brain injury.
Brain Injuries
Protective effects of histone deacetylase inhibition by Scriptaid on brain injury in neonatal rat models of cerebral ischemia and hypoxia.
Brain Injuries
The potential neuroprotective role of a histone deacetylase inhibitor, sodium butyrate, after neonatal hypoxia-ischemia.
Brain Injuries
Uridine protects against hypoxic-ischemic brain injury by reducing histone deacetylase activity in neonatal rats.
Brain Injuries
[Regulatory mechanism of MS275 on the p38 MAPK signaling pathway in rats with convulsion in the developmental stage].
Brain Injuries, Traumatic
Brain proteomic changes by histone deacetylase inhibition after traumatic brain injury.
Brain Injuries, Traumatic
Corrigendum: HDAC1 Silence Promotes Neuroprotective Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Mouse Model of Traumatic Brain Injury via PI3K/AKT Pathway.
Brain Injuries, Traumatic
Development of a novel neuroprotective strategy: combined treatment with hypothermia and valproic acid improves survival in hypoxic hippocampal cells.
Brain Injuries, Traumatic
Effect of pharmacologic resuscitation on the brain gene expression profiles in a swine model of traumatic brain injury and hemorrhage.
Brain Injuries, Traumatic
HDAC1 Silence Promotes Neuroprotective Effects of Human Umbilical Cord-Derived Mesenchymal Stem Cells in a Mouse Model of Traumatic Brain Injury via PI3K/AKT Pathway.
Brain Injuries, Traumatic
Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury.
Brain Injuries, Traumatic
Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury.
Brain Injuries, Traumatic
Isoform 6-selective histone deacetylase inhibition reduces lesion size and brain swelling following traumatic brain injury and hemorrhagic shock.
Brain Injuries, Traumatic
Modulation of Brain Transcriptome By Combined Histone Deacetylase Inhibition and Plasma Treatment Following Traumatic Brain Injury and Hemorrhagic Shock.
Brain Injuries, Traumatic
Scriptaid, a novel histone deacetylase inhibitor, protects against traumatic brain injury via modulation of PTEN and AKT pathway : scriptaid protects against TBI via AKT.
Brain Injuries, Traumatic
Treatment with a histone deacetylase inhibitor, valproic acid, is associated with increased platelet activation in a large animal model of traumatic brain injury and hemorrhagic shock.
Brain Ischemia
Chromatin-Modifying Agents for Epigenetic Reprogramming and Endogenous Neural Stem Cell-Mediated Repair in Stroke.
Brain Ischemia
Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke.
Brain Ischemia
Cycloastragenol upregulates SIRT1 expression, attenuates apoptosis and suppresses neuroinflammation after brain ischemia.
Brain Ischemia
HDAC1 deregulation promotes neuronal loss and deficit of motor function in stroke pathogenesis.
Brain Ischemia
Inhibition of HDAC3 Ameliorates Cerebral Ischemia Reperfusion Injury in Diabetic Mice In Vivo and In Vitro.
Brain Ischemia
Molecular switching from ubiquitin-proteasome to autophagy pathways in mice stroke model.
Brain Ischemia
Neuronal susceptibility to beta-amyloid toxicity and ischemic injury involves histone deacetylase-2 regulation of endophilin-B1.
Brain Ischemia
Neuroprotective effects of histone deacetylase inhibitors in brain ischemia.
Brain Ischemia
Overexpressed microRNA-539-5p inhibits inflammatory response of neurons to impede the progression of cerebral ischemic injury by histone deacetylase 1.
Brain Ischemia
Protective effects of ex-527 on cerebral ischemia-reperfusion injury through necroptosis signaling pathway attenuation.
Brain Ischemia
Protective effects of histone deacetylase inhibition by Scriptaid on brain injury in neonatal rat models of cerebral ischemia and hypoxia.
Brain Ischemia
Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window.
Brain Ischemia
The HDAC inhibitor, sodium butyrate, stimulates neurogenesis in the ischemic brain.
Brain Ischemia
The role of histone deacetylase inhibitors in regulation of Akt/GSK-3? signaling pathway in mice following transient focal cerebral ischemia.
Brain Ischemia
Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition.
Brain Ischemia
Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction.
Brain Neoplasms
A phase I/II trial of the histone deacetylase inhibitor, romidepsin, for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
Brain Neoplasms
Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients.
Brain Neoplasms
Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma.
Brain Neoplasms
Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models.
Brain Neoplasms
Epigenetic regulators Rbbp4 and Hdac1 are overexpressed in a zebrafish model of RB1 embryonal brain tumor, and are required for neural progenitor survival and proliferation.
Brain Neoplasms
Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells.
Brain Neoplasms
Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential.
Brain Neoplasms
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis resistant mammary and brain cancer stem cells thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Brain Neoplasms
Identification of a Drosophila Myb-E2F2/RBF transcriptional repressor complex.
Brain Neoplasms
In silico Design of Novel Histone Deacetylase 4 Inhibitors: Design Guidelines for Improved Binding Affinity.
Brain Neoplasms
Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.
Brain Neoplasms
Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells.
Brain Neoplasms
NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells.
Brain Neoplasms
Novel histone deacetylase inhibitors for the treatment of pediatric brain tumors.
Brain Neoplasms
Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition.
Brain Neoplasms
Roles of Valproic Acid in Improving Radiation Therapy for Glioblastoma: a Review of Literature Focusing on Clinical Evidence.
Brain Neoplasms
Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics.
Brain Neoplasms
The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.
Brain Neoplasms
The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro.
Brain Neoplasms
Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
Breast Neoplasms
17?AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA?MB?231 breast cancer cells.
Breast Neoplasms
18F-Fluoroestradiol (18F-FES)-PET imaging in a Phase II trial of vorinostat to restore endocrine sensitivity in ER+/HER2- metastatic breast cancer.
Breast Neoplasms
4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway.
Breast Neoplasms
5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines.
Breast Neoplasms
?-catenin deacetylation is essential for WNT-induced proliferation of breast cancer cells.
Breast Neoplasms
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Breast Neoplasms
A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382.
Breast Neoplasms
A genomic approach to predict synergistic combinations for breast cancer treatment.
Breast Neoplasms
A Novel Combination of Withaferin A and Sulforaphane Inhibits Epigenetic Machinery, Cellular Viability and Induces Apoptosis of Breast Cancer Cells.
Breast Neoplasms
A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth.
Breast Neoplasms
A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
Breast Neoplasms
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.
Breast Neoplasms
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.
Breast Neoplasms
A role for paralog-specific sumoylation in histone deacetylase 1 stability.
Breast Neoplasms
A Translational Study of a Silicon Phthalocyanine Substituted with a Histone Deacetylase Inhibitor for Photodynamic Therapy.
Breast Neoplasms
Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients.
Breast Neoplasms
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Breast Neoplasms
Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy.
Breast Neoplasms
Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Breast Neoplasms
Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis.
Breast Neoplasms
Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer.
Breast Neoplasms
An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis.
Breast Neoplasms
An HDAC8-selective fluorescent probe for imaging in living tumor cell lines and tissue slices.
Breast Neoplasms
An intrinsically disordered region of methyl-CpG binding domain protein 2 (MBD2) recruits the histone deacetylase core of the NuRD complex.
Breast Neoplasms
Antagonistic Interaction between Histone Deacetylase Inhibitor: Cambinol and Cisplatin-An Isobolographic Analysis in Breast Cancer In Vitro Models.
Breast Neoplasms
Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells.
Breast Neoplasms
Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.
Breast Neoplasms
Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells.
Breast Neoplasms
Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.
Breast Neoplasms
Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells.
Breast Neoplasms
Antitumor effects of a novel histone deacetylase inhibitor NK-HDAC-1 on breast cancer.
Breast Neoplasms
Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer.
Breast Neoplasms
Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
Breast Neoplasms
Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells.
Breast Neoplasms
Association of HDAC8 Expression with Pathological Findings in Triple Negative and Non-Triple Negative Breast Cancer: Implications for Diagnosis.
Breast Neoplasms
ATAT1/MEC-17 acetyltransferase and HDAC6 deacetylase control a balance of acetylation of alpha-tubulin and cortactin and regulate MT1-MMP trafficking and breast tumor cell invasion.
Breast Neoplasms
Autophagy-related genes are induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid via the activation of cathepsin B in human breast cancer cells.
Breast Neoplasms
Bioimpedance rise in response to histone deacetylase inhibitor is a marker of mammary cancer cells within a mixed culture of normal breast cells.
Breast Neoplasms
Biological Effect of a Hybrid Anticancer Agent Based on Kinase and Histone Deacetylase Inhibitors on Triple-Negative (MDA-MB231) Breast Cancer Cells.
Breast Neoplasms
Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ER? coinhibition.
Breast Neoplasms
BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors.
Breast Neoplasms
Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer.
Breast Neoplasms
Breast cancer cells are arrested at different phases of the cell cycle following the re-expression of ARHI.
Breast Neoplasms
Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription.
Breast Neoplasms
Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis.
Breast Neoplasms
Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex.
Breast Neoplasms
Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90.
Breast Neoplasms
Cell cycle regulatory effects of retinoic Acid and forskolin are mediated by the cyclin C gene.
Breast Neoplasms
CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Breast Neoplasms
Chemopreventive and chemotherapeutic effect of a novel histone deacetylase inhibitor, by specificity protein 1 in MDA-MB-231 human breast cancer cells.
Breast Neoplasms
Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells.
Breast Neoplasms
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
Breast Neoplasms
Co-exposure to BPA and DEHP enhances susceptibility of mammary tumors via up-regulating Esr1/HDAC6 pathway in female rats.
Breast Neoplasms
Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study.
Breast Neoplasms
Combination of Histone Deacetylase Inhibitor with Cu(II) 5,5-diethylbarbiturate Complex Induces Apoptosis in Breast Cancer Stem Cells: A Promising Novel Approach.
Breast Neoplasms
Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Breast Neoplasms
Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer.
Breast Neoplasms
Combined treatment with SAHA, bortezomib, and clarithromycin for concomitant targeting of aggresome formation and intracellular proteolytic pathways enhances ER stress-mediated cell death in breast cancer cells.
Breast Neoplasms
Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells.
Breast Neoplasms
Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate.
Breast Neoplasms
Correction: Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer.
Breast Neoplasms
Correction: HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.
Breast Neoplasms
Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Breast Neoplasms
Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells.
Breast Neoplasms
Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class I histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer cells.
Breast Neoplasms
DBC1/CCAR2 and CCAR1 Are Largely Disordered Proteins that Have Evolved from One Common Ancestor.
Breast Neoplasms
Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer.
Breast Neoplasms
Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth.
Breast Neoplasms
Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Breast Neoplasms
Decrease in Cell Viability of Breast Cancer Cells by a Di-Hydroxylated Derivative of N-(2-hydroxyphenyl)-2-Propylpentanamide.
Breast Neoplasms
Defining the Role of Histone Deacetylases in the Inhibition of Mammary Carcinogenesis by Dietary Energy Restriction (DER): Effects of Suberoylanilide Hydroxamic Acid (SAHA) and DER in a Rat Model.
Breast Neoplasms
Design and synthesis of novel Flavone-based histone deacetylase inhibitors antagonizing activation of STAT3 in breast cancer.
Breast Neoplasms
Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
Breast Neoplasms
Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.
Breast Neoplasms
Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6.
Breast Neoplasms
Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Breast Neoplasms
Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1? synthesis, and decreases breast cancer metastasis.
Breast Neoplasms
Differential distribution of unmodified and phosphorylated histone deacetylase 2 in chromatin.
Breast Neoplasms
Differential profiles of HDAC1 substrates and associated proteins in breast cancer cells revealed by trapping.
Breast Neoplasms
Differential Regulation of Estrogen Receptor ? Expression in Breast Cancer Cells by Metastasis-Associated Protein 1.
Breast Neoplasms
Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer.
Breast Neoplasms
Downregulation of HDAC2 and HDAC3 via oleuropein as a potent prevention and therapeutic agent in MCF-7 breast cancer cells.
Breast Neoplasms
Downregulation of Hypoxia-related Responses by Novel Antitumor Histone Deacetylase Inhibitors in MDAMB231 Breast Cancer Cells.
Breast Neoplasms
Downregulation of the Ca(2+)-activated K(+) channel KC a3.1 by histone deacetylase inhibition in human breast cancer cells.
Breast Neoplasms
Downregulation of TXNIP leads to high proliferative activity and estrogen-dependent cell growth in breast cancer.
Breast Neoplasms
Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.
Breast Neoplasms
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
Breast Neoplasms
Effect of histone deacetylase inhibitor LAQ824 on antineoplastic action of 5-Aza-2'-deoxycytidine (decitabine) on human breast carcinoma cells.
Breast Neoplasms
Effect of suberoylanilide hydroxamic acid (SAHA) on breast cancer cells within a tumor-stroma microfluidic model.
Breast Neoplasms
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.
Breast Neoplasms
EFFECTS OF THE PESTICIDE CHLORPYRIFOS ON BREAST CANCER DISEASE. IMPLICATION OF EPIGENETIC MECHANISMS.
Breast Neoplasms
Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt.
Breast Neoplasms
Efficacy of the dietary histone deacetylase inhibitor butyrate alone or in combination with vitamin A against proliferation of MCF-7 human breast cancer cells.
Breast Neoplasms
EGFR-c-Src-Mediated HDAC3 Phosphorylation Exacerbates Invasion of Breast Cancer Cells.
Breast Neoplasms
Endocrine resistant breast cancer cells with loss of ER? expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.
Breast Neoplasms
Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
Breast Neoplasms
Epigenetic control of group V phospholipase A2 expression in human malignant cells.
Breast Neoplasms
Epigenetic Evaluation of N-(2-hydroxyphenyl)-2-propylpentanamide, a Valproic Acid Aryl Derivative with activity against HeLa cells.
Breast Neoplasms
Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells.
Breast Neoplasms
Epigenetic Reactivation of Estrogen Receptor: Promising Tools for Restoring Response to Endocrine Therapy.
Breast Neoplasms
Epigenetic regulation of soluble guanylate cyclase (sGC) ?1 in breast cancer cells.
Breast Neoplasms
Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
Breast Neoplasms
Epigenetic silencing of claudin-6 promotes anchorage-independent growth of breast carcinoma cells.
Breast Neoplasms
Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
Breast Neoplasms
Epigenetic silencing of SOD2 by histone modifications in human breast cancer cells.
Breast Neoplasms
Epigenetic silencing of the tumor suppressor klotho in human breast cancer.
Breast Neoplasms
Epigenetic targeting in breast cancer: therapeutic impact and future direction.
Breast Neoplasms
ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor.
Breast Neoplasms
ERas oncogene expression and epigenetic regulation by histone acetylation in human cancer cells.
Breast Neoplasms
Estrogen signaling in cancer microenvironment and prediction of response to hormonal therapy.
Breast Neoplasms
Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines.
Breast Neoplasms
Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer.
Breast Neoplasms
Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer.
Breast Neoplasms
Exploring the binding mechanism of HDAC8 selective inhibitors: Lessons from the modification of Cap group.
Breast Neoplasms
Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells.
Breast Neoplasms
Expression of HDAC1 and RBBP4 correlate with clinicopathologic characteristics and prognosis in breast cancer.
Breast Neoplasms
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast.
Breast Neoplasms
Expressional Difference of RHEB, HDAC1, and WEE1 Proteins in the Stromal Tumors of the Breast and Their Significance in Tumorigenesis.
Breast Neoplasms
Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
Breast Neoplasms
EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys
Breast Neoplasms
Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
Breast Neoplasms
FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.
Breast Neoplasms
Function of Histone deacetylase 6 as a cofactor of nuclear receptor coregulator LCoR.
Breast Neoplasms
Functional activation of the estrogen receptor-? and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
Breast Neoplasms
Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
Breast Neoplasms
Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.
Breast Neoplasms
Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4.
Breast Neoplasms
Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis.
Breast Neoplasms
Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer.
Breast Neoplasms
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms.
Breast Neoplasms
HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
Breast Neoplasms
HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL.
Breast Neoplasms
HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer.
Breast Neoplasms
HDAC Inhibitors Target HDAC5, Upregulate MicroRNA-125a-5p, and Induce Apoptosis in Breast Cancer Cells.
Breast Neoplasms
HDAC1 Expression in Invasive Ductal Carcinoma of the Breast and Its Value as a Good Prognostic Factor.
Breast Neoplasms
HDAC1 triggers the proliferation and migration of breast cancer cells via upregulation of interleukin-8.
Breast Neoplasms
HDAC1 was involved in placental breast cancer resistance protein regulation in vitro: A preliminary study.
Breast Neoplasms
HDAC2 and HDAC5 Up-Regulations Modulate Survivin and miR-125a-5p Expressions and Promote Hormone Therapy Resistance in Estrogen Receptor Positive Breast Cancer Cells.
Breast Neoplasms
HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer.
Breast Neoplasms
HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
Breast Neoplasms
HDAC3 increases HMGB3 expression to facilitate the immune escape of breast cancer cells via down-regulating microRNA-130a-3p.
Breast Neoplasms
HDAC3 selectively represses CREB3-mediated transcription and migration of metastatic breast cancer cells.
Breast Neoplasms
HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women.
Breast Neoplasms
HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4/6 inhibitor resistance in cancer.
Breast Neoplasms
HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.
Breast Neoplasms
HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
Breast Neoplasms
HDAC5-mediated deacetylation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer.
Breast Neoplasms
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.
Breast Neoplasms
HDAC6 Deacetylates HMGN2 to Regulate Stat5a Activity and Breast Cancer Growth.
Breast Neoplasms
HDAC6 differentially regulates autophagy in stem-like versus differentiated cancer cells.
Breast Neoplasms
HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation.
Breast Neoplasms
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Breast Neoplasms
HDAC6 is required for invadopodia activity and invasion by breast tumor cells.
Breast Neoplasms
HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer.
Breast Neoplasms
HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells.
Breast Neoplasms
HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration.
Breast Neoplasms
HDAC8 promotes the dissemination of breast cancer cells via AKT/GSK-3?/Snail signals.
Breast Neoplasms
HDAC9 overexpression confers invasive and angiogenic potential to triple negative breast cancer cells via modulating microRNA-206.
Breast Neoplasms
High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients.
Breast Neoplasms
Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Breast Neoplasms
Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously.
Breast Neoplasms
Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes.
Breast Neoplasms
Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Breast Neoplasms
Histone deacetylase 3 is negatively regulated by the nuclear protein deleted in breast cancer 1 (DBC1).
Breast Neoplasms
Histone deacetylase 4 mediates SMAD family member 4 deacetylation and induces 5-fluorouracil resistance in breast cancer cells.
Breast Neoplasms
Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis.
Breast Neoplasms
Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway.
Breast Neoplasms
Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals.
Breast Neoplasms
Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Breast Neoplasms
Histone deacetylase activity and vitamin D-dependent gene expressions in relation to sulforaphane in human breast cancer cells.
Breast Neoplasms
Histone deacetylase inhibition and estrogen signalling in human breast cancer cells.
Breast Neoplasms
Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1.
Breast Neoplasms
Histone deacetylase inhibitor AR-42 inhibits breast cancer cell growth and demonstrates a synergistic effect in combination with 5-FU.
Breast Neoplasms
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Breast Neoplasms
Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.
Breast Neoplasms
Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.
Breast Neoplasms
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
Breast Neoplasms
Histone deacetylase inhibitor reverses multidrug resistance by attenuating the nucleophosmin level through PI3K/Akt pathway in breast cancer.
Breast Neoplasms
Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling.
Breast Neoplasms
Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells.
Breast Neoplasms
Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca(2+) Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK.
Breast Neoplasms
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Breast Neoplasms
Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
Breast Neoplasms
Histone deacetylase inhibitor, Trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.
Breast Neoplasms
Histone deacetylase inhibitor- and PMA-induced upregulation of PMCA4b enhances Ca2+ clearance from MCF-7 breast cancer cells.
Breast Neoplasms
Histone deacetylase inhibitors alter the expression of molecular markers in breast cancer cells via microRNAs.
Breast Neoplasms
Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes.
Breast Neoplasms
Histone Deacetylase Inhibitors Enhance Cytotoxicity Towards Breast Tumors While Preserving the Wound-Healing Function of Adipose-Derived Stem Cells.
Breast Neoplasms
Histone deacetylase inhibitors enhance retinoid response in human breast cancer cell lines.
Breast Neoplasms
Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells.
Breast Neoplasms
Histone deacetylase inhibitors induce thymidine phosphorylase expression in cultured breast cancer cell lines.
Breast Neoplasms
Histone deacetylase inhibitors promote ATP2A3 gene expression in hepatocellular carcinoma cells: p300 as a transcriptional regulator.
Breast Neoplasms
Histone deacetylase inhibitors promote the expression of ATP2A3 gene in breast cancer cell lines.
Breast Neoplasms
Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties.
Breast Neoplasms
Histone deacetylase inhibitors sensitize 5-fluorouracil-resistant MDA-MB-468 breast cancer cells to 5-fluorouracil.
Breast Neoplasms
Histone Deacetylase Inhibitors Stimulate Dedifferentiation of Human Breast Cancer Cells through WNT/?-catenin Signaling.
Breast Neoplasms
Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
Breast Neoplasms
Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Breast Neoplasms
Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis.
Breast Neoplasms
Histone Deacetylase-3 Modification of MicroRNA-31 Promotes Cell Proliferation and Aerobic Glycolysis in Breast Cancer and Is Predictive of Poor Prognosis.
Breast Neoplasms
Histone post-translational modifications induced by histone deacetylase inhibition in transcriptional control units of NIS gene.
Breast Neoplasms
Hsp90 regulates HDAC3-dependent gene transcription while HDAC3 regulates the functions of Hsp90.
Breast Neoplasms
Hyaluronate synthase-2 overexpression alters estrogen dependence and induces histone deacetylase inhibitor-like effects on ER-driven genes in MCF7 breast tumor cells.
Breast Neoplasms
Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
Breast Neoplasms
ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line.
Breast Neoplasms
Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis.
Breast Neoplasms
Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells.
Breast Neoplasms
Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Breast Neoplasms
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Breast Neoplasms
Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells.
Breast Neoplasms
Increased expression of the HDAC9 gene is associated with antiestrogen resistance of breast cancers.
Breast Neoplasms
Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.
Breast Neoplasms
Induction of Apoptosis and Autophagy in Breast Cancer Cells by a Novel HDAC8 Inhibitor.
Breast Neoplasms
Induction of apoptosis by Trichostatin A in human breast cancer cell lines: involvement of 15-Lox-1.
Breast Neoplasms
Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.
Breast Neoplasms
Inhibition of HDAC3- and HDAC6-Promoted Survivin Expression Plays an Important Role in SAHA-Induced Autophagy and Viability Reduction in Breast Cancer Cells.
Breast Neoplasms
Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
Breast Neoplasms
Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells.
Breast Neoplasms
Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
Breast Neoplasms
Inhibition of phospholipase D2 augments histone deacetylase inhibitor-induced cell death in breast cancer cells.
Breast Neoplasms
Inhibition of proliferation induced by anti-sense RNA of HDAC1 in MCF-7 cells.
Breast Neoplasms
Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
Breast Neoplasms
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Breast Neoplasms
Inhibitors of histone deacetylase suppress the growth of MCF-7 breast cancer cells.
Breast Neoplasms
Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer.
Breast Neoplasms
Isolation, purification and characterization of naturally derived Crocetin beta-d-glucosyl ester from Crocus sativus L. against breast cancer and its binding chemistry with ER-alpha/HDAC2.
Breast Neoplasms
Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
Breast Neoplasms
KDELR2 promotes breast cancer proliferation via HDAC3-mediated cell cycle progression.
Breast Neoplasms
Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-?-linolenic acid peroxidation dependent mechanism.
Breast Neoplasms
Krüppel-like factor 9 down-regulates matrix metalloproteinase 9 transcription and suppresses human breast cancer invasion.
Breast Neoplasms
Lipid rafts remodeling in estrogen receptor-negative breast cancer is reversed by histone deacetylase inhibitor.
Breast Neoplasms
Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy.
Breast Neoplasms
Loss of Epigenetic Kruppel-like Factor 4 Histone Deacetylase (KLF-4-HDAC)-mediated Transcriptional Suppression Is Crucial in Increasing Vascular Endothelial Growth Factor (VEGF) Expression in Breast Cancer.
Breast Neoplasms
Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor.
Breast Neoplasms
MCF10A and MDA-MB-231 human breast basal epithelial cell co-culture in silicon micro-arrays.
Breast Neoplasms
Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.
Breast Neoplasms
Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer.
Breast Neoplasms
Methylation of C/EBP? by PRMT1 Inhibits Its Tumor-Suppressive Function in Breast Cancer.
Breast Neoplasms
Methylomics of breast cancer: Seeking epimarkers in peripheral blood of young subjects.
Breast Neoplasms
MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions.
Breast Neoplasms
MicroRNA-31 is a transcriptional target of histone deacetylase inhibitors and a regulator of cellular senescence.
Breast Neoplasms
miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis.
Breast Neoplasms
miR-200a Regulates SIRT1 Expression and Epithelial to Mesenchymal Transition (EMT)-like Transformation in Mammary Epithelial Cells.
Breast Neoplasms
MiR-216b-5p inhibits cell proliferation in human breast cancer by down-regulating HDAC8 expression.
Breast Neoplasms
MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer.
Breast Neoplasms
miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8 oncogene.
Breast Neoplasms
MiR-646 prevents proliferation and progression of human breast cancer cell lines by suppressing HDAC2 expression.
Breast Neoplasms
Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells.
Breast Neoplasms
Modulation of sensitivity to doxorubicin by the histone deacetylase inhibitor sodium butyrate in breast cancer cells.
Breast Neoplasms
Modulation of translation factor's gene expression by histone deacetylase inhibitors in breast cancer cells.
Breast Neoplasms
Molecular Signatures Associated with Treatment of Triple-Negative MDA-MB231 Breast Cancer Cells with Histone Deacetylase Inhibitors JAHA and SAHA.
Breast Neoplasms
Moscatilin Suppresses the Breast Cancer Both In Vitro and In Vivo by Inhibiting HDAC3.
Breast Neoplasms
MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
Breast Neoplasms
MTA1 interacts with MAT1, a cyclin-dependent kinase-activating kinase complex ring finger factor, and regulates estrogen receptor transactivation functions.
Breast Neoplasms
Mutant p53 binds to estrogen receptor negative promoter via DNMT1 and HDAC1 in MDA-MB-468 breast cancer cells.
Breast Neoplasms
Nanogel-mediated delivery of a cocktail of epigenetic drugs plus doxorubicin overcomes drug resistance in breast cancer cells.
Breast Neoplasms
Natural Products Extracted from Fungal Species as New Potential Anti-Cancer Drugs: A Structure-Based Drug Repurposing Approach Targeting HDAC7.
Breast Neoplasms
NEDD9 Regulates Actin Dynamics through Cortactin Deacetylation in an AURKA/HDAC6-dependent Manner.
Breast Neoplasms
Negative transcriptional control of ERBB2 gene by MBP-1 and HDAC1: diagnostic implications in breast cancer.
Breast Neoplasms
Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.
Breast Neoplasms
Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.
Breast Neoplasms
Novel HDAC6 selective inhibitors with 4-aminopiperidine-1- carboxamide as the core structure enhanced growth inhibitory activity of bortezomib in MCF-7 cells.
Breast Neoplasms
Novel histone deacetylase 8-selective inhibitor 1,3,4-oxadiazole-alanine hybrid induces apoptosis in breast cancer cells.
Breast Neoplasms
Novel hybrid conjugates with dual estrogen receptor ? degradation and histone deacetylase inhibitory activities for breast cancer therapy.
Breast Neoplasms
Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells.
Breast Neoplasms
Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females.
Breast Neoplasms
Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha.
Breast Neoplasms
Overexpression of the steroidogenic acute regulatory protein in breast cancer: Regulation by histone deacetylase inhibition.
Breast Neoplasms
Peroxisome proliferator-activated receptor alpha expression is regulated by estrogen receptor alpha and modulates the response of MCF-7 cells to sodium butyrate.
Breast Neoplasms
Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer.
Breast Neoplasms
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo.
Breast Neoplasms
Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.
Breast Neoplasms
Phthalates Stimulate the Epithelial to Mesenchymal TransitionThrough an HDAC6-Dependent Mechanism in Human BreastEpithelial Stem Cells.
Breast Neoplasms
PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.
Breast Neoplasms
PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression.
Breast Neoplasms
Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Breast Neoplasms
Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer.
Breast Neoplasms
Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Breast Neoplasms
Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis.
Breast Neoplasms
Prolactin Drives a Dynamic STAT5A/HDAC6/HMGN2 Cis-Regulatory Landscape Exploitable in ER+ Breast Cancer.
Breast Neoplasms
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
Breast Neoplasms
Proteomic Analysis of Epithelial to Mesenchymal Transition (EMT) Reveals Cross-talk between SNAIL and HDAC1 Proteins in Breast Cancer Cells.
Breast Neoplasms
Proteomic Analysis of Inflammatory Biomarkers Associated With Breast Cancer Recurrence.
Breast Neoplasms
Pubertal supplementation of lipotropes in female rats reduces mammary cancer risk by suppressing histone deacetylase 1.
Breast Neoplasms
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
Breast Neoplasms
Quantification of SAHA-Dependent Changes in Histone Modifications Using Data-Independent Acquisition Mass Spectrometry.
Breast Neoplasms
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*.
Breast Neoplasms
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.
Breast Neoplasms
Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1.
Breast Neoplasms
Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation.
Breast Neoplasms
Reciprocal modulation of histone deacetylase inhibitors sodium butyrate and trichostatin a on the energy metabolism of breast cancer cells.
Breast Neoplasms
Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.
Breast Neoplasms
Regulating BMI1 expression via miRNAs promote Mesenchymal to Epithelial Transition (MET) and sensitizes breast cancer cell to chemotherapeutic drug.
Breast Neoplasms
Regulation of estrogen receptor ?1 expression in breast cancer by epigenetic modification of the 5' regulatory region.
Breast Neoplasms
Regulation of human Cripto-1 expression by nuclear receptors and DNA promoter methylation in human embryonal and breast cancer cells.
Breast Neoplasms
Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells.
Breast Neoplasms
Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
Breast Neoplasms
Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor.
Breast Neoplasms
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
Breast Neoplasms
Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells.
Breast Neoplasms
Retraction Note: HDAC6 inhibitor TST strengthens the antiproliferative effects of PI3K/mTOR inhibitor BEZ235 in breast cancer cells via suppressing RTK activation.
Breast Neoplasms
Retraction: Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.
Breast Neoplasms
Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines.
Breast Neoplasms
Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells.
Breast Neoplasms
S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
Breast Neoplasms
Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together.
Breast Neoplasms
Shear stress stimulates integrin ?1 trafficking and increases directional migration of cancer cells via promoting deacetylation of microtubules.
Breast Neoplasms
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
Breast Neoplasms
SMAR1 repression by pluripotency factors and consequent chemoresistance in breast cancer stem-like cells is reversed by aspirin.
Breast Neoplasms
SNP rs4971059 predisposes to breast carcinogenesis and chemoresistance via TRIM46-mediated HDAC1 degradation.
Breast Neoplasms
Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer.
Breast Neoplasms
SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression.
Breast Neoplasms
Starch nanoparticles for delivery of the histone deacetylase inhibitor CG-1521 in breast cancer treatment.
Breast Neoplasms
Subcellular Localization of Maspin Correlates with Histone Deacetylase 1 Expression in Human Breast Cancer.
Breast Neoplasms
Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells.
Breast Neoplasms
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Breast Neoplasms
Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line.
Breast Neoplasms
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Breast Neoplasms
Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.
Breast Neoplasms
Sulforaphane Decrease of SERTAD1 Expression Triggers G1/S Arrest in Breast Cancer Cells.
Breast Neoplasms
Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Breast Neoplasms
Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines.
Breast Neoplasms
Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Breast Neoplasms
Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells.
Breast Neoplasms
Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.
Breast Neoplasms
Synergistic epigenetic reactivation of estrogen receptor-? (ER?) by combined green tea polyphenol and histone deacetylase inhibitor in ER?-negative breast cancer cells.
Breast Neoplasms
Synthesis and structure-activity relationships of novel hybrid ferrocenyl compounds based on a bicyclic core skeleton for breast cancer therapy.
Breast Neoplasms
Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice.
Breast Neoplasms
Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Breast Neoplasms
Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
Breast Neoplasms
Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer.
Breast Neoplasms
Targeting triple negative breast cancer with histone deacetylase inhibitors.
Breast Neoplasms
Tepoxalin increases chemotherapy efficacy in drug-resistant breast cancer cells overexpressing the multidrug transporter gene ABCB1.
Breast Neoplasms
The actin-binding protein, actinin alpha 4 (ACTN4), is a nuclear receptor coactivator that promotes proliferation of MCF-7 breast cancer cells.
Breast Neoplasms
The clinical significance of histone deacetylase-8 in human breast cancer.
Breast Neoplasms
The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy.
Breast Neoplasms
The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor ? expression.
Breast Neoplasms
The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
Breast Neoplasms
The Histone Deacetylase Inhibitor JAHA Down-Regulates pERK and Global DNA Methylation in MDA-MB231 Breast Cancer Cells.
Breast Neoplasms
The histone deacetylase inhibitor PCI-24781 impairs calcium influx and inhibits proliferation and metastasis in breast cancer.
Breast Neoplasms
The histone deacetylase inhibitor sodium butyrate induces breast cancer cell apoptosis through diverse cytotoxic actions including glutathione depletion and oxidative stress.
Breast Neoplasms
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Breast Neoplasms
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Breast Neoplasms
The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells.
Breast Neoplasms
The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
Breast Neoplasms
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
Breast Neoplasms
The hopeful anticancer role of oleuropein in breast cancer through histone deacetylase modulation.
Breast Neoplasms
The Immunohistochemical Expression and Potential Prognostic Value of HDAC6, AR in Invasive Breast Cancer.
Breast Neoplasms
The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat.
Breast Neoplasms
The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ER? expression and enhances hormonal therapy for breast cancer.
Breast Neoplasms
The promise of using histone deacetylase inhibitors in combination treatment against breast cancer and other solid tumors.
Breast Neoplasms
The role and possible molecular mechanism of valproic acid in the growth of MCF-7 breast cancer cells.
Breast Neoplasms
The role of REST and HDAC2 in epigenetic dysregulation of Nav1.5 and nNav1.5 expression in breast cancer.
Breast Neoplasms
The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42.
Breast Neoplasms
The STAT3 inhibitor Stattic acts independently of STAT3 to decrease histone acetylation and modulate gene expression.
Breast Neoplasms
The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2.
Breast Neoplasms
The Tumor Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the Beta-catenin Coactivator BCL9-2 in Breast Cancer Cells.
Breast Neoplasms
Total synthesis and stereochemical assignment of burkholdac B, a depsipeptide HDAC inhibitor.
Breast Neoplasms
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.
Breast Neoplasms
Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells.
Breast Neoplasms
Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
Breast Neoplasms
Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth.
Breast Neoplasms
Trichostatin A alleviates the process of breast carcinoma by downregulating LPAR5.
Breast Neoplasms
Trichostatin A down-regulates CYP19 transcript and protein levels in MCF-7 breast cancer cells.
Breast Neoplasms
Trichostatin A enhances acetylation as well as protein stability of ER alpha through induction of p300 protein.
Breast Neoplasms
Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo.
Breast Neoplasms
Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231.
Breast Neoplasms
Troglitazone inhibits histone deacetylase activity in breast cancer cells.
Breast Neoplasms
Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape.
Breast Neoplasms
Tyrosine phosphorylation of HDAC3 by Src kinase mediates proliferation of HER2-positive breast cancer cells.
Breast Neoplasms
Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer.
Breast Neoplasms
Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation.
Breast Neoplasms
Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells.
Breast Neoplasms
Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression.
Breast Neoplasms
Valproic acid restores ERalpha and antiestrogen sensitivity to ERalpha-negative breast cancer cells.
Breast Neoplasms
Valproic acid Suppresses Breast Cancer Cell Growth Through Triggering Pyruvate Kinase M2 Isoform Mediated Warburg Effect.
Breast Neoplasms
Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells.
Breast Neoplasms
VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin.
Breast Neoplasms
WITHDRAWN: Cross-talk between Wnt and hypoxia signaling pathways in breast cancer cells: Dual role of HDAC1 and beta-catenin.
Breast Neoplasms
ZIP restores estrogen receptor expression and response to Tamoxifen in estrogen receptor negative tumors.
Breast Neoplasms
[Biological mechanism of full-length form of spleen tyrosine kinase regulating gene transcription in breast cancer cells]
Breast Neoplasms
[Expression of melanoma-associated antigen-C2 in breast cancers and mechanism].
Breast Neoplasms
[In vitro study about the inhibitory effect of CDAII in combination with sodium butyrate on breast cancer cells.]
Breast Neoplasms
[Overexpression of histone deacetylase 11 suppresses basal-like breast cancer cell invasion and metastasis].
Breast Neoplasms
[Sodium valproate enhances doxorubicin cytotoxicity in breast cancer cells in vitro].
Bronchitis
Histone deacetylase activity and recurrent bacterial bronchitis in severe eosinophilic asthma.
Bronchopulmonary Dysplasia
Lipopolysaccharide Induces Up-Regulation of TGF-? through HDAC2 in a Rat Model of Bronchopulmonary Dysplasia.
Burkitt Lymphoma
Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
Burkitt Lymphoma
De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Burkitt Lymphoma
Dual inhibition of histone deacetylases and phosphoinositide 3-kinases: effects on Burkitt lymphoma cell growth and migration.
Burkitt Lymphoma
Effect of trichostatin A on Burkitt's lymphoma cells: Inhibition of EPS8 activity through Phospho-Erk1/2 pathway.
Burkitt Lymphoma
Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.
Burkitt Lymphoma
Epstein-Barr virus latent membrane protein-1 induction by histone deacetylase inhibitors mediates induction of intercellular adhesion molecule-1 expression and homotypic aggregation.
Burkitt Lymphoma
HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt's Lymphoma Cells by Impeding the Cell Cycle.
Burkitt Lymphoma
Histone deacetylase 6 activity is critical for the metastasis of Burkitt's lymphoma cells.
Burkitt Lymphoma
Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells.
Burkitt Lymphoma
Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
Burkitt Lymphoma
Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors.
Burkitt Lymphoma
Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Burkitt Lymphoma
Suberoylanilide hydroxamic acid (SAHA) induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Burkitt Lymphoma
The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.
Camurati-Engelmann Syndrome
The new bone biology: pathologic, molecular, and clinical correlates.
Canavan Disease
Acetate supplementation induces growth arrest of NG2/PDGFR?-positive oligodendroglioma-derived tumor-initiating cells.
Candidiasis
Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species.
Candidiasis
Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis.
Carcinogenesis
A concern regarding the current confusion with the human homolog of mouse Np95, ICBP90/UHRF1.
Carcinogenesis
A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer.
Carcinogenesis
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance.
Carcinogenesis
A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
Carcinogenesis
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.
Carcinogenesis
Allele-specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma.
Carcinogenesis
Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
Carcinogenesis
Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer.
Carcinogenesis
Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Carcinogenesis
Carcinogenic Potential of Biliary Epithelium of Congenital Choledochal Cyst Model in Rats: A Special Reference to HDAC Expression.
Carcinogenesis
CDKN1A histone acetylation and gene expression relationship in gastric adenocarcinomas.
Carcinogenesis
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Carcinogenesis
Cloning, purification, crystallization and preliminary crystallographic analysis of the human histone deacetylase sirtuin 1.
Carcinogenesis
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Carcinogenesis
Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2.
Carcinogenesis
Comparative QM/MM Molecular Dynamics and Umbrella Sampling Simulations: Interaction of the Zinc-Bound Intermediate Gem-Diolate Trapoxin A Inhibitor and Acetyl-l-lysine Substrate with Histone Deacetylase 8.
Carcinogenesis
Comprehensive Analysis of HDAC Family Identifies HDAC1 as a Prognostic and Immune Infiltration Indicator and HDAC1-Related Signature for Prognosis in Glioma.
Carcinogenesis
Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans.
Carcinogenesis
Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Carcinogenesis
Curcumin augments the efficacy of antitumor drugs used in leukemia by modulation of heat shock proteins via HDAC6.
Carcinogenesis
Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma.
Carcinogenesis
Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.
Carcinogenesis
Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
Carcinogenesis
Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis.
Carcinogenesis
Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis.
Carcinogenesis
Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest.
Carcinogenesis
Downregulation of a tumor suppressor RECK by hypoxia through recruitment of HDAC1 and HIF-1alpha to reverse HRE site in the promoter.
Carcinogenesis
Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1.
Carcinogenesis
Dual SIRT1 expression patterns strongly suggests its bivalent role in human breast cancer.
Carcinogenesis
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Carcinogenesis
Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II.
Carcinogenesis
Enterocyte-specific inactivation of SIRT1 reduces tumor load in the APC(+/min) mouse model.
Carcinogenesis
Epigenetic actions of environmental factors and promising drugs for cancer therapy.
Carcinogenesis
Epigenetic regulation of p62/SQSTM1 overcomes the radioresistance of head and neck cancer cells via autophagy-dependent senescence induction.
Carcinogenesis
Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: Prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Carcinogenesis
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast.
Carcinogenesis
Expressional Difference of RHEB, HDAC1, and WEE1 Proteins in the Stromal Tumors of the Breast and Their Significance in Tumorigenesis.
Carcinogenesis
FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities.
Carcinogenesis
Functional analysis of a histone deacetylase-like protein of Thermus caldophilus GK24 in mammalian cell.
Carcinogenesis
G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis.
Carcinogenesis
Gene expression mapping of histone deacetylases and co-factors, and correlation with survival time and 1H-HRMAS metabolomic profile in human gliomas.
Carcinogenesis
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.
Carcinogenesis
HDAC10 expression is associated with DNA mismatch repair gene and is a predictor of good prognosis in colon carcinoma.
Carcinogenesis
HDAC11 promotes meiotic apparatus assembly during mouse oocyte maturation via decreasing H4K16 and ?-tubulin acetylation.
Carcinogenesis
HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2.
Carcinogenesis
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
Carcinogenesis
HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape.
Carcinogenesis
HDAC2 enhances esophageal squamous cell carcinoma development through down-regulating microRNA-503-5p and promoting CXCL10.
Carcinogenesis
HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins.
Carcinogenesis
HDAC2 promotes cell migration/invasion abilities through HIF-1? stabilization in human oral squamous cell carcinoma.
Carcinogenesis
HDAC3 is linked to cell cycle machinery in MiaPaCa2 cells by regulating transcription of skp2.
Carcinogenesis
HDAC3-dependent transcriptional repression of FOXA2 regulates FTO/m6A/MYC signaling to contribute to the development of gastric cancer.
Carcinogenesis
HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition.
Carcinogenesis
HDAC5 promotes osteosarcoma progression by upregulation of Twist 1 expression.
Carcinogenesis
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Carcinogenesis
HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-mediated Anti-tumorigenesis and Phagocytosis of Hepatocellular Carcinoma.
Carcinogenesis
HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer.
Carcinogenesis
HDAC6: Physiological function and its selective inhibitors for cancer treatment.
Carcinogenesis
HDAC8 drives spindle organization during meiotic maturation of porcine oocytes.
Carcinogenesis
High expression of SNIP1 correlates with poor prognosis in Non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro.
Carcinogenesis
Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer.
Carcinogenesis
Histone deacetylase 1 facilitates aerobic glycolysis and growth of endometrial cancer.
Carcinogenesis
Histone deacetylase 1 phosphorylation at S421 and S423 is constitutive in vivo, but dispensable in vitro.
Carcinogenesis
Histone deacetylase 1 plays a predominant pro-oncogenic role in E?-myc driven B cell lymphoma.
Carcinogenesis
Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis.
Carcinogenesis
Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration.
Carcinogenesis
Histone deacetylase 3 represses p15(INK4b) and p21(WAF1/cip1) transcription by interacting with Sp1.
Carcinogenesis
Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc.
Carcinogenesis
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Carcinogenesis
Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation.
Carcinogenesis
Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Carcinogenesis
Histone deacetylase HDAC4 promotes the proliferation and invasion of glioma cells.
Carcinogenesis
Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents.
Carcinogenesis
Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-? on pancreatic cancer cells.
Carcinogenesis
Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: A special reference to gene-expression microarray analysis.
Carcinogenesis
Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma.
Carcinogenesis
Histone deacetylase inhibitors reduce WB-F344 oval cell viability and migration capability by suppressing AKT/mTOR signaling in vitro.
Carcinogenesis
Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Against Medullary Thyroid Cancer?
Carcinogenesis
Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Carcinogenesis
Histonedeacetylase 1 mRNA has elevated expression in clinical specimen of bladder cancer.
Carcinogenesis
Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis.
Carcinogenesis
Identification of histone deacetylase 1 protein complexes in liver cancer cells.
Carcinogenesis
Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies.
Carcinogenesis
Impact of histone deacetylase 1 and metastasis-associated gene 1 expression in esophageal carcinogenesis.
Carcinogenesis
In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line
Carcinogenesis
Increased expression of histone deacetylase 2 is found in human gastric cancer.
Carcinogenesis
Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.
Carcinogenesis
Induction of a novel histone deacetylase 1/c-Myc/Mnt/Max complex formation is implicated in parity-induced refractoriness to mammary carcinogenesis.
Carcinogenesis
Influence of miRNA-106b and miRNA-135a on butyrate-regulated expression of p21 and Cyclin D2 in human colon adenoma cells.
Carcinogenesis
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.
Carcinogenesis
Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.
Carcinogenesis
Inhibition of proliferation induced by anti-sense RNA of HDAC1 in MCF-7 cells.
Carcinogenesis
Insights Into the Function and Clinical Application of HDAC5 in Cancer Management.
Carcinogenesis
Integrated analysis of lncRNA and mRNA repertoires in Marek's disease infected spleens identifies genes relevant to resistance.
Carcinogenesis
Investigation of sirtuin 1 polymorphisms in relation to the risk of colorectal cancer by molecular subtype.
Carcinogenesis
Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?
Carcinogenesis
Isoflurane promotes proliferation of squamous cervical cancer cells through mTOR-histone deacetylase 6 pathway.
Carcinogenesis
Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in p53+/- and p53+/+ mice.
Carcinogenesis
Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma.
Carcinogenesis
Mammalian histone deacetylase 1 protein is posttranslationally modified by phosphorylation.
Carcinogenesis
microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity.
Carcinogenesis
MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer.
Carcinogenesis
MicroRNA-383-5p inhibits the progression of gastric carcinoma via targeting HDAC9 expression.
Carcinogenesis
miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis.
Carcinogenesis
MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer.
Carcinogenesis
miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer.
Carcinogenesis
miR-665 targets c-MYC and HDAC8 to inhibit murine neuroblastoma cell growth.
Carcinogenesis
Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells.
Carcinogenesis
Molecular/Genetic therapies in ovarian cancer: future opportunities and challenges.
Carcinogenesis
Never in mitosis gene A-related kinase 6 and aurora kinase A: New gene biomarkers in the conversion from ulcerative colitis to colorectal cancer.
Carcinogenesis
Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma.
Carcinogenesis
Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis.
Carcinogenesis
PAICS contributes to gastric carcinogenesis and participates in DNA damage response by interacting with histone deacetylase 1/2.
Carcinogenesis
Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90.
Carcinogenesis
Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Carcinogenesis
Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer.
Carcinogenesis
Preclinical and clinical studies of chidamide (CS055/HBI-8000), an orally available subtype-selective HDAC inhibitor for cancer therapy.
Carcinogenesis
Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer.
Carcinogenesis
Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer.
Carcinogenesis
Psammaplin A is a natural prodrug that inhibits class I histone deacetylase.
Carcinogenesis
PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors.
Carcinogenesis
Regulation of proliferation, apoptosis and cell cycle in gastrointestinal disorders.
Carcinogenesis
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression.
Carcinogenesis
Selective inhibition of bicyclic tetrapeptide histone deacetylase inhibitor on HDAC4 and K562 leukemia cell.
Carcinogenesis
SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer.
Carcinogenesis
Sirtuin 1 promotes autophagy and proliferation of endometrial cancer cells by reducing acetylation level of LC3.
Carcinogenesis
SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma.
Carcinogenesis
SNP rs4971059 predisposes to breast carcinogenesis and chemoresistance via TRIM46-mediated HDAC1 degradation.
Carcinogenesis
Sodium Phenylbutyrate Inhibits Tumor Growth and the Epithelial-Mesenchymal Transition of Oral Squamous Cell Carcinoma In Vitro and In Vivo.
Carcinogenesis
Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study.
Carcinogenesis
Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apcmin mice.
Carcinogenesis
Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells.
Carcinogenesis
Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms.
Carcinogenesis
Targeting Histone deacetylase 4/Ubc9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells.
Carcinogenesis
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Carcinogenesis
TDP-43/HDAC6 axis promoted tumor progression and regulated nutrient deprivation-induced autophagy in glioblastoma.
Carcinogenesis
The chemopreventive activity of the histone deacetylase inhibitor tributyrin in colon carcinogenesis involves the induction of apoptosis and reduction of DNA damage.
Carcinogenesis
The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.
Carcinogenesis
The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.
Carcinogenesis
The enzyme activity of histone deacetylase 8 is modulated by a redox-switch.
Carcinogenesis
The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma.
Carcinogenesis
The Proteomic Profile of Deleted in Breast Cancer 1 (DBC1) Interactions Points to a Multifaceted Regulation of Gene Expression.
Carcinogenesis
The role of butyrate in surgical and oncological outcomes in colorectal cancer.
Carcinogenesis
The Role of SIRT1 on DNA Damage Response and Epigenetic Alterations in Cancer.
Carcinogenesis
The Up-Regulation of Histone Deacetylase 8 Promotes Proliferation and Inhibits Apoptosis in Hepatocellular Carcinoma.
Carcinogenesis
Time-Dependent Effects of POT1 Knockdown on Proliferation, Tumorigenicity, and HDACi Response of SK-OV3 Ovarian Cancer Cells.
Carcinogenesis
Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects.
Carcinogenesis
Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression.
Carcinogenesis
UHRF1 expression is upregulated and associated with cellular proliferation in colorectal cancer.
Carcinogenesis
Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells.
Carcinoid Tumor
Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors.
Carcinoid Tumor
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
Carcinoid Tumor
Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors.
Carcinoid Tumor
Suberoyl bishydroxamic Acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells.
Carcinoma
18?-Glycyrrhetinic acid potentiates apoptotic effect of trichostatin A on human epithelial ovarian carcinoma cell lines.
Carcinoma
4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells.
Carcinoma
?Np63? promotes the expression and nuclear translocation of PTEN, leading to cisplatin resistance in oral cancer cells.
Carcinoma
A correlation analysis between HDAC1 over-expression and clinical features of laryngeal squamous cell carcinoma.
Carcinoma
A histone deacetylase inhibitor, trichostatin a, enhances radiosensitivity by abrogating g2/m arrest in human carcinoma cells.
Carcinoma
A novel long noncoding RNA, LOC440173, promotes the progression of esophageal squamous cell carcinoma by modulating the miR-30d-5p/HDAC9 axis and the epithelial-mesenchymal transition.
Carcinoma
A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Carcinoma
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.
Carcinoma
A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.
Carcinoma
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Carcinoma
Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Carcinoma
Activation of PAR4 Upregulates p16 through Inhibition of DNMT1 and HDAC2 Expression via MAPK Signals in Esophageal Squamous Cell Carcinoma Cells.
Carcinoma
Activation of the gamma-glutamyltransferase promoter 2 in the rat colon carcinoma cell line CC531 by histone deacetylase inhibitors is mediated through the Sp1 binding motif.
Carcinoma
Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.
Carcinoma
Allele-specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma.
Carcinoma
Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.
Carcinoma
Anti-tumor activity of histone deacetylase inhibitors and the effect on ATP-binding cassette in ovarian carcinoma cells.
Carcinoma
Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells.
Carcinoma
Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
Carcinoma
Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma.
Carcinoma
Apoptosis of U937 human leukemic cells by sodium butyrate is associated with inhibition of telomerase activity.
Carcinoma
Augmentation of Sodium Butyrate-induced Apoptosis by Phosphatidylinositol 3-kinase Inhibition in the Human Cervical Cancer Cell-line.
Carcinoma
BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Carcinoma
Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells.
Carcinoma
Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.
Carcinoma
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Carcinoma
Carnitine palmitoyltransferase I in human carcinomas: a novel role in histone deacetylation?
Carcinoma
CBX4 transcriptionally suppresses KLF6 via interaction with HDAC1 to exert oncogenic activities in clear cell renal cell carcinoma.
Carcinoma
Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids.
Carcinoma
Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter.
Carcinoma
Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.
Carcinoma
Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Carcinoma
Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein.
Carcinoma
Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma.
Carcinoma
Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
Carcinoma
Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma.
Carcinoma
Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer.
Carcinoma
Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy.
Carcinoma
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Carcinoma
Combination Treatment of Renal Cell Carcinoma with Belinostat and 5-Fluorouracil: A Role for Oxidative Stress Induced DNA Damage and HSP90 Regulated Thymidine Synthase.
Carcinoma
Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2.
Carcinoma
Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.
Carcinoma
Combined therapy of colon carcinomas with an oncolytic adenovirus and valproic acid.
Carcinoma
Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Carcinoma
Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma.
Carcinoma
Conjugate of Pt (IV)-Histone Deacetylase Inhibitor as Prodrug for Cancer Chemotherapy.
Carcinoma
Cooperation of histone deacetylase inhibitors SAHA and valproic acid in promoting sodium/iodide symporter expression and function in rat Leydig testicular carcinoma cells.
Carcinoma
Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
Carcinoma
Correction to: Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Carcinoma
Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis.
Carcinoma
Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
Carcinoma
Decreased expression and hypomethylation of HDAC9 lead to poor prognosis and inhibit immune cell infiltration in clear cell renal cell carcinoma.
Carcinoma
Differential protein acetylation induced by novel histone deacetylase inhibitors.
Carcinoma
Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
Carcinoma
Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor.
Carcinoma
Downregulation of HDAC3 by ginsenoside Rg3 inhibits epithelial-mesenchymal transition of cutaneous squamous cell carcinoma through c-Jun acetylation.
Carcinoma
Downregulation of miR-377 Promotes Oral Squamous Cell Carcinoma Growth and Migration by Targeting HDAC9.
Carcinoma
Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.
Carcinoma
Effect of DNA Methyltransferase in Comparison to and
in Combination with Histone Deacetylase Inhibitors on
Hepatocellular Carcinoma HepG2 Cell Line
Carcinoma
Effect of ginsenoside Rh2 on the migratory ability of HepG2 liver carcinoma cells: recruiting histone deacetylase and inhibiting activator protein 1 transcription factors.
Carcinoma
Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.
Carcinoma
Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin.
Carcinoma
Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines.
Carcinoma
Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines.
Carcinoma
Effective and new potent drug combination: Histone deacetylase and Wnt/?-catenin pathway inhibitors in lung carcinoma cells.
Carcinoma
Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma.
Carcinoma
Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.
Carcinoma
Effects of Down-regulation of HDAC6 Expression on Proliferation, Cell Cycling and Migration of Esophageal Squamous Cell Carcinoma Cells and Related Molecular Mechanisms.
Carcinoma
Effects of siRNA-Mediated Knockdown of HDAC1 on the Biological Behavior of Esophageal Carcinoma Cell Lines.
Carcinoma
Effects of suberoylanilide hydroxamic acid and trichostatin A on induction of cytochrome P450 enzymes and benzo[a]pyrene DNA adduct formation in human cells.
Carcinoma
Effects of the histone deacetylase inhibitor trichostatin A on nuclear texture and c-jun gene expression in drug-sensitive and drug-resistant human H69 lung carcinoma cells.
Carcinoma
Effects of trichostatin A on HIF-1? and VEGF expression in human tongue squamous cell carcinoma cells in vitro.
Carcinoma
Efficacy and safety of HDACIs in the treatment of metastatic or unresectable renal cell carcinoma with a clear cell phenotype: A systematic review and meta-analysis.
Carcinoma
Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression.
Carcinoma
Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
Carcinoma
Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
Carcinoma
Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Carcinoma
Epigenetic control of HNF-4? in colon carcinoma cells affects MUC4 expression and malignancy.
Carcinoma
Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
Carcinoma
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.
Carcinoma
Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma.
Carcinoma
Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma.
Carcinoma
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.
Carcinoma
Expression of hMOF, but not HDAC4, is responsible for the global histone H4K16 acetylation in gastric carcinoma.
Carcinoma
Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation.
Carcinoma
Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma.
Carcinoma
Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines.
Carcinoma
Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and Carcinoma.
Carcinoma
Growth arrest of HPV-positive cells after histone deacetylase inhibition is independent of E6/E7 oncogene expression.
Carcinoma
Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells.
Carcinoma
HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression.
Carcinoma
HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9.
Carcinoma
HDAC Inhibitors Synergize Antiproliferative Effect of Sorafenib in Renal Cell Carcinoma Cells.
Carcinoma
HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.
Carcinoma
HDAC1 regulates the chemosensitivity of laryngeal carcinoma cells via modulation of interleukin-8 expression.
Carcinoma
HDAC2 enhances esophageal squamous cell carcinoma development through down-regulating microRNA-503-5p and promoting CXCL10.
Carcinoma
HDAC2 promotes cell migration/invasion abilities through HIF-1? stabilization in human oral squamous cell carcinoma.
Carcinoma
HDAC2 promotes the EMT of colorectal cancer cells and via the modular scaffold function of ENSG00000274093.1.
Carcinoma
HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells.
Carcinoma
HDAC3 positively regulates HE4 expression to promote ovarian carcinoma progression.
Carcinoma
HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition.
Carcinoma
HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma.
Carcinoma
HDAC6 siRNA inhibits proliferation and induces apoptosis of HeLa cells and its related molecular mechanism.
Carcinoma
HDACs and HDAC inhibitors in urothelial carcinoma - perspectives for an antineoplastic treatment.
Carcinoma
Histone Deacetylase (HDAC) 1 and 2 Expression and Chemotherapy in Gastric Cancer.
Carcinoma
Histone deacetylase 1 regulates the malignancy of oral cancer cells via miR-154-5p/PCNA axis.
Carcinoma
Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line.
Carcinoma
Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of ?-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma.
Carcinoma
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.
Carcinoma
Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK-MMP-laminin5?2 signaling pathway.
Carcinoma
Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma.
Carcinoma
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis.
Carcinoma
Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma.
Carcinoma
Histone deacetylase inhibition reveals a tumor-suppressive function of MYC-regulated miRNA in breast and lung carcinoma.
Carcinoma
Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma.
Carcinoma
Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells.
Carcinoma
Histone deacetylase inhibitor OBP?801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1?dependent apoptosis.
Carcinoma
Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo.
Carcinoma
Histone deacetylase inhibitor trichostatin A resensitizes gemcitabine resistant urothelial carcinoma cells via suppression of TG-interacting factor.
Carcinoma
Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
Carcinoma
Histone deacetylase inhibitor-induced sensitization to TNFalpha/TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression.
Carcinoma
Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells.
Carcinoma
Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.
Carcinoma
Histone Deacetylase Inhibitors and Microtubule Inhibitors Induce Apoptosis in Feline Luminal Mammary Carcinoma Cells.
Carcinoma
Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation.
Carcinoma
Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.
Carcinoma
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.
Carcinoma
Histone Deacetylase Inhibitors Modulate Renal Cell Carcinoma Sensitivity to TRAIL/Apo-2L-induced Apoptosis by Enhancing TRAIL-R2 Expression.
Carcinoma
Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells.
Carcinoma
Histone deacetylase inhibitors stimulate mitochondrial HMG-CoA synthase gene expression via a promoter proximal Sp1 site.
Carcinoma
Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis.
Carcinoma
Histone deacetylase inhibitors synergizes with catalytic inhibitors of EZH2 to exhibit anti-tumor activity in small cell carcinoma of the ovary, hypercalcemic type.
Carcinoma
Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo.
Carcinoma
Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.
Carcinoma
Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma.
Carcinoma
Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma.
Carcinoma
Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis.
Carcinoma
Identification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays.
Carcinoma
Immunoexpression of HDAC1, HDAC2, and HAT1 in actinic cheilitis and lip squamous cell carcinoma.
Carcinoma
Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients.
Carcinoma
Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells.
Carcinoma
Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages.
Carcinoma
Inactivation of BRM/SMARCA2 sensitizes clear cell renal cell carcinoma to histone deacetylase complex inhibitors.
Carcinoma
Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells.
Carcinoma
Induction of colon and cervical cancer cell death by cinnamic acid derivatives is mediated through the inhibition of Histone Deacetylases (HDAC).
Carcinoma
Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
Carcinoma
Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy.
Carcinoma
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.
Carcinoma
Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon.
Carcinoma
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Carcinoma
Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression.
Carcinoma
Investigation into the use of histone deacetylase inhibitor MS-275 as a topical agent for the prevention and treatment of cutaneous squamous cell carcinoma in an SKH-1 hairless mouse model.
Carcinoma
Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues.
Carcinoma
L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation.
Carcinoma
Lentivirus-mediated Knockdown of HDAC1 Uncovers Its Role in Esophageal Cancer Metastasis and Chemosensitivity.
Carcinoma
LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition.
Carcinoma
Maspin is a PTEN-Upregulated and p53-Upregulated Tumor Suppressor Gene and Acts as an HDAC1 Inhibitor in Human Bladder Cancer.
Carcinoma
Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells.
Carcinoma
Melittin restores PTEN expression by down-regulating HDAC2 in human hepatocelluar carcinoma HepG2 cells.
Carcinoma
MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
Carcinoma
MicroRNA-383-5p inhibits the progression of gastric carcinoma via targeting HDAC9 expression.
Carcinoma
MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells.
Carcinoma
MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
Carcinoma
miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6.
Carcinoma
MiR-601 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma (ESCC) by targeting HDAC6.
Carcinoma
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Carcinoma
Modulation of growth and differentiation of human colon carcinoma cells by histone deacetylase inhibitory trichostatins.
Carcinoma
Molecular mechanisms underlying eicosapentaenoic acid inhibition of HDAC1 and DNMT expression and activity in carcinoma cells.
Carcinoma
MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
Carcinoma
New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma.
Carcinoma
New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas.
Carcinoma
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts.
Carcinoma
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Carcinoma
Oncogenic IL7R is downregulated by histone deacetylase inhibitor in esophageal squamous cell carcinoma via modulation of acetylated FOXO1.
Carcinoma
Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer.
Carcinoma
Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance.
Carcinoma
Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma.
Carcinoma
Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis.
Carcinoma
Overexpression of Histone Deacetylase 2 Predicts Unfavorable Prognosis in Human Gallbladder Carcinoma.
Carcinoma
Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
Carcinoma
Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma.
Carcinoma
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
Carcinoma
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Carcinoma
Phenylbutyrate inhibits growth of cervical carcinoma cells independent of HPV type and copy number.
Carcinoma
Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.
Carcinoma
Plant polyphenols and oxidative metabolites of the herbal alkenylbenzene methyleugenol suppress histone deacetylase activity in human colon carcinoma cells.
Carcinoma
Positive and negative regulation of podoplanin expression by TGF-? and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines.
Carcinoma
Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro.
Carcinoma
Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma.
Carcinoma
Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
Carcinoma
Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters.
Carcinoma
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
Carcinoma
Quantitative phosphoproteomic analysis reveals ?-bisabolene inducing p53-mediated apoptosis of human oral squamous cell carcinoma via HDAC2 inhibition and ERK1/2 activation.
Carcinoma
R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.
Carcinoma
Rapid detection of apoptosis through real-time reverse transcriptase polymerase chain reaction measurement of the small cytoplasmic RNA Y1.
Carcinoma
Regulation of the human O(6)-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300.
Carcinoma
Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.
Carcinoma
Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor.
Carcinoma
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Carcinoma
Retracted: Potentiation of Mitomycin C Tumoricidal Activity for Transitional Cell Carcinoma by Histone Deacetylase Inhibitors In Vitro.
Carcinoma
Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.
Carcinoma
Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: Enhanced DNA damage response.
Carcinoma
Sensitization to UV-induced apoptosis by the histone deacetylase inhibitor trichostatin A (TSA).
Carcinoma
Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells.
Carcinoma
Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer.
Carcinoma
Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90.
Carcinoma
SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma.
Carcinoma
Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer.
Carcinoma
Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells.
Carcinoma
Sodium Butyrate, a Histone Deacetylase Inhibitor, Regulates Lymphangiogenic Factors in Oral Cancer Cell Line HSC-3.
Carcinoma
SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
Carcinoma
Stat3 inhibits PTPN13 expression in squamous cell lung carcinoma through recruitment of HDAC5.
Carcinoma
Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Carcinoma
Suberoylanilide hydroxamic acid (SAHA) induces viral lytic cycle in Epstein-Barr virus-positive epithelial malignancies and mediates enhanced cell death.
Carcinoma
Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells.
Carcinoma
Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
Carcinoma
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Carcinoma
Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
Carcinoma
Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor.
Carcinoma
Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Carcinoma
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Carcinoma
Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.
Carcinoma
Tambulin Targets Histone Deacetylase 1 Inhibiting Cell Growth and Inducing Apoptosis in Human Lung Squamous Cell Carcinoma.
Carcinoma
The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma.
Carcinoma
The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis.
Carcinoma
The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines.
Carcinoma
The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Carcinoma
The histone deacetylase inhibitor SAHA induces HSP60 nitration and its extracellular release by exosomal vesicles in human lung-derived carcinoma cells.
Carcinoma
The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
Carcinoma
THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID ALTERS GROWTH PROPERTIES OF RENAL CELL CARCINOMA IN VITRO AND IN VIVO.
Carcinoma
The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Carcinoma
The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice.
Carcinoma
Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines.
Carcinoma
Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Carcinoma
Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma.
Carcinoma
Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape.
Carcinoma
Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Carcinoma
Ubiquitin specific peptidase 5 promotes ovarian cancer cell proliferation through deubiquitinating HDAC2.
Carcinoma
UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.
Carcinoma
Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma.
Carcinoma
Upregulated histone deacetylase 2 gene correlates with the progression of oral squamous cell carcinoma.
Carcinoma
Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.
Carcinoma
Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines.
Carcinoma
Valproic acid inhibits irradiation-induced epithelial-mesenchymal transition and stem cell-like characteristics in esophageal squamous cell carcinoma.
Carcinoma
Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance.
Carcinoma
Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
Carcinoma
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
Carcinoma
[Down-regulation of histone deacetylase 2 induces cell apoptosis and inhibits cell proliferation and migration of laryngeal squamous cell carcinoma cells].
Carcinoma
[Effect of down-regulation of histone deacetylase 2 protein expression on cell proliferation and cell cycle in cervical carcinoma].
Carcinoma
[Effect of HDAC6 down-regulation on the growth of xenografted human laryngeal carcinoma cell line Hep-2 in nude mice and underlying mechanism].
Carcinoma
[Effects of downregulation of HDAC6 expression on cell cycle, proliferation and migration of laryngeal squamous cell carcinoma].
Carcinoma
[Enhancive effect of histone deacetylase inhibitor trichostatin a on transfection efficiency of adenovirus in ovarian carcinoma cell line A2780]
Carcinoma
[Multikinase inhibitor sorafenib and HDAC inhibitor suberoylanilide hydroxamic acid suppress confluent resistance of cancer cells to recombinant protein izTRAIL].
Carcinoma
[Role of histone deacetylase in inhibiting invasion of human gastric carcinoma cell line SGC-7901 by PPARgamma-mediated pathway.]
Carcinoma, Basal Cell
Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.
Carcinoma, Ductal
Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients.
Carcinoma, Ductal
Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast.
Carcinoma, Ductal
HDAC1 Expression in Invasive Ductal Carcinoma of the Breast and Its Value as a Good Prognostic Factor.
Carcinoma, Ductal
Histone Deacetylase 7 Gene Overexpression Is Associated with Poor Prognosis of Triple-Negative Breast Cancer Patients.
Carcinoma, Ductal
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
Carcinoma, Ductal
Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy.
Carcinoma, Ductal
The expression patterns and correlations of claudin-6, methy-CpG binding protein 2, DNA methyltransferase 1, histone deacetylase 1, acetyl-histone H3 and acetyl-histone H4 and their clinicopathological significance in breast invasive ductal carcinomas.
Carcinoma, Ductal
The Impact of Androgen Receptor and Histone Deacetylase 1 Expression on the Prognosis of Ductal Carcinoma In Situ.
Carcinoma, Embryonal
A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells.
Carcinoma, Embryonal
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer.
Carcinoma, Embryonal
Molecular profiling of embryonal carcinoma cells following retinoic acid or histone deacetylase inhibitor treatment.
Carcinoma, Hepatocellular
1,25(OH)2D3 inhibits the progression of hepatocellular carcinoma via downregulating HDAC2 and upregulating P21(WAFI/CIP1).
Carcinoma, Hepatocellular
2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression.
Carcinoma, Hepatocellular
A novel treatment strategy in hepatocellular carcinoma by down-regulation of histone deacetylase 1 expression using a shRNA lentiviral system.
Carcinoma, Hepatocellular
A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Aberrant histone deacetylase 1 expression upregulates vimentin expression via an NF-?B-dependent pathway in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins.
Carcinoma, Hepatocellular
Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells.
Carcinoma, Hepatocellular
Activation of the intrinsic apoptosis pathway contributes to the induction of apoptosis in hepatocellular carcinoma cells by valproic acid.
Carcinoma, Hepatocellular
Andrographolide reduced VEGFA expression in hepatoma cancer cells by inactivating HIF-1?: The involvement of JNK and MTA1/HDCA.
Carcinoma, Hepatocellular
Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma.
Carcinoma, Hepatocellular
Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2.
Carcinoma, Hepatocellular
Antitumoral efficacy of four histone deacetylase inhibitors in hepatoma in vitro and in vivo.
Carcinoma, Hepatocellular
Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357.
Carcinoma, Hepatocellular
AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition.
Carcinoma, Hepatocellular
Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.
Carcinoma, Hepatocellular
BAY 87-2243 sensitizes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK-3? activation.
Carcinoma, Hepatocellular
Black tea polyphenols target matrix metalloproteinases, RECK, proangiogenic molecules and histone deacetylase in a rat hepatocarcinogenesis model.
Carcinoma, Hepatocellular
C/EBP? negatively regulates SIRT7 expression via recruiting HDAC3 to the upstream-promoter of hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
cDNA microarray analysis in hepatocyte differentiation in Huh 7 cells.
Carcinoma, Hepatocellular
Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells.
Carcinoma, Hepatocellular
Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy.
Carcinoma, Hepatocellular
Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma.
Carcinoma, Hepatocellular
Correction: Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance.
Carcinoma, Hepatocellular
Cytokeratin 18-associated Histone 3 Modulation in Hepatocellular Carcinoma: A Mini Review.
Carcinoma, Hepatocellular
Destabilization of Fatty Acid Synthase by Acetylation Inhibits De Novo Lipogenesis and Tumor Cell Growth.
Carcinoma, Hepatocellular
Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics.
Carcinoma, Hepatocellular
Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest.
Carcinoma, Hepatocellular
Downregulation of AZGP1 by Ikaros and histone deacetylase promotes tumor progression through the PTEN/Akt and CD44s pathways in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Downregulation of HDAC6 promotes angiogenesis in hepatocellular carcinoma cells and predicts poor prognosis in liver transplantation patients.
Carcinoma, Hepatocellular
Downregulation of matrix metalloproteinases contributes to the inhibition of cell migration and invasion in HepG2 cells by sodium valproate.
Carcinoma, Hepatocellular
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
Carcinoma, Hepatocellular
Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP.
Carcinoma, Hepatocellular
Effect of Decitabine (5-aza-2'-deoxycytidine, 5-aza-CdR) in Comparison with Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) on DNMT1, DNMT3a and DNMT3b, HDAC 1-3, SOCS 1, SOCS 3, JAK2, and STAT3 Gene Expression in Hepatocellular Carcinoma HLE and LCL-PI 11 Cell Lines.
Carcinoma, Hepatocellular
Effect of DNA Methyltransferase in Comparison to and
in Combination with Histone Deacetylase Inhibitors on
Hepatocellular Carcinoma HepG2 Cell Line
Carcinoma, Hepatocellular
Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Cell Viability, and Apoptosis Induction in Hepatocellular Carcinoma HepG2 Cell Line.
Carcinoma, Hepatocellular
Effects of cell density and trichostatin A on the expression of HDAC1 and p57Kip2 in Hep 3B cells.
Carcinoma, Hepatocellular
Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.
Carcinoma, Hepatocellular
Enrichment of Nur77 mediated by retinoic acid receptor ? leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors.
Carcinoma, Hepatocellular
Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Erratum: LukS-PV Inhibits Hepatocellular Carcinoma Progression by Downregulating HDAC2 Expression.
Carcinoma, Hepatocellular
Expression of HDAC4 in Stage B Hepatocellular Carcinoma and Its Influence on Survival.
Carcinoma, Hepatocellular
Expression of microRNA-195 is transactivated by Sp1 but inhibited by histone deacetylase 3 in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma.
Carcinoma, Hepatocellular
HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population.
Carcinoma, Hepatocellular
HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer.
Carcinoma, Hepatocellular
HDAC2 Provides a Critical Support to Malignant Progression of Hepatocellular Carcinoma through Feedback Control of mTORC1 and AKT.
Carcinoma, Hepatocellular
Hdac3 is essential for the maintenance of chromatin structure and genome stability.
Carcinoma, Hepatocellular
HDAC5 promotes cell proliferation in human hepatocellular carcinoma by up-regulating Six1 expression.
Carcinoma, Hepatocellular
HDAC6 functions as a tumor suppressor by activating JNK-mediated beclin 1-dependent autophagic cell death in liver cancer.
Carcinoma, Hepatocellular
HDAC6 promotes hepatocellular carcinoma progression by inhibiting P53 transcriptional activity.
Carcinoma, Hepatocellular
HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-mediated Anti-tumorigenesis and Phagocytosis of Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
HDAC9 Is Preferentially Expressed in Dedifferentiated Hepatocellular Carcinoma Cells and Is Involved in an Anchorage-Independent Growth.
Carcinoma, Hepatocellular
Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4.
Carcinoma, Hepatocellular
Highly expressed histone deacetylase 5 promotes the growth of hepatocellular carcinoma cells by inhibiting the TAp63-maspin pathway.
Carcinoma, Hepatocellular
Histone deacetylase 1 is required for transforming growth factor-beta1-induced epithelial-mesenchymal transition.
Carcinoma, Hepatocellular
Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression.
Carcinoma, Hepatocellular
Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway.
Carcinoma, Hepatocellular
Histone deacetylase 5 promotes the migration and invasion of hepatocellular carcinoma via increasing the transcription of hypoxia-inducible factor-1? under hypoxia condition.
Carcinoma, Hepatocellular
Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
Carcinoma, Hepatocellular
Histone Deacetylase HDAC8 Promotes Insulin Resistance and ?-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy.
Carcinoma, Hepatocellular
Histone deacetylase inhibitor for the treatment of hepatocellular carcinoma: Chemoimmunotherapeutic perspective and prospects.
Carcinoma, Hepatocellular
Histone deacetylase inhibitor resminostat in combination with sorafenib counteracts platelet-mediated pro-tumoral effects in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.
Carcinoma, Hepatocellular
Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells.
Carcinoma, Hepatocellular
Histone Deacetylase Inhibitor-Induced CDKN2B and CDKN2D Contribute to G2/M Cell Cycle Arrest Incurred by Oxidative Stress in Hepatocellular Carcinoma Cells via Forkhead Box M1 Suppression.
Carcinoma, Hepatocellular
Histone deacetylase inhibitors for treatment of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.
Carcinoma, Hepatocellular
Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities.
Carcinoma, Hepatocellular
Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects.
Carcinoma, Hepatocellular
Histone deacetylase inhibitors promote ATP2A3 gene expression in hepatocellular carcinoma cells: p300 as a transcriptional regulator.
Carcinoma, Hepatocellular
Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma via AMPK-FOXO1-ULK1 signaling axis-mediated autophagy.
Carcinoma, Hepatocellular
Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells.
Carcinoma, Hepatocellular
Histone deacetylase?2: A potential regulator and therapeutic target in liver disease (Review).
Carcinoma, Hepatocellular
HOXA10 knockdown inhibits proliferation, induces cell cycle arrest and apoptosis in hepatocellular carcinoma cells through HDAC1.
Carcinoma, Hepatocellular
HOXD3 was negatively regulated by YY1 recruiting HDAC1 to suppress progression of hepatocellular carcinoma cells via ITGA2 pathway.
Carcinoma, Hepatocellular
Hsa-miR-107 regulates chemosensitivity and inhibits tumor growth in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Hypoacetylation in association with histone 3 modulation in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Identification of a TGF-?-miR-195 positive feedback loop in hepatocytes and its deregulation in hepatoma cells.
Carcinoma, Hepatocellular
Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells.
Carcinoma, Hepatocellular
Identification of histone deacetylase 1 protein complexes in liver cancer cells.
Carcinoma, Hepatocellular
Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma.
Carcinoma, Hepatocellular
IFN-? inhibits HBV transcription and replication by promoting HDAC3-mediated de-2-hydroxyisobutyrylation of histone H4K8 on HBV cccDNA minichromosome in liver.
Carcinoma, Hepatocellular
IGF-II and IL-2 act synergistically to alter HDAC1 expression following treatments with trichostatin a.
Carcinoma, Hepatocellular
In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line
Carcinoma, Hepatocellular
Inhibition of autophagy signi?cantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
Carcinoma, Hepatocellular
Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But.
Carcinoma, Hepatocellular
Inhibitory effects of 1,25(OH)2D3 on the proliferation of hepatocellular carcinoma cells through the downregulation of HDAC2.
Carcinoma, Hepatocellular
Involvement of Insulin-like Growth Factor-binding Protein-3 in the Effects of Histone Deacetylase Inhibitor MS-275 in Hepatoma Cells.
Carcinoma, Hepatocellular
Liver-specific methionine adenosyltransferase MAT1A gene expression is associated with a specific pattern of promoter methylation and histone acetylation: implications for MAT1A silencing during transformation.
Carcinoma, Hepatocellular
lncRNA MIR22HG-Derived miR-22-5p Enhances the Radiosensitivity of Hepatocellular Carcinoma by Increasing Histone Acetylation Through the Inhibition of HDAC2 Activity.
Carcinoma, Hepatocellular
LncRNA RUNX1-IT1 which is downregulated by hypoxia-driven histone deacetylase 3 represses proliferation and cancer stem-like properties in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
lncRNA-SNHG15 accelerates the development of hepatocellular carcinoma by targeting miR-490-3p/ histone deacetylase 2 axis.
Carcinoma, Hepatocellular
LukS-PV Inhibits Hepatocellular Carcinoma Progression by Downregulating HDAC2 Expression.
Carcinoma, Hepatocellular
microRNA-889 is downregulated by histone deacetylase inhibitors and confers resistance to natural killer cytotoxicity in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer.
Carcinoma, Hepatocellular
miR-34a regulates HDAC1 expression to affect the proliferation and apoptosis of hepatocellular carcinoma.
Carcinoma, Hepatocellular
miRNA-548ah promotes the replication and expression of hepatitis B virus by targeting histone deacetylase 4.
Carcinoma, Hepatocellular
Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Monitoring Tumor Response After Histone Deacetylase Inhibitor Treatment Using 3'-Deoxy-3'-[(18)F]-fluorothymidine PET.
Carcinoma, Hepatocellular
mRNA levels of related Abcb genes change opposite to each other upon histone deacetylase inhibition in drug-resistant rat hepatoma cells.
Carcinoma, Hepatocellular
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Carcinoma, Hepatocellular
Network pharmacology predicted HDAC6 as a potential target of flavones from Daphne giraldii on hepatocellular carcinoma.
Carcinoma, Hepatocellular
Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase II? degradation in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Nuclear distribution of histone deacetylase: a marker enzyme for the internal nuclear matrix.
Carcinoma, Hepatocellular
Oncogenic potential of CK2? and its regulatory role in EGF-induced HDAC2 expression in human liver cancer.
Carcinoma, Hepatocellular
Overexpression of HDAC6 suppresses tumor cell proliferation and metastasis by inhibition of the canonical Wnt/?-catenin signaling pathway in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Overexpression of Histone Deacetylase and Amyloid Precursor Protein in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
Carcinoma, Hepatocellular
Pharmacological inhibition of HDAC1/3-interacting proteins induced morphological changes, and hindered the cell proliferation and migration of hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Platycodin D reverses histone deacetylase inhibitor resistance in hepatocellular carcinoma cells by repressing ERK1/2-mediated cofilin-1 phosphorylation.
Carcinoma, Hepatocellular
PML suppresses IL-6-induced STAT3 activation by interfering with STAT3 and HDAC3 interaction.
Carcinoma, Hepatocellular
Pre-Senescence Induction in Hepatoma Cells Favors Hepatitis C Virus Replication and Can Be Used in Exploring Antiviral Potential of Histone Deacetylase Inhibitors.
Carcinoma, Hepatocellular
Pterostilbene inhibits MTA1/HDAC1 complex leading to PTEN acetylation in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Radiosensitizing Effect of a Phenylbutyrate-derived Histone Deacetylase Inhibitor in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Repression of the miR-627-5p by histone deacetylase 3 contributes to hypoxia-induced hepatocellular carcinoma progression.
Carcinoma, Hepatocellular
Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis.
Carcinoma, Hepatocellular
Retraction: Identification of Histone Deacetylase 3 as a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-Associated Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
RGFP966 Suppresses Tumor Growth and Migration Through Inhibition of EGFR Expression in Hepatocellular Carcinoma Cells in vitro.
Carcinoma, Hepatocellular
Romidepsin hepatocellular carcinoma suppression in mice is associated with deregulated gene expression of bone morphogenetic protein and Notch signaling pathway components.
Carcinoma, Hepatocellular
Sensitization to oxidative stress and G2/M cell cycle arrest by histone deacetylase inhibition in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Sodium Valproate, a Histone Deacetylase Inhibitor, Provokes Reactive Oxygen Species-Mediated Cytotoxicity in Human Hepatocellular Carcinoma Cells.
Carcinoma, Hepatocellular
Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines.
Carcinoma, Hepatocellular
SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Suppressive Effect of the Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), on Hepatitis C Virus Replication via Epigenetic Changes in Host Cells.
Carcinoma, Hepatocellular
Targeting HDAC6 Reprograms TH 17 Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Targeting Histone deacetylase 4/Ubc9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
The aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl induces distinct patterns of gene expression between hepatoma and glioma cells: chromatin remodeling as a mechanism for selective effects.
Carcinoma, Hepatocellular
The Effects of 5-Aza-2'-Deoxycytidine and Valproic Acid on Apoptosis Induction and Cell Growth Inhibition in Colon Cancer HT 29 Cell Line.
Carcinoma, Hepatocellular
The histone deacetylase 4/Sp1/miR-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma.
Carcinoma, Hepatocellular
The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation.
Carcinoma, Hepatocellular
The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch Signaling.
Carcinoma, Hepatocellular
The ménage à trois of autophagy, lipid droplets and liver disease.
Carcinoma, Hepatocellular
The nuclear translocation of transketolase inhibits the farnesoid receptor expression by promoting the binding of HDAC3 to FXR promoter in hepatocellular carcinoma cell lines.
Carcinoma, Hepatocellular
The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines.
Carcinoma, Hepatocellular
The Up-Regulation of Histone Deacetylase 8 Promotes Proliferation and Inhibits Apoptosis in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Trichostatin A sensitizes hepatoma cells to Taxol more than 5-Aza-dC and dexamethasone.
Carcinoma, Hepatocellular
Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells: alteration of the Sp1/Sp3/HDAC1 multiprotein complex.
Carcinoma, Hepatocellular
Upregulation of miR-362-3p modulates proliferation and anchorage-independent growth by directly targeting Tob2 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells.
Carcinoma, Hepatocellular
Vitamin K3 chloro derivative (VKT-2) inhibits HDAC6, activates autophagy and apoptosis, and inhibits aggresome formation in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor.
Carcinoma, Hepatocellular
[Inhibition of curcumin on histone deacetylase and expression promotion of P21 (WAF1/CIP1) in HepG2 cells]
Carcinoma, Hepatocellular
[RNA interference of HDAC7 expression in hepatocellular carcinoma.]
Carcinoma, Intraductal, Noninfiltrating
Associations between cruciferous vegetable intake and selected biomarkers among women scheduled for breast biopsies.
Carcinoma, Intraductal, Noninfiltrating
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
Carcinoma, Intraductal, Noninfiltrating
Sulforaphane Bioavailability and Chemopreventive Activity in Women Scheduled for Breast Biopsy.
Carcinoma, Intraductal, Noninfiltrating
The Impact of Androgen Receptor and Histone Deacetylase 1 Expression on the Prognosis of Ductal Carcinoma In Situ.
Carcinoma, Large Cell
Expression of HDAC9 in lung cancer--potential role in lung carcinogenesis.
Carcinoma, Merkel Cell
MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
Carcinoma, Mucoepidermoid
Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells.
Carcinoma, Mucoepidermoid
Targeting histone deacetylase and NF?B signaling as a novel therapy for Mucoepidermoid Carcinomas.
Carcinoma, Non-Small-Cell Lung
3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors.
Carcinoma, Non-Small-Cell Lung
A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies.
Carcinoma, Non-Small-Cell Lung
A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.
Carcinoma, Non-Small-Cell Lung
A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors.
Carcinoma, Non-Small-Cell Lung
Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines.
Carcinoma, Non-Small-Cell Lung
Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC.
Carcinoma, Non-Small-Cell Lung
Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model.
Carcinoma, Non-Small-Cell Lung
Aurora A, aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Blocking NF-?B sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
Carcinoma, Non-Small-Cell Lung
cAMP signaling increases histone deacetylase 8 expression by inhibiting JNK-dependent degradation via autophagy and the proteasome system in H1299 lung cancer cells.
Carcinoma, Non-Small-Cell Lung
cAMP signaling increases histone deacetylase 8 expression via the Epac2-Rap1A-Akt pathway in H1299 lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.
Carcinoma, Non-Small-Cell Lung
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Depletion of HDAC6 Enhances Cisplatin-Induced DNA Damage and Apoptosis in Non-Small Cell Lung Cancer Cells.
Carcinoma, Non-Small-Cell Lung
Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.
Carcinoma, Non-Small-Cell Lung
Endothelial progenitor cells contribute to neovascularization of non-small cell lung cancer via histone deacetylase 7-mediated cytoskeleton regulation and angiogenic genes transcription.
Carcinoma, Non-Small-Cell Lung
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Carcinoma, Non-Small-Cell Lung
Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid.
Carcinoma, Non-Small-Cell Lung
Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes.
Carcinoma, Non-Small-Cell Lung
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Carcinoma, Non-Small-Cell Lung
HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment.
Carcinoma, Non-Small-Cell Lung
HDAC1 knockdown inhibits invasion and induces apoptosis in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin.
Carcinoma, Non-Small-Cell Lung
HDAC6 Regulates Radiosensitivity of Non-Small Cell Lung Cancer by Promoting Degradation of Chk1.
Carcinoma, Non-Small-Cell Lung
HDAC9 deficiency promotes tumor progression by decreasing the CD8+ dendritic cell infiltration of the tumor microenvironment.
Carcinoma, Non-Small-Cell Lung
High expression of SNIP1 correlates with poor prognosis in Non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro.
Carcinoma, Non-Small-Cell Lung
Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment.
Carcinoma, Non-Small-Cell Lung
Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
Carcinoma, Non-Small-Cell Lung
Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
Carcinoma, Non-Small-Cell Lung
Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation.
Carcinoma, Non-Small-Cell Lung
Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
Carcinoma, Non-Small-Cell Lung
Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
Carcinoma, Non-Small-Cell Lung
Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation.
Carcinoma, Non-Small-Cell Lung
Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Carcinoma, Non-Small-Cell Lung
Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
In Vivo Evaluation of the Combined Anticancer Effects of Cisplatin and SAHA in Nonsmall Cell Lung Carcinoma Using [18F]FAHA and [18F]FDG PET/CT Imaging.
Carcinoma, Non-Small-Cell Lung
Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Inhibition of HDAC6 Attenuates Tumor Growth of Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo.
Carcinoma, Non-Small-Cell Lung
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Carcinoma, Non-Small-Cell Lung
Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Nuclear HDAC6 inhibits invasion by suppressing NF-?B/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
OIP5-AS1 modulates epigenetic regulator HDAC7 to enhance non-small cell lung cancer metastasis via miR-140-5p.
Carcinoma, Non-Small-Cell Lung
Pax5 Re-Expression In H460 Cells Treated With The Combination Of Demethylating Agent And Histone Deacetylase Inhibitor Is Associated With The Enhancement Of P53 Binding To Pax5 Promoter Region.
Carcinoma, Non-Small-Cell Lung
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Potential Anticancer Properties and Mechanisms of Action of Curcumin.
Carcinoma, Non-Small-Cell Lung
Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Carcinoma, Non-Small-Cell Lung
Rescue of major histocompatibility-DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor.
Carcinoma, Non-Small-Cell Lung
Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells.
Carcinoma, Non-Small-Cell Lung
Silibinin Synergizes with Histone Deacetylase and DNA Methyltransferase Inhibitors in Up-regulating E-cadherin Expression Together with Inhibition of Migration and Invasion of Human Non-small Cell Lung Cancer Cells.
Carcinoma, Non-Small-Cell Lung
Sodium Valproate Sensitizes Non-Small Lung Cancer A549 Cells to ?? T-Cell-Mediated Killing through Upregulating the Expression of MICA.
Carcinoma, Non-Small-Cell Lung
Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Stat3 inhibits Beclin 1 expression through recruitment of HDAC3 in nonsmall cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line.
Carcinoma, Non-Small-Cell Lung
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.
Carcinoma, Non-Small-Cell Lung
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor.
Carcinoma, Non-Small-Cell Lung
Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1.
Carcinoma, Non-Small-Cell Lung
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
Carcinoma, Non-Small-Cell Lung
Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
Carcinoma, Non-Small-Cell Lung
X-radiation inhibits histone deacetylase 1 and 2, upregulates Axin expression and induces apoptosis in non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
18?-Glycyrrhetinic acid potentiates apoptotic effect of trichostatin A on human epithelial ovarian carcinoma cell lines.
Carcinoma, Ovarian Epithelial
C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.
Carcinoma, Ovarian Epithelial
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Carcinoma, Ovarian Epithelial
Histone deacetylase 4 increases progressive epithelial ovarian cancer cells via repression of p21 on fibrillar collagen matrices.
Carcinoma, Ovarian Epithelial
Histone deacetylase inhibitor therapy in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Long non-coding RNA PTPRG-AS1 promotes cell tumorigenicity in epithelial ovarian cancer by decoying microRNA-545-3p and consequently enhancing HDAC4 expression.
Carcinoma, Ovarian Epithelial
Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Carcinoma, Ovarian Epithelial
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
Carcinoma, Ovarian Epithelial
The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines.
Carcinoma, Renal Cell
A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.
Carcinoma, Renal Cell
A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.
Carcinoma, Renal Cell
CBX4 transcriptionally suppresses KLF6 via interaction with HDAC1 to exert oncogenic activities in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.
Carcinoma, Renal Cell
Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial.
Carcinoma, Renal Cell
Combination Treatment of Renal Cell Carcinoma with Belinostat and 5-Fluorouracil: A Role for Oxidative Stress Induced DNA Damage and HSP90 Regulated Thymidine Synthase.
Carcinoma, Renal Cell
Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Carcinoma, Renal Cell
Combining Histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells.
Carcinoma, Renal Cell
Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
Carcinoma, Renal Cell
Decreased expression and hypomethylation of HDAC9 lead to poor prognosis and inhibit immune cell infiltration in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.
Carcinoma, Renal Cell
Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.
Carcinoma, Renal Cell
Efficacy and safety of HDACIs in the treatment of metastatic or unresectable renal cell carcinoma with a clear cell phenotype: A systematic review and meta-analysis.
Carcinoma, Renal Cell
Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
Carcinoma, Renal Cell
Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
Carcinoma, Renal Cell
HDAC Inhibitors Synergize Antiproliferative Effect of Sorafenib in Renal Cell Carcinoma Cells.
Carcinoma, Renal Cell
HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma.
Carcinoma, Renal Cell
Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of ?-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma.
Carcinoma, Renal Cell
Histone deacetylase inhibitors induce human renal cell carcinoma cell apoptosis through p-JNK activation.
Carcinoma, Renal Cell
Histone Deacetylase Inhibitors Modulate Renal Cell Carcinoma Sensitivity to TRAIL/Apo-2L-induced Apoptosis by Enhancing TRAIL-R2 Expression.
Carcinoma, Renal Cell
Inactivation of BRM/SMARCA2 sensitizes clear cell renal cell carcinoma to histone deacetylase complex inhibitors.
Carcinoma, Renal Cell
Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance.
Carcinoma, Renal Cell
Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Recent investigations of histone deacetylase inhibitors in renal cell carcinoma.
Carcinoma, Renal Cell
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Carcinoma, Renal Cell
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Carcinoma, Renal Cell
The Histone Deacetylase Inhibitor Trichostatin A Sensitizes Human Renal Carcinoma Cells to TRAIL-Induced Apoptosis through Down-Regulation of c-FLIPL.
Carcinoma, Renal Cell
THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID ALTERS GROWTH PROPERTIES OF RENAL CELL CARCINOMA IN VITRO AND IN VIVO.
Carcinoma, Renal Cell
The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
Carcinoma, Renal Cell
The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Carcinoma, Renal Cell
Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.
Carcinoma, Renal Cell
[Linkage of Drug Resistance and Metabolome Shift in Renal Cell Carcinoma Cells].
Carcinoma, Small Cell
Histone deacetylase inhibitors synergizes with catalytic inhibitors of EZH2 to exhibit anti-tumor activity in small cell carcinoma of the ovary, hypercalcemic type.
Carcinoma, Squamous Cell
?Np63? promotes the expression and nuclear translocation of PTEN, leading to cisplatin resistance in oral cancer cells.
Carcinoma, Squamous Cell
A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells.
Carcinoma, Squamous Cell
Allele-specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma.
Carcinoma, Squamous Cell
Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Carcinoma, Squamous Cell
Combination of ACY-241 and JQ1 Synergistically Suppresses Metastasis of HNSCC via Regulation of MMP-2 and MMP-9.
Carcinoma, Squamous Cell
Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis.
Carcinoma, Squamous Cell
Downregulation of HDAC3 by ginsenoside Rg3 inhibits epithelial-mesenchymal transition of cutaneous squamous cell carcinoma through c-Jun acetylation.
Carcinoma, Squamous Cell
Effect of downregulation of survivin expression on radiosensitivity of human epidermoid carcinoma cells.
Carcinoma, Squamous Cell
Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines.
Carcinoma, Squamous Cell
Effects of trichostatin A on HIF-1? and VEGF expression in human tongue squamous cell carcinoma cells in vitro.
Carcinoma, Squamous Cell
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.
Carcinoma, Squamous Cell
Expression of HDAC9 in lung cancer--potential role in lung carcinogenesis.
Carcinoma, Squamous Cell
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis.
Carcinoma, Squamous Cell
Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.
Carcinoma, Squamous Cell
Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis.
Carcinoma, Squamous Cell
Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.
Carcinoma, Squamous Cell
Immunoexpression of HDAC1, HDAC2, and HAT1 in actinic cheilitis and lip squamous cell carcinoma.
Carcinoma, Squamous Cell
Immunogenomic Identification for Predicting the Prognosis of Cervical Cancer Patients.
Carcinoma, Squamous Cell
Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy.
Carcinoma, Squamous Cell
Investigation into the use of histone deacetylase inhibitor MS-275 as a topical agent for the prevention and treatment of cutaneous squamous cell carcinoma in an SKH-1 hairless mouse model.
Carcinoma, Squamous Cell
MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
Carcinoma, Squamous Cell
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Carcinoma, Squamous Cell
Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer.
Carcinoma, Squamous Cell
Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.
Carcinoma, Squamous Cell
Positive and negative regulation of podoplanin expression by TGF-? and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines.
Carcinoma, Squamous Cell
Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
Carcinoma, Squamous Cell
Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
Carcinoma, Squamous Cell
Tambulin Targets Histone Deacetylase 1 Inhibiting Cell Growth and Inducing Apoptosis in Human Lung Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines.
Carcinoma, Squamous Cell
The histone deacetylase inhibitor, Trichostatin A, induces G2/M phase arrest and apoptosis in YD-10B oral squamous carcinoma cells.
Carcinoma, Squamous Cell
Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance.
Carcinoma, Squamous Cell
Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.
Carcinoma, Transitional Cell
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Carcinoma, Transitional Cell
Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro.
Carcinoma, Transitional Cell
Retracted: Potentiation of Mitomycin C Tumoricidal Activity for Transitional Cell Carcinoma by Histone Deacetylase Inhibitors In Vitro.
Carcinoma, Transitional Cell
Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor.
Cardio-Renal Syndrome
Cardiac-Specific Overexpression of Silent Information Regulator 1 Protects Against Heart and Kidney Deterioration in Cardiorenal Syndrome via Inhibition of Endoplasmic Reticulum Stress.
Cardiomegaly
Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy.
Cardiomegaly
Casein Kinase-2 Interacting Protein-1 Regulates Physiological Cardiac Hypertrophy via Inhibition of Histone Deacetylase 4 Phosphorylation.
Cardiomegaly
Casein kinase-2?1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart.
Cardiomegaly
CKIP-1 inhibits cardiac hypertrophy by regulating class II histone deacetylase phosphorylation through recruiting PP2A.
Cardiomegaly
Class II HDACs mediate CaMK-dependent signaling to NRSF in ventricular myocytes.
Cardiomegaly
Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy.
Cardiomegaly
Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors.
Cardiomegaly
DPP (Dipeptidyl Peptidase)-4 Inhibitor Attenuates Ang II (Angiotensin II)-Induced Cardiac Hypertrophy via GLP (Glucagon-Like Peptide)-1-Dependent Suppression of Nox (Nicotinamide Adenine Dinucleotide Phosphate Oxidase) 4-HDAC (Histone Deacetylase) 4 Pathway.
Cardiomegaly
Effect of the angiotensin II receptor blocker valsartan on cardiac hypertrophy and myocardial histone deacetylase expression in rats with aortic constriction.
Cardiomegaly
Effects of a novel histone deacetylase inhibitor, N-(2-aminophenyl) benzamide, on a reversible hypertrophy induced by isoproterenol in in situ rat hearts.
Cardiomegaly
Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy.
Cardiomegaly
HATs off to Hop: recruitment of a class I histone deacetylase incriminates a novel transcriptional pathway that opposes cardiac hypertrophy.
Cardiomegaly
HDAC activity regulates entry of mesoderm cells into the cardiac muscle lineage.
Cardiomegaly
HDAC Inhibition Suppresses Cardiac Hypertrophy and Fibrosis in DOCA-Salt Hypertensive Rats via Regulation of HDAC6/HDAC8 Enzyme Activity.
Cardiomegaly
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity.
Cardiomegaly
HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression.
Cardiomegaly
HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling.
Cardiomegaly
Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy.
Cardiomegaly
Histone Deacetylase Inhibition Attenuates Cardiac Hypertrophy and Fibrosis through Acetylation of Mineralocorticoid Receptor in Spontaneously Hypertensive Rats.
Cardiomegaly
Histone deacetylase inhibition has cardiac and vascular protective effects in rats with pressure overload cardiac hypertrophy.
Cardiomegaly
Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series).
Cardiomegaly
Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats.
Cardiomegaly
Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development.
Cardiomegaly
Increased oxidative stress in the nucleus caused by Nox4 mediates oxidation of HDAC4 and cardiac hypertrophy.
Cardiomegaly
Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure.
Cardiomegaly
Inhibition of heat shock protein 70 blocks the development of cardiac hypertrophy by modulating the phosphorylation of histone deacetylase 2.
Cardiomegaly
Insights into mechanisms linking cardiac hypertrophy and atrial fibrosis: evidence for a role of histone deacetylase in atrial fibrillation pathophysiology and therapy.
Cardiomegaly
Krüppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy.
Cardiomegaly
Kruppel-like factor 4 protein regulates isoproterenol-induced cardiac hypertrophy by modulating myocardin expression and activity.
Cardiomegaly
Nuclear calcium/calmodulin-dependent protein kinase IIdelta preferentially transmits signals to histone deacetylase 4 in cardiac cells.
Cardiomegaly
Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation.
Cardiomegaly
Overexpression of peptidase inhibitor 16 attenuates angiotensin II-induced cardiac fibrosis via regulating HDAC1 of cardiac fibroblasts.
Cardiomegaly
Plantamajoside attenuates isoproterenol-induced cardiac hypertrophy associated with the HDAC2 and AKT/ GSK-3? signaling pathway.
Cardiomegaly
Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts.
Cardiomegaly
PP2A negatively regulates the hypertrophic response by dephosphorylating HDAC2 S394 in the heart.
Cardiomegaly
Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5.
Cardiomegaly
Regulation of Acetylation of Histone Deacetylase 2 by p300/CBP-Associated Factor/Histone Deacetylase 5 in the Development of Cardiac Hypertrophy.
Cardiomegaly
Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
Cardiomegaly
Selective HDAC8 Inhibition Attenuates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis via p38 MAPK Pathway.
Cardiomegaly
Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.
Cardiomegaly
Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy.
Cardiomegaly
STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways.
Cardiomegaly
Suppression of HDAC Nuclear Export and Cardiomyocyte Hypertrophy by Novel Irreversible Inhibitors of CRM1.
Cardiomegaly
The mechanism of myocardial hypertrophy regulated by the interaction between mhrt and myocardin.
Cardiomegaly
The role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy.
Cardiomegaly
Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy.
Cardiomegaly
YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5.
Cardiomegaly
[The mechanism underlying histone deacetylases regulating cardiac hypertrophy].
Cardiomyopathies
Calcium/calmodulin-dependent protein kinase II couples Wnt signaling with histone deacetylase 4 and mediates dishevelled-induced cardiomyopathy.
Cardiomyopathies
HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving ?-tubulin acetylation.
Cardiomyopathies
Histone deacetylase inhibition of cardiac autophagy in rats on a high?fat diet with low?dose streptozotocin-induced type 2 diabetes mellitus.
Cardiomyopathies
Inflammation leads through PGE/EP3 signaling to HDAC5/MEF2-dependent transcription in cardiac myocytes.
Cardiomyopathies
The Epigenetic Regulator HDAC1 Modulates Transcription of a Core Cardiogenic Program in Human Cardiac Mesenchymal Stromal Cells Through a p53-Dependent Mechanism.
Cardiomyopathy, Dilated
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility.
Cardiotoxicity
Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors.
Cardiotoxicity
Changes in cardiac NaV1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors.
Cardiotoxicity
HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving ?-tubulin acetylation.
Cardiotoxicity
The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity.
Cardiotoxicity
Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes.
Cardiovascular Diseases
Activation of PPAR alpha by fenofibrate inhibits apoptosis in vascular adventitial fibroblasts partly through SIRT1-mediated deacetylation of FoxO1.
Cardiovascular Diseases
Atherosclerotic Aortic Calcification-Associated Polymorphism in HDAC9 and Associations with Mortality, Cardiovascular Disease, and Kidney Disease.
Cardiovascular Diseases
Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.
Cardiovascular Diseases
Cyclic phosphatidic acid inhibits alkyl-glycerophosphate-induced downregulation of histone deacetylase 2 expression and suppresses the inflammatory response in human coronary artery endothelial cells.
Cardiovascular Diseases
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Cardiovascular Diseases
Hdac9 inhibits medial artery calcification through down-regulation of Osterix.
Cardiovascular Diseases
Histone deacetylase 5 interacts with Krüppel-like factor 2 and inhibits its transcriptional activity in endothelium.
Cardiovascular Diseases
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Cardiovascular Diseases
Histone Deacetylase Inhibition Attenuates Aortic Remodeling in Rats under Pressure Overload.
Cardiovascular Diseases
Histone deacetylase inhibition has cardiac and vascular protective effects in rats with pressure overload cardiac hypertrophy.
Cardiovascular Diseases
Histone deacetylase inhibitors: Keeping momentum for neuromuscular and cardiovascular diseases treatment.
Cardiovascular Diseases
Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid.
Cardiovascular Diseases
Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors.
Cardiovascular Diseases
Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
Cardiovascular Diseases
Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury.
Cardiovascular Diseases
Plantamajoside attenuates isoproterenol-induced cardiac hypertrophy associated with the HDAC2 and AKT/ GSK-3? signaling pathway.
Cardiovascular Diseases
Selective HDAC8 Inhibition Attenuates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis via p38 MAPK Pathway.
Cardiovascular Diseases
SIRT3 attenuates AngII-induced cardiac fibrosis by inhibiting myofibroblasts transdifferentiation via STAT3-NFATc2 pathway.
Cardiovascular Diseases
Sirtuin 1 retards hyperphosphatemia-induced calcification of vascular smooth muscle cells.
Cardiovascular Diseases
Sirtuin 1 rs1467568 and rs7895833 in South African Indians with early-onset coronary artery disease.
Cardiovascular Diseases
Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions.
Cardiovascular Diseases
The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.
Cardiovascular Diseases
Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy.
Carotid Artery Diseases
Association between rs2107595 HDAC9 gene polymorphism and advanced carotid atherosclerosis in the Slovenian cohort.
Carotid Artery Diseases
Evidence HDAC9 Genetic Variant Associated With Ischemic Stroke Increases Risk via Promoting Carotid Atherosclerosis.
Cataract
Effects of microRNA-211 on proliferation and apoptosis of lens epithelial cells by targeting SIRT1 gene in diabetic cataract mice.
Cataract
MiR-22-3p inhibits fibrotic cataract through inactivation of HDAC6 and increase of ?-tubulin acetylation.
Cell Transformation, Neoplastic
Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein.
Central Nervous System Diseases
Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
Central Nervous System Diseases
Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases.
Central Nervous System Diseases
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.
Cerebral Hemorrhage
HDAC inhibition reduces white matter injury after intracerebral hemorrhage.
Cerebral Hemorrhage
Histone Deacetylase Inhibitor Scriptaid Alleviated Neurological Dysfunction after Experimental Intracerebral Hemorrhage in Mice.
Cerebral Hemorrhage
The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Confers Acute Neuroprotection After Intracerebral Hemorrhage in Mice.
Cerebral Hemorrhage
Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation.
Cerebral Infarction
Extracellular Vesicle-Derived microRNA-410 From Mesenchymal Stem Cells Protects Against Neonatal Hypoxia-Ischemia Brain Damage Through an HDAC1-Dependent EGR2/Bcl2 Axis.
Cerebral Infarction
Inhibition of HDAC3 Ameliorates Cerebral Ischemia Reperfusion Injury in Diabetic Mice In Vivo and In Vitro.
Cerebrovascular Disorders
Correlation between Histone Deacetylase 9 and Regulatory T Cell in Patients with Chronic Heart Failure.
Cerebrovascular Disorders
Histone deacetylase 9 inhibition upregulates microRNA-92a to repress the progression of intracranial aneurysm via silencing Bcl-2-like protein 11.
Charcot-Marie-Tooth Disease
A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A.
Charcot-Marie-Tooth Disease
Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease.
Charcot-Marie-Tooth Disease
Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.
Charcot-Marie-Tooth Disease
HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease.
Charcot-Marie-Tooth Disease
HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT.
Charcot-Marie-Tooth Disease
HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.
Charcot-Marie-Tooth Disease
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
Cheilitis
Immunoexpression of HDAC1, HDAC2, and HAT1 in actinic cheilitis and lip squamous cell carcinoma.
Chickenpox
Histone Deacetylase 1 and 2 are Phosphorylated at Novel Sites During Varicella Zoster Virus Infection.
Cholangiocarcinoma
Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1? for Intrahepatic Cholangiocarcinoma.
Cholangiocarcinoma
CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.
Cholangiocarcinoma
Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis.
Cholangiocarcinoma
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Cholangiocarcinoma
Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.
Cholangiocarcinoma
HDAC6 Inhibition Restores Ciliary Expression and Decreases Tumor Growth.
Cholangiocarcinoma
Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition.
Cholangiocarcinoma
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Cholangiocarcinoma
Histone deacetylase inhibitor screening identifies HC toxin as the most effective in intrahepatic cholangiocarcinoma cells.
Cholangiocarcinoma
Histone Deacetylase SIRT1 promotes loss of primary cilia in Cholangiocarcinoma.
Cholangiocarcinoma
Loss of ARID1A induces a stemness gene ALDH1A1 expression with histone acetylation in the malignant subtype of cholangiocarcinoma.
Cholangiocarcinoma
Low levels of pyruvate induced by a positive feedback loop protects cholangiocarcinoma cells from apoptosis.
Cholangiocarcinoma
MiR-433 and miR-22 dysregulations induce HDAC6 overexpression and ciliary loss in cholangiocarcinoma.
Cholangiocarcinoma
Peanut testa extracts possessing histone deacetylase inhibitory activity induce apoptosis in cholangiocarcinoma cells.
Cholangiocarcinoma
Role of histone deacetylase expression in intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
SPRR2a enhances p53 deacetylation through HDAC1 and down regulates p21 promoter activity.
Cholangiocarcinoma
Synergistic anticancer effects of cisplatin and histone deacetylase inhibitors (SAHA and TSA) on cholangiocarcinoma cell lines.
Cholangiocarcinoma
TGF-?1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4.
Choledochal Cyst
Carcinogenic Potential of Biliary Epithelium of Congenital Choledochal Cyst Model in Rats: A Special Reference to HDAC Expression.
Cholestasis
Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitin-1.
Cholestasis, Intrahepatic
Effect of Histone Deacetylase HDAC3 on Cytokines IL-18, IL-12 and TNF-? in Patients with Intrahepatic Cholestasis of Pregnancy.
Chondrosarcoma
Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma.
Chondrosarcoma
Combination BET Family Protein and HDAC Inhibition Synergistically Elicits Chondrosarcoma Cell Apoptosis Through RAD51-Related DNA Damage Repair.
Chondrosarcoma
Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis.
Chondrosarcoma
Effects of HDAC4 on IL-1?-induced matrix metalloproteinase expression regulated partially through the WNT3A/?-catenin pathway.
Chondrosarcoma
HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity.
Chondrosarcoma
HDAC6 inhibition suppresses chondrosarcoma by restoring the expression of primary cilia.
Chondrosarcoma
MicroRNA?10b suppresses the migration and invasion of chondrosarcoma cells by targeting brain?derived neurotrophic factor.
Chondrosarcoma
Suberoylanilide hydroxamic acid (SAHA) induces apoptosis or autophagy-associated cell death in chondrosarcoma cell lines.
Chondrosarcoma
The effects of histone deacetylase inhibitors on the induction of differentiation in chondrosarcoma cells.
Chordoma
Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: An immunohistochemical and functional analysis.
Choriocarcinoma
A new approach combining LC-MS and multivariate statistical analysis for revealing changes in histone modification levels.
Choriocarcinoma
Curcumol Controls Choriocarcinoma Stem-Like Cells Self-Renewal via Repression of DNA Methyltransferase (DNMT)- and Histone Deacetylase (HDAC)-Mediated Epigenetic Regulation.
Choriocarcinoma
Expression and activity of vitamin D receptor in the human placenta and in choriocarcinoma BeWo and JEG-3 cell lines.
Choriocarcinoma
Expression of histone deacetylases 1, 2 and 3 in histological subtypes of testicular germ cell tumours.
Choriocarcinoma
Histone deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in human choriocarcinoma cells.
Choroidal Neovascularization
Attenuation of choroidal neovascularization by histone deacetylase inhibitor.
Choroidal Neovascularization
The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model.
Chronic Kidney Disease-Mineral and Bone Disorder
Klotho preservation via histone deacetylase inhibition attenuates chronic kidney disease-associated bone injury in mice.
Chronic Periodontitis
Class I and II histone deacetylase expression in human chronic periodontitis gingival tissue.
Cleidocranial Dysplasia
The new bone biology: pathologic, molecular, and clinical correlates.
Colitis
A Highly Potent and Selective Histone Deacetylase 6 Inhibitor Prevents DSS-induced Colitis in Mice.
Colitis
An HDAC6 Inhibitor Confers Protection and Selectively Inhibits B-Cell Infiltration in DSS-Induced Colitis in Mice.
Colitis
CaM kinase II in colonic smooth muscle contributes to dysmotility in murine DSS-colitis.
Colitis
Correction: Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
Colitis
Distinct Roles for Intestinal Epithelial Cell-Specific Hdac1 and Hdac2 in the Regulation of Murine Intestinal Homeostasis.
Colitis
Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer.
Colitis
Faecalibacterium prausnitzii produces butyrate to decrease c-Myc-related metabolism and Th17 differentiation by inhibiting histone deacetylase 3.
Colitis
Faecalibacterium prausnitzii Produces Butyrate to Maintain Th17/Treg Balance and to Ameliorate Colorectal Colitis by Inhibiting Histone Deacetylase 1.
Colitis
HDAC inhibitors promote intestinal epithelial regeneration via autocrine TGF?1 signalling in inflammation.
Colitis
Histone deacetylase 1 controls CD4+ T cell trafficking in autoinflammatory diseases.
Colitis
Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice.
Colitis
Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid.
Colitis
Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice.
Colitis
Novel Histone Deacetylase 6 Inhibitor CKD-506 Inhibits NF-?B Signaling in Intestinal Epithelial Cells and Macrophages and Ameliorates Acute and Chronic Murine Colitis.
Colitis
Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
Colitis
The acetylome regulators Hdac1 and Hdac2 differently modulate intestinal epithelial cell dependent homeostatic responses in experimental colitis.
Colitis
The HDAC Inhibitor, SAHA, Prevents Colonic Inflammation by Suppressing Pro-inflammatory Cytokines and Chemokines in DSS-induced Colitis.
Colitis-Associated Neoplasms
Correction: Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
Colitis-Associated Neoplasms
Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
Colonic Neoplasms
3,3'-diindolylmethane enhances the efficacy of butyrate in colon cancer prevention through down-regulation of survivin.
Colonic Neoplasms
9-Hydroxystearic acid interferes with EGF signalling in a human colon adenocarcinoma.
Colonic Neoplasms
A new method of comparing 2D-PAGE maps based on the computation of Zernike moments and multivariate statistical tools.
Colonic Neoplasms
A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells.
Colonic Neoplasms
A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells.
Colonic Neoplasms
A proteomic approach for evaluating the cell response to a novel histone deacetylase inhibitor in colon cancer cells.
Colonic Neoplasms
A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells.
Colonic Neoplasms
Aceroside VIII is a New Natural Selective HDAC6 Inhibitor that Synergistically Enhances the Anticancer Activity of HDAC Inhibitor in HT29 Cells.
Colonic Neoplasms
Adenomatous polyposis coli determines sensitivity to histone deacetylase inhibitor-induced apoptosis in colon cancer cells.
Colonic Neoplasms
Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.
Colonic Neoplasms
Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells.
Colonic Neoplasms
An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1.
Colonic Neoplasms
Anti-invasive effects and proapoptotic activity induction by the rexinoid IIF and valproic acid in combination on colon cancer cell lines.
Colonic Neoplasms
Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients.
Colonic Neoplasms
Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction.
Colonic Neoplasms
Application of partial least squares discriminant analysis and variable selection procedures: a 2D-PAGE proteomic study.
Colonic Neoplasms
Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells.
Colonic Neoplasms
Butyrate suppresses expression of neuropilin I in colorectal cell lines through inhibition of Sp1 transactivation.
Colonic Neoplasms
Calcium-sensing receptor silencing in colorectal cancer is associated with promoter hypermethylation and loss of acetylation on histone 3.
Colonic Neoplasms
Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets.
Colonic Neoplasms
Carbamazepine, a Histone Deacetylase Inhibitor Induces Apoptosis in Human Colon Adenocarcinoma Cell Line HT-29.
Colonic Neoplasms
CBP Activity Mediates Effects of the Histone Deacetylase Inhibitor Butyrate on WNT Activity and Apoptosis in Colon Cancer Cells.
Colonic Neoplasms
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Colonic Neoplasms
Chidamide and 5-flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice.
Colonic Neoplasms
Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo.
Colonic Neoplasms
Colon cancer cells maintain low levels of pyruvate to avoid cell death caused by inhibition of HDAC1/HDAC3.
Colonic Neoplasms
Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells.
Colonic Neoplasms
Common targets for a deadly duo of diabetes mellitus and colon cancer: Catching two fish with one worm.
Colonic Neoplasms
Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity.
Colonic Neoplasms
Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis.
Colonic Neoplasms
Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Colonic Neoplasms
Cyclooxygenase-2 regulation in colon cancer cells: modulation of RNA polymerase II elongation by histone deacetylase inhibitors.
Colonic Neoplasms
Deacetylase Plus Bromodomain Inhibition Downregulates ERCC2 and Suppresses the Growth of Metastatic Colon Cancer Cells.
Colonic Neoplasms
Different involvement of DNA methylation and histone deacetylation in the expression of solute-carrier transporters in 4 colon cancer cell lines.
Colonic Neoplasms
DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory.
Colonic Neoplasms
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
Colonic Neoplasms
Effect of 5-Aza-2'-Deoxycytidine in Comparison to Valproic Acid and Trichostatin A on Histone Deacetylase 1, DNA Methyltransferase 1, and CIP/KIP Family (p21, p27, and p57) Genes Expression, Cell Growth Inhibition, and Apoptosis Induction in Colon Cancer SW480 Cell Line.
Colonic Neoplasms
Effect of Curcumin in Comparison with Trichostatin A on the Reactivation of Estrogen Receptor Alpha gene Expression, Cell Growth Inhibition and Apoptosis Induction in Hepatocellular Carcinoma Hepa 1-6 Cell lLine.
Colonic Neoplasms
Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Cell Viability, and Apoptosis Induction in Hepatocellular Carcinoma HepG2 Cell Line.
Colonic Neoplasms
Enhanced Solubility, Permeability and Anticancer Activity of Vorinostat Using Tailored Mesoporous Silica Nanoparticles.
Colonic Neoplasms
Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy.
Colonic Neoplasms
Epigenetic regulation of the 1,25-dihydroxyvitamin D(3) 24-hydroxylase (CYP24A1) in colon cancer cells.
Colonic Neoplasms
Epigenetic silencing of the sulfate transporter gene DTDST induces sialyl Lewisx expression and accelerates proliferation of colon cancer cells.
Colonic Neoplasms
Evaluation of Novel 3-Hydroxyflavone Analogues as HDAC Inhibitors against Colorectal Cancer.
Colonic Neoplasms
Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer.
Colonic Neoplasms
G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer.
Colonic Neoplasms
Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells.
Colonic Neoplasms
HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha.
Colonic Neoplasms
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.
Colonic Neoplasms
HDAC10 expression is associated with DNA mismatch repair gene and is a predictor of good prognosis in colon carcinoma.
Colonic Neoplasms
HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity.
Colonic Neoplasms
HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling.
Colonic Neoplasms
HDAC3 overexpression and colon cancer cell proliferation and differentiation.
Colonic Neoplasms
Heterocyclic Analogs of Sulforaphane Trigger DNA Damage and Impede DNA Repair in Colon Cancer Cells: Interplay of HATs and HDACs.
Colonic Neoplasms
Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer.
Colonic Neoplasms
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.
Colonic Neoplasms
Histone deacetylase 6 is overexpressed and promotes tumor growth of colon cancer through regulation of the MAPK/ERK signal pathway.
Colonic Neoplasms
Histone deacetylase 6 selective inhibitor ACY1215 inhibits cell proliferation and enhances the chemotherapeutic effect of 5-fluorouracil in HCT116 cells.
Colonic Neoplasms
Histone deacetylase inhibitor scriptaid induces cell cycle arrest and epigenetic change in colon cancer cells.
Colonic Neoplasms
Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein.
Colonic Neoplasms
Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of CDKN1A.
Colonic Neoplasms
Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells.
Colonic Neoplasms
Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells.
Colonic Neoplasms
Histone deacetylase inhibitors upregulate MMP11 gene expression through Sp1/Smad complexes in human colon adenocarcinoma cells.
Colonic Neoplasms
Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly.
Colonic Neoplasms
Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice.
Colonic Neoplasms
Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly.
Colonic Neoplasms
Induction of differentiation of colon cancer cells by combined inhibition of kinases and histone deacetylase.
Colonic Neoplasms
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.
Colonic Neoplasms
Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells.
Colonic Neoplasms
Inhibition of growth and induction of differentiation markers by polyphenolic molecules and histone deacetylase inhibitors in colon cancer cells.
Colonic Neoplasms
Investigation of the Effect of Zebularine in Comparison to and in Combination with Trichostatin A on p21Cip1/Waf1/ Sdi1, p27Kip1, p57Kip2, DNA Methyltransferases and Histone Deacetylases in Colon Cancer LS 180 Cell Line.
Colonic Neoplasms
Mcl-1 Phosphorylation without Degradation Mediates Sensitivity to HDAC Inhibitors by Liberating BH3-Only Proteins.
Colonic Neoplasms
MicroRNA-429 inhibits the migration and invasion of colon cancer cells by targeting PAK6/cofilin signaling.
Colonic Neoplasms
MicroRNAs that respond to histone deacetylase inhibitor SAHA and p53 in HCT116 human colon carcinoma cells.
Colonic Neoplasms
Nardilysin controls intestinal tumorigenesis through HDAC1/p53-dependent transcriptional regulation.
Colonic Neoplasms
Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
Colonic Neoplasms
Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators.
Colonic Neoplasms
Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors.
Colonic Neoplasms
Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
Colonic Neoplasms
PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes.
Colonic Neoplasms
Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat.
Colonic Neoplasms
Quantitative Analysis of Histone Deacetylase-1 Selective Histone Modifications by Differential Mass Spectrometry.
Colonic Neoplasms
Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.
Colonic Neoplasms
RAR? acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.
Colonic Neoplasms
Recruitment of ataxia-telangiectasia mutated to the p21(waf1) promoter by ZBP-89 plays a role in mucosal protection.
Colonic Neoplasms
SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin.
Colonic Neoplasms
Selenium-binding protein 1 is associated with the degree of colorectal cancer differentiation and is regulated by histone modification.
Colonic Neoplasms
SET7 interacts with HDAC6 and suppresses the development of colon cancer through inactivation of HDAC6.
Colonic Neoplasms
Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line.
Colonic Neoplasms
Sp1 is a transcription repressor to stanniocalcin-1 expression in TSA-treated human colon cancer cells, HT29.
Colonic Neoplasms
Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis.
Colonic Neoplasms
Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells.
Colonic Neoplasms
Sulfide-detoxifying enzymes in the human colon are decreased in cancer and upregulated in differentiation.
Colonic Neoplasms
Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells.
Colonic Neoplasms
Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apcmin mice.
Colonic Neoplasms
Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects.
Colonic Neoplasms
Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer in vitro.
Colonic Neoplasms
Synthesis and biological activity of diisothiocyanate-derived mercapturic acids.
Colonic Neoplasms
Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.
Colonic Neoplasms
The Australian fruit Illawarra plum (Podocarpus elatus Endl., Podocarpaceae) inhibits telomerase, increases histone deacetylase activity and decreases proliferation of colon cancer cells.
Colonic Neoplasms
The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling.
Colonic Neoplasms
The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
Colonic Neoplasms
The Effects of 5-Aza-2'-Deoxycytidine and Valproic Acid on Apoptosis Induction and Cell Growth Inhibition in Colon Cancer HT 29 Cell Line.
Colonic Neoplasms
The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells.
Colonic Neoplasms
The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Colonic Neoplasms
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
Colonic Neoplasms
The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Colonic Neoplasms
The Intestinal Epithelial Cell Differentiation Marker Intestinal Alkaline Phosphatase (ALPi) Is Selectively Induced by Histone Deacetylase Inhibitors (HDACi) in Colon Cancer Cells in a Kruppel-like Factor 5 (KLF5)-dependent Manner.
Colonic Neoplasms
The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner.
Colonic Neoplasms
The novel HDAC inhibitor AR-42-induced anti-colon cancer cell activity is associated with ceramide production.
Colonic Neoplasms
The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells.
Colonic Neoplasms
The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer.
Colonic Neoplasms
Trichostatin A induces apoptosis in lung cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway?
Colonic Neoplasms
Trichostatin-A modulates claudin-1 mRNA stability through the modulation of Hu antigen R and tristetraprolin in colon cancer cells.
Colonic Neoplasms
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Colonic Neoplasms
[Regulation of histone acetylation on the expression of cell cycle-associated genes in human colon cancer cell lines]
Colorectal Neoplasms
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer.
Colorectal Neoplasms
A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKC? and E-cadherin.
Colorectal Neoplasms
A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
Colorectal Neoplasms
A novel HDAC1 inhibitor, CBUD?1001, exerts anticancer effects by modulating the apoptosis and EMT of colorectal cancer cells.
Colorectal Neoplasms
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Colorectal Neoplasms
Anti-Tumor Effects of Paeoniflorin on Epithelial-To-Mesenchymal Transition in Human Colorectal Cancer Cells.
Colorectal Neoplasms
Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo.
Colorectal Neoplasms
Association between histone deacetylase activity and vitamin D-dependent gene expressions in relation to sulforaphane in human colorectal cancer cells.
Colorectal Neoplasms
Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.
Colorectal Neoplasms
Butyrate production from high-fiber diet protects against lymphoma tumor.
Colorectal Neoplasms
Butyrate suppresses motility of colorectal cancer cells via deactivating Akt/ERK signaling in histone deacetylase dependent manner.
Colorectal Neoplasms
Carcinoembryonic Antigen Expression and Resistance to Radiation and 5-Fluorouracil-Induced Apoptosis and Autophagy.
Colorectal Neoplasms
CBX4 Suppresses Metastasis via Recruitment of HDAC3 to the Runx2 Promoter in Colorectal Carcinoma.
Colorectal Neoplasms
CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway.
Colorectal Neoplasms
Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer.
Colorectal Neoplasms
Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo.
Colorectal Neoplasms
Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies.
Colorectal Neoplasms
Compound K, a metabolite of ginseng saponin, inhibits colorectal cancer cell growth and induces apoptosis through inhibition of histone deacetylase activity.
Colorectal Neoplasms
Comprehensive suppression of all apoptosis-induced proliferation pathways as a proposed approach to colorectal cancer prevention and therapy.
Colorectal Neoplasms
Deregulated expression of HDAC3 in colorectal cancer and its clinical significance.
Colorectal Neoplasms
Determination of the Role of CBP- and p300-Mediated Wnt Signaling on Colonic Cells.
Colorectal Neoplasms
Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells.
Colorectal Neoplasms
Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer.
Colorectal Neoplasms
Effect of sodium butyrate on HDAC8 mRNA expression in colorectal cancer cell lines and molecular docking study of LHX1 - sodium butyrate interaction.
Colorectal Neoplasms
Effect of Sodium Butyrate on LHX1 mRNA Expression as a Transcription Factor of HDAC8 in Human Colorectal Cancer Cell Lines.
Colorectal Neoplasms
Effects of histone deacetylase inhibitors on ATP-binding cassette transporters in lung cancer A549 and colorectal cancer HCT116 cells.
Colorectal Neoplasms
Enhanced efficacy of 5-fluorouracil in combination with a dual histone deacetylase and phosphatidylinositide 3-kinase inhibitor (CUDC-907) in colorectal cancer cells.
Colorectal Neoplasms
Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer.
Colorectal Neoplasms
Epigenetic modifiers 5-aza-2'-deoxycytidine and valproic acid differentially change viability, DNA damage and gene expression in metastatic and non-metastatic colon cancer cell lines.
Colorectal Neoplasms
ERas oncogene expression and epigenetic regulation by histone acetylation in human cancer cells.
Colorectal Neoplasms
Evaluation of Novel 3-Hydroxyflavone Analogues as HDAC Inhibitors against Colorectal Cancer.
Colorectal Neoplasms
Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay.
Colorectal Neoplasms
Expression of 15-lipoxygenase-1 is regulated by histone acetylation in human colorectal carcinoma.
Colorectal Neoplasms
FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression.
Colorectal Neoplasms
Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and Carcinoma.
Colorectal Neoplasms
GPR126 regulates colorectal cancer cell proliferation by mediating HDAC2 and GLI2 expression.
Colorectal Neoplasms
HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment.
Colorectal Neoplasms
HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
Colorectal Neoplasms
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.
Colorectal Neoplasms
HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population.
Colorectal Neoplasms
HDAC2 and TXNL1 distinguish aneuploid from diploid colorectal cancers.
Colorectal Neoplasms
HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer.
Colorectal Neoplasms
HDAC2 promotes the EMT of colorectal cancer cells and via the modular scaffold function of ENSG00000274093.1.
Colorectal Neoplasms
HDAC3 deteriorates colorectal cancer progression via microRNA-296-3p/TGIF1/TGF? axis.
Colorectal Neoplasms
HDAC5 promotes colorectal cancer cell proliferation by up-regulating DLL4 expression.
Colorectal Neoplasms
HIPK2 phosphorylates HDAC3 for NF-?B acetylation to ameliorate colitis-associated colorectal carcinoma and sepsis.
Colorectal Neoplasms
Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription.
Colorectal Neoplasms
Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster.
Colorectal Neoplasms
Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail.
Colorectal Neoplasms
Histone Deacetylase Inhibitors Activate Tristetraprolin Expression through Induction of Early Growth Response Protein 1 (EGR1) in Colorectal Cancer Cells.
Colorectal Neoplasms
Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects.
Colorectal Neoplasms
Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells.
Colorectal Neoplasms
Histone deacetylase inhibitors regulate P-gp expression in colorectal cancer via transcriptional activation and mRNA stabilization.
Colorectal Neoplasms
Hypothesis: Retinoblastoma protein inactivation mediates effects of histone deacetylase inhibitor-induced Wnt hyperactivation in colorectal cancer cells.
Colorectal Neoplasms
Hypothesis: Sam68 and Pygo2 mediate cell type-specific effects of the modulation of CBP-Wnt and p300-Wnt activities in Colorectal Cancer Cells.
Colorectal Neoplasms
In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer.
Colorectal Neoplasms
Increased transforming growth factor ? and interleukin 10 transcripts in peripheral blood mononuclear cells of colorectal cancer patients.
Colorectal Neoplasms
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.
Colorectal Neoplasms
Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state.
Colorectal Neoplasms
Integrative Transcriptomic Network Analysis of Butyrate Treated Colorectal Cancer Cells.
Colorectal Neoplasms
Ku70 is essential for histone deacetylase inhibitor trichostatin A-induced apoptosis.
Colorectal Neoplasms
Long noncoding RNA SBF2-AS1 promotes colorectal cancer proliferation and invasion by inhibiting miR-619-5p activity and facilitating HDAC3 expression.
Colorectal Neoplasms
Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation.
Colorectal Neoplasms
MicroRNA-455 suppresses the oncogenic function of HDAC2 in human colorectal cancer.
Colorectal Neoplasms
MiR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer.
Colorectal Neoplasms
MiR-761 inhibits colorectal cancer cell proliferation and invasion through targeting HDAC1.
Colorectal Neoplasms
MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-?-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells.
Colorectal Neoplasms
MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells.
Colorectal Neoplasms
Mutational analysis of mononucleotide repeats in HDAC4, 5, 6, 7, 9 and 11 genes in gastric and colorectal carcinomas with microsatellite instability.
Colorectal Neoplasms
Nemo-like kinase (NLK) primes colorectal cancer progression by releasing the E2F1 complex from HDAC1.
Colorectal Neoplasms
Novel ?-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
Colorectal Neoplasms
Nuclear expression of histone deacetylases and their histone modifications predicts clinical outcome in colorectal cancer.
Colorectal Neoplasms
OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.
Colorectal Neoplasms
Potent antitumor activity of Laccaic acid and Phenethyl isothiocyanate combination in colorectal cancer via dual inhibition of DNA methyltransferase-1 and Histone deacetylase-1.
Colorectal Neoplasms
Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
Colorectal Neoplasms
Preclinical Pharmacokinetics and Pharmacodynamics and Content Analysis of Gnetol in Foodstuffs.
Colorectal Neoplasms
Protocatechualdehyde possesses anti-cancer activity through downregulating cyclin D1 and HDAC2 in human colorectal cancer cells.
Colorectal Neoplasms
Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
Colorectal Neoplasms
Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
Colorectal Neoplasms
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
Colorectal Neoplasms
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition.
Colorectal Neoplasms
Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer.
Colorectal Neoplasms
Retinoblastoma protein is required for efficient colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the absence of p21Waf.
Colorectal Neoplasms
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
Colorectal Neoplasms
SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Colorectal Neoplasms
SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter.
Colorectal Neoplasms
Sodium Butyrate as a Histone Deacetylase Inhibitor Affects Toll-Like Receptor 4 Expression in Colorectal Cancer Cell Lines.
Colorectal Neoplasms
SOX4 maintains the stemness of cancer cells via transcriptionally enhancing HDAC1 revealed by comparative proteomics study.
Colorectal Neoplasms
Structure-activity relationship of butyrate analogues on apoptosis, proliferation and histone deacetylase activity in HCT-116 human colorectal cancer cells.
Colorectal Neoplasms
Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells.
Colorectal Neoplasms
Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers.
Colorectal Neoplasms
Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53.
Colorectal Neoplasms
Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action.
Colorectal Neoplasms
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Colorectal Neoplasms
TCF7L1 recruits CtBP and HDAC1 to repress DICKKOPF4 gene expression in human colorectal cancer cells.
Colorectal Neoplasms
The APC tumor suppressor counteracts beta-catenin activation and H3K4 methylation at Wnt target genes.
Colorectal Neoplasms
The contribution of activating transcription factor 3 to apoptosis of human colorectal cancer cells by protocatechualdehyde, a naturally occurring phenolic compound.
Colorectal Neoplasms
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
Colorectal Neoplasms
The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy.
Colorectal Neoplasms
The HDAC1 Inhibitor CBUD-1001 Enhances TRAIL-induced Apoptosis in Colorectal Cancer Cells.
Colorectal Neoplasms
The HDAC6 inhibitor ACY?1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells.
Colorectal Neoplasms
The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death.
Colorectal Neoplasms
The HDAC6 Inhibitor Tubacin Induces Release of CD133(+) Extracellular Vesicles From Cancer Cells.
Colorectal Neoplasms
The histone deacetylase HDAC1 activates HIF1?/VEGFA signal pathway in colorectal cancer.
Colorectal Neoplasms
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
Colorectal Neoplasms
The histone deacetylase inhibitor trichostatin A induces cell cycle arrest and apoptosis in colorectal cancer cells via p53-dependent and -independent pathways.
Colorectal Neoplasms
The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment.
Colorectal Neoplasms
The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes.
Colorectal Neoplasms
The roles of microbial products in the development of colorectal cancer: a review.
Colorectal Neoplasms
The Significance of MicroRNA-449a and Its Potential Target HDAC1 in Patients With Colorectal Cancer.
Colorectal Neoplasms
Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis.
Colorectal Neoplasms
Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells.
Colorectal Neoplasms
Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells.
Colorectal Neoplasms
Untangling the fiber yarn: butyrate feeds Warburg to suppress colorectal cancer.
Colorectal Neoplasms
Up-regulation of UVRAG by HDAC1 Inhibition Attenuates 5FU-induced Cell Death in HCT116 Colorectal Cancer Cells.
Colorectal Neoplasms
Upregulation of AKAP12 with HDAC3 depletion suppresses the progression and migration of colorectal cancer.
Colorectal Neoplasms
USP38 regulates the stemness and chemoresistance of human colorectal cancer via regulation of HDAC3.
Colorectal Neoplasms
Valproic acid protects intestinal organoids against radiation via NOTCH signaling.
Colorectal Neoplasms
Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms.
Colorectal Neoplasms
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models.
Colorectal Neoplasms
Vorinostat and hydroxychloroquine improve immunity and inhibit autophagy in metastatic colorectal cancer.
Colorectal Neoplasms
Whole Exome Sequencing Identifies APCDD1 and HDAC5 Genes as Potentially Cancer Predisposing in Familial Colorectal Cancer.
Colorectal Neoplasms
[Validation and Evaluation of Diagnostic Efficiency of Genes Associated with Colorectal Cancer with Hyperglycemia].
Colorectal Neoplasms, Hereditary Nonpolyposis
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Communicable Diseases
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Communicable Diseases
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy.
Communicable Diseases
Modulation of cathelicidin and defensins by histone deacetylase inhibitors: A potential treatment for multi-drug resistant infectious diseases.
Communicable Diseases
Non-cancer uses of histone deacetylase inhibitors: effects on infectious diseases and beta-hemoglobinopathies.
Congenital Abnormalities
Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen.
Congenital Abnormalities
OCT4A contributes to the stemness and multi-potency of human umbilical cord blood-derived multipotent stem cells (hUCB-MSCs).
Connective Tissue Diseases
[Effect of histone deacetylase 2 and 4 activity on connective tissue disease associated pulmonary fibrosis in mice].
Corneal Neovascularization
Effect of Histone Deacetylase Inhibitor, Butyroyloxymethyl-Diethyl Phosphate (AN-7), on Corneal Neovascularization in a Mouse Model.
Coronary Artery Disease
Deficiency of the stroke relevant HDAC9 gene attenuates atherosclerosis in accord with allele-specific effects at 7p21.1.
Coronary Artery Disease
HDAC9 Variant Rs2107595 Modifies Susceptibility to Coronary Artery Disease and the Severity of Coronary Atherosclerosis in a Chinese Han Population.
Coronary Artery Disease
Polymorphism of HDAC9 Gene Is Associated with Increased Risk of Acute Coronary Syndrome in Chinese Han Population.
Coronary Artery Disease
The Atherosclerosis Risk Variant rs2107595 Mediates Allele-Specific Transcriptional Regulation of HDAC9 via E2F3 and Rb1.
COVID-19
A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection.
COVID-19
Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19.
COVID-19
Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-? signalling in COVID-19 survivors.
COVID-19
The pharmacological mechanism of Huashi Baidu Formula for the treatment of COVID-19 by combined network pharmacology and molecular docking.
Craniocerebral Trauma
[INVOLVEMENT OF EPIGENETIC REGULATION IN CEREBRAL CELL DEATH FOLLOWING TRAUMATIC BRAIN INJURY IN A RAT MODEL].
Craniofacial Abnormalities
Murine craniofacial development requires Hdac3-mediated repression of Msx gene expression.
Cryptorchidism
A De novo HDAC2 variant in a patient with features consistent with Cornelia de Lange syndrome phenotype.
Cushing Syndrome
Histone Deacetylase Inhibition Ameliorates Hypertension and Hyperglycemia in a model of Cushing's Syndrome.
Cushing Syndrome
Histone deacetylase inhibition attenuates hepatic steatosis in rats with experimental Cushing's syndrome.
Cystic Fibrosis
Alleviation of depression-like behavior in a cystic fibrosis mouse model by Hdac6 depletion.
Cystic Fibrosis
CTCF regulates positioning of the human cystic fibrosis gene in association with a histone deacetylase.
Cystic Fibrosis
HDAC6 depletion improves cystic fibrosis mouse airway responses to bacterial challenge.
Cystic Fibrosis
High-expressing cystic fibrosis transmembrane conductance regulator interacts with histone deacetylase 2 to promote the development of Ph+ leukemia through the HDAC2-mediated PTEN pathway.
Cystic Fibrosis
Histone acetylation and deacetylation: importance in inflammatory lung diseases.
Cystic Fibrosis
Improved Growth Patterns in Cystic Fibrosis Mice after Loss of Histone Deacetylase 6.
Cystic Fibrosis
Perinuclear positioning of the inactive human cystic fibrosis gene depends on CTCF, A-type lamins and an active histone deacetylase.
Cystic Fibrosis
Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
Cystic Fibrosis
Regulation of the Coxsackie and adenovirus receptor expression is dependent on cystic fibrosis transmembrane regulator in airway epithelial cells.
Cystic Fibrosis
Rescuing Trafficking Mutants of the ATP-binding Cassette Protein, ABCA4, with Small Molecule Correctors as a Treatment for Stargardt Eye Disease.
Cystic Fibrosis
The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation.
Cystitis
Histone deacetylase inhibitors mediate DNA damage repair in ameliorating hemorrhagic cystitis.
Cysts
Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: inhibition of stage conversion of the parasite cyst form and study of new derivative compounds.
Cysts
AN INHIBITOR OF HISTONE DEACETYLASE 6 ACTIVITY, ACY-1215, REDUCES cAMP and CYST GROWTH IN POLYCYSTIC KIDNEY DISEASE.
Cysts
CCAAT/Enhancer-Binding Protein ? Is Epigenetically Silenced by Histone Deacetylation in Endometriosis and Promotes the Pathogenesis of Endometriosis.
Cysts
Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Cysts
HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis.
Cysts
Histone deacetylase 6 Inhibition reduces cysts by decreasing via cAMP and Ca2+ in knockout mouse models of polycystic kidney disease.
Cysts
Histone Deacetylase Inhibitors Reduce Cysts by Activating Autophagy in Polycystic Kidney Disease.
Cysts
Histone deacetylases 6 increases the cyclic adenosine monophosphate level and promotes renal cyst growth.
Cysts
Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Cysts
Polycystin-dependent fluid flow sensing targets histone deacetylase 5 to prevent the development of renal cysts.
Cysts
The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42.
De Lange Syndrome
A commentary on exome sequencing identifies a de novo mutation in HDAC8 associated with Cornelia de Lange syndrome.
De Lange Syndrome
A De novo HDAC2 variant in a patient with features consistent with Cornelia de Lange syndrome phenotype.
De Lange Syndrome
A Functional Mutation in HDAC8 Gene as Novel Diagnostic Marker for Cornelia De Lange Syndrome.
De Lange Syndrome
A novel de novo HDAC8 missense mutation causing Cornelia de Lange syndrome.
De Lange Syndrome
An in silico mechanistic insight into HDAC8 activation facilitates the discovery of new small-molecule activators.
De Lange Syndrome
Biochemical and structural characterization of HDAC8 mutants associated with Cornelia de Lange syndrome spectrum disorders.
De Lange Syndrome
Compromised structure and function of HDAC8 mutants identified in Cornelia de Lange Syndrome spectrum disorders.
De Lange Syndrome
Exome sequencing identifies a de novo mutation in HDAC8 associated with Cornelia de Lange syndrome.
De Lange Syndrome
HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle.
De Lange Syndrome
Modeling Cornelia de Lange Syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation.
De Lange Syndrome
Molecular characterization of HDAC8 deletions in individuals with atypical Cornelia de Lange syndrome.
De Lange Syndrome
Molecular characterization of two novel intronic variants of NIPBL gene detected in unrelated Cornelia de Lange syndrome patients.
De Lange Syndrome
Mutant cohesin affects RNA polymerase II regulation in Cornelia de Lange syndrome.
De Lange Syndrome
NIPBL Controls RNA Biogenesis to Prevent Activation of the Stress Kinase PKR.
De Lange Syndrome
Rare copy number variants contribute pathogenic alleles in patients with intestinal malrotation.
De Lange Syndrome
Structural analysis of histone deacetylase 8 mutants associated with Cornelia de Lange Syndrome spectrum disorders.
De Lange Syndrome
Structural aspects of HDAC8 mechanism and dysfunction in Cornelia de Lange syndrome spectrum disorders.
De Lange Syndrome
[Clinical and genetic analysis of a neonate with Cornelia de Lange syndrome 5 caused by HDAC8 gene mutation].
Deafness
A core SMRT corepressor complex containing HDAC3 and TBL1, a WD40-repeat protein linked to deafness.
Dehydration
AhHDA1-mediated AhGLK1 promoted chlorophyll synthesis and photosynthesis regulates recovery growth of peanut leaves after water stress.
Dementia
Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions.
Dementia
Arsenic toxicity induced endothelial dysfunction and dementia: Pharmacological interdiction by histone deacetylase and inducible nitric oxide synthase inhibitors.
Dementia
Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.
Dementia
Post-occlusion administration of sodium butyrate attenuates cognitive impairment in a rat model of chronic cerebral hypoperfusion.
Dementia
Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment.
Dementia
Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.
Dementia, Vascular
Donepezil attenuates vascular dementia in rats through increasing BDNF induced by reducing HDAC6 nuclear translocation.
Demyelinating Diseases
Epigenetic in Multiple Sclerosis: Molecular mechanisms and dietary intervention.
Demyelinating Diseases
Fingolimod (FTY720) improves the functional recovery and myelin preservation of the optic pathway in focal demyelination model of rat optic chiasm.
Demyelinating Diseases
HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage.
Demyelinating Diseases
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Dermatitis
The histone deacetylase inhibitor, trichostatin A, inhibits the development of 2,4-dinitrofluorobenzene-induced dermatitis in NC/Nga mice.
Dermatitis, Contact
Entinostat, a histone deacetylase inhibitor, increases the population of IL-10+ regulatory B cells to suppress contact hypersensitivity.
Dermatitis, Contact
Induction of Foxp3+ regulatory T cells with histone deacetylase inhibitors.
Dermatitis, Phototoxic
Novel dual-mode antitumor chlorin-based derivatives as potent photosensitizers and histone deacetylase inhibitors for photodynamic therapy and chemotherapy.
Diabetes Complications
Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy.
Diabetes Mellitus
Acetylation of Hsp90 reverses dexamethasone-mediated inhibition of insulin secretion.
Diabetes Mellitus
Acute exercise and periodized training in different environments affect histone deacetylase activity and interleukin-10 levels in peripheral blood of patients with type 2 diabetes.
Diabetes Mellitus
Co-location of HDAC2 and Insulin Signaling Components in the Adult Mouse Hippocampus.
Diabetes Mellitus
HDAC9 rs11984041 polymorphism is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes mellitus.
Diabetes Mellitus
Histone Deacetylase 3 Aggravates Type 1 Diabetes Mellitus by Inhibiting Lymphocyte Apoptosis Through the microRNA-296-5p/Bcl-xl Axis.
Diabetes Mellitus
Histone deacetylase inhibition of cardiac autophagy in rats on a high?fat diet with low?dose streptozotocin-induced type 2 diabetes mellitus.
Diabetes Mellitus
Interactive Effects of a Combination of the HDAC3 and HDAC9 Genes with Diabetes Mellitus on the Risk of Ischemic Stroke.
Diabetes Mellitus
O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart From Failure.
Diabetes Mellitus
SIRT3 alleviates neuropathic pain by deacetylating FoxO3a in the spinal dorsal horn of diabetic model rats.
Diabetes Mellitus
The role of butyrate, a histone deacetylase inhibitor in diabetes mellitus: experimental evidence for therapeutic intervention.
Diabetes Mellitus, Type 1
Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes.
Diabetes Mellitus, Type 1
Histone Deacetylase 3 Aggravates Type 1 Diabetes Mellitus by Inhibiting Lymphocyte Apoptosis Through the microRNA-296-5p/Bcl-xl Axis.
Diabetes Mellitus, Type 1
Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes.
Diabetes Mellitus, Type 1
Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics.
Diabetes Mellitus, Type 1
Inhibition of HDAC3 prevents diabetic cardiomyopathy in OVE26 mice via epigenetic regulation of DUSP5-ERK1/2 pathway.
Diabetes Mellitus, Type 1
Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes.
Diabetes Mellitus, Type 1
Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice.
Diabetes Mellitus, Type 1
Use of a cocktail regimen consisting of soluble galectin-1, rapamycin and histone deacetylase inhibitor may effectively prevent type 1 diabetes.
Diabetes Mellitus, Type 2
Acute exercise and periodized training in different environments affect histone deacetylase activity and interleukin-10 levels in peripheral blood of patients with type 2 diabetes.
Diabetes Mellitus, Type 2
Class IIa HDACs do not influence beta-cell function under normal or high glucose conditions.
Diabetes Mellitus, Type 2
HDAC3 inhibition prevents blood-brain barrier permeability through Nrf2 activation in type 2 diabetes male mice.
Diabetes Mellitus, Type 2
HDAC7 is overexpressed in human diabetic islets and impairs insulin secretion in rat islets and clonal beta cells.
Diabetes Mellitus, Type 2
HDAC9 rs11984041 polymorphism is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Histone deacetylase 3 inhibition alleviates type 2 diabetes mellitus-induced endothelial dysfunction via Nrf2.
Diabetes Mellitus, Type 2
Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats.
Diabetes Mellitus, Type 2
Histone deacetylase 6 regulates insulin signaling in pancreatic ? cells.
Diabetes Mellitus, Type 2
Histone deacetylase inhibition of cardiac autophagy in rats on a high?fat diet with low?dose streptozotocin-induced type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes.
Diabetes Mellitus, Type 2
Histone deacetylase regulates insulin signaling via two pathways in pancreatic ? cells.
Diabetes Mellitus, Type 2
Histone modifications and skeletal muscle metabolic gene expression.
Diabetes Mellitus, Type 2
Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue.
Diabetes Mellitus, Type 2
MC1568 improves insulin secretion in islets from type 2 diabetes patients and rescues ?-cell dysfunction caused by Hdac7 upregulation.
Diabetes Mellitus, Type 2
O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart From Failure.
Diabetes Mellitus, Type 2
SIRT3 alleviates neuropathic pain by deacetylating FoxO3a in the spinal dorsal horn of diabetic model rats.
Diabetes Mellitus, Type 2
Sirtuin1 (Sirt1) Promotes Cortical Bone Formation by Preventing ?-Catenin Sequestration by FoxO Transcription Factors in Osteoblast Progenitors.
Diabetes Mellitus, Type 2
The Metabolic Regulator Histone Deacetylase 9 Contributes to Glucose Homeostasis Abnormality Induced by Hepatitis C Virus Infection.
Diabetes Mellitus, Type 2
Trichostatin A affects the secretion pathways of beta and intestinal endocrine cells.
Diabetic Cardiomyopathies
Inhibition of HDAC3 prevents diabetic cardiomyopathy in OVE26 mice via epigenetic regulation of DUSP5-ERK1/2 pathway.
Diabetic Cardiomyopathies
O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart From Failure.
Diabetic Nephropathies
Cyclo-RGD Truncated Polymeric Nanoconstruct with Dendrimeric Templates for Targeted HDAC4 Gene Silencing in a Diabetic Nephropathy Mouse Model.
Diabetic Nephropathies
Glomerular mesangial cell and podocyte injuries in diabetic nephropathy.
Diabetic Nephropathies
HDAC4 blocks autophagy to trigger podocyte injury: non-epigenetic action in diabetic nephropathy.
Diabetic Nephropathies
HDAC6-mediated ?-tubulin deacetylation suppresses autophagy and enhances motility of podocytes in diabetic nephropathy.
Diabetic Nephropathies
Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy.
Diabetic Nephropathies
Histone deacetylase inhibitor valproic acid attenuates high glucose?induced endoplasmic reticulum stress and apoptosis in NRK?52E cells.
Diabetic Nephropathies
Histone deacetylase inhibitors: a novel class of therapeutic agents in diabetic nephropathy.
Diabetic Nephropathies
Mesenchymal Stem Cell-Derived Exosomes Carry MicroRNA-125a to Protect Against Diabetic Nephropathy by Targeting Histone Deacetylase 1 and Downregulating Endothelin-1.
Diabetic Nephropathies
Method and its Composition for encapsulation, stabilization, and delivery of siRNA in Anionic polymeric nanoplex: An In vitro- In vivo Assessment.
Diabetic Nephropathies
Silencing of Histone Deacetylase 9 Expression in Podocytes Attenuates Kidney Injury in Diabetic Nephropathy.
Diabetic Retinopathy
Dynamic Expression of HDAC3 in db/db Mouse RGCs and Its Relationship with Apoptosis and Autophagy.
Diabetic Retinopathy
Epigenetic control of early neurodegenerative events in diabetic retinopathy by the histone deacetylase SIRT6.
Diabetic Retinopathy
HDAC9 rs11984041 polymorphism is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes mellitus.
Diabetic Retinopathy
Inhibition of HDAC6 Attenuates Diabetes-Induced Retinal Redox Imbalance and Microangiopathy.
Diabetic Retinopathy
Overexpression of histone deacetylase SIRT1 exerts an anti-angiogenic role in diabetic retinopathy via miR-20a elevation and YAP/HIF1?/VEGFA depletion.
Diabetic Retinopathy
The anti-angiogenesis role of FBXW7 in diabetic retinopathy by facilitating the ubiquitination degradation of c-Myc to orchestrate the HDAC2.
Diffuse Intrinsic Pontine Glioma
Phase 1/2 Trial of Vorinostat and Radiation and Maintenance Vorinostat in Children with Diffuse Intrinsic Pontine Glioma: A Children's Oncology Group Report.
Disorders of Sex Development
Sex differences in autophagy-mediated diseases: toward precision medicine.
Double Outlet Right Ventricle
Histone Deacetylase 3 Coordinates Deacetylase-independent Epigenetic Silencing of Transforming Growth Factor-?1 (TGF-?1) to Orchestrate Second Heart Field Development.
Ductus Arteriosus, Patent
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Dyskinesias
RGFP109, a histone deacetylase inhibitor attenuates l-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: A proof-of-concept study.
Dyslipidemias
MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex.
Embolic Stroke
Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study.
Embolic Stroke
Low-frequency and common genetic variation in ischemic stroke: The METASTROKE collaboration.
Encephalitis
Inhibition of HDAC6 alleviating lipopolysaccharide-induced p38MAPK phosphorylation and neuroinflammation in mice.
Encephalitis, Japanese
Histone deacetylase inhibition by Japanese encephalitis virus in monocyte/macrophages: a novel viral immune evasion strategy.
Encephalitis, Japanese
Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis.
Encephalomyelitis
A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis.
Encephalomyelitis
Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats.
Encephalomyelitis
Histone deacetylase 1 controls CD4+ T cell trafficking in autoinflammatory diseases.
Encephalomyelitis
The epigenetic drug Trichostatin A ameliorates experimental autoimmune encephalomyelitis via T cell tolerance induction and impaired influx of T cells into the spinal cord.
Encephalomyelitis
The Selective HDAC6 Inhibitor ACY-738 Impacts Memory and Disease Regulation in an Animal Model of Multiple Sclerosis.
Encephalomyelitis
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Encephalomyelitis
Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
A T cell-specific deletion of HDAC1 protects against experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats.
Encephalomyelitis, Autoimmune, Experimental
Epigenetics of Multiple Sclerosis: An Updated Review.
Encephalomyelitis, Autoimmune, Experimental
Histone deacetylase 1 controls CD4+ T cell trafficking in autoinflammatory diseases.
Encephalomyelitis, Autoimmune, Experimental
The epigenetic drug Trichostatin A ameliorates experimental autoimmune encephalomyelitis via T cell tolerance induction and impaired influx of T cells into the spinal cord.
Encephalomyelitis, Autoimmune, Experimental
The Selective HDAC6 Inhibitor ACY-738 Impacts Memory and Disease Regulation in an Animal Model of Multiple Sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
Endocrine Gland Neoplasms
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
Endocrine System Diseases
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Endometrial Neoplasms
A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells.
Endometrial Neoplasms
A New Synthetic Histone Deacetylase Inhibitor, MHY2256, Induces Apoptosis and Autophagy Cell Death in Endometrial Cancer Cells via p53 Acetylation.
Endometrial Neoplasms
A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
Endometrial Neoplasms
Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer.
Endometrial Neoplasms
Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4.
Endometrial Neoplasms
Anticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells.
Endometrial Neoplasms
Antioxidants impair anti-tumoral effects of vorinostat, but not anti-neoplastic effects of vorinostat and caspase-8 downregulation.
Endometrial Neoplasms
CBHA Is a Family of Hybrid Polar Compounds That Inhibit Histone Deacetylase, and Induces Growth Inhibition, Cell Cycle Arrest and Apoptosis in Human Endometrial and Ovarian Cancer Cells.
Endometrial Neoplasms
Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
Endometrial Neoplasms
Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Endometrial Neoplasms
Discovery of epigenetically masked tumor suppressor genes in endometrial cancer.
Endometrial Neoplasms
DNMT Inhibitors and HDAC Inhibitors Regulate E-Cadherin and Bcl-2 Expression in Endometrial Carcinoma in vitro and in vivo.
Endometrial Neoplasms
Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment.
Endometrial Neoplasms
HDAC6, modulated by miR-206, promotes endometrial cancer progression through the PTEN/AKT/mTOR pathway.
Endometrial Neoplasms
Histone deacetylase 1 facilitates aerobic glycolysis and growth of endometrial cancer.
Endometrial Neoplasms
Histone deacetylase inhibitor, Romidepsin (FK228) inhibits endometrial cancer cell growth through augmentation of p53-p21 pathway.
Endometrial Neoplasms
Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.
Endometrial Neoplasms
Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells.
Endometrial Neoplasms
Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells.
Endometrial Neoplasms
Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis.
Endometrial Neoplasms
Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells.
Endometrial Neoplasms
M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells.
Endometrial Neoplasms
Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer.
Endometrial Neoplasms
Retraction notice to "M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells" [Gynecol. Oncol. 101 (2006) 108-113].
Endometrial Neoplasms
Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53.
Endometrial Neoplasms
Targeting histone deacetylases in endometrial cancer: a paradigm-shifting therapeutic strategy?
Endometrial Neoplasms
[Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells]
Endometrial Stromal Tumors
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
Endometriosis
Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target.
Endometriosis
CCAAT/Enhancer-Binding Protein ? Is Epigenetically Silenced by Histone Deacetylation in Endometriosis and Promotes the Pathogenesis of Endometriosis.
Endometriosis
Constitutive and Tumor Necrosis Factor-Alpha-Stimulated Activation of Nuclear Factor-KappaB in Immortalized Endometriotic Cells and Their Suppression by Trichostatin A.
Endometriosis
Histone acetylation in reproductive organs: Significance of histone deacetylase inhibitors in gene transcription.
Endometriosis
KRAS Activation and over-expression of SIRT1/BCL6 Contributes to the Pathogenesis of Endometriosis and Progesterone Resistance.
Endometriosis
The Expression of Histone Deacetylase 1, But Not Other Class I Histone Deacetylases, Is Significantly Increased in Endometriosis.
Endometriosis
Trichostatin A, a histone deacetylase inhibitor, attenuates invasiveness and reactivates E-cadherin expression in immortalized endometriotic cells.
Endometriosis
Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice.
Endometriosis
Valproic Acid and Progestin Inhibit Lesion Growth and Reduce Hyperalgesia in Experimentally Induced Endometriosis in Rats.
Endotoxemia
Combinatorial therapy with acetylation and methylation modifiers attenuates lung vascular hyperpermeability in endotoxemia-induced mouse inflammatory lung injury.
Endotoxemia
DNMT and HDAC inhibitors together abrogate endotoxemia mediated macrophage death by STAT3-JMJD3 signaling.
Endotoxemia
HDAC6 inhibition prevents TNF-?-induced caspase 3 activation in lung endothelial cell and maintains cell-cell junctions.
Endotoxemia
HDAC6 Mediates Macrophage iNOS Expression and Excessive Nitric Oxide Production in the Blood During Endotoxemia.
Endotoxemia
HIPK2 phosphorylates HDAC3 for NF-?B acetylation to ameliorate colitis-associated colorectal carcinoma and sepsis.
Endotoxemia
Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model.
Endotoxemia
Novel pharmacologic treatment attenuates septic shock and improves long-term survival.
Enteritis
Clostridium difficile toxin A decreases acetylation of tubulin, leading to microtubule depolymerization through activation of histone deacetylase 6, and this mediates acute inflammation.
Enzootic Bovine Leukosis
Chemoresistance to Valproate Treatment of Bovine Leukemia Virus-Infected Sheep; Identification of Improved HDAC Inhibitors.
Ependymoma
A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat.
Ependymoma
CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models.
Ependymoma
Ongoing Response in a Multiply Relapsed Metastatic Posterior Fossa Ependymoma A After Vorinostat and Concomitant Irradiation.
Ependymoma
Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma or Leukemia.
Epilepsy
A Sensitive Triple Quadrupole Liquid Chromatography Mass Spectrometric Method for the Estimation of Valproic Acid in K2EDTA Human Plasma using Furosemide as the Internal Standard.
Epilepsy
Acetylation regulates the stability of glutamate carboxypeptidase II protein in human astrocytes.
Epilepsy
B56 regulatory subunit of protein phosphatase 2A mediates valproic acid-induced p300 degradation.
Epilepsy
Effects of Histone Deacetylase Inhibitors on the Development of Epilepsy and Psychiatric Comorbidity in WAG/Rij Rats.
Epilepsy
Epigenetic Histone Deacetylation Inhibition Prevents the Development and Persistence of Temporal Lobe Epilepsy.
Epilepsy
Epigenetic Suppression of GADs Expression is Involved in Temporal Lobe Epilepsy and Pilocarpine-Induced Mice Epilepsy.
Epilepsy
Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro.
Epilepsy
Increased expression of histone deacetylases 2 in temporal lobe epilepsy: a study of epileptic patients and rat models.
Epilepsy
Involvement of PML nuclear bodies in CBP degradation through the ubiquitin-proteasome pathway.
Epilepsy
Lacosamide reduces HDAC levels in the brain and improves memory: Potential for treatment of Alzheimer's disease.
Epilepsy
miR-485 inhibits histone deacetylase HDAC5, HIF1? and PFKFB3 expression to alleviate epilepsy in cellular and rodent models.
Epilepsy
Myocardin-related transcription factor and serum response factor regulate cilium turnover by both transcriptional and local mechanisms.
Epilepsy
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.
Epilepsy
Primary cilia in stem cells and neural progenitors are regulated by neutral sphingomyelinase 2 and ceramide.
Epilepsy
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.
Epilepsy
Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway.
Epilepsy
Valproic acid increases NO production via the SH-PTP1-CDK5-eNOS-Ser(116) signaling cascade in endothelial cells and mice.
Epilepsy
Valproic acid induces astrocyte-dependent neurite outgrowth from cultured rat primary cortical neuron via modulation of tPA/PAI-1 activity.
Epilepsy
Valproic acid induces neuronal cell death through a novel calpain-dependent necroptosis pathway.
Epilepsy
Valproic acid induces up- or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions.
Epilepsy
Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.
Epilepsy
Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells.
Epilepsy, Absence
Pain Modulation in WAG/Rij Epileptic Rats (A Genetic Model of Absence Epilepsy): Effects of Biological and Pharmacological Histone Deacetylase Inhibitors.
Epilepsy, Temporal Lobe
Epigenetic Histone Deacetylation Inhibition Prevents the Development and Persistence of Temporal Lobe Epilepsy.
Epilepsy, Temporal Lobe
Increased expression of histone deacetylases 2 in temporal lobe epilepsy: a study of epileptic patients and rat models.
Esophageal Neoplasms
Combined proteasome and histone deacetylase inhibition attenuates epithelial-mesenchymal transition through E-cadherin in esophageal cancer cells.
Esophageal Neoplasms
Effects of siRNA-Mediated Knockdown of HDAC1 on the Biological Behavior of Esophageal Carcinoma Cell Lines.
Esophageal Neoplasms
Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression.
Esophageal Neoplasms
Genome-Wide Profiling of the Toxic Effect of Bortezomib on Human Esophageal Carcinoma Epithelial Cells.
Esophageal Neoplasms
Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
Esophageal Neoplasms
Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C).
Esophageal Neoplasms
Lentivirus-mediated Knockdown of HDAC1 Uncovers Its Role in Esophageal Cancer Metastasis and Chemosensitivity.
Esophageal Neoplasms
Modulation of E-cadherin expression promotes migration ability of esophageal cancer cells.
Esophageal Neoplasms
Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity.
Esophageal Neoplasms
Role of histone deacetylase inhibitor in adenovirus-mediated p53 gene therapy in esophageal cancer.
Esophageal Neoplasms
Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90.
Esophageal Neoplasms
SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
Esophageal Squamous Cell Carcinoma
Activation of PAR4 Upregulates p16 through Inhibition of DNMT1 and HDAC2 Expression via MAPK Signals in Esophageal Squamous Cell Carcinoma Cells.
Esophageal Squamous Cell Carcinoma
Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Effects of Down-regulation of HDAC6 Expression on Proliferation, Cell Cycling and Migration of Esophageal Squamous Cell Carcinoma Cells and Related Molecular Mechanisms.
Esophageal Squamous Cell Carcinoma
HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9.
Esophageal Squamous Cell Carcinoma
HDAC2 enhances esophageal squamous cell carcinoma development through down-regulating microRNA-503-5p and promoting CXCL10.
Esophageal Squamous Cell Carcinoma
HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells.
Esophageal Squamous Cell Carcinoma
Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo.
Esophageal Squamous Cell Carcinoma
Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
MiR-601 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma (ESCC) by targeting HDAC6.
Esophageal Squamous Cell Carcinoma
Oncogenic IL7R is downregulated by histone deacetylase inhibitor in esophageal squamous cell carcinoma via modulation of acetylated FOXO1.
Esophageal Squamous Cell Carcinoma
Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma.
Esophageal Squamous Cell Carcinoma
Pharmacological targeting of TNS3 with histone deacetylase inhibitor as a therapeutic strategy in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.
Esophageal Squamous Cell Carcinoma
Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90.
Esophageal Squamous Cell Carcinoma
The anti-tumor effects of dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A on inducing autophagy in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Esophageal Squamous Cell Carcinoma
Valproic acid inhibits irradiation-induced epithelial-mesenchymal transition and stem cell-like characteristics in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
Esophagitis
Aurora kinase A (AURKA) and never in mitosis gene A-related kinase 6 (NEK6) genes are upregulated in erosive esophagitis and esophageal adenocarcinoma.
Familial Primary Pulmonary Hypertension
Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension.
Familial Primary Pulmonary Hypertension
Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension.
Fanconi Anemia
VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression.
Fatty Liver
An HDAC3-PROX1 corepressor module acts on HNF4? to control hepatic triglycerides.
Fatty Liver
Binge Alcohol-Induced Microvesicular Liver Steatosis and Injury are Associated with Down-Regulation of Hepatic Hdac 1, 7, 9, 10, 11 and Up-Regulation of Hdac 3.
Fatty Liver
Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR?.
Fatty Liver
Histone deacetylase?2: A potential regulator and therapeutic target in liver disease (Review).
Fatty Liver
MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex.
Fatty Liver
The loss of histone deacetylase 4 in macrophages exacerbates hepatic and adipose tissue inflammation in male but not in female mice with diet-induced non-alcoholic steatohepatitis.
Fetal Death
Growth regulation, imprinting, and epigenetic transcription-related gene expression differs in lung of deceased transgenic cloned and normal goats.
Fibroadenoma
HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
Fibrosarcoma
Epigenetic regulation of proMMP-1 expression in the HT1080 human fibrosarcoma cell line.
Fibrosarcoma
Ferroptosis in Neurons and Cancer Cells Is Similar But Differentially Regulated by Histone Deacetylase Inhibitors.
Fibrosarcoma
Hypoacetylation in association with histone 3 modulation in human hepatocellular carcinoma.
Fibrosarcoma
Inhibition of hypoxia-induced angiogenesis by sodium butyrate, a histone deacetylase inhibitor, through hypoxia-inducible factor-1alpha suppression.
Fibrosarcoma
Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells.
Fibrosarcoma
The histone deacetylase inhibitor vorinostat selectively sensitizes fibrosarcoma cells to chemotherapy.
Fibrosarcoma
[Multikinase inhibitor sorafenib and HDAC inhibitor suberoylanilide hydroxamic acid suppress confluent resistance of cancer cells to recombinant protein izTRAIL].
Fibrous Dysplasia, Polyostotic
The new bone biology: pathologic, molecular, and clinical correlates.
Food Hypersensitivity
Flagellin modulates IgE expression in B cells to initiate food allergy in mice.
Fragile X Syndrome
Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome.
Fragile X Syndrome
Intranasal siRNA administration reveals IGF2 deficiency contributes to impaired cognition in Fragile X syndrome mice.
Fragile X Syndrome
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
Friedreich Ataxia
Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing.
Friedreich Ataxia
Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.
Friedreich Ataxia
HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model.
Friedreich Ataxia
Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.
Friedreich Ataxia
Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich's Ataxia: A New Synthetic Route.
Friedreich Ataxia
Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia.
Friedreich Ataxia
Lymphoblast Oxidative Stress Genes as Potential Biomarkers of Disease Severity and Drug Effect in Friedreich's Ataxia.
Friedreich Ataxia
Quantitative Proteomic Analysis Identifies Targets and Pathways of a 2-Aminobenzamide HDAC Inhibitor in Friedreich's Ataxia Patient iPSC-Derived Neural Stem Cells.
Friedreich Ataxia
Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for friedreich ataxia.
Friedreich Ataxia
Reversal of epigenetic promoter silencing in Friedreich ataxia by a class I histone deacetylase inhibitor.
Frontotemporal Dementia
Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.
Frontotemporal Dementia
Exifone Is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration.
Frontotemporal Dementia
HDAC1 dysregulation induces aberrant cell cycle and DNA damage in progress of TDP-43 proteinopathies.
Frontotemporal Lobar Degeneration
Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.
Gallbladder Neoplasms
BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo.
Gallbladder Neoplasms
HDAC1 promoted migration and invasion binding with TCF12 by promoting EMT progress in gallbladder cancer.
Gallbladder Neoplasms
HDAC6 inhibitor, ACY1215 suppress the proliferation and induce apoptosis of gallbladder cancer cells and increased the chemotherapy effect of gemcitabine and oxaliplatin.
Gastritis
A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer.
Gastritis, Atrophic
A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer.
Gastrointestinal Neoplasms
Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress.
Gastrointestinal Neoplasms
Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.
Gastrointestinal Neoplasms
The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy.
Gastrointestinal Neoplasms
[Epigenetic Alterations in Gastrointestinal Cancers: Diagnostic and Therapeutic Applications].
Gaucher Disease
Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones.
Gaucher Disease
Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease.
Genetic Diseases, Inborn
A De novo HDAC2 variant in a patient with features consistent with Cornelia de Lange syndrome phenotype.
Genetic Diseases, Inborn
Analysis of post-transcriptional regulation using the FunREG method.
Genetic Diseases, Inborn
Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases.
Genetic Diseases, Inborn
The new bone biology: pathologic, molecular, and clinical correlates.
Glaucoma
An experimental study of rabbit conjunctival epithelial toxicity using co-treatment with Mitomycin-C and a histone deacetylase inhibitor.
Glaucoma
Epigenetic Modification Prevents Excessive Wound Healing and Scar Formation After Glaucoma Filtration Surgery.
Glaucoma
Integrated microarray analysis provided novel insights to the pathogenesis of glaucoma.
Glaucoma
Modulating Ocular Scarring in Glaucoma Filtration Surgery Using the Epigenetic Adjunct Suberoylanilide Hydroxamic Acid.
Glaucoma, Open-Angle
The relationship between HDAC6, CXCR3, and SIRT1 genes expression levels with progression of primary open-angle glaucoma.
Glioblastoma
(P039) outcomes of patients with glioblastoma receiving concurrent radiation treatment and antiepileptic agents with histone deacetylase inhibitor activity.
Glioblastoma
A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma.
Glioblastoma
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Glioblastoma
Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Glioblastoma
Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
Glioblastoma
Antiglioma effects of combined use of a baculovirual vector expressing wild-type p53 and sodium butyrate.
Glioblastoma
Chemosensitization of glioblastoma cells by the histone deacetylase inhibitor MS275.
Glioblastoma
Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma.
Glioblastoma
Comprehensive Analysis of HDAC Family Identifies HDAC1 as a Prognostic and Immune Infiltration Indicator and HDAC1-Related Signature for Prognosis in Glioma.
Glioblastoma
Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.
Glioblastoma
Corrigendum: Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma.
Glioblastoma
Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.
Glioblastoma
Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas.
Glioblastoma
Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines.
Glioblastoma
Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.
Glioblastoma
Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples.
Glioblastoma
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.
Glioblastoma
Enhanced efficacy of histone deacetylase inhibitor combined with bromodomain inhibitor in glioblastoma.
Glioblastoma
Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma.
Glioblastoma
Epigenetic targeting of SLC30A3 by HDAC1 is related to the malignant phenotype of glioblastoma.
Glioblastoma
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.
Glioblastoma
HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin.
Glioblastoma
HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells.
Glioblastoma
HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism.
Glioblastoma
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma.
Glioblastoma
HDAC6 Signaling at Primary Cilia Promotes Proliferation and Restricts Differentiation of Glioma Cells.
Glioblastoma
HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies.
Glioblastoma
HDAC8 affects MGMT levels in glioblastoma cell lines via interaction with the proteasome receptor ADRM1.
Glioblastoma
Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone.
Glioblastoma
High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma.
Glioblastoma
Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K/AKT and MEK/ERK signaling pathways.
Glioblastoma
Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling.
Glioblastoma
Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway.
Glioblastoma
Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma.
Glioblastoma
Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death.
Glioblastoma
Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication, in human glioblastoma cells.
Glioblastoma
Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma.
Glioblastoma
Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth in vitro and in vivo partially through acetylation of p53.
Glioblastoma
Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-?B-Dependent Transcription in Glioblastoma Cell Lines.
Glioblastoma
Histone deacetylase inhibitor, FK228, induces apoptosis and suppresses cell proliferation of human glioblastoma cells in vitro and in vivo.
Glioblastoma
Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma.
Glioblastoma
Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells.
Glioblastoma
Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
Glioblastoma
Histone deacetylase inhibitors interact with melanoma differentiation associated-7/interleukin-24 to kill primary human glioblastoma cells.
Glioblastoma
Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
Glioblastoma
Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
Glioblastoma
Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells.
Glioblastoma
Inhibition of glioblastoma cell proliferation, invasion, and mechanism of action of a novel hydroxamic acid hybrid molecule.
Glioblastoma
Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
Glioblastoma
Inhibitory Activities of Trichostatin A in U87 Glioblastoma Cells and Tumorsphere-Derived Cells.
Glioblastoma
Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Glioblastoma
Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases.
Glioblastoma
Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma.
Glioblastoma
Live Cell Imaging Supports a Key Role for Histone Deacetylase as a Molecular Target during Glioblastoma Malignancy Downgrade through Tumor Competence Modulation.
Glioblastoma
Mechanisms and Clinical Significance of Histone Deacetylase Inhibitors: Epigenetic Glioblastoma Therapy.
Glioblastoma
Metabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with Temozolomide.
Glioblastoma
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Glioblastoma
Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition.
Glioblastoma
NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the ?-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
Glioblastoma
Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A.
Glioblastoma
Novel Three-Pronged Strategy to Enhance Cancer Cell Killing in Glioblastoma Cell Lines: Histone Deacetylase Inhibitor, Chemotherapy, and Oncolytic Adenovirus dl520.
Glioblastoma
Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.
Glioblastoma
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study.
Glioblastoma
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
Glioblastoma
Radiosensitisation of glioblastoma cells using a histone deacetylase inhibitor (SAHA) comparing carbon ions with X-rays.
Glioblastoma
Regulation of Glioblastoma Stem-like Cells by Id proteins and Olig transcription factors.
Glioblastoma
Remarkable response of a patient with secondary glioblastoma to a histone deacetylase inhibitor.
Glioblastoma
Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics.
Glioblastoma
Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2.
Glioblastoma
Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.
Glioblastoma
Silencing of Histone Deacetylase 6 Decreases Cellular Malignancy and Contributes to Primary Cilium Restoration, Epithelial-to-Mesenchymal Transition Reversion, and Autophagy Inhibition in Glioblastoma Cell Lines.
Glioblastoma
Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells.
Glioblastoma
Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor.
Glioblastoma
Synergism of 4HPR and SAHA increases anti-tumor actions in glioblastoma cells.
Glioblastoma
Targeting JUN, CEBPB, and HDAC3: A Novel Strategy to Overcome Drug Resistance in Hypoxic Glioblastoma.
Glioblastoma
Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
Glioblastoma
The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells.
Glioblastoma
The histone deacetylase inhibitor PCI-24781 as a putative radiosensitizer in pediatric glioblastoma cell lines.
Glioblastoma
The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
Glioblastoma
Tubastatin A, an inhibitor of HDAC6, enhances temozolomide?induced apoptosis and reverses the malignant phenotype of glioblastoma cells.
Glioblastoma
Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
Glioblastoma
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Glioblastoma
Valproic Acid Use During Radiation Therapy for Glioblastoma Associated With Improved Survival.
Glioblastoma
Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.
Glioma
A combination of BRD4 and HDAC3 inhibitors synergistically suppresses glioma stem cell growth by blocking GLI1/IL-6/STAT3 signaling axis.
Glioma
A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Suppresses Cell Migration and Invasion in Monomorphic Malignant Human Glioma Cells by Inhibiting FAK/STAT3 Signaling.
Glioma
A novel HDAC6 inhibitor Tubastatin A: Controls HDAC6-p97/VCP-mediated ubiquitination-autophagy turnover and reverses Temozolomide-induced ER stress-tolerance in GBM cells.
Glioma
A phase I/II trial of the histone deacetylase inhibitor, romidepsin, for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03.
Glioma
Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.
Glioma
Application of Electric Cell-Substrate Impedance Sensing to Investigate the Cytotoxic Effects of Andrographolide on U-87 MG Glioblastoma Cell Migration and Apoptosis.
Glioma
ARID4B Knockdown Suppresses PI3K/AKT Signaling and Induces Apoptosis in Human Glioma Cells.
Glioma
Assessing Treatment Response of Glioblastoma to an HDAC Inhibitor Using Whole-Brain Spectroscopic MRI.
Glioma
Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas.
Glioma
CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells.
Glioma
Chromatin structure and expression of the AMPA receptor subunit Glur2 in human glioma cells: major regulatory role of REST and Sp1.
Glioma
Comprehensive Analysis of HDAC Family Identifies HDAC1 as a Prognostic and Immune Infiltration Indicator and HDAC1-Related Signature for Prognosis in Glioma.
Glioma
Coptis Chinensis affects the function of glioma cells through the down-regulation of phosphorylation of STAT3 by reducing HDAC3.
Glioma
Correction to: ZNF326 promotes malignant phenotype of glioma by up-regulating HDAC7 expression and activating Wnt pathway.
Glioma
Corrigendum to "RGFP966, a histone deacetylase 3 inhibitor, promotes glioma stem cell differentiation by blocking TGF-? signaling via SMAD7" [Biochem. Pharmacol. 180 (2020) 114118].
Glioma
Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid.
Glioma
Effect of trichostatin A, a histone deacetylase inhibitor, on glioma proliferation in vitro by inducing cell cycle arrest and apoptosis.
Glioma
Effect of valproic acid on overall survival in patients with high-grade gliomas undergoing temozolomide: A nationwide population-based cohort study in Taiwan.
Glioma
Effects of caffeine on cell viability and activity of histone deacetylase 1 and histone acetyltransferase in glioma cells.
Glioma
Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples.
Glioma
Emerging therapeutic potential of anti-psychotic drugs in the management of human glioma: A comprehensive review.
Glioma
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275.
Glioma
Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas.
Glioma
Formononetin sensitizes glioma cells to doxorubicin through preventing EMT via inhibition of histone deacetylase 5.
Glioma
Fourier transform infrared microspectroscopy identifies protein propionylation in histone deacetylase inhibitor treated glioma cells.
Glioma
Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma.
Glioma
HDAC3 Expression Correlates with the Prognosis and Grade of Patients with Glioma: A Diversification Analysis Based on Transcriptome and Clinical Evidence.
Glioma
HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation.
Glioma
HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH/Gli1 signaling pathway.
Glioma
HDAC6 Signaling at Primary Cilia Promotes Proliferation and Restricts Differentiation of Glioma Cells.
Glioma
HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells.
Glioma
High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma.
Glioma
Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced.
Glioma
Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K/AKT and MEK/ERK signaling pathways.
Glioma
Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK-MMP-laminin5?2 signaling pathway.
Glioma
Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration.
Glioma
Histone deacetylase 5 promotes the proliferation of glioma cells by upregulation of Notch 1.
Glioma
Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway.
Glioma
Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells.
Glioma
Histone deacetylase inhibitor 4-phenylbutyrate suppresses GAPDH mRNA expression in glioma cells.
Glioma
Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Akt-dependent mechanism.
Glioma
Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth in vitro and in vivo partially through acetylation of p53.
Glioma
Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma.
Glioma
Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro.
Glioma
Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro.
Glioma
Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Glioma
Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe.
Glioma
Histone deacetylase inhibitors promote neurosteroid-mediated cell differentiation and enhance serotonin-stimulated brain-derived neurotrophic factor gene expression in rat C6 glioma cells.
Glioma
Histone deacetylase inhibitors, N-butyric acid and trichostatin A, induce caspase-8- but not caspase-9-dependent apoptosis in human malignant glioma cells.
Glioma
Histone deacetylase SIRT6 inhibits glioma cell growth through down-regulating NOTCH3 expression.
Glioma
Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas.
Glioma
In silico Design of Novel Histone Deacetylase 4 Inhibitors: Design Guidelines for Improved Binding Affinity.
Glioma
In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.
Glioma
Knockdown of HDAC1 expression suppresses invasion and induces apoptosis in glioma cells.
Glioma
Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
Glioma
Late autophagy inhibitor chloroquine improves efficacy of the histone deacetylase inhibitor SAHA and temozolomide in gliomas.
Glioma
Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor-Trichostatin A through Sp1 binding site.
Glioma
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Glioma
MiR-16-5p is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy.
Glioma
Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells.
Glioma
MKK7 transcription positively or negatively regulated by SP1 and KLF5 depends on HDAC4 activity in glioma.
Glioma
Novel histone deacetylase inhibitor N25 exerts anti-tumor effects and induces autophagy in human glioma cells by inhibiting HDAC3.
Glioma
O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.
Glioma
Phase 1/2 Trial of Vorinostat and Radiation and Maintenance Vorinostat in Children with Diffuse Intrinsic Pontine Glioma: A Children's Oncology Group Report.
Glioma
Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Glioma
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Glioma
Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
Glioma
Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene.
Glioma
RGFP966, a histone deacetylase 3 inhibitor, promotes glioma stem cell differentiation by blocking TGF-? signaling via SMAD7.
Glioma
SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study.
Glioma
Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2.
Glioma
SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress.
Glioma
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Glioma
Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells.
Glioma
Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance.
Glioma
The aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl induces distinct patterns of gene expression between hepatoma and glioma cells: chromatin remodeling as a mechanism for selective effects.
Glioma
The histone deacetylase inhibitor valproic acid enhances equine herpesvirus type 1 (EHV-1)-mediated oncolysis of human glioma cells.
Glioma
The histone deacetylase SIRT6 suppresses the expression of the RNA-binding protein PCBP2 in glioma.
Glioma
The possible prognostic role of histone deacetylase and transforming growth factor ?/Smad signaling in high grade gliomas treated by radio-chemotherapy: a preliminary immunohistochemical study.
Glioma
Transcription Factor ZNF326 Upregulates the Expression of ERCC1 and HDAC7 and its Clinicopathologic Significance in Glioma.
Glioma
Transcriptional regulation of cyclooxygenase-1 by histone deacetylase inhibitors in normal human astrocyte cells.
Glioma
Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Glioma
Valproic Acid and Other HDAC Inhibitors Upregulate FGF21 Gene Expression and Promote Process Elongation in Glia by Inhibiting HDAC2 and 3.
Glioma
Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease.
Glioma
Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma.
Glioma
ZNF326 promotes malignant phenotype of glioma by up-regulating HDAC7 expression and activating Wnt pathway.
Glioma
[Effect of monoamine oxidase inhibitor on the differentiation of malignant glioma cell].
Glioma
[Studies on the target cells and molecules with sodium valproate induced differential of human glioma cells]
Glioma
[The Mechanism Study on Histone Acetylation Activating Glioblastoma-derived Neurotrophic Factor Transcription].
Glomerulonephritis
Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice.
Glomerulonephritis, IGA
Correlation analysis between expression of histone deacetylase 6 and clinical parameters in IgA nephropathy patients.
Glucose Intolerance
Conditional ablation of HDAC3 in islet beta cells results in glucose intolerance and enhanced susceptibility to STZ-induced diabetes.
Glucose Intolerance
Histone deacetylase 3-selective inhibitor RGFP966 ameliorates impaired glucose tolerance through ?-cell protection.
Glucose Intolerance
Regulation of small ubiquitin-like modifier-1, nuclear receptor coreceptor, histone deacetylase 3, and peroxisome proliferator-activated receptor-? in human adipose tissue.
Gout
Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression.
Graft vs Host Disease
A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention.
Graft vs Host Disease
Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3.
Graft vs Host Disease
Histone Deacetylase Inhibition by Sodium Valproate Regulates Polarization of Macrophage Subsets.
Graft vs Host Disease
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice.
Graft vs Host Disease
Histone deacetylase inhibition regulates inflammation and enhances Tregs after allogeneic hematopoietic cell transplantation in humans.
Graft vs Host Disease
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.
Graft vs Host Disease
Low-dose chidamide restores immune tolerance in ITP in mice and humans.
Graft vs Host Disease
Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease.
Graft vs Host Disease
Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1.
Granulomatosis with Polyangiitis
Dysregulation of histone deacetylase and histone acetyltransferase in development of Wegener's granulomatosis.
Head and Neck Neoplasms
A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
Head and Neck Neoplasms
HDAC4 degradation by combined TRAIL and valproic acid treatment induces apoptotic cell death of TRAIL-resistant head and neck cancer cells.
Head and Neck Neoplasms
Induction of synergistic non-apoptotic cell death by simultaneously targeting proteasomes with bortezomib and histone deacetylase 6 with ricolinostat in head and neck tumor cells.
Head and Neck Neoplasms
Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer.
Head and Neck Neoplasms
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer.
Head and Neck Neoplasms
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
Headache Disorders, Secondary
HDAC3 role in medication consumption in medication overuse headache patients: a pilot study.
Hearing Loss
Aminophylline restores glucocorticoid sensitivity in a guinea pig model of sudden sensorineural hearing loss induced by lipopolysaccharide.
Hearing Loss
Elucidation of the Hdac2/Sp1/miR-204-5p/Bcl-2 axis as a modulator of cochlear apoptosis via in vivo/in vitro models of acute hearing loss.
Hearing Loss
Histone deacetylase inhibitor sodium butyrate attenuates gentamicin-induced hearing loss in vivo.
Hearing Loss
Sulforaphane attenuates cisplatin-induced hearing loss by inhibiting histone deacetylase expression.
Hearing Loss
The histone deacetylase inhibitor sodium butyrate protects against cisplatin-induced hearing loss in guinea pigs.
Hearing Loss, Noise-Induced
Histone deacetylase 2 polymorphisms associated with noise-induced hearing loss in Chinese workers.
Hearing Loss, Noise-Induced
The histone deacetylase inhibitor sodium butyrate protects against noise-induced hearing loss in Guinea pigs.
Hearing Loss, Sensorineural
Aminophylline restores glucocorticoid sensitivity in a guinea pig model of sudden sensorineural hearing loss induced by lipopolysaccharide.
Hearing Loss, Sensorineural
Elucidation of the Hdac2/Sp1/miR-204-5p/Bcl-2 axis as a modulator of cochlear apoptosis via in vivo/in vitro models of acute hearing loss.
Hearing Loss, Sensorineural
Histone Deacetylase 2 in Sudden Sensorineural Hearing Loss Patients in Response to Intratympanic Methylprednisolone Perfusion.
Hearing Loss, Sensorineural
Response of Glucocorticoid Receptor Alpha and Histone Deacetylase 2 to Glucocorticoid Treatment Predicts the Prognosis of Sudden Sensorineural Hearing Loss.
Hearing Loss, Sensorineural
Theophylline alleviates gentamicin-induced cytotoxicity to sensory hair cells by maintaining HDAC2 expression.
Heart Defects, Congenital
A De novo HDAC2 variant in a patient with features consistent with Cornelia de Lange syndrome phenotype.
Heart Defects, Congenital
Disruption of Planar Cell Polarity Pathway Attributable to Valproic Acid-Induced Congenital Heart Disease through Hdac3 Participation in Mice.
Heart Defects, Congenital
Histone Deacetylase 3 Coordinates Deacetylase-independent Epigenetic Silencing of Transforming Growth Factor-?1 (TGF-?1) to Orchestrate Second Heart Field Development.
Heart Defects, Congenital
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Heart Diseases
5-Fluoronicotinamide Derivatives as HDAC6 Inhibitors for Treating Heart Diseases.
Heart Diseases
Exogenous Hydrogen Sul?de Postconditioning Protects Isolated Rat Hearts From Ischemia/Reperfusion Injury Through Sirt1/PGC-1? Signaling Pathway.
Heart Diseases
HDAC2 is required by the physiological concentration of glucocorticoid to inhibit inflammation in cardiac fibroblasts.
Heart Diseases
HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.
Heart Diseases
Histone deacetylase adaptation in single ventricle heart disease and a young animal model of right ventricular hypertrophy.
Heart Diseases
Retinoic acid and sodium butyrate suppress the cardiac expression of hypertrophic markers and proinflammatory mediators in Npr1 gene-disrupted haplotype mice.
Heart Diseases
Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
Heart Failure
Acute ?-adrenergic activation triggers nuclear import of histone deacetylase 5 and delays G(q)-induced transcriptional activation.
Heart Failure
Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated with IL-6/Stat3 Signaling in Ischemic Heart Failure.
Heart Failure
Antithetical regulation of ?-myosin heavy chain between fetal and adult heart failure though shuttling of HDAC5 regulating YY-1 function.
Heart Failure
Ca2+/calmodulin-dependent protein kinase IIdelta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure.
Heart Failure
CaMKII and PKA-dependent phosphorylation co-regulate nuclear localization of HDAC4 in adult cardiomyocytes.
Heart Failure
Cardiac CD47 drives left ventricular heart failure through Ca2+-CaMKII-regulated induction of HDAC3.
Heart Failure
Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.
Heart Failure
Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes.
Heart Failure
Correlation between Histone Deacetylase 9 and Regulatory T Cell in Patients with Chronic Heart Failure.
Heart Failure
DNA methylation patterns from peripheral blood separate coronary artery disease patients with and without heart failure.
Heart Failure
HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation.
Heart Failure
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity.
Heart Failure
HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling.
Heart Failure
Histone deacetylase 2-dependent ventricular electrical remodeling in a porcine model of early heart failure.
Heart Failure
Histone deacetylase 3 suppresses the expression of SHP-1 via deacetylation of DNMT1 to promote heart failure.
Heart Failure
Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure.
Heart Failure
Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure.
Heart Failure
Histone deacetylase inhibition reduces cardiac connexin43 expression and gap junction communication.
Heart Failure
Histone Deacetylase Inhibitor Phenylbutyrate Exaggerates Heart Failure in Pressure Overloaded Mice independently of HDAC inhibition.
Heart Failure
Histone deacetylase inhibitor SAHA treatment prevents the development of heart failure after myocardial infarction via an induction of heat-shock proteins in rats.
Heart Failure
Isoform-selective HDAC inhibitors: Closing in on translational medicine for the heart.
Heart Failure
Novel Histone Deacetylase Inhibitor Modulates Cardiac Peroxisome Proliferator-Activated Receptors and Inflammatory Cytokines in Heart Failure.
Heart Failure
Nuclear calcium/calmodulin-dependent protein kinase IIdelta preferentially transmits signals to histone deacetylase 4 in cardiac cells.
Heart Failure
O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart From Failure.
Heart Failure
S-Nitrosylation of Histone Deacetylase 2 by Neuronal Nitric Oxide Synthase as a Mechanism of Diastolic Dysfunction.
Heart Failure
Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.
Heart Failure
The crosstalk of HDAC3, microRNA-18a and ADRB3 in the progression of heart failure.
Heart Failure
Transplantation of Epigenetically Modified Adult Cardiac c-Kit+ Cells Retards Remodeling and Improves Cardiac Function in Ischemic Heart Failure Model.
Heart Failure
YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5.
Heart Septal Defects, Atrial
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Heart Septal Defects, Ventricular
Histone Deacetylase 3 Coordinates Deacetylase-independent Epigenetic Silencing of Transforming Growth Factor-?1 (TGF-?1) to Orchestrate Second Heart Field Development.
Heart Septal Defects, Ventricular
Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development.
Heart Septal Defects, Ventricular
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Hematologic Diseases
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Hematologic Diseases
Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
Hematologic Neoplasms
10058-F4, a c-Myc inhibitor, markedly increases valproic acid-induced cell death in Jurkat and CCRF-CEM T-lymphoblastic leukemia cells.
Hematologic Neoplasms
A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Hematologic Neoplasms
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.
Hematologic Neoplasms
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Hematologic Neoplasms
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Hematologic Neoplasms
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Hematologic Neoplasms
Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies.
Hematologic Neoplasms
An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts.
Hematologic Neoplasms
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
Hematologic Neoplasms
Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.
Hematologic Neoplasms
Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.
Hematologic Neoplasms
Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors.
Hematologic Neoplasms
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells.
Hematologic Neoplasms
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Hematologic Neoplasms
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
Hematologic Neoplasms
Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Hematologic Neoplasms
Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?
Hematologic Neoplasms
Could valproic acid be an effective anticancer agent? The evidence so far.
Hematologic Neoplasms
Current limitations and future opportunities for epigenetic therapies.
Hematologic Neoplasms
Decitabine and its role in the treatment of hematopoietic malignancies.
Hematologic Neoplasms
Differential effects of epigenetic modifiers on the expansion and maintenance of human cord blood stem/progenitor cells.
Hematologic Neoplasms
Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
Hematologic Neoplasms
DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies.
Hematologic Neoplasms
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.
Hematologic Neoplasms
Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies.
Hematologic Neoplasms
Enhanced expression of the nuclear envelope LAP2 transcriptional repressors in normal and malignant activated lymphocytes.
Hematologic Neoplasms
Epigenetic pathways in macrophages emerge as novel targets in atherosclerosis.
Hematologic Neoplasms
Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.
Hematologic Neoplasms
Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors.
Hematologic Neoplasms
Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia.
Hematologic Neoplasms
Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
Hematologic Neoplasms
Finding the place of histone deacetylase inhibitors in prostate cancer therapy.
Hematologic Neoplasms
Functional interplay between histone demethylase and deacetylase enzymes.
Hematologic Neoplasms
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
Hematologic Neoplasms
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Hematologic Neoplasms
Histone Deacetylase (HDAC) Inhibition Induces I?B Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Hematologic Neoplasms
Histone deacetylase 1 plays a predominant pro-oncogenic role in E?-myc driven B cell lymphoma.
Hematologic Neoplasms
Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies.
Hematologic Neoplasms
Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.
Hematologic Neoplasms
Histone deacetylase inhibition modulates cell fate decisions during myeloid differentiation.
Hematologic Neoplasms
Histone Deacetylase Inhibitors and Phenotypical Transformation of Cancer Cells.
Hematologic Neoplasms
Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes.
Hematologic Neoplasms
Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro.
Hematologic Neoplasms
Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Hematologic Neoplasms
Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.
Hematologic Neoplasms
Histone deacetylase inhibitors in the treatment of hematological malignancies.
Hematologic Neoplasms
Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.
Hematologic Neoplasms
Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma via AMPK-FOXO1-ULK1 signaling axis-mediated autophagy.
Hematologic Neoplasms
Histone deacetylase inhibitors: clinical implications for hematological malignancies.
Hematologic Neoplasms
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Hematologic Neoplasms
Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway.
Hematologic Neoplasms
Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer.
Hematologic Neoplasms
JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity.
Hematologic Neoplasms
MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-?-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells.
Hematologic Neoplasms
Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy.
Hematologic Neoplasms
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
Hematologic Neoplasms
Oxidative stress by targeted agents promotes cytotoxicity in hematological malignancies.
Hematologic Neoplasms
Panobinostat inhibits the proliferation of CD34+ CD38- cells under stimulation of hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.
Hematologic Neoplasms
Phase I study of domatinostat (4SC-202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies.
Hematologic Neoplasms
Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies.
Hematologic Neoplasms
Potential non-oncological applications of histone deacetylase inhibitors.
Hematologic Neoplasms
Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
Hematologic Neoplasms
Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg.
Hematologic Neoplasms
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies.
Hematologic Neoplasms
SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.
Hematologic Neoplasms
Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
Hematologic Neoplasms
Sin3a-associated Hdac1 and Hdac2 are essential for hematopoietic stem cell homeostasis and contribute differentially to hematopoiesis.
Hematologic Neoplasms
Strong Correlation between the Expression Levels of HDAC4 and SIRT6 in Hematological Malignancies of the Adults.
Hematologic Neoplasms
Subchronic Toxicities of HZ1006, a Hydroxamate-Based Histone Deacetylase Inhibitor, in Beagle Dogs and Sprague-Dawley Rats.
Hematologic Neoplasms
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Hematologic Neoplasms
Systemic cell-cycle suppression by Apicidin, a histone deacetylase inhibitor, in MDA-MB-435 cells.
Hematologic Neoplasms
Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Hematologic Neoplasms
Tempol prevents genotoxicity induced by vorinostat: role of oxidative DNA damage.
Hematologic Neoplasms
The aggresome pathway as a target for therapy in hematologic malignancies.
Hematologic Neoplasms
The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine.
Hematologic Neoplasms
The Effect of MGCD0103 on CYP450 Isoforms Activity of Rats by Cocktail Method.
Hematologic Neoplasms
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
Hematologic Neoplasms
The Histone Deacetylase Inhibitor MGCD0103 Induces Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells through a Mitochondria-Mediated Caspase Activation Cascade.
Hematologic Neoplasms
The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.
Hematologic Neoplasms
The rationale and use of hypomethylation agents in adult acute myeloid leukemia.
Hematologic Neoplasms
The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
Hematologic Neoplasms
The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer.
Hematologic Neoplasms
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
Hematologic Neoplasms
Transcriptomic and Epigenomic Profiling of Histone Deacetylase Inhibitor Treatment Reveals Distinct Gene Regulation Profiles Leading to Impaired Neutrophil Development.
Hematologic Neoplasms
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer.
Hematologic Neoplasms
Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients.
Hematologic Neoplasms
Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.
Hematologic Neoplasms
Valproic acid treatment is associated with altered leukocyte subset development.
Hematologic Neoplasms
Valproic acid triggers erythro/megakaryocyte lineage decision through induction of GFI1B and MLLT3 expression.
Hematologic Neoplasms
Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance.
Hematologic Neoplasms
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Hemoglobinopathies
Hydroxamide derivatives of short-chain fatty acid have erythropoietic activity and induce gamma gene expression in vivo.
Hemolytic-Uremic Syndrome
Butyrate upregulates endogenous host defense peptides to enhance disease resistance in piglets via histone deacetylase inhibition.
Hepatitis
Sodium butyrate potentiates carbon tetrachloride-induced acute liver injury in mice.
Hepatitis B
Coexpression of SALL4 with HDAC1 and/or HDAC2 is associated with underexpression of PTEN and poor prognosis in patients with hepatocellular carcinoma.
Hepatitis B
Hepatitis B Virus Replication Is Regulated by the Acetylation Status of Hepatitis B Virus cccDNA-Bound H3 and H4 Histones.
Hepatitis B
Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells.
Hepatitis B
Hepatitis B virus-X protein recruits histone deacetylase 1 to repress insulin-like growth factor binding protein 3 transcription.
Hepatitis B
Histone deacetylase inhibitor suberoylanilide hydroxamic acid suppresses the pro-oncogenic effects induced by hepatitis B virus pre-S2 mutant oncoprotein and represents a potential chemopreventive agent in high-risk chronic HBV patients.
Hepatitis B
Histone Deacetylase Inhibitors Romidepsin and Vorinostat Promote Hepatitis B Virus Replication by Inducing Cell Cycle Arrest.
Hepatitis B
miRNA-548ah promotes the replication and expression of hepatitis B virus by targeting histone deacetylase 4.
Hepatitis B
Modulation of hepatitis B virus pregenomic RNA stability and splicing by histone deacetylase 5 enhances viral biosynthesis.
Hepatitis B, Chronic
Role of histone deacetylase expression levels and activity in the inflammatory responses of patients with chronic hepatitis B.
Hepatitis C
Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4.
Hepatitis C
Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity.
Hepatitis C
Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression.
Hepatitis C
Pre-Senescence Induction in Hepatoma Cells Favors Hepatitis C Virus Replication and Can Be Used in Exploring Antiviral Potential of Histone Deacetylase Inhibitors.
Hepatitis C
Ribavirin restores ESR1 gene expression and tamoxifen sensitivity in ESR1 negative breast cancer cell lines.
Hepatitis C
Role of HDAC9-FoxO1 Axis in the Transcriptional Program Associated with Hepatic Gluconeogenesis.
Hepatitis C
Selective inhibitor of histone deacetylase 6 (tubastatin A) suppresses proliferation of hepatitis C virus replicon in culture of human hepatocytes.
Hepatitis C
Suppressive Effect of the Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), on Hepatitis C Virus Replication via Epigenetic Changes in Host Cells.
Hepatitis C
The Metabolic Regulator Histone Deacetylase 9 Contributes to Glucose Homeostasis Abnormality Induced by Hepatitis C Virus Infection.
Hepatoblastoma
Differential responsiveness of human hepatoma cells versus normal hepatocytes to TRAIL in combination with either histone deacetylase inhibitors or conventional cytostatics.
Hepatoblastoma
HDAC1-Dependent Repression of Markers of Hepatocytes and P21 Is Involved in Development of Pediatric Liver Cancer.
Hepatomegaly
New synthetic conjugates of ursodeoxycholic acid inhibit cystogenesis in experimental models of polycystic liver disease.
Herpes Simplex
Epigenetic Regulation of Histone H3 Serine 10 Phosphorylation Status by HCF-1 Proteins in C. elegans and Mammalian Cells.
Herpes Simplex
Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6.
Herpes Simplex
Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma.
Herpes Simplex
Histone deacetylase inhibitors improve the replication of oncolytic herpes simplex virus in breast cancer cells.
Herpes Simplex
Histone deacetylase inhibitors induce reactivation of herpes simplex virus type 1 in a latency-associated transcript-independent manner in neuronal cells.
Herpes Simplex
Histone Deacetylase Inhibitors Reduce the Number of Herpes Simplex Virus-1 Genomes Initiating Expression in Individual Cells.
Herpes Simplex
Quantitative Temporal Proteomic Analysis of Vaccinia Virus Infection Reveals Regulation of Histone Deacetylases by an Interferon Antagonist.
Herpes Zoster
Histone Deacetylase 1 and 2 are Phosphorylated at Novel Sites During Varicella Zoster Virus Infection.
Hirschsprung Disease
Novel smooth muscle markers reveal abnormalities of the intestinal musculature in severe colorectal motility disorders.
histone deacetylase deficiency
A direct HDAC4-MAP kinase crosstalk activates muscle atrophy program.
histone deacetylase deficiency
Conditional deletion of histone deacetylase-4 in the central nervous system has no major effect on brain architecture or neuronal viability.
histone deacetylase deficiency
Correction: HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition.
histone deacetylase deficiency
Epigenetic-sensitive pathways in personalized therapy of major cardiovascular diseases.
histone deacetylase deficiency
Fine particulate matter exposure promotes M2 macrophage polarization through inhibiting histone deacetylase 2 in the pathogenesis of chronic obstructive pulmonary disease.
histone deacetylase deficiency
HDAC1 and HDAC2 independently regulate common and specific intrinsic responses in murine enteroids.
histone deacetylase deficiency
HDAC1 modulates OGG1-initiated oxidative DNA damage repair in the aging brain and Alzheimer's disease.
histone deacetylase deficiency
HDAC2 deficiency sensitizes colon cancer cells to TNFalpha-induced apoptosis through inhibition of NF-kappaB activity.
histone deacetylase deficiency
HDAC2 negatively regulates memory formation and synaptic plasticity.
histone deacetylase deficiency
Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity.
histone deacetylase deficiency
Hdac3 Deficiency Increases Marrow Adiposity and Induces Lipid Storage and Glucocorticoid Metabolism in Osteochondroprogenitor Cells.
histone deacetylase deficiency
HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition.
histone deacetylase deficiency
Hdac3 deletion in myeloid progenitor cells enhances bone healing in females and limits osteoclast fusion via Pmepa1.
histone deacetylase deficiency
HDAC3 Is Required for Posterior Lateral Line Development in Zebrafish.
histone deacetylase deficiency
Hdac3 regulates bone modeling by suppressing osteoclast responsiveness to RANKL.
histone deacetylase deficiency
HDAC4 regulates vascular inflammation via activation of autophagy.
histone deacetylase deficiency
HDAC5 controls MEF2C-driven sclerostin expression in osteocytes.
histone deacetylase deficiency
HDAC6 alleviates prion peptide-mediated neuronal death via modulating PI3K-Akt-mTOR pathway.
histone deacetylase deficiency
HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy.
histone deacetylase deficiency
HDAC6 deficiency induces apoptosis in mesenchymal stem cells through p53 K120 acetylation.
histone deacetylase deficiency
HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
histone deacetylase deficiency
HDAC6 regulates aggresome-autophagy degradation pathway of ?-synuclein in response to MPP(+) -induced stress.
histone deacetylase deficiency
HDAC6 regulates IL-17 expression in T lymphocytes: implications for HDAC6-targeted therapies.
histone deacetylase deficiency
HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.
histone deacetylase deficiency
HDAC9 deficiency promotes tumor progression by decreasing the CD8+ dendritic cell infiltration of the tumor microenvironment.
histone deacetylase deficiency
HDAC9 promotes brain ischemic injury by provoking I?B?/NF-?B and MAPKs signaling pathways.
histone deacetylase deficiency
Histone deacetylase 1 controls CD4+ T cell trafficking in autoinflammatory diseases.
histone deacetylase deficiency
Histone Deacetylase 1 Deficiency Impairs Differentiation and Electrophysiological Properties of Cardiomyocytes Derived from Induced Pluripotent Cells.
histone deacetylase deficiency
Histone deacetylase 3 controls lung alveolar macrophage development and homeostasis.
histone deacetylase deficiency
Histone deacetylase 6 modulates macrophage infiltration during inflammation.
histone deacetylase deficiency
Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability.
histone deacetylase deficiency
Histone Deacetylase 9 Deficiency Protects against Effector T Cell-mediated Systemic Autoimmunity.
histone deacetylase deficiency
Impairment of human terminal erythroid differentiation by histone deacetylase 5 deficiency.
histone deacetylase deficiency
Inhibition of myeloid HDAC2 upregulates glutaredoxin 1 expression, improves protein thiol redox state and protects against high-calorie diet-induced monocyte dysfunction and atherosclerosis.
histone deacetylase deficiency
Modeling Cornelia de Lange Syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation.
histone deacetylase deficiency
Neural Differentiation in HDAC1-Depleted Cells Is Accompanied by Coilin Downregulation and the Accumulation of Cajal Bodies in Nucleoli.
histone deacetylase deficiency
Nrf2 deficiency influences susceptibility to steroid resistance via HDAC2 reduction.
histone deacetylase deficiency
Proteomic identification and functional characterization of MYH9, Hsc70, and DNAJA1 as novel substrates of HDAC6 deacetylase activity.
histone deacetylase deficiency
Repression of Somatic Genes by Selective Recruitment of HDAC3 by BLIMP1 Is Essential for Mouse Primordial Germ Cell Fate Determination.
histone deacetylase deficiency
Role of histone deacetylases(HDACs) in progression and reversal of liver fibrosis.
histone deacetylase deficiency
Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities.
histone deacetylase deficiency
Targeting macrophage Histone deacetylase 3 stabilizes atherosclerotic lesions.
histone deacetylase deficiency
The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation.
histone deacetylase deficiency
The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc.
HIV Infections
A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection.
HIV Infections
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.
HIV Infections
Marbostat 100 defines a new class of potent and selective antiinflammatory and antirheumatic histone deacetylase 6 inhibitors.
HIV Infections
Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors.
Hodgkin Disease
Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma.
Hodgkin Disease
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.
Hodgkin Disease
Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.
Hodgkin Disease
Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study.
Hodgkin Disease
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
Hodgkin Disease
PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF-{kappa}B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells.
Hodgkin Disease
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.
Hodgkin Disease
Resminostat in patients with relapsed or refractory Hodgkin lymphoma: results of the phase II SAPHIRE study.
Hodgkin Disease
Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma.
Hodgkin Disease
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
Hodgkin Disease
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Hodgkin Disease
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Hodgkin Disease
The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.
Huntington Disease
A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.
Huntington Disease
Blocking the association of HDAC4 with MAP1S accelerates autophagy clearance of mutant Huntingtin.
Huntington Disease
Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing.
Huntington Disease
Correction: Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington's Disease.
Huntington Disease
Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.
Huntington Disease
Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations.
Huntington Disease
Effects of the Pimelic Diphenylamide Histone Deacetylase Inhibitor HDACi 4b on the R6/2 and N171-82Q Mouse Models of Huntington's Disease.
Huntington Disease
Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington's Disease.
Huntington Disease
Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.
Huntington Disease
Genetic deletion of the Histone Deacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease.
Huntington Disease
Genetic Knock-Down of Hdac3 Does Not Modify Disease-Related Phenotypes in a Mouse Model of Huntington's Disease.
Huntington Disease
Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease.
Huntington Disease
Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.
Huntington Disease
Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease.
Huntington Disease
Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
Huntington Disease
Histone Deacetylase 4 (HDAC4) Inhibitors: A Promising Treatment for Huntington's Disease.
Huntington Disease
Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation.
Huntington Disease
Histone deacetylase class II and acetylated core histone immunohistochemistry in human brains with Huntington's disease.
Huntington Disease
Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.
Huntington Disease
Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment.
Huntington Disease
Histone deacetylase inhibitors as therapeutics for polyglutamine disorders.
Huntington Disease
Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.
Huntington Disease
Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).
Huntington Disease
Histone deacetylase knockouts modify transcription, CAG instability and nuclear pathology in Huntington disease mice.
Huntington Disease
Induction of DARPP-32 by brain-derived neurotrophic factor in striatal neurons in vitro is modified by histone deacetylase inhibitors and Nab2.
Huntington Disease
Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease.
Huntington Disease
Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors.
Huntington Disease
Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors.
Huntington Disease
Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo.
Huntington Disease
Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Huntington Disease
Quantitative Proteomic Analysis Identifies Targets and Pathways of a 2-Aminobenzamide HDAC Inhibitor in Friedreich's Ataxia Patient iPSC-Derived Neural Stem Cells.
Huntington Disease
Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice; implications for the ubiquitin-proteasomal and autophagy systems.
Huntington Disease
Small-molecule modulation of HDAC6 activity: The propitious therapeutic strategy to vanquish neurodegenerative disorders.
Huntington Disease
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.
Huntington Disease
The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice.
Huntington Disease
The Effects of Selective Inhibition of Histone Deacetylase 1 and 3 in Huntington's Disease Mice.
Hyperalgesia
Activation of HDAC4 and GR signaling contributes to stress-induced hyperalgesia in the medial prefrontal cortex of rats.
Hyperalgesia
Baicalin ameliorates neuropathic pain by suppressing HDAC1 expression in the spinal cord of spinal nerve ligation rats.
Hyperalgesia
Cell-specific role of histone deacetylase 6 in chemotherapy-induced mechanical allodynia and loss of intraepidermal nerve fibers.
Hyperalgesia
Dysregulation of EAAT2 and VGLUT2 Spinal Glutamate Transports via Histone Deacetylase 2 (HDAC2) Contributes to Paclitaxel-induced Painful Neuropathy.
Hyperalgesia
Effect of Histone Deacetylase Inhibitor on Ethanol Withdrawal-Induced Hyperalgesia in Rats.
Hyperalgesia
Epigenetic suppression of liver X receptor ? in anterior cingulate cortex by HDAC5 drives CFA-induced chronic inflammatory pain.
Hyperalgesia
GluN2B/CaMKII mediates CFA-induced hyperalgesia via HDAC4-modified spinal COX2 transcription.
Hyperalgesia
HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.
Hyperalgesia
HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice.
Hyperalgesia
Histone deacetylase 5 (HDAC5) regulates neuropathic pain through SRY-related HMG-box 10 (SOX10)-dependent mechanism in mice.
Hyperalgesia
Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain.
Hyperalgesia
Melatonin relieves neuropathic allodynia through spinal MT2-enhanced PP2Ac and downstream HDAC4 shuttling-dependent epigenetic modification of hmgb1 transcription.
Hyperalgesia
Microinjection of valproic acid into the ventrolateral orbital cortex exerts an antinociceptive effect in a rat of neuropathic pain.
Hyperalgesia
Normalizing HDAC2 Levels in the Spinal Cord Alleviates Thermal and Mechanical Hyperalgesia After Peripheral Nerve Injury and Promotes GAD65 and KCC2 Expression.
Hyperalgesia
Suppression of HDAC2 in Spinal Cord Alleviates Mechanical Hyperalgesia and Restores KCC2 Expression in a Rat Model of Bone Cancer Pain.
Hyperalgesia
Trichostatin A, a histone deacetylase inhibitor, reduces lesion growth and hyperalgesia in experimentally induced endometriosis in mice.
Hyperandrogenism
A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells.
Hypereosinophilic Syndrome
Differentiation of eosinophilic leukemia EoL-1 cells into eosinophils induced by histone deacetylase inhibitors.
Hypereosinophilic Syndrome
Possible mechanism of action of the histone deacetylase inhibitors for the induction of differentiation of HL-60 clone 15 cells into eosinophils.
Hyperglycemia
Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance.
Hyperglycemia
Histone Deacetylase Inhibition Ameliorates Hypertension and Hyperglycemia in a model of Cushing's Syndrome.
Hyperglycemia
Histone Deacetylase Inhibition Restores Retinal Pigment Epithelium Function in Hyperglycemia.
Hyperglycemia
MicroRNA-29a Promotion of Nephrin Acetylation Ameliorates Hyperglycemia-Induced Podocyte Dysfunction.
Hyperglycemia
Repression of Transcriptional Activity of Forkhead Box O1 by Histone Deacetylase Inhibitors Ameliorates Hyperglycemia in Type 2 Diabetic Rats.
Hyperglycemia
Role of histone acetylation in the development of diabetic retinopathy and the metabolic memory phenomenon.
Hyperglycemia
Sodium butyrate mitigates type 2 diabetes by inhibiting PERK-CHOP pathway of endoplasmic reticulum stress.
Hyperglycemia
Targeting Oxidative Stress Reduction and Inhibition of HDAC1, MECP2, and NF-kB Pathways in Rats With Experimentally Induced Hyperglycemia by Administration of Thymus marshallianus Willd. Extracts.
Hyperglycemia
[Validation and Evaluation of Diagnostic Efficiency of Genes Associated with Colorectal Cancer with Hyperglycemia].
Hyperhomocysteinemia
Valproic acid downregulates RBP4 and elicits hypervitaminosis A-teratogenesis--a kinetic analysis on retinol/retinoic acid homeostatic system.
Hyperinsulinism
Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance.
Hypersensitivity
Arabidopsis Paired Amphipathic Helix Proteins SNL1 and SNL2 Redundantly Regulate Primary Seed Dormancy via Abscisic Acid-Ethylene Antagonism Mediated by Histone Deacetylation.
Hypersensitivity
Complex regulation of the regulator of synaptic plasticity histone deacetylase 2 in the rodent dorsal horn after peripheral injury.
Hypersensitivity
Early-life stress-induced visceral hypersensitivity and anxiety behavior is reversed by histone deacetylase inhibition.
Hypersensitivity
Epigenetic modulation of chronic anxiety and pain by histone deacetylation.
Hypersensitivity
EXPRESS: Histone hyperacetylation modulates spinal type II metabotropic glutamate receptor alleviating stress-induced visceral hypersensitivity in female rats.
Hypersensitivity
Functional and physical interactions between yeast 14-3-3 proteins, acetyltransferases, and deacetylases in response to DNA replication perturbations.
Hypersensitivity
Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
Hypersensitivity
HDAC2, but not HDAC1, regulates Kv1.2 expression to mediate neuropathic pain in CCI rats.
Hypersensitivity
HDAC6 Regulates Androgen Receptor Hypersensitivity and Nuclear Localization via Modulating Hsp90 Acetylation in Castration-Resistant Prostate Cancer.
Hypersensitivity
HDAC6 regulates sensitivity to cell death in response to stress and post-stress recovery.
Hypersensitivity
HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice.
Hypersensitivity
Histone deacetylase 5 (HDAC5) regulates neuropathic pain through SRY-related HMG-box 10 (SOX10)-dependent mechanism in mice.
Hypersensitivity
Histone deacetylase inhibitors prevent persistent hypersensitivity in an orofacial neuropathic pain model.
Hypersensitivity
Integrin engagement increases histone H3 acetylation and reduces histone H1 association with DNA in murine lung endothelial cells.
Hypersensitivity
MiR-34a affects dexmedetomidine-inhibited chronic inflammatory visceral pain by targeting to HDAC2.
Hypersensitivity
Resistance to histone deacetylase inhibitors confers hypersensitivity to oncolytic reovirus therapy.
Hypersensitivity
Selective class I histone deacetylase inhibitors suppress persistent spontaneous nociception and thermal hypersensitivity in a rat model of bee venom-induced inflammatory pain.
Hypersensitivity
The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines.
Hypersensitivity
The WD40 Domain Protein MSI1 Functions in a Histone Deacetylase Complex to Fine-Tune Abscisic Acid Signaling.
Hypersensitivity
Valproate Prevents Dysregulation of Spinal Glutamate and Reduces the Development of Hypersensitivity in Rats After Peripheral Nerve Injury.
Hypersensitivity
[Epigenetic regulation of abiotic stress response in plants to improve the stress tolerance].
Hypertelorism
Loss-of-function HDAC8 mutations cause a phenotypic spectrum of Cornelia de Lange syndrome-like features, ocular hypertelorism, large fontanelle and X-linked inheritance.
Hypertension
Altered expression of norepinephrine transporter participate in hypertension and depression through regulated TNF-? and IL-6.
Hypertension
Angiotensin II-induced overexpression of sirtuin 1 contributes to enhanced expression of Gi? proteins and hyperproliferation of vascular smooth muscle cells.
Hypertension
Atherosclerotic Aortic Calcification-Associated Polymorphism in HDAC9 and Associations with Mortality, Cardiovascular Disease, and Kidney Disease.
Hypertension
Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension.
Hypertension
Chronic HDAC6 Activation Induces Atrial Fibrillation Through Atrial Electrical and Structural Remodeling in Transgenic Mice.
Hypertension
Class I histone deacetylase inhibitor MS-275 attenuates vasoconstriction and inflammation in angiotensin II-induced hypertension.
Hypertension
Expression and localization of calmodulin-related proteins in brain, heart and kidney from spontaneously hypertensive rats.
Hypertension
Gallic acid attenuates hypertension, cardiac remodeling, and fibrosis in mice with NG-nitro-L-arginine methyl ester-induced hypertension via regulation of histone deacetylase 1 or histone deacetylase 2.
Hypertension
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.
Hypertension
HDAC Inhibition Suppresses Cardiac Hypertrophy and Fibrosis in DOCA-Salt Hypertensive Rats via Regulation of HDAC6/HDAC8 Enzyme Activity.
Hypertension
HDAC4 and GATA6 Regulate Arterial Remodeling in Angiotensin II-Induced Hypertension.
Hypertension
HDAC4 mediates development of hypertension via vascular inflammation in spontaneous hypertensive rats.
Hypertension
HDAC5 inhibition reduces angiotensin II-induced vascular contraction, hypertrophy, and oxidative stress in a mouse model.
Hypertension
HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension.
Hypertension
Histone deacetylase 4 controls neointimal hyperplasia via stimulating proliferation and migration of vascular smooth muscle cells.
Hypertension
Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine ?-lyase protein degradation.
Hypertension
Histone Deacetylase Inhibition Ameliorates Hypertension and Hyperglycemia in a model of Cushing's Syndrome.
Hypertension
Histone deacetylase inhibition attenuates transcriptional activity of mineralocorticoid receptor through its acetylation and prevents development of hypertension.
Hypertension
Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production.
Hypertension
Histone deacetylase inhibitor LMK235 attenuates vascular constriction and aortic remodelling in hypertension.
Hypertension
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic Acid and suberoylanilide hydroxamic Acid.
Hypertension
Human GRK4?142V Variant Promotes Angiotensin II Type I Receptor-Mediated Hypertension via Renal Histone Deacetylase Type 1 Inhibition.
Hypertension
Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension.
Hypertension
Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension.
Hypertension
Left Ventricular Hypertrophy: Roles of Mitochondria CYP1B1 and Melatonergic Pathways in Co-Ordinating Wider Pathophysiology.
Hypertension
Melatonin prevents neonatal dexamethasone induced programmed hypertension: histone deacetylase inhibition.
Hypertension
Renal mechanisms of salt-sensitive hypertension: contribution of two steroid receptor-associated pathways.
Hypertension
Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/angiotensin II axis.
Hypertension
Roles of HDAC2 and HDAC8 in Cardiac Remodeling in Renovascular Hypertensive Rats and the Effects of Valproic Acid Sodium.
Hypertension
Selective inhibition of histone deacetylase 8 improves vascular hypertrophy, relaxation, and inflammation in angiotensin II hypertensive mice.
Hypertension
Sirtuin-1 contributes to the overexpression of Gi? proteins and hyperproliferation of vascular smooth muscle cells from spontaneously hypertensive rats.
Hypertension
Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension.
Hypertension, Pulmonary
Expression of Class I and Class II a/b Histone Deacetylase is Dysregulated in Hypertensive Animal Models.
Hypertension, Pulmonary
HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension.
Hypertension, Pulmonary
Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series).
Hyperthyroidism
MicroRNA-1 overexpression blunts cardiomyocyte hypertrophy elicited by thyroid hormone.
Hypertrophy, Left Ventricular
Cardiac genes show contextual SWI/SNF interactions with distinguishable gene activities.
Hypertrophy, Left Ventricular
S-Nitrosylation of Histone Deacetylase 2 by Neuronal Nitric Oxide Synthase as a Mechanism of Diastolic Dysfunction.
Hypertrophy, Left Ventricular
Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats.
Hypertrophy, Right Ventricular
Histone deacetylase adaptation in single ventricle heart disease and a young animal model of right ventricular hypertrophy.
Hypertrophy, Right Ventricular
Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.
Hypertrophy, Right Ventricular
Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats.
Hypesthesia
HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.
Hypogonadism
X-exome sequencing identifies a HDAC8 variant in a large pedigree with X-linked intellectual disability, truncal obesity, gynaecomastia, hypogonadism and unusual face.
Hypopigmentation
ITAC induces the melanocytic migration and hypopigmentation through destabilizing p53 via HDAC5: A possible role of ITAC in pigment-related disorders.
Hypothyroidism
A histone deacetylase inhibitor improves hypothyroidism caused by a TR?1 mutant.
Hypothyroidism
Histone deacetylase inhibition reduces hypothyroidism-induced neurodevelopmental defects in rats.
Hypoxia-Ischemia, Brain
Uridine protects against hypoxic-ischemic brain injury by reducing histone deacetylase activity in neonatal rats.
Idiopathic Pulmonary Fibrosis
Abrogation of TGF-{beta}1-induced Fibroblast-Myofibroblast Differentiation by Histone Deacetylase (HDAC) Inhibition.
Idiopathic Pulmonary Fibrosis
Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
Idiopathic Pulmonary Fibrosis
Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors.
Idiopathic Pulmonary Fibrosis
Histone Deacetylase 3-Mediated Inhibition of microRNA-19a-3p Facilitates the Development of Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Immune System Diseases
Autoantigenic nuclear proteins of a clinically atypical renal vasculitis.
Immune System Diseases
Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Immune System Diseases
Histone deacetylase 6 modulates macrophage infiltration during inflammation.
Immune System Diseases
Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group.
Immune System Diseases
Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents.
Infarction, Middle Cerebral Artery
HDAC inhibitors mitigate ischemia-induced oligodendrocyte damage: potential roles of oligodendrogenesis, VEGF, and anti-inflammation.
Infarction, Middle Cerebral Artery
HDAC3 Downregulation Improves Cerebral Ischemic Injury via Regulation of the SDC1-Dependent JAK1/STAT3 Signaling Pathway Through miR-19a Upregulation.
Infarction, Middle Cerebral Artery
HDAC9 Silencing Exerts Neuroprotection Against Ischemic Brain Injury via miR-20a-Dependent Downregulation of NeuroD1.
Infarction, Middle Cerebral Artery
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Infarction, Middle Cerebral Artery
Inhibition of HDAC3 Ameliorates Cerebral Ischemia Reperfusion Injury in Diabetic Mice In Vivo and In Vitro.
Infarction, Middle Cerebral Artery
Neuronal susceptibility to beta-amyloid toxicity and ischemic injury involves histone deacetylase-2 regulation of endophilin-B1.
Infarction, Middle Cerebral Artery
Neuroprotective Effects of Selective Inhibition of Histone Deacetylase 3 in Experimental Stroke.
Infarction, Middle Cerebral Artery
Nuclear translocation of histone deacetylase 4 induces neuronal death in stroke.
Infarction, Middle Cerebral Artery
Opposite effects of HDAC5 and p300 on MRTF-A-related neuronal apoptosis during ischemia/reperfusion injury in rats.
Infarction, Middle Cerebral Artery
Sp3/REST/HDAC1/HDAC2 Complex Represses and Sp1/HIF-1/p300 Complex Activates ncx1 Gene Transcription, in Brain Ischemia and in Ischemic Brain Preconditioning, by Epigenetic Mechanism.
Infarction, Middle Cerebral Artery
Stroke Induces Nuclear Shuttling of Histone Deacetylase 4.
Infarction, Middle Cerebral Artery
Tubastatin A, an HDAC6 inhibitor, alleviates stroke-induced brain infarction and functional deficits: potential roles of ?-tubulin acetylation and FGF-21 up-regulation.
Infarction, Middle Cerebral Artery
Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction.
Infections
A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer.
Infections
A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.
Infections
A role for the histone deacetylase HDAC4 in the life-cycle of HIV-1-based vectors.
Infections
Adenovirus transforming protein E1A induces c-Myc in quiescent cells by a novel mechanism.
Infections
Agonist-induced nuclear export of GFP-HDAC5 in isolated adult rat ventricular myocytes.
Infections
Alterations of Nuclear Architecture and Epigenetic Signatures during African Swine Fever Virus Infection.
Infections
Anaplasma phagocytophilum increases the levels of histone modifying enzymes to inhibit cell apoptosis and facilitate pathogen infection in the tick vector Ixodes scapularis.
Infections
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Infections
Aspergillus fumigatus phospholipase D may enhance reactive oxygen species production by accumulation of histone deacetylase 6.
Infections
Bovine herpesvirus 1 immediate-early protein (bICP0) interacts with the histone acetyltransferase p300, which stimulates productive infection and gC promoter activity.
Infections
c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter.
Infections
Components of the REST/CoREST/histone deacetylase repressor complex are disrupted, modified, and translocated in HSV-1-infected cells.
Infections
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Infections
Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection.
Infections
Endoplasmic Reticulum Homeostasis Is Modulated by the Forkhead Transcription Factor FKH-9 During Infection of Caenorhabditis elegans.
Infections
Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
Infections
Epigenetic regulation of defense genes by histone deacetylase1 in human cell line-derived macrophages promotes intracellular survival of Leishmania donovani.
Infections
Epigenetic Regulation of Matrix Metalloproteinase-1 and -3 Expression in Mycobacterium tuberculosis Infection.
Infections
Epigenetic silencing of host cell defense genes enhances intracellular survival of the rickettsial pathogen Anaplasma phagocytophilum.
Infections
Epithelial Histone Deacetylase 3 Instructs Intestinal Immunity by Coordinating Local Lymphocyte Activation.
Infections
Equine herpesvirus type 1 replication is delayed in CD172a+ monocytic cells and controlled by histone deacetylases.
Infections
Functional interaction between class II histone deacetylases and ICP0 of herpes simplex virus type 1.
Infections
Functional interaction of the human cytomegalovirus IE2 protein with histone deacetylase 2 in infected human fibroblasts.
Infections
HDAC3 inhibitor RGFP966 controls bacterial growth and modulates macrophage signaling during Mycobacterium tuberculosis infection.
Infections
HDAC5 promotes Mycoplasma pneumoniae-induced inflammation in macrophages through NF-?B activation.
Infections
HDAC6 controls innate immune and autophagy responses to TLR-mediated signalling by the intracellular bacteria Listeria monocytogenes.
Infections
HDAC6 depletion improves cystic fibrosis mouse airway responses to bacterial challenge.
Infections
HDAC6 Restricts Influenza A Virus by Deacetylation of the RNA Polymerase PA Subunit.
Infections
HDAC6, A Novel Cargo for Autophagic Clearance of Stress Granules, Mediates the Repression of the Type I Interferon Response During Coxsackievirus A16 Infection.
Infections
HDAC7 is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages.
Infections
Helicobacter pylori inhibits autophagic flux and promotes its intracellular survival and colonization by down-regulating SIRT1.
Infections
Histone acetylation and flagellin are essential for Legionella pneumophila-induced cytokine expression.
Infections
Histone deacetylase 1 interacts with HIV-1 Integrase and modulates viral replication.
Infections
Histone Deacetylase 2 Is a Component of Influenza A Virus-Induced Host Antiviral Response.
Infections
Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression.
Infections
Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6.
Infections
Histone deacetylase 6 inhibitor enhances resistance to Mycobacterium tuberculosis infection through innate and adaptive immunity in mice.
Infections
Histone Deacetylase 6 Inhibits Influenza A Virus Release by Downregulating the Trafficking of Viral Components to the Plasma Membrane via Its Substrate, Acetylated Microtubules.
Infections
Histone Deacetylase 6 Knockout Mice Exhibit Higher Susceptibility to Influenza A Virus Infection.
Infections
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Infections
Histone deacetylase 8 is required for centrosome cohesion and influenza A virus entry.
Infections
Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication.
Infections
Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function.
Infections
Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus.
Infections
Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection.
Infections
Histone deacetylase inhibitors impair the host immune response against Mycobacterium tuberculosis infection.
Infections
Histone deacetylase inhibitors increase virus gene expression but decrease CD8+ cell antiviral function in HTLV-1 infection.
Infections
Histone deacetylase inhibitors suppress RSV infection and alleviate virus-induced airway inflammation.
Infections
Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches.
Infections
Imipramine exploits histone deacetylase 11 to increase the IL-12/IL-10 ratio in macrophages infected with antimony-resistant Leishmania donovani and clears organ parasites in experimental infection.
Infections
Influenza A virus dysregulates host histone deacetylase 1 that inhibits viral infection in lung epithelial cells.
Infections
Influenza A virus infection dysregulates the expression of microRNA-22 and its targets; CD147 and HDAC4, in epithelium of asthmatics.
Infections
Inhibiting Histone Deacetylases in Human Macrophages Promotes Glycolysis, IL-1?, and T Helper Cell Responses to Mycobacterium tuberculosis.
Infections
Inhibition of Viral Pathogenesis and Promotion of the Septic Shock Response to Bacterial Infection by IRF-3 Are Regulated by the Acetylation and Phosphorylation of Its Coactivators.
Infections
Latent Kaposi's sarcoma-associated herpesvirus infection in bladder cancer cells promotes drug resistance by reducing reactive oxygen species.
Infections
Lessons from Anaplasma phagocytophilum: chromatin remodeling by bacterial effectors.
Infections
microRNA-34a aggravates coxsackievirus B3-induced apoptosis of cardiomyocytes through the SIRT1-p53 pathway.
Infections
MicroRNA-455 suppresses the oncogenic function of HDAC2 in human colorectal cancer.
Infections
Mycobacteria inhibition of IFN-gamma induced HLA-DR gene expression by up-regulating histone deacetylation at the promoter region in human THP-1 monocytic cells.
Infections
Mycobacterium tuberculosis infection induces IL-10 gene expression by disturbing histone deacetylase 6 and histonedeacetylase 11 equilibrium in macrophages.
Infections
NF-?Bp50 and HDAC1 Interaction Is Implicated in the Host Tolerance to Infection Mediated by the Bacterial Quorum Sensing Signal 2-Aminoacetophenone.
Infections
Novel Carboline Fungal Histone Deacetylase (HDAC) Inhibitors for Combinational Treatment of Azole-Resistant Candidiasis.
Infections
Overexpression of Histone Deacetylase 6 Enhances Resistance to Porcine Reproductive and Respiratory Syndrome Virus in Pigs.
Infections
Oxidative and Nitrosative Stress and Histone Deacetylase-2 Activity in Exacerbations of COPD.
Infections
Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0.
Infections
PKC alpha regulates Sendai virus-mediated interferon induction through HDAC6 and ?-catenin.
Infections
Porcine Epidemic Diarrhea Virus Inhibits HDAC1 Expression To Facilitate Its Replication via Binding of Its Nucleocapsid Protein to Host Transcription Factor Sp1.
Infections
Positive role of promyelocytic leukemia protein in type I interferon response and its regulation by human cytomegalovirus.
Infections
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.
Infections
Primary macrophages rely on histone deacetylase 1 and 2 expression to induce type I interferon in response to gammaherpesvirus infection.
Infections
Protein acetylation derepresses Serotonin Synthesis to potentiate Pancreatic Beta-Cell Function through HDAC1-PKA-Tph1 signaling.
Infections
Quantitative Temporal Proteomic Analysis of Vaccinia Virus Infection Reveals Regulation of Histone Deacetylases by an Interferon Antagonist.
Infections
Rabies Virus Infection Induces Microtubule Depolymerization to Facilitate Viral RNA Synthesis by Upregulating HDAC6.
Infections
Reactivation of Latent HIV-1 Expression by Engineered TALE Transcription Factors.
Infections
Recurrent Herpes Simplex Virus Type 1 (HSV-1) Infection Modulates Neuronal Aging Marks in In Vitro and In Vivo Models.
Infections
Regulation of disease-responsive genes mediated by epigenetic factors: interaction of Arabidopsis-Pseudomonas.
Infections
Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100.
Infections
RFXB and its splice variant RFXBSV mediate the antagonism between IFNgamma and TGFbeta on COL1A2 transcription in vascular smooth muscle cells.
Infections
Risk of infection associated with new therapies for lymphoproliferative syndromes.
Infections
Sargassum polysaccharide inhibits inflammatory response in PCV2 infected-RAW264.7 cells by regulating histone acetylation.
Infections
Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro.
Infections
SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis.
Infections
Sodium butyrate: a chemical inducer of in vivo reactivation of herpes simplex virus type 1 in the ocular mouse model.
Infections
Suppression of complement component 2 expression by hepatitis B virus contributes to the viral persistence in chronic hepatitis B patients.
Infections
The CDK inhibitor p21Cip1/WAF1 is induced by Fc{gamma}R activation and restricts the replication of HIV-1 and related primate lentiviruses in human macrophages.
Infections
The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury.
Infections
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.
Infections
The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells.
Infections
The Major Capsid Protein, VP1, of the Mouse Polyomavirus Stimulates the Activity of Tubulin Acetyltransferase 1 by Microtubule Stabilization.
Infections
The Metabolic Regulator Histone Deacetylase 9 Contributes to Glucose Homeostasis Abnormality Induced by Hepatitis C Virus Infection.
Infections
Tissue-targeted in vivo gene transfer coupled with histone deacetylase inhibitor depsipeptide (FK228) enhances adenoviral infection in rat renal cancer allograft model systems.
Infections
Transcription Repressor Protein ZBTB25 Associates with HDAC1-Sin3a Complex in Mycobacterium tuberculosis-Infected Macrophages, and Its Inhibition Clears Pathogen by Autophagy.
Infections
Transcriptional networks are associated with resistance to Mycobacterium tuberculosis infection.
Infections
Trichostatin A, a Histone Deacetylase Inhibitor, Alleviates Eosinophilic Meningitis Induced by Angiostrongylus cantonensis Infection in Mice.
Infections
VEGF stimulates HDAC7 phosphorylation and cytoplasmic accumulation modulating matrix metalloproteinase expression and angiogenesis.
Infections
Vesicular Stomatitis Virus Infection Promotes Immune Evasion by Preventing NKG2D-Ligand Surface Expression.
Infections
ZBP-89 reduces histone deacetylase 3 by degrading IkappaB in the presence of Pin1.
Infertility
HDAC3 controls male fertility through enzyme-independent transcriptional regulation at the meiotic exit of spermatogenesis.
Infertility
Histone Deacetylase 2 (HDAC2) Regulates Chromosome Segregation and Kinetochore Function via H4K16 Deacetylation during Oocyte Maturation in Mouse.
Infertility
SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging.
Infertility
The C. elegans histone deacetylase HDA-1 is required for cell migration and axon pathfinding.
Infertility, Female
Blocking histone deacetylation in Arabidopsis induces pleiotropic effects on plant gene regulation and development.
Infertility, Female
Loss of HDAC3 results in nonreceptive endometrium and female infertility.
Infertility, Male
In vivo application of histone deacetylase inhibitor trichostatin-a impairs murine male meiosis.
Inflammatory Bowel Diseases
An HDAC6 Inhibitor Confers Protection and Selectively Inhibits B-Cell Infiltration in DSS-Induced Colitis in Mice.
Inflammatory Bowel Diseases
Cinnamyl Sulfonamide Hydroxamate Derivatives Inhibited LPS-Stimulated NF-kB Expression in RAW 264.7 Cells in In Vitro and Mitigated Experimental Colitis in Wistar Rats in In Vivo.
Inflammatory Bowel Diseases
Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction.
Inflammatory Bowel Diseases
Histone deacetylase inhibitors and their potential role in inflammatory bowel diseases.
Inflammatory Bowel Diseases
Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice.
Inflammatory Bowel Diseases
Novel Histone Deacetylase 6 Inhibitor CKD-506 Inhibits NF-?B Signaling in Intestinal Epithelial Cells and Macrophages and Ameliorates Acute and Chronic Murine Colitis.
Inflammatory Bowel Diseases
Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases.
Inflammatory Bowel Diseases
The roles of microbial products in the development of colorectal cancer: a review.
Inflammatory Breast Neoplasms
Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.
Inflammatory Breast Neoplasms
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.
Inflammatory Breast Neoplasms
Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Inflammatory Breast Neoplasms
Histone deacetylase inhibitors modulate miRNA and mRNA expression, block metaphase, and induce apoptosis in inflammatory breast cancer cells.
Inflammatory Breast Neoplasms
The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.
Influenza, Human
HDAC6 Restricts Influenza A Virus by Deacetylation of the RNA Polymerase PA Subunit.
Influenza, Human
Histone Deacetylase 1 Plays an Acetylation-Independent Role in Influenza A Virus Replication.
Influenza, Human
Histone Deacetylase 2 Is a Component of Influenza A Virus-Induced Host Antiviral Response.
Influenza, Human
Histone Deacetylase 6 Inhibits Influenza A Virus Release by Downregulating the Trafficking of Viral Components to the Plasma Membrane via Its Substrate, Acetylated Microtubules.
Influenza, Human
Histone Deacetylase 6 Knockout Mice Exhibit Higher Susceptibility to Influenza A Virus Infection.
Influenza, Human
Histone deacetylase 8 is required for centrosome cohesion and influenza A virus entry.
Influenza, Human
Influenza A virus dysregulates host histone deacetylase 1 that inhibits viral infection in lung epithelial cells.
Influenza, Human
Influenza A virus infection dysregulates the expression of microRNA-22 and its targets; CD147 and HDAC4, in epithelium of asthmatics.
Influenza, Human
Influenza A virus-induced caspase-3 cleaves the histone deacetylase 6 in infected epithelial cells.
Influenza, Human
Influenza A virus-induced host caspase and viral PA-X antagonize the antiviral host factor, histone deacetylase 4.
Influenza, Human
Small RNA Profiling of Influenza A Virus-Infected Cells Identifies miR-449b as a Regulator of Histone Deacetylase 1 and Interferon Beta.
Insulin Resistance
A Class I Histone Deacetylase Inhibitor Attenuates Insulin Resistance and Inflammation in Palmitate-Treated C2C12 Myotubes and Muscle of HF/HFr Diet Mice.
Insulin Resistance
A Review of Mitochondrial-derived Fatty Acids in Epigenetic Regulation of Obesity and Type 2 Diabetes.
Insulin Resistance
Acetylation of insulin receptor substrate-1 is permissive for tyrosine phosphorylation.
Insulin Resistance
Adipose tissue mRNA expression of HDAC1, HDAC3 and HDAC9 in obese women in relation to obesity indices and insulin resistance.
Insulin Resistance
Afadin is a scaffold protein repressing insulin action via HDAC6 in adipose tissue.
Insulin Resistance
Class I and II Histone Deacetylase Inhibitors Differentially Regulate Thermogenic Gene Expression in Brown Adipocytes.
Insulin Resistance
Co-activator binding protein PIMT mediates TNF-? induced insulin resistance in skeletal muscle via the transcriptional down-regulation of MEF2A and GLUT4.
Insulin Resistance
Conditional deletion of Hdac3 in osteoprogenitor cells attenuates diet-induced systemic metabolic dysfunction.
Insulin Resistance
Dissociation of muscle insulin sensitivity from exercise endurance in mice by HDAC3 depletion.
Insulin Resistance
DNA methylation and histone deacetylation regulating insulin sensitivity due to chronic cold exposure.
Insulin Resistance
GATA3, HDAC6, and BCL6 Regulate FOXP3+ Treg Plasticity and Determine Treg Conversion into Either Novel Antigen-Presenting Cell-Like Treg or Th1-Treg.
Insulin Resistance
Haplotypes of the Mutated SIRT2 Promoter Contributing to Transcription Factor Binding and Type 2 Diabetes Susceptibility.
Insulin Resistance
HDAC6-mediated acetylation of lipid droplet-binding protein CIDEC regulates fat-induced lipid storage.
Insulin Resistance
HDAC9 knockout mice are protected from adipose tissue dysfunction and systemic metabolic disease during high fat feeding.
Insulin Resistance
Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration.
Insulin Resistance
Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance.
Insulin Resistance
Histone deacetylase 9 promoter hypomethylation associated with adipocyte dysfunction is a statin-related metabolic effect.
Insulin Resistance
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Insulin Resistance
Histone Deacetylase HDAC8 Promotes Insulin Resistance and ?-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma.
Insulin Resistance
Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes.
Insulin Resistance
Induction of Dbp by a histone deacetylase inhibitor is involved in amelioration of insulin sensitivity via adipocyte differentiation in ob/ob mice.
Insulin Resistance
Inhibition of HDAC3 promotes ligand-independent PPAR? activation by protein acetylation.
Insulin Resistance
Leptin-mediated increases in catecholamine signaling reduce adipose tissue inflammation via activation of macrophage HDAC4.
Insulin Resistance
Linking a role of lncRNAs (long non-coding RNAs) with insulin resistance, accelerated senescence, and inflammation in patients with type 2 diabetes.
Insulin Resistance
Loss of Hdac3 in osteoprogenitors increases bone expression of osteoprotegerin, improving systemic insulin sensitivity.
Insulin Resistance
Proteomics Analysis of Human Obesity Reveals the Epigenetic Factor HDAC4 as a Potential Target for Obesity.
Insulin Resistance
Regulation of SIRT1 determines initial step of endometrial receptivity by controlling E-cadherin expression.
Insulin Resistance
The histone deacetylase inhibiting drug Entinostat induces lipid accumulation in differentiated HepaRG cells.
Insulin Resistance
The histone deacetylase inhibitor sodium butyrate improves insulin signalling in palmitate-induced insulin resistance in L6 rat muscle cells through epigenetically-mediated up-regulation of Irs1.
Insulin Resistance
Trichostatin A improves insulin stimulated glucose utilization and insulin signaling transduction through the repression of HDAC2.
Insulin Resistance
Upregulation of skeletal muscle inflammatory genes links inflammation with insulin resistance in women with the metabolic syndrome.
Intellectual Disability
Confirmed rare copy number variants implicate novel genes in schizophrenia.
Intellectual Disability
De novo satellited 2q associated with corpus callosum dysgenesis, short stature, mental retardation and developmental delay.
Intellectual Disability
Dose dependent expression of HDAC4 causes variable expressivity in a novel inherited case of brachydactyly mental retardation syndrome.
Intellectual Disability
Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems.
Intellectual Disability
Haploinsufficiency of HDAC4 does not cause intellectual disability in all affected individuals.
Intellectual Disability
HDAC4 governs a transcriptional program essential for synaptic plasticity and memory.
Intellectual Disability
Increased long-term potentiation at medial-perforant path-dentate granule cell synapses induced by selective inhibition of histone deacetylase 3 requires Fragile X mental retardation protein.
Intellectual Disability
Loss of function of NCOR1 and NCOR2 impairs memory through a novel GABAergic hypothalamus-CA3 projection.
Intellectual Disability
Missense substitutions at a conserved 14-3-3 binding site in HDAC4 cause a novel intellectual disability syndrome.
Intellectual Disability
Modeling Cornelia de Lange Syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation.
Intellectual Disability
Primary hyperoxaluria type 1 and brachydactyly mental retardation syndrome caused by a novel mutation in AGXT and a terminal deletion of chromosome 2.
Intellectual Disability
The clinical and molecular features of three Turkish patients with a rare genetic disorder: 2q37 deletion syndrome.
Intellectual Disability
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Intellectual Disability
The first familial case of inherited 2q37.3 interstitial deletion with isolated skeletal abnormalities including brachydactyly type E and short stature.
Intellectual Disability
Transcriptome analysis of genes and gene networks involved in aggressive behavior in mouse and zebrafish.
Intellectual Disability
X-exome sequencing identifies a HDAC8 variant in a large pedigree with X-linked intellectual disability, truncal obesity, gynaecomastia, hypogonadism and unusual face.
Intellectual Disability
[Analysis of clinical phenotypes and genetic variations in a Chinese family affected with craniofacial and skeletal deformities].
Intervertebral Disc Degeneration
Inhibition of HDAC4 by GSK3? leads to downregulation of KLF5 and ASK1 and prevents the progression of intravertebral disc degeneration.
Intestinal Pseudo-Obstruction
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Intracranial Aneurysm
Associations among Genetic Variants and Intracranial Aneurysm in a Chinese Population.
Intracranial Aneurysm
Histone deacetylase 9 inhibition upregulates microRNA-92a to repress the progression of intracranial aneurysm via silencing Bcl-2-like protein 11.
Intracranial Aneurysm
Rs10230207 genotype confers changes in HDAC9 and TWIST1, but not FERD3L in lymphoblasts from patients with intracranial aneurysm.
Intracranial Hemorrhages
Pharmacokinetics and Acute Toxicity of a Histone Deacetylase Inhibitor, Scriptaid, and Its Neuroprotective Effects in Mice After Intracranial Hemorrhage.
Invasive Fungal Infections
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Iron Overload
Memory impairment induced by brain iron overload is accompanied by reduced H3K9 acetylation and ameliorated by sodium butyrate.
Ischemic Attack, Transient
Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack.
Ischemic Attack, Transient
TOPK Promotes Microglia/Macrophage Polarization towards M2 Phenotype via Inhibition of HDAC1 and HDAC2 Activity after Transient Cerebral Ischemia.
Ischemic Stroke
APOL1, CDKN2A/CDKN2B, and HDAC9 polymorphisms and small vessel ischemic stroke.
Ischemic Stroke
Association between Histone Deacetylase 9 Gene Polymorphism and Stroke in Chinese Han Population.
Ischemic Stroke
Association Between the Gene Polymorphisms of HDAC9 and the Risk of Atherosclerosis and Ischemic Stroke.
Ischemic Stroke
Association of a Multigenetic Pro-Inflammatory Profile with Ischaemic Stroke.
Ischemic Stroke
Association of GWAS-supported loci rs2107595 in HDAC9 gene with ischemic stroke in southern Han Chinese.
Ischemic Stroke
Atherosclerotic Aortic Calcification-Associated Polymorphism in HDAC9 and Associations with Mortality, Cardiovascular Disease, and Kidney Disease.
Ischemic Stroke
Evidence HDAC9 Genetic Variant Associated With Ischemic Stroke Increases Risk via Promoting Carotid Atherosclerosis.
Ischemic Stroke
Expression of Histone Deacetylases HDAC1 and HDAC2 and Their Role in Apoptosis in the Penumbra Induced by Photothrombotic Stroke.
Ischemic Stroke
Expression patterns of histone deacetylases in experimental stroke and potential targets for neuroprotection.
Ischemic Stroke
Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke.
Ischemic Stroke
HDAC6 dysfunction contributes to impaired maturation of adult neurogenesis in vivo: vital role on functional recovery after ischemic stroke.
Ischemic Stroke
HDAC9 exacerbates endothelial injury in cerebral ischaemia/reperfusion injury.
Ischemic Stroke
HDAC9 promotes brain ischemic injury by provoking I?B?/NF-?B and MAPKs signaling pathways.
Ischemic Stroke
Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury.
Ischemic Stroke
Interactive Effects of a Combination of the HDAC3 and HDAC9 Genes with Diabetes Mellitus on the Risk of Ischemic Stroke.
Ischemic Stroke
Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study.
Ischemic Stroke
Long Noncoding RNA H19 Promotes Neuroinflammation in Ischemic Stroke by Driving Histone Deacetylase 1-Dependent M1 Microglial Polarization.
Ischemic Stroke
Meta-Analysis of Genome-Wide Association Studies Identifies Genetic Risk Factors for Stroke in African Americans.
Ischemic Stroke
Neuroprotective Effects of Selective Inhibition of Histone Deacetylase 3 in Experimental Stroke.
Ischemic Stroke
Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack.
Ischemic Stroke
The Effect of Histone Deacetylase Inhibitors Panobinostat or Entinostat on Motor Recovery in Mice After Ischemic Stroke.
Ischemic Stroke
The histone deacetylase inhibitor, sodium butyrate, exhibits neuroprotective effects for ischemic stroke in middle-aged female rats.
Ischemic Stroke
The relationship between the prognosis of children with acute arterial stroke and polymorphisms of CDKN2B, HDAC9, NINJ2, NAA25 genes.
Ischemic Stroke
Updating a Strategy for Histone Deacetylases and Its Inhibitors in the Potential Treatment of Cerebral Ischemic Stroke.
Ischemic Stroke
[Expression of HDAC9 in different brain regions in mice with cerebral ischemic stroke].
Ischemic Stroke
[Research progress of histone deacetylase 6 inhibitors in the therapy of ischemic stroke].
Keloid
CUDC?907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2.
Ketosis
The role of microglia in neuroprogressive disorders: mechanisms and possible neurotherapeutic effects of induced ketosis.
Kidney Diseases
Atherosclerotic Aortic Calcification-Associated Polymorphism in HDAC9 and Associations with Mortality, Cardiovascular Disease, and Kidney Disease.
Kidney Diseases
Correlation analysis between expression of histone deacetylase 6 and clinical parameters in IgA nephropathy patients.
Kidney Diseases
HDAC6 Inhibition Promotes Transcription Factor EB Activation and Is Protective in Experimental Kidney Disease.
Kidney Diseases
Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease.
Kidney Diseases
Podocyte histone deacetylase activity regulates murine and human glomerular diseases.
Kidney Diseases
Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase.
Kidney Diseases
The Nephroprotective Effect of MS-275 on Lipopolysaccharide (LPS)-Induced Acute Kidney Injury by Inhibiting Reactive Oxygen Species (ROS)-Oxidative Stress and Endoplasmic Reticulum Stress.
Kidney Diseases
Trichostatin A ameliorates renal tubulointerstitial fibrosis through modulation of the JNK-dependent Notch-2 signaling pathway.
Kidney Diseases
Up-Regulation of SIRT1 Reduces Endoplasmic Reticulum Stress and Renal Fibrosis.
Kidney Diseases, Cystic
Deletion of ADP Ribosylation Factor-Like GTPase 13B Leads to Kidney Cysts.
Kidney Neoplasms
17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
Kidney Neoplasms
A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.
Kidney Neoplasms
A novel gamma-lactam-based histone deacetylase inhibitor potently inhibits the growth of human breast and renal cancer cells.
Kidney Neoplasms
Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells.
Kidney Neoplasms
Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors.
Kidney Neoplasms
Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.
Kidney Neoplasms
Gene microarray analysis of human renal cell carcinoma: The effects of HDAC inhibition and retinoid treatment.
Kidney Neoplasms
HDAC4 protein regulates HIF1? protein lysine acetylation and cancer cell response to hypoxia.
Kidney Neoplasms
Panobinostat and Nelfinavir Inhibit Renal Cancer Growth by Inducing Endoplasmic Reticulum Stress.
Kidney Neoplasms
Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
Kidney Neoplasms
Tissue-targeted in vivo gene transfer coupled with histone deacetylase inhibitor depsipeptide (FK228) enhances adenoviral infection in rat renal cancer allograft model systems.
Kidney Neoplasms
VPA inhibits renal cancer cell migration by targeting HDAC2 and down-regulating HIF-1?.
Laryngeal Neoplasms
Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells.
Latent Infection
An HIV-1 replication pathway utilizing reverse transcript products that fail to integrate.
Latent Infection
HSV carrying WT REST establishes latency but reactivates only if the synthesis of REST is suppressed.
Latent Infection
Quantitative evaluation and optimization of co-drugging to improve anti-HIV latency therapy.
Latent Infection
Unique characteristics of histone deacetylase inhibitors in reactivation of latent HIV-1 in Bcl-2-transduced primary resting CD4+ T cells.
Latent Tuberculosis
Transcriptional networks are associated with resistance to Mycobacterium tuberculosis infection.
Leiomyoma
Use of Histone Deacetylase 8 (HDAC8), a New Marker of Smooth Muscle Differentiation, in the Classification of Mesenchymal Tumors of the Uterus.
Leiomyosarcoma
The combination of histone deacetylase and p53 expressions and histological subtype has prognostic implication in uterine leiomyosarcoma.
Leiomyosarcoma
Use of Histone Deacetylase 8 (HDAC8), a New Marker of Smooth Muscle Differentiation, in the Classification of Mesenchymal Tumors of the Uterus.
Leishmaniasis
Epigenetic regulation of defense genes by histone deacetylase1 in human cell line-derived macrophages promotes intracellular survival of Leishmania donovani.
Leishmaniasis
KH-TFMDI, a novel sirtuin inhibitor, alters the cytoskeleton and mitochondrial metabolism promoting cell death in Leishmania amazonensis.
Leishmaniasis, Cutaneous
Leishmania amazonensis downregulates macrophage iNOS expression via Histone Deacetylase 1 (HDAC1): a novel parasite evasion mechanism.
Leishmaniasis, Visceral
A nanodelivered Vorinostat derivative is a promising oral compound for the treatment of visceral leishmaniasis.
Lentivirus Infections
A novel treatment strategy in hepatocellular carcinoma by down-regulation of histone deacetylase 1 expression using a shRNA lentiviral system.
Lentivirus Infections
HDAC9 exacerbates endothelial injury in cerebral ischaemia/reperfusion injury.
Leprosy
Effect of dialyzable leukocyte extract, sodium butyrate, and valproic acid in the development of anergy in murine leprosy.
Leukemia
8a, a New Acridine Antiproliferative and Pro-Apoptotic Agent Targeting HDAC1/DNMT1.
Leukemia
A combination of low-dose decitabine and chidamide resulted in synergistic effects on the proliferation and apoptosis of human myeloid leukemia cell lines.
Leukemia
A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF.
Leukemia
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Leukemia
A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
Leukemia
A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis.
Leukemia
Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia.
Leukemia
Active repression by unliganded retinoid receptors in development: less is sometimes more.
Leukemia
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells.
Leukemia
Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis?
Leukemia
An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells.
Leukemia
Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
Leukemia
Antiproliferative and proapoptotic effects of proteasome inhibitors and their combination with histone deacetylase inhibitors on leukemia cells.
Leukemia
Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells.
Leukemia
Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells.
Leukemia
Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways.
Leukemia
BCR-ABL1 kinase facilitates localization of acetylated histones 3 and 4 on DNA double-strand breaks.
Leukemia
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
Leukemia
Blockade of MEK signaling potentiates 5-Aza-2'-deoxycytidine-induced apoptosis and upregulation of p21(waf1) in acute myelogenous leukemia cells.
Leukemia
Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
Leukemia
C/EBP? and PU.1 are involved in distinct differentiation responses of acute promyelocytic leukemia HL-60 and NB4 cells via chromatin remodeling.
Leukemia
Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy.
Leukemia
Characterization of cells resistant to the potent histone deacetylase inhibitor spiruchostatin B (SP-B) and effect of overexpressed p21waf1/cip1 on the SP-B resistance or susceptibility of human leukemia cells.
Leukemia
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Leukemia
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.
Leukemia
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Leukemia
Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
Leukemia
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Leukemia
Combinatorial Effects of PARP Inhibitor PJ34 and Histone Deacetylase Inhibitor Vorinostat on Leukemia Cell Lines.
Leukemia
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.
Leukemia
Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Leukemia
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Leukemia
Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
Leukemia
Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
Leukemia
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Leukemia
CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1-arrest,ROS-dependent apoptosis and differentiation in human leukemia cells.
Leukemia
Curcumin augments the efficacy of antitumor drugs used in leukemia by modulation of heat shock proteins via HDAC6.
Leukemia
Design, synthesis and biological evaluation of a phenyl butyric acid derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 inhibitor with anti-proliferative activity on cervix cancer and leukemia cells.
Leukemia
Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.
Leukemia
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Leukemia
Dynamic analysis of proviral induction and De Novo methylation: implications for a histone deacetylase-independent, methylation density-dependent mechanism of transcriptional repression.
Leukemia
Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells.
Leukemia
Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Leukemia
Effect of valproic acid, a histone deacetylase inhibitor, on cell death and molecular changes caused by low-dose irradiation.
Leukemia
Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.
Leukemia
Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines.
Leukemia
Effects of histone deacetylase inhibitors, sodium phenyl butyrate and vitamin B3, in combination with retinoic acid on granulocytic differentiation of human promyelocytic leukemia HL-60 cells.
Leukemia
Effects of trichostatin A on HDAC8 expression, proliferation and cell cycle of molt-4 cells.
Leukemia
Epigallocatechin-3-gallate enhances differentiation of acute promyelocytic leukemia cells via inhibition of PML-RAR? and HDAC1.
Leukemia
Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
Leukemia
Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia.
Leukemia
Epigenetic regulation of the human telomerase reverse transciptase gene: A potential therapeutic target for the treatment of leukemia (Review).
Leukemia
Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.
Leukemia
Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays.
Leukemia
Erratum to Design, Synthesis and Biological Evaluation of a Phenyl Butyric Acid Derivative, N-(4-chlorophenyl)-4- phenylbutanamide: A HDAC6 Inhibitor with Anti-proliferative Activity on Cervix Cancer and Leukemia Cells.
Leukemia
Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol.
Leukemia
Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937).
Leukemia
Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia.
Leukemia
Expression of leukemia associated fusion proteins increases sensitivity to histone deacetylase inhibitor induced DNA damage and apoptosis.
Leukemia
Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer.
Leukemia
Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.
Leukemia
FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Leukemia
Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.
Leukemia
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
Leukemia
Gene expression profiling of KBH-A42, a novel histone deacetylase inhibitor, in human leukemia and bladder cancer cell lines.
Leukemia
Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
Leukemia
HDAC and HMT Inhibitors in Combination with Conventional Therapy: A Novel Treatment Option for Acute Promyelocytic Leukemia.
Leukemia
HDAC Inhibitor LBH589 Suppresses the Proliferation but Enhances the Antileukemic Effect of Human ??T Cells.
Leukemia
HDAC1 and Klf4 interplay critically regulates human myeloid leukemia cell proliferation.
Leukemia
HDAC1 Is a Required Cofactor of CBF?-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
Leukemia
HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia.
Leukemia
HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
Leukemia
HDAC9 regulates the alternative lengthening of telomere (ALT) pathway via the formation of ALT-associated PML bodies.
Leukemia
High-expressing cystic fibrosis transmembrane conductance regulator interacts with histone deacetylase 2 to promote the development of Ph+ leukemia through the HDAC2-mediated PTEN pathway.
Leukemia
Histone Deacetylase 3 Mediates Allergic Skin Inflammation by Regulating Expression of MCP1 Protein.
Leukemia
Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc.
Leukemia
Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells.
Leukemia
Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein.
Leukemia
Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
Leukemia
Histone Deacetylase Inhibitor M344 Inhibits Cell Proliferation and Induces Apoptosis in Human THP-1 Leukemia Cells.
Leukemia
Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDI-dependent apoptosis?
Leukemia
Histone deacetylase inhibitors activate NF-?B in human leukemia cells through an ATM/NEMO-related pathway.
Leukemia
Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway.
Leukemia
Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy.
Leukemia
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Leukemia
Histone deacetylase inhibitors in plasma cell leukemia treatment: effect of bone marrow microenvironment.
Leukemia
Histone deacetylase inhibitors induce leukemia gene expression in cord blood hematopoietic stem cells expanded ex vivo.
Leukemia
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
Leukemia
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Leukemia
Histone deacetylase inhibitors suppress IFNalpha-induced up-regulation of promyelocytic leukemia protein.
Leukemia
Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
Leukemia
Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera.
Leukemia
Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
Leukemia
Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin A.
Leukemia
In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy.
Leukemia
In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi).
Leukemia
In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR{alpha} blockade in the pathogenesis of acute promyelocytic leukemia.
Leukemia
In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice.
Leukemia
Inactivating a cellular intrinsic immune defense mediated by Daxx is the mechanism through which the human cytomegalovirus pp71 protein stimulates viral immediate-early gene expression.
Leukemia
Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells.
Leukemia
Increased HDAC1 deposition at hematopoietic promoters in AML and its association with patient survival.
Leukemia
Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
Leukemia
Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways.
Leukemia
Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia.
Leukemia
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Leukemia
Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition.
Leukemia
Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
Leukemia
Inhibitory activity of linoleic acid isolated from proso and Japanese millet toward histone deacetylase.
Leukemia
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.
Leukemia
Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
Leukemia
Involvement of p21waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells.
Leukemia
Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
Leukemia
KBH-A42, a histone deacetylase inhibitor, inhibits the growth of doxorubicin-resistant leukemia cells expressing P-glycoprotein.
Leukemia
LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.
Leukemia
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Leukemia
Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Leukemia
Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha.
Leukemia
MicroRNA-34a-mediated death of acute myeloid leukemia stem cells through apoptosis induction and exosome shedding inhibition via histone deacetylase 2 targeting.
Leukemia
MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi).
Leukemia
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
Leukemia
Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.
Leukemia
Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells.
Leukemia
MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Leukemia
MTA1 modulated by miR-30e contributes to epithelial-to-mesenchymal transition in hepatocellular carcinoma through an ErbB2-dependent pathway.
Leukemia
Neutrophilic differentiation modulates the apoptotic response of HL-60 cells to sodium butyrate and sodium valproate.
Leukemia
Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound {beta}-phenylethyl isothiocyanate.
Leukemia
Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance.
Leukemia
PCFT/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells.
Leukemia
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Leukemia
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Leukemia
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
Leukemia
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
Leukemia
Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Leukemia
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).
Leukemia
PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Leukemia
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Leukemia
Prolonged molecular remission in PML-RARalpha-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate.
Leukemia
Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity.
Leukemia
Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells.
Leukemia
Re: Dasmahapatra G, Almenara JA, and Grant S, "Flavopiridol and Histone Deacetylase Inhibitors Promote Mitochondrial Injury and Cell Death in Human Leukemia Cells that Overexpress Bcl-2." Mol Pharmacol January 2006 69:288-298; doi:10.1124/mol.105.016154.
Leukemia
Re: Rosato RR, Maggio SC, Almenara JA, Payne SG, Atadja P, Spiegel S, Dent P, and Grant S, "The Histone Deacetylase Inhibitor LAQ824 Induces Human Leukemia Cell Death through a Process Involving XIAP Down-Regulation, Oxidative Injury, and the Acid Sphingomyelinase-Dependent Generation of Ceramide." Mol Pharmacol January 2006 69:216-225; doi:10.1124/mol.105.017145.
Leukemia
Re: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
Leukemia
Relationship between the induction of leukemia cell differentiation and the enhancement of reporter gene expression in 3T3 Swiss cells.
Leukemia
Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
Leukemia
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo.
Leukemia
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.
Leukemia
Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells.
Leukemia
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia.
Leukemia
Selective inhibition of bicyclic tetrapeptide histone deacetylase inhibitor on HDAC4 and K562 leukemia cell.
Leukemia
Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Leukemia
Signal-dependent regulation of transcription by histone deacetylase 7 involves recruitment to promyelocytic leukemia protein nuclear bodies.
Leukemia
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.
Leukemia
Spiruchostatin A and B, novel histone deacetylase inhibitors, induce apoptosis through reactive oxygen species-mitochondria pathway in human lymphoma U937 cells.
Leukemia
Strong Correlation between the Expression Levels of HDAC4 and SIRT6 in Hematological Malignancies of the Adults.
Leukemia
Structural insight into the separate roles of inositol tetraphosphate and deacetylase-activating domain in activation of histone deacetylase 3.
Leukemia
Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells.
Leukemia
Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by induction p21WAF1 expression and cell cycle arrest.
Leukemia
Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.
Leukemia
Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress.
Leukemia
Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
Leukemia
Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
Leukemia
Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells.
Leukemia
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.
Leukemia
Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
Leukemia
Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.
Leukemia
TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells.
Leukemia
Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
Leukemia
Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response.
Leukemia
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression.
Leukemia
The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells.
Leukemia
The antiparasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity.
Leukemia
The combination of a histone deacetylase inhibitor with the Bcl-2 homology domain-3 mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
Leukemia
The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.
Leukemia
The gene signature in CCAAT-enhancer-binding protein ? dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors.
Leukemia
The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
Leukemia
The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming.
Leukemia
The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation.
Leukemia
The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide.
Leukemia
The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
Leukemia
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
Leukemia
The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
Leukemia
The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines.
Leukemia
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Leukemia
The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.
Leukemia
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
Leukemia
Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia.
Leukemia
Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
Leukemia
Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines.
Leukemia
Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia.
Leukemia
Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells.
Leukemia
Tumor SHB gene expression affects disease characteristics in human acute myeloid leukemia.
Leukemia
Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.
Leukemia
VDUP1 upregulated by TGF-beta1 and 1,25-dihydorxyvitamin D3 inhibits tumor cell growth by blocking cell-cycle progression.
Leukemia
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
Leukemia
Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.
Leukemia
[Dexamethasone and vorinostat cooperatively promote differentiation and apoptosis in Kasumi-1 leukemia cells through ubiquitination and degradation of AML1-ETO.]
Leukemia
[Down-regulation of HDAC6 Expression Can Influence KG1? Cell Proliferation by Inhibiting ERK Pathway].
Leukemia
[Down-regulation of HDAC6 Expression Promotes Apoptosis of Human Leukemia K562 Cells].
Leukemia
[Effect of downregulation the expression of HDAC1 on cells differentiation of HL-60 cells].
Leukemia
[Effect of inhibitors for demethylation and histone deacetylase on proliferation of cell line K562 and expression of tumor related genes]
Leukemia
[Effects of histone deacetylase inhibitor on the expression of angiogenesis related factors in Kasumi-1 leukemic cell line.]
Leukemia
[Mechanism of Leukemia Cell Apoptosis Induced by Sodium Butyrate activating TRAIL pathway.]
Leukemia
[Phenol butyrate inhibits cell cycle of leukemia cell lines through up-regulation of p21WAF1/CIP1 gene]
Leukemia
[Phenylhexyl isothiocyanate induces gene p15 demethylation by down-regulating DNA methyltransferases in molt-4 cells]
Leukemia
[The re-expression of p15(INK4B) gene in leukemia cells induced by in vitro DNA methyltransferase and histone deacetylase inhibition]
Leukemia, B-Cell
Characterization of cells resistant to the potent histone deacetylase inhibitor spiruchostatin B (SP-B) and effect of overexpressed p21waf1/cip1 on the SP-B resistance or susceptibility of human leukemia cells.
Leukemia, B-Cell
Involvement of p21waf1/cip1 expression in the cytotoxicity of the potent histone deacetylase inhibitor spiruchostatin B towards susceptible NALM-6 human B cell leukemia cells.
Leukemia, B-Cell
MEF2D-BCL9 Fusion Gene Is Associated With High-Risk Acute B-Cell Precursor Lymphoblastic Leukemia in Adolescents.
Leukemia, Erythroblastic, Acute
Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
Leukemia, Erythroblastic, Acute
Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation.
Leukemia, Erythroblastic, Acute
Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase.
Leukemia, Erythroblastic, Acute
Effect of inhibitors of histone deacetylase on the induction of cell differentiation in murine and human erythroleukemia cell lines.
Leukemia, Erythroblastic, Acute
Histone deacetylase 9 activates gamma-globin gene expression in primary erythroid cells.
Leukemia, Erythroblastic, Acute
Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Leukemia, Erythroblastic, Acute
Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin.
Leukemia, Erythroblastic, Acute
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Leukemia, Erythroblastic, Acute
Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
Leukemia, Erythroblastic, Acute
[Regulatory effect of ginsenoside Rh2 on HDAC1/2 activity and cyclin in human erythroleukemia K562 cells].
Leukemia, Hairy Cell
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Leukemia, Lymphocytic, Chronic, B-Cell
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein.
Leukemia, Lymphocytic, Chronic, B-Cell
Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis.
Leukemia, Lymphocytic, Chronic, B-Cell
Global histone deacetylase enzymatic activity is an independent prognostic marker associated with a shorter overall survival in chronic lymphocytic leukemia patients.
Leukemia, Lymphocytic, Chronic, B-Cell
Histone deacetylase in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Synergistic Induction of Apoptosis in Primary B-CLL Cells after Treatment with Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Histone Deacetylase Inhibitors.
Leukemia, Lymphocytic, Chronic, B-Cell
The Histone Deacetylase Inhibitor MGCD0103 Induces Apoptosis in B-Cell Chronic Lymphocytic Leukemia Cells through a Mitochondria-Mediated Caspase Activation Cascade.
Leukemia, Lymphocytic, Chronic, B-Cell
The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces apoptosis, downregulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Basic fibroblast growth factor inhibits p38-mediated cell differentiation and growth inhibition by activin A but not by histone deacetylase inhibitors in CML cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination of SK-7041, one of novel histone deacetylase inhibitors, and STI571-induced synergistic apoptosis in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inactivation of HDAC3 and STAT3 is Critically Involved in 1-Stearoyl-sn-Glycero-3-Phosphocholine-Induced Apoptosis in Chronic Myelogenous Leukemia K562 Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Proteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell death of chronic myeloid leukemia cells by an ROS-mediated mechanism and downregulation of the Bcr-Abl fusion protein.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Synergistic effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid with imatinib on K562 cells].
Leukemia, Myeloid
An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells.
Leukemia, Myeloid
Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells.
Leukemia, Myeloid
HDAC1 and Klf4 interplay critically regulates human myeloid leukemia cell proliferation.
Leukemia, Myeloid
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo.
Leukemia, Myeloid
Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy.
Leukemia, Myeloid
Histone deacetylase inhibitors induce the expression of tumor suppressor genes Per1 and Per2 in human gastric cancer cells.
Leukemia, Myeloid
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Leukemia, Myeloid
Induction of myelogenous leukemia cells with histone deacetylase inhibitors through down-regulating the Daxx protein expression.
Leukemia, Myeloid
MYB down-regulation enhances sensitivity of U937 myeloid leukemia cells to the histone deacetylase inhibitor LBH589 in vitro and in vivo.
Leukemia, Myeloid
The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process.
Leukemia, Myeloid
Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages.
Leukemia, Myeloid
[Epigenetic regulation of expression of retinoic acid receptor beta gene in leukemia cell]
Leukemia, Myeloid, Acute
5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Leukemia, Myeloid, Acute
A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor.
Leukemia, Myeloid, Acute
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.
Leukemia, Myeloid, Acute
Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies.
Leukemia, Myeloid, Acute
Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
Leukemia, Myeloid, Acute
Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Avian erythroleukemia: a model for corepressor function in cancer.
Leukemia, Myeloid, Acute
Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
Leukemia, Myeloid, Acute
c-Myc suppresses miR-451?YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway.
Leukemia, Myeloid, Acute
Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
Leukemia, Myeloid, Acute
Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.
Leukemia, Myeloid, Acute
Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases.
Leukemia, Myeloid, Acute
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Leukemia, Myeloid, Acute
Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid.
Leukemia, Myeloid, Acute
DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.
Leukemia, Myeloid, Acute
Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.
Leukemia, Myeloid, Acute
Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.
Leukemia, Myeloid, Acute
Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry.
Leukemia, Myeloid, Acute
Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors.
Leukemia, Myeloid, Acute
Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia.
Leukemia, Myeloid, Acute
Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia.
Leukemia, Myeloid, Acute
Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Leukemia, Myeloid, Acute
Epigenetic modifiers: basic understanding and clinical development.
Leukemia, Myeloid, Acute
Epigenetic targeting in acute myeloid leukemia: use of flow cytometry in monitoring therapeutic effects.
Leukemia, Myeloid, Acute
Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.
Leukemia, Myeloid, Acute
Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling.
Leukemia, Myeloid, Acute
Expression Levels of Warburg-Effect Related microRNAs Correlate with each Other and that of Histone Deacetylase Enzymes in Adult Hematological Malignancies with Emphasis on Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Leukemia, Myeloid, Acute
G1 cell-cycle arrest and apoptosis by histone deacetylase inhibition in MLL-AF9 acute myeloid leukemia cells is p21 dependent and MLL-AF9 independent.
Leukemia, Myeloid, Acute
Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia.
Leukemia, Myeloid, Acute
HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
Leukemia, Myeloid, Acute
HDAC1 Is a Required Cofactor of CBF?-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape.
Leukemia, Myeloid, Acute
HDAC6 as a target for antileukemic drugs in acute myeloid leukemia.
Leukemia, Myeloid, Acute
HDAC8 promotes daunorubicin resistance of human acute myeloid leukemia cells via regulation of IL-6 and IL-8.
Leukemia, Myeloid, Acute
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Leukemia, Myeloid, Acute
Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myeloid leukemia (AML) cells.
Leukemia, Myeloid, Acute
Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.
Leukemia, Myeloid, Acute
Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction Chemotherapy in Older Patients with Acute Myeloid Leukemia: Phase I Study Results.
Leukemia, Myeloid, Acute
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.
Leukemia, Myeloid, Acute
Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells.
Leukemia, Myeloid, Acute
Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy.
Leukemia, Myeloid, Acute
Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Leukemia, Myeloid, Acute
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
Leukemia, Myeloid, Acute
Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine.
Leukemia, Myeloid, Acute
In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells.
Leukemia, Myeloid, Acute
Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells.
Leukemia, Myeloid, Acute
Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Leukemia, Myeloid, Acute
Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.
Leukemia, Myeloid, Acute
Increased PRAME-Specific CTL Killing of Acute Myeloid Leukemia Cells by Either a Novel Histone Deacetylase Inhibitor Chidamide Alone or Combined Treatment with Decitabine.
Leukemia, Myeloid, Acute
Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors.
Leukemia, Myeloid, Acute
Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell.
Leukemia, Myeloid, Acute
ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study.
Leukemia, Myeloid, Acute
Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study.
Leukemia, Myeloid, Acute
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Leukemia, Myeloid, Acute
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Leukemia, Myeloid, Acute
Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
Leukemia, Myeloid, Acute
MECHANISMS OF SYNERGISTIC ANTILEUKEMIC INTERACTIONS BETWEEN VALPROIC ACID AND CYTARABINE IN PEDIATRIC ACUTE MYELOID LEUKEMIA.
Leukemia, Myeloid, Acute
MicroRNA-34a-mediated death of acute myeloid leukemia stem cells through apoptosis induction and exosome shedding inhibition via histone deacetylase 2 targeting.
Leukemia, Myeloid, Acute
Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.
Leukemia, Myeloid, Acute
Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction.
Leukemia, Myeloid, Acute
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Leukemia, Myeloid, Acute
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
Leukemia, Myeloid, Acute
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Leukemia, Myeloid, Acute
Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia.
Leukemia, Myeloid, Acute
Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia.
Leukemia, Myeloid, Acute
Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells.
Leukemia, Myeloid, Acute
SIRT2 mediates multidrug resistance in acute myelogenous leukemia cells via ERK1/2 signaling pathway.
Leukemia, Myeloid, Acute
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Leukemia, Myeloid, Acute
Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
Leukemia, Myeloid, Acute
Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.
Leukemia, Myeloid, Acute
Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response.
Leukemia, Myeloid, Acute
tert-Butylcarbamate-Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells.
Leukemia, Myeloid, Acute
The combination of a histone deacetylase inhibitor with the BH3-mimetic GX15-070 has synergistic antileukemia activity by activating both apoptosis and autophagy.
Leukemia, Myeloid, Acute
The gene signature in CCAAT-enhancer-binding protein ? dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors.
Leukemia, Myeloid, Acute
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
Leukemia, Myeloid, Acute
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
Leukemia, Myeloid, Acute
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
Leukemia, Myeloid, Acute
The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
Leukemia, Myeloid, Acute
The new low-toxic histone deacetylase inhibitor S-(2) induces apoptosis in various acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.
Leukemia, Myeloid, Acute
Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Leukemia, Myeloid, Acute
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
Leukemia, Myeloid, Acute
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.
Leukemia, Myeloid, Acute
Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
Leukemia, Myeloid, Acute
Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells.
Leukemia, Myeloid, Acute
[Antitumor activity of histone deacetylase inhibitor suberic bishydroxamate on acute myeloid leukemia cell lines].
Leukemia, Myeloid, Acute
[Effect of Valproic Acid against Angiogenesis of Kasumi-1 Xenograft Tumor in Nude Mice].
Leukemia, Myeloid, Acute
[Efflect of miR-34a-Tangeted Regulation of HDACI on Apoptosis of AML Cells].
Leukemia, Myeloid, Acute
[Histone deacetylase inhibitor SAHA induces inactivation of MAPK signaling and apoptosis in HL-60 cells]
Leukemia, Myeloid, Acute
[Molecular diagnosis of and molecular targeting therapy for leukemia]
Leukemia, Myeloid, Acute
[Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
Leukemia, Myelomonocytic, Chronic
Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Leukemia, Plasma Cell
Histone deacetylase inhibitors in plasma cell leukemia treatment: effect of bone marrow microenvironment.
Leukemia, Promyelocytic, Acute
A retinoid/butyric acid prodrug overcomes retinoic acid resistance in leukemias by induction of apoptosis.
Leukemia, Promyelocytic, Acute
Active repression by unliganded retinoid receptors in development: less is sometimes more.
Leukemia, Promyelocytic, Acute
Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells.
Leukemia, Promyelocytic, Acute
Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
Leukemia, Promyelocytic, Acute
Epigallocatechin-3-gallate enhances differentiation of acute promyelocytic leukemia cells via inhibition of PML-RAR? and HDAC1.
Leukemia, Promyelocytic, Acute
Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
Leukemia, Promyelocytic, Acute
Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays.
Leukemia, Promyelocytic, Acute
Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.
Leukemia, Promyelocytic, Acute
HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia.
Leukemia, Promyelocytic, Acute
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
Leukemia, Promyelocytic, Acute
Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
Leukemia, Promyelocytic, Acute
In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR{alpha} blockade in the pathogenesis of acute promyelocytic leukemia.
Leukemia, Promyelocytic, Acute
In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice.
Leukemia, Promyelocytic, Acute
Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance.
Leukemia, Promyelocytic, Acute
PPARgamma-Active Triterpenoid CDDO Enhances ATRA-Induced Differentiation in APL.
Leukemia, Promyelocytic, Acute
Prolonged molecular remission in PML-RARalpha-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate.
Leukemia, Promyelocytic, Acute
Re: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
Leukemia, Promyelocytic, Acute
Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
Leukemia, Promyelocytic, Acute
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo.
Leukemia, Promyelocytic, Acute
Targeted removal of PML-RARalpha protein is required prior to inhibition of histone deacetylase for overcoming all-trans retinoic acid differentiation resistance in acute promyelocytic leukemia.
Leukemia, Promyelocytic, Acute
The methyl-CpG binding protein MBD1 is required for PML-RARalpha function.
Leukemia, Promyelocytic, Acute
Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.
Leukemia, Promyelocytic, Acute
Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.
Leukemia, Promyelocytic, Acute
[Acute promyelocytic leukemia, histone deacetylase, and response to retinoids]
Leukemia, Promyelocytic, Acute
[Molecular diagnosis of and molecular targeting therapy for leukemia]
Leukemia, T-Cell
Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells.
Leukemia, T-Cell
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Leukemia, T-Cell
Retraction. Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Journal of Virology, Volume 78, no. 9, p. 4582-90, 2004.
Leukemia, T-Cell
Tax relieves transcriptional repression by promoting histone deacetylase 1 release from the human T-cell leukemia virus type 1 long terminal repeat.
Leukemia, T-Cell
Therapeutic potential and functional interaction of carfilzomib and vorinostat in T-cell leukemia/lymphoma.
Leukemia-Lymphoma, Adult T-Cell
Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells.
Leukemia-Lymphoma, Adult T-Cell
Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma.
Leukemia-Lymphoma, Adult T-Cell
Retraction. Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. Journal of Virology, Volume 78, no. 9, p. 4582-90, 2004.
Leukemia-Lymphoma, Adult T-Cell
The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia.
Lipodystrophy
Inhibition of Glyceroneogenesis by Histone Deacetylase 3 Contributes to Lipodystrophy in Mice with Adipose Tissue Inflammation.
Liposarcoma
Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma.
Liver Cirrhosis
A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-? and vascular endothelial growth factor signalling.
Liver Cirrhosis
Activation of Mir-29a in Activated Hepatic Stellate Cells Modulates Its Profibrogenic Phenotype through Inhibition of Histone Deacetylases 4.
Liver Cirrhosis
Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis.
Liver Cirrhosis
Effect of histone deacetylase inhibitor on epithelial-mesenchymal transition of liver fibrosis.
Liver Cirrhosis
Histone deacetylase 8 inhibition alleviates cholestatic liver injury and fibrosis.
Liver Cirrhosis
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Liver Cirrhosis
Histone deacetylase inhibitor givinostat alleviates liver fibrosis by regulating hepatic stellate cell activation.
Liver Cirrhosis
Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis.
Liver Cirrhosis
Histone deacetylase inhibitor suberoylanilide hydroxamic acid alleviates liver fibrosis by suppressing the transforming growth factor-?1 signal pathway.
Liver Cirrhosis
Histone deacetylase?2: A potential regulator and therapeutic target in liver disease (Review).
Liver Cirrhosis
HNHA, new histone deacetylase inhibitor, improves liver fibrosis in BDL rats through suppression of hepatic stellate cells.
Liver Cirrhosis
Relationship between Liver Pathology and Disease Progression in a Murine Model of Amyotrophic Lateral Sclerosis.
Liver Cirrhosis
Role of histone deacetylases(HDACs) in progression and reversal of liver fibrosis.
Liver Cirrhosis
Sirtuin 6 attenuates epithelial-mesenchymal transition by suppressing the TGF-?1/Smad3 pathway and c-Jun in asthma models.
Liver Cirrhosis
Sodium valproate, a histone deacetylase inhibitor, with praziquantel ameliorates Schistosoma mansoni-induced liver fibrosis in mice.
Liver Cirrhosis
The miR-455-3p/HDAC2 axis plays a pivotal role in the progression and reversal of liver fibrosis and is regulated by epigenetics.
Liver Cirrhosis, Biliary
Histone deacetylase 9 plays a role in the antifibrogenic effect of astaxanthin in hepatic stellate cells.
Liver Diseases
Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor.
Liver Diseases
Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Liver Diseases
Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.
Liver Diseases
Histone deacetylase 8 inhibition alleviates cholestatic liver injury and fibrosis.
Liver Diseases
Histone deacetylase?2: A potential regulator and therapeutic target in liver disease (Review).
Liver Diseases
MeCP2 co-ordinates liver lipid metabolism with the NCoR1/HDAC3 corepressor complex.
Liver Diseases
Nutrient sensor-mediated programmed nonalcoholic fatty liver disease in low birthweight offspring.
Liver Diseases
Phenylbutyrate exerts adverse effects on liver regeneration and amino acid concentrations in partially hepatectomized rats.
Liver Diseases
Regulation of P300 and HDAC1 on endoplasmic reticulum stress in isoniazid-induced HL-7702 hepatocyte injury.
Liver Diseases, Alcoholic
Tributyrin Inhibits Ethanol-Induced Epigenetic Repression of CPT-1A and Attenuates Hepatic Steatosis and Injury.
Liver Failure
Role of histone deacetylase expression levels and activity in the inflammatory responses of patients with chronic hepatitis B.
Liver Failure, Acute
HDAC2 inhibitor CAY10683 reduces intestinal epithelial cell apoptosis by inhibiting mitochondrial apoptosis pathway in acute liver failure.
Liver Failure, Acute
HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F-actin signalling pathway.
Liver Failure, Acute
Histone deacetylase 2 regulates ULK1 mediated pyroptosis during acute liver failure by the K68 acetylation site.
Liver Failure, Acute
Histone deacetylase 6 inhibitor ACY-1215 protects against experimental acute liver failure by regulating the TLR4-MAPK/NF-?B pathway.
Liver Failure, Acute
Histone deacetylase 6 inhibitor ACY1215 ameliorates mitochondrial dynamic and function injury in hepatocytes by activating AMPK signaling pathway in acute liver failure mice.
Liver Failure, Acute
Histone deacetylase 6 inhibitor ACY1215 offers a protective effect through the autophagy pathway in acute liver failure.
Liver Failure, Acute
Histone Deacetylase 6 Regulates the Activation of M1 Macrophages by the Glycolytic Pathway During Acute Liver Failure.
Liver Failure, Acute
Modulations of Histone Deacetylase 2 Offer a Protective Effect through the Mitochondrial Apoptosis Pathway in Acute Liver Failure.
Liver Failure, Acute
Quantitative Proteomic Analysis Reveals the Sites Related to Acetylation and Mechanism of ACY-1215 in Acute Liver Failure Mice.
Liver Failure, Acute
The Protective Mechanism of CAY10683 on Intestinal Mucosal Barrier in Acute Liver Failure through LPS/TLR4/MyD88 Pathway.
Liver Neoplasms
Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins.
Liver Neoplasms
Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2.
Liver Neoplasms
Bcl-2 related proteins are dramatically induced at the early stage of differentiation in human liver cancer cells by a histone deacetylase inhibitor projecting an anti-apoptotic role during this period.
Liver Neoplasms
Combined inhibition of sonic Hedgehog signaling and histone deacetylase is an effective treatment for liver cancer.
Liver Neoplasms
Correction: HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition.
Liver Neoplasms
Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate.
Liver Neoplasms
Epigenetic targets in hepatocellular carcinoma cells: identification of chaperone protein complexes with histone deacetylases.
Liver Neoplasms
Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor.
Liver Neoplasms
HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population.
Liver Neoplasms
HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer.
Liver Neoplasms
HDAC2 Provides a Critical Support to Malignant Progression of Hepatocellular Carcinoma through Feedback Control of mTORC1 and AKT.
Liver Neoplasms
HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition.
Liver Neoplasms
Hdac3 is essential for the maintenance of chromatin structure and genome stability.
Liver Neoplasms
HDAC6 functions as a tumor suppressor by activating JNK-mediated beclin 1-dependent autophagic cell death in liver cancer.
Liver Neoplasms
Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification.
Liver Neoplasms
Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway.
Liver Neoplasms
Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
Liver Neoplasms
Histone deacetylase inhibitor MGCD0103 causes cell cycle arrest, apoptosis, and autophagy in liver cancer cells.
Liver Neoplasms
Histone deacetylase inhibitors facilitate dihydroartemisinin-induced apoptosis in liver cancer in vitro and in vivo.
Liver Neoplasms
Histone deacetylase SIRT6 regulates chemosensitivity in liver cancer cells via modulation of FOXO3 activity.
Liver Neoplasms
Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells.
Liver Neoplasms
Identification of histone deacetylase 1 protein complexes in liver cancer cells.
Liver Neoplasms
Inhibition of histone deacetylase 11 promotes human liver cancer cell apoptosis.
Liver Neoplasms
Involvement of Insulin-like Growth Factor-binding Protein-3 in the Effects of Histone Deacetylase Inhibitor MS-275 in Hepatoma Cells.
Liver Neoplasms
lncRNA MIR22HG-Derived miR-22-5p Enhances the Radiosensitivity of Hepatocellular Carcinoma by Increasing Histone Acetylation Through the Inhibition of HDAC2 Activity.
Liver Neoplasms
MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer.
Liver Neoplasms
MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer.
Liver Neoplasms
O-GlcNAcylation of histone deacetylases 1 in hepatocellular carcinoma promotes cancer progression.
Liver Neoplasms
Oncogenic potential of CK2? and its regulatory role in EGF-induced HDAC2 expression in human liver cancer.
Liver Neoplasms
Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations.
Liver Neoplasms
Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor.
Liver Neoplasms
Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines.
Liver Neoplasms
Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Liver Neoplasms
Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo.
Liver Neoplasms
Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells.
Liver Neoplasms
Targeting Histone deacetylase 4/Ubc9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells.
Liver Neoplasms
The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
Liver Neoplasms
Transcriptional and translational regulation of C/EBP?-HDAC1 protein complexes controls different levels of p53, SIRT1, and PGC1? proteins at the early and late stages of liver cancer.
Liver Neoplasms, Experimental
Activity of histone deacetylase in rat liver and Novikoff hepatoma.
Loeys-Dietz Syndrome
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Lung Diseases
Carbocysteine restores steroid sensitivity by targeting histone deacetylase 2 in a thiol/GSH-dependent manner.
Lung Diseases
Conserved responses to trichostatin A in rodent lungs exposed to endotoxin or stretch.
Lung Diseases
Oxidative Imbalance as a Crucial Factor in Inflammatory Lung Diseases: Could Antioxidant Treatment Constitute a New Therapeutic Strategy?
Lung Diseases, Interstitial
Expression of GR-? and HDAC2 in steroid-Sensitive and steroid-Insensitive interstitial lung disease.
Lung Diseases, Interstitial
Histone Deacetylase 3-Mediated Inhibition of microRNA-19a-3p Facilitates the Development of Rheumatoid Arthritis-Associated Interstitial Lung Disease.
Lung Injury
Combinatorial therapy with acetylation and methylation modifiers attenuates lung vascular hyperpermeability in endotoxemia-induced mouse inflammatory lung injury.
Lung Injury
FoxF1 protects rats from paraquat-evoked lung injury following HDAC2 inhibition via the microRNA-342/KLF5/I?B/NF-?B p65 axis.
Lung Injury
Foxp1/2/4-NuRD interactions regulate gene expression and epithelial injury response in the lung via regulation of interleukin-6.
Lung Injury
HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury.
Lung Injury
Histone deacetylase 6 regulates endothelial MyD88-dependent canonical TLR signaling, lung inflammation, and alveolar remodeling in the developing lung.
Lung Injury
Protective Effects of Valproic Acid, a Histone Deacetylase Inhibitor, against Hyperoxic Lung Injury in a Neonatal Rat Model.
Lung Injury
Transcriptome of nasopharyngeal samples from COVID-19 patients and a comparative analysis with other SARS-CoV-2 infection models reveal disparate host responses against SARS-CoV-2.
Lung Neoplasms
2-Benzazolyl-4-Piperazin-1-Ylsulfonylbenzenecarbohydroxamic Acids as Novel Selective Histone Deacetylase-6 Inhibitors with Antiproliferative Activity.
Lung Neoplasms
3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors.
Lung Neoplasms
A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer.
Lung Neoplasms
A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies.
Lung Neoplasms
A novel combinatorial strategy using Seliciclib(®) and Belinostat(®) for eradication of non-small cell lung cancer via apoptosis induction and BID activation.
Lung Neoplasms
A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
Lung Neoplasms
A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.
Lung Neoplasms
A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors.
Lung Neoplasms
A phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in pretreated patients with small-cell lung cancer.
Lung Neoplasms
AMPK-Dependent Phosphorylation of HDAC8 Triggers PGM1 Expression to Promote Lung Cancer Cell Survival under Glucose Starvation.
Lung Neoplasms
Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids.
Lung Neoplasms
Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines.
Lung Neoplasms
Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC.
Lung Neoplasms
Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model.
Lung Neoplasms
Antitumor effects of histone deacetylase inhibitor suberoylanilide hydroxamic acid in epidermal growth factor receptor-mutant non-small-cell lung cancer lines in vitro and in vivo.
Lung Neoplasms
Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.
Lung Neoplasms
Aurora A, aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer.
Lung Neoplasms
Blocking NF-?B sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
Lung Neoplasms
Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation.
Lung Neoplasms
cAMP signaling increases histone deacetylase 8 expression by inhibiting JNK-dependent degradation via autophagy and the proteasome system in H1299 lung cancer cells.
Lung Neoplasms
cAMP signaling increases histone deacetylase 8 expression via the Epac2-Rap1A-Akt pathway in H1299 lung cancer cells.
Lung Neoplasms
Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.
Lung Neoplasms
Carfilzomib combined with suberanilohydroxamic acid (SAHA) synergistically promotes endoplasmic reticulum stress in non-small cell lung cancer cell lines.
Lung Neoplasms
Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas.
Lung Neoplasms
Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer.
Lung Neoplasms
Chidamide-induced ROS accumulation and miR-129-3p-dependent cell cycle arrest in non-small lung cancer cells.
Lung Neoplasms
Class I HDACs Are Mediators of Smoke Carcinogen-Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer.
Lung Neoplasms
Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Lung Neoplasms
Combination of Arsenic Trioxide and Valproic Acid Efficiently Inhibits Growth of Lung Cancer Cells via G2/M-Phase Arrest and Apoptotic Cell Death.
Lung Neoplasms
Combination of azacitidine and trichostatin A decreased the tumorigenic potential of lung cancer cells.
Lung Neoplasms
Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Lung Neoplasms
Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells.
Lung Neoplasms
Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death.
Lung Neoplasms
Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
Lung Neoplasms
Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer.
Lung Neoplasms
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.
Lung Neoplasms
Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.
Lung Neoplasms
Conserved responses to trichostatin A in rodent lungs exposed to endotoxin or stretch.
Lung Neoplasms
Copper oxide nanoparticles induce anticancer activity in A549 lung cancer cells by inhibition of histone deacetylase.
Lung Neoplasms
Corrigendum to"Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo"[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086].
Lung Neoplasms
Cucurbitacin B Alters the Expression of Tumor-Related Genes by Epigenetic Modifications in NSCLC and Inhibits NNK-Induced Lung Tumorigenesis.
Lung Neoplasms
Depletion of HDAC6 Enhances Cisplatin-Induced DNA Damage and Apoptosis in Non-Small Cell Lung Cancer Cells.
Lung Neoplasms
Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors.
Lung Neoplasms
Distinct Molecular Mechanisms Analysis of Three Lung Cancer Subtypes Based on Gene Expression Profiles.
Lung Neoplasms
DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.
Lung Neoplasms
Down-regulation of histone deacetylase 4, -5 and -6 as a mechanism of synergistic enhancement of apoptosis in human lung cancer cells treated with the combination of a synthetic retinoid, Am80 and green tea catechin.
Lung Neoplasms
Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.
Lung Neoplasms
Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.
Lung Neoplasms
DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
Lung Neoplasms
Effect of epigenetic histone modifications on E-cadherin splicing and expression in lung cancer.
Lung Neoplasms
Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.
Lung Neoplasms
Effect of trichostatin A and paclitaxel on the proliferation and apoptosis of lung adenocarcinoma cells.
Lung Neoplasms
Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer.
Lung Neoplasms
Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells.
Lung Neoplasms
Effects of histone deacetylase inhibitors on ATP-binding cassette transporters in lung cancer A549 and colorectal cancer HCT116 cells.
Lung Neoplasms
Effects of histone deacetylase inhibitors Tricostatin A and Quisinostat on tight junction proteins of human lung adenocarcinoma A549 cells and normal lung epithelial cells.
Lung Neoplasms
Efficient Palladium-Triggered Release of Vorinostat from a Bioorthogonal Precursor.
Lung Neoplasms
Endothelial progenitor cells contribute to neovascularization of non-small cell lung cancer via histone deacetylase 7-mediated cytoskeleton regulation and angiogenic genes transcription.
Lung Neoplasms
Energy metabolism in h460 lung cancer cells: effects of histone deacetylase inhibitors.
Lung Neoplasms
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Lung Neoplasms
Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment.
Lung Neoplasms
Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.
Lung Neoplasms
Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells.
Lung Neoplasms
Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid.
Lung Neoplasms
Epigenetic silencing of microRNA-373 to epithelial-mesenchymal transition in non-small cell lung cancer through IRAK2 and LAMP1 axes.
Lung Neoplasms
Epigenetic-Based Biomarkers in the Malignant Transformation of BEAS-2B Cells Induced by Coal Tar Pitch Extract.
Lung Neoplasms
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Lung Neoplasms
Fentanyl Inhibits Lung Cancer Viability and Invasion via Upregulation of miR-331-3p and Repression of HDAC5.
Lung Neoplasms
Genetic blockade of IGF-1R via recombinant adenovirus in lung cancer can be enhanced by histone deacetylase inhibitor, vorinostat.
Lung Neoplasms
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Lung Neoplasms
HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment.
Lung Neoplasms
HDAC1 is indirectly involved in the epigenetic regulation of p38 MAPK that drive the lung cancer progression.
Lung Neoplasms
HDAC1 knockdown inhibits invasion and induces apoptosis in non-small cell lung cancer cells.
Lung Neoplasms
HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins.
Lung Neoplasms
HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin.
Lung Neoplasms
HDAC6 Regulates Radiosensitivity of Non-Small Cell Lung Cancer by Promoting Degradation of Chk1.
Lung Neoplasms
HDAC9 deficiency promotes tumor progression by decreasing the CD8+ dendritic cell infiltration of the tumor microenvironment.
Lung Neoplasms
High expression of SNIP1 correlates with poor prognosis in Non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro.
Lung Neoplasms
Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer.
Lung Neoplasms
Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.
Lung Neoplasms
Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
Lung Neoplasms
Histone deacetylase 7 inhibits plakoglobin expression to promote lung cancer cell growth and metastasis.
Lung Neoplasms
Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment.
Lung Neoplasms
Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer.
Lung Neoplasms
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis.
Lung Neoplasms
Histone Deacetylase Inhibition Enhances the Antitumor Activity of a MEK Inhibitor in Lung Cancer Cells Harboring
Lung Neoplasms
Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
Lung Neoplasms
Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21 expression.
Lung Neoplasms
Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Lung Neoplasms
Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation.
Lung Neoplasms
Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation.
Lung Neoplasms
Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
Lung Neoplasms
Histone deacetylase inhibitor SAHA-induced epithelial-mesenchymal transition by upregulating Slug in lung cancer cells.
Lung Neoplasms
Histone Deacetylase Inhibitor Sensitizes ERCC1-High Non-small-Cell Lung Cancer Cells to Cisplatin via Regulating miR-149.
Lung Neoplasms
Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
Lung Neoplasms
Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells.
Lung Neoplasms
Histone deacetylase inhibitors promote the expression of ATP2A3 gene in breast cancer cell lines.
Lung Neoplasms
Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation.
Lung Neoplasms
Histone Deacetylase Inhibitors Sensitize Lung Cancer Cells to Hyperthermia: Involvement of Ku70/SirT-1 in Thermo-Protection.
Lung Neoplasms
Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Lung Neoplasms
Histone deacetylase, proteasome, and heat shock protein inhibitors for the treatment of lung cancer.
Lung Neoplasms
Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer.
Lung Neoplasms
Histone deacetylase 5 promotes the proliferation and invasion of lung cancer cells.
Lung Neoplasms
Hybrid artificial cell-mediated epigenetic inhibition in metastatic lung cancer.
Lung Neoplasms
Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer.
Lung Neoplasms
Identification of differentially expressed genes between lung adenocarcinoma and lung squamous cell carcinoma by gene expression profiling.
Lung Neoplasms
Identification of four potential epigenetic modulators from the NCI structural diversity library using a cell-based assay.
Lung Neoplasms
Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.
Lung Neoplasms
In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.
Lung Neoplasms
In Vivo Evaluation of the Combined Anticancer Effects of Cisplatin and SAHA in Nonsmall Cell Lung Carcinoma Using [18F]FAHA and [18F]FDG PET/CT Imaging.
Lung Neoplasms
Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells.
Lung Neoplasms
Induction of E-cadherin in lung cancer and interaction with growth suppression by histone deacetylase inhibition.
Lung Neoplasms
Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo.
Lung Neoplasms
Isobolographic analysis demonstrates additive effect of cisplatin and HDIs combined treatment augmenting their anti-cancer activity in lung cancer cell lines.
Lung Neoplasms
Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
Lung Neoplasms
Isoproterenol increases histone deacetylase 6 expression and cell migration by inhibiting ERK signaling via PKA and Epac pathways in human lung cancer cells.
Lung Neoplasms
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Lung Neoplasms
Long noncoding RNA CBR3 antisense RNA 1 promotes the aggressive phenotypes of non?small?cell lung cancer by sponging microRNA?509?3p and competitively upregulating HDAC9 expression.
Lung Neoplasms
Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.
Lung Neoplasms
Methyl CpG-binding domain protein 3 mediates cancer-selective cytotoxicity by histone deacetylase inhibitors via differential transcriptional reprogramming in lung cancer cells.
Lung Neoplasms
NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells.
Lung Neoplasms
No association between polymorphisms in the histone deacetylase genes and the risk of lung cancer.
Lung Neoplasms
Novel genetic variants in HDAC2 and PPARGC1A of the CREB-binding protein pathway predict survival of non-small-cell lung cancer.
Lung Neoplasms
Novel histone deacetylase inhibitors derived from Magnolia officinalis significantly enhance TRAIL-induced apoptosis in non-small cell lung cancer.
Lung Neoplasms
Nuclear HDAC6 inhibits invasion by suppressing NF-?B/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer.
Lung Neoplasms
O6-Methylguanine-DNA methyltransferase hypermethylation modulated by 17beta-estradiol in lung cancer cells.
Lung Neoplasms
OIP5-AS1 modulates epigenetic regulator HDAC7 to enhance non-small cell lung cancer metastasis via miR-140-5p.
Lung Neoplasms
Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Lung Neoplasms
Oncogenic zinc finger protein ZNF322A promotes stem cell-like properties in lung cancer through transcriptional suppression of c-Myc expression.
Lung Neoplasms
Osthole extracted from a citrus fruit that affects apoptosis on A549 cell line by histone deacetylasese inhibition (HDACs).
Lung Neoplasms
Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Lung Neoplasms
Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat.
Lung Neoplasms
Pax5 Re-Expression In H460 Cells Treated With The Combination Of Demethylating Agent And Histone Deacetylase Inhibitor Is Associated With The Enhancement Of P53 Binding To Pax5 Promoter Region.
Lung Neoplasms
PFN2a Suppresses C2C12 Myogenic Development by Inhibiting Proliferation and Promoting Apoptosis via the p53 Pathway.
Lung Neoplasms
Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer.
Lung Neoplasms
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Lung Neoplasms
Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.
Lung Neoplasms
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Lung Neoplasms
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).
Lung Neoplasms
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
Lung Neoplasms
Pin1 coordinates HDAC6 upregulation with cell migration in lung cancer cells.
Lung Neoplasms
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
Lung Neoplasms
Potentiation of anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the cyclin-dependent kinase inhibitor P276-00 in human non-small-cell lung cancer cell lines.
Lung Neoplasms
Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Lung Neoplasms
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Lung Neoplasms
Quercetin enhances the antitumor activity of trichostatin A through up-regulation of p300 protein expression in p53 null cancer cells.
Lung Neoplasms
Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small-Cell Lung Cancer.
Lung Neoplasms
Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.
Lung Neoplasms
Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients.
Lung Neoplasms
Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism.
Lung Neoplasms
Retraction: Histone Deacetylase Inhibitors Sensitize Lung Cancer Cells to Hyperthermia: Involvement of Ku70/SirT-1 in Thermo-Protection.
Lung Neoplasms
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
Lung Neoplasms
Screening Novel SAHA Derivatives as Anti-lung Carcinoma Agents: Synthesis, Biological Evaluation, Docking Studies and Further Mechanism Research between Apoptosis and Autophagy.
Lung Neoplasms
Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation.
Lung Neoplasms
Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells.
Lung Neoplasms
SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome.
Lung Neoplasms
Silibinin Synergizes with Histone Deacetylase and DNA Methyltransferase Inhibitors in Up-regulating E-cadherin Expression Together with Inhibition of Migration and Invasion of Human Non-small Cell Lung Cancer Cells.
Lung Neoplasms
Sodium Valproate Sensitizes Non-Small Lung Cancer A549 Cells to ?? T-Cell-Mediated Killing through Upregulating the Expression of MICA.
Lung Neoplasms
Sodium valproate, a histone deacetylase inhibitor, enhances the efficacy of vinorelbine-cisplatin-based chemoradiation in non-small cell lung cancer cells.
Lung Neoplasms
Stat3 inhibits Beclin 1 expression through recruitment of HDAC3 in nonsmall cell lung cancer cells.
Lung Neoplasms
Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Lung Neoplasms
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Lung Neoplasms
Suberoylanilide hydroxamic acid treatment reveals crosstalks among proteome, ubiquitylome and acetylome in non-small cell lung cancer A549 cell line.
Lung Neoplasms
Sulforaphane suppresses in vitro and in vivo lung tumorigenesis through downregulation of HDAC activity.
Lung Neoplasms
Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6-mediated matrix metalloproteinase 9.
Lung Neoplasms
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.
Lung Neoplasms
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.
Lung Neoplasms
Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma.
Lung Neoplasms
Targeting histone deacetylase in lung cancer for early diagnosis: (18)F-FAHA PET/CT imaging of NNK-treated A/J mice model.
Lung Neoplasms
Targeting the invasive phenotype of cisplatin-resistant Non-Small Cell Lung Cancer cells by a novel histone deacetylase inhibitor.
Lung Neoplasms
The anticancer effect of histone deacetylase inhibitors and combination with the cytotoxic agents in lung cancer cells: biological analyses for future clinical application.
Lung Neoplasms
The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells.
Lung Neoplasms
The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells.
Lung Neoplasms
The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer.
Lung Neoplasms
The Rexinoids LG100268 and LG101506 Inhibit Inflammation and Suppress Lung Carcinogenesis in A/J Mice.
Lung Neoplasms
The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors.
Lung Neoplasms
Transcription factor Sox4 is required for PUMA-mediated apoptosis induced by histone deacetylase inhibitor, TSA.
Lung Neoplasms
Transcriptional Repression of Histone Deacetylase 3 by the Histone Demethylase KDM2A Is Coupled to Tumorigenicity of Lung Cancer Cells.
Lung Neoplasms
UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.
Lung Neoplasms
Up-regulation of BRAF activated non-coding RNA is associated with radiation therapy for lung cancer.
Lung Neoplasms
Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells.
Lung Neoplasms
Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1.
Lung Neoplasms
VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach.
Lung Neoplasms
Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study.
Lung Neoplasms
Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial.
Lung Neoplasms
X-radiation inhibits histone deacetylase 1 and 2, upregulates Axin expression and induces apoptosis in non-small cell lung cancer.
Lung Neoplasms
[Protein expressions of HDAC1 and DNMT1 in non-small-cell lung cancer and its clinical significance].
Lung Neoplasms
[Synergistic cytotoxicity effect of histone deacetylase inhibitor combined with paclitaxel on lung cancer cell lines and its mechanism]
Lupus Erythematosus, Systemic
Downregulation of microRNA-101-3p participates in systemic lupus erythematosus progression via negatively regulating HDAC9.
Lupus Erythematosus, Systemic
HDAC1 potentiates CD4 + T cell activation by inhibiting miR-124 and promoting IRF1 in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
JHDM1D and HDAC1-3 mRNA expression levels in peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Methylation and gene expression of histone deacetylases 6 in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Potential non-oncological applications of histone deacetylase inhibitors.
Lupus Erythematosus, Systemic
RFX1 regulates CD70 and CD11a expression in lupus T cells by recruiting the histone methyltransferase SUV39H1.
Lupus Erythematosus, Systemic
Selective HDAC6 inhibition decreases early stage of lupus nephritis by downregulating both innate and adaptive immune responses.
Lupus Erythematosus, Systemic
Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.
Lupus Erythematosus, Systemic
The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice.
Lupus Erythematosus, Systemic
Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells.
Lupus Nephritis
Selective HDAC6 inhibition decreases early stage of lupus nephritis by downregulating both innate and adaptive immune responses.
Lupus Nephritis
Treatment with a selective histone deacetylase 6 inhibitor decreases lupus nephritis in NZB/W mice.
Lymphatic Metastasis
A correlation analysis between HDAC1 over-expression and clinical features of laryngeal squamous cell carcinoma.
Lymphatic Metastasis
Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer.
Lymphatic Metastasis
AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.
Lymphatic Metastasis
Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma.
Lymphatic Metastasis
Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation.
Lymphatic Metastasis
HDAC1 promoted migration and invasion binding with TCF12 by promoting EMT progress in gallbladder cancer.
Lymphatic Metastasis
HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
Lymphatic Metastasis
HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells.
Lymphatic Metastasis
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.
Lymphatic Metastasis
Identification of candidate biomarkers that involved in the epigenetic transcriptional regulation for detection gastric cancer by iTRAQ based quantitative proteomic analysis.
Lymphatic Metastasis
Increased expression of histone deacetylase 2 is found in human gastric cancer.
Lymphatic Metastasis
Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females.
Lymphatic Metastasis
Overexpression of Histone Deacetylase 2 Predicts Unfavorable Prognosis in Human Gallbladder Carcinoma.
Lymphatic Metastasis
Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis.
Lymphoma
5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study.
Lymphoma
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.
Lymphoma
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Lymphoma
A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas.
Lymphoma
A new method of comparing 2D-PAGE maps based on the computation of Zernike moments and multivariate statistical tools.
Lymphoma
A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
Lymphoma
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
Lymphoma
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Lymphoma
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
Lymphoma
A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.
Lymphoma
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Lymphoma
Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat.
Lymphoma
Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Lymphoma
An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Lymphoma
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
Lymphoma
Antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and depsipeptide on Raji lymphoma cells.
Lymphoma
Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.
Lymphoma
Antitumor effect of liposomal histone deacetylase inhibitor-lipid conjugates in vitro.
Lymphoma
Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells.
Lymphoma
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Lymphoma
Carfilzomib Interacts Synergistically With Histone Deacetylase Inhibitors In Mantle Cell Lymphoma Cells In Vitro And In Vivo.
Lymphoma
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Lymphoma
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Lymphoma
Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptor?2, via histone acetylation.
Lymphoma
Combination therapies improve the anticancer activities of retinoids in neuroblastoma.
Lymphoma
Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma.
Lymphoma
Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
Lymphoma
Combined Inhibition of ALK and HDAC Induces Synergistic Cytotoxicity in Neuroblastoma Cell Lines.
Lymphoma
Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Lymphoma
Compounds targeting class II histone deacetylases do not cause panHDACI-associated impairment of megakaryocyte differentiation.
Lymphoma
Conserved crosstalk between histone deacetylation and H3K79 methylation generates DOT1L-dose dependency in HDAC1-deficient thymic lymphoma.
Lymphoma
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
Lymphoma
CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer.
Lymphoma
Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.
Lymphoma
Design, synthesis and biological evaluation of a phenyl butyric acid derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 inhibitor with anti-proliferative activity on cervix cancer and leukemia cells.
Lymphoma
Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities.
Lymphoma
Differences in nuclear positioning of 1q12 pericentric heterochromatin in normal and tumor B lymphocytes with 1q rearrangements.
Lymphoma
Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
Lymphoma
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
Lymphoma
Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma.
Lymphoma
Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.
Lymphoma
Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.
Lymphoma
Effects of SAHA and EGCG on Growth Potentiation of Triple-Negative Breast Cancer Cells.
Lymphoma
Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.
Lymphoma
Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma.
Lymphoma
Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes.
Lymphoma
Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development.
Lymphoma
Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas.
Lymphoma
Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance.
Lymphoma
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
Lymphoma
First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.
Lymphoma
Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.
Lymphoma
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
Lymphoma
HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
Lymphoma
HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
Lymphoma
Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma (ENKTL).
Lymphoma
Histone deacetylase 1 plays a predominant pro-oncogenic role in E?-myc driven B cell lymphoma.
Lymphoma
Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function.
Lymphoma
Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7.
Lymphoma
Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma.
Lymphoma
Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.
Lymphoma
Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma.
Lymphoma
Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma.
Lymphoma
Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
Lymphoma
Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents.
Lymphoma
Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
Lymphoma
Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.
Lymphoma
Histone deacetylase inhibitors interrupt HSP90RASGRP1 and HSP90CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.
Lymphoma
Histone deacetylase inhibitors promote mice corneal allograft survival through alteration of CD4+ effector T cells and induction of Foxp3+ regulatory T cells.
Lymphoma
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Lymphoma
In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma.
Lymphoma
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Lymphoma
Induction of murine H-rev107 gene expression by growth arrest and histone acetylation: involvement of an Sp1/Sp3-binding GC-box.
Lymphoma
Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.
Lymphoma
Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.
Lymphoma
Low-dose spiruchostatin-B, a potent histone deacetylase inhibitor enhances radiation-induced apoptosis in human lymphoma U937 cells via modulation of redox signaling.
Lymphoma
Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy.
Lymphoma
Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas.
Lymphoma
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Lymphoma
Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.
Lymphoma
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
Lymphoma
Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response.
Lymphoma
NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death.
Lymphoma
Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs.
Lymphoma
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Lymphoma
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
Lymphoma
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
Lymphoma
Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases.
Lymphoma
Reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al.
Lymphoma
Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo.
Lymphoma
Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
Lymphoma
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
Lymphoma
Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma.
Lymphoma
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
Lymphoma
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
Lymphoma
Serum chemokine levels differentially regulated by vorinostat in a Sézary syndrome patient.
Lymphoma
Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma.
Lymphoma
Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance.
Lymphoma
Spiruchostatin A and B, novel histone deacetylase inhibitors, induce apoptosis through reactive oxygen species-mitochondria pathway in human lymphoma U937 cells.
Lymphoma
Synergistic effects of vorinostat (SAHA) and azoles against Aspergillus species and their biofilms.
Lymphoma
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Lymphoma
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Lymphoma
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Lymphoma
Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
Lymphoma
Targeting HDAC3 in CREBBP-Mutant Lymphomas Counterstrikes Unopposed Enhancer Deacetylation of B-cell Signaling and Immune Response Genes.
Lymphoma
Tetraspanin CD9 modulates human lymphoma cellular proliferation via histone deacetylase activity.
Lymphoma
The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.
Lymphoma
The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms.
Lymphoma
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
Lymphoma
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Lymphoma
The histone deacetylase inhibitor FK228 distinctly sensitizes the human leukemia cells to retinoic acid-induced differentiation.
Lymphoma
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
Lymphoma
The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-?B.
Lymphoma
The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways.
Lymphoma
The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.
Lymphoma
Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis.
Lymphoma
Vorinostat and Mithramycin A in combination therapy as an interesting strategy for the treatment of Sézary T lymphoma: a transcriptomic approach.
Lymphoma
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Lymphoma
Vorinostat is genotoxic and epigenotoxic in the mouse bone marrow cells at the human equivalent doses.
Lymphoma
Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Lymphoma
[Mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by valproic acid combined with temsirolimus].
Lymphoma
[Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells.]
Lymphoma, B-Cell
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.
Lymphoma, B-Cell
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Lymphoma, B-Cell
A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma.
Lymphoma, B-Cell
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Lymphoma, B-Cell
Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
Lymphoma, B-Cell
Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma.
Lymphoma, B-Cell
Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.
Lymphoma, B-Cell
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Lymphoma, B-Cell
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Lymphoma, B-Cell
Combined inhibition of Bcl-2 and NF?B synergistically induces cell death in cutaneous T-cell lymphoma.
Lymphoma, B-Cell
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
Lymphoma, B-Cell
Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.
Lymphoma, B-Cell
Effect of trichostatin A on Burkitt's lymphoma cells: Inhibition of EPS8 activity through Phospho-Erk1/2 pathway.
Lymphoma, B-Cell
Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Lymphoma, B-Cell
Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas.
Lymphoma, B-Cell
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
Lymphoma, B-Cell
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
Lymphoma, B-Cell
Fluorodeoxyglucose-based positron emission tomography imaging to monitor drug responses in hematological tumors.
Lymphoma, B-Cell
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene expression and epigenetic profiles in models of DLBCL.
Lymphoma, B-Cell
HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC.
Lymphoma, B-Cell
HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
Lymphoma, B-Cell
HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Histone deacetylase 1 plays a predominant pro-oncogenic role in E?-myc driven B cell lymphoma.
Lymphoma, B-Cell
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Lymphoma, B-Cell
Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.
Lymphoma, B-Cell
Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas.
Lymphoma, B-Cell
Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape.
Lymphoma, B-Cell
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Lymphoma, B-Cell
Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.
Lymphoma, B-Cell
Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.
Lymphoma, B-Cell
Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway.
Lymphoma, B-Cell
Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines.
Lymphoma, B-Cell
microRNA-139-5p alleviates neurological deficit in hypoxic-ischemic brain damage via HDAC4 depletion and BCL-2 activation.
Lymphoma, B-Cell
miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the E?-miR-155 transgenic mouse model.
Lymphoma, B-Cell
Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.
Lymphoma, B-Cell
Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.
Lymphoma, B-Cell
Paradoxical regulation of hypoxia inducible factor-1? (HIF-1?) by histone deacetylase inhibitor in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.
Lymphoma, B-Cell
Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro.
Lymphoma, B-Cell
Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance.
Lymphoma, B-Cell
Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones.
Lymphoma, B-Cell
Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
Lymphoma, B-Cell
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Lymphoma, B-Cell
Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
Lymphoma, B-Cell
The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms.
Lymphoma, B-Cell
The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.
Lymphoma, B-Cell
The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.
Lymphoma, B-Cell
The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
Lymphoma, B-Cell
Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).
Lymphoma, B-Cell
Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion.
Lymphoma, B-Cell
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID).
Lymphoma, B-Cell
[Mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by valproic acid combined with temsirolimus].
Lymphoma, Follicular
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Lymphoma, Follicular
Histone deacetylase inhibition as a mechanism for the therapeutic effect of statins (3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors) in follicular lymphoma.
Lymphoma, Follicular
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
Lymphoma, Follicular
Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study.
Lymphoma, Large B-Cell, Diffuse
8a, a New Acridine Antiproliferative and Pro-Apoptotic Agent Targeting HDAC1/DNMT1.
Lymphoma, Large B-Cell, Diffuse
A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
Lymphoma, Large B-Cell, Diffuse
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Lymphoma, Large B-Cell, Diffuse
Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma.
Lymphoma, Large B-Cell, Diffuse
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Lymphoma, Large B-Cell, Diffuse
Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.
Lymphoma, Large B-Cell, Diffuse
Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
Lymphoma, Large B-Cell, Diffuse
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene expression and epigenetic profiles in models of DLBCL.
Lymphoma, Large B-Cell, Diffuse
HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Lymphoma, Large B-Cell, Diffuse
Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Lymphoma, Large B-Cell, Diffuse
Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.
Lymphoma, Large B-Cell, Diffuse
Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib.
Lymphoma, Large B-Cell, Diffuse
Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines.
Lymphoma, Large B-Cell, Diffuse
miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the E?-miR-155 transgenic mouse model.
Lymphoma, Large B-Cell, Diffuse
Paradoxical regulation of hypoxia inducible factor-1? (HIF-1?) by histone deacetylase inhibitor in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance.
Lymphoma, Large B-Cell, Diffuse
Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones.
Lymphoma, Large B-Cell, Diffuse
Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
Lymphoma, Large B-Cell, Diffuse
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Lymphoma, Large B-Cell, Diffuse
The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms.
Lymphoma, Large B-Cell, Diffuse
The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.
Lymphoma, Large B-Cell, Diffuse
The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
Lymphoma, Large B-Cell, Diffuse
Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion.
Lymphoma, Large B-Cell, Diffuse
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID).
Lymphoma, Large B-Cell, Diffuse
[Mechanism of inhibiting the cell growth in diffuse large B-cell lymphoma by valproic acid combined with temsirolimus].
Lymphoma, Mantle-Cell
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.
Lymphoma, Mantle-Cell
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Lymphoma, Mantle-Cell
Carfilzomib Interacts Synergistically With Histone Deacetylase Inhibitors In Mantle Cell Lymphoma Cells In Vitro And In Vivo.
Lymphoma, Mantle-Cell
Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
Lymphoma, Mantle-Cell
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
Lymphoma, Mantle-Cell
Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells.
Lymphoma, Mantle-Cell
Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function.
Lymphoma, Mantle-Cell
Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Lymphoma, Mantle-Cell
In vitro and in vivo activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma.
Lymphoma, Mantle-Cell
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Lymphoma, Mantle-Cell
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
Lymphoma, Mantle-Cell
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Lymphoma, Mantle-Cell
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
Lymphoma, Mantle-Cell
Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In Vivo.
Lymphoma, Mantle-Cell
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Lymphoma, Mantle-Cell
Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms.
Lymphoma, Mantle-Cell
The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor.
Lymphoma, Non-Hodgkin
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas.
Lymphoma, Non-Hodgkin
An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.
Lymphoma, Non-Hodgkin
Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.
Lymphoma, Non-Hodgkin
Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies.
Lymphoma, Non-Hodgkin
Histone deacetylase inhibitor chidamide induces growth inhibition and apoptosis in NK/T lymphoma cells through ATM-Chk2-p53-p21 signalling pathway.
Lymphoma, Non-Hodgkin
Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Lymphoma, Non-Hodgkin
In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells.
Lymphoma, Non-Hodgkin
Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors.
Lymphoma, Non-Hodgkin
PCI-24781 Induces Caspase and Reactive Oxygen Species-Dependent Apoptosis Through NF-{kappa}B Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells.
Lymphoma, Non-Hodgkin
Peptide mass mapping of acetylated isoforms of histone H4 from mouse lymphosarcoma cells treated with histone deacetylase (HDACs) inhibitors.
Lymphoma, Non-Hodgkin
Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.
Lymphoma, Non-Hodgkin
Retraction: In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells.
Lymphoma, Non-Hodgkin
Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075).
Lymphoma, Non-Hodgkin
The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models.
Lymphoma, T-Cell
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas.
Lymphoma, T-Cell
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.
Lymphoma, T-Cell
Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo.
Lymphoma, T-Cell
Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
Lymphoma, T-Cell
Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras.
Lymphoma, T-Cell
CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio.
Lymphoma, T-Cell
Chidamide based combination regimen for treatment of monomorphic epitheliotropic intestinal T cell lymphoma following radical operation: Two case reports.
Lymphoma, T-Cell
Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine.
Lymphoma, T-Cell
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Lymphoma, T-Cell
Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine incutaneous t-cell lymphoma in HUT78 cells.
Lymphoma, T-Cell
Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine.
Lymphoma, T-Cell
Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
Lymphoma, T-Cell
Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma.
Lymphoma, T-Cell
HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.
Lymphoma, T-Cell
Hdac1 and Hdac2 are essential for physiological maturation of a Cx3cr1 expressing subset of T-lymphocytes.
Lymphoma, T-Cell
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Lymphoma, T-Cell
Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogenic stem cell transplant.
Lymphoma, T-Cell
Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing.
Lymphoma, T-Cell
Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.
Lymphoma, T-Cell
Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Lymphoma, T-Cell
Induction of apoptosis by HBI-8000 in adult T-cell leukemia/lymphoma is associated with activation of Bim and NLRP3.
Lymphoma, T-Cell
Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.
Lymphoma, T-Cell
Kinetic and Thermodynamic Rationale for SAHA Being a Preferential Human HDAC8 Inhibitor as Compared to the Structurally Similar Ligand, TSA.
Lymphoma, T-Cell
Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration.
Lymphoma, T-Cell
New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Lymphoma, T-Cell
Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors.
Lymphoma, T-Cell
Phase I trial of a new schedule of romidepsin in patients with advanced cancers.
Lymphoma, T-Cell
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma.
Lymphoma, T-Cell
Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies.
Lymphoma, T-Cell
Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer.
Lymphoma, T-Cell
Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program.
Lymphoma, T-Cell
Synergistic antitumor effect of suberoylanilide hydroxamic acid and cisplatin in osteosarcoma cells.
Lymphoma, T-Cell
Synthesis, bioevaluation and docking study of 5-substitutedphenyl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Lymphoma, T-Cell
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.
Lymphoma, T-Cell
The combination of hypomethylating agents and histone deacetylase inhibitors (HDACi) are synergistically cytotoxic and reverse the malignant phenotype in preclinical models of T-cell lymphoma.
Lymphoma, T-Cell
The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma.
Lymphoma, T-Cell
The emerging role of histone deacetylase inhibitors in treating T-cell lymphomas.
Lymphoma, T-Cell
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
Lymphoma, T-Cell
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines.
Lymphoma, T-Cell
The novel IKK2 inhibitor LY2409881 potently synergizes with histone deacetylase inhibitors in preclinical models of lymphoma through the downregulation of NF-?B.
Lymphoma, T-Cell
Vorinostat ameliorates IL-1?-induced reduction of type II collagen by inhibiting the expression of ELF3 in chondrocytes.
Lymphoma, T-Cell
Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies.
Lymphoma, T-Cell, Cutaneous
A facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapy.
Lymphoma, T-Cell, Cutaneous
A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
Lymphoma, T-Cell, Cutaneous
A novel hydroxysuberamide derivative potentiates MG132-mediated anticancer activity against human hormone refractory prostate cancers--the role of histone deacetylase and endoplasmic reticulum stress.
Lymphoma, T-Cell, Cutaneous
An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis.
Lymphoma, T-Cell, Cutaneous
AN-7, a butyric acid prodrug, sensitizes cutaneous T-cell lymphoma cell lines to doxorubicin via inhibition of DNA double strand breaks repair.
Lymphoma, T-Cell, Cutaneous
Antitumor activity of SAHA, a novel histone deacetylase inhibitor, against murine B cell lymphoma A20 cells in vitro and in vivo.
Lymphoma, T-Cell, Cutaneous
Antitumor effect of liposomal histone deacetylase inhibitor-lipid conjugates in vitro.
Lymphoma, T-Cell, Cutaneous
ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types.
Lymphoma, T-Cell, Cutaneous
BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.
Lymphoma, T-Cell, Cutaneous
Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.
Lymphoma, T-Cell, Cutaneous
Cognitive Improvement by Vorinostat through Modulation of Endoplasmic Reticulum Stress in a Corticosterone-Induced Chronic Stress Model in Mice.
Lymphoma, T-Cell, Cutaneous
Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptor?2, via histone acetylation.
Lymphoma, T-Cell, Cutaneous
Combination therapies improve the anticancer activities of retinoids in neuroblastoma.
Lymphoma, T-Cell, Cutaneous
Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD.
Lymphoma, T-Cell, Cutaneous
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Contribution of STAT3 and RAD23B in Primary Sézary Cells to Histone Deacetylase Inhibitor FK228 Resistance.
Lymphoma, T-Cell, Cutaneous
Current status of histone deacetylase inhibitors in cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Depsipeptide and roxithromycin induce apoptosis of lymphoma cells by blocking extracellular signal-regulated kinase activation.
Lymphoma, T-Cell, Cutaneous
Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain.
Lymphoma, T-Cell, Cutaneous
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
Lymphoma, T-Cell, Cutaneous
Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
Lymphoma, T-Cell, Cutaneous
Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus macaques.
Lymphoma, T-Cell, Cutaneous
Effects of SAHA and EGCG on Growth Potentiation of Triple-Negative Breast Cancer Cells.
Lymphoma, T-Cell, Cutaneous
Effects of suberoylanilide hydroxamic acid on rat cytochrome P450 enzyme activities.
Lymphoma, T-Cell, Cutaneous
Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes.
Lymphoma, T-Cell, Cutaneous
Enhancing the apoptotic and therapeutic effects of HDAC inhibitors.
Lymphoma, T-Cell, Cutaneous
Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Lymphoma, T-Cell, Cutaneous
Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Factors influencing epigenetic mechanisms and related diseases.
Lymphoma, T-Cell, Cutaneous
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
Lymphoma, T-Cell, Cutaneous
HDAC pharmacological inhibition promotes cell death through the eIF2? kinases PKR and GCN2.
Lymphoma, T-Cell, Cutaneous
Histone Deacetylase 3 Is Required for Efficient T Cell Development.
Lymphoma, T-Cell, Cutaneous
Histone Deacetylase Inhibition Increases Levels of Choline Kinase ? and Phosphocholine Facilitating Noninvasive Imaging in Human Cancers.
Lymphoma, T-Cell, Cutaneous
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Histone Deacetylase Inhibitor SAHA Induces Expression of Fatty Acid-Binding Protein 4 and Inhibits Replication of Human Cytomegalovirus.
Lymphoma, T-Cell, Cutaneous
Histone deacetylase inhibitors as novel anticancer therapeutics.
Lymphoma, T-Cell, Cutaneous
Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Lymphoma, T-Cell, Cutaneous
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Histone deacetylase inhibitors interrupt HSP90RASGRP1 and HSP90CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.
Lymphoma, T-Cell, Cutaneous
Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
Lymphoma, T-Cell, Cutaneous
Histone deacetylase inhibitors: emerging mechanisms of resistance.
Lymphoma, T-Cell, Cutaneous
Histone deacetylase inhibitors: new treatment options for inflammatory joint disease?
Lymphoma, T-Cell, Cutaneous
Hydroxamic acid derivatives of mycophenolic acid inhibit histone deacetylase at the cellular level.
Lymphoma, T-Cell, Cutaneous
Inhibition of cell-mediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
Lymphoma, T-Cell, Cutaneous
Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma.
Lymphoma, T-Cell, Cutaneous
Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Low-Dose Electron Beam Radiation and Romidepsin Therapy for Symptomatic Cutaneous T-Cell Lymphoma Lesions.
Lymphoma, T-Cell, Cutaneous
Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.
Lymphoma, T-Cell, Cutaneous
Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells.
Lymphoma, T-Cell, Cutaneous
Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
Lymphoma, T-Cell, Cutaneous
Mutagenesis studies of the 14 Å internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design.
Lymphoma, T-Cell, Cutaneous
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
Lymphoma, T-Cell, Cutaneous
Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide.
Lymphoma, T-Cell, Cutaneous
Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat.
Lymphoma, T-Cell, Cutaneous
Overexpression of miR-4433 by suberoylanilide hydroxamic acid suppresses growth of CML cells and induces apoptosis through targeting Bcr-Abl.
Lymphoma, T-Cell, Cutaneous
Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs.
Lymphoma, T-Cell, Cutaneous
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Lymphoma, T-Cell, Cutaneous
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Lymphoma, T-Cell, Cutaneous
Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Lymphoma, T-Cell, Cutaneous
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma.
Lymphoma, T-Cell, Cutaneous
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Photosensitization by iodinated DNA minor groove binding ligands: Evaluation of DNA double-strand break induction and repair.
Lymphoma, T-Cell, Cutaneous
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Potential non-oncological applications of histone deacetylase inhibitors.
Lymphoma, T-Cell, Cutaneous
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells.
Lymphoma, T-Cell, Cutaneous
QT interval prolongation and torsades de pointes in a patient undergoing treatment with vorinostat: A case report and review of the literature.
Lymphoma, T-Cell, Cutaneous
Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood.
Lymphoma, T-Cell, Cutaneous
Response to hydralazine-valproate in a patient with mycosis fungoides.
Lymphoma, T-Cell, Cutaneous
Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
Lymphoma, T-Cell, Cutaneous
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies.
Lymphoma, T-Cell, Cutaneous
Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice.
Lymphoma, T-Cell, Cutaneous
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
Lymphoma, T-Cell, Cutaneous
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Lymphoma, T-Cell, Cutaneous
Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Lymphoma, T-Cell, Cutaneous
Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma (October).
Lymphoma, T-Cell, Cutaneous
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.
Lymphoma, T-Cell, Cutaneous
Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.
Lymphoma, T-Cell, Cutaneous
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action.
Lymphoma, T-Cell, Cutaneous
Selective inhibition of HDAC6 sensitizes cutaneous T-cell lymphoma to PI3K inhibitors.
Lymphoma, T-Cell, Cutaneous
Serum chemokine levels differentially regulated by vorinostat in a Sézary syndrome patient.
Lymphoma, T-Cell, Cutaneous
Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Small-molecule chromatin-modifying agents: therapeutic applications.
Lymphoma, T-Cell, Cutaneous
Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Subchronic Toxicities of HZ1006, a Hydroxamate-Based Histone Deacetylase Inhibitor, in Beagle Dogs and Sprague-Dawley Rats.
Lymphoma, T-Cell, Cutaneous
Suberoylanilide Hydroxamic Acid (SAHA) Reduces Fibrosis Markers and Deactivates Human Stellate Cells via the Epithelial-Mesenchymal Transition (EMT).
Lymphoma, T-Cell, Cutaneous
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Lymphoma, T-Cell, Cutaneous
Synergistic effects of vorinostat (SAHA) and azoles against Aspergillus species and their biofilms.
Lymphoma, T-Cell, Cutaneous
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Lymphoma, T-Cell, Cutaneous
Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
Lymphoma, T-Cell, Cutaneous
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.
Lymphoma, T-Cell, Cutaneous
The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
Lymphoma, T-Cell, Cutaneous
The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
The spectrum of cutaneous T-cell lymphomas: new insights into biology and therapy.
Lymphoma, T-Cell, Cutaneous
The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
Lymphoma, T-Cell, Cutaneous
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.
Lymphoma, T-Cell, Cutaneous
Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Vorinostat is genotoxic and epigenotoxic in the mouse bone marrow cells at the human equivalent doses.
Lymphoma, T-Cell, Cutaneous
Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
Lymphoma, T-Cell, Cutaneous
Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance.
Lymphoma, T-Cell, Cutaneous
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.
Lymphoma, T-Cell, Peripheral
A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
Lymphoma, T-Cell, Peripheral
Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Lymphoma, T-Cell, Peripheral
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma.
Lymphoma, T-Cell, Peripheral
Belinostat, at Its Clinically Relevant Concentrations, Inhibits Rifampicin-Induced CYP3A4 and MDR1 Gene Expression.
Lymphoma, T-Cell, Peripheral
Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
Lymphoma, T-Cell, Peripheral
c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors.
Lymphoma, T-Cell, Peripheral
Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.
Lymphoma, T-Cell, Peripheral
Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas.
Lymphoma, T-Cell, Peripheral
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Lymphoma, T-Cell, Peripheral
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
Lymphoma, T-Cell, Peripheral
Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.
Lymphoma, T-Cell, Peripheral
Complete remission with romidepsin in a patient with T-cell acute lymphoblastic leukemia refractory to induction hyper-CVAD.
Lymphoma, T-Cell, Peripheral
Determination of chidamide in rat plasma and cerebrospinal fluid.
Lymphoma, T-Cell, Peripheral
Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application.
Lymphoma, T-Cell, Peripheral
Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report.
Lymphoma, T-Cell, Peripheral
Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin.
Lymphoma, T-Cell, Peripheral
Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
Lymphoma, T-Cell, Peripheral
Epigenetic modifiers: basic understanding and clinical development.
Lymphoma, T-Cell, Peripheral
Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.
Lymphoma, T-Cell, Peripheral
Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas.
Lymphoma, T-Cell, Peripheral
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
Lymphoma, T-Cell, Peripheral
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Lymphoma, T-Cell, Peripheral
Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
Lymphoma, T-Cell, Peripheral
Histone deacetylase inhibitors: emerging mechanisms of resistance.
Lymphoma, T-Cell, Peripheral
In vitro characterization of belinostat glucuronidation: demonstration of both UGT1A1 and UGT2B7 as the main contributing isozymes.
Lymphoma, T-Cell, Peripheral
Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
Lymphoma, T-Cell, Peripheral
LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.
Lymphoma, T-Cell, Peripheral
Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
Lymphoma, T-Cell, Peripheral
Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies.
Lymphoma, T-Cell, Peripheral
Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Lymphoma, T-Cell, Peripheral
Prolonging the Half-Life of Histone Deacetylase Inhibitor Belinostat via 50 nm Scale Liposomal Subcutaneous Delivery System for Peripheral T-Cell Lymphoma.
Lymphoma, T-Cell, Peripheral
Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
Lymphoma, T-Cell, Peripheral
Romidepsin Controls Chronic Lymphocytic Leukemia in a Patient with Mycosis Fungoides.
Lymphoma, T-Cell, Peripheral
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
Lymphoma, T-Cell, Peripheral
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Lymphoma, T-Cell, Peripheral
Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Lymphoma, T-Cell, Peripheral
Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature.
Lymphoma, T-Cell, Peripheral
Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications.
Lymphoma, T-Cell, Peripheral
Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma.
Lymphoma, T-Cell, Peripheral
T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma.
Lymphoma, T-Cell, Peripheral
The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study.
Lymphoma, T-Cell, Peripheral
UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.
Lymphopenia
In vivo conditional deletion of HDAC7 reveals its requirement to establish proper B lymphocyte identity and development.
Lymphoproliferative Disorders
The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease.
Machado-Joseph Disease
Sodium valproate increases activity of the sirtuin pathway resulting in beneficial effects for spinocerebellar ataxia-3 in vivo.
Macular Degeneration
Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain.
Malaria
An apicomplexan ankyrin-repeat histone deacetylase with relatives in photosynthetic eukaryotes.
Malaria
Comparative Gene Expression Profiling of P. falciparum Malaria Parasites Exposed to Three Different Histone Deacetylase Inhibitors.
Malaria
Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria.
Malaria
Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
Malaria
Inhibition of Plasmodium falciparum proliferation in vitro by double-stranded RNA directed against malaria histone deacetylase.
Malaria
Lysine acetylation in sexual stage malaria parasites is a target for antimalarial small molecules.
Malaria
One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
Malaria, Falciparum
Discovery of FNDR-20123, a histone deacetylase inhibitor for the treatment of Plasmodium falciparum malaria.
Malnutrition
Histone Deacetylase Activity and the Renin-Angiotensin-Aldosterone System: Key Elements in Cardiorenal Alterations Provoked by Chronic Malnutrition in Male Adult Rats.
Malnutrition
Variants in the SIRT1 gene may affect diabetes risk in interaction with prenatal exposure to famine.
Malocclusion
Epigenetic influence of KAT6B and HDAC4 in the development of skeletal malocclusion.
Mania
HDAC inhibitors reverse mania-like behavior and modulate epigenetic regulatory enzymes in an animal model of mania induced by Ouabain.
Mania
Histone deacetylase activity and brain-derived neurotrophic factor (BDNF) levels in a pharmacological model of mania.
Mania
Histone deacetylase inhibitors reverse manic-like behaviors and protect the rat brain from energetic metabolic alterations induced by ouabain.
Mania
Role of epigenetic regulatory enzymes in animal models of mania induced by amphetamine and paradoxical sleep deprivation.
Mania
Sodium butyrate has an antimanic effect and protects the brain against oxidative stress in an animal model of mania induced by ouabain.
Mania
The Effects of Histone Deacetylase Inhibition on the Levels of Cerebral Cytokines in an Animal Model of Mania Induced by Dextroamphetamine.
Mania
Treating post-dengue mania: Is role of valproate and quetiapine related to histone deacetylase inhibition?
Mastocytoma
Trichostatin A induces apoptosis of p815 mastocytoma cells in histone acetylation- and mitochondria-dependent fashion.
Mastocytosis
Histone Methyltransferase Inhibition Has a Cytotoxic Impact on Transformed Mast Cells: Implications for Mastocytosis.
Mastocytosis, Systemic
Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
Measles
Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.
Measles
Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus.
Medulloblastoma
A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma.
Medulloblastoma
Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.
Medulloblastoma
Combination Treatment of CI-994 With Etoposide Potentiates Anticancer Effects Through a Topoisomerase II-Dependent Mechanism in Atypical Teratoid/Rhabdoid Tumor (AT/RT).
Medulloblastoma
Dickkopf-1 is an epigenetically silenced candidate tumor suppressor gene in medulloblastoma.
Medulloblastoma
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.
Medulloblastoma
Expression patterns and potential roles of SIRT1 in human medulloblastoma cells in vivo and in vitro.
Medulloblastoma
Fingolimod (FTY720) reduces viability and survival and increases histone H3 acetylation in medulloblastoma cells.
Medulloblastoma
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
Medulloblastoma
Histone Deacetylase 6 Represents a Novel Drug Target in the Oncogenic Hedgehog Signaling Pathway.
Medulloblastoma
Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation.
Medulloblastoma
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
Medulloblastoma
Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
Medulloblastoma
Histone deacetylase inhibitors induce medulloblastoma cell death independent of HDACs recruited in REST repression complexes.
Medulloblastoma
Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation.
Medulloblastoma
Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma.
Medulloblastoma
Histone Deacetylases 5 and 9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth.
Medulloblastoma
Identification and Characterization of KCASH2 and KCASH3, 2 Novel Cullin3 Adaptors Suppressing Histone Deacetylase and Hedgehog Activity in Medulloblastoma.
Medulloblastoma
Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.
Medulloblastoma
Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model.
Medulloblastoma
Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma or Leukemia.
Medulloblastoma
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.
Medulloblastoma
Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA).
Medulloblastoma
Sonic hedgehog-induced histone deacetylase activation is required for cerebellar granule precursor hyperplasia in medulloblastoma.
Medulloblastoma
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.
Medulloblastoma
The histone deacetylase inhibitor sodium butyrate in combination with brain-derived neurotrophic factor reduces the viability of DAOY human medulloblastoma cells.
Medulloblastoma
The Histone Deacetylase Inhibitor Sodium Butyrate Promotes Cell Death and Differentiation and Reduces Neurosphere Formation in Human Medulloblastoma Cells.
Medulloblastoma
Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis.
Medulloblastoma
Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists.
Megacolon
Novel smooth muscle markers reveal abnormalities of the intestinal musculature in severe colorectal motility disorders.
Melanoma
6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells.
Melanoma
A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma.
Melanoma
A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma.
Melanoma
Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor.
Melanoma
ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
Melanoma
ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.
Melanoma
Adipocytes contribute to resistance of human melanoma cells to chemotherapy and targeted therapy.
Melanoma
Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.
Melanoma
An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers.
Melanoma
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
Melanoma
Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk.
Melanoma
BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers.
Melanoma
Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.
Melanoma
Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells.
Melanoma
BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials.
Melanoma
Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription.
Melanoma
Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation.
Melanoma
Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP.
Melanoma
Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells.
Melanoma
Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
Melanoma
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
Melanoma
Combining Histone deacetylase inhibitors with MDA-7/IL-24 enhances killing of renal carcinoma cells.
Melanoma
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
Melanoma
Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells.
Melanoma
Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.
Melanoma
Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
Melanoma
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
Melanoma
DNA methylation and histone acetylation regulate the expression of MGMT and chemosensitivity to temozolomide in malignant melanoma cell lines.
Melanoma
Down-regulated HDAC3 elevates microRNA-495-3p to restrain epithelial-mesenchymal transition and oncogenicity of melanoma cells via reducing TRAF5.
Melanoma
Down-regulation of deacetylase HDAC6 inhibits the melanoma cell line A375.S2 growth through ROS-dependent mitochondrial pathway.
Melanoma
Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma.
Melanoma
Effects of retinoic acid and sodium butyrate on gene expression, histone acetylation and inhibition of proliferation of melanoma cells.
Melanoma
Elevated osteopontin levels in metastatic melanoma correlate with epigenetic silencing of breast cancer metastasis suppressor 1.
Melanoma
Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
Melanoma
Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma.
Melanoma
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance.
Melanoma
Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells.
Melanoma
Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus.
Melanoma
Evaluation of [11C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma.
Melanoma
Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.
Melanoma
Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.
Melanoma
Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation.
Melanoma
Green tea polyphenols inhibit malignant melanoma progression via regulating circ_MITF/miR-30e-3p/HDAC2 axis.
Melanoma
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma.
Melanoma
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
Melanoma
HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma.
Melanoma
HDAC2 Inhibitor Valproic Acid Increases Radiation Sensitivity of Drug-Resistant Melanoma Cells.
Melanoma
HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
Melanoma
HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy.
Melanoma
Histone deacetylase inhibitor (HDACi) upregulates activin A and activates the Smad signaling pathway in melanomas.
Melanoma
Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
Melanoma
Histone Deacetylase Inhibitor Sensitizes Apoptosis-Resistant Melanomas to Cytotoxic Human T Lymphocytes through Regulation of TRAIL/DR5 Pathway.
Melanoma
Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca(2+) Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK.
Melanoma
Histone deacetylase inhibitor valproic acid sensitizes B16F10 melanoma cells to cucurbitacin B treatment.
Melanoma
Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.
Melanoma
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.
Melanoma
Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
Melanoma
Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells.
Melanoma
Histone deacetylase inhibitors interact with melanoma differentiation associated-7/interleukin-24 to kill primary human glioblastoma cells.
Melanoma
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity.
Melanoma
Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.
Melanoma
Histone Deacetylase Inhibitors Sensitize Murine B16F10 Melanoma Cells to Carbon Ion Irradiation by Inducing G1 Phase Arrest.
Melanoma
Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
Melanoma
Histone deacetylase-3mediates positive feedback relationship between anaphylaxis and tumor metastasis.
Melanoma
Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by Cisplatin.
Melanoma
Identification of AP-2-regulated genes by macroarray profiling of gene expression in human A375P melanoma.
Melanoma
Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma.
Melanoma
Identification of four potential epigenetic modulators from the NCI structural diversity library using a cell-based assay.
Melanoma
Identification of histone deacetylase inhibitors with (arylidene)aminoxy scaffold active in uveal melanoma cell lines.
Melanoma
Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors.
Melanoma
In vitro effects of histone deacetylase inhibitors and mitomycin C on tenon capsule fibroblasts and conjunctival melanoma cells.
Melanoma
Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-? and valproic acid.
Melanoma
Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis.
Melanoma
miR-92a-3p and MYCBP2 are involved in MS-275-induced and c-myc-mediated TRAIL-sensitivity in melanoma cells.
Melanoma
Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.
Melanoma
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Melanoma
Non-canonical EphA2 signaling is a driver of tumor-endothelial cell interactions and metastatic dissemination in BRAF inhibitor resistant melanoma.
Melanoma
NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2.
Melanoma
Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays.
Melanoma
Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways.
Melanoma
Nucleus accumbens-associated 1 contributes to cortactin deacetylation and augments the migration of melanoma cells.
Melanoma
Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway.
Melanoma
Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-Mhigh melanoma cell populations.
Melanoma
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.
Melanoma
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Melanoma
PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma.
Melanoma
Polyphenols from green tea inhibit the growth of melanoma cells through inhibition of class I histone deacetylases and induction of DNA damage.
Melanoma
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Melanoma
Predictive Gene Signature for Pyrazolopyrimidine Derivative c-Src Inhibitor 10a Sensitivity in Melanoma Cells.
Melanoma
Preparation and evaluation of tributyrin emulsion as a potent anti-cancer agent against melanoma.
Melanoma
Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models.
Melanoma
Regulation of the ORF61 promoter and ORF61 functions in varicella-zoster virus replication and pathogenesis.
Melanoma
Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.
Melanoma
Selective Inhibition of Histone Deacetylation in Melanoma Increases Targeted Gene Delivery by a Bacteriophage Viral Vector.
Melanoma
Signature of VDR miRNAs and epigenetic modulation of vitamin D signaling in melanoma cell lines.
Melanoma
SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation.
Melanoma
SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling.
Melanoma
Sulforaphane and iberin are potent epigenetic modulators of histone acetylation and methylation in malignant melanoma.
Melanoma
Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models.
Melanoma
Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression.
Melanoma
Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.
Melanoma
Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas.
Melanoma
The 14-3-3sigma gene promoter is methylated in both human melanocytes and melanoma.
Melanoma
The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
Melanoma
The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Melanoma
The HDAC3 inhibitor RGFP966 ameliorated ischemic brain damage by downregulating the AIM2 inflammasome.
Melanoma
The HDAC6 Inhibitor Tubacin Induces Release of CD133(+) Extracellular Vesicles From Cancer Cells.
Melanoma
The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel.
Melanoma
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.
Melanoma
The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells.
Melanoma
The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis.
Melanoma
The interaction with Sp1 and reduction in the activity of histone deacetylase 1 are critical for the constitutive gene expression of IL-1 alpha in human melanoma cells.
Melanoma
The overriding of TRAIL resistance by the histone deacetylase inhibitor MS-275 involves c-myc up-regulation in cutaneous, uveal, and mucosal melanoma.
Melanoma
Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).
Melanoma
Transducin-like enhancer of split 3 regulates proliferation of melanoma cells via histone deacetylase activity.
Melanoma
Trichostatin A and 5-aza-2'-deoxycytidine switch S1P from an inhibitor to a stimulator of motility through epigenetic regulation of S1P receptors.
Melanoma
Upregulated Histone Deacetylase 6 Associates with Malignant Progression of Melanoma and Predicts the Prognosis of Patients.
Melanoma
Violacein induces death of RAS-mutated metastatic melanoma by impairing autophagy process.
Melanoma
Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
Melanoma, Experimental
Tbx2 is overexpressed and plays an important role in maintaining proliferation and suppression of senescence in melanomas.
Memory Disorders
Cinnamic acid rescues behavioral deficits in a mouse model of traumatic brain injury by targeting miR-455-3p/HDAC2.
Memory Disorders
CREB binding protein is required for both short-term and long-term memory formation.
Memory Disorders
Dual influences of early-life maternal deprivation on histone deacetylase activity and recognition memory in rats.
Memory Disorders
HDAC2 hyperexpression alters hippocampal neuronal transcription and microglial activity in neuroinflammation-induced cognitive dysfunction.
Memory Disorders
HDAC3 negatively regulates spatial memory in a mouse model of Alzheimer's disease.
Memory Disorders
HDAC7 Ubiquitination by the E3 Ligase CBX4 Is Involved in Contextual Fear Conditioning Memory Formation.
Memory Disorders
Hippocampal chromatin-modifying enzymes are pivotal for scopolamine-induced synaptic plasticity gene expression changes and memory impairment.
Memory Disorders
Hippocampal proteomics defines pathways associated with memory decline and resilience in normal aging and Alzheimer's disease mouse models.
Memory Disorders
Histone deacetylase inhibition prevents the impairing effects of hippocampal gastrin-releasing peptide receptor antagonism on memory consolidation and extinction.
Memory Disorders
Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers.
Memory Disorders
Lentivirus-Mediated HDAC3 Inhibition Attenuates Oxidative Stress in APPswe/PS1dE9 Mice.
Memory Disorders
Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity.
Memory Disorders
Long-Term Memory in Drosophila Is Influenced by Histone Deacetylase HDAC4 Interacting with SUMO-Conjugating Enzyme Ubc9.
Memory Disorders
Regulation of CRE-dependent transcription by presenilins: prospects for therapy of Alzheimer's disease.
Memory Disorders
Repeated mild traumatic brain injury causes persistent changes in histone deacetylase function in hippocampus: Implications in learning and memory deficits in rats.
Memory Disorders
Sodium Butyrate Reduces Brain Amyloid-? Levels and Improves Cognitive Memory Performance in an Alzheimer's Disease Transgenic Mouse Model at an Early Disease Stage.
Memory Disorders
The Class IIa histone deacetylase HDAC4 and neuronal function: Nuclear nuisance and cytoplasmic stalwart?
Memory Disorders
Tuning acetylation levels with HAT activators: Therapeutic strategy in neurodegenerative diseases.
Memory Disorders
Vorinostat, a histone deacetylase inhibitor, ameliorates the sociability and cognitive memory in an Ash1L-deletion-induced ASD/ID mouse model.
Meningioma
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Meningioma
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Meningioma
Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.
Meningitis
Trichostatin A, a Histone Deacetylase Inhibitor, Alleviates Eosinophilic Meningitis Induced by Angiostrongylus cantonensis Infection in Mice.
Meningitis, Bacterial
Sodium Butyrate Prevents Memory Impairment by Re-establishing BDNF and GDNF Expression in Experimental Pneumococcal Meningitis.
Mesothelioma
A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL.
Mesothelioma
Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Mesothelioma
Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma.
Mesothelioma
Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma.
Mesothelioma
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
Mesothelioma
Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.
Mesothelioma
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.
Mesothelioma
New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
Mesothelioma
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
Mesothelioma
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid.
Mesothelioma
Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation.
Mesothelioma
The levels of HDAC1 and thioredoxin1 are related to the death of mesothelioma cells by suberoylanilide hydroxamic acid.
Mesothelioma
The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy.
Mesothelioma
Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
Mesothelioma
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent.
Mesothelioma, Malignant
Biallelic germline and somatic mutations in malignant mesothelioma: Multiple mutations in transcription regulators including mSWI/SNF genes.
Mesothelioma, Malignant
Histone Deacetylase Inhibitors as Potential Therapeutic Agents For The Treatment Of Malignant Mesothelioma.
Mesothelioma, Malignant
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.
Mesothelioma, Malignant
New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
Mesothelioma, Malignant
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
Metabolic Diseases
Class IIa HDACs do not influence beta-cell function under normal or high glucose conditions.
Metabolic Diseases
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Metabolic Diseases
HDAC9 knockout mice are protected from adipose tissue dysfunction and systemic metabolic disease during high fat feeding.
Metabolic Diseases
Histone deacetylase 3 is negatively regulated by the nuclear protein deleted in breast cancer 1 (DBC1).
Metabolic Diseases
Histone deacetylase 9 promoter hypomethylation associated with adipocyte dysfunction is a statin-related metabolic effect.
Metabolic Diseases
Liver-Specific Knockdown of Class IIa HDACs Has Limited Efficacy on Glucose Metabolism but Entails Severe Organ Side Effects in Mice.
Metabolic Diseases
Potential mechanisms by which polyphenol-rich grapes prevent obesity-mediated inflammation and metabolic diseases.
Metabolic Diseases
Role of histone deacetylase 9 in regulating adipogenic differentiation and high fat diet-induced metabolic disease.
Metabolic Diseases
Silencing of Histone Deacetylase 9 Expression in Podocytes Attenuates Kidney Injury in Diabetic Nephropathy.
Metabolic Syndrome
Botanicals as epigenetic modulators for mechanisms contributing to development of metabolic syndrome.
Metabolic Syndrome
High expression of liver histone deacetylase 3 contributes to high-fat-diet-induced metabolic syndrome by suppressing the PPAR-? and LXR-?-pathways in E3 rats.
Metabolic Syndrome
Pioglitazone up-regulates long non-coding RNA MEG3 to protect endothelial progenitor cells via increasing HDAC7 expression in metabolic syndrome.
Metabolic Syndrome
SAHA induces white fat browning and rectifies metabolic dysfunctions via activation of ZFPs.
Microcephaly
Murine craniofacial development requires Hdac3-mediated repression of Msx gene expression.
Microphthalmos
Protein inhibitor of activated STAT 3 modulates osteoclastogenesis by down-regulation of NFATc1 and osteoclast-associated receptor.
Migraine Disorders
Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 inhibition.
Mitochondrial Diseases
Reduction of Rpd3 suppresses defects in locomotive ability and neuronal morphology induced by the knockdown of Drosophila SLC25A46 via an epigenetic pathway.
Mitochondrial Diseases
The Heart in Friedreich's Ataxia: Basic Findings and Clinical Implications.
Mononeuropathies
The new HDAC1 inhibitor LG325 ameliorates neuropathic pain in a mouse model.
Motor Neuron Disease
HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients.
Motor Neuron Disease
Histone deacetylase inhibitors: therapeutic agents and research tools for deciphering motor neuron diseases.
Motor Neuron Disease
MicroRNAs and HDAC4 protein expression in the skeletal muscle of ALS patients.
Mouth Neoplasms
Effects of demethylating agent 5-aza-2(')-deoxycytidine and histone deacetylase inhibitor FR901228 on maspin gene expression in oral cancer cell lines.
Mouth Neoplasms
Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer.
Mouth Neoplasms
Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: Prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Mouth Neoplasms
HDAC2 promotes cell migration/invasion abilities through HIF-1? stabilization in human oral squamous cell carcinoma.
Mouth Neoplasms
Histone deacetylase 1 regulates the malignancy of oral cancer cells via miR-154-5p/PCNA axis.
Mouth Neoplasms
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.
Mouth Neoplasms
Sodium Butyrate, a Histone Deacetylase Inhibitor, Regulates Lymphangiogenic Factors in Oral Cancer Cell Line HSC-3.
Mouth Neoplasms
The in vitro apoptotic effects of A248 and A1659, newly synthetic histone deacetylase inhibitors in oral cancer cells.
Moyamoya Disease
Panobinostat, a histone deacetylase inhibitor, rescues the angiogenic potential of endothelial colony-forming cells in moyamoya disease.
Mucositis
Efficacy of Azatyrosine-Phenylbutyric Hydroxamides, a Histone Deacetylase Inhibitor, on Chemotherapy-Induced Gastrointestinal Mucositis.
Multiple Myeloma
(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.
Multiple Myeloma
A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.
Multiple Myeloma
A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma.
Multiple Myeloma
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.
Multiple Myeloma
A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma.
Multiple Myeloma
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.
Multiple Myeloma
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimens.
Multiple Myeloma
A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.
Multiple Myeloma
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
Multiple Myeloma
Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma.
Multiple Myeloma
Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.
Multiple Myeloma
ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types.
Multiple Myeloma
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Multiple Myeloma
Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.
Multiple Myeloma
CDKN1A Gene Expression in Two Multiple Myeloma Cell Lines With Different P53 Functionality.
Multiple Myeloma
Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner.
Multiple Myeloma
Chidamide, a novel histone deacetylase inhibitor, inhibits multiple myeloma cells proliferation through succinate dehydrogenase subunit A.
Multiple Myeloma
Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy.
Multiple Myeloma
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Multiple Myeloma
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma.
Multiple Myeloma
Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor.
Multiple Myeloma
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma.
Multiple Myeloma
Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.
Multiple Myeloma
Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.
Multiple Myeloma
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Multiple Myeloma
Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies.
Multiple Myeloma
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
Multiple Myeloma
Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
Multiple Myeloma
Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Multiple Myeloma
Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.
Multiple Myeloma
Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
Multiple Myeloma
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
Multiple Myeloma
Effect of 5-aza-2'-deoxycytidine combined with trichostatin A on RPMI-8226 cell proliferation, apoptosis and DLC-1 gene expression.
Multiple Myeloma
Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo.
Multiple Myeloma
Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Multiple Myeloma
Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.
Multiple Myeloma
Efficacy and toxicity of histone deacetylase inhibitors in relapsed/refractory multiple myeloma: Systematic review and meta-analysis of clinical trials.
Multiple Myeloma
Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells.
Multiple Myeloma
Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects.
Multiple Myeloma
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells.
Multiple Myeloma
EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation.
Multiple Myeloma
HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications.
Multiple Myeloma
HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Multiple Myeloma
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.
Multiple Myeloma
Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.
Multiple Myeloma
Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies.
Multiple Myeloma
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
Multiple Myeloma
Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway.
Multiple Myeloma
Histone deacetylase inhibitor LMK-235-mediated HO-1 expression induces apoptosis in multiple myeloma cells via the JNK/AP-1 signaling pathway.
Multiple Myeloma
Histone deacetylase inhibitor NaBut suppresses cell proliferation and induces apoptosis by targeting p21 in multiple myeloma.
Multiple Myeloma
Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma.
Multiple Myeloma
Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor.
Multiple Myeloma
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.
Multiple Myeloma
Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.
Multiple Myeloma
Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy.
Multiple Myeloma
Histone deacetylase inhibitors interrupt HSP90RASGRP1 and HSP90CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.
Multiple Myeloma
Identification and Structure-Activity Relationship of HDAC6 Zinc-Finger Ubiquitin Binding Domain Inhibitors.
Multiple Myeloma
In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Multiple Myeloma
Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma.
Multiple Myeloma
Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors.
Multiple Myeloma
Kinase inhibitors as potential agents in the treatment of multiple myeloma.
Multiple Myeloma
LCL161 interacts synergystically with panobinostat in multiple myeloma cells through non-canonical NF-?B- and caspase-8-dependent mechanisms.
Multiple Myeloma
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Multiple Myeloma
MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4.
Multiple Myeloma
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
Multiple Myeloma
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
Multiple Myeloma
Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).
Multiple Myeloma
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
Multiple Myeloma
Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat.
Multiple Myeloma
Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.
Multiple Myeloma
Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat.
Multiple Myeloma
Panobinostat: A histone deacetylase inhibitor for the treatment of relapsed or refractory multiple myeloma.
Multiple Myeloma
Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma.
Multiple Myeloma
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
Multiple Myeloma
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.
Multiple Myeloma
Physiologically-based pharmacokinetic model predictions of panobinostat (LBH589) as a victim and perpetrator of drug-drug interactions.
Multiple Myeloma
Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.
Multiple Myeloma
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Multiple Myeloma
Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.
Multiple Myeloma
Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
Multiple Myeloma
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
Multiple Myeloma
Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.
Multiple Myeloma
Rational cotargeting of HDAC6 and BET proteins yields synergistic antimyeloma activity.
Multiple Myeloma
Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Multiple Myeloma
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
Multiple Myeloma
Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Multiple Myeloma
Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.
Multiple Myeloma
Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma.
Multiple Myeloma
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies.
Multiple Myeloma
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.
Multiple Myeloma
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS.
Multiple Myeloma
Subchronic Toxicities of HZ1006, a Hydroxamate-Based Histone Deacetylase Inhibitor, in Beagle Dogs and Sprague-Dawley Rats.
Multiple Myeloma
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.
Multiple Myeloma
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Multiple Myeloma
Synthesis and biological evaluation of the natural product komaroviquinone and related compounds aiming at a potential therapeutic lead compound for high-risk multiple myeloma.
Multiple Myeloma
Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling.
Multiple Myeloma
The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
Multiple Myeloma
The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.
Multiple Myeloma
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma.
Multiple Myeloma
The European Medicines Agency Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma.
Multiple Myeloma
The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death.
Multiple Myeloma
The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
Multiple Myeloma
The histone deacetylase inhibitor UCL67022 has potent activity in multiple myeloma and non-Hodgkin lymphoma pre-clinical models.
Multiple Myeloma
The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage.
Multiple Myeloma
The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.
Multiple Myeloma
The novel histone deacetylase inhibitor, AR-42, inhibits gp130/STAT3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.
Multiple Myeloma
The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.
Multiple Myeloma
The oral histone deacetylase inhibitor LBH589 is a potential and promising therapeutic agent in multiple myeloma after at least two lines of chemotherapy including bortezomib or lenalidomide.
Multiple Myeloma
The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.
Multiple Myeloma
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.
Multiple Myeloma
The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.
Multiple Myeloma
The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma.
Multiple Myeloma
The short-term effect of histone deacetylase inhibitors, chidamide and valproic acid, on the NF??B pathway in multiple myeloma cells.
Multiple Myeloma
Therapeutic effects of the novel subtype-selective histone deacetylase inhibitor chidamide on myeloma-associated bone disease.
Multiple Myeloma
Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.
Multiple Myeloma
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
Multiple Myeloma
Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.
Multiple Myeloma
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab.
Multiple Myeloma
[Drug-Resistant Mechanism of Multiple Myeloma and Its Therapy Combined with HDACi -Review].
Multiple Myeloma
[Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma].
Multiple Myeloma
[Inhibitory effect of histone deacetylase inhibitor LBH589 on multiple myeloma MM1R cells in vitro].
Multiple Myeloma
[Inhibitory Effect of Histone Deacetylase Inhibitor SAHA on Proliferation of Mouse Multiple Myeloma Cell Line SP2/0 in vitro and in vivo].
Multiple Myeloma
[Methods and clinical values for minimal residual disease detection in patients with multiple myeloma].
Multiple Myeloma
[Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
Multiple Sclerosis
HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage.
Multiple Sclerosis
Histone deacetylase gene variants predict brain volume changes in multiple sclerosis.
Multiple Sclerosis
Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis.
Multiple Sclerosis
Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis.
Multiple Sclerosis
The epigenetic drug Trichostatin A ameliorates experimental autoimmune encephalomyelitis via T cell tolerance induction and impaired influx of T cells into the spinal cord.
Multiple Sclerosis
The Selective HDAC6 Inhibitor ACY-738 Impacts Memory and Disease Regulation in an Animal Model of Multiple Sclerosis.
Multiple Sclerosis
Tolerogenic dendritic cells generated by in vitro treatment with SAHA are not stable in vivo.
Multiple Sclerosis
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Multiple System Atrophy
Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions.
Multiple System Atrophy
Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.
Multiple System Atrophy
Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration.
Multiple System Atrophy
Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms.
Muscle Cramp
Role of 4-hydroxybutyrate in increased resistance to surgical site infections associated with surgical meshes.
Muscular Atrophy
Diarylcyclopropane hydroxamic acid inhibitors of histone deacetylase 4 designed by combinatorial approach and QM/MM calculations.
Muscular Atrophy
Differential expression of HDAC and HAT genes in atrophying skeletal muscle.
Muscular Atrophy
HDAC1 activates FoxO and is both sufficient and required for skeletal muscle atrophy.
Muscular Atrophy
HDAC4 Knockdown Alleviates Denervation-Induced Muscle Atrophy by Inhibiting Myogenin-Dependent Atrogene Activation.
Muscular Atrophy
HDAC4 preserves skeletal muscle structure following long-term denervation by mediating distinct cellular responses.
Muscular Atrophy
Hepatocyte Growth Factor Regulates the miR-206-HDAC4 Cascade to Control Neurogenic Muscle Atrophy following Surgical Denervation in Mice.
Muscular Atrophy
Histone Deacetylase 2 Suppresses Skeletal Muscle Atrophy and Senescence via NF-?B Signaling Pathway in Cigarette Smoke-Induced Mice with Emphysema.
Muscular Atrophy
Histone deacetylase 4 protects from denervation and skeletal muscle atrophy in a murine model of amyotrophic lateral sclerosis.
Muscular Atrophy
Histone Deacetylase 6 Is a FoxO Transcription Factor-dependent Effector in Skeletal Muscle Atrophy.
Muscular Atrophy
Immobilization induces nuclear accumulation of HDAC4 in rat skeletal muscle.
Muscular Atrophy
Long-term cigarette smoke exposure inhibits histone deacetylase 2 expression and enhances the nuclear factor-?B activation in skeletal muscle of mice.
Muscular Atrophy
MicroRNAs and HDAC4 protein expression in the skeletal muscle of ALS patients.
Muscular Atrophy
MiR-206 Attenuates Denervation-Induced Skeletal Muscle Atrophy in Rats Through Regulation of Satellite Cell Differentiation via TGF-?1, Smad3, and HDAC4 Signaling.
Muscular Atrophy
Skeletal muscle denervation causes skeletal muscle atrophy through a pathway that involves both Gadd45a and HDAC4.
Muscular Atrophy
The histone deacetylase inhibitor butyrate improves metabolism and reduces muscle atrophy during aging.
Muscular Atrophy
The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy.
Muscular Atrophy
Trichostatin A, a histone deacetylase inhibitor, modulates unloaded-induced skeletal muscle atrophy.
Muscular Atrophy
[Effect of electroacupuncture on muscular atrophy and expression of microRNAs and muscle satellite cell proliferation related proteins in denervated gastrocnemius muscle rats].
Muscular Atrophy, Spinal
Applicability of Histone Deacetylase Inhibition for the Treatment of Spinal Muscular Atrophy.
Muscular Atrophy, Spinal
Carboxylic acid derivatives of histone deacetylase inhibitors induce full length SMN2 transcripts: a promising target for spinal muscular atrophy therapeutics.
Muscular Atrophy, Spinal
Combinatorial treatment for spinal muscular atrophy: An Editorial for 'Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells' on doi: 10.1111/jnc.14935.
Muscular Atrophy, Spinal
Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
Muscular Atrophy, Spinal
Histone deacetylase inhibition activity and molecular docking of (e )-resveratrol: its therapeutic potential in spinal muscular atrophy.
Muscular Atrophy, Spinal
Histone deacetylase inhibition suppresses myogenin-dependent atrogene activation in spinal muscular atrophy mice.
Muscular Atrophy, Spinal
Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy.
Muscular Atrophy, Spinal
In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy.
Muscular Atrophy, Spinal
Increasing SMN levels using the histone deacetylase inhibitor SAHA ameliorates defects in skeletal muscle microvasculature in a mouse model of severe spinal muscular atrophy.
Muscular Atrophy, Spinal
LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate.
Muscular Atrophy, Spinal
Small-molecule modulation of HDAC6 activity: The propitious therapeutic strategy to vanquish neurodegenerative disorders.
Muscular Atrophy, Spinal
Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition.
Muscular Atrophy, Spinal
Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition.
Muscular Atrophy, Spinal
The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells.
Muscular Atrophy, Spinal
The Smn-independent beneficial effects of trichostatin A on an intermediate mouse model of spinal muscular atrophy.
Muscular Atrophy, Spinal
Transcript, methylation and molecular docking analyses of the effects of HDAC inhibitors, SAHA and Dacinostat, on SMN2 expression in fibroblasts of SMA patients.
Muscular Atrophy, Spinal
Valproate and bone loss: iTRAQ proteomics show that valproate reduces collagens and osteonectin in SMA cells.
Muscular Diseases
HDAC4 Controls Muscle Homeostasis through Deacetylation of Myosin Heavy Chain, PGC-1?, and Hsc70.
Muscular Diseases
Histone deacetylases 1 and 2 regulate autophagy flux and skeletal muscle homeostasis in mice.
Muscular Dystrophies
Concise Review: Epigenetic Regulation of Myogenesis in Health and Disease.
Muscular Dystrophies
Fam65b is important for formation of the HDAC6-dysferlin protein complex during myogenic cell differentiation.
Muscular Dystrophies
Histone deacetylase inhibitors in the treatment of muscular dystrophies: epigenetic drugs for genetic diseases.
Muscular Dystrophies
Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBP?-regulated atrogin1 expression in cancer cachexia.
Muscular Dystrophies, Limb-Girdle
Fam65b is important for formation of the HDAC6-dysferlin protein complex during myogenic cell differentiation.
Muscular Dystrophy, Duchenne
Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy.
Muscular Dystrophy, Duchenne
HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment.
Muscular Dystrophy, Duchenne
Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy.
Muscular Dystrophy, Duchenne
MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway.
Muscular Dystrophy, Duchenne
Preclinical studies in the mdx mouse model of duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat.
Muscular Dystrophy, Duchenne
Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment.
Muscular Dystrophy, Duchenne
Steroid Responsiveness in Duchenne Muscular Dystrophy - Predictive Value of Epigenetic Regulator Histone Deacetylase 2.
Muscular Dystrophy, Duchenne
Targeting HDAC8 to ameliorate skeletal muscle differentiation in Duchenne muscular dystrophy.
Muscular Dystrophy, Emery-Dreifuss
PCAF Involvement in Lamin A/C-HDAC2 Interplay during the Early Phase of Muscle Differentiation.
Mycosis Fungoides
A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and Sézary syndrome.
Mycosis Fungoides
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma.
Mycosis Fungoides
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Mycosis Fungoides
Romidepsin: evidence for its potential use to manage previously treated cutaneous T cell lymphoma.
Mycosis Fungoides
Treatment of mycosis fungoides and Sezary syndrome with romidepsin: a series of 32 cases of the French Study Group for Cutaneous Lymphoma.
Myelitis
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Myelodysplastic Syndromes
A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
Myelodysplastic Syndromes
Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
Myelodysplastic Syndromes
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Myelodysplastic Syndromes
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Myelodysplastic Syndromes
Epigenetic modifiers: basic understanding and clinical development.
Myelodysplastic Syndromes
Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling.
Myelodysplastic Syndromes
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Myelodysplastic Syndromes
Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Myelodysplastic Syndromes
Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?
Myelodysplastic Syndromes
Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Myelodysplastic Syndromes
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Myelodysplastic Syndromes
Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
Myelodysplastic Syndromes
Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?
Myelodysplastic Syndromes
Myelodysplastic syndrome associated with chronic valproic acid therapy: A case report and review of the literature.
Myelodysplastic Syndromes
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Myelodysplastic Syndromes
Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).
Myelodysplastic Syndromes
Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome.
Myelodysplastic Syndromes
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
Myelodysplastic Syndromes
Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Myelodysplastic Syndromes
Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.
Myelodysplastic Syndromes
[Sodium valproate synergizes adriamycin to inhibit proliferation and induce apoptosis in myelodysplastic syndrome cell line]
Myocardial Infarction
Atherosclerotic Aortic Calcification-Associated Polymorphism in HDAC9 and Associations with Mortality, Cardiovascular Disease, and Kidney Disease.
Myocardial Infarction
CaMKII exacerbates heart failure progression by activating class I HDACs.
Myocardial Infarction
Exercise improves cardiac function and glucose metabolism in mice with experimental myocardial infarction through inhibiting HDAC4 and upregulating GLUT1 expression.
Myocardial Infarction
Givinostat reduces adverse cardiac remodeling through regulating fibroblasts activation.
Myocardial Infarction
HDAC9 exacerbates myocardial infarction via inactivating Nrf2 pathways.
Myocardial Infarction
Histone deacetylase inhibitor SAHA treatment prevents the development of heart failure after myocardial infarction via an induction of heat-shock proteins in rats.
Myocardial Infarction
LncRNA TUG1 mediates ischemic myocardial injury by targeting miR-132-3p/HDAC3 axis.
Myocardial Infarction
Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor.
Myocardial Infarction
Specific inhibition of HDAC4 in cardiac progenitor cells enhances myocardial repairs.
Myocardial Infarction
Transgenic overexpression of active HDAC4 in the heart attenuates cardiac function and exacerbates remodeling in infarcted myocardium.
Myocardial Infarction
Transplantation of Epigenetically Modified Adult Cardiac c-Kit+ Cells Retards Remodeling and Improves Cardiac Function in Ischemic Heart Failure Model.
Myocardial Infarction
[Electroacupuncture for myocardial ischemia injury in rats via AMPK-HDAC5-HIF-1? signaling].
Myocardial Ischemia
Myocyte-specific overexpressing HDAC4 promotes myocardial ischemia/reperfusion injury.
Myocardial Ischemia
The histone deacetylase inhibitor, sodium butyrate, exhibits neuroprotective effects for ischemic stroke in middle-aged female rats.
Myocardial Ischemia
[Electroacupuncture for myocardial ischemia injury in rats via AMPK-HDAC5-HIF-1? signaling].
Myocarditis
Histone deacetylase inhibitors suppress coxsackievirus B3 growth in vitro and myocarditis induced in mice.
Myocarditis
Inhibition of Histone Deacetylase Activity Aggravates Coxsackievirus B3-Induced Myocarditis by Promoting Viral Replication and Myocardial Apoptosis.
Nasal Polyps
Effects of histone deacetylase inhibitor on extracellular matrix production in human nasal polyp organ cultures.
Nasal Polyps
Epigenetic regulation of myofibroblast differentiation and extracellular matrix production in nasal polyp-derived fibroblasts.
Nasal Polyps
The role of transcriptional factor p63 in regulation of epithelial barrier and ciliogenesis of human nasal epithelial cells.
Nasopharyngeal Carcinoma
Autophagy-Dependent Reactivation of Epstein-Barr Virus Lytic Cycle and Combinatorial Effects of Autophagy-Dependent and Independent Lytic Inducers in Nasopharyngeal Carcinoma.
Nasopharyngeal Carcinoma
Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Nasopharyngeal Carcinoma
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Nasopharyngeal Carcinoma
Critical role of p53 in histone deacetylase inhibitor-induced Epstein-Barr virus Zta expression.
Nasopharyngeal Carcinoma
Dissection of Anti-tumor Activity of Histone Deacetylase Inhibitor SAHA in Nasopharyngeal Carcinoma Cells via Quantitative Phosphoproteomics.
Nasopharyngeal Carcinoma
Essential role of PKC{delta} in histone deacetylase inhibitor-induced Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells.
Nasopharyngeal Carcinoma
HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target.
Nasopharyngeal Carcinoma
HDAC7 promotes the oncogenicity of nasopharyngeal carcinoma cells by miR-4465-EphA2 signaling axis.
Nasopharyngeal Carcinoma
Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability.
Nasopharyngeal Neoplasms
LncRNA NEAT1/miR-129/Bcl-2 signaling axis contributes to HDAC inhibitor tolerance in nasopharyngeal cancer.
Neonatal Sepsis
Histone deacetylase 6 regulates endothelial MyD88-dependent canonical TLR signaling, lung inflammation, and alveolar remodeling in the developing lung.
Neoplasm Metastasis
15-Lipoxygenase-1 expression suppresses the invasive properties of colorectal carcinoma cell lines HCT-116 and HT-29.
Neoplasm Metastasis
A correlation analysis between HDAC1 over-expression and clinical features of laryngeal squamous cell carcinoma.
Neoplasm Metastasis
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Neoplasm Metastasis
Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer.
Neoplasm Metastasis
Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients.
Neoplasm Metastasis
Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis.
Neoplasm Metastasis
Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer.
Neoplasm Metastasis
An N-terminal truncated carboxypeptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers.
Neoplasm Metastasis
Anticancer Effects of Valproic Acid via Regulation of Epigenetic Mechanisms in Non-small-cell Lung Cancer A549 Cell Line.
Neoplasm Metastasis
AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.
Neoplasm Metastasis
BAY 87-2243 sensitizes hepatocellular carcinoma Hep3B cells to histone deacetylase inhibitors treatment via GSK-3? activation.
Neoplasm Metastasis
Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells.
Neoplasm Metastasis
Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription.
Neoplasm Metastasis
Breast cancer metastasis suppressor 1 functions as a corepressor by enhancing histone deacetylase 1-mediated deacetylation of RelA/p65 and promoting apoptosis.
Neoplasm Metastasis
Butyrate suppresses motility of colorectal cancer cells via deactivating Akt/ERK signaling in histone deacetylase dependent manner.
Neoplasm Metastasis
CBX4 Suppresses Metastasis via Recruitment of HDAC3 to the Runx2 Promoter in Colorectal Carcinoma.
Neoplasm Metastasis
Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells.
Neoplasm Metastasis
Chfr is linked to tumour metastasis through the downregulation of HDAC1.
Neoplasm Metastasis
Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis.
Neoplasm Metastasis
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
Neoplasm Metastasis
Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma.
Neoplasm Metastasis
Comprehensive genomic analyses of a metastatic colon cancer to the lung by whole exome sequencing and gene expression analysis.
Neoplasm Metastasis
Correction: Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer.
Neoplasm Metastasis
Crosstalk between ATF4 and MTA1/HDAC1 promotes osteosarcoma progression.
Neoplasm Metastasis
Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Neoplasm Metastasis
DDX23-Linc00630-HDAC1 axis activates the Notch pathway to promote metastasis.
Neoplasm Metastasis
Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer.
Neoplasm Metastasis
Decreased expression and hypomethylation of HDAC9 lead to poor prognosis and inhibit immune cell infiltration in clear cell renal cell carcinoma.
Neoplasm Metastasis
Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma.
Neoplasm Metastasis
Design and optimization of novel hydroxamate-based histone deacetylase inhibitors of Bis-substituted aromatic amides bearing potent activities against tumor growth and metastasis.
Neoplasm Metastasis
Diallyl trisulfides, a natural histone deacetylase inhibitor, attenuate HIF-1? synthesis, and decreases breast cancer metastasis.
Neoplasm Metastasis
Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Neoplasm Metastasis
Down-Regulated Expression of HSP70 in Correlation with Clinicopathology of Cholangiocarcinoma.
Neoplasm Metastasis
Down-regulation of matrix metalloproteinase-7 inhibits metastasis of human anaplastic thyroid cancer cell line.
Neoplasm Metastasis
Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.
Neoplasm Metastasis
Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis.
Neoplasm Metastasis
Effect of the histone deacetylase inhibitor SNDX-275 on fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.
Neoplasm Metastasis
EPIGENETIC CHANGES IN MALIGNANT UVEAL MELANOMA AND POSSIBILITIES OF THEIR THERAPEUTIC TARGETING.
Neoplasm Metastasis
Epigenetic suppression of E-cadherin expression by Snail2 during the metastasis of colorectal cancer.
Neoplasm Metastasis
Epithelial-Mesenchymal Transition: A Special Focus on Phthalates and Bisphenol A.
Neoplasm Metastasis
Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.
Neoplasm Metastasis
Expression of HDAC1 and RBBP4 correlate with clinicopathologic characteristics and prognosis in breast cancer.
Neoplasm Metastasis
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Neoplasm Metastasis
Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications.
Neoplasm Metastasis
Expression profiles of histone modification genes in gastric cancer progression.
Neoplasm Metastasis
Gd-Metallofullerenol Nanomaterial Suppresses Pancreatic Cancer Metastasis by Inhibiting the Interaction of Histone Deacetylase 1 and Metastasis-Associated Protein 1.
Neoplasm Metastasis
Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis.
Neoplasm Metastasis
Gene signature associated with benign neurofibroma transformation to malignant peripheral nerve sheath tumors.
Neoplasm Metastasis
Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation.
Neoplasm Metastasis
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma.
Neoplasm Metastasis
HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
Neoplasm Metastasis
HDAC1 promoted migration and invasion binding with TCF12 by promoting EMT progress in gallbladder cancer.
Neoplasm Metastasis
HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer.
Neoplasm Metastasis
HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
Neoplasm Metastasis
HDAC2 promotes the EMT of colorectal cancer cells and via the modular scaffold function of ENSG00000274093.1.
Neoplasm Metastasis
HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin.
Neoplasm Metastasis
HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells.
Neoplasm Metastasis
HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target.
Neoplasm Metastasis
HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin.
Neoplasm Metastasis
HDAC6 deacetylase activity is required for hypoxia-induced invadopodia formation and cell invasion.
Neoplasm Metastasis
HDAC6, modulated by miR-206, promotes endometrial cancer progression through the PTEN/AKT/mTOR pathway.
Neoplasm Metastasis
HDAC6: Physiological function and its selective inhibitors for cancer treatment.
Neoplasm Metastasis
HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration.
Neoplasm Metastasis
HIF-1? and HDAC1 mediated regulation of FAM99A-miR92a signaling contributes to hypoxia induced HCC metastasis.
Neoplasm Metastasis
Histone Deacetylase (HDAC) 10 Suppresses Cervical Cancer Metastasis through Inhibition of Matrix Metalloproteinase (MMP) 2 and 9 Expression.
Neoplasm Metastasis
Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes.
Neoplasm Metastasis
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.
Neoplasm Metastasis
Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Neoplasm Metastasis
Histone deacetylase 5 promotes the migration and invasion of hepatocellular carcinoma via increasing the transcription of hypoxia-inducible factor-1? under hypoxia condition.
Neoplasm Metastasis
Histone deacetylase 6 activity is critical for the metastasis of Burkitt's lymphoma cells.
Neoplasm Metastasis
Histone deacetylase 6 structure and molecular basis of catalysis and inhibition.
Neoplasm Metastasis
Histone deacetylase 7 inhibits plakoglobin expression to promote lung cancer cell growth and metastasis.
Neoplasm Metastasis
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Neoplasm Metastasis
Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells.
Neoplasm Metastasis
Histone deacetylase-1 as a prognostic factor and mediator of gastric cancer progression by enhancing glycolysis.
Neoplasm Metastasis
Histone deacetylase-3mediates positive feedback relationship between anaphylaxis and tumor metastasis.
Neoplasm Metastasis
Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane.
Neoplasm Metastasis
Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis.
Neoplasm Metastasis
Identification of candidate biomarkers that involved in the epigenetic transcriptional regulation for detection gastric cancer by iTRAQ based quantitative proteomic analysis.
Neoplasm Metastasis
Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.
Neoplasm Metastasis
Inactivating mutation in histone deacetylase 3 stabilizes its active conformation.
Neoplasm Metastasis
Increased expression of histone deacetylase 2 is found in human gastric cancer.
Neoplasm Metastasis
Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.
Neoplasm Metastasis
Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells.
Neoplasm Metastasis
Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But.
Neoplasm Metastasis
Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer.
Neoplasm Metastasis
KLF5 inhibits STAT3 activity and tumor metastasis in prostate cancer by suppressing IGF1 transcription cooperatively with HDAC1.
Neoplasm Metastasis
Knockdown of HDAC1 expression suppresses invasion and induces apoptosis in glioma cells.
Neoplasm Metastasis
Lentivirus-mediated Knockdown of HDAC1 Uncovers Its Role in Esophageal Cancer Metastasis and Chemosensitivity.
Neoplasm Metastasis
Long noncoding RNA SBF2-AS1 promotes colorectal cancer proliferation and invasion by inhibiting miR-619-5p activity and facilitating HDAC3 expression.
Neoplasm Metastasis
MAPK phosphatase-1 contributes to trichostatin A inhibition of cyclooxygenase-2 expression in human umbilical vascular endothelial cells exposed to lipopolysaccharide.
Neoplasm Metastasis
Matairesinol, an active constituent of HC9 polyherbal formulation, exhibits HDAC8 inhibitory and anticancer activity.
Neoplasm Metastasis
MCM5 Aggravates the HDAC1-Mediated Malignant Progression of Lung Cancer.
Neoplasm Metastasis
MDA-9/Syntenin-Slug transcriptional complex promote epithelial-mesenchymal transition and invasion/metastasis in lung adenocarcinoma.
Neoplasm Metastasis
Metastasis-associated Protein 1 Drives Tumor Cell Migration and Invasion through Transcriptional Repression of RING Finger Protein 144A.
Neoplasm Metastasis
Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1.
Neoplasm Metastasis
Metastatic prostate cancer-associated P62 inhibits autophagy flux and promotes epithelial to mesenchymal transition by sustaining the level of HDAC6.
Neoplasm Metastasis
MicroRNA-383-5p inhibits the progression of gastric carcinoma via targeting HDAC9 expression.
Neoplasm Metastasis
miR-1236 regulates hypoxia-induced epithelial-mesenchymal transition and cell migration/invasion through repressing SENP1 and HDAC3.
Neoplasm Metastasis
miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6.
Neoplasm Metastasis
MiR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer.
Neoplasm Metastasis
MiR-601 inhibits the proliferation and metastasis of esophageal squamous cell carcinoma (ESCC) by targeting HDAC6.
Neoplasm Metastasis
MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.
Neoplasm Metastasis
Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial-mesenchymal transition in cancer cells.
Neoplasm Metastasis
NEDD9 Regulates Actin Dynamics through Cortactin Deacetylation in an AURKA/HDAC6-dependent Manner.
Neoplasm Metastasis
NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2.
Neoplasm Metastasis
Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.
Neoplasm Metastasis
Nuclear HDAC6 inhibits invasion by suppressing NF-?B/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer.
Neoplasm Metastasis
OIP5-AS1 modulates epigenetic regulator HDAC7 to enhance non-small cell lung cancer metastasis via miR-140-5p.
Neoplasm Metastasis
Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance.
Neoplasm Metastasis
Overexpression of HDAC6 suppresses tumor cell proliferation and metastasis by inhibition of the canonical Wnt/?-catenin signaling pathway in hepatocellular carcinoma.
Neoplasm Metastasis
Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females.
Neoplasm Metastasis
Overexpression of Histone Deacetylase 2 Predicts Unfavorable Prognosis in Human Gallbladder Carcinoma.
Neoplasm Metastasis
Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells.
Neoplasm Metastasis
PFN2a Suppresses C2C12 Myogenic Development by Inhibiting Proliferation and Promoting Apoptosis via the p53 Pathway.
Neoplasm Metastasis
Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6.
Neoplasm Metastasis
Phthalates Stimulate the Epithelial to Mesenchymal TransitionThrough an HDAC6-Dependent Mechanism in Human BreastEpithelial Stem Cells.
Neoplasm Metastasis
PKC? phosphorylates MIIP and promotes colorectal cancer metastasis through inhibition of RelA deacetylation.
Neoplasm Metastasis
Polymerized vorinostat mediated photodynamic therapy using lysosomal spatiotemporal synchronized drug release complex.
Neoplasm Metastasis
Potential therapeutic effect of epigenetic therapy on treatment-induced neuroendocrine prostate cancer.
Neoplasm Metastasis
Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Neoplasm Metastasis
Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis.
Neoplasm Metastasis
Radiosynthesis and preliminary evaluation of an 18 F-labeled tubastatin A analog for PET imaging of histone deacetylase 6.
Neoplasm Metastasis
Repression of the Long Noncoding RNA-LET by Histone Deacetylase 3 Contributes to Hypoxia-Mediated Metastasis.
Neoplasm Metastasis
RNF168 promotes RHOC degradation by ubiquitination to restrain gastric cancer progression via decreasing HDAC1 expression.
Neoplasm Metastasis
Role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer.
Neoplasm Metastasis
Runx3 Induces a Cell Shape Change and Suppresses Migration and Metastasis of Melanoma Cells by Altering a Transcriptional Profile.
Neoplasm Metastasis
Selective Inhibition of HDAC1 by Macrocyclic Polypeptide for the Treatment of Glioblastoma: A Binding Mechanistic Analysis Based on Molecular Dynamics.
Neoplasm Metastasis
SETD6 controls the expression of estrogen-responsive genes and proliferation of breast carcinoma cells.
Neoplasm Metastasis
Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Neoplasm Metastasis
Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
Neoplasm Metastasis
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
Neoplasm Metastasis
Targeting BMI-1-mediated epithelial-mesenchymal transition to inhibit colorectal cancer liver metastasis.
Neoplasm Metastasis
Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.
Neoplasm Metastasis
TGF-?1 Reduces miR-29a Expression to Promote Tumorigenicity and Metastasis of Cholangiocarcinoma by Targeting HDAC4.
Neoplasm Metastasis
The aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl induces distinct patterns of gene expression between hepatoma and glioma cells: chromatin remodeling as a mechanism for selective effects.
Neoplasm Metastasis
The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.
Neoplasm Metastasis
The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities.
Neoplasm Metastasis
The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
Neoplasm Metastasis
The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis.
Neoplasm Metastasis
The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
Neoplasm Metastasis
The histone deacetylase inhibitor PCI-24781 impairs calcium influx and inhibits proliferation and metastasis in breast cancer.
Neoplasm Metastasis
The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases.
Neoplasm Metastasis
The inhibition of microRNA-326 by SP1/HDAC1 contributes to proliferation and metastasis of osteosarcoma through promoting SMO expression.
Neoplasm Metastasis
The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity.
Neoplasm Metastasis
The Significance of MicroRNA-449a and Its Potential Target HDAC1 in Patients With Colorectal Cancer.
Neoplasm Metastasis
Trichostatin A alleviates the process of breast carcinoma by downregulating LPAR5.
Neoplasm Metastasis
Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression.
Neoplasm Metastasis
Upregulated Histone Deacetylase 6 Associates with Malignant Progression of Melanoma and Predicts the Prognosis of Patients.
Neoplasm Metastasis
Upregulation of AKAP12 with HDAC3 depletion suppresses the progression and migration of colorectal cancer.
Neoplasm Metastasis
v-Src-mediated down-regulation of SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex.
Neoplasm Metastasis
Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung.
Neoplasm Metastasis
Vitamin K3 chloro derivative (VKT-2) inhibits HDAC6, activates autophagy and apoptosis, and inhibits aggresome formation in hepatocellular carcinoma cells.
Neoplasm Metastasis
Yixin-Fumai granules improve sick sinus syndrome in aging mice through Nrf-2/HO-1 pathway: A new target for sick sinus syndrome.
Neoplasm Metastasis
[Overexpression of histone deacetylase 11 suppresses basal-like breast cancer cell invasion and metastasis].
Neoplasm Micrometastasis
The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases.
Neoplasms
1,3,4-oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
Neoplasms
1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents.
Neoplasms
15-LOX-1 transcription suppression through the NuRD complex in colon cancer cells.
Neoplasms
2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: Design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors.
Neoplasms
2-aroylindoles and 2-aroylbenzofurans with N-hydroxyacrylamide substructures as a novel series of rationally designed histone deacetylase inhibitors.
Neoplasms
3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.
Neoplasms
3-Deazaneplanocin A and neplanocin A analogues and their effects on apoptotic cell death.
Neoplasms
3D-QSAR (CoMFA, CoMSIA) and Molecular Docking Studies on Histone Deacetylase 1 Selective Inhibitors.
Neoplasms
4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors.
Neoplasms
4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway.
Neoplasms
4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90? chaperone activity against prostate cancer.
Neoplasms
4sc-202 and Ink-128 cooperate to reverse the epithelial to mesenchymal transition in OSCC.
Neoplasms
A Bioluminescent Probe for Simultaneously Imaging Esterase and Histone Deacetylase Activity in a Tumor.
Neoplasms
A C-terminus-dependent conformational change is required for HDAC3 activation by nuclear receptor corepressors.
Neoplasms
A concern regarding the current confusion with the human homolog of mouse Np95, ICBP90/UHRF1.
Neoplasms
A correlation analysis between HDAC1 over-expression and clinical features of laryngeal squamous cell carcinoma.
Neoplasms
A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer.
Neoplasms
A direct intersection between p53 and transforming growth factor beta pathways targets chromatin modification and transcription repression of the alpha-fetoprotein gene.
Neoplasms
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance.
Neoplasms
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer.
Neoplasms
A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner.
Neoplasms
A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells.
Neoplasms
A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer.
Neoplasms
A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies.
Neoplasms
A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Neoplasms
A library of aminoglycoside-derived lipopolymer nanoparticles for delivery of small molecules and nucleic acids.
Neoplasms
A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
Neoplasms
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.
Neoplasms
A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Suppresses Cell Migration and Invasion in Monomorphic Malignant Human Glioma Cells by Inhibiting FAK/STAT3 Signaling.
Neoplasms
A monoclonal antibody specific for prophase phosphorylation of histone deacetylase 1: a readout for early mitotic cells.
Neoplasms
A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells.
Neoplasms
A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1.
Neoplasms
A New Histone Deacetylase Inhibitor, MHY4381, Induces Apoptosis via Generation of Reactive Oxygen Species in Human Prostate Cancer Cells.
Neoplasms
A new method of comparing 2D-PAGE maps based on the computation of Zernike moments and multivariate statistical tools.
Neoplasms
A New Molecular Mechanism Underlying the Antitumor Effect of DNA Methylation Inhibitors via an Antiviral Immune Response.
Neoplasms
A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma.
Neoplasms
A new SIRT1 inhibitor, MHY2245, induces autophagy and inhibits energy metabolism via PKM2/mTOR pathway in human ovarian cancer cells.
Neoplasms
A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity.
Neoplasms
A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKC? and E-cadherin.
Neoplasms
A novel combination of oridonin and valproic acid in enhancement of apoptosis induction of HL-60 leukemia cells.
Neoplasms
A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma.
Neoplasms
A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma.
Neoplasms
A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cells
Neoplasms
A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.
Neoplasms
A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer.
Neoplasms
A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Neoplasms
A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells.
Neoplasms
A novel histone deacetylase inhibitor Chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes.
Neoplasms
A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
Neoplasms
A novel histone deacetylase inhibitor LT-548-133-1 induces apoptosis by inhibiting HDAC and interfering with microtubule assembly in MCF-7 cells.
Neoplasms
A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
Neoplasms
A novel hydroxysuberamide derivative potentiates MG132-mediated anticancer activity against human hormone refractory prostate cancers--the role of histone deacetylase and endoplasmic reticulum stress.
Neoplasms
A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells.
Neoplasms
A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
Neoplasms
A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Neoplasms
A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth.
Neoplasms
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
Neoplasms
A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Neoplasms
A phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.
Neoplasms
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
Neoplasms
A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.
Neoplasms
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Neoplasms
A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.
Neoplasms
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
Neoplasms
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas.
Neoplasms
A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Neoplasms
A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.
Neoplasms
A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.
Neoplasms
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
Neoplasms
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
Neoplasms
A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.
Neoplasms
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Neoplasms
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
Neoplasms
A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
Neoplasms
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
Neoplasms
A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.
Neoplasms
A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.
Neoplasms
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational study.
Neoplasms
A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors.
Neoplasms
A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
Neoplasms
A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors.
Neoplasms
A Photoactivatable Platinum(IV) Complex Targeting Genomic DNA and Histone Deacetylases.
Neoplasms
A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma.
Neoplasms
A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status.
Neoplasms
A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy.
Neoplasms
A Potential Role for Epigenetic Modulatory Drugs in the Enhancement of Cancer/Germ-Line Antigen Vaccine Efficacy.
Neoplasms
A potentiated cooperation of carbonic anhydrase IX and histone deacetylase inhibitors against cancer.
Neoplasms
A Prognostic Model for Brain Glioma Patients Based on 9 Signature Glycolytic Genes.
Neoplasms
A quantitative high-throughput screen identifies potential epigenetic modulators of gene expression.
Neoplasms
A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Neoplasms
A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.
Neoplasms
A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.
Neoplasms
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
Neoplasms
A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma.
Neoplasms
A Sensitive Triple Quadrupole Liquid Chromatography Mass Spectrometric Method for the Estimation of Valproic Acid in K2EDTA Human Plasma using Furosemide as the Internal Standard.
Neoplasms
A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment.
Neoplasms
A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.
Neoplasms
A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities.
Neoplasms
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
Neoplasms
A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis.
Neoplasms
A Thoroughly Validated Virtual Screening Strategy for Discovery of Novel HDAC3 Inhibitors.
Neoplasms
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition.
Neoplasms
A valproic acid-modified platinum diimine complex as potential photosensitizer for photodynamic therapy.
Neoplasms
A248, a novel synthetic HDAC inhibitor, induces apoptosis through the inhibition of specificity protein 1 and its downstream proteins in human prostate cancer cells.
Neoplasms
A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells.
Neoplasms
Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer.
Neoplasms
Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients.
Neoplasms
Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins.
Neoplasms
Aberrant SIRT6 expression contributes to melanoma growth: Role of the autophagy paradox and IGF-AKT signaling.
Neoplasms
ABIN1 inhibits HDAC1 ubiquitination and protects it from both proteasome- and lysozyme-dependent degradation.
Neoplasms
Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation.
Neoplasms
ABT737 enhances ovarian cancer cells sensitivity to cisplatin through regulation of mitochondrial fission via Sirt3 activation.
Neoplasms
Acetylated Sp1 inhibits PTEN expression through binding to PTEN core promoter and recruitment of HDAC1 and promotes cancer cell migration and invasion.
Neoplasms
Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors.
Neoplasms
Acetylation of FoxO1 activates Bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment.
Neoplasms
Acetylation of PML is involved in histone deacetylase inhibitor-mediated apoptosis.
Neoplasms
Acetylation-dependent oncogenic activity of metastasis-associated protein 1 co-regulator.
Neoplasms
Acetylation-dependent regulation of TPD52 isoform 1 modulates chaperone-mediated autophagy in prostate cancer.
Neoplasms
Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class I HDAC Enzymes and Cancer Cell Proliferation.
Neoplasms
Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells.
Neoplasms
Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat.
Neoplasms
Activating transcription factor 3 interferes with p21 activation in histone deacetylase inhibitor-induced growth inhibition of epidermoid carcinoma cells.
Neoplasms
Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination.
Neoplasms
Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Neoplasms
Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors.
Neoplasms
Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C.
Neoplasms
Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3.
Neoplasms
Activation of the intrinsic apoptosis pathway contributes to the induction of apoptosis in hepatocellular carcinoma cells by valproic acid.
Neoplasms
Activation of tissue transglutaminase transcription by histone deacetylase inhibition as a therapeutic approach for Myc oncogenesis.
Neoplasms
Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
Neoplasms
ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer.
Neoplasms
ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma.
Neoplasms
ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation.
Neoplasms
Acyclic retinoid synergises with valproic acid to inhibit growth in human hepatocellular carcinoma cells.
Neoplasms
Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.
Neoplasms
Adoptive transfer of immature myeloid cells lacking NF-?B p50 (p50-IMC) impedes the growth of MHC-matched high-risk neuroblastoma.
Neoplasms
Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.
Neoplasms
Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
Neoplasms
Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors.
Neoplasms
Alkylating agent methyl methanesulfonate (MMS) induces a wave of global protein hyperacetylation: implications in cancer cell death.
Neoplasms
Allele-specific imbalance mapping identifies HDAC9 as a candidate gene for cutaneous squamous cell carcinoma.
Neoplasms
Allelic variation and differential expression of the mSIN3A histone deacetylase complex gene Arid4b promote mammary tumor growth and metastasis.
Neoplasms
Allyl mercaptan, a garlic-derived organosulfur compound, inhibits histone deacetylase and enhances Sp3 binding on the P21WAF1 promoter.
Neoplasms
Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells.
Neoplasms
Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.
Neoplasms
Alterations in expression levels of genes in p53-related pathways determined using RNA-Seq analysis in patients with breast cancer following CIK therapy.
Neoplasms
Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer.
Neoplasms
Alternative Modes of Binding of Recombinant Human Histone Deacetylase 8 to Colloidal Gold Nanoparticles.
Neoplasms
Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation.
Neoplasms
Aminoglycoside-induced histone deacetylation and hair cell death in the mouse cochlea.
Neoplasms
AMPK-HDAC5 pathway facilitates nuclear accumulation of HIF-1? and functional activation of HIF-1 by deacetylating Hsp70 in the cytosol.
Neoplasms
An anticonvulsive drug, valproic acid (valproate), has effects on the biosynthesis of fatty acids and polyketides in microorganisms.
Neoplasms
An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells.
Neoplasms
An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis.
Neoplasms
An Endogenous Reactive Oxygen Species (ROS)-Activated Histone Deacetylase Inhibitor Prodrug for Cancer Chemotherapy.
Neoplasms
An epithelial marker promoter induction screen identifies histone deacetylase inhibitors to restore epithelial differentiation and abolishes anchorage independence growth in cancers.
Neoplasms
An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA.
Neoplasms
An HDAC6 Inhibitor Confers Protection and Selectively Inhibits B-Cell Infiltration in DSS-Induced Colitis in Mice.
Neoplasms
An HDAC8-selective fluorescent probe for imaging in living tumor cell lines and tissue slices.
Neoplasms
An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression.
Neoplasms
An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis.
Neoplasms
An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1.
Neoplasms
An intrinsically disordered region of methyl-CpG binding domain protein 2 (MBD2) recruits the histone deacetylase core of the NuRD complex.
Neoplasms
An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Neoplasms
An unbiased approach to identify endogenous substrates of "histone" deacetylase 8.
Neoplasms
An unexpected role for p53 in regulating cancer cell-intrinsic PD-1 by acetylation.
Neoplasms
Analysis of class I and II histone deacetylase gene expression in human leukemia.
Neoplasms
Analysis of Epigenetic Regulation of Hypoxia-Induced Epithelial-Mesenchymal Transition in Cancer Cells by Quantitative Chromatin Immunoprecipitation of Histone Deacetylase 3 (HDAC3).
Neoplasms
Analysis of gene expression profiles of gastric normal and cancer tissues by SAGE.
Neoplasms
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.
Neoplasms
Analysis of the role of DAMTC in lung adenocarcinoma cells based on the DNA microarrays.
Neoplasms
Andrographolide reduced VEGFA expression in hepatoma cancer cells by inactivating HIF-1?: The involvement of JNK and MTA1/HDCA.
Neoplasms
Antagonistic effects of sequential administration of BL1521, a histone deacetylase inhibitor, and gemcitabine to neuroblastoma cells.
Neoplasms
Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor.
Neoplasms
Anti-Cancer Effect of 3-(4-dimethylamino phenyl)-N-hydroxy-2-propenamide in MCF-7 Human Breast Cancer.
Neoplasms
Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways.
Neoplasms
Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
Neoplasms
Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents.
Neoplasms
Anti-Melanoma Effects of Vorinostat in Combination with Polyphenolic Antioxidant (-)-Epigallocatechin-3-Gallate (EGCG).
Neoplasms
Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
Neoplasms
Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids.
Neoplasms
Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4.
Neoplasms
Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T- and natural killer- cell lymphoma.
Neoplasms
Anticancer Activity of MPT0E028, a Novel Potent Histone Deacetylase Inhibitor, in Human Colorectal Cancer HCT116 Cells In Vitro and In Vivo.
Neoplasms
Anticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells.
Neoplasms
Anticancer activity of topical ointments with histone deacetylase inhibitor, trichostatin A.
Neoplasms
Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma.
Neoplasms
Anticancer Effect of Rh2, a Histone Deacetylase Inhibitor, in HepG2 Cells and HepG2 Cell-Derived Xenograft Tumors Occurs via the Inhibition of HDACs and Activation of the MAPK Signaling Pathway.
Neoplasms
Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
Neoplasms
Anticancer Effects of Valproic Acid via Regulation of Epigenetic Mechanisms in Non-small-cell Lung Cancer A549 Cell Line.
Neoplasms
Anticancer Peptidylarginine Deiminase (PAD) Inhibitors Regulate the Autophagy Flux and the Mammalian Target of Rapamycin Complex 1 Activity.
Neoplasms
Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue?
Neoplasms
Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review.
Neoplasms
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.
Neoplasms
Anticolon cancer activity of largazole, a marine-derived tunable histone deacetylase inhibitor.
Neoplasms
Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy.
Neoplasms
Antiglioma effects of combined use of a baculovirual vector expressing wild-type p53 and sodium butyrate.
Neoplasms
Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1.
Neoplasms
Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines.
Neoplasms
Antiproliferative and phenotype-transforming antitumor agents derived from cysteine.
Neoplasms
Antiproliferative effect of trichostatin A and HC-toxin in T47D human breast cancer cells.
Neoplasms
Antitumor activities of valproic acid on Epstein-Barr virus-associated T and natural killer lymphoma cells.
Neoplasms
Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor.
Neoplasms
Antitumor activity of histone deacetylase inhibitor trichostatin A in osteosarcoma cells.
Neoplasms
Antitumor activity of suberoylanilide hydroxamic acid against human oral squamous cell carcinoma cell lines in vitro and in vivo.
Neoplasms
Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.
Neoplasms
Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer.
Neoplasms
Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells.
Neoplasms
Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer.
Neoplasms
Antitumor effect of liposomal histone deacetylase inhibitor-lipid conjugates in vitro.
Neoplasms
Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma.
Neoplasms
Antitumor histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy.
Neoplasms
Antitumor platinum(IV) derivatives of carboplatin and the histone deacetylase inhibitor 4-phenylbutyric acid.
Neoplasms
Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.
Neoplasms
Apicidin induces endoplasmic reticulum stress- and mitochondrial dysfunction-associated apoptosis via phospholipase C?1- and Ca(2+)-dependent pathway in mouse Neuro-2a neuroblastoma cells.
Neoplasms
Apicidin Inhibited Proliferation and Invasion and Induced Apoptosis via Mitochondrial Pathway in Non-small Cell Lung Cancer GLC-82 Cells.
Neoplasms
Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
Neoplasms
Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin.
Neoplasms
Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells.
Neoplasms
Apicidin-resistant HA22T hepatocellular carcinoma cells massively promote pro-survival capability via IGF-IR/PI3K/Akt signaling pathway activation.
Neoplasms
Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70-Bax interaction in prostate cancer.
Neoplasms
APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy.
Neoplasms
Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.
Neoplasms
Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity.
Neoplasms
Apoptotic Effects of N-(2-hydroxyphenyl)-2-propylpentanamide on U87-MG and U-2 OS Cells and Antiangiogenic Properties.
Neoplasms
Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
Neoplasms
Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer.
Neoplasms
Application of machine learning to large in-vitro databases to identify cancer cell characteristics: telomerase reverse transcriptase (TERT) expression.
Neoplasms
Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy.
Neoplasms
Applying the chicken embryo chorioallantoic membrane assay to study treatment approaches in urothelial carcinoma.
Neoplasms
Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
Neoplasms
Array-based approaches for the identification of epigenetic silenced tumor suppressor genes.
Neoplasms
Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6.
Neoplasms
Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Neoplasms
Aspirin Inhibits Natural Killer/T-Cell Lymphoma by Modulation of VEGF Expression and Mitochondrial Function.
Neoplasms
Assessment of female and male fertility in Sprague-Dawley rats administered vorinostat, a histone deacetylase inhibitor.
Neoplasms
Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
Neoplasms
Assessment of Synergistic Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Sarcoma.
Neoplasms
Association of HDAC8 Expression with Pathological Findings in Triple Negative and Non-Triple Negative Breast Cancer: Implications for Diagnosis.
Neoplasms
Associations between cruciferous vegetable intake and selected biomarkers among women scheduled for breast biopsies.
Neoplasms
Astrocytes are HIV reservoirs in the brain: A cell type with poor HIV infectivity and replication but efficient cell-to-cell viral transfer.
Neoplasms
ATF3 Coordinates Antitumor Synergy between Epigenetic Drugs and Protein Disulfide Isomerase Inhibitors.
Neoplasms
Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.
Neoplasms
Autism's cancer connection: the anti-proliferation hypothesis and why it may matter.
Neoplasms
Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Neoplasms
Autophagy and mTOR pathways in mouse embryonic stem cell, lung cancer and somatic fibroblast cell lines.
Neoplasms
Autophagy inhibitor sensitizes MCF-7 breast cancer cells to novel cyclic tetrapeptide CTS203-induced caspase-9-dependent apoptotic cell death.
Neoplasms
Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma.
Neoplasms
Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via PKC?-mediated AHR-HDAC interactions.
Neoplasms
Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways.
Neoplasms
BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers.
Neoplasms
Bcl-2 Inhibition or FBXW7 Mutation Sensitizes Solid Tumor Cells to HDAC Inhibition In Vitro but Could Prove Difficult to Validate in Patients.
Neoplasms
Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review.
Neoplasms
Belinostat suppresses cell proliferation by inactivating Wnt/?-catenin pathway and promotes apoptosis through regulating PKC pathway in breast cancer.
Neoplasms
Benzodithiophenes potentiate differentiation of acute promyelocytic leukemia cells by lowering the threshold for ligand-mediated corepressor/coactivator exchange with retinoic acid receptor alpha and enhancing changes in all-trans-retinoic acid-regulated gene expression.
Neoplasms
Benzothiazole-containing hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Neoplasms
Benzyl isothiocyanate-mediated inhibition of histone deacetylase leads to NF-kappaB turnoff in human pancreatic carcinoma cells.
Neoplasms
BET inhibitors repress expression of Interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.
Neoplasms
Beta-adrenergic signaling promotes tumor angiogenesis and prostate cancer progression through HDAC2-mediated suppression of thrombospondin-1.
Neoplasms
Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation.
Neoplasms
Beyond regulations at DNA levels: A review of epigenetic therapeutics targeting cancer stem cells.
Neoplasms
Bicyclic tetrapeptide histone deacetylase inhibitors with methoxymethyl ketone and boronic acid zinc-binding groups.
Neoplasms
Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.
Neoplasms
Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6.
Neoplasms
Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors.
Neoplasms
Bis-anthracycline WP760 abrogates melanoma cell growth by transcription inhibition, p53 activation and IGF1R downregulation.
Neoplasms
Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.
Neoplasms
Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
Neoplasms
Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.
Neoplasms
Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models.
Neoplasms
Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death.
Neoplasms
Blocking NF-?B sensitizes non-small cell lung cancer cells to histone deacetylase inhibitor induced extrinsic apoptosis through generation of reactive oxygen species.
Neoplasms
Bmf contributes to histone deacetylase inhibitor-mediated enhancing effects on apoptosis after ionizing radiation.
Neoplasms
Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation.
Neoplasms
Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.
Neoplasms
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Neoplasms
Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Neoplasms
BOS is associated with decreased HDAC2 from steroid resistant lymphocytes in the small airways.
Neoplasms
Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells.
Neoplasms
Brain region-specific regulation of histone acetylation and efflux transporters in mice.
Neoplasms
BRCA1 regulates the cancer stem cell fate of breast cancer cells in the context of hypoxia and histone deacetylase inhibitors.
Neoplasms
BRG1, the ATPase subunit of SWI/SNF chromatin remodeling complex, interacts with HDAC2 to modulate telomerase expression in human cancer cells.
Neoplasms
Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways.
Neoplasms
Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells.
Neoplasms
Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells.
Neoplasms
Butyrate inhibits HBV replication and HBV-induced hepatoma cell proliferation via modulating SIRT-1/Ac-p53 regulatory axis.
Neoplasms
Butyrate regulates the expression of inflammatory and chemotactic cytokines in human acute leukemic cells during apoptosis.
Neoplasms
Butyrate rich colonic microenvironment is a relevant selection factor for metabolically adapted tumour cells.
Neoplasms
c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors.
Neoplasms
C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and ?-tubulin hyperacetylation both in vitro and in vivo.
Neoplasms
CAMSAP2-mediated noncentrosomal microtubule acetylation drives hepatocellular carcinoma metastasis.
Neoplasms
Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.
Neoplasms
Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization.
Neoplasms
Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Neoplasms
Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1? for Intrahepatic Cholangiocarcinoma.
Neoplasms
Carbonyl- and sulfur-containing analogs of suberoylanilide hydroxamic acid: Potent inhibition of histone deacetylases.
Neoplasms
Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells.
Neoplasms
Carnitine palmitoyltransferase I in human carcinomas: a novel role in histone deacetylation?
Neoplasms
Carrier-Free Supramolecular Hydrogel Composed of Dual Drugs for Conquering Drug Resistance.
Neoplasms
Cathepsin S Activity Controls Injury-Related Vascular Repair in Mice via the TLR2-Mediated p38MAPK and PI3K-Akt/p-HDAC6 Signaling Pathway.
Neoplasms
CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy.
Neoplasms
CBX4 Suppresses Metastasis via Recruitment of HDAC3 to the Runx2 Promoter in Colorectal Carcinoma.
Neoplasms
CBX4 transcriptionally suppresses KLF6 via interaction with HDAC1 to exert oncogenic activities in clear cell renal cell carcinoma.
Neoplasms
CCAAT box is required for the induction of human thrombospondin-1 gene by trichostatin A.
Neoplasms
CCAR1 and CCAR2 as gene chameleons with antagonistic duality: Preclinical, human translational, and mechanistic basis.
Neoplasms
CCR7 preservation via histone deacetylase inhibition promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells.
Neoplasms
CD1d induction in solid tumor cells by histone deacetylase inhibitors through inhibition of HDAC1/2 and activation of Sp1.
Neoplasms
CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells.
Neoplasms
CDKN1A histone acetylation and gene expression relationship in gastric adenocarcinomas.
Neoplasms
Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids.
Neoplasms
Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21WAF1/CIP1 and p27KIP1 in Cancer Cells.
Neoplasms
Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells.
Neoplasms
Change in gene expression profiles of secreted frizzled-related proteins (SFRPs) by sodium butyrate in gastric cancers: Induction of promoter demethylation and histone modification causing inhibition of Wnt signaling.
Neoplasms
Changes in Chromatin Structure in NIH 3T3 Cells Induced by Valproic Acid and Trichostatin A.
Neoplasms
Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers?
Neoplasms
Changes in the Expression of TBP-2 in Response to Histone Deacetylase Inhibitor Treatment in Human Endometrial Cells.
Neoplasms
Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin A.
Neoplasms
Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin.
Neoplasms
Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems.
Neoplasms
Characterization of the HDAC1 complex that regulates the sensitivity of cancer cells to oxidative stress.
Neoplasms
Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype.
Neoplasms
CHD4 as an important mediator in regulating the malignant behaviors of colorectal cancer.
Neoplasms
Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer.
Neoplasms
Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation.
Neoplasms
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.
Neoplasms
Chemopreventive and chemotherapeutic effect of a novel histone deacetylase inhibitor, by specificity protein 1 in MDA-MB-231 human breast cancer cells.
Neoplasms
Chemopreventive effects of an HDAC2-selective inhibitor on rat colon carcinogenesis and APCmin/+ mouse intestinal tumorigenesis.
Neoplasms
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Neoplasms
Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas.
Neoplasms
Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia.
Neoplasms
Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl?2 pathway.
Neoplasms
Chidamide Inhibits Cell Proliferation via the PI3K/AKT Pathway in K562 Cells Based on Network Pharmacology and Experimental Validation.
Neoplasms
Chidamide suppresses the glycolysis of triple negative breast cancer cells partially by targeting the miR?33a?5p?LDHA axis.
Neoplasms
Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
Neoplasms
Chidamide, a histone deacetylase inhibitor, induces growth arrest and apoptosis in multiple myeloma cells in a caspase-dependent manner.
Neoplasms
Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia.
Neoplasms
Chidamide, a novel histone deacetylase inhibitor, inhibits multiple myeloma cells proliferation through succinate dehydrogenase subunit A.
Neoplasms
Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling.
Neoplasms
Chlorogenic-induced inhibition of non-small cancer cells occurs through regulation of histone deacetylase 6.
Neoplasms
Chromatin modification requirements for 15-lipoxygenase-1 transcriptional reactivation in colon cancer cells.
Neoplasms
Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells.
Neoplasms
Chromatin remodeling underlies the senescence-associated secretory phenotype of tumor stromal fibroblasts that supports cancer progression.
Neoplasms
Chromosomal organization and localization of the human histone deacetylase 5 gene (HDAC5).
Neoplasms
Chromosomal organization and localization of the human histone deacetylase 9 gene (HDAC9).
Neoplasms
Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model.
Neoplasms
Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
Neoplasms
Chrysin: a histone deacetylase 8 inhibitor with anticancer activity and a suitable candidate for the standardization of Chinese propolis.
Neoplasms
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Neoplasms
Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer.
Neoplasms
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Neoplasms
Class I histone deacetylase inhibitor suppresses vasculogenic mimicry by enhancing the expression of tumor suppressor and anti-angiogenesis genes in aggressive human TNBC cells.
Neoplasms
Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer.
Neoplasms
Class I histone deacetylases sequentially interact with MyoD and pRb during skeletal myogenesis.
Neoplasms
Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Neoplasms
Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1{alpha}.
Neoplasms
Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors.
Neoplasms
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma.
Neoplasms
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.
Neoplasms
Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC.
Neoplasms
Clinical Potential of Histone Deacetylase Inhibitors as Stand Alone Therapeutics and in Combination with Other Chemotherapeutics or Radiotherapy for Cancer.
Neoplasms
Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma.
Neoplasms
Clinical Significance of Histone Deacetylase (HDAC)-1, -2, -4 and -6 Expression in Salivary Gland Tumors.
Neoplasms
Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma.
Neoplasms
Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC.
Neoplasms
Clinical use and applications of histone deacetylase inhibitors in multiple myeloma.
Neoplasms
Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma.
Neoplasms
Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor.
Neoplasms
Cloning of a GADD34-like gene that interacts with the zinc-finger transcription factor which binds to the p21(WAF) promoter.
Neoplasms
CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models.
Neoplasms
Colon cancer stemness as a reversible epigenetic state: Implications for anticancer therapies.
Neoplasms
Combination of Arsenic Trioxide and Valproic Acid Efficiently Inhibits Growth of Lung Cancer Cells via G2/M-Phase Arrest and Apoptotic Cell Death.
Neoplasms
Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.
Neoplasms
Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
Neoplasms
Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer.
Neoplasms
Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Neoplasms
Combination of polymorphisms within the HDAC1 and HDAC3 gene predict tumor recurrence in hepatocellular carcinoma patients that have undergone transplant therapy.
Neoplasms
Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism.
Neoplasms
Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
Neoplasms
Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptor?2, via histone acetylation.
Neoplasms
Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma.
Neoplasms
Combination of vorinostat and adenovirus-TRAIL exhibits a synergistic antitumor effect by increasing transduction and transcription of TRAIL in lung cancer cells.
Neoplasms
Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells.
Neoplasms
Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways.
Neoplasms
Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
Neoplasms
Combination therapy induces unfolded protein response and cytoskeletal rearrangement leading to mitochondrial apoptosis in prostate cancer.
Neoplasms
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
Neoplasms
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.
Neoplasms
Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response.
Neoplasms
Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model.
Neoplasms
Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer.
Neoplasms
Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2.
Neoplasms
Combined comparative molecular field analysis, comparative molecular similarity indices analysis, molecular docking and molecular dynamics studies of histone deacetylase 6 inhibitors.
Neoplasms
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Neoplasms
Combined HDAC and Bromodomain Protein Inhibition Reprograms Tumor Cell Metabolism and Elicits Synthetic Lethality in Glioblastoma.
Neoplasms
Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.
Neoplasms
Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Neoplasms
Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer.
Neoplasms
Combined Treatment with Valproic Acid and 5-Aza-2'-Deoxycytidine Synergistically Inhibits Human Clear Cell Renal Cell Carcinoma Growth and Migration.
Neoplasms
Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.
Neoplasms
Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.
Neoplasms
Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.
Neoplasms
Comparative application of antibody and gene array for expression profiling in human squamous cell lung carcinoma.
Neoplasms
Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells.
Neoplasms
Comparative QM/MM Molecular Dynamics and Umbrella Sampling Simulations: Interaction of the Zinc-Bound Intermediate Gem-Diolate Trapoxin A Inhibitor and Acetyl-l-lysine Substrate with Histone Deacetylase 8.
Neoplasms
Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells.
Neoplasms
Compounds that inhibit histone deacetylases in class I and class II effectively suppress human osteoclasts in vitro.
Neoplasms
Comprehensive Analysis of HDAC Family Identifies HDAC1 as a Prognostic and Immune Infiltration Indicator and HDAC1-Related Signature for Prognosis in Glioma.
Neoplasms
Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
Neoplasms
Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors.
Neoplasms
Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
Neoplasms
Computer-Driven Development of an in Silico Tool for Finding Selective Histone Deacetylase 1 Inhibitors.
Neoplasms
Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics.
Neoplasms
Concerted functions of HDAC1 and microRNA-574-5p repress alternatively spliced ceramide synthase 1 expression in human cancer cells.
Neoplasms
Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment.
Neoplasms
Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.
Neoplasms
Correction: Aryl hydrocarbon receptor regulates histone deacetylase 8 expression to repress tumor suppressive activity in hepatocellular carcinoma.
Neoplasms
Correction: Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Neoplasms
Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
Neoplasms
Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?
Neoplasms
Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance.
Neoplasms
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.
Neoplasms
CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo.
Neoplasms
Cracking a cancer code histone deacetylation in epigenetic: the implication from molecular dynamics simulations on efficacy assessment of histone deacetylase inhibitors.
Neoplasms
CRISPR screen identifies the NCOR/HDAC3 complex as a major suppressor of differentiation in rhabdomyosarcoma.
Neoplasms
Critical role of deoxynucleotidyl transferase terminal interacting protein 1 in oral cancer.
Neoplasms
Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans.
Neoplasms
Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
Neoplasms
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
Neoplasms
Crystallographic structure versus homology model: a case study of molecular dynamics simulation of human and zebrafish histone deacetylase 10.
Neoplasms
CTSL2 is a pro-apoptotic target of E2F1 and a modulator of histone deacetylase inhibitor and DNA damage-induced apoptosis.
Neoplasms
Cucurbitacin B Alters the Expression of Tumor-Related Genes by Epigenetic Modifications in NSCLC and Inhibits NNK-Induced Lung Tumorigenesis.
Neoplasms
CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Neoplasms
Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6.
Neoplasms
Curcumin augments the efficacy of antitumor drugs used in leukemia by modulation of heat shock proteins via HDAC6.
Neoplasms
Curcumin p38-dependently enhances the anticancer activity of valproic acid in human leukemia cells.
Neoplasms
Current status of healthy human skin models: can histone deacetylase inhibitors potentially improve the present replacement models?
Neoplasms
CXCL1 Clone Evolution Induced by the HDAC Inhibitor Belinostat Might Be a Favorable Prognostic Indicator in Triple-Negative Breast Cancer.
Neoplasms
CXCL1/GRO? increases cell migration and invasion of prostate cancer by decreasing fibulin-1 expression through NF-?B/HDAC1 epigenetic regulation.
Neoplasms
Cyclic Disulfides as Functional Mimics of the Histone Deacetylase Inhibitor FK-228.
Neoplasms
Cytokeratin 18-associated Histone 3 Modulation in Hepatocellular Carcinoma: A Mini Review.
Neoplasms
Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications.
Neoplasms
dbEM: A database of epigenetic modifiers curated from cancerous and normal genomes.
Neoplasms
Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex.
Neoplasms
Deacetylase Plus Bromodomain Inhibition Downregulates ERCC2 and Suppresses the Growth of Metastatic Colon Cancer Cells.
Neoplasms
DEC1 coordinates with HDAC8 to differentially regulate TAp73 and ?Np73 expression.
Neoplasms
Deciphering the molecular events necessary for synergistic tumor cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and the BH3 mimetic ABT-737.
Neoplasms
Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Neoplasms
Decoy Receptor 3 Enhances Tumor Progression via Induction of Tumor-Associated Macrophages.
Neoplasms
Decreased expression and hypomethylation of HDAC9 lead to poor prognosis and inhibit immune cell infiltration in clear cell renal cell carcinoma.
Neoplasms
Decreased expression of HDAC8 indicates poor prognosis in patients with intrahepatic cholangiocarcinoma.
Neoplasms
Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.
Neoplasms
Defining the minimal peptide sequence of the ING1b tumour suppressor capable of efficiently inducing apoptosis.
Neoplasms
Delineating binding potential, stability of Sulforaphane-N-acetyl-cysteine in the active site of histone deacetylase 2 and testing its cytotoxicity against distinct cancer lines through stringent molecular dynamics, DFT and cell-based assays.
Neoplasms
Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine.
Neoplasms
Depletion of HDAC6 Enhances Cisplatin-Induced DNA Damage and Apoptosis in Non-Small Cell Lung Cancer Cells.
Neoplasms
Depletion of histone deacetylase protein: a common consequence of inflammatory cytokine signaling?
Neoplasms
Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549).
Neoplasms
Deregulated expression of HDAC3 in colorectal cancer and its clinical significance.
Neoplasms
Deregulated expression of HDAC9 in B cells promotes development of lymphoproliferative disease and lymphoma in mice.
Neoplasms
Design and conduct of early-phase radiotherapy trials with targeted therapeutics: Lessons from the PRAVO experience.
Neoplasms
Design and optimization of novel hydroxamate-based histone deacetylase inhibitors of Bis-substituted aromatic amides bearing potent activities against tumor growth and metastasis.
Neoplasms
Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.
Neoplasms
Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
Neoplasms
Design and synthesis of novel HDAC8 inhibitory 2,5-disubstituted-1,3,4-oxadiazoles containing glycine and alanine hybrids with anti cancer activity.
Neoplasms
Design and synthesis of novel pyrimidine hydroxamic acid inhibitors of histone deacetylases.
Neoplasms
Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
Neoplasms
Design of N-substituted aminobutyric hydroxamic acid histone deacetylase inhibitors reveal an essential role for cap atomic composition.
Neoplasms
Design, synthesis and activity evaluation of indole-based double - Branched HDAC1 inhibitors.
Neoplasms
Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Neoplasms
Design, synthesis and biological evaluation of 4-piperazinyl-containing Chidamide derivatives as HDACs inhibitors.
Neoplasms
Design, synthesis and biological evaluation of a phenyl butyric acid derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 inhibitor with anti-proliferative activity on cervix cancer and leukemia cells.
Neoplasms
Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents.
Neoplasms
Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
Neoplasms
Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
Neoplasms
Design, synthesis and biological evaluation of novel HDAC inhibitors with improved pharmacokinetic profile in breast cancer.
Neoplasms
Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
Neoplasms
Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Neoplasms
Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
Neoplasms
Design, Synthesis and Biological Evaluation of Quinazoline Derivatives as Dual HDAC1 and HDAC6 Inhibitors for the Treatment of Cancer.
Neoplasms
Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors.
Neoplasms
Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
Neoplasms
Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects.
Neoplasms
Design, synthesis and evaluate of novel dual FGFR1 and HDAC inhibitors bearing an indazole scaffold.
Neoplasms
Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
Neoplasms
Design, synthesis and in vitro evaluation of amidoximes as histone deacetylase inhibitors for cancer therapy.
Neoplasms
Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents.
Neoplasms
Design, synthesis, and antitumor evaluation of histone deacetylase inhibitors with L-phenylglycine scaffold.
Neoplasms
Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
Neoplasms
Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.
Neoplasms
Design, synthesis, and preliminary bioactivity evaluation of N-benzylpyrimidin-2-amine derivatives as novel histone deacetylase inhibitor.
Neoplasms
Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
Neoplasms
Design, Synthesis, Structure-Selectivity Relationship, and Effect on Human Cancer Cells of a Novel Series of Histone Deacetylase 6-Selective Inhibitors.
Neoplasms
Detection of proneural/mesenchymal marker expression in glioblastoma: temporospatial dynamics and association with chromatin-modifying gene expression.
Neoplasms
Development and optimization of a binding assay for histone deacetylase 4 using surface plasmon resonance.
Neoplasms
Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application.
Neoplasms
Development and Validation of High-Content Analysis for Screening HDAC6-Selective Inhibitors.
Neoplasms
Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC.
Neoplasms
Development of a Novel Histone Deacetylase-Targeted Near-Infrared Probe for Hepatocellular Carcinoma Imaging and Fluorescence Image-Guided Surgery.
Neoplasms
Development of an ELISA-Based HDAC Activity Assay for Characterization of Isoform-Selective Inhibitors.
Neoplasms
Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China.
Neoplasms
Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities.
Neoplasms
Development of decision trees to discriminate HDAC8 inhibitors and non-inhibitors using recursive partitioning.
Neoplasms
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia.
Neoplasms
Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity.
Neoplasms
Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.
Neoplasms
Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
Neoplasms
Development of Selective Clk1 and -4 Inhibitors for Cellular Depletion of Cancer-Relevant Proteins.
Neoplasms
Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Neoplasms
Development of sulforaphane-encapsulated microspheres for cancer epigenetic therapy.
Neoplasms
Development of Tetrahydroisoquinoline-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.
Neoplasms
Development of Vorinostat-Loaded Solid Lipid Nanoparticles to Enhance Pharmacokinetics and Efficacy against Multidrug-Resistant Cancer Cells.
Neoplasms
Developmental programming: Prenatal bisphenol A treatment disrupts mediators of placental function in sheep.
Neoplasms
Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition.
Neoplasms
Differences in Functional Expression of Connexin43 and NaV1.5 by Pan- and Class-Selective Histone Deacetylase Inhibition in Heart.
Neoplasms
Differences in nuclear positioning of 1q12 pericentric heterochromatin in normal and tumor B lymphocytes with 1q rearrangements.
Neoplasms
Different effect of protein kinase B/Akt and extracellular signal-regulated kinase inhibition on trichostatin A-induced apoptosis in epithelial ovarian carcinoma cell lines.
Neoplasms
Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Neoplasms
Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance?
Neoplasms
Differential effects of hydroxamate histone deacetylase inhibitors on cellular functionality and gap junctions in primary cultures of mitogen-stimulated hepatocytes.
Neoplasms
Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
Neoplasms
Differential effects of trichostatin A on gelatinase A expression in 3T3 fibroblasts and HT-1080 fibrosarcoma cells: implications for use of TSA in cancer therapy.
Neoplasms
Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A.
Neoplasms
Differential expression of selected histone modifier genes in human solid cancers.
Neoplasms
Differential induction of reactive oxygen species through Erk1/2 and Nox-1 by FK228 for selective apoptosis of oncogenic H-Ras-expressing human urinary bladder cancer J82 cells.
Neoplasms
Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells.
Neoplasms
Differential mRNA expression levels of human histone-modifying enzymes in normal karyotype B cell pediatric acute lymphoblastic leukemia.
Neoplasms
Differential profiles of HDAC1 substrates and associated proteins in breast cancer cells revealed by trapping.
Neoplasms
Differential role of epigenetic modulators in malignant and normal stem cells: a novel tool in preclinical in vitro toxicology and clinical therapy.
Neoplasms
Differential SIRT1 Expression in Hepatocellular Carcinomas and Cholangiocarcinoma of the Liver.
Neoplasms
Direct monitoring of breast and endometrial cancer cell epigenetic response to DNA methyltransferase and histone deacetylase inhibitors.
Neoplasms
Discovery and Characterization of R/S-N-3-Cyanophenyl-N'-(6-tert-butoxycarbonylamino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-4-yl)urea, a New Histone Deacetylase Class III Inhibitor Exerting Antiproliferative Activity against Cancer Cell Lines.
Neoplasms
Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.
Neoplasms
Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines.
Neoplasms
Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent.
Neoplasms
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Neoplasms
Discovery of a small molecular compound simultaneously targeting RXR and HADC: design, synthesis, molecular docking and bioassay.
Neoplasms
Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability.
Neoplasms
Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells.
Neoplasms
Discovery of N-hydroxy-4-(3-phenylpropanamido)benzamide derivative 5j, a novel histone deacetylase inhibitor, as a potential therapeutic agent for human breast cancer.
Neoplasms
Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
Neoplasms
Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
Neoplasms
Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase (HDAC) Dual Inhibitors.
Neoplasms
Discovery of Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) and Histone Deacetylase 1 (HDAC1) Dual Inhibitors Derived from the Natural Product Saprorthoquinone.
Neoplasms
Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
Neoplasms
Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation.
Neoplasms
Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency.
Neoplasms
Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
Neoplasms
Discovery of Potent and Selective Histone Deacetylase Inhibitors via Focused Combinatorial Libraries of Cyclic alpha(3)beta-Tetrapeptides.
Neoplasms
Discovery of Potent Natural-Product-Derived SIRT2 Inhibitors Using Structure-Based Exploration of SIRT2 Pharmacophoric Space Coupled With QSAR Analyses.
Neoplasms
Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
Neoplasms
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
Neoplasms
Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Neoplasms
Discovery of STAT3 and Histone Deacetylase (HDAC) Dual-Pathway Inhibitors for the Treatment of Solid Cancer.
Neoplasms
Disparate Impact of Butyroyloxymethyl Diethylphosphate (AN-7), a Histone Deacetylase Inhibitor, and Doxorubicin in Mice Bearing a Mammary Tumor.
Neoplasms
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
Neoplasms
Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis.
Neoplasms
Distinct epigenetic domains separated by a CTCF bound insulator between the tandem genes, BLU and RASSF1A.
Neoplasms
Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas.
Neoplasms
Disulfide cross-linked micelles of novel HDAC inhibitor thailandepsin A for the treatment of breast cancer.
Neoplasms
Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis.
Neoplasms
Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity.
Neoplasms
DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
Neoplasms
DNA methylation and histone modification regulate silencing of epithelial cell adhesion molecule for tumor invasion and progression.
Neoplasms
DNA methylation maintains the CLDN1-EPHB6-SLUG axis to enhance chemotherapeutic efficacy and inhibit lung cancer progression.
Neoplasms
DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability.
Neoplasms
DNA-PKcs inhibition impairs HDAC6-mediated HSP90 chaperone function on Aurora A and enhances HDACs inhibitor-induced cell killing by increasing mitotic aberrant spindle assembly.
Neoplasms
DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters.
Neoplasms
Docking and QSAR studies of aryl-valproic acid derivatives to identify anti-proliferative agents targeting the HDAC8.
Neoplasms
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation.
Neoplasms
Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).
Neoplasms
Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function.
Neoplasms
Down-regulated HDAC3 elevates microRNA-495-3p to restrain epithelial-mesenchymal transition and oncogenicity of melanoma cells via reducing TRAF5.
Neoplasms
Down-regulation of deacetylase HDAC6 inhibits the melanoma cell line A375.S2 growth through ROS-dependent mitochondrial pathway.
Neoplasms
Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest.
Neoplasms
Down-regulation of matrix metalloproteinase-7 inhibits metastasis of human anaplastic thyroid cancer cell line.
Neoplasms
Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties.
Neoplasms
Downregulation of a tumor suppressor RECK by hypoxia through recruitment of HDAC1 and HIF-1alpha to reverse HRE site in the promoter.
Neoplasms
Downregulation of AZGP1 by Ikaros and histone deacetylase promotes tumor progression through the PTEN/Akt and CD44s pathways in hepatocellular carcinoma.
Neoplasms
Downregulation of Ca2+-activated Cl- channel TMEM16A by the inhibition of histone deacetylase in TMEM16A-expressing cancer cells.
Neoplasms
Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells.
Neoplasms
Downregulation of HDAC2 and HDAC3 via oleuropein as a potent prevention and therapeutic agent in MCF-7 breast cancer cells.
Neoplasms
Downregulation of HDAC3 by ginsenoside Rg3 inhibits epithelial-mesenchymal transition of cutaneous squamous cell carcinoma through c-Jun acetylation.
Neoplasms
Downregulation of HDAC6 promotes angiogenesis in hepatocellular carcinoma cells and predicts poor prognosis in liver transplantation patients.
Neoplasms
Downregulation of HDAC9 inhibits cell proliferation and tumor formation by inducing cell cycle arrest in retinoblastoma.
Neoplasms
Downregulation of histone deacetylase 1 by microRNA-520h contributes to the chemotherapeutic effect of doxorubicin.
Neoplasms
Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor.
Neoplasms
Downregulation of Mcl-1 by Panobinostat Potentiates Proton Beam Therapy in Hepatocellular Carcinoma Cells.
Neoplasms
Downregulation of serine protease HTRA1 is associated with poor survival in breast cancer.
Neoplasms
Downregulation of SIRT2 Inhibits Invasion of Hepatocellular Carcinoma by Inhibiting Energy Metabolism.
Neoplasms
Downregulation of survivin and aurora a by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy.
Neoplasms
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
Neoplasms
Downregulation of the Ca(2+)-activated K(+) channel KC a3.1 by histone deacetylase inhibition in human breast cancer cells.
Neoplasms
Droxinostat sensitizes human colon cancer cells to apoptotic cell death via induction of oxidative stress.
Neoplasms
Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
Neoplasms
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
Neoplasms
Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.
Neoplasms
Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells.
Neoplasms
Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.
Neoplasms
Dual Screen for Efficacy and Toxicity Identifies HDAC Inhibitor with Distinctive Activity Spectrum for BAP1-Mutant Uveal Melanoma.
Neoplasms
Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ER?-negative Breast Cancers to Tamoxifen through ER? Reexpression.
Neoplasms
Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors.
Neoplasms
Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Neoplasms
Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.
Neoplasms
Dual Targeting Strategies On Histone Deacetylase 6 (HDAC6) And Heat Shock Protein 90 (Hsp90).
Neoplasms
Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
Neoplasms
Dynamic interaction of HDAC1 with a glucocorticoid receptor-regulated gene is modulated by the activity state of the promoter.
Neoplasms
Dynamic Structure-Based Pharmacophore Model Development: A New and Effective Addition in the Histone Deacetylase 8 (HDAC8) Inhibitor Discovery.
Neoplasms
Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress.
Neoplasms
Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.
Neoplasms
Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies.
Neoplasms
E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells.
Neoplasms
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
Neoplasms
Ectopic expression of activation-induced cytidine deaminase caused by epigenetics modification.
Neoplasms
Ectopic SOX9 mediates extracellular matrix deposition characteristic of organ fibrosis.
Neoplasms
Editorial: Epigenetic Therapy With Histone Deacetylase Inhibitors: Implications for Cancer Treatment.
Neoplasms
Effect of Genistein in Comparison with Trichostatin A on Reactivation of DNMTs Genes in Hepatocellular Carcinoma.
Neoplasms
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Neoplasms
Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines.
Neoplasms
Effect of histone deacetylase inhibitors on cell apoptosis and expression of the tumor suppressor genes RUNX3 and ARHI in ovarian tumors.
Neoplasms
Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells.
Neoplasms
Effect of suberoylanilide hydroxamic acid on peripheral blood mononuclear cell cytotoxicity towards tumor cells in canines.
Neoplasms
Effect of the histone deacetylase inhibitor trichostatin a in human peripheral blood lymphocytes as a function of donor age.
Neoplasms
Effect of the histone deacetylase inhibitor trichostatin a on the metabolome of cultured primary hepatocytes.
Neoplasms
Effect of trans-2,3-dimethoxycinnamoyl azide on enhancing antitumor activity of romidepsin on human bladder cancer.
Neoplasms
Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments.
Neoplasms
Effect of Valproic Acid on the Class I Histone Deacetylase 1, 2 and 3, Tumor Suppressor Genes p21WAF1/CIP1 and p53, and Intrinsic Mitochondrial Apoptotic Pathway, Pro- (Bax, Bak, and Bim) and anti- (Bcl-2, Bcl-xL, and Mcl-1) Apoptotic Genes Expression, Cell Viability, and Apoptosis Induction in Hepatocellular Carcinoma HepG2 Cell Line.
Neoplasms
Effectiveness of trichostatin A as a potential candidate for anticancer therapy in non-small-cell lung cancer.
Neoplasms
Effects of apicidin, a histone deacetylase inhibitor, on the regulation of apoptosis in H-ras-transformed breast epithelial cells.
Neoplasms
Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma.
Neoplasms
Effects of chidamide and its combination with decitabine on proliferation and apoptosis of leukemia cell lines.
Neoplasms
Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells.
Neoplasms
Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo.
Neoplasms
Effects of histone deacetylase inhibitor trichostatin A combined with cisplatin on apoptosis of A549 cell line.
Neoplasms
Effects of Histone Deacetylase Inhibitors on Modulating H3K4 Methylation Marks - A Novel Cross-Talk Mechanism between Histone-Modifying Enzymes.
Neoplasms
Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.
Neoplasms
Effects of siRNA-Mediated Knockdown of HDAC1 on the Biological Behavior of Esophageal Carcinoma Cell Lines.
Neoplasms
Effects of the histone deacetylases inhibitors sodium butyrate and trichostatin A on the inhibition of gap junctional intercellular communication by H2O2- and 12-O-tetradecanoylphorbol-13-acetate in rat liver epithelial cells.
Neoplasms
Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.
Neoplasms
Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II.
Neoplasms
Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
Neoplasms
Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma.
Neoplasms
Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma.
Neoplasms
Efficacy of the dietary histone deacetylase inhibitor butyrate alone or in combination with vitamin A against proliferation of MCF-7 human breast cancer cells.
Neoplasms
Efficient organic monoliths prepared by ?-radiation induced polymerization in the evaluation of histone deacetylase inhibitors by capillary(nano)-high performance liquid chromatography and ion trap mass spectrometry.
Neoplasms
Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents.
Neoplasms
EGFR phosphorylates HDAC1 to regulate its expression and anti-apoptotic function.
Neoplasms
EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor.
Neoplasms
Elevated expression of HDAC6 in clinical peritoneal dialysis patients and its pathogenic role on peritoneal angiogenesis.
Neoplasms
Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer.
Neoplasms
Elucidating the mechanism of regulation of transforming growth factor ? Type II receptor expression in human lung cancer cell lines.
Neoplasms
Endocrine resistant breast cancer cells with loss of ER? expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.
Neoplasms
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy.
Neoplasms
Endothelial progenitor cells contribute to neovascularization of non-small cell lung cancer via histone deacetylase 7-mediated cytoskeleton regulation and angiogenic genes transcription.
Neoplasms
Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes.
Neoplasms
Enhanced activation of NAD(P)H: quinone oxidoreductase 1 attenuates spontaneous hypertension by improvement of endothelial nitric oxide synthase coupling via tumor suppressor kinase liver kinase B1/adenosine 5'-monophosphate-activated protein kinase-mediated guanosine 5'-triphosphate cyclohydrolase 1 preservation.
Neoplasms
Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228.
Neoplasms
Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Neoplasms
Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824.
Neoplasms
Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes.
Neoplasms
Enhanced Cytotoxic Effects of Combined Valproic Acid and the Aurora Kinase Inhibitor VE465 on Gynecologic Cancer Cells.
Neoplasms
Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis.
Neoplasms
Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung.
Neoplasms
Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.
Neoplasms
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Neoplasms
Enhanced in vitro cytotoxicity and anti-tumor activity of vorinostat-loaded pluronic micelles with prolonged release and reduced hepatic and renal toxicities.
Neoplasms
Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
Neoplasms
Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275.
Neoplasms
Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression.
Neoplasms
Enhanced suppression of proliferation and migration in highly-metastatic lung cancer cells by combination of valproic acid and coumarin-3-carboxylic acid and its molecular mechanisms of action.
Neoplasms
Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
Neoplasms
Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors.
Neoplasms
Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.
Neoplasms
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
Neoplasms
Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma.
Neoplasms
Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8.
Neoplasms
Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway.
Neoplasms
Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.
Neoplasms
Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Neoplasms
Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6.
Neoplasms
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
Neoplasms
Epigenetic activation of alpha4, beta2 and beta6 integrins involved in cell migration in trichostatin A-treated Hep3B cells.
Neoplasms
Epigenetic Alterations and MicroRNA Misexpression in Cancer and Autoimmune Diseases: a Critical Review.
Neoplasms
Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
Neoplasms
Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.
Neoplasms
EPIGENETIC CHANGES IN MALIGNANT UVEAL MELANOMA AND POSSIBILITIES OF THEIR THERAPEUTIC TARGETING.
Neoplasms
Epigenetic changes in tumor Fas levels determine immune escape and response to therapy.
Neoplasms
Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies.
Neoplasms
Epigenetic control of gene expression: Potential implications for cancer treatment.
Neoplasms
Epigenetic Drugs for Cancer and microRNAs: A Focus on Histone Deacetylase Inhibitors.
Neoplasms
Epigenetic inactivation of calcium-sensing receptor in colorectal carcinogenesis.
Neoplasms
Epigenetic inhibition assisted chemotherapeutic treatment of lung cancer based on artificial exosomes.
Neoplasms
Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.
Neoplasms
Epigenetic Modifiers in Myeloid Malignancies: The Role of Histone Deacetylase Inhibitors.
Neoplasms
Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity.
Neoplasms
Epigenetic modulation of gene expression of human leukemia cell lines - induction of cell death and senescence.
Neoplasms
Epigenetic modulation of immunotherapy cofactors to enhance tumor response in lung cancer.
Neoplasms
Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: Potential role of histone deacetylase 6.
Neoplasms
Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.
Neoplasms
Epigenetic Modulators as Potential Multi-targeted Drugs Against Hedgehog Pathway for Treatment of Cancer.
Neoplasms
Epigenetic modulators hydralazine and sodium valproate act synergistically in VEGI-mediated anti-angiogenesis and VEGF interference in human osteosarcoma and vascular endothelial cells.
Neoplasms
Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells.
Neoplasms
Epigenetic regulation of metallothionein-i gene expression: differential regulation of methylated and unmethylated promoters by DNA methyltransferases and methyl CpG binding proteins.
Neoplasms
Epigenetic regulation of soluble guanylate cyclase (sGC) ?1 in breast cancer cells.
Neoplasms
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance.
Neoplasms
Epigenetic regulators Rbbp4 and Hdac1 are overexpressed in a zebrafish model of RB1 embryonal brain tumor, and are required for neural progenitor survival and proliferation.
Neoplasms
Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status.
Neoplasms
Epigenetic Silencing of Apoptosis-Inducing Gene Expression Can Be Efficiently Overcome by Combined SAHA and TRAIL Treatment in Uterine Sarcoma Cells.
Neoplasms
Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.
Neoplasms
Epigenetic Targeting of Transforming Growth Factor beta Receptor II and Implications for Cancer Therapy.
Neoplasms
Epigenetic therapies in patients with solid tumors: Focus on monotherapy with deoxyribonucleic acid methyltransferase inhibitors and histone deacetylase inhibitors.
Neoplasms
Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Neoplasms
Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer.
Neoplasms
Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma.
Neoplasms
Epigenetic upregulation of urokinase plasminogen activator promotes the tropism of mesenchymal stem cells for tumor cells.
Neoplasms
Epigenetically active drugs inhibiting DNA methylation and histone deacetylation.
Neoplasms
Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches.
Neoplasms
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Neoplasms
Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer.
Neoplasms
Epigenomics in respiratory epithelium carcinogenesis: prevention and therapeutic challenges.
Neoplasms
Epithelial-Mesenchymal Transition: A Special Focus on Phthalates and Bisphenol A.
Neoplasms
Epstein-Barr virus-infected Akata cells are sensitive to histone deacetylase inhibitor TSA-provoked apoptosis.
Neoplasms
Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies.
Neoplasms
ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).
Neoplasms
ERK1/2 activation plays important roles in the opposite effects of Trichostatin A in non-cancer and cancer cells.
Neoplasms
Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.
Neoplasms
Essential elements regulating HDAC8 inhibition: a classification based structural analysis and enzyme-inhibitor interaction study of hydroxamate based HDAC8 inhibitors.
Neoplasms
Essential role of DNA methyltransferase 1-mediated transcription of insulin-like Growth Factor 2 in Resistance to Histone Deacetylase Inhibitors.
Neoplasms
Establishment of an orthotopic transplantable gastric cancer animal model for studying the immunological effects of new cancer therapeutic modules.
Neoplasms
Esterase-sensitive cleavable histone deacetylase inhibitor-coupled hyaluronic acid nanoparticles for boosting anticancer activities against lung adenocarcinoma.
Neoplasms
Estrogen receptor enhances the antiproliferative effects of trichostatin A and HC-toxin in human breast cancer cells.
Neoplasms
Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Neoplasms
Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.
Neoplasms
Evaluation of Histone Deacetylase Inhibitors as Radiosensitizers for Proton and Light Ion Radiotherapy.
Neoplasms
Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.
Neoplasms
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Neoplasms
Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.
Neoplasms
Evaluation of the Effects of Valproic Acid Treatment on Cell Survival and Epithelial-Mesenchymal Transition-Related Features of Human Gastric Cancer Cells.
Neoplasms
Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.
Neoplasms
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Neoplasms
Evaluation of [11C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma.
Neoplasms
Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis.
Neoplasms
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies.
Neoplasms
Examining the stability of binding modes of the co-crystallized inhibitors of human HDAC8 by molecular dynamics simulation.
Neoplasms
Expanding the Biotherapeutics Realm via miR-34a: "Potent Clever Little" Agent in Breast Cancer Therapy.
Neoplasms
Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides.
Neoplasms
Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer.
Neoplasms
Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
Neoplasms
Exploring the binding mechanism of HDAC8 selective inhibitors: Lessons from the modification of Cap group.
Neoplasms
Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function.
Neoplasms
Expression analysis of a subset of coregulators and three nuclear receptors in human colorectal carcinoma.
Neoplasms
Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma.
Neoplasms
Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts.
Neoplasms
Expression and prognostic analyses of HDACs in human gastric cancer based on bioinformatic analysis.
Neoplasms
Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma.
Neoplasms
Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study.
Neoplasms
Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas.
Neoplasms
Expression of HDAC4 in Stage B Hepatocellular Carcinoma and Its Influence on Survival.
Neoplasms
Expression of histone deacetylase 1 and metastasis-associated protein 1 as prognostic factors in colon cancer.
Neoplasms
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Neoplasms
Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance.
Neoplasms
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
Neoplasms
Expression of hMOF, but not HDAC4, is responsible for the global histone H4K16 acetylation in gastric carcinoma.
Neoplasms
Expression of leukemia associated fusion proteins increases sensitivity to histone deacetylase inhibitor induced DNA damage and apoptosis.
Neoplasms
Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas.
Neoplasms
Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB.
Neoplasms
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.
Neoplasms
Expressional Difference of RHEB, HDAC1, and WEE1 Proteins in the Stromal Tumors of the Breast and Their Significance in Tumorigenesis.
Neoplasms
EZH2 Regulates Protein Stability via Recruiting USP7 to Mediate Neuronal Gene Expression in Cancer Cells.
Neoplasms
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Neoplasms
Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
Neoplasms
Fc?RI-HDAC3-MCP1 Signaling Axis Promotes Passive Anaphylaxis Mediated by Cellular Interactions.
Neoplasms
Fentanyl Inhibits Lung Cancer Viability and Invasion via Upregulation of miR-331-3p and Repression of HDAC5.
Neoplasms
Ferroptosis in Neurons and Cancer Cells Is Similar But Differentially Regulated by Histone Deacetylase Inhibitors.
Neoplasms
Fine particulate matter exposure promotes M2 macrophage polarization through inhibiting histone deacetylase 2 in the pathogenesis of chronic obstructive pulmonary disease.
Neoplasms
First non-radioactive assay for in vitro screening of histone deacetylase inhibitors.
Neoplasms
First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma.
Neoplasms
First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
Neoplasms
First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors.
Neoplasms
FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Neoplasms
FK228 induces mitotic catastrophe in A549 cells by mistargeting chromosomal passenger complex localization through changing centromeric H3K9 hypoacetylation.
Neoplasms
Flavonoids potentiated anticancer activity of cisplatin in non-small cell lung cancer cells in vitro by inhibiting histone deacetylases.
Neoplasms
Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
Neoplasms
Fourier transform infrared microspectroscopy identifies protein propionylation in histone deacetylase inhibitor treated glioma cells.
Neoplasms
FOXA1 Regulation Turns Benzamide HDACi Treatment Effect-Specific in BC, Promoting NIS Gene-Mediated Targeted Radioiodine Therapy.
Neoplasms
FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.
Neoplasms
From Anti-infective Agents to Cancer Therapy: a Drug Repositioning Study Revealed a New Use for Nitrofuran Derivatives.
Neoplasms
Functional activation of the estrogen receptor-? and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
Neoplasms
Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Neoplasms
Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer.
Neoplasms
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
Neoplasms
Functionalized MoS2 Nanosheets as Multi-Gene Delivery Vehicles for In Vivo Pancreatic Cancer Therapy.
Neoplasms
Fungus-specific sirtuin HstD coordinates secondary metabolism and development through control of LaeA.
Neoplasms
Further characterization of HDAC and SIRT gene expression patterns in pancreatic cancer and their relation to disease outcome.
Neoplasms
G Protein-coupled Receptor Kinase 2 (GRK2) Promotes Breast Tumorigenesis Through a HDAC6-Pin1 Axis.
Neoplasms
G protein-coupled receptor kinase 5 modifies cancer cell resistance to paclitaxel.
Neoplasms
Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression.
Neoplasms
Gd-Metallofullerenol Nanomaterial Suppresses Pancreatic Cancer Metastasis by Inhibiting the Interaction of Histone Deacetylase 1 and Metastasis-Associated Protein 1.
Neoplasms
Gelsolin gene silencing involving unusual hypersensitivities to dimethylsulfate and KMnO4 in vivo footprinting on its promoter region.
Neoplasms
Gelsolin: a novel thyroid hormone receptor-beta interacting protein that modulates tumor progression in a mouse model of follicular thyroid cancer.
Neoplasms
Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor.
Neoplasms
Gene expression mapping of histone deacetylases and co-factors, and correlation with survival time and 1H-HRMAS metabolomic profile in human gliomas.
Neoplasms
Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells.
Neoplasms
Gene Ontology-driven transcriptional analysis of CD34+ cell-initiated megakaryocytic cultures identifies new transcriptional regulators of megakaryopoiesis.
Neoplasms
Genes methylated in cancer that are resistant to activation by DNA demethylating agents and histone deacetylase inhibitors.
Neoplasms
Genetic alterations and oncogenic pathways associated with breast cancer subtypes.
Neoplasms
Genetic Interaction-Based Biomarkers Identification for Drug Resistance and Sensitivity in Cancer Cells.
Neoplasms
Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer.
Neoplasms
Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers.
Neoplasms
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.
Neoplasms
Genome-wide study of DNA methylation alterations in response to diazinon exposure in vitro.
Neoplasms
Genomic DNA hypomethylation by HDAC inhibition implicates DNMT1 nuclear dynamics.
Neoplasms
Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers.
Neoplasms
Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
Neoplasms
Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation.
Neoplasms
Global Histone H4 Acetylation and HDAC2 Expression in Colon Adenoma and Carcinoma.
Neoplasms
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms.
Neoplasms
Grand Rounds at the National Institutes of Health: HDAC Inhibitors as Radiation Modifiers, from Bench to Clinic.
Neoplasms
GRHL1 Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3.
Neoplasms
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Neoplasms
Growth of human prostate cancer cells is significantly suppressed in vitro with sodium butyrate through apoptosis.
Neoplasms
Growth-inhibiting activity of transcription factor C/EBPalpha, its role in haematopoiesis and its tumour suppressor or oncogenic properties in leukaemias.
Neoplasms
Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells.
Neoplasms
Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma.
Neoplasms
Haploinsufficiency of the mSds3 chromatin regulator promotes chromosomal instability and cancer only upon complete neutralization of p53.
Neoplasms
Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on?
Neoplasms
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
Neoplasms
HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
Neoplasms
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells.
Neoplasms
HDAC Inhibition Suppresses Primary Immune Responses, Enhances Secondary Immune Responses, and Abrogates Autoimmunity During Tumor Immunotherapy.
Neoplasms
HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression.
Neoplasms
HDAC inhibitor entinostat restores responsiveness of letrozole resistant MCF-7Ca xenografts to AIs through modulation of Her-2.
Neoplasms
HDAC Inhibitor Oxamflatin Induces Morphological Changes and has Strong Cytostatic Effects in Ovarian Cancer Cell Lines.
Neoplasms
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.
Neoplasms
HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen.
Neoplasms
HDAC inhibitor trichostatin A suppresses esophageal squamous cell carcinoma metastasis through HADC2 reduced MMP-2/9.
Neoplasms
HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review).
Neoplasms
HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells.
Neoplasms
HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy.
Neoplasms
HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization.
Neoplasms
HDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma.
Neoplasms
HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells.
Neoplasms
HDAC inhibitors induce global changes in histone lysine and arginine methylation and alter expression of lysine demethylases.
Neoplasms
HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade.
Neoplasms
HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression.
Neoplasms
HDAC Inhibitors Target HDAC5, Upregulate MicroRNA-125a-5p, and Induce Apoptosis in Breast Cancer Cells.
Neoplasms
HDAC inhibitors Tubastatin A and SAHA affect parasite cell division and are potential anti-Toxoplasma gondii chemotherapeutics.
Neoplasms
HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
Neoplasms
HDAC inhibitors, trichostatin A and valproic acid, increase E?cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells.
Neoplasms
HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation.
Neoplasms
HDAC Overexpression in a NUT Midline Carcinoma of the Parotid Gland with Exceptional Survival: A Case Report.
Neoplasms
HDAC pharmacological inhibition promotes cell death through the eIF2? kinases PKR and GCN2.
Neoplasms
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.
Neoplasms
HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis.
Neoplasms
Hdac1 and Hdac2 are essential for physiological maturation of a Cx3cr1 expressing subset of T-lymphocytes.
Neoplasms
HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer.
Neoplasms
HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population.
Neoplasms
HDAC1 and Klf4 interplay critically regulates human myeloid leukemia cell proliferation.
Neoplasms
HDAC1 Expression in Invasive Ductal Carcinoma of the Breast and Its Value as a Good Prognostic Factor.
Neoplasms
HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer.
Neoplasms
HDAC1 is indirectly involved in the epigenetic regulation of p38 MAPK that drive the lung cancer progression.
Neoplasms
HDAC1 knockdown inhibits invasion and induces apoptosis in non-small cell lung cancer cells.
Neoplasms
HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage.
Neoplasms
HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer.
Neoplasms
HDAC1 promotes liver proliferation in young mice via interactions with C/EBPbeta.
Neoplasms
HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells.
Neoplasms
HDAC1-Dependent Repression of Markers of Hepatocytes and P21 Is Involved in Development of Pediatric Liver Cancer.
Neoplasms
HDAC10 expression is associated with DNA mismatch repair gene and is a predictor of good prognosis in colon carcinoma.
Neoplasms
HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC.
Neoplasms
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms.
Neoplasms
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
Neoplasms
HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape.
Neoplasms
HDAC2 enhances esophageal squamous cell carcinoma development through down-regulating microRNA-503-5p and promoting CXCL10.
Neoplasms
HDAC2 Expression and Variable Number of Repeats in Exon 1 of the HDAC2 Gene in Corticotroph Adenomas.
Neoplasms
HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer.
Neoplasms
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.
Neoplasms
HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins.
Neoplasms
HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer.
Neoplasms
HDAC2 promotes cell migration/invasion abilities through HIF-1? stabilization in human oral squamous cell carcinoma.
Neoplasms
HDAC2 promotes the migration and invasion of non-small cell lung cancer cells via upregulation of fibronectin.
Neoplasms
HDAC2 Provides a Critical Support to Malignant Progression of Hepatocellular Carcinoma through Feedback Control of mTORC1 and AKT.
Neoplasms
HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells.
Neoplasms
HDAC2 Regulates Site-Specific Acetylation of MDM2 and Its Ubiquitination Signaling in Tumor Suppression.
Neoplasms
HDAC3 controls gap 2/mitosis progression in adult neural stem/progenitor cells by regulating CDK1 levels.
Neoplasms
HDAC3 deteriorates colorectal cancer progression via microRNA-296-3p/TGIF1/TGF? axis.
Neoplasms
HDAC3 impacts multiple oncogenic pathways in colon cancer cells with effects on Wnt and vitamin D signaling.
Neoplasms
HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
Neoplasms
HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.
Neoplasms
HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer.
Neoplasms
HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.
Neoplasms
HDAC3i-Finder: A Machine Learning-based Computational Tool to Screen for HDAC3 Inhibitors.
Neoplasms
HDAC4 and HDAC6 sustain DNA double strand break repair and stem-like phenotype by promoting radioresistance in glioblastoma cells.
Neoplasms
HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements.
Neoplasms
HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway.
Neoplasms
HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target.
Neoplasms
HDAC4 protein regulates HIF1? protein lysine acetylation and cancer cell response to hypoxia.
Neoplasms
HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism.
Neoplasms
HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity.
Neoplasms
HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition.
Neoplasms
HDAC5 is required for maintenance of pericentric heterochromatin, and controls cell-cycle progression and survival of human cancer cells.
Neoplasms
HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4/6 inhibitor resistance in cancer.
Neoplasms
HDAC6 activity is not required for basal autophagic flux in metastatic prostate cancer cells.
Neoplasms
HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin.
Neoplasms
HDAC6 and SIRT2 Regulate the Acetylation State and Oncogenic Activity of Mutant K-RAS.
Neoplasms
HDAC6 deacetylase activity is required for hypoxia-induced invadopodia formation and cell invasion.
Neoplasms
HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis.
Neoplasms
HDAC6 differentially regulates autophagy in stem-like versus differentiated cancer cells.
Neoplasms
HDAC6 functions as a tumor suppressor by activating JNK-mediated beclin 1-dependent autophagic cell death in liver cancer.
Neoplasms
HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the E?-TCL1 Model.
Neoplasms
HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.
Neoplasms
HDAC6 inhibition induces glioma stem cells differentiation and enhances cellular radiation sensitivity through the SHH/Gli1 signaling pathway.
Neoplasms
HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving ?-tubulin acetylation.
Neoplasms
HDAC6 inhibition suppresses chondrosarcoma by restoring the expression of primary cilia.
Neoplasms
HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer.
Neoplasms
HDAC6 inhibition up-regulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
Neoplasms
HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.
Neoplasms
HDAC6 inhibitor, ACY1215 suppress the proliferation and induce apoptosis of gallbladder cancer cells and increased the chemotherapy effect of gemcitabine and oxaliplatin.
Neoplasms
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation.
Neoplasms
HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization.
Neoplasms
HDAC6 Plays a Noncanonical Role in the Regulation of Antitumor Immune Responses, Dissemination, and Invasiveness of Breast Cancer.
Neoplasms
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma.
Neoplasms
HDAC6 Regulates Androgen Receptor Hypersensitivity and Nuclear Localization via Modulating Hsp90 Acetylation in Castration-Resistant Prostate Cancer.
Neoplasms
HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process.
Neoplasms
HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.
Neoplasms
HDAC6 serves as a biomarker for the prognosis of patients with renal cell carcinoma.
Neoplasms
HDAC6 Signaling at Primary Cilia Promotes Proliferation and Restricts Differentiation of Glioma Cells.
Neoplasms
HDAC6 Substrate Discovery Using Proteomics-Based Substrate Trapping: HDAC6 Deacetylates PRMT5 to Influence Methyltransferase Activity.
Neoplasms
HDAC6 Suppresses Let-7i-5p to Elicit TSP1/CD47-mediated Anti-tumorigenesis and Phagocytosis of Hepatocellular Carcinoma.
Neoplasms
HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer.
Neoplasms
HDAC6, modulated by miR-206, promotes endometrial cancer progression through the PTEN/AKT/mTOR pathway.
Neoplasms
HDAC6-dependent ciliophagy is involved in ciliary loss and cholangiocarcinoma growth in human cells and murine models.
Neoplasms
HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension.
Neoplasms
HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies.
Neoplasms
HDAC7 promotes the oncogenicity of nasopharyngeal carcinoma cells by miR-4465-EphA2 signaling axis.
Neoplasms
HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells.
Neoplasms
HDAC7-mediated control of tumour microenvironment maintains proliferative and stemness competence of human mammary epithelial cells.
Neoplasms
HDAC8 Inhibition Blocks SMC3 Deacetylation and Delays Cell Cycle Progression without Affecting Cohesin-dependent Transcription in MCF7 Cancer Cells.
Neoplasms
HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?
Neoplasms
HDAC8 promotes the dissemination of breast cancer cells via AKT/GSK-3?/Snail signals.
Neoplasms
HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST).
Neoplasms
HDAC8, A Potential Therapeutic Target, Regulates Proliferation and Differentiation of Bone Marrow Stromal Cells in Fibrous Dysplasia.
Neoplasms
HDAC9 deficiency promotes tumor progression by decreasing the CD8+ dendritic cell infiltration of the tumor microenvironment.
Neoplasms
HDAC9 Is Preferentially Expressed in Dedifferentiated Hepatocellular Carcinoma Cells and Is Involved in an Anchorage-Independent Growth.
Neoplasms
HDAC9 promotes brain ischemic injury by provoking I?B?/NF-?B and MAPKs signaling pathways.
Neoplasms
HDACi: molecular mechanisms and therapeutic implications in the innate immune system.
Neoplasms
HDACs control RUNX2 expression in cancer cells through redundant and cell context-dependent mechanisms.
Neoplasms
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
Neoplasms
Hereditary/familial versus sporadic prostate cancer: few indisputable genetic differences and many similar clinicopathological features.
Neoplasms
High expression of SNIP1 correlates with poor prognosis in Non-small cell lung cancer and SNIP1 interferes with the recruitment of HDAC1 to RB in vitro.
Neoplasms
High HDAC9 is associated with poor prognosis and promotes malignant progression in pancreatic ductal adenocarcinoma.
Neoplasms
High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas.
Neoplasms
High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients.
Neoplasms
High resolution physical mapping of human HDAC3, a potential tumor suppressor gene in the 5q31 region.
Neoplasms
High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma.
Neoplasms
High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma.
Neoplasms
Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells.
Neoplasms
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.
Neoplasms
Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis.
Neoplasms
Histone deacetylase (HDAC) 9: versatile biological functions and emerging roles in human cancer.
Neoplasms
Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors.
Neoplasms
Histone Deacetylase (HDAC) Inhibition Induces I?B Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Neoplasms
Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.
Neoplasms
Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.
Neoplasms
Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Neoplasms
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.
Neoplasms
Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.
Neoplasms
Histone deacetylase (HDAC) inhibitory and antiproliferative activities of phenolic-rich extracts derived from the rhizome of Hydnophytum formicarum Jack.: sinapinic acid acts as HDAC inhibitor.
Neoplasms
Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.
Neoplasms
Histone deacetylase 1 and 2 regulate Wnt and p53 pathways in the ureteric bud epithelium.
Neoplasms
Histone deacetylase 1 facilitates aerobic glycolysis and growth of endometrial cancer.
Neoplasms
Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia.
Neoplasms
Histone deacetylase 1 is required for exocrine pancreatic epithelial proliferation in development and cancer.
Neoplasms
Histone deacetylase 1 plays a predominant pro-oncogenic role in E?-myc driven B cell lymphoma.
Neoplasms
Histone deacetylase 1 promotes glioblastoma cell proliferation and invasion via activation of PI3K/AKT and MEK/ERK signaling pathways.
Neoplasms
Histone deacetylase 1 regulates the malignancy of oral cancer cells via miR-154-5p/PCNA axis.
Neoplasms
Histone deacetylase 1 represses the small GTPase RhoB expression in human nonsmall lung carcinoma cell line.
Neoplasms
Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas.
Neoplasms
Histone deacetylase 1/Sp1/microRNA-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma.
Neoplasms
Histone Deacetylase 10 Regulates the Cell Cycle G2/M Phase Transition via a Novel Let-7-HMGA2-Cyclin A2 Pathway.
Neoplasms
Histone deacetylase 10 suppresses proliferation and invasion by inhibiting the phosphorylation of ?-catenin and serves as an independent prognostic factor for human clear cell renal cell carcinoma.
Neoplasms
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1.
Neoplasms
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.
Neoplasms
Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.
Neoplasms
Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Neoplasms
Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity.
Neoplasms
Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
Neoplasms
Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
Neoplasms
Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer.
Neoplasms
Histone deacetylase 3 controls a transcriptional network required for B cell maturation.
Neoplasms
Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration.
Neoplasms
Histone Deacetylase 3 Inhibitor Suppresses Hepatitis C Virus Replication by Regulating Apo-A1 and LEAP-1 Expression.
Neoplasms
Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer.
Neoplasms
Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5.
Neoplasms
Histone deacetylase 3 is negatively regulated by the nuclear protein deleted in breast cancer 1 (DBC1).
Neoplasms
Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition.
Neoplasms
Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway.
Neoplasms
Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling.
Neoplasms
Histone deacetylase 3 suppresses Erk phosphorylation and matrix metalloproteinase (Mmp)-13 activity in chondrocytes.
Neoplasms
Histone deacetylase 4 increases progressive epithelial ovarian cancer cells via repression of p21 on fibrillar collagen matrices.
Neoplasms
Histone deacetylase 4 inhibits NF-?B activation by facilitating I?B? sumoylation.
Neoplasms
Histone Deacetylase 4 Promotes Osteosarcoma Cell Proliferation and Invasion by Regulating Expression of Proliferating Cell Nuclear Antigen.
Neoplasms
Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis.
Neoplasms
Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells.
Neoplasms
Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies.
Neoplasms
Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells.
Neoplasms
Histone deacetylase 6 expression in metastatic lymph nodes is a valuable prognostic marker for resected node-positive esophageal squamous cell cancer.
Neoplasms
Histone deacetylase 6 inhibition impairs effector CD8 T-cell functions during skin inflammation.
Neoplasms
Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment.
Neoplasms
Histone deacetylase 6 is overexpressed and promotes tumor growth of colon cancer through regulation of the MAPK/ERK signal pathway.
Neoplasms
Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes.
Neoplasms
Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway.
Neoplasms
Histone deacetylase 6 regulates the immunosuppressive properties of cancer-associated fibroblasts in breast cancer through the STAT3-COX2-dependent pathway.
Neoplasms
Histone Deacetylase 6 Represents a Novel Drug Target in the Oncogenic Hedgehog Signaling Pathway.
Neoplasms
Histone deacetylase 6 selective inhibitor ACY1215 inhibits cell proliferation and enhances the chemotherapeutic effect of 5-fluorouracil in HCT116 cells.
Neoplasms
Histone Deacetylase 7 Gene Overexpression Is Associated with Poor Prognosis of Triple-Negative Breast Cancer Patients.
Neoplasms
Histone deacetylase 7 inhibits plakoglobin expression to promote lung cancer cell growth and metastasis.
Neoplasms
Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation.
Neoplasms
Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis.
Neoplasms
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
Neoplasms
Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function.
Neoplasms
Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment.
Neoplasms
Histone deacetylase 8 safeguards the human ever-shorter telomeres 1B (hEST1B) protein from ubiquitin-mediated degradation.
Neoplasms
Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals.
Neoplasms
Histone deacetylase 9 (HDAC9) regulates the functions of the ATDC (TRIM29) protein.
Neoplasms
Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment.
Neoplasms
Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Neoplasms
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Neoplasms
Histone deacetylase activity represses gamma interferon-inducible HLA-DR gene expression following the establishment of a DNase I-hypersensitive chromatin conformation.
Neoplasms
Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation.
Neoplasms
Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein.
Neoplasms
Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases.
Neoplasms
Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
Neoplasms
Histone deacetylase HDAC1 downregulates transcription of the serotonin transporter (5-HTT) gene in tumor cells.
Neoplasms
Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysis.
Neoplasms
Histone deacetylase HDAC4 participates in the pathological process of myocardial ischemia-reperfusion injury via MEKK1/JNK pathway by binding to miR-206.
Neoplasms
Histone Deacetylase HDAC8 Promotes Insulin Resistance and ?-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma.
Neoplasms
Histone deacetylase inhibition and blockade of the glycolytic pathway synergistically induce glioblastoma cell death.
Neoplasms
Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells.
Neoplasms
Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy.
Neoplasms
Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy.
Neoplasms
Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.
Neoplasms
Histone deacetylase inhibition down-regulates cyclin D1 transcription by inhibiting nuclear factor-kappaB/p65 DNA binding.
Neoplasms
Histone Deacetylase Inhibition Downregulates Collagen 3A1 in Fibrotic Lung Fibroblasts.
Neoplasms
Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor.
Neoplasms
Histone Deacetylase Inhibition Increases Levels of Choline Kinase ? and Phosphocholine Facilitating Noninvasive Imaging in Human Cancers.
Neoplasms
Histone deacetylase inhibition leads to regulatory histone mark alterations and impairs meiosis in oocytes.
Neoplasms
Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice.
Neoplasms
Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1.
Neoplasms
Histone deacetylase inhibition reduces cardiac connexin43 expression and gap junction communication.
Neoplasms
Histone Deacetylase Inhibition Restores Expression of Hypoxia-Inducible Protein NDRG1 in Pancreatic Cancer.
Neoplasms
Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects.
Neoplasms
Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells.
Neoplasms
Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series).
Neoplasms
Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts.
Neoplasms
Histone Deacetylase Inhibitor (HDACi) Conjugated Polycaprolactone for Combination Cancer Therapy.
Neoplasms
Histone deacetylase inhibitor and demethylating agent chromatin compaction and the radiation response by cancer cells.
Neoplasms
Histone deacetylase inhibitor AR-42 inhibits breast cancer cell growth and demonstrates a synergistic effect in combination with 5-FU.
Neoplasms
Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-? on pancreatic cancer cells.
Neoplasms
Histone Deacetylase Inhibitor Belinostat Represses Survivin Expression through Reactivation of Transforming Growth Factor {beta} (TGF{beta}) Receptor II Leading to Cancer Cell Death.
Neoplasms
Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins.
Neoplasms
Histone deacetylase inhibitor CG200745 ameliorates high-fat diet-induced hypertension via inhibition of angiotensin II production.
Neoplasms
Histone deacetylase inhibitor chidamide promotes reactivation of latent human immunodeficiency virus by introducing histone acetylation.
Neoplasms
Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma.
Neoplasms
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells.
Neoplasms
Histone deacetylase inhibitor enhances the anti-leukemic activity of an established nucleoside analogue.
Neoplasms
Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: A special reference to gene-expression microarray analysis.
Neoplasms
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Neoplasms
Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
Neoplasms
Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models.
Neoplasms
Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma.
Neoplasms
Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies.
Neoplasms
Histone deacetylase inhibitor induced pVHL-independent degradation of HIF-1? and hierarchical quality control of pVHL via chaperone system.
Neoplasms
Histone Deacetylase Inhibitor Induced Radiation Sensitization Effects on Human Cancer Cells after Photon and Hadron Radiation Exposure.
Neoplasms
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
Neoplasms
Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression.
Neoplasms
Histone Deacetylase Inhibitor Induction of P-Glycoprotein Transcription Requires Both Histone Deacetylase 1 Dissociation and Recruitment of CAAT/Enhancer Binding Protein {beta} and pCAF to the Promoter Region.
Neoplasms
Histone deacetylase inhibitor MGCD0103 causes cell cycle arrest, apoptosis, and autophagy in liver cancer cells.
Neoplasms
Histone Deacetylase Inhibitor Modulates NKG2D Receptor Expression and Memory Phenotype of Human Gamma/Delta T Cells Upon Interaction With Tumor Cells.
Neoplasms
Histone deacetylase inhibitor MPT0B291 suppresses Glioma Growth in vitro and in vivo partially through acetylation of p53.
Neoplasms
Histone deacetylase inhibitor pracinostat in doublet therapy: a unique strategy to improve therapeutic efficacy and to tackle herculean cancer chemoresistance.
Neoplasms
Histone deacetylase inhibitor prodrugs in nanoparticle vector enhanced gene expression in human cancer cells.
Neoplasms
Histone deacetylase inhibitor reverses multidrug resistance by attenuating the nucleophosmin level through PI3K/Akt pathway in breast cancer.
Neoplasms
Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma.
Neoplasms
Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma.
Neoplasms
Histone Deacetylase Inhibitor SAHA Induces Expression of Fatty Acid-Binding Protein 4 and Inhibits Replication of Human Cytomegalovirus.
Neoplasms
Histone deacetylase inhibitor SAHA-induced epithelial-mesenchymal transition by upregulating Slug in lung cancer cells.
Neoplasms
Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling.
Neoplasms
Histone deacetylase inhibitor stimulates E2 and P4 secretion in sika deer ovarian granulosa cells at a moderate dose.
Neoplasms
Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells.
Neoplasms
Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth
Neoplasms
Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line.
Neoplasms
Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo.
Neoplasms
Histone deacetylase inhibitor trichostatin A induced caspase-independent apoptosis in human gastric cancer cell.
Neoplasms
Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines.
Neoplasms
Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells.
Neoplasms
Histone deacetylase inhibitor trichostatin A sustains sodium pervanadate-induced NF-kappaB activation by delaying IkappaBalpha mRNA resynthesis: comparison with tumor necrosis factor alpha.
Neoplasms
Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion.
Neoplasms
Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein.
Neoplasms
Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing.
Neoplasms
Histone deacetylase inhibitor, AR-42, exerts antitumor effects by inducing apoptosis and cell cycle arrest in Y79 cells.
Neoplasms
Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography.
Neoplasms
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Neoplasms
Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells.
Neoplasms
Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53.
Neoplasms
Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism.
Neoplasms
Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin.
Neoplasms
Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53.
Neoplasms
Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation.
Neoplasms
Histone deacetylase inhibitors (HDACIs). Structure-activity relationships: history and new QSAR perspectives.
Neoplasms
Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.
Neoplasms
Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
Neoplasms
Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.
Neoplasms
Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis.
Neoplasms
Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration.
Neoplasms
Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells.
Neoplasms
Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials?
Neoplasms
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.
Neoplasms
Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations? delivery systems.
Neoplasms
Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
Neoplasms
Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
Neoplasms
Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
Neoplasms
Histone Deacetylase Inhibitors as Treatment for Targeting Multiple Components in Cancer Therapy.
Neoplasms
Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.
Neoplasms
Histone Deacetylase Inhibitors Augment Antitumor Efficacy of Herpes-based Oncolytic Viruses.
Neoplasms
Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes.
Neoplasms
Histone deacetylase inhibitors control the transcription and alternative splicing of prohibitin in thyroid tumor cells.
Neoplasms
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
Neoplasms
Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells.
Neoplasms
Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy.
Neoplasms
Histone deacetylase inhibitors deplete myeloid-derived suppressor cells induced by 4T1 mammary tumors in vivo and in vitro.
Neoplasms
Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
Neoplasms
Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity.
Neoplasms
Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.
Neoplasms
Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus.
Neoplasms
Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma.
Neoplasms
Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs.
Neoplasms
Histone Deacetylase Inhibitors Equipped with Estrogen Receptor Modulation Activity.
Neoplasms
Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success.
Neoplasms
Histone Deacetylase Inhibitors for the Treatment of Colorectal Cancer: Recent Progress and Future Prospects.
Neoplasms
Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.
Neoplasms
Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?
Neoplasms
Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
Neoplasms
Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents.
Neoplasms
Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell.
Neoplasms
Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
Neoplasms
Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential.
Neoplasms
Histone deacetylase inhibitors in the generation of the anti-tumour immune response.
Neoplasms
Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives.
Neoplasms
Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.
Neoplasms
Histone deacetylase inhibitors increase human arylamine N-acetyltransferase-1 expression in human tumor cells.
Neoplasms
Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression.
Neoplasms
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
Neoplasms
Histone deacetylase inhibitors induce attenuation of Wnt signaling and TCF7L2 depletion in colorectal carcinoma cells.
Neoplasms
Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.
Neoplasms
Histone deacetylase inhibitors induce cell death in supratentorial primitive neuroectodermal tumor cells.
Neoplasms
Histone deacetylase inhibitors induce cell death selectively in cells that harbor activated kRasV12: The role of signal transducers and activators of transcription 1 and p21.
Neoplasms
Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells.
Neoplasms
Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad.
Neoplasms
Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
Neoplasms
Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein.
Neoplasms
Histone deacetylase inhibitors induce the expression of tumor suppressor genes Per1 and Per2 in human gastric cancer cells.
Neoplasms
Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation.
Neoplasms
Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Neoplasms
Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors.
Neoplasms
Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.
Neoplasms
Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin dependent mechanism.
Neoplasms
Histone deacetylase inhibitors interrupt HSP90RASGRP1 and HSP90CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.
Neoplasms
Histone deacetylase inhibitors mediate post-transcriptional regulation of p21(WAF1) through novel cis-acting elements in the 3' untranslated region.
Neoplasms
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Neoplasms
Histone deacetylase inhibitors potentiate photochemotherapy in cutaneous T-cell lymphoma MyLa cells.
Neoplasms
Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.
Neoplasms
Histone deacetylase inhibitors prevent activation of tumour-reactive NK cells and T cells but do not interfere with their cytolytic effector functions.
Neoplasms
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity.
Neoplasms
Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms.
Neoplasms
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
Neoplasms
Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms.
Neoplasms
Histone deacetylase inhibitors promote epithelial-mesenchymal transition in Hepatocellular Carcinoma via AMPK-FOXO1-ULK1 signaling axis-mediated autophagy.
Neoplasms
Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.
Neoplasms
Histone deacetylase inhibitors reduce glycoprotein VI expression and platelet responses to collagen related peptide.
Neoplasms
Histone deacetylase inhibitors regulate p21WAF1 gene expression at the post-transcriptional level in HepG2 cells.
Neoplasms
Histone deacetylase inhibitors reinforce the phenotypical markers of breast epithelial or mesenchymal cancer cells but inhibit their migratory properties.
Neoplasms
Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha.
Neoplasms
Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells.
Neoplasms
Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis resistant mammary and brain cancer stem cells thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
Neoplasms
Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Neoplasms
Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity.
Neoplasms
Histone deacetylase inhibitors sensitize 5-fluorouracil-resistant MDA-MB-468 breast cancer cells to 5-fluorouracil.
Neoplasms
Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP.
Neoplasms
Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation.
Neoplasms
Histone Deacetylase Inhibitors Sensitize TRAIL-Induced Apoptosis in Colon Cancer Cells.
Neoplasms
Histone deacetylase inhibitors sensitize tumour cells for cytotoxic effects of natural killer cells.
Neoplasms
Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Neoplasms
Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis.
Neoplasms
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.
Neoplasms
Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells.
Neoplasms
Histone Deacetylase Inhibitors Suppress the Expression of Inflammatory and Innate Immune Response Genes in Human Microglia and Astrocytes.
Neoplasms
Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Neoplasms
Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
Neoplasms
Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation.
Neoplasms
Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.
Neoplasms
Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.
Neoplasms
Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.
Neoplasms
Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
Neoplasms
Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Neoplasms
Histone deacetylase inhibitors, N-butyric acid and trichostatin A, induce caspase-8- but not caspase-9-dependent apoptosis in human malignant glioma cells.
Neoplasms
Histone deacetylase inhibitors: a new class of potential therapeutic agents for cancer treatment.
Neoplasms
Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies.
Neoplasms
Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors.
Neoplasms
Histone deacetylase inhibitors: current status and overview of recent clinical trials.
Neoplasms
Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer.
Neoplasms
Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
Neoplasms
Histone deacetylase inhibitors: from chromatin remodeling to experimental cancer therapeutics.
Neoplasms
Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer.
Neoplasms
Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
Neoplasms
Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Neoplasms
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.
Neoplasms
Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?
Neoplasms
Histone deacetylase inhibitors: new treatment options for inflammatory joint disease?
Neoplasms
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect.
Neoplasms
Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex).
Neoplasms
Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors.
Neoplasms
Histone Deacetylase Inhibitory Activity of Peanut Testa Extracts against Human Cancer Cell Lines
Neoplasms
Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis.
Neoplasms
Histone deacetylase-1 as a prognostic factor and mediator of gastric cancer progression by enhancing glycolysis.
Neoplasms
Histone Deacetylase-3 Modification of MicroRNA-31 Promotes Cell Proliferation and Aerobic Glycolysis in Breast Cancer and Is Predictive of Poor Prognosis.
Neoplasms
Histone deacetylase-3mediates positive feedback relationship between anaphylaxis and tumor metastasis.
Neoplasms
Histone deacetylases 1 and 2 regulate DNA replication and DNA repair: potential targets for genome stability-mechanism-based therapeutics for a subset of cancers.
Neoplasms
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.
Neoplasms
Histone Deacetylases 5 and 9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth.
Neoplasms
Histone deacetylases and cancer-associated angiogenesis: current understanding of the biology and clinical perspectives.
Neoplasms
Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers.
Neoplasms
Histone deacetylases as targets for dietary cancer preventive agents: lessons learned with butyrate, diallyl disulfide, and sulforaphane.
Neoplasms
Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities.
Neoplasms
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes.
Neoplasms
Histone Deacetylases Inhibit the Snail2-Mediated EMT During Metastasis of Hepatocellular Carcinoma Cells.
Neoplasms
Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Neoplasms
Histone deacetylases inhibitors (HDACis) as novel therapeutic application in various clinical diseases.
Neoplasms
Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Neoplasms
Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma.
Neoplasms
Histone H4 deacetylation facilitates 53BP1 DNA damage signaling and double-strand break repair.
Neoplasms
Histone hyperacetylation during meiosis interferes with large-scale chromatin remodeling, axial chromatid condensation and sister chromatid separation in the mammalian oocyte.
Neoplasms
Histonedeacetylase 1 mRNA has elevated expression in clinical specimen of bladder cancer.
Neoplasms
HIV cure and eradication: how will we get from the laboratory to effective clinical trials?
Neoplasms
HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells.
Neoplasms
HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.
Neoplasms
Homology modeling and atomic level binding study of Leishmania MAPK with inhibitors.
Neoplasms
Homology modeling, force field design, and free energy simulation studies to optimize the activities of histone deacetylase inhibitors.
Neoplasms
HOXA10 promotion of HDAC1 underpins the development of lung adenocarcinoma through the DNMT1-KLF4 axis.
Neoplasms
hsa-miR-20a-5p attenuates allergic inflammation in HMC-1 cells by targeting HDAC4.
Neoplasms
Hsp90 regulates HDAC3-dependent gene transcription while HDAC3 regulates the functions of Hsp90.
Neoplasms
Human ATP-Binding Cassette transporters ABCB1 and ABCG2 confer resistance to CUDC-101, a multi-acting inhibitor of histone deacetylase, epidermal growth factor receptor and human epidermal growth factor receptor 2.
Neoplasms
Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines.
Neoplasms
Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis.
Neoplasms
Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid.
Neoplasms
Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining.
Neoplasms
Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest.
Neoplasms
Human ZNF312b oncogene is regulated by Sp1 binding to its promoter region through DNA demethylation and histone acetylation in gastric cancer.
Neoplasms
Hyaluronic acid promotes the expression of progesterone receptor membrane component 1 via epigenetic silencing of miR-139-5p in human and rat granulosa cells.
Neoplasms
Hyaluronic Acid-Functionalized Nanomicelles Enhance SAHA Efficacy in 3D Endometrial Cancer Models.
Neoplasms
Hybrid mesoporous nanorods with deeply grooved lateral faces toward cytosolic drug delivery.
Neoplasms
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.
Neoplasms
Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras-Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation.
Neoplasms
Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer.
Neoplasms
Hydrogen peroxide induces Sp1 methylation and thereby suppresses cyclin B1 via recruitment of Suv39H1 and HDAC1 in cancer cells.
Neoplasms
Hydrogen Sulfide Protects Cardiomyocytes against Apoptosis in Ischemia/Reperfusion through MiR-1-Regulated Histone Deacetylase 4 Pathway.
Neoplasms
Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines.
Neoplasms
Hydroxygenkwanin Inhibits Class I HDAC Expression and Synergistically Enhances the Antitumor Activity of Sorafenib in Liver Cancer Cells.
Neoplasms
Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer.
Neoplasms
Hypoacetylation in association with histone 3 modulation in human hepatocellular carcinoma.
Neoplasms
Hypoxia promotes colorectal cancer cell migration and invasion in a SIRT1-dependent manner.
Neoplasms
Hypoxia-Induced Downregulation of DUSP-2 Phosphatase Drives Colon Cancer Stemness.
Neoplasms
I-7ab inhibited the growth of TNBC cells via targeting HDAC3 and promoting the acetylation of p53.
Neoplasms
ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain.
Neoplasms
Identification and Characterization of KCASH2 and KCASH3, 2 Novel Cullin3 Adaptors Suppressing Histone Deacetylase and Hedgehog Activity in Medulloblastoma.
Neoplasms
Identification and characterization of the variants of metastasis-associated protein 1 generated following alternative splicing.
Neoplasms
Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.
Neoplasms
Identification of a better Homo sapiens Class II HDAC inhibitor through binding energy calculations and descriptor analysis.
Neoplasms
Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.
Neoplasms
Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr virus.
Neoplasms
Identification of a novel polyprenylated acylphloroglucinol?derived SIRT1 inhibitor with cancer?specific anti-proliferative and invasion-suppressing activities.
Neoplasms
Identification of an intrinsic determinant critical for maspin subcellular localization and function.
Neoplasms
Identification of and Molecular Basis for SIRT6 Loss-of-Function Point Mutations in Cancer.
Neoplasms
Identification of CASZ1 NES reveals potential mechanisms for loss of CASZ1 tumor suppressor activity in neuroblastoma.
Neoplasms
Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes.
Neoplasms
Identification of Dacinostat as a potential anti-obesity compound through transcriptional activation of adipose thermogenesis in mice.
Neoplasms
Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer.
Neoplasms
Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma.
Neoplasms
Identification of Histone Deacetylase Inhibitors with Benzoylhydrazide Scaffold that Selectively Inhibit Class I Histone Deacetylases.
Neoplasms
Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer.
Neoplasms
Identification of Hydroxamic Acid Based Selective HDAC1 Inhibitors: Computer Aided Drug Design Studies.
Neoplasms
Identification of LIV1, a putative zinc transporter gene responsible for HDACi-induced apoptosis, using a functional gene screen approach.
Neoplasms
Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
Neoplasms
Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group.
Neoplasms
Identification of novel isoform-selective inhibitors within class I histone deacetylases.
Neoplasms
Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy.
Neoplasms
Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein.
Neoplasms
Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
Neoplasms
Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines.
Neoplasms
Identification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays.
Neoplasms
Identifying molecular targets mediating the anticancer activity of histone deacetylase inhibitors: a work in progress.
Neoplasms
Identifying Novel Type ZBGs and Nonhydroxamate HDAC Inhibitors Through a SVM Based Virtual Screening Approach.
Neoplasms
IFN-? potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer.
Neoplasms
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy.
Neoplasms
Immunohistochemical analysis of acetylation, proliferation, mitosis, and apoptosis in tumor xenografts following administration of a histone deacetylase inhibitor--a pilot study.
Neoplasms
Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells.
Neoplasms
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.
Neoplasms
Impact of histone deacetylase 1 and metastasis-associated gene 1 expression in esophageal carcinogenesis.
Neoplasms
Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
Neoplasms
Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme.
Neoplasms
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.
Neoplasms
Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages.
Neoplasms
Impact of The Hybrid-Polar Histone Deacetylase Inhibitor M-Carboxycinnamic Acid Bis-Hydroxamide on Human Pancreatic Adenocarcinoma Cells.
Neoplasms
Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer.
Neoplasms
Implantable HDAC-inhibiting chemotherapeutics derived from hydrophobic amino acids for localized anticancer therapy.
Neoplasms
Importance of TFEB acetylation in control of its transcriptional activity and lysosomal function in response to histone deacetylase inhibitors.
Neoplasms
Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.
Neoplasms
Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides.
Neoplasms
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
Neoplasms
Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options.
Neoplasms
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.
Neoplasms
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development.
Neoplasms
In silico Design of Novel Sirtuin 1 Enzyme Activators for Treatment of Age-related Diseases and Life Span.
Neoplasms
In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).
Neoplasms
In Silico Screening Reveals Histone Deacetylase 7 and ERK1/2 as Potential Targets for Artemisinin Dimer and Artemisinin Dimer Hemisuccinate.
Neoplasms
In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.
Neoplasms
In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?
Neoplasms
In Vitro Effect of the Histone Deacetylase Inhibitor Valproic Acid on Viability and Apoptosis of the PLC/PRF5 Human Hepatocellular Carcinoma Cell Line
Neoplasms
In vitro evaluation of histone deacetylase inhibitors as combination agents for colorectal cancer.
Neoplasms
In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors.
Neoplasms
In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.
Neoplasms
In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model.
Neoplasms
Inactivating mutation in histone deacetylase 3 stabilizes its active conformation.
Neoplasms
Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells.
Neoplasms
Inactivation of the Akt/FOXM1 Signaling Pathway by Panobinostat Suppresses the Proliferation and Metastasis of Gastric Cancer Cells.
Neoplasms
Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression.
Neoplasms
Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist.
Neoplasms
Increase of Hspa1a and Hspa1b genes in the resting B cells of Sirt1 knockout mice.
Neoplasms
Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma.
Neoplasms
Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis.
Neoplasms
Increased expression of the HDAC9 gene is associated with antiestrogen resistance of breast cancers.
Neoplasms
Increased Histone Deacetylase Activity Involved in the Suppressed Invasion of Cancer Cells Survived from ALA-Mediated Photodynamic Treatment.
Neoplasms
Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹?F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.
Neoplasms
Increasing CD44+/CD24- tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis.
Neoplasms
Individualised Multimodal Treatment Strategies for Anaplastic and Poorly Differentiated Thyroid Cancer.
Neoplasms
Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease.
Neoplasms
Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells.
Neoplasms
Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
Neoplasms
Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells.
Neoplasms
Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C).
Neoplasms
Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.
Neoplasms
Induction of cell differentiation activates transcription of the Sarco/Endoplasmic Reticulum calcium-ATPase 3 gene (ATP2A3) in gastric and colon cancer cells.
Neoplasms
Induction of differentiation and apoptosis in leukaemic cell lines by the novel benzamide family histone deacetylase 2 and 3 inhibitor MI-192.
Neoplasms
Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha.
Neoplasms
Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib.
Neoplasms
Induction of murine H-rev107 gene expression by growth arrest and histone acetylation: involvement of an Sp1/Sp3-binding GC-box.
Neoplasms
Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors.
Neoplasms
Induction of Sodium/Iodide Symporter (NIS) Expression and Radioiodine Uptake in Non-Thyroid Cancer Cells.
Neoplasms
Induction of synergistic non-apoptotic cell death by simultaneously targeting proteasomes with bortezomib and histone deacetylase 6 with ricolinostat in head and neck tumor cells.
Neoplasms
Induction of the liver cancer-down-regulated long noncoding RNA uc002mbe.2 mediates trichostatin-induced apoptosis of liver cancer cells.
Neoplasms
Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53.
Neoplasms
Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Neoplasms
Influence of Histone Deacetylase Inhibitors and DNA-Methyltransferase Inhibitors on the NK Cell-Mediated Lysis of Pediatric B-Lineage Leukemia.
Neoplasms
ING2, a tumor associated gene, enhances PAI?1 and HSPA1A expression with HDAC1 and mSin3A through the PHD domain and C?terminal.
Neoplasms
Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-I? Expression.
Neoplasms
Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Neoplasms
Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.
Neoplasms
Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy.
Neoplasms
Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.
Neoplasms
Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells.
Neoplasms
Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.
Neoplasms
Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells.
Neoplasms
Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
Neoplasms
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer.
Neoplasms
Inhibition of HDAC3- and HDAC6-Promoted Survivin Expression Plays an Important Role in SAHA-Induced Autophagy and Viability Reduction in Breast Cancer Cells.
Neoplasms
Inhibition of HDAC6 activity through interaction with RanBPM and its associated CTLH complex.
Neoplasms
Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer.
Neoplasms
Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism.
Neoplasms
Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1.
Neoplasms
Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma.
Neoplasms
Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma.
Neoplasms
Inhibition of histone deacetylase 3 stimulates apoptosis induced by heat shock under acidic conditions in human maxillary cancer.
Neoplasms
Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells.
Neoplasms
Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
Neoplasms
Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Neoplasms
Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state.
Neoplasms
Inhibition of histone deacetylase activity is a novel function of the antifolate drug methotrexate.
Neoplasms
Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.
Neoplasms
Inhibition of Histone Deacetylase Attenuates Hypoxia-Induced Migration and Invasion of Cancer Cells via the Restoration of RECK Expression.
Neoplasms
Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Neoplasms
Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.
Neoplasms
Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer.
Neoplasms
Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage.
Neoplasms
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.
Neoplasms
Inhibition of histone deacetylation and DNA methylation improves gene expression mediated by the adeno-associated virus/phage in cancer cells.
Neoplasms
Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
Neoplasms
Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer.
Neoplasms
Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-But, a hyaluronic butyric ester: a preliminary report.
Neoplasms
Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
Neoplasms
Inhibition of mouse B16 melanoma by sodium butyrate correlated to tumor associated macrophages differentiation suppression.
Neoplasms
Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model.
Neoplasms
Inhibition of phospholipase D2 augments histone deacetylase inhibitor-induced cell death in breast cancer cells.
Neoplasms
Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA.
Neoplasms
Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors.
Neoplasms
Inhibition of store-operated Ca(2+) entry counteracts the apoptosis of nasopharyngeal carcinoma cells induced by sodium butyrate.
Neoplasms
Inhibition of tribbles protein-1 attenuates radioresistance in human glioma cells.
Neoplasms
Inhibition of tumor necrosis factor-alpha-inducible inflammatory genes by interferon-gamma is associated with altered nuclear factor-kappaB transactivation and enhanced histone deacetylase activity.
Neoplasms
Inhibition of type I histone deacetylase increases resistance of checkpoint-deficient cells to genotoxic agents through mitotic delay.
Neoplasms
Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
Neoplasms
Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.
Neoplasms
Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.
Neoplasms
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
Neoplasms
Inhibitory effects of cancer cell proliferation by novel histone deacetylase inhibitors involve p21/WAF1 induction and G2/M arrest.
Neoplasms
Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program.
Neoplasms
Innovative DNA-Targeted Metallo-prodrug Strategy Combining Histone Deacetylase Inhibition with Oxidative Stress.
Neoplasms
Insights into structural features of HDAC1 and its selectivity inhibition elucidated by Molecular dynamic simulation and Molecular Docking.
Neoplasms
Insights Into the Function and Clinical Application of HDAC5 in Cancer Management.
Neoplasms
Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy.
Neoplasms
Integration of pan-cancer transcriptomics with RPPA proteomics reveals mechanisms of epithelial-mesenchymal transition.
Neoplasms
Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.
Neoplasms
Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
Neoplasms
Interferon-inducible TRIM22 contributes to maintenance of HIV-1 proviral latency in T cell lines.
Neoplasms
Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer.
Neoplasms
Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer.
Neoplasms
Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity.
Neoplasms
Investigation of HDAC8-ligands' intermolecular forces through molecular dynamics simulations: profiling of non-bonding energies to design potential compounds as new anti-cancer agents.
Neoplasms
Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Neoplasms
Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Neoplasms
Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms.
Neoplasms
Involvement of epigenetics and microRNA-29b in the urethane induced inception and establishment of mouse lung tumors.
Neoplasms
Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone].
Neoplasms
Involvement of histone deacetylase 1/2 in adrenocorticotropic hormone synthesis and proliferation of corticotroph tumor AtT-20 cells.
Neoplasms
Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells.
Neoplasms
Involvement of p21(Waf1/Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate.
Neoplasms
Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228).
Neoplasms
Is level of acetylation directly correlated to radiation sensitivity of cancer cell?
Neoplasms
Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
Neoplasms
Isoproterenol increases histone deacetylase 6 expression and cell migration by inhibiting ERK signaling via PKA and Epac pathways in human lung cancer cells.
Neoplasms
Isotype-Specific Inhibition of Histone Deacetylases: Identification of Optimal Targets for Radiosensitization.
Neoplasms
It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.
Neoplasms
Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
Neoplasms
Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Neoplasms
JNJ-26481585, a Novel "Second-Generation" Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity.
Neoplasms
Karyotypically abnormal human ESCs are sensitive to HDAC inhibitors and show altered regulation of genes linked to cancers and neurological diseases.
Neoplasms
KBH-A42, a histone deacetylase inhibitor, inhibits the growth of doxorubicin-resistant leukemia cells expressing P-glycoprotein.
Neoplasms
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.
Neoplasms
KLF5 inhibits STAT3 activity and tumor metastasis in prostate cancer by suppressing IGF1 transcription cooperatively with HDAC1.
Neoplasms
Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ?-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs.
Neoplasms
Knockdown of HDAC1 expression suppresses invasion and induces apoptosis in glioma cells.
Neoplasms
Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.
Neoplasms
Kruppel-Like Factor 9 Loss-of-Expression in Human Endometrial Carcinoma Links Altered Expression of Growth-Regulatory Genes with Aberrant Proliferative Response to Estrogen.
Neoplasms
L1 retrotransposon and retinoblastoma: molecular linkages between epigenetics and cancer.
Neoplasms
Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in p53+/- and p53+/+ mice.
Neoplasms
Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms.
Neoplasms
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
Neoplasms
Lactam-based HDAC inhibitors for anticancer chemotherapy: restoration of RUNX3 by posttranslational modification and epigenetic control.
Neoplasms
Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases.
Neoplasms
Largazole, a class I histone deacetylase inhibitor, enhances TNF-?-induced ICAM-1 and VCAM-1 expression in rheumatoid arthritis synovial fibroblasts.
Neoplasms
LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate.
Neoplasms
LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma.
Neoplasms
Leishmania donovani Targets Host Transcription Factor NRF2 To Activate Antioxidant Enzyme HO-1 and Transcriptional Repressor ATF3 for Establishing Infection.
Neoplasms
Lentivirus-mediated Knockdown of HDAC1 Uncovers Its Role in Esophageal Cancer Metastasis and Chemosensitivity.
Neoplasms
LGP1, A histone deacetylase inhibitor analogue of FR235222, sensitizes promyelocytic leukaemia U937 cells to TRAIL-mediated apoptosis.
Neoplasms
Ligand Based Pharmacophore Modeling and Virtual Screening Studies to Design Novel HDAC2 Inhibitors.
Neoplasms
Light-Trigerred Cellular Epigenetic Molecule Release To Reverse Tumor Multidrug Resistance.
Neoplasms
LIM domain only 4 protein promotes granulocyte colony-stimulating factor-induced signaling in neurons.
Neoplasms
lin-35/Rb and the CoREST ortholog spr-1 coordinately regulate vulval morphogenesis and gonad development in C. elegans.
Neoplasms
Lipid rafts remodeling in estrogen receptor-negative breast cancer is reversed by histone deacetylase inhibitor.
Neoplasms
Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study.
Neoplasms
Live Cell Imaging Supports a Key Role for Histone Deacetylase as a Molecular Target during Glioblastoma Malignancy Downgrade through Tumor Competence Modulation.
Neoplasms
Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks.
Neoplasms
Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents.
Neoplasms
LncRNA RUNX1-IT1 which is downregulated by hypoxia-driven histone deacetylase 3 represses proliferation and cancer stem-like properties in hepatocellular carcinoma cells.
Neoplasms
Long non-coding RNA ARAP1-AS1 accelerates cell proliferation and migration in breast cancer through miR-2110/HDAC2/PLIN1 axis.
Neoplasms
Long non-coding RNA GAS5 suppresses rheumatoid arthritis progression via miR-128-3p/HDAC4 axis.
Neoplasms
Long-term cigarette smoke exposure inhibits histone deacetylase 2 expression and enhances the nuclear factor-?B activation in skeletal muscle of mice.
Neoplasms
Long-term use of valproic acid and the prevalence of cancers in bipolar disorder patients in a Taiwanese population: An association analysis using the National Health Insurance Research Database (NHIRD).
Neoplasms
Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer.
Neoplasms
Loop interactions and dynamics tune the enzymatic activity of the human histone deacetylase 8.
Neoplasms
Loss of Epigenetic Kruppel-like Factor 4 Histone Deacetylase (KLF-4-HDAC)-mediated Transcriptional Suppression Is Crucial in Increasing Vascular Endothelial Growth Factor (VEGF) Expression in Breast Cancer.
Neoplasms
Loss of histone deacetylase 4 causes segregation defects during mitosis of p53-deficient human tumor cells.
Neoplasms
Loss of RUNX3 expression by histone deacetylation is associated with biliary tract carcinogenesis.
Neoplasms
Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma.
Neoplasms
Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria.
Neoplasms
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Neoplasms
Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells.
Neoplasms
Low concentrations of vorinostat decrease EB1 expression in GBM cells and affect microtubule dynamics, cell survival and migration.
Neoplasms
Low levels of pyruvate induced by a positive feedback loop protects cholangiocarcinoma cells from apoptosis.
Neoplasms
Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumour Growth Arrest and Multi-lineage Differentiation of Malignant Rhabdoid Tumours.
Neoplasms
Low-dose tubacin promotes BMSCs proliferation and morphological changes through the ERK pathway.
Neoplasms
Low-Dose Valproic Acid Enhances Radiosensitivity of Prostate Cancer through Acetylated p53-Dependent Modulation of Mitochondrial Membrane Potential and Apoptosis.
Neoplasms
Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B.
Neoplasms
LukS-PV Inhibits Hepatocellular Carcinoma Progression by Downregulating HDAC2 Expression.
Neoplasms
Lysine acetylation in sexual stage malaria parasites is a target for antimalarial small molecules.
Neoplasms
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
Neoplasms
Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC.
Neoplasms
M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells.
Neoplasms
Macromolecular crowding effect is critical for maintaining SIRT1's nuclear localization in cancer cells.
Neoplasms
MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents.
Neoplasms
Maintenance of open DNA base pairs through histone acetylated lysine-purine interaction leading to transcriptional activation: a proposed mechanism.
Neoplasms
Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids.
Neoplasms
MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with a MEK inhibitor.
Neoplasms
MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF, NRAS, and NF1 mutant melanomas.
Neoplasms
Marbostat 100 defines a new class of potent and selective antiinflammatory and antirheumatic histone deacetylase 6 inhibitors.
Neoplasms
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Neoplasms
Maspin is a PTEN-Upregulated and p53-Upregulated Tumor Suppressor Gene and Acts as an HDAC1 Inhibitor in Human Bladder Cancer.
Neoplasms
Matairesinol, an active constituent of HC9 polyherbal formulation, exhibits HDAC8 inhibitory and anticancer activity.
Neoplasms
Maternal high-methyl diet suppresses mammary carcinogenesis in female rat offspring.
Neoplasms
MDA-9/Syntenin-Slug transcriptional complex promote epithelial-mesenchymal transition and invasion/metastasis in lung adenocarcinoma.
Neoplasms
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
Neoplasms
Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells.
Neoplasms
Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells.
Neoplasms
Mechanism of increased coxsackie and adenovirus receptor gene expression and adenovirus uptake by phytoestrogen and histone deacetylase inhibitor in human bladder cancer cells and the potential clinical application.
Neoplasms
Mechanism of N-Acylthiourea-mediated Activation of Human Histone Deacetylase 8 (HDAC8) at Molecular and Cellular Levels.
Neoplasms
Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
Neoplasms
Mechanisms of G1 cell cycle arrest and apoptosis in myeloma cells induced by hybrid-compound histone deacetylase inhibitor.
Neoplasms
Mechanisms of Histone Deacetylase Inhibitor-Regulated Gene Expression in Cancer Cells.
Neoplasms
Mechanisms of resistance to histone deacetylase inhibitors and their therapeutic implications.
Neoplasms
Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis.
Neoplasms
Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
Neoplasms
Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies.
Neoplasms
Metabolism-related liabilities of a potent histone deacetylase (HDAC) inhibitor and relevance of the route of administration on its metabolic fate.
Neoplasms
Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival.
Neoplasms
Metastasis-associated Protein 1 Drives Tumor Cell Migration and Invasion through Transcriptional Repression of RING Finger Protein 144A.
Neoplasms
Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1.
Neoplasms
Metastasis-associated Protein 1/Histone Deacetylase 4-Nucleosome Remodeling and Deacetylase Complex Regulates Phosphatase and Tensin Homolog Gene Expression and Function.
Neoplasms
Metastasis-associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer.
Neoplasms
Metastasis-associated protein 2 promotes the metastasis of non-small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways.
Neoplasms
Metastatic prostate cancer-associated P62 inhibits autophagy flux and promotes epithelial to mesenchymal transition by sustaining the level of HDAC6.
Neoplasms
Metformin ameliorates endotoxemia-induced endothelial pro-inflammatory responses via AMPK-dependent mediation of HDAC5 and KLF2.
Neoplasms
Metformin Augments Panobinostat's Anti-Bladder Cancer Activity by Activating AMP-Activated Protein Kinase.
Neoplasms
Metformin Synergistically Enhances Antitumor Activity of Histone Deacetylase Inhibitor Trichostatin A Against Osteosarcoma Cell Line.
Neoplasms
Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
Neoplasms
Methyl CpG-binding domain protein 3 mediates cancer-selective cytotoxicity by histone deacetylase inhibitors via differential transcriptional reprogramming in lung cancer cells.
Neoplasms
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
Neoplasms
Methylation of C/EBP? by PRMT1 Inhibits Its Tumor-Suppressive Function in Breast Cancer.
Neoplasms
Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells.
Neoplasms
Microarray gene expression profiling reveals potential mechanisms of tumor suppression by the class I HDAC-selective benzoylhydrazide inhibitors.
Neoplasms
Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines.
Neoplasms
Microarray study of mechanism of trichostatin a inducing apoptosis of Molt-4 cells.
Neoplasms
Microbial butyrate and its role for barrier function in the gastrointestinal tract.
Neoplasms
MicroRNA expression and protein acetylation pattern in respiratory and limb muscles of Parp-1(-/-) and Parp-2(-/-) mice with lung cancer cachexia.
Neoplasms
MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer.
Neoplasms
MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8.
Neoplasms
MicroRNA-22 negatively regulates LPS-induced inflammatory responses by targeting HDAC6 in macrophages.
Neoplasms
microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity.
Neoplasms
MicroRNA-221 governs tumor suppressor HDAC6 to potentiate malignant progression of liver cancer.
Neoplasms
MicroRNA-223 controls the expression of histone deacetylase 2: a novel axis in COPD.
Neoplasms
MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas.
Neoplasms
Microtubule-associated histone deacetylase 6 supports the calcium store sensor STIM1 in mediating malignant cell behaviors.
Neoplasms
Minichromosome Maintenance Complex Is a Critical Node in the miR-183 Signaling Network of MYCN-Amplified Neuroblastoma Cells.
Neoplasms
miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis.
Neoplasms
MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer.
Neoplasms
miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer.
Neoplasms
miR-326-histone deacetylase-3 feedback loop regulates the invasion and tumorigenic and angiogenic response to anti-cancer drugs.
Neoplasms
miR-335 Targets SIAH2 and Confers Sensitivity to Anti-Cancer Drugs by Increasing the Expression of HDAC3.
Neoplasms
MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer.
Neoplasms
miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6.
Neoplasms
miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8 oncogene.
Neoplasms
MiR-489 inhibited the development of gastric cancer via regulating HDAC7 and PI3K/AKT pathway.
Neoplasms
MiR-489 suppresses tumor growth and invasion by targeting HDAC7 in colorectal cancer.
Neoplasms
miR-489-3p inhibits proliferation and migration of bladder cancer cells through downregulation of histone deacetylase 2.
Neoplasms
miR-490-3p modulates the progression of prostate cancer through regulating histone deacetylase 2.
Neoplasms
MiR-584-5p potentiates vincristine and radiation response by inducing spindle defects and DNA damage in medulloblastoma.
Neoplasms
MiR-761 inhibits colorectal cancer cell proliferation and invasion through targeting HDAC1.
Neoplasms
Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
Neoplasms
Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents.
Neoplasms
MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells.
Neoplasms
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.
Neoplasms
Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors.
Neoplasms
Modulating chromatin structure and DNA accessibility by deacetylase inhibition enhances the anti-cancer activity of silver nanoparticles.
Neoplasms
Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
Neoplasms
Modulation of antigen-presenting cells by HDAC inhibitors: implications in autoimmunity and cancer.
Neoplasms
Modulation of histone deacetylase activity by dietary isothiocyanates and allyl sulfides: studies with sulforaphane and garlic organosulfur compounds.
Neoplasms
Modulation of NKG2D-ligand Cell Surface Expression Enhances Immune Cell Therapy of Cancer.
Neoplasms
Molecular and cellular effects of a novel hydroxamate-based HDAC inhibitor - belinostat - in glioblastoma cell lines: a preliminary report.
Neoplasms
Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor.
Neoplasms
Molecular basis of histone deacetylase inhibitors as new drugs for the treatment of inflammatory diseases and cancer.
Neoplasms
Molecular characterization of the grape seeds extract's effect against chemically induced liver cancer: In vivo and in vitro analyses.
Neoplasms
Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells.
Neoplasms
Molecular dynamics simulation of complex Histones Deacetylase (HDAC) Class II Homo Sapiens with suberoylanilide hydroxamic acid (SAHA) and its derivatives as inhibitors of cervical cancer.
Neoplasms
Molecular mechanisms underlying eicosapentaenoic acid inhibition of HDAC1 and DNMT expression and activity in carcinoma cells.
Neoplasms
Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo.
Neoplasms
Molecular Probing and Imaging of Histone Deacetylase Inhibitors in Cancer Treatment.
Neoplasms
Molecular profiling of embryonal carcinoma cells following retinoic acid or histone deacetylase inhibitor treatment.
Neoplasms
Molecular, biological characterization and drug sensitivity of chidamide-resistant non-small cell lung cancer cells.
Neoplasms
Monitoring Tumor Response After Histone Deacetylase Inhibitor Treatment Using 3'-Deoxy-3'-[(18)F]-fluorothymidine PET.
Neoplasms
MPT0G612, a Novel HDAC6 Inhibitor, Induces Apoptosis and Suppresses IFN-?-Induced Programmed Death-Ligand 1 in Human Colorectal Carcinoma Cells.
Neoplasms
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
Neoplasms
MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
Neoplasms
MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis.
Neoplasms
MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells.
Neoplasms
MTA3-SOX2 Module Regulates Cancer Stemness and Contributes to Clinical Outcomes of Tongue Carcinoma.
Neoplasms
MUC1-C Activates The NuRD Complex To Drive Dedifferentiation of Triple-Negative Breast Cancer Cells.
Neoplasms
Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition.
Neoplasms
Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Neoplasms
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
Neoplasms
Multigene expression-based predictors for sensitivity to Vorinostat and Velcade in non-small cell lung cancer.
Neoplasms
Multiple pathways regulating the anti-apoptotic protein clusterin in breast cancer.
Neoplasms
Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 inhibitors.
Neoplasms
Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol-3-kinase (PI3K): Current and Future Prospects.
Neoplasms
Mutagenesis studies of the 14 Å internal cavity of histone deacetylase 1: insights toward the acetate-escape hypothesis and selective inhibitor design.
Neoplasms
N-(2-hydroxyphenyl)-2-propylpentanamide, a valproic acid aryl derivative designed in silico with improved anti-proliferative activity in HeLa, rhabdomyosarcoma and breast cancer cells.
Neoplasms
Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors.
Neoplasms
Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial-mesenchymal transition in cancer cells.
Neoplasms
Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer.
Neoplasms
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Neoplasms
Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity.
Neoplasms
NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.
Neoplasms
Negative and positive regulation of gene expression by mouse histone deacetylase 1.
Neoplasms
Nemo-like kinase (NLK) primes colorectal cancer progression by releasing the E2F1 complex from HDAC1.
Neoplasms
Neuroblastoma stem cells - mechanisms of chemoresistance and histonedeacetylase inhibitors.
Neoplasms
New Benzothiazole/thiazole-Containing Hydroxamic Acids as Potent Histone Deacetylase Inhibitors and Antitumor Agents.
Neoplasms
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.
Neoplasms
New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.
Neoplasms
New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells.
Neoplasms
New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas.
Neoplasms
New Platinum-Based Prodrug Pt(IV)Ac-POA: Antitumour Effects in Rat C6 Glioblastoma Cells.
Neoplasms
New therapeutic approaches for solid tumors: Histone deacetylase, methyltransferase and proteasome inhibitors.
Neoplasms
NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells.
Neoplasms
Nicotine inhibits the proliferation by upregulation of nitric oxide and increased HDAC1 in mouse neural stem cells.
Neoplasms
NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.
Neoplasms
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss.
Neoplasms
Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability.
Neoplasms
Non-homologous end joining, but not homologous recombination, enables survival for cells exposed to a histone deacetylase inhibitor.
Neoplasms
Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton.
Neoplasms
Non-viral delivery of the connexin 43 gene with histone deacetylase inhibitor to human nasopharyngeal tumor cells enhances gene expression and inhibits in vivo tumor growth.
Neoplasms
NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2.
Neoplasms
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
Neoplasms
Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma.
Neoplasms
Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
Neoplasms
Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR.
Neoplasms
Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.
Neoplasms
Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach.
Neoplasms
Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays.
Neoplasms
Novel folate-hydroxamate based antimetabolites: synthesis and biological evaluation.
Neoplasms
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Neoplasms
Novel HDAC11 inhibitors suppress lung adenocarcinoma stem cell self-renewal and overcome drug resistance by suppressing Sox2.
Neoplasms
Novel Histone Deacetylase 6 Inhibitors for Treating Alzheimer's Disease and Cancer.
Neoplasms
Novel histone deacetylase 8-selective inhibitor 1,3,4-oxadiazole-alanine hybrid induces apoptosis in breast cancer cells.
Neoplasms
Novel histone deacetylase inhibitor CG200745 induces clonogenic cell death by modulating acetylation of p53 in cancer cells.
Neoplasms
Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
Neoplasms
Novel histone deacetylase inhibitors and embryo aggregation enhance cloned embryo development and ES cell derivation in pigs.
Neoplasms
Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.
Neoplasms
Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling.
Neoplasms
Novel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
Neoplasms
Novel Non-Congeneric Derivatives of the Choline Kinase Alpha Inhibitor ICL-CCIC-0019.
Neoplasms
Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.
Neoplasms
Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.
Neoplasms
Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
Neoplasms
Novel Three-Pronged Strategy to Enhance Cancer Cell Killing in Glioblastoma Cell Lines: Histone Deacetylase Inhibitor, Chemotherapy, and Oncolytic Adenovirus dl520.
Neoplasms
Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.
Neoplasms
Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
Neoplasms
Nrf2 status affects tumor growth, HDAC3 gene promoter associations, and the response to sulforaphane in the colon.
Neoplasms
Nrf2-miR-129-3p-mTOR Axis Controls an miRNA Regulatory Network Involved in HDACi-Induced Autophagy.
Neoplasms
Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate.
Neoplasms
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Neoplasms
Nuclear HDAC6 inhibits invasion by suppressing NF-?B/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer.
Neoplasms
Nuclear import of histone deacetylase 5 by requisite nuclear localization signal phosphorylation.
Neoplasms
Nuclear Respiratory Factor 1 (NRF1) Transcriptional Activity-Driven Gene Signature Association with Severity of Astrocytoma and Poor Prognosis of Glioblastoma.
Neoplasms
Of old and new diseases: genetics of pituitary ACTH excess (Cushing) and deficiency.
Neoplasms
OIP5-AS1 modulates epigenetic regulator HDAC7 to enhance non-small cell lung cancer metastasis via miR-140-5p.
Neoplasms
Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells.
Neoplasms
Oncolytic viruses and histone deacetylase inhibitors-A multi-pronged strategy to target tumor cells.
Neoplasms
Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide.
Neoplasms
Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation.
Neoplasms
Opposing roles of the two isoforms of ErbB3 binding protein 1 in human cancer cells.
Neoplasms
Optimization of a series of potent and selective ketone histone deacetylase inhibitors.
Neoplasms
Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes.
Neoplasms
Optimization of histone deacetylase inhibitor activity in non-secosteroidal vitamin D-receptor agonist hybrids.
Neoplasms
Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
Neoplasms
ORAL 5-AZACYTIDINE AND ROMIDEPSIN EXHIBIT MARKED ACTIVITY IN PATIENTS WITH PTCL: A MULTICENTER PHASE I STUDY.
Neoplasms
Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo.
Neoplasms
Ornithine decarboxylase activity in tumor cell lines correlates with sensitivity to cell death induced by histone deacetylase inhibitors.
Neoplasms
Osteoblasts modulate Ca(2+) signaling in bone-metastatic prostate and breast cancer cells.
Neoplasms
OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.
Neoplasms
Overcome the tumor immunotherapy resistance by combination of the HDAC6 inhibitors with antitumor immunomodulatory agents.
Neoplasms
Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations.
Neoplasms
Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma.
Neoplasms
Overexpression of HDAC6 suppresses tumor cell proliferation and metastasis by inhibition of the canonical Wnt/?-catenin signaling pathway in hepatocellular carcinoma.
Neoplasms
Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females.
Neoplasms
Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis.
Neoplasms
Overexpression of Histone Deacetylase 2 Predicts Unfavorable Prognosis in Human Gallbladder Carcinoma.
Neoplasms
Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells.
Neoplasms
Overexpression of Histone Deacetylase and Amyloid Precursor Protein in Hepatocellular Carcinoma.
Neoplasms
Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha.
Neoplasms
Overexpression of Human ABCB1 and ABCG2 Reduces the Susceptibility of Cancer Cells to the Histone Deacetylase 6-Specific Inhibitor Citarinostat.
Neoplasms
Overexpression of miR-140 inhibits proliferation of osteosarcoma cells via suppression of histone deacetylase 4.
Neoplasms
Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer.
Neoplasms
p21 and CK2 interaction-mediated HDAC2 phosphorylation modulates KLF4 acetylation to regulate bladder cancer cell proliferation.
Neoplasms
p21 Downregulation is an important component of PAX3/FKHR oncogenicity and its reactivation by HDAC inhibitors enhances combination treatment.
Neoplasms
P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
Neoplasms
p300 promotes differentiation of Th17 cells via positive regulation of the nuclear transcription factor ROR?t in acute respiratory distress syndrome.
Neoplasms
p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death.
Neoplasms
p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y.
Neoplasms
Paclitaxel disrupts polarized entry of membrane-permeable C6 ceramide into ovarian cancer cells resulting in synchronous induction of cell death.
Neoplasms
Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial.
Neoplasms
Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.
Neoplasms
Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
Neoplasms
Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
Neoplasms
Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Neoplasms
Paraneoplastic limbic encephalitis in a patient with extensive disease small-cell lung cancer.
Neoplasms
Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Primary and Recurrent Meningioma.
Neoplasms
PCDH17 functions as a common tumor suppressor gene in acute leukemia and its transcriptional downregulation is mediated primarily by aberrant histone acetylation, not DNA methylation.
Neoplasms
PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway.
Neoplasms
PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells.
Neoplasms
Peanut testa extracts possessing histone deacetylase inhibitory activity induce apoptosis in cholangiocarcinoma cells.
Neoplasms
PEGylated and Functionalized Aliphatic Polycarbonate Polyplex Nanoparticles for Intravenous Administration of HDAC5 siRNA in Cancer Therapy.
Neoplasms
Pendant HDAC inhibitor SAHA derivatised polymer as a novel prodrug micellar carrier for anticancer drugs.
Neoplasms
Peptide Based Macrocycles: Selective Histone Deacetylase Inhibitors with Antiproliferative Activity.
Neoplasms
Peptide-templated gold nanoparticle nanosensor for simultaneous detection of multiple posttranslational modification enzymes.
Neoplasms
Peroxisome proliferator-activated receptor alpha expression is regulated by estrogen receptor alpha and modulates the response of MCF-7 cells to sodium butyrate.
Neoplasms
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.
Neoplasms
Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Neoplasms
Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy.
Neoplasms
Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer.
Neoplasms
Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue.
Neoplasms
Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101.
Neoplasms
Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
Neoplasms
Pharmacological Characterization of Histone Deacetylase Inhibitor and Tumor Cell-Growth Inhibition Properties of New Benzofuranone Compounds.
Neoplasms
Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment.
Neoplasms
Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications.
Neoplasms
Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.
Neoplasms
Pharmacophore Based 3D-QSAR, Virtual Screening and Docking Studies on Novel Series of HDAC Inhibitors with Thiophen Linker as Anticancer Agents.
Neoplasms
Pharmacophore modeling and virtual screening studies to design some potential histone deacetylase inhibitors as new leads.
Neoplasms
Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6.
Neoplasms
Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer.
Neoplasms
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Neoplasms
Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.
Neoplasms
Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Neoplasms
Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.
Neoplasms
Phase 1/1b study of pembrolizumab plus vorinostat in advanced/metastatic non-small cell lung cancer.
Neoplasms
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
Neoplasms
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies.
Neoplasms
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Neoplasms
Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.
Neoplasms
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
Neoplasms
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.
Neoplasms
Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors.
Neoplasms
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.
Neoplasms
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
Neoplasms
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.
Neoplasms
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
Neoplasms
Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
Neoplasms
Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844).
Neoplasms
Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.
Neoplasms
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
Neoplasms
Phase I trial of ATRA-IV and depakote in patients with advanced solid tumor malignancies.
Neoplasms
Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.
Neoplasms
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung.
Neoplasms
Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Neoplasms
Phase I trial of induction histone deacetylase and proteasome inhibition followed by surgery in non-small-cell lung cancer.
Neoplasms
Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies.
Neoplasms
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Neoplasms
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
Neoplasms
Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma or Leukemia.
Neoplasms
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Neoplasms
Phase II Multicenter Trial of Oral Quisinostat, a Histone Deacetylase Inhibitor, in Patients with Previously Treated Stage IB-IVA Mycosis Fungoides/Sézary Syndrome.
Neoplasms
Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).
Neoplasms
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Neoplasms
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
Neoplasms
Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect.
Neoplasms
Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells.
Neoplasms
Phenylbutyrate Mouthwash Mitigates Oral Mucositis During Radiotherapy or Chemoradiotherapy in Patients with Head and Neck Cancer.
Neoplasms
Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation.
Neoplasms
Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury.
Neoplasms
Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line.
Neoplasms
Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo.
Neoplasms
Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma.
Neoplasms
PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast cancer: a novel regulation of estrogen receptor expression.
Neoplasms
Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.
Neoplasms
PIWIL2 suppresses Siah2-mediated degradation of HDAC3 and facilitates CK2?-mediated HDAC3 phosphorylation.
Neoplasms
PKC? phosphorylates MIIP and promotes colorectal cancer metastasis through inhibition of RelA deacetylation.
Neoplasms
Plant flavone apigenin inhibits HDAC and remodels chromatin to induce growth arrest and apoptosis in human prostate cancer cells: In vitro and in vivo study.
Neoplasms
Plant polyphenols and oxidative metabolites of the herbal alkenylbenzene methyleugenol suppress histone deacetylase activity in human colon carcinoma cells.
Neoplasms
Poly(beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer.
Neoplasms
Polycythemia vera: the current status of preclinical models and therapeutic targets.
Neoplasms
Polymerized vorinostat mediated photodynamic therapy using lysosomal spatiotemporal synchronized drug release complex.
Neoplasms
Polyphotosensitizer nanogels for GSH-responsive histone deacetylase inhibitors delivery and enhanced cancer photodynamic therapy.
Neoplasms
Polysaccharide Nanoparticles Bearing HDAC Inhibitor as Nontoxic Nanocarrier for Drug Delivery.
Neoplasms
Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Neoplasms
Possible mechanisms of action of clarithromycin and its clinical application as a repurposing drug for treating multiple myeloma.
Neoplasms
Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
Neoplasms
Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo.
Neoplasms
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
Neoplasms
Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer.
Neoplasms
Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
Neoplasms
Potentiation of mitomycin C tumoricidal activity for transitional cell carcinoma by histone deacetylase inhibitors in vitro.
Neoplasms
Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01.
Neoplasms
PPARgamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2.
Neoplasms
Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
Neoplasms
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Neoplasms
Preclinical antileukemia activity of JNJ-26481585, a potent second-generation histone deacetylase inhibitor.
Neoplasms
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors.
Neoplasms
Preclinical evaluation and molecular docking of 1,3-benzodioxole propargyl ether derivatives as novel inhibitor for combating the histone deacetylase enzyme in cancer.
Neoplasms
Preclinical Pharmacokinetics and Pharmacodynamics and Content Analysis of Gnetol in Foodstuffs.
Neoplasms
Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents.
Neoplasms
Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer.
Neoplasms
Preparation and evaluation of tributyrin emulsion as a potent anti-cancer agent against melanoma.
Neoplasms
Primary macrophages rely on histone deacetylase 1 and 2 expression to induce type I interferon in response to gammaherpesvirus infection.
Neoplasms
Pro-apoptotic activity of oncogenic H-Ras for histone deacetylase inhibitor to induce apoptosis of human cancer HT29 cells.
Neoplasms
Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells.
Neoplasms
Profile of panobinostat and its potential for treatment in solid tumors: an update.
Neoplasms
Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: A meta-analysis.
Neoplasms
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma.
Neoplasms
Progress in the Discovery of Macrocyclic Histone Deacetylase Inhibitors for the Treatment of Cancer.
Neoplasms
Promoter Hypomethylation and miR-145-5p Downregulation- Mediated HDAC11 Overexpression Promotes Sorafenib Resistance and Metastasis of Hepatocellular Carcinoma Cells.
Neoplasms
Promoter methylation status of tumor suppressor genes and inhibition of expression of DNA methyltransferase 1 in non-small cell lung cancer.
Neoplasms
Promotion of Metastasis-associated Gene Expression in Survived PANC-1 Cells Following Trichostatin A Treatment.
Neoplasms
Promyelocytic Leukemia Nuclear Bodies Link the DNA Damage Repair Pathway with Hepatitis B Virus Replication: Implications for Hepatitis B Virus Exacerbation during Chemotherapy and Radiotherapy.
Neoplasms
Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action.
Neoplasms
Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
Neoplasms
Proteasome inhibitors trigger mutations via activation of caspases and CAD, but mutagenesis provoked by the HDAC inhibitors vorinostat and romidepsin is caspase/CAD-independent.
Neoplasms
Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer.
Neoplasms
Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression.
Neoplasms
Protein kinase CK2 is a key activator of histone deacetylase in hypoxia-associated tumors.
Neoplasms
Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells.
Neoplasms
Proteomic analysis identifies protein targets responsible for depsipeptide sensitivity in tumor cells.
Neoplasms
Proteomic analysis of cervical cancer cells treated with suberonylanilide hydroxamic acid.
Neoplasms
Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid.
Neoplasms
Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A.
Neoplasms
Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies.
Neoplasms
Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat.
Neoplasms
Proteomic study identified HSP 70 kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms.
Neoplasms
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
Neoplasms
Pt(IV) pro-drugs with an axial HDAC inhibitor demonstrate multimodal mechanisms involving DNA damage and apoptosis independent of cisplatin resistance in A2780/A2780cis cells.
Neoplasms
PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition.
Neoplasms
Pterostilbene inhibits MTA1/HDAC1 complex leading to PTEN acetylation in hepatocellular carcinoma.
Neoplasms
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
Neoplasms
Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection.
Neoplasms
PXD101 analogs with L-phenylglycine-containing branched cap as histone deacetylase inhibitors.
Neoplasms
Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
Neoplasms
Quantitative Analysis of Histone Deacetylase-1 Selective Histone Modifications by Differential Mass Spectrometry.
Neoplasms
Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry.
Neoplasms
Quercetin inhibited the proliferation and invasion of hepatoblastoma cells through facilitating SIRT6-medicated FZD4 silence.
Neoplasms
Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small-Cell Lung Cancer.
Neoplasms
Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets.
Neoplasms
R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.
Neoplasms
Radical-Mediated Thiol-Ene Strategy: Photoactivation of Thiol-Containing Drugs in Cancer Cells.
Neoplasms
Radio- and chemo-sensitization of human erythroleukemic K562 cells by the histone deacetylase inhibitor Trichostatin A.
Neoplasms
Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression.
Neoplasms
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition.
Neoplasms
Radiosynthesis and preliminary evaluation of an 18 F-labeled tubastatin A analog for PET imaging of histone deacetylase 6.
Neoplasms
Rapid and profound potentiation of Apo2L/TRAIL-mediated cytotoxicity and apoptosis in thoracic cancer cells by the histone deacetylase inhibitor Trichostatin A: the essential role of the mitochondria-mediated caspase activation cascade.
Neoplasms
Ras/MAP kinase pathways are involved in Ras specific apoptosis induced by sodium butyrate.
Neoplasms
RASSF1A Regulates Spindle Organization by Modulating Tubulin Acetylation via SIRT2 and HDAC6 in Mouse Oocytes.
Neoplasms
Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models.
Neoplasms
Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
Neoplasms
Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.
Neoplasms
RB independent G1-phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor and histone deacetylase inhibitor.
Neoplasms
RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest.
Neoplasms
Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation.
Neoplasms
Real-time gene expression analysis in human xenografts for evaluation of histone deacetylase inhibitors.
Neoplasms
Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.
Neoplasms
Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition.
Neoplasms
Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy.
Neoplasms
Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.
Neoplasms
Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.
Neoplasms
Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition.
Neoplasms
Regulated Polarization of Tumor-Associated Macrophages by miR-145 via Colorectal Cancer-Derived Extracellular Vesicles.
Neoplasms
Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Neoplasms
Regulation of CD133 by HDAC6 promotes ?-catenin signaling to suppress cancer cell differentiation.
Neoplasms
Regulation of Glioblastoma Stem-like Cells by Id proteins and Olig transcription factors.
Neoplasms
Regulation of histone deacetylase 4 expression by the SP family of transcription factors.
Neoplasms
Regulation of Nuclear Translocation of HDAC3 by I{kappa}B{alpha} Is Required for Tumor Necrosis Factor Inhibition of Peroxisome Proliferator-activated Receptor {gamma} Function.
Neoplasms
Regulation of radiosensitivity by HDAC inhibitor trichostatin A in the human cervical carcinoma cell line Hela.
Neoplasms
Regulation of vascular endothelial growth factor D by orphan receptors hepatocyte nuclear factor-4 alpha and chicken ovalbumin upstream promoter transcription factors 1 and 2.
Neoplasms
Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.
Neoplasms
Renoprotective Effect of the Histone Deacetylase Inhibitor CG200745 in DOCA-Salt Hypertensive Rats.
Neoplasms
Repositioning antipsychotic chlorpromazine for treating colorectal cancer by inhibiting sirtuin 1.
Neoplasms
Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.
Neoplasms
Repression of hepatocyte nuclear factor 4alpha tumor suppressor p53: involvement of the ligand-binding domain and histone deacetylase activity.
Neoplasms
Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer.
Neoplasms
Requirement of HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition.
Neoplasms
Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.
Neoplasms
Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential.
Neoplasms
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Neoplasms
Resveratrol reverses morphine-induced neuroinflammation in morphine-tolerant rats by reversal HDAC1 expression.
Neoplasms
Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells.
Neoplasms
Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Neoplasms
Retraction: Identification of Histone Deacetylase 3 as a Biomarker for Tumor Recurrence Following Liver Transplantation in HBV-Associated Hepatocellular Carcinoma.
Neoplasms
Retraction: Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator.
Neoplasms
Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine.
Neoplasms
Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways.
Neoplasms
Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth.
Neoplasms
RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells.
Neoplasms
Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression.
Neoplasms
Role of ATF3 in synergistic cancer cell killing by a combination of HDAC inhibitors and agonistic anti-DR5 antibody through ER stress in human colon cancer cells.
Neoplasms
Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors.
Neoplasms
Role of histone deacetylase 3 in ankylosing spondylitis via negative feedback loop with microRNA-130a and enhancement of tumor necrosis factor-1? expression in peripheral blood mononuclear cells.
Neoplasms
Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma.
Neoplasms
Role of Histone Deacetylases and Their Inhibitors in Cancer Biology and Treatment.
Neoplasms
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies.
Neoplasms
Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Neoplasms
Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents.
Neoplasms
Role of p53 status in chemosensitivity determination of cancer cells against histone deacetylase inhibitor sodium butyrate.
Neoplasms
Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition?
Neoplasms
Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation.
Neoplasms
Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines.
Neoplasms
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression.
Neoplasms
ROLE OF Wip1-p53 AXIS IN RESPONSE OF MURINE CELLS TO TREATMENT WITH SODIUM BUTYRATE AND MEK/ERK SIGNALLING PATHWAY INHIBITOR.
Neoplasms
Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression.
Neoplasms
Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer.
Neoplasms
Romidepsin (FK228), An Histone Deacetylase Inhibitor, and its Analogues in Cancer Chemotherapy.
Neoplasms
Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.
Neoplasms
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.
Neoplasms
Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.
Neoplasms
Romidepsin-associated cardiac toxicity and ECG changes: A case report and review of the literature.
Neoplasms
Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage.
Neoplasms
RuvBL2 Is Involved in Histone Deacetylase Inhibitor PCI-24781-Induced Cell Death in SK-N-DZ Neuroblastoma Cells.
Neoplasms
Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.
Neoplasms
Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial.
Neoplasms
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Neoplasms
SAHA (vorinostat) facilitates functional polymer-based gene transfection via upregulation of ROS and synergizes with TRAIL gene delivery for cancer therapy.
Neoplasms
SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease.
Neoplasms
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
Neoplasms
SAHA Inhibits the Growth of Colon Tumors by Decreasing Histone Deacetylase and the Expression of Cyclin D1 and Survivin.
Neoplasms
SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
Neoplasms
SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells.
Neoplasms
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
Neoplasms
Screening of Novel Histone Deacetylase 7 Inhibitors through Molecular Docking Followed by a Combination of Molecular Dynamics Simulations and Ligand-Based Approach.
Neoplasms
Screening of selective histone deacetylase inhibitors by proteochemometric modeling.
Neoplasms
Scriptaid cause histone deacetylase inhibition and cell cycle arrest in HeLa cancer cells: A study on structural and functional aspects.
Neoplasms
Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation.
Neoplasms
Search for the pharmacophore of histone deacetylase inhibitors using pharmacophore query and docking study.
Neoplasms
Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease.
Neoplasms
Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824.
Neoplasms
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.
Neoplasms
Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
Neoplasms
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.
Neoplasms
Selective Histone Deacetylase 6 Inhibitor 23BB Alleviated Rhabdomyolysis-Induced Acute Kidney Injury by Regulating Endoplasmic Reticulum Stress and Apoptosis.
Neoplasms
Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
Neoplasms
Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma.
Neoplasms
Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation.
Neoplasms
Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models.
Neoplasms
Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma.
Neoplasms
Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors.
Neoplasms
Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors.
Neoplasms
Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together.
Neoplasms
Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.
Neoplasms
Sequential 5-Aza-2'-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1.
Neoplasms
Serendipitous discovery of potent human head and neck squamous cell carcinoma anti-cancer molecules: A fortunate failure of a rational molecular design.
Neoplasms
SET7 interacts with HDAC6 and suppresses the development of colon cancer through inactivation of HDAC6.
Neoplasms
SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy.
Neoplasms
Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6.
Neoplasms
Short-term stimulation with histone deacetylase inhibitor trichostatin a induces epithelial-mesenchymal transition in nasopharyngeal carcinoma cells without increasing cell invasion ability.
Neoplasms
Signal Therapy of Breast Cancers by the HDAC Inhibitor FK228 That Blocks the Activation of PAK1 and Abrogates the Tamoxifen-Resistance.
Neoplasms
Signal Therapy of NF1-Deficient Tumor Xenograft in Mice by the Anti-PAK1 Drug FK228.
Neoplasms
Signal-dependent regulation of transcription by histone deacetylase 7 involves recruitment to promyelocytic leukemia protein nuclear bodies.
Neoplasms
Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer.
Neoplasms
Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90.
Neoplasms
Silencing of histone deacetylase 2 suppresses malignancy for proliferation, migration, and invasion of glioblastoma cells and enhances temozolomide sensitivity.
Neoplasms
Silencing of Histone Deacetylase 6 Decreases Cellular Malignancy and Contributes to Primary Cilium Restoration, Epithelial-to-Mesenchymal Transition Reversion, and Autophagy Inhibition in Glioblastoma Cell Lines.
Neoplasms
Silencing of Histone Deacetylase 9 Expression in Podocytes Attenuates Kidney Injury in Diabetic Nephropathy.
Neoplasms
Simple Fluorogenic Cellular Assay for Histone Deacetylase Inhibitors Based on Split-Yellow Fluorescent Protein and Intrabodies.
Neoplasms
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.
Neoplasms
Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS.
Neoplasms
Simultaneous NF-?B inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo.
Neoplasms
Simvastatin reduces the carcinogenic effect of 3-methylcholanthrene in renal epithelial cells through histone deacetylase 1 inhibition and RhoA reactivation.
Neoplasms
Single Conformation Spectroscopy of Suberoylanilide Hydroxamic Acid: A Molecule Bites Its Tail.
Neoplasms
SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells.
Neoplasms
SIRT1 expression is associated with good prognosis for head and neck squamous cell carcinoma patients.
Neoplasms
SIRT1 Modulates the Sensitivity of Prostate Cancer Cells to Vesicular Stomatitis Virus Oncolysis.
Neoplasms
SIRT1 regulates oncogenesis via a mutant p53-dependent pathway in hepatocellular carcinoma.
Neoplasms
SIRT2 reduces actin polymerization and cell migration through deacetylation and degradation of HSP90.
Neoplasms
SIRT6 Suppresses Cancer Stem-like Capacity in Tumors with PI3K Activation Independently of Its Deacetylase Activity.
Neoplasms
Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway.
Neoplasms
Sirtuin 3 inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3?/BCL2-associated X protein-dependent apoptotic pathway.
Neoplasms
Sirtuin1 (Sirt1) Promotes Cortical Bone Formation by Preventing ?-Catenin Sequestration by FoxO Transcription Factors in Osteoblast Progenitors.
Neoplasms
Sirtuin1 expression predicts the efficacy of neoadjuvant chemotherapy for locally advanced uterine cervical cancer.
Neoplasms
Site-specific acetylation of p53 directs selective transcription complex assembly.
Neoplasms
Small Molecule Antagonists of the Interaction between the Histone Deacetylase 6 Zinc-Finger Domain and Ubiquitin.
Neoplasms
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Neoplasms
Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013).
Neoplasms
SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria.
Neoplasms
Sodium butyrate and panobinostat induce apoptosis of chronic myeloid leukemia cells via multiple pathways.
Neoplasms
Sodium butyrate increases P-gp expression in lung cancer by upregulation of STAT3 and mRNA stabilization of ABCB1.
Neoplasms
Sodium butyrate induces apoptosis in MSN neuroblastoma cells in a calcium independent pathway.
Neoplasms
Sodium butyrate induces cell death by autophagy and reactivates a tumor suppressor gene DIRAS1 in renal cell carcinoma cell line UOK146.
Neoplasms
Sodium Butyrate Induces Growth Inhibition and Apoptosis in Human Prostate Cancer DU145 Cells by Up-Regulation of the Expression of Annexin A1.
Neoplasms
Sodium butyrate induces NIH3T3 cells to senescence-like state and enhances promoter activity of p21WAF/CIP1 in p53-independent manner.
Neoplasms
Sodium butyrate inhibits migration and induces AMPK-mTOR pathway-dependent autophagy and ROS-mediated apoptosis via the miR-139-5p/Bmi-1 axis in human bladder cancer cells.
Neoplasms
Sodium butyrate reduces bovine mammary epithelial cell inflammatory responses induced by exogenous lipopolysaccharide, by inactivating NF-?B signaling.
Neoplasms
Sodium butyrate regulates androgen receptor expression and cell cycle arrest in human prostate cancer cells.
Neoplasms
Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis.
Neoplasms
Sodium butyrate-dependent sensitization of human colon adenocarcinoma COLO 205 cells to TNF-alpha-induced apoptosis.
Neoplasms
SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive esophageal cancer cells.
Neoplasms
SOX4 maintains the stemness of cancer cells via transcriptionally enhancing HDAC1 revealed by comparative proteomics study.
Neoplasms
Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor.
Neoplasms
Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.
Neoplasms
Specific and redundant functions of histone deacetylases in regulation of cell cycle and apoptosis.
Neoplasms
Spectroscopic analysis of the interaction of valproic acid with histone H1 in solution and in chromatin structure.
Neoplasms
Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation.
Neoplasms
SQAP, an acyl sulfoquinovosyl derivative, suppresses expression of histone deacetylase and induces cell death of cancer cells under hypoxic conditions.
Neoplasms
Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells.
Neoplasms
SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors.
Neoplasms
SRSF2 is required for sodium butyrate-mediated p21(WAF1) induction and premature senescence in human lung carcinoma cell lines.
Neoplasms
Stabilization of HDAC1 via TCL1-pAKT-CHFR axis is a key element for NANOG-mediated multi-resistance and stem-like phenotype in immune-edited tumor cells.
Neoplasms
Stabilized Peptide HDAC Inhibitors Derived from HDAC1 Substrate H3K56 for the Treatment of Cancer Stem-Like Cells In Vivo.
Neoplasms
Starch nanoparticles for delivery of the histone deacetylase inhibitor CG-1521 in breast cancer treatment.
Neoplasms
Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
Neoplasms
Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data.
Neoplasms
Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance.
Neoplasms
Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung.
Neoplasms
Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6.
Neoplasms
Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6.
Neoplasms
Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.
Neoplasms
Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study.
Neoplasms
Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
Neoplasms
Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
Neoplasms
Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
Neoplasms
Structure-Based Design and Biological Characterization of Selective Histone Deacetylase 8 (HDAC8) Inhibitors with Anti-Neuroblastoma Activity.
Neoplasms
Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma.
Neoplasms
Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
Neoplasms
Structure-based drug design of small molecule SIRT1 modulators to treat cancer and metabolic disorders.
Neoplasms
Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
Neoplasms
Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.
Neoplasms
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors.
Neoplasms
Subcellular Localization of Maspin Correlates with Histone Deacetylase 1 Expression in Human Breast Cancer.
Neoplasms
Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells.
Neoplasms
Suberoyl bishydroxamic Acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells.
Neoplasms
Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells.
Neoplasms
Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.
Neoplasms
Suberoylanilide hydroxamic acid (SAHA; vorinostat) causes bone loss by inhibiting immature osteoblasts.
Neoplasms
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Neoplasms
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Neoplasms
Suberoylanilide Hydroxamic Acid as a Radiosensitizer through Modulation of RAD51 Protein and Inhibition of Homology-Directed Repair in Multiple Myeloma.
Neoplasms
Suberoylanilide hydroxamic acid enhances the radiosensitivity of lung cancer cells through acetylated wild-type and mutant p53-dependent modulation of mitochondrial apoptosis.
Neoplasms
Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants.
Neoplasms
Suberoylanilide hydroxamic acid induces thioredoxin1-mediated apoptosis in lung cancer cells via up-regulation of miR-129-5p.
Neoplasms
Suberoylanilide Hydroxamic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing Nuclear Factor-{kappa}B Activation.
Neoplasms
Suberoylanilide hydroxamic acid upregulates histone acetylation and activates endoplasmic reticulum stress to induce apoptosis in HepG2 liver cancer cells.
Neoplasms
Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.
Neoplasms
SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
Neoplasms
Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
Neoplasms
Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines.
Neoplasms
Sulforaphane Reverses the Expression of Various Tumor Suppressor Genes by Targeting DNMT3B and HDAC1 in Human Cervical Cancer Cells.
Neoplasms
Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by induction p21WAF1 expression and cell cycle arrest.
Neoplasms
Superior antimitogenic and chemosensitization activities of the combination treatment of the histone deacetylase inhibitor apicidin and proteasome inhibitors on human colorectal cancer cells.
Neoplasms
Suppression of Akt-mediated HDAC3 expression and CDK2 T39 phosphorylation by a bichalcone analog contributes to S phase retardation of cancer cells.
Neoplasms
Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities.
Neoplasms
Suppression of HDAC2 in Spinal Cord Alleviates Mechanical Hyperalgesia and Restores KCC2 Expression in a Rat Model of Bone Cancer Pain.
Neoplasms
Suppression of HIF-1? by Valproic Acid Sustains Self-Renewal of Mouse Embryonic Stem Cells under Hypoxia In Vitro.
Neoplasms
Suppression of histone deacetylase 3 (HDAC3) enhances apoptosis induced by paclitaxel in human maxillary cancer cells in vitro and in vivo.
Neoplasms
Suppression of miR-22, a tumor suppressor in cervical cancer, by human papillomavirus 16 E6 via a p53/miR-22/HDAC6 pathway.
Neoplasms
Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.
Neoplasms
Suppressive Effect of the Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), on Hepatitis C Virus Replication via Epigenetic Changes in Host Cells.
Neoplasms
Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor.
Neoplasms
Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors.
Neoplasms
Synergetic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes.
Neoplasms
Synergistic anticancer activity of valproate combined with nicotinamide enhances anti-proliferation response and apoptosis in MIAPaca2 cells.
Neoplasms
Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics.
Neoplasms
Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.
Neoplasms
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Neoplasms
Synergistic combination of histone deacetylase inhibitor suberoylanilide hydroxamic acid and oncolytic adenovirus ZD55-TRAIL as a therapy against cervical cancer.
Neoplasms
Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas.
Neoplasms
Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer in vitro.
Neoplasms
Synergistic effect of p53 on TSA-induced stanniocalcin 1 expression in human nasopharyngeal carcinoma cells, CNE2.
Neoplasms
Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.
Neoplasms
Synergistic effects of histone deacetylase inhibitor in combination with mTOR inhibitor in the treatment of prostate carcinoma.
Neoplasms
Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation.
Neoplasms
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.
Neoplasms
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Neoplasms
Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action.
Neoplasms
Synergistic Induction of Apoptosis in Primary B-CLL Cells after Treatment with Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Histone Deacetylase Inhibitors.
Neoplasms
Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.
Neoplasms
Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Neoplasms
Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures.
Neoplasms
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Neoplasms
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.
Neoplasms
Synergy of hypoxia relief and chromatin remodeling to overcome tumor radiation resistance.
Neoplasms
Synthesis and activity of tumor-homing peptide iRGD and histone deacetylase inhibitor valproic acid conjugate.
Neoplasms
Synthesis and antitumor effects of novel 18?-glycyrrhetinic acid derivatives featuring an exocyclic ?,?-unsaturated carbonyl moiety in ring A.
Neoplasms
Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy.
Neoplasms
Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
Neoplasms
Synthesis and Biological Evaluation of ortho-Aryl N-Hydroxycinnamides as Potent Histone Deacetylase (HDAC) 8 Isoform-Selective Inhibitors.
Neoplasms
Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
Neoplasms
Synthesis and cancer antiproliferative activity of new histone deacetylase inhibitors: hydrophilic hydroxamates and 2-aminobenzamide-containing derivatives.
Neoplasms
Synthesis and evaluation of N?,N?-diacetyl-l-lysine-inositol conjugates as cancer-selective probes for metabolic engineering of GPIs and GPI-anchored proteins.
Neoplasms
Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression.
Neoplasms
Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors.
Neoplasms
Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group.
Neoplasms
Synthesis of N-hydroxycinnamides capped with a naturally occurring moiety as inhibitors of histone deacetylase.
Neoplasms
Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
Neoplasms
Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold.
Neoplasms
Synthesis, anticancer activity, structure-activity relationship and binding mode of interaction studies of substituted pentanoic acids.
Neoplasms
Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors.
Neoplasms
Synthetic Lethal Drug Combinations Targeting Proteasome and Histone Deacetylase Inhibitors in TP53-Mutated Cancers.
Neoplasms
Systemic co-administration of depsipeptide selectively targets transfection enhancement to specific tissues and cell types.
Neoplasms
T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance.
Neoplasms
Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.
Neoplasms
Tambulin Targets Histone Deacetylase 1 Inhibiting Cell Growth and Inducing Apoptosis in Human Lung Squamous Cell Carcinoma.
Neoplasms
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.
Neoplasms
Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer.
Neoplasms
Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
Neoplasms
Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.
Neoplasms
Targeted therapy for mTORC1-driven tumours through HDAC inhibition by exploiting innate vulnerability of mTORC1 hyper-activation.
Neoplasms
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
Neoplasms
Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer.
Neoplasms
Targeting cancer and neuropathy with histone deacetylase inhibitors: two birds with one stone?
Neoplasms
Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells.
Neoplasms
Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance.
Neoplasms
Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer.
Neoplasms
Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
Neoplasms
Targeting Histone deacetylase 4/Ubc9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells.
Neoplasms
Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases.
Neoplasms
Targeting histone deacetylase SIRT1 selectively eradicates EGFR TKI-resistant cancer stem cells via regulation of mitochondrial oxidative phosphorylation in lung adenocarcinoma.
Neoplasms
Targeting histone deacetylases in endometrial cancer: a paradigm-shifting therapeutic strategy?
Neoplasms
Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
Neoplasms
Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Neoplasms
Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer.
Neoplasms
Targeting mitochondrial hexokinases increases efficacy of histone deacetylase inhibitors in solid tumor models.
Neoplasms
Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595.
Neoplasms
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma.
Neoplasms
Targeting Proteasomal Pathways by Dietary Curcumin for Cancer Prevention and Treatment.
Neoplasms
Targeting the 'garbage-bin' to fight cancer: HDAC6 inhibitor WT161 has an anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.
Neoplasms
Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.
Neoplasms
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Neoplasms
Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.
Neoplasms
TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer.
Neoplasms
TCGA data and patient-derived orthotopic xenografts highlight pancreatic cancer-associated angiogenesis.
Neoplasms
Telomerase expression and cell proliferation in ovarian cancer cells induced by histone deacetylase inhibitors.
Neoplasms
Temozolomide-resistant Glioblastoma Depends on HDAC6 Activity Through Regulation of DNA Mismatch Repair.
Neoplasms
tert-Butylcarbamate-Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells.
Neoplasms
TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion.
Neoplasms
Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer.
Neoplasms
Tetrandrine enhances antitumor effects of the histone deacetylase inhibitor MS-275 in human cancer in a Bax- and p53-dependent manner.
Neoplasms
TGF-{beta} type II Receptor mRNA in Retinoblastoma Cell Lines is induced by Trichostatin A.
Neoplasms
Thalidomide as a multi-template for development of biologically active compounds.
Neoplasms
The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
Neoplasms
The Antiangiogenesis Role of Histone Deacetylase Inhibitors: Their Potential Application to Tumor Therapy and Tissue Repair.
Neoplasms
The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells.
Neoplasms
The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
Neoplasms
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.
Neoplasms
The application of epigenetic modifiers on the treatment of prostate and bladder cancer.
Neoplasms
The aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl induces distinct patterns of gene expression between hepatoma and glioma cells: chromatin remodeling as a mechanism for selective effects.
Neoplasms
The Cancer/Testis Antigen Gene VCX2 Is Rarely Expressed in Malignancies but Can Be Epigenetically Activated Using DNA Methyltransferase and Histone Deacetylase Inhibitors.
Neoplasms
The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.
Neoplasms
The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism.
Neoplasms
The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment.
Neoplasms
The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects.
Neoplasms
The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
Neoplasms
The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.
Neoplasms
The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy.
Neoplasms
The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.
Neoplasms
The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities.
Neoplasms
The Deubiquitinase USP38 Promotes NHEJ Repair through Regulation of HDAC1 Activity and Regulates Cancer Cell Response to Genotoxic Insults.
Neoplasms
The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay.
Neoplasms
The Effect of 5-Aza-2'-Deoxycytidine in Combination to and in Comparison with Vorinostat on DNA Methyltransferases, Histone Deacetylase 1, Glutathione S-Transferase 1 and Suppressor of Cytokine Signaling 1 Genes Expression, Cell Growth Inhibition and Apoptotic Induction in Hepatocellular LCL-PI 11 Cell Line.
Neoplasms
The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
Neoplasms
The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells.
Neoplasms
The effect of oxamflatin on the E-cadherin expression in gastric cancer cell line.
Neoplasms
The Effect of Vicinal Difluorination on the Conformation and Potency of Histone Deacetylase Inhibitors.
Neoplasms
The Effect of VPA on Increasing Radiosensitivity in Osteosarcoma Cells and Primary-Culture Cells from Chemical Carcinogen-Induced Breast Cancer in Rats.
Neoplasms
The Effects of Histone Deacetylase Inhibition on the Levels of Cerebral Cytokines in an Animal Model of Mania Induced by Dextroamphetamine.
Neoplasms
The Effects of Histone Deacetylase Inhibitors on Glioblastoma-Derived Stem Cells.
Neoplasms
The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy?
Neoplasms
The Effects of Molecular Hydrogen and Suberoylanilide Hydroxamic Acid on Paraquat-Induced Production of Reactive Oxygen Species and TNF-? in Macrophages.
Neoplasms
The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
Neoplasms
The efficacy of combination therapy using adeno-associated virus--interferon beta and trichostatin A in vitro and in a murine model of neuroblastoma.
Neoplasms
The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
Neoplasms
The endogenous danger signals HSP70 and MICA cooperate in the activation of cytotoxic effector functions of NK cells.
Neoplasms
The enhanced apoptosis and antiproliferative response to combined treatment with valproate and nicotinamide in MCF-7 breast cancer cells.
Neoplasms
The epigenetic agents suberoylanilide hydroxamic acid and 5?AZA?2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo.
Neoplasms
The estrogen-responsive B box protein is a novel regulator of the retinoid signal.
Neoplasms
The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy.
Neoplasms
The fission yeast inhibitor of growth (ING) protein PNG1P functions in response to DNA damage.
Neoplasms
The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage.
Neoplasms
The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
Neoplasms
The HDAC Inhibitor LBH589 Induces ERK-Dependent Prometaphase Arrest in Prostate Cancer via HDAC6 Inactivation and Down-Regulation.
Neoplasms
The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer.
Neoplasms
The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death.
Neoplasms
The HDAC6 Inhibitor Tubacin Induces Release of CD133(+) Extracellular Vesicles From Cancer Cells.
Neoplasms
The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines.
Neoplasms
The histone deacetylase HDAC1 activates HIF1?/VEGFA signal pathway in colorectal cancer.
Neoplasms
The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1.
Neoplasms
The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
Neoplasms
The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
Neoplasms
The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells.
Neoplasms
The histone deacetylase inhibitor entinostat enhances polymer-mediated transgene expression in cancer cell lines.
Neoplasms
The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems.
Neoplasms
The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells.
Neoplasms
The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells.
Neoplasms
The histone deacetylase inhibitor MGCD0103 has both deacetylase and microtubule inhibitory activity.
Neoplasms
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Neoplasms
The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest.
Neoplasms
The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.
Neoplasms
The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Neoplasms
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
Neoplasms
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines.
Neoplasms
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.
Neoplasms
The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines.
Neoplasms
The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process.
Neoplasms
The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells.
Neoplasms
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Neoplasms
The histone deacetylase inhibitor trichostatin A blocks progesterone receptor-mediated transactivation of the mouse mammary tumor virus promoter in vivo.
Neoplasms
The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells.
Neoplasms
THE HISTONE DEACETYLASE INHIBITOR VALPROIC ACID ALTERS GROWTH PROPERTIES OF RENAL CELL CARCINOMA IN VITRO AND IN VIVO.
Neoplasms
The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro.
Neoplasms
The Histone Deacetylase Inhibitor, Trichostatin A, Enhances Radiation Sensitivity and Accumulation of gammaH2A.X.
Neoplasms
The histone deacetylase inhibitor, Trichostatin A, induces G2/M phase arrest and apoptosis in YD-10B oral squamous carcinoma cells.
Neoplasms
The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss.
Neoplasms
The histone deacetylase inhibitor, Vorinostat, represses hypoxia inducible factor 1 alpha expression through translational inhibition.
Neoplasms
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy.
Neoplasms
The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism.
Neoplasms
The HIV-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the multiple myeloma cells proliferation in vitro and in vivo.
Neoplasms
The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.
Neoplasms
The in vitro apoptotic effects of A248 and A1659, newly synthetic histone deacetylase inhibitors in oral cancer cells.
Neoplasms
The ING1a Tumor Suppressor Regulates Endocytosis to Induce Cellular Senescence Via the Rb-E2F Pathway.
Neoplasms
The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma.
Neoplasms
The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells.
Neoplasms
The metastasis-associated proteins 1 and 2 form distinct protein complexes with histone deacetylase activity.
Neoplasms
The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.
Neoplasms
The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells.
Neoplasms
The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment.
Neoplasms
The new low-toxic histone deacetylase inhibitor S-(2) induces apoptosis in various acute myeloid leukemia cells.
Neoplasms
The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells.
Neoplasms
The novel HDAC inhibitor OBP-801/YM753 enhances the effects of 5-fluorouracil with radiation on esophageal squamous carcinoma cells.
Neoplasms
The novel histone deacetylase inhibitor 4-Me2N-BAVAH differentially affects cell junctions between primary hepatocytes.
Neoplasms
The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA.
Neoplasms
The novel human endogenous retrovirus related gene, psiTPTE22-HERV, is silenced by DNA methylation in cancers.
Neoplasms
The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer.
Neoplasms
The Oncoprotein SKI Acts as A Suppressor of NK Cell-Mediated Immunosurveillance in PDAC.
Neoplasms
The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer.
Neoplasms
The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression.
Neoplasms
The promise of using histone deacetylase inhibitors in combination treatment against breast cancer and other solid tumors.
Neoplasms
The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner.
Neoplasms
The proteomic analysis of endogenous FAT10 substrates identifies p62/SQSTM1 as a substrate of FAT10ylation.
Neoplasms
The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
Neoplasms
The role and possible molecular mechanism of valproic acid in the growth of MCF-7 breast cancer cells.
Neoplasms
The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.
Neoplasms
The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc.
Neoplasms
The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells.
Neoplasms
The roles of microbial products in the development of colorectal cancer: a review.
Neoplasms
The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy.
Neoplasms
The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase Inhibitors with Special Reference to Panobinostat in Gastrointestinal Tumors: A Review of Preclinical and Clinical Studies.
Neoplasms
The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Neoplasms
The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma.
Neoplasms
The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity.
Neoplasms
The Significance of MicroRNA-449a and Its Potential Target HDAC1 in Patients With Colorectal Cancer.
Neoplasms
The significance of strong histone deacetylase 1 expression in the progression of prostate cancer.
Neoplasms
The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming.
Neoplasms
The SIRT3 and SIRT6 Promote Prostate Cancer Progression by Inhibiting Necroptosis-Mediated Innate Immune Response.
Neoplasms
The sno gene, which encodes a component of the histone deacetylase complex, acts as a tumor suppressor in mice.
Neoplasms
The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment.
Neoplasms
The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.
Neoplasms
The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.
Neoplasms
The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene.
Neoplasms
The Tumor Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the Beta-catenin Coactivator BCL9-2 in Breast Cancer Cells.
Neoplasms
The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases.
Neoplasms
Therapeutic efficacy of valproic Acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension.
Neoplasms
Therapeutic Opportunities of Targeting Histone Deacetylase Isoforms to Eradicate Cancer Stem Cells.
Neoplasms
Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.
Neoplasms
Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma.
Neoplasms
Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
Neoplasms
Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms.
Neoplasms
Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.
Neoplasms
Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms.
Neoplasms
Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Neoplasms
TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism.
Neoplasms
Toward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer.
Neoplasms
Transcription Factor ZNF326 Upregulates the Expression of ERCC1 and HDAC7 and its Clinicopathologic Significance in Glioma.
Neoplasms
Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer.
Neoplasms
Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.
Neoplasms
Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis.
Neoplasms
Transcriptional modulation of monoaminergic neurotransmission genes by the histone deacetylase inhibitor trichostatin A in neuroblastoma cells.
Neoplasms
Transcriptional silencing of Dickkopf gene family by CpG island hypermethylation in human gastrointestinal cancer.
Neoplasms
Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects.
Neoplasms
Transcriptome screening and verification of genes related to metabolism affected by histone deacetylase inhibitors.
Neoplasms
Transforming growth factor-beta inhibits telomerase through SMAD3 and E2F transcription factors.
Neoplasms
Treatment of tumor cells with histone deacetylase inhibitors results in altered recruitment of methyl-CpG binding proteins to a methylated CpG island.
Neoplasms
Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy.
Neoplasms
Tricho-rhino-phalangeal syndrome 1 protein functions as a scaffold required for ubiquitin-specific protease 4-directed histone deacetylase 2 de-ubiquitination and tumor growth.
Neoplasms
Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.
Neoplasms
Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity.
Neoplasms
Trichostatin A Enhances the Apoptotic Potential of Palladium Nanoparticles in Human Cervical Cancer Cells.
Neoplasms
Trichostatin A increases radiosensitization of tongue squamous cell carcinoma via miR?375.
Neoplasms
Trichostatin A induces apoptosis of p815 mastocytoma cells in histone acetylation- and mitochondria-dependent fashion.
Neoplasms
Trichostatin A inhibits inflammation in phorbol myristate acetate?induced macrophages by regulating the acetylation of histone and/or non?histone proteins.
Neoplasms
Trichostatin a inhibits phenotypic transition and induces apoptosis of the TAF-treated normal colonic epithelial cells through regulation of TGF-? pathway.
Neoplasms
Trichostatin A promotes GLI1 degradation and P21 expression in multiple myeloma cells.
Neoplasms
Trichostatin A protects against intestinal injury in rats with acute liver failure.
Neoplasms
Trichostatin A reverses epithelial-mesenchymal transition and attenuates invasion and migration in MCF-7 breast cancer cells.
Neoplasms
Trichostatin A suppresses lung adenocarcinoma development in Grg1 overexpressing transgenic mice.
Neoplasms
Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231.
Neoplasms
Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1).
Neoplasms
Trichostatin Differentially Regulates Th1 and Th2 Responses and Alleviates Rheumatoid Arthritis in Mice.
Neoplasms
Trichostatin A induces bladder cancer cell death via intrinsic apoptosis at the early phase and Sp1?survivin downregulation at the late phase of treatment.
Neoplasms
TRPM2 Mediates Histone Deacetylase Inhibition-Induced Apoptosis in Bladder Cancer Cells.
Neoplasms
TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC.
Neoplasms
TSA-induced DNMT1 down-regulation represses hTERT expression via recruiting CTCF into demethylated core promoter region of hTERT in HCT116.
Neoplasms
TSA-induced JMJD2B downregulation is associated with Cyclin B1-dependent survivin degradation and apoptosis in LNCap cells.
Neoplasms
Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells.
Neoplasms
Tubastatin A, a deacetylase inhibitor, as a tool to study the division, cell cycle and microtubule cytoskeleton of trypanosomatids.
Neoplasms
Tubulin Beta3 Serves as a Target of HDAC3 and Mediates Resistance to Microtubule-Targeting Drugs.
Neoplasms
Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer.
Neoplasms
Tumor Necrosis Factor Receptor-Associated Factor 6 Promotes Hepatocarcinogenesis by Interacting With Histone Deacetylase 3 to Enhance c-Myc Gene Expression and Protein Stability.
Neoplasms
Tumor necrosis factor-alpha enhances neutrophil adhesiveness: induction of vascular cell adhesion molecule-1 via activation of Akt and CaM kinase II and modifications of histone acetyltransferase and histone deacetylase 4 in human tracheal smooth muscle cells.
Neoplasms
Tumor SHB gene expression affects disease characteristics in human acute myeloid leukemia.
Neoplasms
Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex.
Neoplasms
Tumor-necrosis-factor-related apoptosis-inducing ligand and the regulation of hematopoiesis.
Neoplasms
Tumour necrosis factor-alpha depletes histone deacetylase 1 protein through IKK2.
Neoplasms
Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Neoplasms
Ubiquitin B in cervical cancer: critical for the maintenance of cancer stem-like cell characters.
Neoplasms
UHRF1 Induces Methylation of the TXNIP Promoter and Down-Regulates Gene Expression in Cervical Cancer.
Neoplasms
Under-expression of VHL and over-expression of HDAC-1, HIF-1alpha, LL-37, and IAP-2 in affected skin biopsies of patients with psoriasis.
Neoplasms
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer.
Neoplasms
Understanding Histone Deacetylases in the Cancer Development and Treatment: An Epigenetic Perspective of Cancer Chemotherapy.
Neoplasms
Unique anti-glioblastoma activities of hypericin are at the crossroad of biochemical and epigenetic events and culminate in tumor cell differentiation.
Neoplasms
Unique functional roles for class I and class II histone deacetylases in central nervous system development and function.
Neoplasms
Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.
Neoplasms
Unlocking repression of the human luteinizing hormone receptor gene by trichostatin A-induced cell-specific phosphatase release.
Neoplasms
Unprecedented behavior of (9R)-9-hydroxystearic acid loaded keratin nanoparticles on cancer cell cycle.
Neoplasms
Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma.
Neoplasms
Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity.
Neoplasms
Up-regulation of UVRAG by HDAC1 Inhibition Attenuates 5FU-induced Cell Death in HCT116 Colorectal Cancer Cells.
Neoplasms
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities.
Neoplasms
Updates on Receptors Targeted by Heterocyclic Scaffolds: New Horizon in Anticancer Drug Development.
Neoplasms
Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells.
Neoplasms
Upregulated histone deacetylase 2 gene correlates with the progression of oral squamous cell carcinoma.
Neoplasms
Upregulated Histone Deacetylase 6 Associates with Malignant Progression of Melanoma and Predicts the Prognosis of Patients.
Neoplasms
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.
Neoplasms
Upregulation of peroxisome proliferator-activated receptor-? and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer.
Neoplasms
Uptake and metabolism of the short-chain fatty acid butyrate, a critical review of the literature.
Neoplasms
Use of Histone Deacetylase 8 (HDAC8), a New Marker of Smooth Muscle Differentiation, in the Classification of Mesenchymal Tumors of the Uterus.
Neoplasms
USP38 regulates the stemness and chemoresistance of human colorectal cancer via regulation of HDAC3.
Neoplasms
Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
Neoplasms
Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.
Neoplasms
Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.
Neoplasms
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial.
Neoplasms
Valproic acid activity in androgen-sensitive and -insensitive human prostate cancer cells.
Neoplasms
Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B.
Neoplasms
Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers.
Neoplasms
Valproic Acid Enhances the Efficacy of Chemotherapy in EBV-Positive Tumors by Increasing Lytic Viral Gene Expression.
Neoplasms
Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells.
Neoplasms
Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.
Neoplasms
Valproic Acid Induces Endocytosis-Mediated Doxorubicin Internalization and Shows Synergistic Cytotoxic Effects in Hepatocellular Carcinoma Cells.
Neoplasms
Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
Neoplasms
Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines.
Neoplasms
Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo.
Neoplasms
Valproic Acid Inhibits Proliferation and Reduces Invasiveness in Glioma Stem Cells Through Wnt/? Catenin Signalling Activation.
Neoplasms
Valproic acid inhibits tumor angiogenesis in mice transplanted with Kasumi?1 leukemia cells.
Neoplasms
Valproic acid promotes the epithelial-to-mesenchymal transition of breast cancer cells through stabilization of Snail and transcriptional upregulation of Zeb1.
Neoplasms
Valproic acid protects septic mice from renal injury by reducing the inflammatory response.
Neoplasms
Valproic acid sensitizes breast cancer cells to hydroxyurea through inhibiting RPA2 hyperphosphorylation-mediated DNA repair pathway.
Neoplasms
Valproic acid sensitizes K562 erythroleukemia cells to TRAIL/Apo2L-induced apoptosis.
Neoplasms
Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway.
Neoplasms
Valproic acid suppresses the self-renewal and proliferation of head and neck cancer stem cells.
Neoplasms
Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma.
Neoplasms
Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
Neoplasms
Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation.
Neoplasms
Vascular endothelial growth factor production is induced by histone deacetylase 1 and suppressed by von Hippel-Lindau protein in HaCaT cells.
Neoplasms
Vitamin K3 chloro derivative (VKT-2) inhibits HDAC6, activates autophagy and apoptosis, and inhibits aggresome formation in hepatocellular carcinoma cells.
Neoplasms
Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation.
Neoplasms
Vorinostat differentially alters 3D nuclear structure of cancer and non-cancerous esophageal cells.
Neoplasms
Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells.
Neoplasms
Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.
Neoplasms
Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.
Neoplasms
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.
Neoplasms
Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures.
Neoplasms
Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake.
Neoplasms
Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha.
Neoplasms
Vorinostat triggers miR-769-5p/3p-mediated suppression of proliferation and induces apoptosis via the STAT3-IGF1R-HDAC3 complex in human gastric cancer.
Neoplasms
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
Neoplasms
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.
Neoplasms
Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.
Neoplasms
Vulnerability of IDH1 mutant cancers to histone deacetylase inhibition via orthogonal suppression of DNA repair.
Neoplasms
Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2.
Neoplasms
Whole Exome Sequencing Identifies APCDD1 and HDAC5 Genes as Potentially Cancer Predisposing in Familial Colorectal Cancer.
Neoplasms
Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
Neoplasms
Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Neoplasms
X-ray crystal structures, density functional theory and docking on deacetylase enzyme for antiproliferative activity of hispolon derivatives on HCT116 colon cancer.
Neoplasms
Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents.
Neoplasms
Xenografting of Cancer Cell Lines for In Vivo Screening of the Therapeutic Potential of HDAC Inhibitors.
Neoplasms
YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
Neoplasms
YY1 promotes HDAC1 expression and decreases sensitivity of hepatocellular carcinoma cells to HDAC inhibitor.
Neoplasms
ZBP-89 reduces histone deacetylase 3 by degrading IkappaB in the presence of Pin1.
Neoplasms
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Neoplasms
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.
Neoplasms
Zinc dependent Histone deacetylase inhibitors in cancer therapeutics: Recent update.
Neoplasms
ZIP restores estrogen receptor expression and response to Tamoxifen in estrogen receptor negative tumors.
Neoplasms
[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.
Neoplasms
[A histone deacetylase inhibitor and tumor suppressing gene p53 induction synergistically induce apoptosis of cancer cells]
Neoplasms
[Combination of phenylbutyrate and 5-Aza-2'deoxycytidine inhibits human Kasumi-1 xenograft tumor growth in nude mice.]
Neoplasms
[Effect of inhibitors for demethylation and histone deacetylase on proliferation of cell line K562 and expression of tumor related genes]
Neoplasms
[Effect of trichostatin A on the osteogenic differentiation potential of periodontal ligament stem cells in inflammatory microenvironment induced by tumor necrosis factor-? stimulation].
Neoplasms
[Effects of trichostatin A and paclitaxel on apoptosis and mitochondrial membrane potential of human endometrial carcinoma Ark2 cells]
Neoplasms
[Epigenetic Alterations in Gastrointestinal Cancers: Diagnostic and Therapeutic Applications].
Neoplasms
[Experimental study on the mechanism of the apoptosis of leukemic cells induced by valproic acid]
Neoplasms
[Gene-regulating chemoprevention against cancer--as a model for "molecular-targeting prevention" of cancer]
Neoplasms
[Ginsenoside Rh?-induced inhibition of histone deacetylase 6 promotes K562 cells autophagy and apoptosis in vivo].
Neoplasms
[HDAC1 expression and effect of TSA on proliferation and apoptosis of A549 cells]
Neoplasms
[Inhibitory effect of valproic acid on xenografted Kasumi-1 tumor growth in nude mouse and its mechanism].
Neoplasms
[Legionella pneumophila activates Nrf2-Keap1 pathway to inhibit autophagy of mouse RAW264.7 macrophages].
Neoplasms
[Mechanism of apoptosis induced by trichostatin a in leaukemia molt-4 cells analyzed by microarray.]
Neoplasms
[Mechanisms of cytotoxic action of a series of directionally synthesized heterocyclic hydroxamic acids].
Neoplasms
[Molecular mechanism of inhibition of sodium butyrate on activation of tumor associated aromatase promoters]
Neoplasms
[Morphological reversion of tumor cells by histone deacetylase inhibitors and radicicol]
Neoplasms
[Overexpression of histone deacetylase 11 suppresses basal-like breast cancer cell invasion and metastasis].
Neoplasms
[Sodium valproate synergizes adriamycin to inhibit proliferation and induce apoptosis in myelodysplastic syndrome cell line]
Neoplasms
[Synergistic effect of DNA methylation inhibitor and histone deacetylase inhibitor on RASSF1A gene expression in U266 cells.]
Neoplasms
[Synthesis and anti-tumor activity of novel histone deacetylase inhibitors based on dihydropyridin-2-one scaffold].
Neoplasms
[Validation and Evaluation of Diagnostic Efficiency of Genes Associated with Colorectal Cancer with Hyperglycemia].
Neoplasms, Germ Cell and Embryonal
A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment.
Neoplasms, Germ Cell and Embryonal
Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer.
Neoplasms, Glandular and Epithelial
Metastasis-associated protein (MTA)1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes.
Neoplasms, Squamous Cell
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
Neoplasms, Squamous Cell
Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
Neoplasms, Squamous Cell
Histone deacetylase 6 expression in metastatic lymph nodes is a valuable prognostic marker for resected node-positive esophageal squamous cell cancer.
Neoplastic Cells, Circulating
Expression profile of histone deacetylase 1 in gastric cancer tissues.
Nephritis, Hereditary
CG200745, a Novel HDAC Inhibitor, Attenuates Kidney Fibrosis in a Murine Model of Alport Syndrome.
Nephrotic Syndrome
Reciprocal Relationship Between HDAC2 and P-Glycoprotein/MRP-1 and Their Role in Steroid Resistance in Childhood Nephrotic Syndrome.
Nephrotic Syndrome
Role of P-gp and HDAC2 and their Reciprocal Relationship in Uncontrolled Asthma.
Nervous System Diseases
3',4'-Dimethoxyflavone and valproic acid promotes the proliferation of human hematopoietic stem cells.
Nervous System Diseases
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
Nervous System Diseases
Characteristics of Adult T-Cell Leukemia/Lymphoma Patients with Long Survival: Prognostic Significance of Skin Lesions and Possible Beneficial Role of Valproic Acid.
Nervous System Diseases
Cloning and structural characterization of the human histone deacetylase 6 gene.
Nervous System Diseases
Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
Nervous System Diseases
Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia.
Nervous System Diseases
Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors.
Nervous System Diseases
HDAC3 inhibition prevents oxygen glucose deprivation/reoxygenation-induced transendothelial permeability by elevating PPAR? activity in vitro.
Nervous System Diseases
HDAC6 Modulates Signaling Pathways Relevant to Synaptic Biology and Neuronal Differentiation in Human Stem-Cell-Derived Neurons.
Nervous System Diseases
Histone Deacetylase 2 Inhibition Attenuates Downregulation of Hippocampal Plasticity Gene Expression during Aging.
Nervous System Diseases
Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling.
Nervous System Diseases
Histone deacetylase 3 suppresses Erk phosphorylation and matrix metalloproteinase (Mmp)-13 activity in chondrocytes.
Nervous System Diseases
How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
Nervous System Diseases
MS-275 inhibits aroclor 1254-induced SH-SY5Y neuronal cell toxicity by preventing the formation of the HDAC3/REST complex on the synapsin-1 promoter.
Nervous System Diseases
Neuroprotective effects of valproic acid in a rat model of cauda equina injury.
Nervous System Diseases
Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
Nervous System Diseases
Oral Administration of the Pimelic Diphenylamide HDAC Inhibitor HDACi 4b Is Unsuitable for Chronic Inhibition of HDAC Activity in the CNS In Vivo.
Nervous System Diseases
Regional and cell-type specific distribution of HDAC2 in the adult mouse brain.
Nervous System Diseases
Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.
Nervous System Diseases
The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer's disease.
Nervous System Diseases
Trichostatin A decreases the levels of MeCP2 expression and phosphorylation and increases its chromatin binding affinity.
Nervous System Diseases
Valproic acid exerts specific cellular and molecular anti-inflammatory effects in post-operative conjunctiva.
Nervous System Diseases
Valproic acid mitigates spinal nerve ligation-induced neuropathic pain in rats by modulating microglial function and inhibiting neuroinflammatory response.
Neural Tube Defects
Histone deacetylase inhibitor Trichostatin A induces neural tube defects and promotes neural crest specification in the chicken neural tube.
Neural Tube Defects
S-2-pentyl-4-pentynoic hydroxamic acid and its metabolite s-2-pentyl-4-pentynoic acid in the NMRI-exencephaly-mouse model: pharmacokinetic profiles, teratogenic effects, and histone deacetylase inhibition abilities of further valproic acid hydroxamates and amides.
Neuralgia
Attenuation of neuropathic pain by sodium butyrate in an experimental model of chronic constriction injury in rats.
Neuralgia
Baicalin ameliorates neuropathic pain by suppressing HDAC1 expression in the spinal cord of spinal nerve ligation rats.
Neuralgia
Central Endothelin-1 Confers Analgesia by Triggering Spinal Neuronal Histone Deacetylase 5 (HDAC5) Nuclear Exclusion in Peripheral Neuropathic Pain in Mice.
Neuralgia
Complex regulation of the regulator of synaptic plasticity histone deacetylase 2 in the rodent dorsal horn after peripheral injury.
Neuralgia
Dual BET/HDAC inhibition to relieve neuropathic pain: recent advances, perspectives, and future opportunities.
Neuralgia
Effect of HDAC2/Inpp5f on neuropathic pain and cognitive function through regulating PI3K/Akt/GSK-3? signal pathway in rats with neuropathic pain.
Neuralgia
HDAC inhibitor TSA ameliorates mechanical hypersensitivity and potentiates analgesic effect of morphine in a rat model of bone cancer pain by restoring ?-opioid receptor in spinal cord.
Neuralgia
HDAC2, but not HDAC1, regulates Kv1.2 expression to mediate neuropathic pain in CCI rats.
Neuralgia
HDAC3 in hippocampus contributes to memory impairment following chronic constriction injury of sciatic nerve in mice.
Neuralgia
Histone deacetylase 5 (HDAC5) regulates neuropathic pain through SRY-related HMG-box 10 (SOX10)-dependent mechanism in mice.
Neuralgia
Histone deacetylase inhibition inhibits brachial plexus avulsion-induced neuropathic pain.
Neuralgia
Histone deacetylase inhibitor-induced emergence of synaptic ?-opioid receptors and behavioral antinociception in persistent neuropathic pain.
Neuralgia
Histone deacetylase inhibitors prevent persistent hypersensitivity in an orofacial neuropathic pain model.
Neuralgia
Histone deacetylase inhibitors relieve morphine resistance in neuropathic pain after peripheral nerve injury.
Neuralgia
Intervertebral Foramen Injection of Ozone Relieves Mechanical Allodynia and Enhances Analgesic Effect of Gabapentin in Animal Model of Neuropathic Pain.
Neuralgia
MiR-206-3p alleviates chronic constriction injury-induced neuropathic pain through targeting HDAC4.
Neuralgia
Modulation of Nerve Injury-induced HDAC4 Cytoplasmic Retention Contributes to Neuropathic Pain in Rats.
Neuralgia
NF-?B p65-dependent transcriptional regulation of histone deacetylase 2 contributes to the chronic constriction injury-induced neuropathic pain via the microRNA-183/TXNIP/NLRP3 axis.
Neuralgia
Normalizing HDAC2 Levels in the Spinal Cord Alleviates Thermal and Mechanical Hyperalgesia After Peripheral Nerve Injury and Promotes GAD65 and KCC2 Expression.
Neuralgia
SIRT1 Decreases Emotional Pain Vulnerability with Associated CaMKII? Deacetylation in Central Amygdala.
Neuralgia
SIRT1 Mediates Neuropathic Pain Induced by Sciatic Nerve Chronic Constrictive Injury in the VTA-NAc Pathway.
Neuralgia
SIRT3 alleviates neuropathic pain by deacetylating FoxO3a in the spinal dorsal horn of diabetic model rats.
Neuralgia
The etiological changes of acetylation in peripheral nerve injury-induced neuropathic hypersensitivity.
Neuralgia
The HDAC1/c-JUN complex is essential in the promotion of nerve injury-induced neuropathic pain through JNK signaling.
Neuralgia
[Trichostatin A suppresses up-regulation of histone deacetylase 4 and reverses differential expressions of miRNAs in the spinal cord of rats with chronic constrictive injury].
Neurilemmoma
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Neurilemmoma
Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy.
Neuritis
MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis.
Neuritis, Autoimmune, Experimental
MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis.
Neurobehavioral Manifestations
Reduction of Tet2 exacerbates early stage Alzheimer's pathology and cognitive impairments in 2?×?Tg-ad mice.
Neuroblastoma
A gastrin-releasing peptide receptor antagonist stimulates Neuro2a neuroblastoma cell growth: prevention by a histone deacetylase inhibitor.
Neuroblastoma
A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Neuroblastoma
A new method of comparing 2D-PAGE maps based on the computation of Zernike moments and multivariate statistical tools.
Neuroblastoma
A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.
Neuroblastoma
Amide-based derivatives of ?-alanine hydroxamic acid as histone deacetylase inhibitors: Attenuation of potency through resonance effects.
Neuroblastoma
An HDAC8-selective fluorescent probe for imaging in living tumor cell lines and tissue slices.
Neuroblastoma
Antagonistic effects of sequential administration of BL1521, a histone deacetylase inhibitor, and gemcitabine to neuroblastoma cells.
Neuroblastoma
Anti-neuroblastoma activity of Helminthosporium carbonum (HC)-toxin is superior to that of other differentiating compounds in vitro.
Neuroblastoma
Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Neuroblastoma
Autoregulation of the N-myc gene is operative in neuroblastoma and involves histone deacetylase 2.
Neuroblastoma
Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
Neuroblastoma
BM88/Cend1 is involved in histone deacetylase inhibition-mediated growth arrest and differentiation of neuroblastoma cells.
Neuroblastoma
Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53.
Neuroblastoma
Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells.
Neuroblastoma
Combined sialic acid and HDAC inhibitor treatment upregulates the neuroblastoma antigen GD2.
Neuroblastoma
Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells.
Neuroblastoma
Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine.
Neuroblastoma
CREB-binding protein is a mediator of neuroblastoma cell death induced by the histone deacetylase inhibitor trichostatin A.
Neuroblastoma
CTIP2 associates with the NuRD complex on the promoter of p57KIP2, a newly identified CTIP2 target gene.
Neuroblastoma
De novo Identification of MIZ-1 (ZBTB17) Encoding a MYC-Interacting Zinc-Finger Protein as a New Favorable Neuroblastoma Gene.
Neuroblastoma
Design and synthesis of diazine-based panobinostat analogues for HDAC8 inhibition.
Neuroblastoma
Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction.
Neuroblastoma
Differential effect of long-term drug selection with doxorubicin and vorinostat on neuroblastoma cells with cancer stem cell characteristics.
Neuroblastoma
Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines.
Neuroblastoma
Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
Neuroblastoma
Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.
Neuroblastoma
Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells.
Neuroblastoma
Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
Neuroblastoma
Epigenetic Regulation of Cytosolic Phospholipase A2 in SH-SY5Y Human Neuroblastoma Cells.
Neuroblastoma
Expression of DHA-Metabolizing Enzyme Alox15 is Regulated by Selective Histone Acetylation in Neuroblastoma Cells.
Neuroblastoma
Expression Profiles of SIRT1 and APP Genes in Human Neuroblastoma SK-N-SH Cells Treated with Two Epigenetic Agents.
Neuroblastoma
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation.
Neuroblastoma
Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma.
Neuroblastoma
GRHL1 Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3.
Neuroblastoma
HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells.
Neuroblastoma
HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process.
Neuroblastoma
Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Neuroblastoma
Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomas.
Neuroblastoma
Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1.
Neuroblastoma
Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc.
Neuroblastoma
Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis.
Neuroblastoma
Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells.
Neuroblastoma
Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins.
Neuroblastoma
Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells.
Neuroblastoma
Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro.
Neuroblastoma
Histone deacetylase inhibitors regulate retinoic acid receptor beta expression in neuroblastoma cells by both transcriptional and posttranscriptional mechanisms.
Neuroblastoma
Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
Neuroblastoma
Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells.
Neuroblastoma
HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: Implication for HIV-associated neurocognitive disorder (HAND).
Neuroblastoma
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.
Neuroblastoma
Hypoxia-inducible factor-1? mediates up-regulation of neprilysin by histone deacetylase-1 under hypoxia condition in neuroblastoma cells.
Neuroblastoma
Identification of CASZ1 NES reveals potential mechanisms for loss of CASZ1 tumor suppressor activity in neuroblastoma.
Neuroblastoma
Identification of novel targets for PGC-1alpha and histone deacetylase inhibitors in neuroblastoma cells.
Neuroblastoma
Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Neuroblastoma
Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
Neuroblastoma
Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.
Neuroblastoma
Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors.
Neuroblastoma
LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p.
Neuroblastoma
Mechanism of N-Acylthiourea-mediated Activation of Human Histone Deacetylase 8 (HDAC8) at Molecular and Cellular Levels.
Neuroblastoma
Minichromosome Maintenance Complex Is a Critical Node in the miR-183 Signaling Network of MYCN-Amplified Neuroblastoma Cells.
Neuroblastoma
MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.
Neuroblastoma
Neuroblastoma stem cells - mechanisms of chemoresistance and histonedeacetylase inhibitors.
Neuroblastoma
New Insights into Epigenetic and Pharmacological Regulation of Amyloid-Degrading Enzymes.
Neuroblastoma
p38/Sp1/Sp4/HDAC4/BDNF Axis Is a Novel Molecular Pathway of the Neurotoxic Effect of the Methylmercury.
Neuroblastoma
PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma.
Neuroblastoma
Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors.
Neuroblastoma
Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma or Leukemia.
Neuroblastoma
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
Neuroblastoma
Rapid In Vivo Validation of HDAC Inhibitor-Based Treatments in Neuroblastoma Zebrafish Xenografts.
Neuroblastoma
Regulation of cellular processes by PPARgamma ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression.
Neuroblastoma
Regulation of neuronal nitric oxide synthase exon 1f gene expression by nuclear factor-kappaB acetylation in human neuroblastoma cells.
Neuroblastoma
RuvBL2 Is Involved in Histone Deacetylase Inhibitor PCI-24781-Induced Cell Death in SK-N-DZ Neuroblastoma Cells.
Neuroblastoma
Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation.
Neuroblastoma
Successful treatment of refractory metastatic neuroblastoma with panobinostat in combination with chemotherapy agents and iodine-131-meta-iodobenzylguanidine therapy.
Neuroblastoma
Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors.
Neuroblastoma
Targeted inhibition of HDAC8 increases the doxorubicin sensitivity of neuroblastoma cells via up regulation of miR-137.
Neuroblastoma
The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Neuroblastoma
The circadian expression of c-MYC is modulated by the histone deacetylase inhibitor trichostatin A in synchronized murine neuroblastoma cells.
Neuroblastoma
The effect of vorinostat on the development of resistance to Doxorubicin in neuroblastoma.
Neuroblastoma
The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death.
Neuroblastoma
The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines.
Neuroblastoma
The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells.
Neuroblastoma
The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.
Neuroblastoma
The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells.
Neuroblastoma
The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells.
Neuroblastoma
Transcriptional modulation of monoaminergic neurotransmission genes by the histone deacetylase inhibitor trichostatin A in neuroblastoma cells.
Neuroblastoma
Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects.
Neuroblastoma
Valproic acid stimulates clusterin expression in human astrocytes: Implications for Alzheimer's disease.
Neurodegenerative Diseases
A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot-Marie-Tooth disease type 1A.
Neurodegenerative Diseases
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019).
Neurodegenerative Diseases
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity.
Neurodegenerative Diseases
A selective histone deacetylase-6 inhibitor improves BDNF trafficking in hippocampal neurons from Mecp2 knockout mice: implications for Rett syndrome.
Neurodegenerative Diseases
A Thoroughly Validated Virtual Screening Strategy for Discovery of Novel HDAC3 Inhibitors.
Neurodegenerative Diseases
Aberrant Expression of Histone Deacetylases 4 in Cognitive Disorders: Molecular Mechanisms and a Potential Target.
Neurodegenerative Diseases
Aminoglycoside-induced histone deacetylation and hair cell death in the mouse cochlea.
Neurodegenerative Diseases
An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
Neurodegenerative Diseases
Autophagy induced by the class III histone deacetylase Sirt1 prevents prion peptide neurotoxicity.
Neurodegenerative Diseases
Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury.
Neurodegenerative Diseases
Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing.
Neurodegenerative Diseases
Chiral mercaptoacetamides display enantioselective inhibition of histone deacetylase?6 and exhibit neuroprotection in cortical neuron models of oxidative stress.
Neurodegenerative Diseases
Cholesterol derivatives induce dephosphorylation of the histone deacetylases Rpd3/HDAC1 to upregulate autophagy.
Neurodegenerative Diseases
Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model.
Neurodegenerative Diseases
Chronic restraint stress impairs cognition via modulating HDAC2 expression.
Neurodegenerative Diseases
Cognitive deficits triggered by early life stress: The role of histone deacetylase 1.
Neurodegenerative Diseases
Cognitive Function in Health and Disease: The Role of Epigenetic Mechanisms.
Neurodegenerative Diseases
Compensatory Motor Neuron Response to Chromatolysis in the Murine hSOD1(G93A) Model of Amyotrophic Lateral Sclerosis.
Neurodegenerative Diseases
Complex neuroprotective and neurotoxic effects of histone deacetylases.
Neurodegenerative Diseases
Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
Neurodegenerative Diseases
Creating zinc monkey wrenches in the treatment of epigenetic disorders.
Neurodegenerative Diseases
Crystallographic structure versus homology model: a case study of molecular dynamics simulation of human and zebrafish histone deacetylase 10.
Neurodegenerative Diseases
Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex.
Neurodegenerative Diseases
Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.
Neurodegenerative Diseases
Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Neurodegenerative Diseases
Developmental neurotoxicity in the context of multiple sevoflurane exposures: Potential role of histone deacetylase 6.
Neurodegenerative Diseases
Direct binding with histone deacetylase 6 mediates the reversible recruitment of parkin to the centrosome.
Neurodegenerative Diseases
Discovery of a Novel HDAC2 Inhibitor by a Scaffold-Merging Hybrid Query.
Neurodegenerative Diseases
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
Neurodegenerative Diseases
Effects of histone deacetylase inhibition on the survival, proliferation and migration of Schwann cells, as well as on the expression of neurotrophic factors and genes associated with myelination.
Neurodegenerative Diseases
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Neurodegenerative Diseases
Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.
Neurodegenerative Diseases
Evaluation of [11C]KB631 as a PET tracer for in vivo visualisation of HDAC6 in B16.F10 melanoma.
Neurodegenerative Diseases
Examining the stability of binding modes of the co-crystallized inhibitors of human HDAC8 by molecular dynamics simulation.
Neurodegenerative Diseases
Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
Neurodegenerative Diseases
Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Neurodegenerative Diseases
HDAC inhibitor trichostatin A-inhibited survival of dopaminergic neuronal cells.
Neurodegenerative Diseases
HDAC inhibitors and neurodegeneration: At the edge between protection and damage.
Neurodegenerative Diseases
HDAC1 dysregulation induces aberrant cell cycle and DNA damage in progress of TDP-43 proteinopathies.
Neurodegenerative Diseases
HDAC3i-Finder: A Machine Learning-based Computational Tool to Screen for HDAC3 Inhibitors.
Neurodegenerative Diseases
HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements.
Neurodegenerative Diseases
HDAC6 ?-tubulin deacetylase: A potential therapeutic target in neurodegenerative diseases.
Neurodegenerative Diseases
HDAC6 alleviates prion peptide-mediated neuronal death via modulating PI3K-Akt-mTOR pathway.
Neurodegenerative Diseases
HDAC6 as a potential therapeutic target for peripheral nerve disorders.
Neurodegenerative Diseases
HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
Neurodegenerative Diseases
HDAC6 at the Intersection of Autophagy, the Ubiquitin-Proteasome System and Neurodegeneration.
Neurodegenerative Diseases
HDAC6 inhibition by tubastatin A is protective against oxidative stress in a photoreceptor cell line and restores visual function in a zebrafish model of inherited blindness.
Neurodegenerative Diseases
HDAC6 inhibition restores TDP-43 pathology and axonal transport defects in human motor neurons with TARDBP mutations.
Neurodegenerative Diseases
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation.
Neurodegenerative Diseases
Histone deacetylase 2: A potential therapeutic target for cancer and neurodegenerative disorders.
Neurodegenerative Diseases
Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review.
Neurodegenerative Diseases
Histone Deacetylase 6 and the Disease Mechanisms of ?-Synucleinopathies.
Neurodegenerative Diseases
Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation.
Neurodegenerative Diseases
Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes.
Neurodegenerative Diseases
Histone deacetylase inhibition decreases cholesterol levels in neuronal cells by modulating key genes in cholesterol synthesis, uptake and efflux.
Neurodegenerative Diseases
Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration.
Neurodegenerative Diseases
Histone Deacetylase Inhibitors and Neurodegenerative Disorders: Holding the Promise.
Neurodegenerative Diseases
Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?
Neurodegenerative Diseases
Histone deacetylase inhibitors: possible implications for neurodegenerative disorders.
Neurodegenerative Diseases
Histone deacetylase-3 interacts with ataxin-7 and is altered in a spinocerebellar ataxia type 7 mouse model.
Neurodegenerative Diseases
Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities.
Neurodegenerative Diseases
Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition.
Neurodegenerative Diseases
Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich's Ataxia: A New Synthetic Route.
Neurodegenerative Diseases
Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration.
Neurodegenerative Diseases
Increased Abundance of Nuclear HDAC4 Impairs Neuronal Development and Long-Term Memory.
Neurodegenerative Diseases
Increased acetylation of Peroxiredoxin1 by HDAC6 inhibition leads to recovery of A?-induced impaired axonal transport.
Neurodegenerative Diseases
Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury.
Neurodegenerative Diseases
Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism.
Neurodegenerative Diseases
Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Neurodegenerative Diseases
Interplay Between HDAC6 and Its Interacting Partners: Essential Roles in the Aggresome-Autophagy Pathway and Neurodegenerative Diseases.
Neurodegenerative Diseases
Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Neurodegenerative Diseases
Involvement of HDAC6 in ischaemia and reperfusion-induced rat retinal injury.
Neurodegenerative Diseases
JAZ (Znf346), a SIRT1-interacting protein, protects neurons by stimulating p21 (WAF/CIP1) protein expression.
Neurodegenerative Diseases
Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers.
Neurodegenerative Diseases
Knock-Down of HDAC2 in Human Induced Pluripotent Stem Cell Derived Neurons Improves Neuronal Mitochondrial Dynamics, Neuronal Maturation and Reduces Amyloid Beta Peptides.
Neurodegenerative Diseases
LBH589 induces up to 10-fold SMN protein levels by several independent mechanisms and is effective even in cells from SMA patients non-responsive to valproate.
Neurodegenerative Diseases
Liposomal-formulated curcumin [Lipocurc] targeting HDAC (histone deacetylase) prevents apoptosis and improves motor deficits in Park 7 (DJ-1)-knockout rat model of Parkinson's disease: implications for epigenetics-based nanotechnology-driven drug platform.
Neurodegenerative Diseases
Lysine deacetylases and mitochondrial dynamics in neurodegeneration.
Neurodegenerative Diseases
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer's Disease Mouse Model.
Neurodegenerative Diseases
Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
Neurodegenerative Diseases
Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor.
Neurodegenerative Diseases
Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
Neurodegenerative Diseases
Neuronal Nitric Oxide Synthase in Neural Stem Cells Induces Neuronal Fate Commitment via the Inhibition of Histone Deacetylase 2.
Neurodegenerative Diseases
Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation.
Neurodegenerative Diseases
Novel Combinatorial Therapeutic Targeting of PAI-1 (SERPINE1) Gene Expression in Alzheimer's Disease.
Neurodegenerative Diseases
Nuclear Accumulation of Histone Deacetylase 4 (HDAC4) Exerts Neurotoxicity in Models of Parkinson's Disease.
Neurodegenerative Diseases
Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model.
Neurodegenerative Diseases
Pharmacological intervention of histone deacetylase enzymes in the neurodegenerative disorders.
Neurodegenerative Diseases
Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.
Neurodegenerative Diseases
Post-translational modifications of tubulin in the nervous system.
Neurodegenerative Diseases
Potential non-oncological applications of histone deacetylase inhibitors.
Neurodegenerative Diseases
Preclinical Evaluation of an 18F-Labeled SW-100 Derivative for PET Imaging of Histone Deacetylase 6 in the Brain.
Neurodegenerative Diseases
Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Neurodegenerative Diseases
Proteomic analysis identifies NPTX1 and HIP1R as potential targets of histone deacetylase-3-mediated neurodegeneration.
Neurodegenerative Diseases
Proteomic analysis reveals differentially regulated protein acetylation in human amyotrophic lateral sclerosis spinal cord.
Neurodegenerative Diseases
Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain.
Neurodegenerative Diseases
Quantitative Proteomic Analysis Identifies Targets and Pathways of a 2-Aminobenzamide HDAC Inhibitor in Friedreich's Ataxia Patient iPSC-Derived Neural Stem Cells.
Neurodegenerative Diseases
Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.
Neurodegenerative Diseases
Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for friedreich ataxia.
Neurodegenerative Diseases
Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Neurodegenerative Diseases
Resveratrol via sirtuin-1 downregulates RE1-silencing transcription factor (REST) expression preventing PCB-95-induced neuronal cell death.
Neurodegenerative Diseases
Rosiglitazone Synergizes the Neuroprotective Effects of Valproic Acid Against Quinolinic Acid-Induced Neurotoxicity in Rats: Targeting PPAR? and HDAC Pathways.
Neurodegenerative Diseases
SAHA is neuroprotective in in vitro and in situ models of retinitis pigmentosa.
Neurodegenerative Diseases
Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
Neurodegenerative Diseases
Simple Fluorogenic Cellular Assay for Histone Deacetylase Inhibitors Based on Split-Yellow Fluorescent Protein and Intrabodies.
Neurodegenerative Diseases
Small-molecule modulation of HDAC6 activity: The propitious therapeutic strategy to vanquish neurodegenerative disorders.
Neurodegenerative Diseases
Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease.
Neurodegenerative Diseases
Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons.
Neurodegenerative Diseases
Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6.
Neurodegenerative Diseases
Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6.
Neurodegenerative Diseases
Structural insight into the separate roles of inositol tetraphosphate and deacetylase-activating domain in activation of histone deacetylase 3.
Neurodegenerative Diseases
Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors.
Neurodegenerative Diseases
Synthesis of Potent and Selective HDAC6 Inhibitors Bearing a Cyclohexane- or Cycloheptane-Annulated 1,5-Benzothiazepine Scaffold.
Neurodegenerative Diseases
Targeting histone deacetylase 8 as a therapeutic approach to cancer and neurodegenerative diseases.
Neurodegenerative Diseases
Targeting specific HATs for neurodegenerative disease treatment: translating basic biology to therapeutic possibilities.
Neurodegenerative Diseases
Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.
Neurodegenerative Diseases
Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
Neurodegenerative Diseases
The development prospection of HDAC inhibitors as a potential therapeutic direction in Alzheimer's disease.
Neurodegenerative Diseases
The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay.
Neurodegenerative Diseases
The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model.
Neurodegenerative Diseases
The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease.
Neurodegenerative Diseases
To prevent neurodegeneration: HDAC6 uses different strategies for different challenges.
Neurodegenerative Diseases
Translation of HDAC6 PET Imaging Using [18F]EKZ-001-cGMP Production and Measurement of HDAC6 Target Occupancy in Nonhuman Primates.
Neurodegenerative Diseases
Tuning acetylation levels with HAT activators: Therapeutic strategy in neurodegenerative diseases.
Neurodegenerative Diseases
Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: Current targets and future perspective.
Neurodegenerative Diseases
Upregulation of histone deacetylase 2 in laser capture nigral microglia in Parkinson's disease.
Neurodegenerative Diseases
Valproic acid induces astrocyte-dependent neurite outgrowth from cultured rat primary cortical neuron via modulation of tPA/PAI-1 activity.
Neuroectodermal Tumors, Primitive
Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
Neuroectodermal Tumors, Primitive
Histone deacetylase inhibitors induce cell death in supratentorial primitive neuroectodermal tumor cells.
Neuroectodermal Tumors, Primitive
Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.
Neuroendocrine Tumors
A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors.
Neuroendocrine Tumors
Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
Neuroendocrine Tumors
Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors.
Neuroendocrine Tumors
Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
Neuroendocrine Tumors
Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment.
Neuroendocrine Tumors
Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.
Neuroendocrine Tumors
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
Neuroendocrine Tumors
Valproic acid induces Notch1 signaling in small cell lung cancer cells.
Neurofibromatoses
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies.
Neurofibrosarcoma
Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Neurofibrosarcoma
Autophagy blockade enhances HDAC inhibitors' pro-apoptotic effects: Potential implications for the treatment of a therapeutic-resistant malignancy.
Neurofibrosarcoma
Correction: Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Neurofibrosarcoma
Evaluating the Effect of HDAC8 Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Neurofibrosarcoma
HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST).
Neuroinflammatory Diseases
Biomarkers in amyotrophic lateral sclerosis: a review of new developments.
Neuroinflammatory Diseases
Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection.
Neuroinflammatory Diseases
Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency.
Neuroinflammatory Diseases
Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression.
Neuroinflammatory Diseases
HDAC3 inhibition ameliorates ischemia/reperfusion-induced brain injury by regulating the microglial cGAS-STING pathway.
Neuroinflammatory Diseases
HDAC3 inhibition prevents blood-brain barrier permeability through Nrf2 activation in type 2 diabetes male mice.
Neuroinflammatory Diseases
HDAC6 mediates HIV-1 tat-induced proinflammatory responses by regulating MAPK-NF-kappaB/AP-1 pathways in astrocytes.
Neuroinflammatory Diseases
Histone Deacetylase 2 Inhibitor CAY10683 Alleviates Lipopolysaccharide Induced Neuroinflammation Through Attenuating TLR4/NF-?B Signaling Pathway.
Neuroinflammatory Diseases
Histone Deacetylase Inhibitor MS-275 Alleviates Postoperative Cognitive Dysfunction in Rats by Inhibiting Hippocampal Neuroinflammation.
Neuroinflammatory Diseases
Histone Deacetylase Inhibitor Trichostatin A Ameliorated Endotoxin-Induced Neuroinflammation and Cognitive Dysfunction.
Neuroinflammatory Diseases
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Neuroinflammatory Diseases
Increased transcription of TSPO, HDAC2, and HDAC6 in the amygdala of males with alcohol use disorder.
Neuroinflammatory Diseases
Inhibition of Amyloid-Beta Production, Associated Neuroinflammation, and Histone Deacetylase 2-Mediated Epigenetic Modifications Prevent Neuropathology in Alzheimer's Disease in vitro Model.
Neuroinflammatory Diseases
Inhibition of HDAC6 alleviating lipopolysaccharide-induced p38MAPK phosphorylation and neuroinflammation in mice.
Neuroinflammatory Diseases
Inhibition of histone deacetylase 1 or 2 reduces induced cytokine expression in microglia through a protein synthesis independent mechanism.
Neuroinflammatory Diseases
Long Noncoding RNA H19 Promotes Neuroinflammation in Ischemic Stroke by Driving Histone Deacetylase 1-Dependent M1 Microglial Polarization.
Neuroinflammatory Diseases
Opening a New Time Window for Treatment of Stroke by Targeting HDAC2.
Neuroinflammatory Diseases
Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model.
Neuroinflammatory Diseases
Resveratrol reverses morphine-induced neuroinflammation in morphine-tolerant rats by reversal HDAC1 expression.
Neuroinflammatory Diseases
Suppression of histone deacetylases by SAHA relieves bone cancer pain in rats via inhibiting activation of glial cells in spinal dorsal horn and dorsal root ganglia.
Neuroinflammatory Diseases
The inhibitory effects of class I histone deacetylases on hippocampal neuroinflammatory regulation in aging mice with postoperative cognitive dysfunction.
Neuroinflammatory Diseases
The Mechanisms by Which the Ketone Body D-?-Hydroxybutyrate May Improve the Multiple Cellular Pathologies of Parkinson's Disease.
Neuroinflammatory Diseases
Understanding the role of histone deacetylase and their inhibitors in neurodegenerative disorders: Current targets and future perspective.
Neuroma, Acoustic
AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Neuroma, Acoustic
Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas.
Neuromuscular Diseases
The deacetylase HDAC4 controls myocyte enhancing factor-2-dependent structural gene expression in response to neural activity.
Neuromuscular Diseases
The histone deacetylase HDAC4 connects neural activity to muscle transcriptional reprogramming.
Nevus
Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi.
Nevus
Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways.
Nevus, Pigmented
Down-regulated HDAC3 elevates microRNA-495-3p to restrain epithelial-mesenchymal transition and oncogenicity of melanoma cells via reducing TRAF5.
Nevus, Pigmented
Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi.
Nevus, Pigmented
Histone deacetylase inhibitor Vorinostat (SAHA) suppresses micropthalmia transcription factor expression and induces cell death in nevocytes from large/giant congenital melanocytic nevi.
Niemann-Pick Disease, Type C
An "exacerbate-reverse" strategy in yeast identifies histone deacetylase inhibition as a correction for cholesterol and sphingolipid transport defects in human Niemann-Pick type C disease.
Niemann-Pick Disease, Type C
Defective cholesterol traffic and neuronal differentiation in neural stem cells of Niemann-Pick type C disease improved by valproic acid, a histone deacetylase inhibitor.
Niemann-Pick Disease, Type C
The Potential of Histone Deacetylase Inhibitors in Niemann-Pick Type C Disease.
Niemann-Pick Disease, Type C
Treatment of Niemann-Pick Type C Disease by Histone Deacetylase Inhibitors.
Non-alcoholic Fatty Liver Disease
Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR?.
Non-alcoholic Fatty Liver Disease
Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis.
Non-alcoholic Fatty Liver Disease
Nutrient sensor-mediated programmed nonalcoholic fatty liver disease in low birthweight offspring.
Non-alcoholic Fatty Liver Disease
Role of histone deacetylase on nonalcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
The ménage à trois of autophagy, lipid droplets and liver disease.
non-specific protein-tyrosine kinase deficiency
Neuronal gene repression in Niemann-Pick type C models is mediated by the c-Abl/HDAC2 signaling pathway.
Non-ST Elevated Myocardial Infarction
HDAC9 Variant Rs2107595 Modifies Susceptibility to Coronary Artery Disease and the Severity of Coronary Atherosclerosis in a Chinese Han Population.
Nutritional and Metabolic Diseases
Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Obesity
A Class I Histone Deacetylase Inhibitor Attenuates Insulin Resistance and Inflammation in Palmitate-Treated C2C12 Myotubes and Muscle of HF/HFr Diet Mice.
Obesity
A Review of Mitochondrial-derived Fatty Acids in Epigenetic Regulation of Obesity and Type 2 Diabetes.
Obesity
Adaptor protein APPL1 coordinates HDAC3 to modulate brown adipose tissue thermogenesis in mice.
Obesity
Adipose tissue mRNA expression of HDAC1, HDAC3 and HDAC9 in obese women in relation to obesity indices and insulin resistance.
Obesity
Association between HDACs and pro-inflammatory cytokine gene expressions in obesity.
Obesity
Attenuation of diet-induced obesity and induction of white fat browning with a chemical inhibitor of histone deacetylases.
Obesity
Deletion of intestinal Hdac3 remodels the lipidome of enterocytes and protects mice from diet-induced obesity.
Obesity
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
Obesity
Genome-wide analysis reveals that altered methylation in specific CpG loci is associated with childhood obesity.
Obesity
Hepatocyte DACH1 Is Increased in Obesity via Nuclear Exclusion of HDAC4 and Promotes Hepatic Insulin Resistance.
Obesity
Histone Deacetylase 1 (HDAC1) Negatively Regulates Thermogenic Program in Brown Adipocytes via Coordinated Regulation of Histone H3 Lysine 27 (H3K27) Deacetylation and Methylation.
Obesity
Histone Deacetylase 3 Regulates Adipocyte Phenotype at Early Stages of Differentiation.
Obesity
Histone deacetylase 9 promoter hypomethylation associated with adipocyte dysfunction is a statin-related metabolic effect.
Obesity
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Obesity
Histone Deacetylase HDAC8 Promotes Insulin Resistance and ?-Catenin Activation in NAFLD-Associated Hepatocellular Carcinoma.
Obesity
Impaired histone deacetylases 5 and 6 expression mimics the effects of obesity and hypoxia on adipocyte function.
Obesity
In silico Design of Novel Sirtuin 1 Enzyme Activators for Treatment of Age-related Diseases and Life Span.
Obesity
Inhibition of HDAC3 promotes ligand-independent PPAR? activation by protein acetylation.
Obesity
Leptin-mediated increases in catecholamine signaling reduce adipose tissue inflammation via activation of macrophage HDAC4.
Obesity
MS-275, a class 1 histone deacetylase inhibitor augments glucagon-like peptide-1 receptor agonism to improve glycemic control and reduce obesity in diet-induced obese mice.
Obesity
Proteomics Analysis of Human Obesity Reveals the Epigenetic Factor HDAC4 as a Potential Target for Obesity.
Obesity
Regulation of small ubiquitin-like modifier-1, nuclear receptor coreceptor, histone deacetylase 3, and peroxisome proliferator-activated receptor-? in human adipose tissue.
Obesity
Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1/angiotensin II axis.
Obesity
SAHA induces white fat browning and rectifies metabolic dysfunctions via activation of ZFPs.
Obesity
Scriptaid enhances skeletal muscle insulin action and cardiac function in obese mice.
Obesity
Sodium Butyrate Protects Against High Fat Diet-induced Cardiac Dysfunction and Metabolic Disorders in Type II Diabetic Mice.
Obesity
Structure-based drug design of small molecule SIRT1 modulators to treat cancer and metabolic disorders.
Obesity
The intestinal microbiota programs diurnal rhythms in host metabolism through histone deacetylase 3.
Obesity
The loss of histone deacetylase 4 in macrophages exacerbates hepatic and adipose tissue inflammation in male but not in female mice with diet-induced non-alcoholic steatohepatitis.
Obesity
X-exome sequencing identifies a HDAC8 variant in a large pedigree with X-linked intellectual disability, truncal obesity, gynaecomastia, hypogonadism and unusual face.
Obesity, Maternal
A maternal high-fat diet modulates fetal SIRT1 histone and protein deacetylase activity in nonhuman primates.
Ocular Hypertension
Ischemic preconditioning, retinal neuroprotection and histone deacetylase activities.
Oligodendroglioma
Triacetin-based acetate supplementation as a chemotherapeutic adjuvant therapy in glioma.
Optic Nerve Injuries
Combined HDAC1 and HDAC2 Depletion Promotes Retinal Ganglion Cell Survival After Injury Through Reduction of p53 Target Gene Expression.
Optic Nerve Injuries
HDAC5 promotes optic nerve regeneration by activating the mTOR pathway.
Optic Nerve Injuries
Histone deacetylase 3 (HDAC3) plays an important role in retinal ganglion cell death after acute optic nerve injury.
Optic Nerve Injuries
Targeting HDAC3 Activity with RGFP966 Protects Against Retinal Ganglion Cell Nuclear Atrophy and Apoptosis After Optic Nerve Injury.
Optic Nerve Injuries
Valproic acid promotes neural regeneration of olfactory epithelium in adult mice after methimazole-induced damage.
Osteoarthritis
Adenovirus-mediated transduction with Histone Deacetylase 4 ameliorates disease progression in an osteoarthritis rat model.
Osteoarthritis
Alleviation of osteoarthritis by Trichostatin A, a histone deacetylase inhibitor, in experimental osteoarthritis.
Osteoarthritis
Chondrocyte mTORC1 activation stimulates miR-483-5p via HDAC4 in osteoarthritis progression.
Osteoarthritis
Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis.
Osteoarthritis
Decreased histone deacetylase 4 is associated with human osteoarthritis cartilage degeneration by releasing histone deacetylase 4 inhibition of runt-related transcription factor-2 and increasing osteoarthritis-related genes: a novel mechanism of human osteoarthritis cartilage degeneration.
Osteoarthritis
Histone deacetylase inhibition activates Nrf2 and protects against osteoarthritis.
Osteoarthritis
Histone Deacetylase Inhibitor Vorinostat (SAHA) Suppresses IL-1?-Induced Matrix Metallopeptidase-13 Expression by Inhibiting IL-6 in Osteoarthritis Chondrocyte.
Osteoarthritis
Histone deacetylase inhibitors increase microRNA-146a expression and enhance negative regulation of interleukin-1? signaling in osteoarthritis fibroblast-like synoviocytes.
Osteoarthritis
Histone Deacetylase Inhibitory Approaches for the Management of Osteoarthritis.
Osteoarthritis
Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis.
Osteoarthritis
Inhibition of HDAC6 by Tubastatin A reduces chondrocyte oxidative stress in chondrocytes and ameliorates mouse osteoarthritis by activating autophagy.
Osteoarthritis
Inhibition of histone deacetylase 6 by Tubastatin A attenuates the progress of osteoarthritis via improving mitochondrial function.
Osteoarthritis
Mechanical and IL-1? Responsive miR-365 Contributes to Osteoarthritis Development by Targeting Histone Deacetylase 4.
Osteoarthritis
MicroRNA-92a-3p regulates the expression of cartilage-specific genes by directly targeting histone deacetylase 2 in chondrogenesis and degradation.
Osteoarthritis
miR-193b-5p regulates chondrocytes metabolism by directly targeting histone deacetylase 7 in interleukin-1?-induced osteoarthritis.
Osteoarthritis
Trichostatin A increases the TIMP-1/MMP ratio to protect against osteoarthritis in an animal model of the disease.
Osteoarthritis, Knee
Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis.
Osteochondroma
Histone Deacetylase 4 Promotes Osteosarcoma Cell Proliferation and Invasion by Regulating Expression of Proliferating Cell Nuclear Antigen.
Osteogenesis Imperfecta
The new bone biology: pathologic, molecular, and clinical correlates.
Osteolysis
The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss.
Osteophyte
Adenovirus-mediated transduction with Histone Deacetylase 4 ameliorates disease progression in an osteoarthritis rat model.
Osteoporosis
A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans.
Osteoporosis
HDAC6 inactivates Runx2 promoter to block osteogenesis of bone marrow stromal cells in age-related bone loss of mice.
Osteoporosis
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases.
Osteoporosis
Impaired autophagy triggered by HDAC9 in mesenchymal stem cells accelerates bone mass loss.
Osteoporosis
Mechanical stimulation orchestrates the osteogenic differentiation of human bone marrow stromal cells by regulating HDAC1.
Osteoporosis
MicroRNA-29a mitigates glucocorticoid induction of bone loss and fatty marrow by rescuing Runx2 acetylation.
Osteoporosis
MiR-29a promotes osteogenic differentiation of mesenchymal stem cells via targeting HDAC4.
Osteoporosis
miR-365 Ameliorates Dexamethasone-Induced Suppression of Osteogenesis in MC3T3-E1 Cells by Targeting HDAC4.
Osteoporosis
MiRNA-19a-3p alleviates the progression of osteoporosis by targeting HDAC4 to promote the osteogenic differentiation of hMSCs.
Osteoporosis
PPAR? forms a bridge between DNA methylation and histone acetylation at the C/EBP? gene promoter to regulate the balance between osteogenesis and adipogenesis of bone marrow stromal cells.
Osteoporosis
Puerarin alleviates streptozotocin (STZ)-induced osteoporosis in rats through suppressing inflammation and apoptosis via HDAC1/HDAC3 signaling.
Osteoporosis
[Mechanisms of electroacupuncture underlying treatment of osteoporosis based on HDAC2-mediated osteoblast differentiation pathway].
Osteosarcoma
A mutation in the 3'-UTR of the HDAC6 gene abolishing the post-transcriptional regulation mediated by hsa-miR-433 is linked to a new form of dominant X-linked chondrodysplasia.
Osteosarcoma
Antitumor activity of histone deacetylase inhibitor trichostatin A in osteosarcoma cells.
Osteosarcoma
Downregulation of matrix metalloproteinase-9 mRNA by valproic acid plays a role in inhibiting the shedding of MHC class I-related molecules A and B on the surface of human osteosarcoma cells.
Osteosarcoma
Effect of the histone deacetylase inhibitor SNDX-275 on fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.
Osteosarcoma
Efficacy In Vitro of Caffeine and Valproic Acid on Patient-Derived Undifferentiated Pleomorphic Sarcoma and Rhabdomyosarcoma Cell Lines.
Osteosarcoma
Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition.
Osteosarcoma
Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications.
Osteosarcoma
HDAC2 depletion promotes osteosarcoma's stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy.
Osteosarcoma
HDAC5 promotes osteosarcoma progression by upregulation of Twist 1 expression.
Osteosarcoma
HDAC6 inhibitor WT161 performs anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.
Osteosarcoma
Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.
Osteosarcoma
Histone Deacetylase 4 Promotes Osteosarcoma Cell Proliferation and Invasion by Regulating Expression of Proliferating Cell Nuclear Antigen.
Osteosarcoma
Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis.
Osteosarcoma
Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription.
Osteosarcoma
Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.
Osteosarcoma
Histone deacetylase inhibition sensitizes osteosarcoma to heavy ion radiotherapy.
Osteosarcoma
Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling.
Osteosarcoma
Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation.
Osteosarcoma
Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Osteosarcoma
Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone].
Osteosarcoma
Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells.
Osteosarcoma
Knockdown of CircCRIM1 Inhibits HDAC4 to Impede Osteosarcoma Proliferation, Migration, and Invasion and Facilitate Autophagy by Targeting miR-432-5p.
Osteosarcoma
Kruppel-Like Factor 9 Loss-of-Expression in Human Endometrial Carcinoma Links Altered Expression of Growth-Regulatory Genes with Aberrant Proliferative Response to Estrogen.
Osteosarcoma
Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells.
Osteosarcoma
Metformin Synergistically Enhances Antitumor Activity of Histone Deacetylase Inhibitor Trichostatin A Against Osteosarcoma Cell Line.
Osteosarcoma
MicroRNA-145-3p suppresses proliferation and promotes apotosis and autophagy of osteosarcoma cell by targeting HDAC4.
Osteosarcoma
Natural product pectolinarigenin inhibits osteosarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibition.
Osteosarcoma
Overexpression of miR-140 inhibits proliferation of osteosarcoma cells via suppression of histone deacetylase 4.
Osteosarcoma
Panobinostat mediated cell death: a novel therapeutic approach for osteosarcoma.
Osteosarcoma
Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model.
Osteosarcoma
RNA sequencing identifies gene expression profile changes associated with ?-estradiol treatment in U2OS osteosarcoma cells.
Osteosarcoma
Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines.
Osteosarcoma
Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma.
Osteosarcoma
Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP.
Osteosarcoma
Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo.
Osteosarcoma
Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity.
Osteosarcoma
Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death.
Osteosarcoma
Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells.
Osteosarcoma
Suberoylanilide hydroxamic acid affects ?H2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation.
Osteosarcoma
Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells.
Osteosarcoma
Targeting the 'garbage-bin' to fight cancer: HDAC6 inhibitor WT161 has an anti-tumor effect on osteosarcoma and synergistically interacts with 5-FU.
Osteosarcoma
Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.
Osteosarcoma
The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth.
Osteosarcoma
The Effect of VPA on Increasing Radiosensitivity in Osteosarcoma Cells and Primary-Culture Cells from Chemical Carcinogen-Induced Breast Cancer in Rats.
Osteosarcoma
The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.
Osteosarcoma
The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases.
Osteosarcoma
Tubulin polymerization promoting protein 1 (TPPP1) increases ?-catenin expression through inhibition of HDAC6 activity in U2OS osteosarcoma cells.
Osteosarcoma
Up-regulation of HDAC9 promotes cell proliferation through suppressing p53 transcription in osteosarcoma.
Osteosarcoma
Upregulation of Polo-like kinase 2 gene expression by GATA-1 acetylation in human osteosarcoma MG-63 cells.
Osteosarcoma
Valproic acid cooperates with hydralazine to augment the susceptibility of human osteosarcoma cells to Fas- and NK cell-mediated cell death.
Osteosarcoma
[Histone deacetylase inhibits the growth and migration of human osteosarcoma cells].
Ototoxicity
Histone deacetylase inhibition protects hearing against acute ototoxicity by activating the Nf-?B pathway.
Ototoxicity
Histone Deacetylase Inhibitors Are Protective in Acute but Not in Chronic Models of Ototoxicity.
Ototoxicity
The histone deacetylase inhibitor sodium butyrate protects against cisplatin-induced hearing loss in guinea pigs.
Ototoxicity
Theophylline alleviates gentamicin-induced cytotoxicity to sensory hair cells by maintaining HDAC2 expression.
Ovarian Neoplasms
A novel histone deacetylase inhibitor, Scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells.
Ovarian Neoplasms
A novel platinum complex of the histone deacetylase inhibitor belinostat: rational design, development and in vitro cytotoxicity.
Ovarian Neoplasms
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study.
Ovarian Neoplasms
A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.
Ovarian Neoplasms
A unique histone deacetylase inhibitor alters microRNA expression and signal transduction in chemoresistant ovarian cancer cells.
Ovarian Neoplasms
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies.
Ovarian Neoplasms
Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
Ovarian Neoplasms
Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells.
Ovarian Neoplasms
Association of histone deacetylase expression with histology and prognosis of ovarian cancer.
Ovarian Neoplasms
Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.
Ovarian Neoplasms
CBHA Is a Family of Hybrid Polar Compounds That Inhibit Histone Deacetylase, and Induces Growth Inhibition, Cell Cycle Arrest and Apoptosis in Human Endometrial and Ovarian Cancer Cells.
Ovarian Neoplasms
Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins.
Ovarian Neoplasms
Chimeric NKG2D CAR-Expressing T Cell-Mediated Attack of Human Ovarian Cancer Is Enhanced by Histone Deacetylase Inhibition.
Ovarian Neoplasms
Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer.
Ovarian Neoplasms
Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.
Ovarian Neoplasms
Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer.
Ovarian Neoplasms
Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Ovarian Neoplasms
Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.
Ovarian Neoplasms
Design, synthesis and biological evaluation of a phenyl butyric acid derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 inhibitor with anti-proliferative activity on cervix cancer and leukemia cells.
Ovarian Neoplasms
Differential Effects of Estradiol and Bisphenol A on SET8 and SIRT1 Expression in Ovarian Cancer Cells.
Ovarian Neoplasms
DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells.
Ovarian Neoplasms
Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.
Ovarian Neoplasms
Effect of histone deacetylase inhibitors on cell apoptosis and expression of the tumor suppressor genes RUNX3 and ARHI in ovarian tumors.
Ovarian Neoplasms
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Ovarian Neoplasms
Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells.
Ovarian Neoplasms
Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian cancer cells.
Ovarian Neoplasms
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
Ovarian Neoplasms
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
Ovarian Neoplasms
Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells.
Ovarian Neoplasms
Epigenetic-mediated immune suppression of positive co-stimulatory molecules in chemoresistant ovarian cancer cells.
Ovarian Neoplasms
Expression loss and revivification of RhoB gene in ovary carcinoma carcinogenesis and development.
Ovarian Neoplasms
Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues.
Ovarian Neoplasms
From Anti-infective Agents to Cancer Therapy: a Drug Repositioning Study Revealed a New Use for Nitrofuran Derivatives.
Ovarian Neoplasms
Genetics Helps to Find Synergy for Immune Checkpoint and Targeted Combination Therapies.
Ovarian Neoplasms
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.
Ovarian Neoplasms
HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells.
Ovarian Neoplasms
HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer.
Ovarian Neoplasms
Histone Deacetylase (HDAC) Inhibition Induces I?B Kinase (IKK)-dependent Interleukin-8/CXCL8 Expression in Ovarian Cancer Cells.
Ovarian Neoplasms
Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
Ovarian Neoplasms
Histone deacetylase 4 increases progressive epithelial ovarian cancer cells via repression of p21 on fibrillar collagen matrices.
Ovarian Neoplasms
Histone deacetylase inhibitor trichostatin A modulates cell cycles in A2780 human ovarian cancer cell lines.
Ovarian Neoplasms
Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.
Ovarian Neoplasms
Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing.
Ovarian Neoplasms
Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells.
Ovarian Neoplasms
Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status.
Ovarian Neoplasms
Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad.
Ovarian Neoplasms
HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.
Ovarian Neoplasms
Human endometrial and ovarian cancer cells: histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis.
Ovarian Neoplasms
Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.
Ovarian Neoplasms
Impact of the histone deacetylase inhibitor trichostatin A on active uptake, volume-sensitive release of taurine, and cell fate in human ovarian cancer cells.
Ovarian Neoplasms
In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
Ovarian Neoplasms
In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Ovarian Neoplasms
Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation.
Ovarian Neoplasms
Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Ovarian Neoplasms
Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.
Ovarian Neoplasms
Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1?-mediated regulation of apoptosis and autophagy.
Ovarian Neoplasms
Investigation of the expression patterns and correlation of DNA methyltransferases and class I histone deacetylases in ovarian cancer tissues.
Ovarian Neoplasms
Loss of betaglycan expression in ovarian cancer: role in motility and invasion.
Ovarian Neoplasms
M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells.
Ovarian Neoplasms
Metastatic Phosphatase PRL-3 Induces Ovarian Cancer Stem Cell Sub-population through Phosphatase-Independent Deacetylation Modulations.
Ovarian Neoplasms
MiRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1.
Ovarian Neoplasms
Overcoming immune suppression with epigenetic modification in ovarian cancer.
Ovarian Neoplasms
Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
Ovarian Neoplasms
PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells.
Ovarian Neoplasms
Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.
Ovarian Neoplasms
Prognosis Analysis of Histone Deacetylases mRNA Expression in Ovarian Cancer Patients.
Ovarian Neoplasms
Retraction notice to "M344 is a novel synthesized histone deacetylase inhibitor that induces growth inhibition, cell cycle arrest, and apoptosis in human endometrial cancer and ovarian cancer cells" [Gynecol. Oncol. 101 (2006) 108-113].
Ovarian Neoplasms
Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Ovarian Neoplasms
Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovarian cancer cell lines.
Ovarian Neoplasms
Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
Ovarian Neoplasms
Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines.
Ovarian Neoplasms
Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells.
Ovarian Neoplasms
Synergistic Efficacy in Human Ovarian Cancer Cells by Histone Deacetylase Inhibitor TSA and Proteasome Inhibitor PS-341.
Ovarian Neoplasms
Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
Ovarian Neoplasms
Targeting CD146 in combination with vorinostat for the treatment of ovarian cancer cells.
Ovarian Neoplasms
Telomerase expression and cell proliferation in ovarian cancer cells induced by histone deacetylase inhibitors.
Ovarian Neoplasms
Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy.
Ovarian Neoplasms
The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Ovarian Neoplasms
The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells.
Ovarian Neoplasms
The effect of the histone deacetylase inhibitor M344 on BRCA1 expression in breast and ovarian cancer cells.
Ovarian Neoplasms
The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells.
Ovarian Neoplasms
The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21.
Ovarian Neoplasms
The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.
Ovarian Neoplasms
The histone deacetylase SIRT6 inhibits ovarian cancer cell proliferation via down-regulation of Notch 3 expression.
Ovarian Neoplasms
The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines.
Ovarian Neoplasms
The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
Ovarian Neoplasms
The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer.
Ovarian Neoplasms
Three-Combined Treatment, a Novel HDAC Inhibitor OBP-801/YM753, 5-Fluorouracil and Paclitaxel, Induces G2-Phase Arrest Through the p38 Pathway in Human Ovarian Cancer Cells.
Ovarian Neoplasms
Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway.
Ovarian Neoplasms
Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells.
Ovarian Neoplasms
Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Ovarian Neoplasms
Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor.
Ovarian Neoplasms
Ubiquitin specific peptidase 5 promotes ovarian cancer cell proliferation through deubiquitinating HDAC2.
Ovarian Neoplasms
Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells.
Overnutrition
Leptin-mediated increases in catecholamine signaling reduce adipose tissue inflammation via activation of macrophage HDAC4.
Pancreatic Neoplasms
A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells.
Pancreatic Neoplasms
A histone deacetylase inhibitor, panobinostat, enhances chimeric receptor antigen T cell anti-tumor effect against pancreatic cancer.
Pancreatic Neoplasms
A new method of comparing 2D-PAGE maps based on the computation of Zernike moments and multivariate statistical tools.
Pancreatic Neoplasms
Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer.
Pancreatic Neoplasms
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Pancreatic Neoplasms
An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors.
Pancreatic Neoplasms
Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer.
Pancreatic Neoplasms
Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models.
Pancreatic Neoplasms
ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2/?-catenin signaling pathway.
Pancreatic Neoplasms
Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study.
Pancreatic Neoplasms
c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.
Pancreatic Neoplasms
Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
Pancreatic Neoplasms
Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells.
Pancreatic Neoplasms
Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Pancreatic Neoplasms
CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
Pancreatic Neoplasms
Current evidence for histone deacetylase inhibitors in pancreatic cancer.
Pancreatic Neoplasms
Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine.
Pancreatic Neoplasms
Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers.
Pancreatic Neoplasms
Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays.
Pancreatic Neoplasms
Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Pancreatic Neoplasms
Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Pancreatic Neoplasms
Effects of a histone deacetylase inhibitor, sodium butyrate, on 53-kDa protein expression and sensitivity to anticancer drugs of pancreatic cancer cells.
Pancreatic Neoplasms
Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
Pancreatic Neoplasms
Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling.
Pancreatic Neoplasms
Epigenetic Regulation Affects N-myc Downstream-Regulated Gene 1 Expression Indirectly in Pancreatic Cancer Cells.
Pancreatic Neoplasms
Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells.
Pancreatic Neoplasms
Epigenetic Silencing of MicroRNA miR-107 Regulates Cyclin-Dependent Kinase 6 Expression in Pancreatic Cancer.
Pancreatic Neoplasms
Erratum to: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells.
Pancreatic Neoplasms
Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
Pancreatic Neoplasms
Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.
Pancreatic Neoplasms
Expression of MTA1, a metastasis-associated gene with histone deacetylase activity in pancreatic cancer.
Pancreatic Neoplasms
FBP1 binds to the bromodomain of BRD4 to inhibit pancreatic cancer progression.
Pancreatic Neoplasms
FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.
Pancreatic Neoplasms
Gd-Metallofullerenol Nanomaterial Suppresses Pancreatic Cancer Metastasis by Inhibiting the Interaction of Histone Deacetylase 1 and Metastasis-Associated Protein 1.
Pancreatic Neoplasms
Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
Pancreatic Neoplasms
Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells.
Pancreatic Neoplasms
Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.
Pancreatic Neoplasms
HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Pancreatic Neoplasms
HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment.
Pancreatic Neoplasms
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.
Pancreatic Neoplasms
HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA.
Pancreatic Neoplasms
HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer.
Pancreatic Neoplasms
Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3B1, a novel epithelial-mesenchymal transition inducer in pancreatic cancer.
Pancreatic Neoplasms
High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo.
Pancreatic Neoplasms
Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors.
Pancreatic Neoplasms
Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.
Pancreatic Neoplasms
Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax.
Pancreatic Neoplasms
Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells.
Pancreatic Neoplasms
Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.
Pancreatic Neoplasms
Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
Pancreatic Neoplasms
Histone Deacetylase Inhibition Restores Expression of Hypoxia-Inducible Protein NDRG1 in Pancreatic Cancer.
Pancreatic Neoplasms
Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-? on pancreatic cancer cells.
Pancreatic Neoplasms
Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells.
Pancreatic Neoplasms
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
Pancreatic Neoplasms
Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials?
Pancreatic Neoplasms
Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines.
Pancreatic Neoplasms
Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.
Pancreatic Neoplasms
Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.
Pancreatic Neoplasms
Identification and Characterization of AES-135, a Hydroxamic Acid-based HDAC Inhibitor that Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.
Pancreatic Neoplasms
Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.
Pancreatic Neoplasms
Impact of The Hybrid-Polar Histone Deacetylase Inhibitor M-Carboxycinnamic Acid Bis-Hydroxamide on Human Pancreatic Adenocarcinoma Cells.
Pancreatic Neoplasms
Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells.
Pancreatic Neoplasms
Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-But, a hyaluronic butyric ester: a preliminary report.
Pancreatic Neoplasms
Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer.
Pancreatic Neoplasms
Keratin 23 (K23), a novel acidic keratin, is highly induced by histone deacetylase inhibitors during differentiation of pancreatic cancer cells.
Pancreatic Neoplasms
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Pancreatic Neoplasms
MicroRNA-221 induces autophagy through suppressing HDAC6 expression and promoting apoptosis in pancreatic cancer.
Pancreatic Neoplasms
Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
Pancreatic Neoplasms
Molecular determinants of the antitumor effects of trichostatin A in pancreatic cancer cells.
Pancreatic Neoplasms
MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer.
Pancreatic Neoplasms
Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
Pancreatic Neoplasms
Neuronal pentraxin II (NPTX2) Is Frequently Down-Regulated by Promoter Hypermethylation in Pancreatic Cancers.
Pancreatic Neoplasms
Novel epi-virotherapeutic treatment of pancreatic cancer combining the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus.
Pancreatic Neoplasms
Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways.
Pancreatic Neoplasms
Plant derived inhibitor Sulforaphane in combinatorial therapy against therapeutically challenging Pancreatic Cancer.
Pancreatic Neoplasms
Possible role of autophagy in the treatment of pancreatic cancer with histone deacetylase inhibitors.
Pancreatic Neoplasms
Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer.
Pancreatic Neoplasms
Rationale for possible targeting of histone deacetylase signaling in cancer diseases with a special reference to pancreatic cancer.
Pancreatic Neoplasms
Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer.
Pancreatic Neoplasms
Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi).
Pancreatic Neoplasms
SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin.
Pancreatic Neoplasms
Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer.
Pancreatic Neoplasms
SiRNA Delivery with PEGylated Graphene Oxide Nanosheets for Combined Photothermal and Genetherapy for Pancreatic Cancer.
Pancreatic Neoplasms
SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines.
Pancreatic Neoplasms
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses vasculogenic mimicry and proliferation of highly aggressive pancreatic cancer PaTu8988 cells.
Pancreatic Neoplasms
Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.
Pancreatic Neoplasms
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.
Pancreatic Neoplasms
Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agents.
Pancreatic Neoplasms
Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595.
Pancreatic Neoplasms
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.
Pancreatic Neoplasms
The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.
Pancreatic Neoplasms
The role of oxysterol binding protein-related protein 5 in pancreatic cancer.
Pancreatic Neoplasms
Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.
Pancreatic Neoplasms
Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects.
Pancreatic Neoplasms
Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.
Pancreatic Neoplasms
Tyrphostin B42 attenuates trichostatin A-mediated resistance in pancreatic cancer cells by antagonizing IL-6/JAK2/STAT3 signaling.
Pancreatic Neoplasms
Upregulated histone deacetylase 1 expression in pancreatic ductal adenocarcinoma and specific siRNA inhibits the growth of cancer cells.
Pancreatic Neoplasms
Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer.
Pancreatic Neoplasms
Use of herbal medicines and natural products: an alternative approach to overcoming the apoptotic resistance of pancreatic cancer.
Pancreatic Neoplasms
Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway.
Pancreatitis
ATF4-mediated histone deacetylase HDAC1 promotes the progression of acute pancreatitis.
Pancreatitis
Class I histone deacetylase inhibition improves pancreatitis outcome by limiting leukocyte recruitment and acinar-to-ductal metaplasia.
Pancreatitis
Histone Deacetylase Regulates Trypsin Activation, Inflammation, and Tissue Damage in Acute Pancreatitis in Mice.
Pancreatitis, Chronic
Histone deacetylase 2 is involved in µ?opioid receptor suppression in the spinal dorsal horn in a rat model of chronic pancreatitis pain.
Papilloma
The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth.
Paralysis
Botulinum toxin A-induced muscle paralysis stimulates Hdac4 and differential miRNA expression.
Paralysis
Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms.
Paramyxoviridae Infections
Histone Deacetylase Inhibitors Enhance Cell Killing and Block Interferon-Beta Synthesis Elicited by Infection with an Oncolytic Parainfluenza Virus.
Paraparesis, Spastic
Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients.
Paraproteinemias
Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.
Parasitic Diseases
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy.
Parasitic Diseases
Exploring the binding mechanism of HDAC8 selective inhibitors: Lessons from the modification of Cap group.
Parasitic Diseases
Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases.
Parasitic Diseases
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives.
Parasitic Diseases
Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
Parasitic Diseases
Toxoplasma gondii Infection Inhibits Histone Crotonylation to Regulate Immune Response of Porcine Alveolar Macrophages.
Parkinson Disease
A novel histone deacetylase 1 and 2 isoform-specific inhibitor alleviates experimental Parkinson's disease.
Parkinson Disease
Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions.
Parkinson Disease
Acetylation of NDUFV1 induced by a newly synthesized HDAC6 inhibitor HGC rescues dopaminergic neuron loss in Parkinson models.
Parkinson Disease
Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.
Parkinson Disease
Brain expression level and activity of HDAC6 protein in neurodegenerative dementia.
Parkinson Disease
Exifone Is a Potent HDAC1 Activator with Neuroprotective Activity in Human Neuronal Models of Neurodegeneration.
Parkinson Disease
Gene Co-expression Analysis Identifies Histone Deacetylase 5 and 9 Expression in Midbrain Dopamine Neurons and as Regulators of Neurite Growth via Bone Morphogenetic Protein Signaling.
Parkinson Disease
HDAC6-mediated Hsp90 deacetylation reduces aggregation and toxicity of the protein alpha-synuclein by regulating chaperone-mediated autophagy.
Parkinson Disease
How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
Parkinson Disease
Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration.
Parkinson Disease
Inhibition of HDAC6 activity protects dopaminergic neurons from alpha-synuclein toxicity.
Parkinson Disease
Inhibition of HDAC6 increases acetylation of peroxiredoxin1/2 and ameliorates 6-OHDA induced dopaminergic injury.
Parkinson Disease
Nuclear Accumulation of Histone Deacetylase 4 (HDAC4) Exerts Neurotoxicity in Models of Parkinson's Disease.
Parkinson Disease
Pharmacological Inhibition of HDAC6 Attenuates NLRP3 Inflammatory Response and Protects Dopaminergic Neurons in Experimental Models of Parkinson's Disease.
Parkinson Disease
Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
Parkinson Disease
Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms.
Parkinson Disease
PINK1 positively regulates HDAC3 to suppress dopaminergic neuronal cell death.
Parkinson Disease
Small-molecule modulation of HDAC6 activity: The propitious therapeutic strategy to vanquish neurodegenerative disorders.
Parkinson Disease
The Histone Deacetylase Inhibitor Nicotinamide Exacerbates Neurodegeneration in the Lactacystin Rat Model of Parkinson's Disease.
Parkinson Disease
Upregulation of histone deacetylase 2 in laser capture nigral microglia in Parkinson's disease.
Parkinsonian Disorders
A dual inhibitor targeting HMG-CoA reductase and histone deacetylase mitigates neurite degeneration in LRRK2-G2019S parkinsonism.
Parkinsonian Disorders
Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms.
Parkinsonian Disorders
Sex differences in autophagy-mediated diseases: toward precision medicine.
Pediatric Obesity
Associations between placental CpG methylation of metastable epialleles and childhood body mass index across ages one, two and ten in the Extremely Low Gestational Age Newborns (ELGAN) cohort.
Penile Induration
Silencing histone deacetylase 2 using small hairpin RNA induces regression of fibrotic plaque in a rat model of Peyronie's disease.
Penile Induration
Silencing Histone Deacetylase 7 Alleviates Transforming Growth Factor-?1-Induced Profibrotic Responses in Fibroblasts Derived from Peyronie's Plaque.
Pericarditis
Histone deacetylase inhibition attenuates atrial arrhythmogenesis in sterile pericarditis.
Periodontal Diseases
HDAC3 Regulates Gingival Fibroblast Inflammatory Responses in Periodontitis.
Periodontal Diseases
MicroRNA-22 Promoted Osteogenic Differentiation of Human Periodontal Ligament Stem Cells by Targeting HDAC6.
Peripheral Nerve Injuries
A histone deacetylase 3-dependent pathway delimits peripheral myelin growth and functional regeneration.
Peripheral Nerve Injuries
HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice.
Peripheral Nerve Injuries
Histone deacetylase inhibitors relieve morphine resistance in neuropathic pain after peripheral nerve injury.
Peripheral Nerve Injuries
Normalizing HDAC2 Levels in the Spinal Cord Alleviates Thermal and Mechanical Hyperalgesia After Peripheral Nerve Injury and Promotes GAD65 and KCC2 Expression.
Peripheral Nervous System Diseases
Cell-specific role of histone deacetylase 6 in chemotherapy-induced mechanical allodynia and loss of intraepidermal nerve fibers.
Peripheral Nervous System Diseases
Charcot-Marie-Tooth disease: emerging mechanisms and therapies.
Peripheral Nervous System Diseases
Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
Peripheral Nervous System Diseases
HDAC6 as a potential therapeutic target for peripheral nerve disorders.
Peripheral Nervous System Diseases
HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.
Peripheral Nervous System Diseases
HDAC6 inhibition promotes ?-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice.
Peripheral Nervous System Diseases
HDAC6 Inhibitors Rescued the Defective Axonal Mitochondrial Movement in Motor Neurons Derived from the Induced Pluripotent Stem Cells of Peripheral Neuropathy Patients with HSPB1 Mutation.
Peripheral Nervous System Diseases
HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.
Peripheral Nervous System Diseases
HDAC6: A Key Link Between Mitochondria and Development of Peripheral Neuropathy.
Peripheral Nervous System Diseases
Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
Peripheral Nervous System Diseases
Protective Effects of ACY-1215 Against Chemotherapy-Related Cognitive Impairment and Brain Damage in Mice.
Peripheral Nervous System Diseases
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer.
Peritoneal Fibrosis
HDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal.
Peritoneal Fibrosis
Histone deacetylase 6 inhibition counteracts the epithelial-mesenchymal transition of peritoneal mesothelial cells and prevents peritoneal fibrosis.
Peritoneal Fibrosis
Requirement of Histone Deacetylase 6 for Interleukin-6 Induced Epithelial-Mesenchymal Transition, Proliferation, and Migration of Peritoneal Mesothelial Cells.
Peritoneal Neoplasms
Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.
Peritonitis
Elevated expression of HDAC6 in clinical peritoneal dialysis patients and its pathogenic role on peritoneal angiogenesis.
Persistent Infection
Dysfunctional gastric emptying with downregulation of muscle-specific microRNAs in Helicobacter pylori-infected mice.
Persistent Infection
Reactivation of feline foamy virus from a chronically infected feline renal cell line by trichostatin A.
Pheochromocytoma
Histone Deacetylase 5 Is an Early Epigenetic Regulator of Intermittent Hypoxia Induced Sympathetic Nerve Activation and Blood Pressure.
Pheochromocytoma
Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells.
Pheochromocytoma
HPOB, an HDAC6 inhibitor, attenuates corticosterone-induced injury in rat adrenal pheochromocytoma PC12 cells by inhibiting mitochondrial GR translocation and the intrinsic apoptosis pathway.
Pheochromocytoma
Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹?F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.
Pheochromocytoma
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
phosphatidate phosphatase deficiency
Lipin1 is required for skeletal muscle development by regulating MEF2c and MyoD expression.
phosphoribosylaminoimidazole carboxylase deficiency
PAICS contributes to gastric carcinogenesis and participates in DNA damage response by interacting with histone deacetylase 1/2.
Pituitary ACTH Hypersecretion
Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease.
Pituitary ACTH Hypersecretion
Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease.
Pituitary Neoplasms
Histone deacetylase 11 suppresses p53 expression in pituitary tumor cells.
Pituitary Neoplasms
Regulation of cell growth and expression of 7B2, PC2, and PC1/3 by TGFbeta 1 and sodium butyrate in a human pituitary cell line (HP75).
Pituitary Neoplasms
Suberoylanilide hydroxamic acid (SAHA) induces growth arrest and apoptosis in pituitary adenoma cells.
Pneumococcal Infections
Histone Deacetylase Inhibition Protects Mice Against Lethal Postinfluenza Pneumococcal Infection.
Pneumonia
Carbon black nanoparticle induces HDAC6-mediated inflammatory responses in 16HBE cells.
Pneumonia
Combinatorial therapy with acetylation and methylation modifiers attenuates lung vascular hyperpermeability in endotoxemia-induced mouse inflammatory lung injury.
Pneumonia
HDAC5 promotes Mycoplasma pneumoniae-induced inflammation in macrophages through NF-?B activation.
Pneumonia
HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury.
Pneumonia
Histone Deacetylase 2 is Phosphorylated, Ubiquitinated and Degraded by Cigarette Smoke.
Pneumonia
Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation.
Pneumonia
Histone deacetylase 6 regulates endothelial MyD88-dependent canonical TLR signaling, lung inflammation, and alveolar remodeling in the developing lung.
Pneumonia
Histone Deacetylase 7 Inhibition in A Murine Model of Gram-Negative Pneumonia-Induced Acute Lung Injury.
Pneumonia
Histone Deacetylase Inhibition Protects Mice Against Lethal Postinfluenza Pneumococcal Infection.
Pneumonia
Histone Deacetylase Inhibitor Treatment Attenuates MAP Kinase Pathway Activation and Pulmonary Inflammation Following Hemorrhagic Shock in a Rodent Model.
Pneumonia
Nrf2 deficiency influences susceptibility to steroid resistance via HDAC2 reduction.
Pneumonia
Remote Burn Injury Increases Pulmonary Histone Deacetylase 1 and Reduces Histone Acetylation.
Pneumonia
Sirt1 protects against thrombomodulin down-regulation and lung coagulation after particulate matter exposure.
Pneumonia
The anti-malaria drug artesunate inhibits cigarette smoke and ovalbumin concurrent exposure-induced airway inflammation and might reverse glucocorticoid insensitivity.
Pneumonia
Trichostatin A attenuates ventilation-augmented epithelial-mesenchymal transition in mice with bleomycin-induced acute lung injury by suppressing the Akt pathway.
Pneumonia
Update on Molecular Mechanisms of Corticosteroid Resistance in Chronic Obstructive Pulmonary Disease.
Polycystic Kidney Diseases
AN INHIBITOR OF HISTONE DEACETYLASE 6 ACTIVITY, ACY-1215, REDUCES cAMP and CYST GROWTH IN POLYCYSTIC KIDNEY DISEASE.
Polycystic Kidney Diseases
Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Polycystic Kidney Diseases
Downregulation of HDAC1 suppresses media degeneration by inhibiting the migration and phenotypic switch of aortic vascular smooth muscle cells in aortic dissection.
Polycystic Kidney Diseases
HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells.
Polycystic Kidney Diseases
Histone deacetylase 6 Inhibition reduces cysts by decreasing via cAMP and Ca2+ in knockout mouse models of polycystic kidney disease.
Polycystic Kidney Diseases
Histone Deacetylase Inhibitors Reduce Cysts by Activating Autophagy in Polycystic Kidney Disease.
Polycystic Kidney Diseases
Inhibition of HDAC6 activity in kidney diseases: a new perspective.
Polycystic Kidney Diseases
Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Polycystic Kidney, Autosomal Dominant
AN INHIBITOR OF HISTONE DEACETYLASE 6 ACTIVITY, ACY-1215, REDUCES cAMP and CYST GROWTH IN POLYCYSTIC KIDNEY DISEASE.
Polycystic Kidney, Autosomal Dominant
Dopamine receptor antagonists as potential therapeutic agents for ADPKD.
Polycystic Kidney, Autosomal Dominant
Histone deacetylase 6 Inhibition reduces cysts by decreasing via cAMP and Ca2+ in knockout mouse models of polycystic kidney disease.
Polycystic Kidney, Autosomal Dominant
Histone Deacetylase Inhibitors Reduce Cysts by Activating Autophagy in Polycystic Kidney Disease.
Polycystic Kidney, Autosomal Dominant
Histone deacetylases 6 increases the cyclic adenosine monophosphate level and promotes renal cyst growth.
Polycystic Kidney, Autosomal Dominant
Inhibition of HDAC6 activity in kidney diseases: a new perspective.
Polycystic Kidney, Autosomal Dominant
Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease.
Polycystic Ovary Syndrome
A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells.
Polycythemia
Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.
Polycythemia
Polycythemia vera: the current status of preclinical models and therapeutic targets.
Polycythemia Vera
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.
Polycythemia Vera
Polycythemia vera: the current status of preclinical models and therapeutic targets.
Polycythemia Vera
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
Porcine Reproductive and Respiratory Syndrome
Overexpression of Histone Deacetylase 6 Enhances Resistance to Porcine Reproductive and Respiratory Syndrome Virus in Pigs.
Pre-Eclampsia
Dysregulation of HDAC9 represses trophoblast cell migration and invasion through TIMP3 activation in preeclampsia.
Pre-Eclampsia
HDAC4 Knockdown Induces Preeclampsia Cell Autophagy and Apoptosis by miR-29b.
Pre-Eclampsia
Histone deacetylase 6 negatively regulated microRNA-199a-5p induces the occurrence of preeclampsia by targeting VEGFA in vitro.
Pre-Eclampsia
Histone deacetylase inhibition disturbs the balance between ACE and chymase expression in endothelial cells: a potential mechanism of chymase activation in preeclampsia.
Pre-Eclampsia
Reduced mRNA Expression of RGS2 (Regulator of G Protein Signaling-2) in the Placenta Is Associated With Human Preeclampsia and Sufficient to Cause Features of the Disorder in Mice.
Pre-Eclampsia
Up-regulation of miR-299 suppressed the invasion and migration of HTR-8/SVneo trophoblast cells partly via targeting HDAC2 in pre-eclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A small molecular compound CC1007 induces cross-lineage differentiation by inhibiting HDAC7 expression and HDAC7/MEF2C interaction in BCR-ABL1- pre-B-ALL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-?B and autophagy on panobinostat cytotoxicity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CXCR4 chemokine receptors, histone deacetylase inhibitors and acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effect of the histone deacetylase inhibitor depsipeptide on B-cell differentiation in both TEL-AML1-positive and negative childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Histone deacetylase inhibition improves differentiation of dendritic cells from leukemic blasts of patients with TEL/AML1-positive acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hyper-activation of WNT/?-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of histone deacetylase 6 as a therapeutic strategy for acute lymphocytic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Targeting Epigenetics through Histone Deacetylase Inhibitors in Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The sequence of application of methotrexate and histone deacetylase inhibitors determines either a synergistic or an antagonistic response in childhood acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
TAL1/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
The expression of histone deacetylase 4 is associated with prednisone poor-response in childhood acute lymphoblastic leukemia.
Prediabetic State
Histone deacetylase 9 promoter hypomethylation associated with adipocyte dysfunction is a statin-related metabolic effect.
Premature Birth
Prostaglandin dehydrogenase is a target for successful induction of cervical ripening.
Primary Myelofibrosis
A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).
Primary Myelofibrosis
Enhanced histone deacetylase enzyme activity in primary myelofibrosis.
Primary Myelofibrosis
Polycythemia vera: the current status of preclinical models and therapeutic targets.
Primary Myelofibrosis
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis.
Prion Diseases
Autophagy induced by the class III histone deacetylase Sirt1 prevents prion peptide neurotoxicity.
Prion Diseases
HDAC6 alleviates prion peptide-mediated neuronal death via modulating PI3K-Akt-mTOR pathway.
Prostatic Hyperplasia
Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Prostatic Hyperplasia
Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate.
Prostatic Intraepithelial Neoplasia
Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma.
Prostatic Intraepithelial Neoplasia
Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria.
Prostatic Intraepithelial Neoplasia
The significance of strong histone deacetylase 1 expression in the progression of prostate cancer.
Prostatic Neoplasms
1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells.
Prostatic Neoplasms
3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.
Prostatic Neoplasms
4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90? chaperone activity against prostate cancer.
Prostatic Neoplasms
A histone deacetylation-dependent mechanism for transcriptional repression of the gap junction gene cx43 in prostate cancer cells.
Prostatic Neoplasms
A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors.
Prostatic Neoplasms
A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1.
Prostatic Neoplasms
A New Histone Deacetylase Inhibitor, MHY4381, Induces Apoptosis via Generation of Reactive Oxygen Species in Human Prostate Cancer Cells.
Prostatic Neoplasms
A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone or in combination with retinoids on proliferation of human prostate cancer cells.
Prostatic Neoplasms
A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Prostatic Neoplasms
A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-(XL).
Prostatic Neoplasms
A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Prostatic Neoplasms
A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy.
Prostatic Neoplasms
A transcriptional repressor co-regulatory network governing androgen response in prostate cancers.
Prostatic Neoplasms
A248, a novel synthetic HDAC inhibitor, induces apoptosis through the inhibition of specificity protein 1 and its downstream proteins in human prostate cancer cells.
Prostatic Neoplasms
Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications.
Prostatic Neoplasms
Aberrant methylation of the vascular endothelial growth factor receptor-1 gene in prostate cancer.
Prostatic Neoplasms
Acetylation and phosphorylation of high-mobility group A1 proteins in PC-3 human tumor cells.
Prostatic Neoplasms
Acetylation-dependent regulation of TPD52 isoform 1 modulates chaperone-mediated autophagy in prostate cancer.
Prostatic Neoplasms
Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
Prostatic Neoplasms
Adamantanyl-Histone Deacetylase Inhibitor H6CAHA Exhibits Favorable Pharmacokinetics and Augments Prostate Cancer Radiation Sensitivity.
Prostatic Neoplasms
Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells.
Prostatic Neoplasms
Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
Prostatic Neoplasms
Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.
Prostatic Neoplasms
Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study.
Prostatic Neoplasms
Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
Prostatic Neoplasms
Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
Prostatic Neoplasms
Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines.
Prostatic Neoplasms
Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB.
Prostatic Neoplasms
Broccoli Sprouts Delay Prostate Cancer Formation and Decrease Prostate Cancer Severity with a Concurrent Decrease in HDAC3 Protein Expression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) Mice.
Prostatic Neoplasms
Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression.
Prostatic Neoplasms
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.
Prostatic Neoplasms
Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.
Prostatic Neoplasms
Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Prostatic Neoplasms
Class IIb HDAC Inhibition Enhances the Inhibitory Effect of Am80, a Synthetic Retinoid, in Prostate Cancer.
Prostatic Neoplasms
Combination Therapy with the Histone Deacetylase Inhibitor LBH589 and Radiation Is an Effective Regimen for Prostate Cancer Cells.
Prostatic Neoplasms
Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
Prostatic Neoplasms
Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer.
Prostatic Neoplasms
Correction to: A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Prostatic Neoplasms
Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer.
Prostatic Neoplasms
CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
Prostatic Neoplasms
Cytostatic Action of Novel Histone Deacetylase Inhibitors in Androgen Receptor-Null Prostate Cancer Cells.
Prostatic Neoplasms
Delphinidin induces apoptosis via cleaved HDAC3-mediated p53 acetylation and oligomerization in prostate cancer cells.
Prostatic Neoplasms
Delphinidin sensitizes prostate cancer cells to TRAIL-induced apoptosis, by inducing DR5 and causing caspase-mediated HDAC3 cleavage.
Prostatic Neoplasms
Design, synthesis and primary activity assay of tripeptidomimetics as histone deacetylase inhibitors with linear linker and branched cap group.
Prostatic Neoplasms
Design, synthesis, and evaluation of novel mutual prodrugs (hybrid drugs) of all-trans-retinoic acid and histone deacetylase inhibitors with enhanced anticancer activities in breast and prostate cancer cells in vitro.
Prostatic Neoplasms
Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment.
Prostatic Neoplasms
Down-regulation of HLA class I antigens in prostate cancer tissues and up-regulation by histone deacetylase inhibition.
Prostatic Neoplasms
Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
Prostatic Neoplasms
Downregulation of androgen receptors by NaAsO2 via inhibition of AKT-NF-?B and HSP90 in castration resistant prostate cancer.
Prostatic Neoplasms
Early clinical data and potential clinical utility of novel histone deacetylase inhibitors in prostate cancer.
Prostatic Neoplasms
Effect of HDAC9 inhibition on epithelial-mesenchymal transition in CD133+ prostate cancer cell lines.
Prostatic Neoplasms
Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
Prostatic Neoplasms
Effectiveness of the Histone Deacetylase Inhibitor (S)-2 against LNCaP and PC3 Human Prostate Cancer Cells.
Prostatic Neoplasms
Effects of Histone Deacetylase Inhibitors on Modulating H3K4 Methylation Marks - A Novel Cross-Talk Mechanism between Histone-Modifying Enzymes.
Prostatic Neoplasms
Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel.
Prostatic Neoplasms
Epigenetic regulation of androgen receptor gene expression in human prostate cancers.
Prostatic Neoplasms
Epigenetic regulation of androgen receptor signaling in prostate cancer.
Prostatic Neoplasms
Epigenetic Regulation of Phosphatidylinositol 3,4,5-Triphosphate-dependent Rac Exchanger 1 Gene Expression in Prostate Cancer Cells.
Prostatic Neoplasms
Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Expression and significance of cortactin and HDAC6 in human prostatic foamy gland carcinoma.
Prostatic Neoplasms
Expression profile of class I histone deacetylases in human cancer tissues.
Prostatic Neoplasms
Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Prostatic Neoplasms
Finding the place of histone deacetylase inhibitors in prostate cancer therapy.
Prostatic Neoplasms
Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Prostatic Neoplasms
Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.
Prostatic Neoplasms
Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression.
Prostatic Neoplasms
Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
Prostatic Neoplasms
Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Prostatic Neoplasms
Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function.
Prostatic Neoplasms
Glutathione-S-transferase pi 1(GSTP1) gene silencing in prostate cancer cells is reversed by the histone deacetylase inhibitor depsipeptide.
Prostatic Neoplasms
Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases.
Prostatic Neoplasms
Green tea-induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes.
Prostatic Neoplasms
Growth of human prostate cancer cells is significantly suppressed in vitro with sodium butyrate through apoptosis.
Prostatic Neoplasms
HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression.
Prostatic Neoplasms
HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer.
Prostatic Neoplasms
HDAC3-mediated silencing of miR-451 decreases chemosensitivity of patients with metastatic castration-resistant prostate cancer by targeting NEDD9.
Prostatic Neoplasms
HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4/6 inhibitor resistance in cancer.
Prostatic Neoplasms
HDAC6 activity is not required for basal autophagic flux in metastatic prostate cancer cells.
Prostatic Neoplasms
HDAC6 Regulates Androgen Receptor Hypersensitivity and Nuclear Localization via Modulating Hsp90 Acetylation in Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Prostatic Neoplasms
Histone deacetylase and DNA methyltransferase in human prostate cancer.
Prostatic Neoplasms
Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor.
Prostatic Neoplasms
Histone Deacetylase Inhibitor Potentiates Anticancer Effect of Docetaxel via Modulation of Bcl-2 Family Proteins and Tubulin in Hormone Refractory Prostate Cancer Cells.
Prostatic Neoplasms
Histone deacetylase inhibitor sulforaphane: The phytochemical with vibrant activity against prostate cancer.
Prostatic Neoplasms
Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells.
Prostatic Neoplasms
Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
Prostatic Neoplasms
Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells.
Prostatic Neoplasms
Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials.
Prostatic Neoplasms
Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells.
Prostatic Neoplasms
Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-?B-dependent autophagy.
Prostatic Neoplasms
Histone deacetylase inhibitors restore cell surface expression of the coxsackie adenovirus receptor and enhance CMV promoter activity in castration-resistant prostate cancer cells.
Prostatic Neoplasms
Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation.
Prostatic Neoplasms
Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation, in part, via transcriptional repression of histone H3 lysine 4 demethylases.
Prostatic Neoplasms
Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells.
Prostatic Neoplasms
Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.
Prostatic Neoplasms
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy.
Prostatic Neoplasms
Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.
Prostatic Neoplasms
Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
Prostatic Neoplasms
Hyper-acetylation contributes to the sensitivity of chemo-resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A.
Prostatic Neoplasms
Hypoacetylation, hypomethylation, and dephosphorylation of H2B histones and excessive histone deacetylase activity in DU-145 prostate cancer cells.
Prostatic Neoplasms
Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.
Prostatic Neoplasms
I?B? mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor.
Prostatic Neoplasms
Imaging assisted evaluation of antitumor efficacy of a new histone deacetylase inhibitor in the castration-resistant prostate cancer.
Prostatic Neoplasms
Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells.
Prostatic Neoplasms
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
Prostatic Neoplasms
In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer.
Prostatic Neoplasms
In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
Prostatic Neoplasms
Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells.
Prostatic Neoplasms
Inducible expression of cancer-testis antigens in human prostate cancer.
Prostatic Neoplasms
Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid.
Prostatic Neoplasms
Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro.
Prostatic Neoplasms
Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation.
Prostatic Neoplasms
Inhibitory activity of linoleic acid isolated from proso and Japanese millet toward histone deacetylase.
Prostatic Neoplasms
Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
Prostatic Neoplasms
Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor.
Prostatic Neoplasms
Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion.
Prostatic Neoplasms
KLF5 downregulation desensitizes castration-resistant prostate cancer cells to docetaxel by increasing BECN1 expression and inducing cell autophagy.
Prostatic Neoplasms
KLF5 inhibits STAT3 activity and tumor metastasis in prostate cancer by suppressing IGF1 transcription cooperatively with HDAC1.
Prostatic Neoplasms
Long non-coding RNA BLACAT1 inhibits prostate cancer cell proliferation through sponging miR-361.
Prostatic Neoplasms
Long non?coding RNA BCYRN1 promotes prostate cancer progression via elevation of HDAC11.
Prostatic Neoplasms
Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer.
Prostatic Neoplasms
Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells.
Prostatic Neoplasms
Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion.
Prostatic Neoplasms
Low-Dose Valproic Acid Enhances Radiosensitivity of Prostate Cancer through Acetylated p53-Dependent Modulation of Mitochondrial Membrane Potential and Apoptosis.
Prostatic Neoplasms
Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration.
Prostatic Neoplasms
Mechanism of growth inhibition of prostate cancer xenografts by valproic acid.
Prostatic Neoplasms
Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells.
Prostatic Neoplasms
Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model.
Prostatic Neoplasms
Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2.
Prostatic Neoplasms
MiR-204 enhances mitochondrial apoptosis in doxorubicin-treated prostate cancer cells by targeting SIRT1/p53 pathway.
Prostatic Neoplasms
miR-490-3p modulates the progression of prostate cancer through regulating histone deacetylase 2.
Prostatic Neoplasms
Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis.
Prostatic Neoplasms
MRJF4, a novel histone deacetylase inhibitor, induces p21 mediated autophagy in PC3 prostate cancer cells.
Prostatic Neoplasms
MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours.
Prostatic Neoplasms
Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer.
Prostatic Neoplasms
Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate.
Prostatic Neoplasms
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.
Prostatic Neoplasms
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).
Prostatic Neoplasms
PKD2 and PKD3 Promote Prostate Cancer Cell Invasion via uPA by Shifting Balance Between NF-?B and HDAC1.
Prostatic Neoplasms
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Prostatic Neoplasms
Polyphotosensitizer nanogels for GSH-responsive histone deacetylase inhibitors delivery and enhanced cancer photodynamic therapy.
Prostatic Neoplasms
Potential therapeutic effect of epigenetic therapy on treatment-induced neuroendocrine prostate cancer.
Prostatic Neoplasms
Prostate cancer stem cells, telomerase biology, epigenetic modifiers, and molecular systemic therapy for the androgen-independent lethal phenotype.
Prostatic Neoplasms
Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers.
Prostatic Neoplasms
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation.
Prostatic Neoplasms
Retraction: Antitumor Effects of a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, (S)-HDAC-42, in Prostate Cancer.
Prostatic Neoplasms
Retraction: Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation.
Prostatic Neoplasms
Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells.
Prostatic Neoplasms
Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition?
Prostatic Neoplasms
Role of SMAD4 in the mechanism of valproic acid's inhibitory effect on prostate cancer cell invasiveness.
Prostatic Neoplasms
Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines.
Prostatic Neoplasms
Screening of histone deacetylases (HDAC) expression in human prostate cancer reveals distinct class I HDAC profiles between epithelial and stromal cells.
Prostatic Neoplasms
Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors.
Prostatic Neoplasms
Signal Therapy of NF1-Deficient Tumor Xenograft in Mice by the Anti-PAK1 Drug FK228.
Prostatic Neoplasms
Smad7 Enhances TGF-?-Induced Transcription of c-Jun and HDAC6 Promoting Invasion of Prostate Cancer Cells.
Prostatic Neoplasms
Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin.
Prostatic Neoplasms
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Prostatic Neoplasms
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Prostatic Neoplasms
Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6.
Prostatic Neoplasms
Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.
Prostatic Neoplasms
Synergistic anticancer activity of combined histone deacetylase and proteasomal inhibitor-loaded zein nanoparticles in metastatic prostate cancers.
Prostatic Neoplasms
Synergistic Interaction of Histone Deacetylase 6- and MEK-Inhibitors in Castration-Resistant Prostate Cancer Cells.
Prostatic Neoplasms
Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Prostatic Neoplasms
Targeting MTA1/HIF-1? signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression.
Prostatic Neoplasms
Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors.
Prostatic Neoplasms
Targeting prostate cancer cells with enzalutamide-HDAC inhibitor hybrid drug 2-75.
Prostatic Neoplasms
Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
Prostatic Neoplasms
Targeting radiation-induced upstream stimulatory factor-1 by histone deacetylase inhibitors to reverse radioresistance in prostate cancer.
Prostatic Neoplasms
The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.
Prostatic Neoplasms
The development of differentiation agents for the treatment of prostate cancer.
Prostatic Neoplasms
The Effect of a Histone Deacetylase Inhibitor (AR-42) on Canine Prostate Cancer Growth and Metastasis.
Prostatic Neoplasms
The HDAC Inhibitor LBH589 Induces ERK-Dependent Prometaphase Arrest in Prostate Cancer via HDAC6 Inactivation and Down-Regulation.
Prostatic Neoplasms
The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.
Prostatic Neoplasms
The Immunohistochemical Expression and Potential Prognostic Value of HDAC6, AR in Invasive Breast Cancer.
Prostatic Neoplasms
The novel imprinted carboxypeptidase A4 gene ( CPA4) in the 7q32 imprinting domain.
Prostatic Neoplasms
The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
Prostatic Neoplasms
The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment.
Prostatic Neoplasms
The significance of strong histone deacetylase 1 expression in the progression of prostate cancer.
Prostatic Neoplasms
The STAT3 inhibitor Stattic acts independently of STAT3 to decrease histone acetylation and modulate gene expression.
Prostatic Neoplasms
TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Prostatic Neoplasms
Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer.
Prostatic Neoplasms
Trichostatin A, a histone deacetylase inhibitor, reverses epithelial-mesenchymal transition in colorectal cancer SW480 and prostate cancer PC3 cells.
Prostatic Neoplasms
TSA-induced cell death in prostate cancer cell lines is caspase-2 dependent and involves the PIDDosome.
Prostatic Neoplasms
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer.
Prostatic Neoplasms
Up-regulation of TIF1? by valproic acid inhibits the epithelial mesenchymal transition in prostate carcinoma through TGF-?/Smad signaling pathway.
Prostatic Neoplasms
Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.
Prostatic Neoplasms
Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
Prostatic Neoplasms
Valproic acid induces autophagy by suppressing the Akt/mTOR pathway in human prostate cancer cells.
Prostatic Neoplasms
Valproic acid synergistically enhances the cytotoxicity of gossypol in DU145 prostate cancer cells: An iTRTAQ-based quantitative proteomic analysis.
Prostatic Neoplasms
Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
Prostatic Neoplasms
[Expressions of HDAC1 and HDAC2 in prostate cancer and their clinical implications].
protein-tyrosine-phosphatase deficiency
MAP Kinase Phosphatase 3 (MKP-3) Deficient Mice Are Resistant to Diet Induced-Obesity.
Proteinuria
MicroRNA-29a Promotion of Nephrin Acetylation Ameliorates Hyperglycemia-Induced Podocyte Dysfunction.
Proteinuria
Podocyte histone deacetylase activity regulates murine and human glomerular diseases.
Proteostasis Deficiencies
The extracellular HDAC6 ZnF UBP domain modulates the actin network and post-translational modifications of Tau.
Protozoan Infections
Targeting histone acetylation/deacetylation in parasites: an update (2017-2020).
Pseudohypoparathyroidism
The new bone biology: pathologic, molecular, and clinical correlates.
Pseudorabies
Corrigendum to "Inhibition of histone deacetylase 1 suppresses pseudorabies virus infection through cGAS-STING antiviral innate immunity" [Mol. Immunol. 136 (2021) 55-64].
Pseudorabies
Inhibition of histone deacetylase 1 suppresses pseudorabies virus infection through cGAS-STING antiviral innate immunity.
Psoriasis
GATA3, HDAC6, and BCL6 Regulate FOXP3+ Treg Plasticity and Determine Treg Conversion into Either Novel Antigen-Presenting Cell-Like Treg or Th1-Treg.
Psoriasis
Histone Deacetylase 1 and Sirtuin 1 Expression in Psoriatic Skin: A Comparison between Guttate and Plaque Psoriasis.
Psoriasis
Lack of preclinical support for the efficacy of histone deacetylase inhibitors in the treatment of psoriasis.
Psoriasis
Resveratrol induces human keratinocyte damage via the activation of class III histone deacetylase, Sirt1.
Psoriasis
SIRT1, a Class III histone deacetylase, regulates LPS-induced inflammation in human keratinocytes and mediates the anti-inflammatory effects of hinokitiol.
Pulmonary Arterial Hypertension
HDAC6: A Novel Histone Deacetylase Implicated in Pulmonary Arterial Hypertension.
Pulmonary Arterial Hypertension
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic Acid and suberoylanilide hydroxamic Acid.
Pulmonary Arterial Hypertension
Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension.
Pulmonary Disease, Chronic Obstructive
A mucoactive drug carbocisteine ameliorates steroid resistance in rat COPD model.
Pulmonary Disease, Chronic Obstructive
A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition.
Pulmonary Disease, Chronic Obstructive
A prospective randomized controlled study: Theophylline on oxidative stress and steroid sensitivity in chronic obstructive pulmonary disease patients.
Pulmonary Disease, Chronic Obstructive
Altered Histone Deacetylase Activity and iNOS Expression in Cells Isolated from Induced Sputum of COPD Patients Treated with Tiotropium.
Pulmonary Disease, Chronic Obstructive
Anti-inflammatory effects of budesonide in human lung fibroblast are independent of histone deacetylase 2.
Pulmonary Disease, Chronic Obstructive
Autophagy induction by SIRT6 through attenuation of insulin-like growth factor signaling is involved in the regulation of human bronchial epithelial cell senescence.
Pulmonary Disease, Chronic Obstructive
Cathelicidin LL-37 restoring glucocorticoid function in smoking and lipopolysaccharide-induced airway inflammation in rats.
Pulmonary Disease, Chronic Obstructive
Changes in airway histone deacetylase2 in smokers and COPD with inhaled corticosteroids: a randomized controlled trial.
Pulmonary Disease, Chronic Obstructive
Cigarette smoke impairs phagocytosis of apoptotic neutrophils by alveolar macrophages via inhibition of the histone deacetylase/Rac/CD9 pathways.
Pulmonary Disease, Chronic Obstructive
Conserved responses to trichostatin A in rodent lungs exposed to endotoxin or stretch.
Pulmonary Disease, Chronic Obstructive
Corticosteroid resistance and novel anti-inflammatory therapies in chronic obstructive pulmonary disease: current evidence and future direction.
Pulmonary Disease, Chronic Obstructive
Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase.
Pulmonary Disease, Chronic Obstructive
Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Critical role of proteostasis-imbalance in pathogenesis of COPD and severe emphysema.
Pulmonary Disease, Chronic Obstructive
Curcumin modulates the effect of histone modification on the expression of chemokines by type II alveolar epithelial cells in a rat COPD model.
Pulmonary Disease, Chronic Obstructive
Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD.
Pulmonary Disease, Chronic Obstructive
Decreased Histone Deacetylase 2 (HDAC2) in Peripheral Blood Monocytes (PBMCs) of COPD Patients.
Pulmonary Disease, Chronic Obstructive
Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress.
Pulmonary Disease, Chronic Obstructive
Decreased histone deacetylase activity in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Defect of adaptation to hypoxia in COPD patients due to reduction of histone deacetylase 7.
Pulmonary Disease, Chronic Obstructive
Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients.
Pulmonary Disease, Chronic Obstructive
Do epigenetic events take place in the vastus lateralis of patients with mild chronic obstructive pulmonary disease?
Pulmonary Disease, Chronic Obstructive
Downregulated Peroxisome Proliferator-activated Receptor ? (PPAR?) in Lung Epithelial Cells Promotes a PPAR? Agonist-reversible Proinflammatory Phenotype in Chronic Obstructive Pulmonary Disease (COPD).
Pulmonary Disease, Chronic Obstructive
Effect of Quanzhenyiqitang on apoptosis of alveolar macrophages and expression of histone deacetylase 2 in rats with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Epigenetic mechanisms in respiratory muscle dysfunction of patients with chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Epigenetic Modifications and Therapy in Chronic Obstructive Pulmonary Disease (COPD): An Update Review.
Pulmonary Disease, Chronic Obstructive
Epigenetics and chromatin remodeling play a role in lung disease.
Pulmonary Disease, Chronic Obstructive
Epigenetics in asthma and other inflammatory lung diseases.
Pulmonary Disease, Chronic Obstructive
Erythromycin enhances the anti-inflammatory activity of budesonide in COPD rat model.
Pulmonary Disease, Chronic Obstructive
Experimental therapeutics of Nrf2 as a target for prevention of bacterial exacerbations in COPD.
Pulmonary Disease, Chronic Obstructive
Expression level of histone deacetylase 2 correlates with occurring of chronic obstructive pulmonary diseases.
Pulmonary Disease, Chronic Obstructive
Fine particulate matter exposure promotes M2 macrophage polarization through inhibiting histone deacetylase 2 in the pathogenesis of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Genetic ablation of histone deacetylase 2 leads to lung cellular senescence and lymphoid follicle formation in COPD/emphysema.
Pulmonary Disease, Chronic Obstructive
HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-?B p65 transcriptional activity.
Pulmonary Disease, Chronic Obstructive
HDAC2 Suppresses IL17A-Mediated Airway Remodeling in Human and Experimental Modeling of COPD.
Pulmonary Disease, Chronic Obstructive
HDAC6 Activates ERK in Airway and Pulmonary Vascular Remodeling of COPD.
Pulmonary Disease, Chronic Obstructive
Histone acetylation and deacetylation: importance in inflammatory lung diseases.
Pulmonary Disease, Chronic Obstructive
Histone Deacetylase 2 is Phosphorylated, Ubiquitinated and Degraded by Cigarette Smoke.
Pulmonary Disease, Chronic Obstructive
Histone Deacetylase 2 Suppresses Skeletal Muscle Atrophy and Senescence via NF-?B Signaling Pathway in Cigarette Smoke-Induced Mice with Emphysema.
Pulmonary Disease, Chronic Obstructive
Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-{kappa}B suppression.
Pulmonary Disease, Chronic Obstructive
Histone deacetylase 6-mediated selective autophagy regulates COPD-associated cilia dysfunction.
Pulmonary Disease, Chronic Obstructive
Histone deacetylase activity is decreased in peripheral blood monocytes in patients with COPD.
Pulmonary Disease, Chronic Obstructive
Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue.
Pulmonary Disease, Chronic Obstructive
Histone deacetylase pathway: an evolving therapeutic target in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Histone deacetylation: an important mechanism in inflammatory lung diseases.
Pulmonary Disease, Chronic Obstructive
Hop functions downstream of Nkx2.1 and GATA6 to mediate HDAC-dependent negative regulation of pulmonary gene expression.
Pulmonary Disease, Chronic Obstructive
How corticosteroids control inflammation: Quintiles Prize Lecture 2005.
Pulmonary Disease, Chronic Obstructive
IL-10 disrupts the Brd4-docking sites to inhibit LPS-induced CXCL8 and TNF-? expression in monocytes: Implications for chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
IL-17A induces chromatin remodeling promoting IL-8 release in bronchial epithelial cells: Effect of Tiotropium.
Pulmonary Disease, Chronic Obstructive
Impact of protein acetylation in inflammatory lung diseases.
Pulmonary Disease, Chronic Obstructive
Inflammation 2005 - Seventh World Congress. Respiratory inflammation.
Pulmonary Disease, Chronic Obstructive
Jinwei Tang modulates HDAC2 expression in a rat model of COPD.
Pulmonary Disease, Chronic Obstructive
Long-term effects of acupuncture treatment on airway smooth muscle in a rat model of smoke-induced chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Lymphocyte senescence in COPD is associated with decreased histone deacetylase 2 expression by pro-inflammatory lymphocytes.
Pulmonary Disease, Chronic Obstructive
MicroRNA-223 controls the expression of histone deacetylase 2: a novel axis in COPD.
Pulmonary Disease, Chronic Obstructive
Modulation of steroid activity in chronic inflammation: a novel anti-inflammatory role for curcumin.
Pulmonary Disease, Chronic Obstructive
Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2.
Pulmonary Disease, Chronic Obstructive
Over-expression of prothymosin-? antagonizes TGF? signalling to promote the development of emphysema.
Pulmonary Disease, Chronic Obstructive
Oxidative and Nitrosative Stress and Histone Deacetylase-2 Activity in Exacerbations of COPD.
Pulmonary Disease, Chronic Obstructive
Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages.
Pulmonary Disease, Chronic Obstructive
Patterns of Inflammatory Responses in Large and Small Airways in Smokers with and without Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
Quadriceps muscle weakness and atrophy are associated with a differential Epigenetic Profile in Advanced COPD.
Pulmonary Disease, Chronic Obstructive
Reduced histone deacetylase in COPD: clinical implications.
Pulmonary Disease, Chronic Obstructive
Restoration of HDAC2 and Nrf2 by andrographolide overcomes corticosteroid resistance in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Retraction: Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients.
Pulmonary Disease, Chronic Obstructive
Role of histone deacetylase 2 in epigenetics and cellular senescence: implications in lung inflammaging and COPD.
Pulmonary Disease, Chronic Obstructive
Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells.
Pulmonary Disease, Chronic Obstructive
Safety of valproic acid in patients with chronic obstructive pulmonary disease: a population-based cohort study.
Pulmonary Disease, Chronic Obstructive
Smoke exposure of human macrophages reduces HDAC3 activity, resulting in enhanced inflammatory cytokine production.
Pulmonary Disease, Chronic Obstructive
Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment.
Pulmonary Disease, Chronic Obstructive
Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
The potential of lipid-polymer nanoparticles as epigenetic and ROS control approaches for COPD.
Pulmonary Disease, Chronic Obstructive
The role of histone deacetylases in asthma and allergic diseases.
Pulmonary Disease, Chronic Obstructive
The Study of Efficacy, Tolerability and Safety of Theophylline Given Along with Formoterol Plus Budesonide in COPD.
Pulmonary Disease, Chronic Obstructive
Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages.
Pulmonary Disease, Chronic Obstructive
Treating patients with respiratory disease who smoke.
Pulmonary Disease, Chronic Obstructive
Treatment effects of low dose theophylline combined with an inhaled corticosteroid in COPD.
Pulmonary Disease, Chronic Obstructive
USP17-mediated deubiquitination and stabilization of HDAC2 in cigarette smoke extract-induced inflammation.
Pulmonary Disease, Chronic Obstructive
[New development of pharmacotherapy--physiological basis and future possibility]
Pulmonary Disease, Chronic Obstructive
[Relationship between expression of HDAC2, IL-8, TNF-? in lung adenocarcinoma tissues and smoking].
Pulmonary Disease, Chronic Obstructive
[The pathogenesis of chronic obstructive pulmonary disease, steroid resistance and the place of theophylline in the treatment]
Pulmonary Edema
Selective HDAC6 inhibition prevents TNF-?-induced lung endothelial cell barrier disruption and endotoxin-induced pulmonary edema.
Pulmonary Fibrosis
Effects of dynamic changes in histone acetylation and deacetylase activity on pulmonary fibrosis.
Pulmonary Fibrosis
Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice.
Pulmonary Fibrosis
Histone deacetylase inhibitor restores surfactant protein-C expression in alveolar-epithelial type II cells and attenuates bleomycin-induced pulmonary fibrosis in vivo.
Pulmonary Fibrosis
Inhibiting HDAC3 (Histone Deacetylase 3) Aberration and the Resultant Nrf2 (Nuclear Factor Erythroid-Derived 2-Related Factor-2) Repression Mitigates Pulmonary Fibrosis.
Pulmonary Fibrosis
Prevention of Pulmonary Fibrosis via Trichostatin A (TSA) in Bleomycin Induced Rats.
Pulmonary Fibrosis
Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-? signalling in COVID-19 survivors.
Pulmonary Fibrosis
TGF-?1 Stimulates HDAC4 Nucleus to Cytoplasm Translocation and NADPH Oxidase4-Derived Reactive Oxygen Species in Normal Human Lung Fibroblasts.
Pulmonary Fibrosis
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.
Pulmonary Fibrosis
Tubastatin ameliorates pulmonary fibrosis by targeting the TGF?-PI3K-Akt pathway.
Pulmonary Fibrosis
[Effect and mechanism of inhibition of lipopolysaccharide-induced pulmonary fibrosis by butyric acid].
Pulmonary Fibrosis
[Effect of histone deacetylase 2 and 4 activity on connective tissue disease associated pulmonary fibrosis in mice].
Rabies
Rabies Virus Infection Induces Microtubule Depolymerization to Facilitate Viral RNA Synthesis by Upregulating HDAC6.
Radiculopathy
Immunohistochemical analysis of histone H3 acetylation in the trigeminal root entry zone in an animal model of trigeminal neuralgia.
Rectal Neoplasms
Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.
Rectal Neoplasms
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
Renal Insufficiency, Chronic
HDAC6 Inhibition Promotes Transcription Factor EB Activation and Is Protective in Experimental Kidney Disease.
Renal Insufficiency, Chronic
Histone deacetylase 3 aberration inhibits Klotho transcription and promotes renal fibrosis.
Renal Insufficiency, Chronic
Treatment of chronic kidney diseases with histone deacetylase inhibitors.
Reperfusion Injury
Beneficial effects of histone deacetylase inhibition with severe hemorrhage and ischemia-reperfusion injury.
Reperfusion Injury
Cross-Talk Between Sirtuin 1 and High-Mobility Box 1 in Steatotic Liver Graft Preservation.
Reperfusion Injury
HDAC1 localizes to the mitochondria of cardiac myocytes and contributes to early cardiac reperfusion injury.
Reperfusion Injury
HDAC2 targeting stabilizes the CoREST complex in renal tubular cells and protects against renal ischemia/reperfusion injury.
Reperfusion Injury
HDAC6 Inhibition Protects against OGDR-Induced Golgi Fragmentation and Apoptosis.
Reperfusion Injury
High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity.
Reperfusion Injury
Histone deacetylase HDAC4 participates in the pathological process of myocardial ischemia-reperfusion injury via MEKK1/JNK pathway by binding to miR-206.
Reperfusion Injury
Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy.
Reperfusion Injury
Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice.
Reperfusion Injury
Inhibited HDAC3 or Elevated MicroRNA-494-3p Plays a Protective Role in Myocardial Ischemia-Reperfusion Injury via Suppression of BRD4.
Reperfusion Injury
Inhibited histone deacetylase 3 ameliorates myocardial ischemia-reperfusion injury in a rat model by elevating microRNA-19a-3p and reducing cyclin-dependent kinase 2.
Reperfusion Injury
Inhibition of HDAC3 Ameliorates Cerebral Ischemia Reperfusion Injury in Diabetic Mice In Vivo and In Vitro.
Reperfusion Injury
Inhibition of histone deacetylase by butyrate protects rat liver from ischemic reperfusion injury.
Reperfusion Injury
Interference with long noncoding RNA SNHG3 alleviates cerebral ischemia-reperfusion injury by inhibiting microglial activation.
Reperfusion Injury
Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury.
Reperfusion Injury
Myocyte-specific overexpressing HDAC4 promotes myocardial ischemia/reperfusion injury.
Reperfusion Injury
Nuclear Factor (Erythroid-Derived 2)-Like 2 (Nrf2) Contributes to the Neuroprotective Effects of Histone Deacetylase Inhibitors In Retinal Ischemia-Reperfusion Injury.
Respiratory Distress Syndrome
Role of HDAC6 inhibition in sepsis-induced acute respiratory distress syndrome (Review).
Respiratory Hypersensitivity
The anti-malaria drug artesunate inhibits cigarette smoke and ovalbumin concurrent exposure-induced airway inflammation and might reverse glucocorticoid insensitivity.
Retinal Degeneration
A Brain-Derived Neurotrophic Factor Mimetic Is Sufficient to Restore Cone Photoreceptor Visual Function in an Inherited Blindness Model.
Retinal Degeneration
Autophagy Induction by HDAC Inhibitors Is Unlikely to be the Mechanism of Efficacy in Prevention of Retinal Degeneration Caused by P23H Rhodopsin.
Retinal Degeneration
Ischemic preconditioning, retinal neuroprotection and histone deacetylase activities.
Retinitis
Epigenetic changes: An emerging potential pharmacological target in allergic rhinitis.
Retinitis Pigmentosa
A short N-terminal domain of HDAC4 preserves photoreceptors and restores visual function in retinitis pigmentosa.
Retinitis Pigmentosa
Inhibition of Epigenetic Modifiers LSD1 and HDAC1 Blocks Rod Photoreceptor Death in Mouse Models of Retinitis Pigmentosa.
Retinitis Pigmentosa
Opposing Effects of Valproic Acid Treatment Mediated by Histone Deacetylase Inhibitor Activity in Four Transgenic X. laevis Models of Retinitis Pigmentosa.
Retinitis Pigmentosa
SAHA is neuroprotective in in vitro and in situ models of retinitis pigmentosa.
Retinoblastoma
3-Methylcholanthrene, an AhR Agonist, Caused Cell-Cycle Arrest by Histone Deacetylation through a RhoA-Dependent Recruitment of HDAC1 and pRb2 to E2F1 Complex.
Retinoblastoma
Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription.
Retinoblastoma
Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer.
Retinoblastoma
Cooperation of E2F-p130 and Sp1-pRb complexes in repression of the Chinese hamster dhfr gene.
Retinoblastoma
DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters.
Retinoblastoma
Downregulation of HDAC9 inhibits cell proliferation and tumor formation by inducing cell cycle arrest in retinoblastoma.
Retinoblastoma
E2F-1 regulates the expression of a subset of target genes during skeletal myoblast hypertrophy.
Retinoblastoma
Epigenetic control of trefoil factor family (TFF) peptide expression in human retinoblastoma cell lines.
Retinoblastoma
Epigenetic regulators Rbbp4 and Hdac1 are overexpressed in a zebrafish model of RB1 embryonal brain tumor, and are required for neural progenitor survival and proliferation.
Retinoblastoma
Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer.
Retinoblastoma
Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
Retinoblastoma
EZH2-specific microRNA-98 inhibits human ovarian cancer stem cell proliferation via regulating the pRb-E2F pathway.
Retinoblastoma
Heregulin regulates the ability of the ErbB3-binding protein Ebp1 to bind E2F promoter elements and repress E2F-mediated transcription.
Retinoblastoma
Histone deacetylase inhibitors differentially regulate c-Myc expression in retinoblastoma cells.
Retinoblastoma
Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation.
Retinoblastoma
HPV E7 viral oncoprotein disrupts transcriptional regulation of L1Md retrotransposon.
Retinoblastoma
Human papillomavirus type 16 E7 maintains elevated levels of the cdc25A tyrosine phosphatase during deregulation of cell cycle arrest.
Retinoblastoma
Hypothesis: Retinoblastoma protein inactivation mediates effects of histone deacetylase inhibitor-induced Wnt hyperactivation in colorectal cancer cells.
Retinoblastoma
Inhibition of histone deacetylation by butyrate induces morphological changes in Y79 retinoblastoma cells.
Retinoblastoma
Karyotypically abnormal human ESCs are sensitive to HDAC inhibitors and show altered regulation of genes linked to cancers and neurological diseases.
Retinoblastoma
Knockdown of long non?coding RNA HCP5 suppresses the malignant behavior of retinoblastoma by sponging miR?3619?5p to target HDAC9.
Retinoblastoma
Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism.
Retinoblastoma
MicroRNA-101-3p inhibits proliferation in retinoblastoma cells by targeting EZH2 and HDAC9.
Retinoblastoma
MicroRNA?936 inhibits the malignant phenotype of retinoblastoma by directly targeting HDAC9 and deactivating the PI3K/AKT pathway.
Retinoblastoma
Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Retinoblastoma
Overexpression of HDAC1 induces cellular senescence by Sp1/PP2A/pRb pathway.
Retinoblastoma
Phosphorylation of Drosophila Brahma on CDK-phosphorylation sites is important for cell cycle regulation and differentiation.
Retinoblastoma
pRb2/p130 and p107 control cell growth by multiple strategies and in association with different compartments within the nucleus.
Retinoblastoma
Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.
Retinoblastoma
Prohibitin, a protein downregulated by androgens, represses androgen receptor activity.
Retinoblastoma
Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1.
Retinoblastoma
Rb-associated protein 46 (RbAp46) suppresses the tumorigenicity of adenovirus-transformed human embryonic kidney 293 cells.
Retinoblastoma
RbAp48 belongs to the histone deacetylase complex that associates with the retinoblastoma protein.
Retinoblastoma
RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of retinoblastoma tumor suppressor family proteins found in limited discrete regions of the nucleus at growth arrest.
Retinoblastoma
Regulation of cellular processes by PPARgamma ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression.
Retinoblastoma
Retinoblastoma binding protein 4 represses HIV-1 long terminal repeat-mediated transcription by recruiting NR2F1 and histone deacetylase.
Retinoblastoma
Retinoblastoma protein complexes with C/EBP proteins and activates C/EBP-mediated transcription.
Retinoblastoma
Retinoblastoma protein is required for efficient colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the absence of p21Waf.
Retinoblastoma
Retinoblastoma protein recruits histone deacetylase to repress transcription.
Retinoblastoma
Retinoblastoma protein represses transcription by recruiting a histone deacetylase.
Retinoblastoma
Retinoblastoma protein transcriptional repression through histone deacetylation of a single nucleosome.
Retinoblastoma
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
Retinoblastoma
Targeting Piezo1 unleashes innate immunity against cancer and infectious disease.
Retinoblastoma
The retinoblastoma gene product interacts with maintenance human DNA (cytosine-5) methyltransferase and modulates its activity.
Retinoblastoma
UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis.
Rhabdoid Tumor
Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
Rhabdoid Tumor
Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.
Rhabdoid Tumor
In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model.
Rhabdoid Tumor
Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through AIF translocation.
Rhabdoid Tumor
Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood.
Rhabdoid Tumor
Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumour Growth Arrest and Multi-lineage Differentiation of Malignant Rhabdoid Tumours.
Rhabdoid Tumor
Suberoylanilide hydroxamic acid affects ?H2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation.
Rhabdoid Tumor
The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.
Rhabdoid Tumor
The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA.
Rhabdoid Tumor
The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors.
Rhabdomyolysis
Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury.
Rhabdomyosarcoma
Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells - An Isobolographic Analysis.
Rhabdomyosarcoma
BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways.
Rhabdomyosarcoma
BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis.
Rhabdomyosarcoma
Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.
Rhabdomyosarcoma
CRISPR screen identifies the NCOR/HDAC3 complex as a major suppressor of differentiation in rhabdomyosarcoma.
Rhabdomyosarcoma
Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition.
Rhabdomyosarcoma
Epigenetic Evaluation of N-(2-hydroxyphenyl)-2-propylpentanamide, a Valproic Acid Aryl Derivative with activity against HeLa cells.
Rhabdomyosarcoma
HDAC6 promotes growth, migration/invasion, and self-renewal of rhabdomyosarcoma.
Rhabdomyosarcoma
HDAC8 regulates canonical Wnt pathway to promote differentiation in skeletal muscles.
Rhabdomyosarcoma
Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.
Rhabdomyosarcoma
Histone Deacetylase Inhibitors Inhibit Rhabdomyosarcoma by Reactive Oxygen Species-Dependent Targeting of Specificity Protein Transcription Factors.
Rhabdomyosarcoma
Low Dose Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Promotes Adenoviral Transduction in Human Rhabdomyosarcoma Cell Lines.
Rhabdomyosarcoma
NIK is required for NF-?B-mediated induction of BAG3 upon inhibition of constitutive protein degradation pathways.
Rhabdomyosarcoma
OBP?801, a novel histone deacetylase inhibitor, induces M?phase arrest and apoptosis in rhabdomyosarcoma cells.
Rhabdomyosarcoma
Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer.
Rhabdomyosarcoma
Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation.
Rhabdomyosarcoma
The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
Rhabdomyosarcoma
[Erratum] OBP?801, a novel histone deacetylase inhibitor, induces M?phase arrest and apoptosis in rhabdomyosarcoma cells.
Rhabdomyosarcoma, Alveolar
Evaluation of entinostat alone and in combination with standard-of-care cytotoxic agents against rhabdomyosarcoma xenograft models.
Rhabdomyosarcoma, Alveolar
Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Rhabdomyosarcoma, Embryonal
Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal Rhabdomyosarcoma.
Rhinitis
Epigenetic changes: An emerging potential pharmacological target in allergic rhinitis.
Rhinitis
Outside-in hypothesis revisited: The role of microbial, epithelial, and immune interactions.
Rhinitis, Allergic
Blocking histone deacetylase activity as a novel target for epithelial barrier defects in patients with allergic rhinitis.
Rhinitis, Allergic
Epigenetic changes: An emerging potential pharmacological target in allergic rhinitis.
Rhinitis, Allergic
HDAC inhibitor sodium butyrate prevents allergic rhinitis and alters lncRNA and mRNA expression profiles in the nasal mucosa of mice.
Rhinitis, Allergic
Histone deacetylase 11 inhibits interleukin 10 in B cells of subjects with allergic rhinitis.
Rhinitis, Allergic
Regulation of Trek1 expression in nasal mucosa with allergic rhinitis by specific immunotherapy.
Rhinitis, Allergic
RGFP966, a selective HDAC3 inhibitor, ameliorates allergic and inflammatory responses in an OVA-induced allergic rhinitis mouse model.
Rhinitis, Allergic
Therapeutic Effect of Histone Deacetylase Inhibitor, Sodium Butyrate, on Allergic Rhinitis In Vivo.
ring-type e3 ubiquitin transferase deficiency
Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells.
RNA Virus Infections
Regulation of Retinoic Acid Inducible Gene-I (RIG-I) Activation by the Histone Deacetylase 6.
Sarcoma
A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas.
Sarcoma
Assessment of Synergistic Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Sarcoma.
Sarcoma
Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis.
Sarcoma
Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma.
Sarcoma
Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma.
Sarcoma
Correction: Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma.
Sarcoma
Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.
Sarcoma
Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling.
Sarcoma
Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells.
Sarcoma
Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma.
Sarcoma
Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
Sarcoma
Histone deacetylase inhibitor PCI-24781 enhances chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines.
Sarcoma
Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Sarcoma
Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models.
Sarcoma
Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines.
Sarcoma
Immunohistochemical Characterization of Histone Deacetylase as a Potential Prognostic Marker and Therapeutic Target in Endometrial Stromal Sarcoma.
Sarcoma
Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients.
Sarcoma
Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.
Sarcoma
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Sarcoma
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.
Sarcoma
Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Sarcoma
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
Sarcoma
SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy.
Sarcoma
Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?
Sarcoma
The histone deacetylase inhibitor LBH589 inhibits undifferentiated pleomorphic sarcoma growth via downregulation of FOS-like antigen 1.
Sarcoma
Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells.
Sarcoma, Clear Cell
Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models.
Sarcoma, Clear Cell
Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.
Sarcoma, Endometrial Stromal
Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling.
Sarcoma, Endometrial Stromal
Immunohistochemical Characterization of Histone Deacetylase as a Potential Prognostic Marker and Therapeutic Target in Endometrial Stromal Sarcoma.
Sarcoma, Endometrial Stromal
SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
Sarcoma, Endometrial Stromal
Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells.
Sarcoma, Ewing
Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis.
Sarcoma, Ewing
Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.
Sarcoma, Ewing
In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.
Sarcoma, Ewing
Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells.
Sarcoma, Ewing
Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma or Leukemia.
Sarcoma, Ewing
Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells.
Sarcoma, Ewing
Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma.
Sarcoma, Ewing
Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines.
Sarcoma, Ewing
Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
Sarcoma, Ewing
Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma.
Sarcoma, Ewing
Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Sarcoma, Synovial
EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor.
Sarcoma, Synovial
Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Sarcoma, Synovial
Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo.
Sarcoma, Synovial
Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma.
Sarcoma, Synovial
SYT, a partner of SYT-SSX oncoprotein in synovial sarcomas, interacts with mSin3A, a component of histone deacetylase complex.
Schistosomiasis
Isophthalic Acid-Based HDAC Inhibitors as Potent Inhibitors of HDAC8 from Schistosoma mansoni.
Schistosomiasis
Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis.
Scleroderma, Systemic
Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis.
Scleroderma, Systemic
Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis.
Scleroderma, Systemic
Histone deacetylase SIRT1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting TGF-ß signaling.
Scleroderma, Systemic
Identification of Cysteine-Rich Angiogenic Inducer 61 as a Potential Antifibrotic and Proangiogenic Mediator in Scleroderma.
Seizures
An epigenetic intervention interacts with genetic strain differences to modulate the stress-induced reduction of flurazepam's antiseizure efficacy in the mouse.
Seizures
Histone deacetylase inhibitors restore normal hippocampal synaptic plasticity and seizure threshold in a mouse model of Tuberous Sclerosis Complex.
Seizures
Loss of the putative catalytic domain of HDAC4 leads to reduced thermal nociception and seizures while allowing normal none development.
Seizures
Repeated treatment with electroconvulsive seizures induces HDAC2 expression and down-regulation of NMDA receptor-related genes through histone deacetylation in the rat frontal cortex.
Seizures
The ketogenic diet increases Neuregulin 1 expression via elevating histone acetylation and its anti-seizure effect requires ErbB4 kinase activity.
Seizures
Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity.
Seizures
Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons.
Seizures
Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Seizures
Valproic Acid Use During Radiation Therapy for Glioblastoma Associated With Improved Survival.
Seizures
[Regulatory mechanism of MS275 on the p38 MAPK signaling pathway in rats with convulsion in the developmental stage].
Seminoma
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer.
Sepsis
Class IIa HDAC inhibitor TMP195 alleviates lipopolysaccharide-induced acute kidney injury.
Sepsis
Degradation of histone deacetylase 4 via the TLR4/JAK/STAT1 signaling pathway promotes the acetylation of high mobility group box 1 (HMGB1) in lipopolysaccharide-activated macrophages.
Sepsis
HDAC6 promotes sepsis development by impairing PHB1-mediated mitochondrial respiratory chain function.
Sepsis
HIPK2 phosphorylates HDAC3 for NF-?B acetylation to ameliorate colitis-associated colorectal carcinoma and sepsis.
Sepsis
Histone deacetylase 2 is essential for LPS-induced inflammatory responses in macrophages.
Sepsis
Histone Deacetylase 6 Inhibition Improves Survival in a Swine Model of Lethal Hemorrhage, Polytrauma and Bacteremia.
Sepsis
Histone deacetylase 6 regulates endothelial MyD88-dependent canonical TLR signaling, lung inflammation, and alveolar remodeling in the developing lung.
Sepsis
Histone deacetylase III as a potential therapeutic target for the treatment of lethal sepsis.
Sepsis
Histone deacetylase inhibitor treatment attenuates coagulation imbalance in a lethal murine model of sepsis.
Sepsis
Histone Deacetylase Inhibitors Attenuate Acute Lung Injury During Cecal Ligation and Puncture-Induced Polymicrobial Sepsis.
Sepsis
Histone deactylase gene expression profiles are associated with outcomes in blunt trauma patients.
Sepsis
Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model.
Sepsis
Metformin ameliorates endotoxemia-induced endothelial pro-inflammatory responses via AMPK-dependent mediation of HDAC5 and KLF2.
Sepsis
Role of HDAC6 inhibition in sepsis-induced acute respiratory distress syndrome (Review).
Sepsis
Selective histone deacetylase 6 inhibition prolongs survival in a lethal two-hit model.
Sepsis
Sepsis and glucocorticoids upregulate p300 and downregulate HDAC6 expression and activity in skeletal muscle.
Sepsis
The Novel HDAC8 Inhibitor WK2-16 Attenuates Lipopolysaccharide-Activated Matrix Metalloproteinase-9 Expression in Human Monocytic Cells and Improves Hypercytokinemia In Vivo.
Sepsis-Associated Encephalopathy
Class I Histone Deacetylase Inhibitor Valproic Acid Reverses Cognitive Deficits in a Mouse Model of Septic Encephalopathy.
Severe Acute Respiratory Syndrome
Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.
Shock, Septic
Creating a prosurvival phenotype through a histone deacetylase inhibitor in a lethal two-hit model.
Shock, Septic
HDAC6 Mediates Macrophage iNOS Expression and Excessive Nitric Oxide Production in the Blood During Endotoxemia.
Shock, Septic
Histone deacetylase 2 is essential for LPS-induced inflammatory responses in macrophages.
Shock, Septic
Identification of citrullinated histone H3 as a potential serum protein biomarker in a lethal model of lipopolysaccharide-induced shock.
Shock, Septic
Modulation of Acetylation: Creating a Pro-survival and Anti-Inflammatory Phenotype in Lethal Hemorrhagic and Septic Shock.
Shock, Septic
Selective inhibition of histone deacetylase 6 promotes survival in a rat model of hemorrhagic shock.
Shock, Septic
Treatment with histone deacetylase inhibitor attenuates MAP kinase mediated liver injury in a lethal model of septic shock.
Sialadenitis
Epigallocatechin gallate stimulates the neuroreactive salivary secretomotor system in autoimmune sialadenitis of MRL-Fas(lpr) mice via activation of cAMP-dependent protein kinase A and inactivation of nuclear factor ?B.
Sick Sinus Syndrome
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Skin Diseases
Histone Deacetylase 1 Reduces Lipogenesis by Suppressing SREBP1 Transcription in Human Sebocyte Cell Line SZ95.
Skin Diseases
Regulation of the Glycerol Transporter, Aquaporin-3, by Histone Deacetylase-3 and p53 in Keratinocytes.
Skin Diseases
Resveratrol induces human keratinocyte damage via the activation of class III histone deacetylase, Sirt1.
Sleep Deprivation
Role of epigenetic regulatory enzymes in animal models of mania induced by amphetamine and paradoxical sleep deprivation.
Small Cell Lung Carcinoma
Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
Small Cell Lung Carcinoma
Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).
Small Cell Lung Carcinoma
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat.
Small Cell Lung Carcinoma
Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.
Small Cell Lung Carcinoma
The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells.
Small Cell Lung Carcinoma
The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model.
Small Cell Lung Carcinoma
UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.
Smear Layer
Release of bio-active dentine extracellular matrix components by histone deacetylase inhibitors (HDACi).
Smith-Magenis Syndrome
Haploinsufficiency of HDAC4 causes brachydactyly mental retardation syndrome, with brachydactyly type E, developmental delays, and behavioral problems.
Spasms, Infantile
Embryonic forebrain transcriptome of mice with polyalanine expansion mutations in the ARX homeobox gene.
sphingosine kinase deficiency
SPHK1 deficiency protects mice from acetaminophen-induced ER stress and mitochondrial permeability transition.
Spinal Cord Injuries
Age-dependent autophagy induction after injury promotes axon regeneration by limiting NOTCH.
Spinal Cord Injuries
Author Correction: HDAC3 inhibition ameliorates spinal cord injury by immunomodulation.
Spinal Cord Injuries
Class I histone deacetylase (HDAC) inhibitor CI-994 promotes functional recovery following spinal cord injury.
Spinal Cord Injuries
Diversified transcriptional responses of myeloid and glial cells in spinal cord injury shaped by HDAC3 activity.
Spinal Cord Injuries
Effects of valproic acid, a histone deacetylase inhibitor, on improvement of locomotor function in rat spinal cord injury based on epigenetic science.
Spinal Cord Injuries
HDAC3 Inhibition Promotes Alternative Activation of Macrophages but Does Not Affect Functional Recovery after Spinal Cord Injury.
Spinal Cord Injuries
HDAC6 Regulates the Chaperone-Mediated Autophagy to Prevent Oxidative Damage in Injured Neurons after Experimental Spinal Cord Injury.
Spinal Cord Injuries
HDAC8 Inhibition Reduces Lesional Iba-1+ Cell Infiltration after Spinal Cord Injury without Effects on Functional Recovery.
Spinal Cord Injuries
Histone deacetylase 6 inhibition restores autophagic flux to promote functional recovery after spinal cord injury.
Spinal Cord Injuries
Increased HDAC3 and decreased miRNA-130a expression in PBMCs through recruitment HDAC3 in patients with spinal cord injuries.
Spinal Cord Injuries
Ketogenic Metabolism Inhibits Histone Deacetylase (HDAC) and Reduces Oxidative Stress After Spinal Cord Injury in Rats.
Spinal Cord Injuries
miR-27a promotion resulting from silencing of HDAC3 facilitates the recovery of spinal cord injury by inhibiting PAK6 expression in rats.
Spinal Cord Injuries
PP4-dependent HDAC3 dephosphorylation discriminates between axonal regeneration and regenerative failure.
Spinal Cord Injuries
Systemic administration of valproic acid stimulates overexpression of microtubule-associated protein 2 in the spinal cord injury model to promote neurite outgrowth.
Spinal Cord Injuries
Valproic acid attenuates microgliosis in injured spinal cord and purinergic P2X4 receptor expression in activated microglia.
Spinal Cord Injuries
Valproic acid improves outcome after rodent spinal cord injury: Potential roles of histone deacetylase inhibition.
Spinocerebellar Ataxias
Mechanistic Insights into the Binding of Class IIa HDAC Inhibitors toward Spinocerebellar Ataxia Type-2: A 3D-QSAR and Pharmacophore Modeling Approach.
Spinocerebellar Ataxias
The histone deacetylase HDAC3 is essential for Purkinje cell function, potentially complicating the use of HDAC inhibitors in SCA1.
Spondylitis, Ankylosing
Role of histone deacetylase 3 in ankylosing spondylitis via negative feedback loop with microRNA-130a and enhancement of tumor necrosis factor-1? expression in peripheral blood mononuclear cells.
Squamous Cell Carcinoma of Head and Neck
A correlation analysis between HDAC1 over-expression and clinical features of laryngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Azacitidine, as a DNMT inhibitor decreases hTERT gene expression and telomerase activity more effective compared with HDAC inhibitor in human Head and neck squamous cell carcinoma cell lines.
Squamous Cell Carcinoma of Head and Neck
Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Squamous Cell Carcinoma of Head and Neck
Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid.
Squamous Cell Carcinoma of Head and Neck
Combination of ACY-241 and JQ1 Synergistically Suppresses Metastasis of HNSCC via Regulation of MMP-2 and MMP-9.
Squamous Cell Carcinoma of Head and Neck
Combined class I histone deacetylase and mTORC1/C2 inhibition suppresses the initiation and recurrence of oral squamous cell carcinomas by repressing SOX2.
Squamous Cell Carcinoma of Head and Neck
Downregulation of miR-377 Promotes Oral Squamous Cell Carcinoma Growth and Migration by Targeting HDAC9.
Squamous Cell Carcinoma of Head and Neck
Effect of resveratrol on cancer progression through the REG ? expression pathway in head and neck cancer cells.
Squamous Cell Carcinoma of Head and Neck
Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines.
Squamous Cell Carcinoma of Head and Neck
Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Growth-suppressive effect of suberoylanilide hydroxamic acid (SAHA) on human oral cancer cells.
Squamous Cell Carcinoma of Head and Neck
HDAC inhibitor apicidin suppresses murine oral squamous cell carcinoma cell growth in vitro and in vivo via inhibiting HDAC8 expression.
Squamous Cell Carcinoma of Head and Neck
HDAC inhibitors suppress the proliferation, migration and invasiveness of human head and neck squamous cell carcinoma cells via p63?mediated tight junction molecules and p21?mediated growth arrest.
Squamous Cell Carcinoma of Head and Neck
HDAC2 promotes cell migration/invasion abilities through HIF-1? stabilization in human oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Histone deacetylase 1 regulates the malignancy of oral cancer cells via miR-154-5p/PCNA axis.
Squamous Cell Carcinoma of Head and Neck
Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients.
Squamous Cell Carcinoma of Head and Neck
Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Histone deacetylase inhibitors in oral squamous cell carcinoma treatment.
Squamous Cell Carcinoma of Head and Neck
Histone deacetylase inhibitors suppress aggressiveness of head and neck squamous cell carcinoma via histone acetylation-independent blockade of the EGFR-Arf1 axis.
Squamous Cell Carcinoma of Head and Neck
Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy.
Squamous Cell Carcinoma of Head and Neck
MicroRNA-204-5p is a tumor suppressor and potential therapeutic target in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway.
Squamous Cell Carcinoma of Head and Neck
miR-433 inhibits oral squamous cell carcinoma (OSCC) cell growth and metastasis by targeting HDAC6.
Squamous Cell Carcinoma of Head and Neck
Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Squamous Cell Carcinoma of Head and Neck
Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis.
Squamous Cell Carcinoma of Head and Neck
Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Quantitative phosphoproteomic analysis reveals ?-bisabolene inducing p53-mediated apoptosis of human oral squamous cell carcinoma via HDAC2 inhibition and ERK1/2 activation.
Squamous Cell Carcinoma of Head and Neck
Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Sodium Butyrate, a Histone Deacetylase Inhibitor, Regulates Lymphangiogenic Factors in Oral Cancer Cell Line HSC-3.
Squamous Cell Carcinoma of Head and Neck
Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs.
Squamous Cell Carcinoma of Head and Neck
The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines.
Squamous Cell Carcinoma of Head and Neck
Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Upregulated histone deacetylase 2 gene correlates with the progression of oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Valproic Acid Synergizes With Cisplatin and Cetuximab in vitro and in vivo in Head and Neck Cancer by Targeting the Mechanisms of Resistance.
Squamous Cell Carcinoma of Head and Neck
[Down-regulation of histone deacetylase 2 induces cell apoptosis and inhibits cell proliferation and migration of laryngeal squamous cell carcinoma cells].
Squamous Cell Carcinoma of Head and Neck
[Effects of downregulation of HDAC6 expression on cell cycle, proliferation and migration of laryngeal squamous cell carcinoma].
ST Elevation Myocardial Infarction
HDAC9 Variant Rs2107595 Modifies Susceptibility to Coronary Artery Disease and the Severity of Coronary Atherosclerosis in a Chinese Han Population.
Starvation
Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4).
Starvation
AMPK-Dependent Phosphorylation of HDAC8 Triggers PGM1 Expression to Promote Lung Cancer Cell Survival under Glucose Starvation.
Starvation
Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function.
Starvation
Chromatin remodeling system p300-HDAC2-Sin3A is involved in Arginine Starvation-Induced HIF-1? Degradation at the ASS1 promoter for ASS1 Derepression.
Starvation
Cooperation of E2F-p130 and Sp1-pRb complexes in repression of the Chinese hamster dhfr gene.
Starvation
HDAC6 regulates lipid droplet turnover in response to nutrient deprivation via p62-mediated selective autophagy.
Starvation
Large-scale analysis of mRNA translation states during sucrose starvation in arabidopsis cells identifies cell proliferation and chromatin structure as targets of translational control.
Starvation
LC3B-II deacetylation by histone deacetylase 6 is involved in serum-starvation-induced autophagic degradation.
Starvation
MFN1 deacetylation activates adaptive mitochondrial fusion and protects metabolically challenged mitochondria.
Starvation
MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4.
Starvation
Mutually exclusive acetylation and ubiquitylation of the splicing factor SRSF5 control tumor growth.
Starvation
Passport control for foreign integrated DNAs: An unexpected checkpoint by class II HDAC4 revealed by amino acid starvation.
Starvation
Sorting, recognition and activation of the misfolded protein degradation pathways through macroautophagy and the proteasome.
Starvation
Stra13 expression is associated with growth arrest and represses transcription through histone deacetylase (HDAC)-dependent and HDAC-independent mechanisms.
Starvation
The histone deacetylase HDA19 controls root cell elongation and modulates a subset of phosphate starvation responses in Arabidopsis.
Starvation
Ubiquitin-dependent degradation of HDAC4, a new regulator of random cell motility.
Status Epilepticus
Expression of class II HDACs in two mouse models of temporal lobe epilepsy.
Stomach Neoplasms
4-Phenybutyric acid promotes gastric cancer cell migration via histone deacetylase inhibition-mediated HER3/HER4 up-regulation.
Stomach Neoplasms
4-phenylbutyric acid promotes migration of gastric cancer cells by histone deacetylase inhibition-mediated IL-8 upregulation.
Stomach Neoplasms
A Decrease of Histone Deacetylase 6 Expression Caused by Helicobacter Pylori Infection is Associated with Oncogenic Transformation in Gastric Cancer.
Stomach Neoplasms
A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer.
Stomach Neoplasms
AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity.
Stomach Neoplasms
Association of NDRG1 Gene Promoter Methylation with Reduced NDRG1 Expression in Gastric Cancer Cells and Tissue Specimens.
Stomach Neoplasms
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.
Stomach Neoplasms
CHFR promotes the migration of human gastric cancer cells by inducing epithelial-to-mesenchymal transition in a HDAC1-dependent manner.
Stomach Neoplasms
Depletion of histone deacetylase 1 inhibits metastatic abilities of gastric cancer cells by regulating the miR-34a/CD44 pathway.
Stomach Neoplasms
Development of a novel microRNA promoter microarray for ChIP-on-chip assay to identify epigenetically regulated microRNAs.
Stomach Neoplasms
Differential expression of histone deacetylase and acetyltransferase genes in gastric cancer and their modulation by trichostatin A.
Stomach Neoplasms
Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer.
Stomach Neoplasms
Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1.
Stomach Neoplasms
Downregulation of ID4 by promoter hypermethylation in gastric adenocarcinoma.
Stomach Neoplasms
Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents.
Stomach Neoplasms
Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy.
Stomach Neoplasms
ERK inhibition enhances TSA-induced gastric cancer cell apoptosis via NF-?B-dependent and Notch-independent mechanism.
Stomach Neoplasms
Expression of hMOF, but not HDAC4, is responsible for the global histone H4K16 acetylation in gastric carcinoma.
Stomach Neoplasms
Expression of the clustered NeuAc?2-3Gal? O-glycan determines the cell differentiation state of the cells.
Stomach Neoplasms
Expression profile of class I histone deacetylases in human cancer tissues.
Stomach Neoplasms
HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway.
Stomach Neoplasms
HDAC6 sustains growth stimulation by prolonging the activation of EGF receptor through the inhibition of rabaptin-5-mediated early endosome fusion in gastric cancer.
Stomach Neoplasms
High-throughput screening of genome fragments bound to differentially acetylated histones.
Stomach Neoplasms
Histone Deacetylase (HDAC) 1 and 2 Expression and Chemotherapy in Gastric Cancer.
Stomach Neoplasms
Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy.
Stomach Neoplasms
Histone deacetylase 3 inhibits expression of PUMA in gastric cancer cells.
Stomach Neoplasms
Histone deacetylase 3 inhibits new tumor suppressor gene DTWD1 in gastric cancer.
Stomach Neoplasms
Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5.
Stomach Neoplasms
Histone deacetylase HDAC4 promotes gastric cancer SGC-7901 cells progression via p21 repression.
Stomach Neoplasms
Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.
Stomach Neoplasms
Histone deacetylase inhibitor trichostatin A induced caspase-independent apoptosis in human gastric cancer cell.
Stomach Neoplasms
Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells.
Stomach Neoplasms
Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Stomach Neoplasms
Histone deacetylase inhibitors induce the expression of tumor suppressor genes Per1 and Per2 in human gastric cancer cells.
Stomach Neoplasms
Histone deacetylase-1 as a prognostic factor and mediator of gastric cancer progression by enhancing glycolysis.
Stomach Neoplasms
Human ZNF312b oncogene is regulated by Sp1 binding to its promoter region through DNA demethylation and histone acetylation in gastric cancer.
Stomach Neoplasms
Identification of candidate biomarkers that involved in the epigenetic transcriptional regulation for detection gastric cancer by iTRAQ based quantitative proteomic analysis.
Stomach Neoplasms
Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.
Stomach Neoplasms
Identification of HDAC9 as a viable therapeutic target for the treatment of gastric cancer.
Stomach Neoplasms
In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs.
Stomach Neoplasms
Increased expression of histone deacetylase 2 is found in human gastric cancer.
Stomach Neoplasms
Inhibited HDAC3 promotes microRNA-376c-3p to suppress malignant phenotypes of gastric cancer cells by reducing WNT2b.
Stomach Neoplasms
Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells.
Stomach Neoplasms
Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells.
Stomach Neoplasms
Inhibition of histone deacetylase activity down-regulates urokinase plasminogen activator and matrix metalloproteinase-9 expression in gastric cancer.
Stomach Neoplasms
KIAA1324 Suppresses Gastric Cancer Progression by Inhibiting the Oncoprotein GRP78.
Stomach Neoplasms
LncRNA HRCEG, regulated by HDAC1, inhibits cells proliferation and epithelial-mesenchymal-transition in gastric cancer.
Stomach Neoplasms
Long Noncoding RNA RGMB-AS1 Acts as a microRNA-574 Sponge Thereby Enhancing the Aggressiveness of Gastric Cancer via HDAC4 Upregulation [Retraction].
Stomach Neoplasms
Long Noncoding RNA RGMB-AS1 Acts as a microRNA-574 Sponge Thereby Enhancing the Aggressiveness of Gastric Cancer via HDAC4 Upregulation.
Stomach Neoplasms
LRRC3B, encoding a leucine-rich repeat-containing protein, is a putative tumor suppressor gene in gastric cancer.
Stomach Neoplasms
Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells.
Stomach Neoplasms
MiR-489 inhibited the development of gastric cancer via regulating HDAC7 and PI3K/AKT pathway.
Stomach Neoplasms
Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial.
Stomach Neoplasms
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.
Stomach Neoplasms
RAD51 potentiates synergistic effects of chemotherapy with PCI-24781 and cis-diamminedichloroplatinum on gastric cancer.
Stomach Neoplasms
Randomized Phase II trial of paclitaxel plus valproic acid vs paclitaxel alone as second-line therapy for patients with advanced gastric cancer.
Stomach Neoplasms
RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer.
Stomach Neoplasms
Regulation of CRADD-caspase 2 cascade by histone deacetylase 1 in gastric cancer.
Stomach Neoplasms
Regulation of demethylation and re-expression of RASSF1A gene in gastric cancer cell lines by combined treatment of 5-Aza-CdR and NaB.
Stomach Neoplasms
RNF168 promotes RHOC degradation by ubiquitination to restrain gastric cancer progression via decreasing HDAC1 expression.
Stomach Neoplasms
RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells.
Stomach Neoplasms
Role of HDAC1 in the progression of gastric cancer and the correlation with lncRNAs.
Stomach Neoplasms
SIRT1 expression is associated with a poor prognosis, whereas DBC1 is associated with favorable outcomes in gastric cancer.
Stomach Neoplasms
Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a.
Stomach Neoplasms
Targeted inactivation of HDAC2 restores p16INK4a activity and exerts antitumor effects on human gastric cancer.
Stomach Neoplasms
The expression of HDAC7 in cancerous gastric tissues is positively associated with distant metastasis and poor patient prognosis.
Stomach Neoplasms
The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy.
Stomach Neoplasms
The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells.
Stomach Neoplasms
The inhibition of histone deacetylase 8 suppresses proliferation and inhibits apoptosis in gastric adenocarcinoma.
Stomach Neoplasms
The relationship of CD133, histone deacetylase 1 and thrombospondin-1 in gastric cancer.
Stomach Neoplasms
Therapeutic targets associated to E-cadherin dysfunction in gastric cancer.
Stomach Neoplasms
Transcriptional induction of DLC-1 gene through Sp1 sites by histone deacetylase inhibitors in gastric cancer cells.
Stomach Neoplasms
Trichostatin A potentiates TRAIL-induced antitumor effects via inhibition of ERK/FOXM1 pathway in gastric cancer.
Stomach Neoplasms
Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis.
Stomach Neoplasms
Weighted gene co-expression network analysis and connectivity map identifies lovastatin as a treatment option of gastric cancer by inhibiting HDAC2.
Stomach Neoplasms
[Effect of siRNA targeting HDAC1 gene on proliferation, apoptosis, histone acetylation, and histone metylation in gastric cancer cells in vitro].
Stomach Neoplasms
[Effects of sodium butyrate on proliferation of human gastric cancer cells and expression of p16 gene]
Stomach Neoplasms
[The relationship of mTOR signaling pathway and histone acetylation in human gastric cancer cell lines]
Stomatitis
Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: Prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Stroke
?lass II histone deacetylases in the post-stroke recovery period-expression, cellular, and subcellular localization-promising targets for neuroprotection.
Stroke
Association between Histone Deacetylase 9 Gene Polymorphism and Stroke in Chinese Han Population.
Stroke
Association Between the Gene Polymorphisms of HDAC9 and the Risk of Atherosclerosis and Ischemic Stroke.
Stroke
Chromatin-Modifying Agents for Epigenetic Reprogramming and Endogenous Neural Stem Cell-Mediated Repair in Stroke.
Stroke
Class IIa histone deacetylases affect neuronal remodeling and functional outcome after stroke.
Stroke
Deficiency of the stroke relevant HDAC9 gene attenuates atherosclerosis in accord with allele-specific effects at 7p21.1.
Stroke
Early Histone Deacetylase Inhibition Mitigates Ischemia/Reperfusion Brain Injury by Reducing Microglia Activation and Modulating Their Phenotype.
Stroke
Emerging role of epigenetics in stroke: part 1: DNA methylation and chromatin modifications.
Stroke
Evidence HDAC9 Genetic Variant Associated With Ischemic Stroke Increases Risk via Promoting Carotid Atherosclerosis.
Stroke
Expression of Class I Histone Deacetylases in Ipsilateral and Contralateral Hemispheres after the Focal Photothrombotic Infarction in the Mouse Brain.
Stroke
Expression of Histone Deacetylases HDAC1 and HDAC2 and Their Role in Apoptosis in the Penumbra Induced by Photothrombotic Stroke.
Stroke
Expression patterns of histone deacetylases in experimental stroke and potential targets for neuroprotection.
Stroke
Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke.
Stroke
GWAS-linked hot loci predict short-term functional outcome and recurrence of ischemic stroke in Chinese population.
Stroke
HDAC1 deregulation promotes neuronal loss and deficit of motor function in stroke pathogenesis.
Stroke
HDAC2 (Histone deacetylase 2): A critical factor in environmental enrichment-mediated stroke recovery.
Stroke
HDAC4 and HDAC5 form a complex with DREAM that epigenetically down-regulates NCX3 gene and its pharmacological inhibition reduces neuronal stroke damage.
Stroke
HDAC4/5-HMGB1 signalling mediated by NADPH oxidase activity contributes to cerebral ischaemia/reperfusion injury.
Stroke
HDAC6 dysfunction contributes to impaired maturation of adult neurogenesis in vivo: vital role on functional recovery after ischemic stroke.
Stroke
HDAC9 Polymorphism Alters Blood Gene Expression in Patients with Large Vessel Atherosclerotic Stroke.
Stroke
HDAC9 Polymorphisms Predict Susceptibility, Severity, and Short-Term Outcome of Large Artery Atherosclerotic Stroke in Chinese Population.
Stroke
HDAC9 promotes brain ischemic injury by provoking I?B?/NF-?B and MAPKs signaling pathways.
Stroke
HDAC9 Variant Rs2107595 Modifies Susceptibility to Coronary Artery Disease and the Severity of Coronary Atherosclerosis in a Chinese Han Population.
Stroke
HDAC9, TWIST1 and FERD3L gene expression in asymptomatic stable and unstable carotid plaques.
Stroke
Histone deacetylase 9 represses cholesterol efflux and alternatively activated macrophages in atherosclerosis development.
Stroke
Histone deacetylase inhibition activates transcription factor Nrf2 and protects against cerebral ischemic damage.
Stroke
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action.
Stroke
Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition.
Stroke
Inhibition of HDAC3 Ameliorates Cerebral Ischemia Reperfusion Injury in Diabetic Mice In Vivo and In Vitro.
Stroke
Inhibition of Histone Deacetylase 3 (HDAC3) Mediates Ischemic Preconditioning and Protects Cortical Neurons against Ischemia in Rats.
Stroke
Inhibition of histone deacetylase 3 by MiR-494 alleviates neuronal loss and improves neurological recovery in experimental stroke.
Stroke
Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study.
Stroke
Meta-Analysis of Genome-Wide Association Studies Identifies Genetic Risk Factors for Stroke in African Americans.
Stroke
MS-275, a Class I histone deacetylase inhibitor, protects the p53-deficient mouse against ischemic injury.
Stroke
Neuronal susceptibility to beta-amyloid toxicity and ischemic injury involves histone deacetylase-2 regulation of endophilin-B1.
Stroke
Neuroprotective Effects of Selective Inhibition of Histone Deacetylase 3 in Experimental Stroke.
Stroke
Novel Protective Effects of Histone Deacetylase Inhibition on Stroke and White Matter Ischemic Injury.
Stroke
Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of ?-phenyl tropolone, HPOB, and sodium valproate.
Stroke
Polymorphism of HDAC9 Gene Is Associated with Increased Risk of Acute Coronary Syndrome in Chinese Han Population.
Stroke
Sodium Butyrate, a Histone Deacetylase Inhibitor, Exhibits Neuroprotective/Neurogenic Effects in a Rat Model of Neonatal Hypoxia-Ischemia.
Stroke
Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack.
Stroke
The association between HDAC9 gene polymorphisms and stroke risk in the Chinese population: A meta-analysis.
Stroke
The Atherosclerosis Risk Variant rs2107595 Mediates Allele-Specific Transcriptional Regulation of HDAC9 via E2F3 and Rb1.
Stroke
The Effect of Histone Deacetylase Inhibitors Panobinostat or Entinostat on Motor Recovery in Mice After Ischemic Stroke.
Stroke
The HDAC3 inhibitor RGFP966 ameliorated ischemic brain damage by downregulating the AIM2 inflammasome.
Stroke
The histone deacetylase inhibitor, sodium butyrate, exhibits neuroprotective effects for ischemic stroke in middle-aged female rats.
Stroke
The Neuroprotective Effect of the HDAC2/3 Inhibitor MI192 on the Penumbra After Photothrombotic Stroke in the Mouse Brain.
Stroke
The relationship between the prognosis of children with acute arterial stroke and polymorphisms of CDKN2B, HDAC9, NINJ2, NAA25 genes.
Subarachnoid Hemorrhage
Astrocytic histone deacetylase 2 facilitates delayed depression and memory impairment after subarachnoid hemorrhage by negatively regulating glutamate transporter-1.
Subarachnoid Hemorrhage
Enhancement of Autophagy by Histone Deacetylase Inhibitor Trichostatin A Ameliorates Neuronal Apoptosis After Subarachnoid Hemorrhage in Rats.
Subarachnoid Hemorrhage
Inhibition of HDAC4 Attenuated JNK/c-Jun-Dependent Neuronal Apoptosis and Early Brain Injury Following Subarachnoid Hemorrhage by Transcriptionally Suppressing MKK7.
Superinfection
Differences in Activation of HIV-1 Replication by Superinfection With HIV-1 and HIV-2 in U1 Cells.
Sweet Syndrome
Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
Synucleinopathies
Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms.
Tauopathies
A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.
Tauopathies
An HDAC6-dependent surveillance mechanism suppresses tau-mediated neurodegeneration and cognitive decline.
Tauopathies
Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition.
Tauopathies
Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms.
TDP-43 Proteinopathies
HDAC1 dysregulation induces aberrant cell cycle and DNA damage in progress of TDP-43 proteinopathies.
Teratocarcinoma
Activation of the mouse cytokeratin A (endo A) gene in teratocarcinoma F9 cells by the histone deacetylase inhibitor Trichostatin A.
Teratocarcinoma
The class I-specific HDAC inhibitor MS-275 modulates the differentiation potential of mouse embryonic stem cells.
Teratoma
Crucial function of histone deacetylase 1 for differentiation of teratomas in mice and humans.
Teratoma
Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis.
Teratoma
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer.
Testicular Neoplasms
DNMT1 and HDAC1 gene expression in impaired spermatogenesis and testicular cancer.
Testicular Neoplasms
LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition.
Tetralogy of Fallot
The expanding phenotypes of cohesinopathies: one ring to rule them all!
Thalassemia
Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia.
Thanatophoric Dysplasia
HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
Thrombocythemia, Essential
Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat.
Thrombocythemia, Essential
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).
Thrombocytopenia
Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase Inhibitor.
Thrombocytopenia
Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect.
Thrombocytopenia
Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia.
Thrombocytopenia
Novel method for selecting immunosuppressive histone deacetylase (HDAC) inhibitors with minimal thrombocytopenia.
Thrombocytopenia
Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis.
Thrombocytopenia
Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation.
Thrombocytopenia
Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms.
Thrombosis
Inducing heat shock protein 70 expression provides a robust antithrombotic effect with minimal bleeding risk.
Thrombosis
Synergistic Expression of Histone Deacetylase 9 and Matrix Metalloproteinase 12 in M4 Macrophages in Advanced Carotid Plaques.
Thrombosis
Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.
Thymoma
Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.
Thymoma
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.
Thymoma
Skeletal muscle-specific Prmt1 deletion causes muscle atrophy via deregulation of the PRMT6-FOXO3 axis.
Thyroid Cancer, Papillary
Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
Thyroid Cancer, Papillary
Histone deacetylase inhibitor depsipeptide represses nicotinamide N-methyltransferase and hepatocyte nuclear factor-1beta gene expression in human papillary thyroid cancer cells.
Thyroid Cancer, Papillary
MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAFV600E: An In Vitro Study.
Thyroid Carcinoma, Anaplastic
1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer.
Thyroid Carcinoma, Anaplastic
Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells.
Thyroid Carcinoma, Anaplastic
Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
Thyroid Carcinoma, Anaplastic
Effect of valproic acid on miRNAs affecting histone deacetylase in a model of anaplastic thyroid cancer.
Thyroid Carcinoma, Anaplastic
Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib.
Thyroid Carcinoma, Anaplastic
HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization.
Thyroid Carcinoma, Anaplastic
HISTONE DEACETYLASE INHIBITION AFFECTS SODIUM IODIDE SYMPORTER (NIS) EXPRESSION AND INDUCES ¹³¹I CYTOTOXICITY IN ANAPLASTIC THYROID CANCER CELLS.
Thyroid Carcinoma, Anaplastic
Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells.
Thyroid Carcinoma, Anaplastic
Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma.
Thyroid Carcinoma, Anaplastic
Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells.
Thyroid Carcinoma, Anaplastic
Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin.
Thyroid Carcinoma, Anaplastic
Novel Heat Shock Protein 90 Inhibitor NVP-AUY922 Synergizes With the Histone Deacetylase Inhibitor PXD101 in Induction of Death of Anaplastic Thyroid Carcinoma Cells.
Thyroid Carcinoma, Anaplastic
The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
Thyroid Carcinoma, Anaplastic
The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.
Thyroid Carcinoma, Anaplastic
Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells.
Thyroid Carcinoma, Anaplastic
Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial.
Thyroid Neoplasms
1,25-dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer.
Thyroid Neoplasms
5-aza-2'-deoxycytidine has minor effects on differentiation in human thyroid cancer cell lines, but modulates genes that are involved in adaptation in vitro.
Thyroid Neoplasms
A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy.
Thyroid Neoplasms
A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin.
Thyroid Neoplasms
Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.
Thyroid Neoplasms
Construction of gene therapy vectors targeting thyroid cells: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the cyclic adenosine 3',5'-monophosphate pathway and demonstration of activity in follicular and anaplastic thyroid carcinoma cells.
Thyroid Neoplasms
Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.
Thyroid Neoplasms
Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells.
Thyroid Neoplasms
Experimental studies of boron neutron capture therapy (BNCT) using histone deacetylase inhibitor (HDACI) sodium butyrate, as a complementary drug for the treatment of poorly differentiated thyroid cancer (PDTC).
Thyroid Neoplasms
Expression and Biologic Significance of Adiponectin Receptors in Papillary Thyroid Carcinoma.
Thyroid Neoplasms
Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.
Thyroid Neoplasms
HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer.
Thyroid Neoplasms
HDACs control RUNX2 expression in cancer cells through redundant and cell context-dependent mechanisms.
Thyroid Neoplasms
Histone deacetylase enzyme silencing using shRNAs enhances radiosensitivity of SW579 thyroid cancer cells.
Thyroid Neoplasms
Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin.
Thyroid Neoplasms
Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.
Thyroid Neoplasms
Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer.
Thyroid Neoplasms
Improvement of the boron neutron capture therapy (BNCT) by the previous administration of the histone deacetylase inhibitor sodium butyrate for the treatment of thyroid carcinoma.
Thyroid Neoplasms
Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor.
Thyroid Neoplasms
Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells.
Thyroid Neoplasms
Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.
Thyroid Neoplasms
Inhibition of Growth in Medullary Thyroid Cancer Cells with Histone Deacetylase Inhibitors and Lithium Chloride.
Thyroid Neoplasms
Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.
Thyroid Neoplasms
Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells.
Thyroid Neoplasms
MiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells.
Thyroid Neoplasms
Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors.
Thyroid Neoplasms
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors.
Thyroid Neoplasms
Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation.
Thyroid Neoplasms
Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.
Thyroid Neoplasms
Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone deacetylase sodium butyrate and valproic acid.
Thyroid Neoplasms
Robust Thyroid Gene Expression and Radioiodine Uptake Induced by Simultaneous Suppression of BRAF V600E and Histone Deacetylase in Thyroid Cancer Cells.
Thyroid Neoplasms
SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.
Thyroid Neoplasms
The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.
Thyroid Neoplasms
Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275.
Thyroid Neoplasms
Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor-gamma agonists.
Thyroid Neoplasms
Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.
Thyroid Neoplasms
Valproic acid downregulates NF-?B p50 activity and IRAK-1 in a progressive thyroid carcinoma cell line.
Thyroid Neoplasms
Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells.
Thyroid Neoplasms
Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells.
Tics
Analysis of Chromatin Opening in Heterochromatic Non-Small Cell Lung Cancer Tumor-Initiating Cells in Relation to DNA-Damaging Antitumor Treatment.
Tics
Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Tongue Neoplasms
Alterations of 63 hub genes during lingual carcinogenesis in C57BL/6J mice.
Tongue Neoplasms
Oncogenic roles of Bmi1 and its therapeutic inhibition by histone deacetylase inhibitor in tongue cancer.
Toxoplasmosis
An apicomplexan ankyrin-repeat histone deacetylase with relatives in photosynthetic eukaryotes.
Toxoplasmosis
Histone deacetylase SIR2 in Toxoplasma gondii modulates functions of murine macrophages in vitro and protects mice against acute toxoplasmosis in vivo.
Tracheal Stenosis
Expression of histone deacetylase 2 in tracheal stenosis models and its relationship with tracheal granulation tissue proliferation.
Tracheal Stenosis
Nintedanib ameliorates tracheal stenosis by activating HDAC2 and suppressing IL-8 and VEGF in rabbit.
Trauma, Nervous System
Histone Deacetylase Inhibitors as Therapeutic Agents for Acute Central Nervous System Injuries.
Trauma, Nervous System
Injury-induced HDAC5 nuclear export is essential for axon regeneration.
Triple Negative Breast Neoplasms
A New Histone Deacetylase Inhibitor Enhances Radiation Sensitivity through the Induction of Misfolded Protein Aggregation and Autophagy in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
A novel histone deacetylase inhibitor TMU-35435 enhances etoposide cytotoxicity through the proteasomal degradation of DNA-PKcs in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
Triple Negative Breast Neoplasms
Chemoresistance in the Human Triple-Negative Breast Cancer Cell Line MDA-MB-231 Induced by Doxorubicin Gradient Is Associated with Epigenetic Alterations in Histone Deacetylase.
Triple Negative Breast Neoplasms
Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Triple Negative Breast Neoplasms
Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
Triple Negative Breast Neoplasms
Cytotoxic Activity of the Histone Deacetylase 3-Selective Inhibitor Pojamide on MDA-MB-231 Triple-Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity.
Triple Negative Breast Neoplasms
Effects of SAHA and EGCG on Growth Potentiation of Triple-Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
Triple Negative Breast Neoplasms
EZH2 and histone deacetylase inhibitors induce apoptosis in triple negative breast cancer cells by differentially increasing H3 Lys
Triple Negative Breast Neoplasms
Genome-wide chromatin accessibility, DNA methylation and gene expression analysis of histone deacetylase inhibition in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms.
Triple Negative Breast Neoplasms
HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.
Triple Negative Breast Neoplasms
HDAC6 inhibition enhances the anti-tumor effect of eribulin through tubulin acetylation in triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation.
Triple Negative Breast Neoplasms
HDAC9 overexpression confers invasive and angiogenic potential to triple negative breast cancer cells via modulating microRNA-206.
Triple Negative Breast Neoplasms
Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Triple Negative Breast Neoplasms
Histone Deacetylase 7 Gene Overexpression Is Associated with Poor Prognosis of Triple-Negative Breast Cancer Patients.
Triple Negative Breast Neoplasms
Histone deacetylase 8 triggers the migration of triple negative breast cancer cells via regulation of YAP signals.
Triple Negative Breast Neoplasms
Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Triple Negative Breast Neoplasms
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism.
Triple Negative Breast Neoplasms
Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
Triple Negative Breast Neoplasms
miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8 oncogene.
Triple Negative Breast Neoplasms
Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
Triple Negative Breast Neoplasms
Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
Triple Negative Breast Neoplasms
Reactivation of Estrogen Receptor ? by Vorinostat Sensitizes Mesenchymal-Like Triple-Negative Breast Cancer to Aminoflavone, a Ligand of the Aryl Hydrocarbon Receptor.
Triple Negative Breast Neoplasms
SAHA and EGCG Promote Apoptosis in Triple-negative Breast Cancer Cells, Possibly Through the Modulation of cIAP2.
Triple Negative Breast Neoplasms
Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC).
Triple Negative Breast Neoplasms
Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Triple Negative Breast Neoplasms
Targeting breast cancer stem cells by novel HDAC3-selective inhibitors.
Triple Negative Breast Neoplasms
Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Triple Negative Breast Neoplasms
Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
Triple Negative Breast Neoplasms
Targeting triple negative breast cancer with histone deacetylase inhibitors.
Triple Negative Breast Neoplasms
Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Triple Negative Breast Neoplasms
Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.
Triple Negative Breast Neoplasms
The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
Triple Negative Breast Neoplasms
Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Window-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker.
Trypanosomiasis, African
Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).
Tuberculosis
Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis.
Tuberculosis
HDAC3 inhibitor RGFP966 controls bacterial growth and modulates macrophage signaling during Mycobacterium tuberculosis infection.
Tuberculosis
Histone deacetylase 6 inhibitor enhances resistance to Mycobacterium tuberculosis infection through innate and adaptive immunity in mice.
Tuberculosis
Histone deacetylase inhibitors impair the host immune response against Mycobacterium tuberculosis infection.
Tuberculosis
Mycobacteria inhibition of IFN-gamma induced HLA-DR gene expression by up-regulating histone deacetylation at the promoter region in human THP-1 monocytic cells.
Tuberculosis
Mycobacterium tuberculosis infection induces IL-10 gene expression by disturbing histone deacetylase 6 and histonedeacetylase 11 equilibrium in macrophages.
Tuberculosis
Transcription Repressor Protein ZBTB25 Associates with HDAC1-Sin3a Complex in Mycobacterium tuberculosis-Infected Macrophages, and Its Inhibition Clears Pathogen by Autophagy.
Tuberculosis, Pulmonary
Histone H3K14 hypoacetylation and H3K27 hypermethylation along with HDAC1 up-regulation and KDM6B down-regulation are associated with active pulmonary tuberculosis disease.
Tuberous Sclerosis
Alterations in expression levels of genes in p53-related pathways determined using RNA-Seq analysis in patients with breast cancer following CIK therapy.
Tuberous Sclerosis
Histone deacetylase inhibitors restore normal hippocampal synaptic plasticity and seizure threshold in a mouse model of Tuberous Sclerosis Complex.
Urea Cycle Disorders, Inborn
Acute effects of phenylbutyrate on glutamine, branched-chain amino acid and protein metabolism in skeletal muscles of rats.
Urea Cycle Disorders, Inborn
Clinical and experimental applications of sodium phenylbutyrate.
Uremia
DNA methylation profiling reveals differences in the three human monocyte subsets and identifies uremia to induce DNA methylation changes during differentiation.
Ureteral Obstruction
Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling.
Ureteral Obstruction
Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-? and EGFR signaling pathways in obstructive nephropathy.
Ureteral Obstruction
Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury.
Ureteral Obstruction
Identification of histone deacetylase 8 as a novel therapeutic target for renal fibrosis.
Ureteral Obstruction
Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy.
Ureteral Obstruction
Piceatannol Attenuates Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Downregulation of Histone Deacetylase 4/5 or p38-MAPK Signaling.
Ureteral Obstruction
Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction.
Ureteral Obstruction
Selective inhibition of class IIa histone deacetylases alleviates renal fibrosis.
Urinary Bladder Neoplasms
A Histone Deacetylase Inhibitor, OBP-801, and Celecoxib Synergistically Inhibit the Cell Growth with Apoptosis via a DR5-Dependent Pathway in Bladder Cancer Cells.
Urinary Bladder Neoplasms
Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems.
Urinary Bladder Neoplasms
Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1.
Urinary Bladder Neoplasms
Comprehensive analysis of Transcription Factors identified novel prognostic biomarker in human bladder cancer.
Urinary Bladder Neoplasms
Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells.
Urinary Bladder Neoplasms
E3 ligase cIAP2 mediates downregulation of MRE11 and radiosensitization in response to HDAC inhibition in bladder cancer.
Urinary Bladder Neoplasms
Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.
Urinary Bladder Neoplasms
Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells.
Urinary Bladder Neoplasms
FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells.
Urinary Bladder Neoplasms
Gene expression profiling of KBH-A42, a novel histone deacetylase inhibitor, in human leukemia and bladder cancer cell lines.
Urinary Bladder Neoplasms
HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells.
Urinary Bladder Neoplasms
HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
Urinary Bladder Neoplasms
HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions.
Urinary Bladder Neoplasms
HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin.
Urinary Bladder Neoplasms
Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment.
Urinary Bladder Neoplasms
Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment.
Urinary Bladder Neoplasms
Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest.
Urinary Bladder Neoplasms
Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
Urinary Bladder Neoplasms
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Urinary Bladder Neoplasms
Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells.
Urinary Bladder Neoplasms
Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer.
Urinary Bladder Neoplasms
Histonedeacetylase 1 mRNA has elevated expression in clinical specimen of bladder cancer.
Urinary Bladder Neoplasms
Identification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays.
Urinary Bladder Neoplasms
Induction of caspase mediated apoptosis and down-regulation of nuclear factor-?B and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
Urinary Bladder Neoplasms
Inhibition of bladder tumour growth by histone deacetylase inhibitor.
Urinary Bladder Neoplasms
Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction.
Urinary Bladder Neoplasms
Latent Kaposi's sarcoma-associated herpesvirus infection in bladder cancer cells promotes drug resistance by reducing reactive oxygen species.
Urinary Bladder Neoplasms
Maspin is a PTEN-Upregulated and p53-Upregulated Tumor Suppressor Gene and Acts as an HDAC1 Inhibitor in Human Bladder Cancer.
Urinary Bladder Neoplasms
Mechanism of increased coxsackie and adenovirus receptor gene expression and adenovirus uptake by phytoestrogen and histone deacetylase inhibitor in human bladder cancer cells and the potential clinical application.
Urinary Bladder Neoplasms
miR-489-3p inhibits proliferation and migration of bladder cancer cells through downregulation of histone deacetylase 2.
Urinary Bladder Neoplasms
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer.
Urinary Bladder Neoplasms
p21 and CK2 interaction-mediated HDAC2 phosphorylation modulates KLF4 acetylation to regulate bladder cancer cell proliferation.
Urinary Bladder Neoplasms
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879.
Urinary Bladder Neoplasms
Potential Anticancer Properties and Mechanisms of Action of Curcumin.
Urinary Bladder Neoplasms
Potential of histone deacetylase inhibitors for bladder cancer treatment.
Urinary Bladder Neoplasms
Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma.
Urinary Bladder Neoplasms
Radiosensitisation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity.
Urinary Bladder Neoplasms
Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential.
Urinary Bladder Neoplasms
Role of reactive oxygen species in proapoptotic ability of oncogenic H-Ras to increase human bladder cancer cell susceptibility to histone deacetylase inhibitor for caspase induction.
Urinary Bladder Neoplasms
Simvastatin-romidepsin combination kills bladder cancer cells synergistically.
Urinary Bladder Neoplasms
Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities.
Urinary Bladder Neoplasms
Synergy of histone-deacetylase inhibitor AR-42 with cisplatin in bladder cancer.
Urinary Bladder Neoplasms
The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo.
Urinary Bladder Neoplasms
The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line.
Urinary Bladder Neoplasms
The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer.
Urinary Bladder Neoplasms
The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy.
Urinary Bladder Neoplasms
TRPM2 Mediates Histone Deacetylase Inhibition-Induced Apoptosis in Bladder Cancer Cells.
Urinary Bladder Neoplasms
Valproic Acid Decreases Urothelial Cancer Cell Proliferation and Induces Thrombospondin-1 Expression.
Urinary Retention
Histone Deacetylase 6 Regulates Bladder Architecture and Host Susceptibility to Uropathogenic Escherichia coli.
Urogenital Neoplasms
Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells.
Urologic Neoplasms
Manipulating the epigenome for the treatment of urological malignancies.
Urologic Neoplasms
The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
Uterine Cervical Neoplasms
Acetylation of intragenic histones on HPV16 correlates with enhanced HPV16 gene expression.
Uterine Cervical Neoplasms
Apicidin down-regulates human papillomavirus type 16 E6 and E7 transcripts and proteins in SiHa cervical cancer cells.
Uterine Cervical Neoplasms
CDH1 and SNAI1 are regulated by E7 from human papillomavirus types 16 and 18.
Uterine Cervical Neoplasms
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
Uterine Cervical Neoplasms
Cytotoxic effects of peanut phenolics possessing histone deacetylase inhibitory activity in breast and cervical cancer cell lines.
Uterine Cervical Neoplasms
Design, synthesis and biological evaluation of a phenyl butyric acid derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 inhibitor with anti-proliferative activity on cervix cancer and leukemia cells.
Uterine Cervical Neoplasms
Effect of downregulated histone deacetylase 2 expression on cell proliferation and cell cycle in cervical cancer.
Uterine Cervical Neoplasms
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
Uterine Cervical Neoplasms
Epigenetics of cervical cancer. An overview and therapeutic perspectives.
Uterine Cervical Neoplasms
Erratum to Design, Synthesis and Biological Evaluation of a Phenyl Butyric Acid Derivative, N-(4-chlorophenyl)-4- phenylbutanamide: A HDAC6 Inhibitor with Anti-proliferative Activity on Cervix Cancer and Leukemia Cells.
Uterine Cervical Neoplasms
Evidence of an Epigenetic Modification in Cell-cycle Arrest Caused by the Use of Ultra-highly-diluted Gonolobus Condurango Extract.
Uterine Cervical Neoplasms
Gene expression profiles in squamous cell cervical carcinoma using array-based comparative genomic hybridization analysis.
Uterine Cervical Neoplasms
HDAC1/DNMT3A-Containing Complex Is Associated with Suppression of Oct4 in Cervical Cancer Cells.
Uterine Cervical Neoplasms
HDAC6 suppresses microRNA-199a transcription and augments HPV-positive cervical cancer progression through Wnt5a upregulation.
Uterine Cervical Neoplasms
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.
Uterine Cervical Neoplasms
Histone Deacetylase (HDAC) 10 Suppresses Cervical Cancer Metastasis through Inhibition of Matrix Metalloproteinase (MMP) 2 and 9 Expression.
Uterine Cervical Neoplasms
Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells.
Uterine Cervical Neoplasms
Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells.
Uterine Cervical Neoplasms
Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells.
Uterine Cervical Neoplasms
Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus.
Uterine Cervical Neoplasms
Histone deacetylase inhibitors inducing human cervical cancer cell apoptosis by decreasing DNA-methyltransferase 3B.
Uterine Cervical Neoplasms
HPV16 activates the promoter of Oct4 gene by sequestering HDAC1 from repressor complex to target it to proteasomal degradation.
Uterine Cervical Neoplasms
Integrated Analysis of ceRNA Regulatory Network Associated With Tumor Stage in Cervical Cancer.
Uterine Cervical Neoplasms
Isoflurane promotes proliferation of squamous cervical cancer cells through mTOR-histone deacetylase 6 pathway.
Uterine Cervical Neoplasms
Microtubule-associated histone deacetylase 6 supports the calcium store sensor STIM1 in mediating malignant cell behaviors.
Uterine Cervical Neoplasms
N-(2'-Hydroxyphenyl)-2-Propylpentanamide (HO-AAVPA) Inhibits HDAC1 and Increases the Translocation of HMGB1 Levels in Human Cervical Cancer Cells.
Uterine Cervical Neoplasms
Novel chemotherapy using histone deacetylase inhibitors in cervical cancer.
Uterine Cervical Neoplasms
Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6.
Uterine Cervical Neoplasms
Overexpression of HDAC1 induces cellular senescence by Sp1/PP2A/pRb pathway.
Uterine Cervical Neoplasms
Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells.
Uterine Cervical Neoplasms
PKCepsilon is essential for gelsolin expression by histone deacetylase inhibitor apicidin in human cervix cancer cells.
Uterine Cervical Neoplasms
Proteomic analysis of cervical cancer cells treated with suberonylanilide hydroxamic acid.
Uterine Cervical Neoplasms
Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate.
Uterine Cervical Neoplasms
Retinoic acid and histone deacetylase inhibitor BML-210 inhibit proliferation of human cervical cancer HeLa cells.
Uterine Cervical Neoplasms
Role of hTERT in apoptosis of cervical cancer induced by histone deacetylase inhibitor.
Uterine Cervical Neoplasms
Sevoflurane Enhances Proliferation, Metastatic Potential of Cervical Cancer Cells via the Histone Deacetylase 6 Modulation In Vitro.
Uterine Cervical Neoplasms
Sulforaphane Reverses the Expression of Various Tumor Suppressor Genes by Targeting DNMT3B and HDAC1 in Human Cervical Cancer Cells.
Uterine Cervical Neoplasms
Suppression of miR-22, a tumor suppressor in cervical cancer, by human papillomavirus 16 E6 via a p53/miR-22/HDAC6 pathway.
Uterine Cervical Neoplasms
Synergistic combination of histone deacetylase inhibitor suberoylanilide hydroxamic acid and oncolytic adenovirus ZD55-TRAIL as a therapy against cervical cancer.
Uterine Cervical Neoplasms
The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.
Uterine Cervical Neoplasms
The role of ADCYAP1, adenylate cyclase activating polypeptide 1, as a methylation biomarker for the early detection of cervical cancer.
Uterine Cervical Neoplasms
Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells.
Uterine Cervical Neoplasms
Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid.
Uterine Cervical Neoplasms
Valproic acid exhibits different cell growth arrest effect in three HPV-positive/negative cervical cancer cells and possibly via inducing Notch1 cleavage and E6 downregulation.
Uterine Cervical Neoplasms
Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1?/VEGF signals.
Uterine Cervical Neoplasms
Vorinostat targets UBE2C to reverse epithelial-mesenchymal transition and control cervical cancer growth through the ubiquitination pathway.
Uveitis
Vorinostat Modulates the Imbalance of T Cell Subsets, Suppresses Macrophage Activity, and Ameliorates Experimental Autoimmune Uveoretinitis.
Vaccinia
Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.
Vaccinia
Histone deacetylase 4 promotes type I interferon signaling, restricts DNA viruses, and is degraded via vaccinia virus protein C6.
Varicella Zoster Virus Infection
Histone Deacetylase 1 and 2 are Phosphorylated at Novel Sites During Varicella Zoster Virus Infection.
Vascular Calcification
Deacetylation of cGAS by HDAC1 regulates vascular calcification by promoting autophagy.
Vascular Calcification
HDAC9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype.
Vascular Calcification
MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification.
Vascular Calcification
New Aspects of Vascular Calcification: Histone Deacetylases and Beyond.
Vascular Calcification
Salt-inducible kinase induces cytoplasmic histone deacetylase 4 to promote vascular calcification.
Vascular Calcification
The microRNA miR-134-5p induces calcium deposition by inhibiting histone deacetylase 5 in vascular smooth muscle cells.
Vascular Calcification
Trichostatin A, an HDAC Class I/II Inhibitor, Promotes Pi-Induced Vascular Calcification Via Up-Regulation of the Expression of Alkaline Phosphatase.
Vascular Diseases
HDAC9 complex inhibition improves smooth muscle-dependent stenotic vascular disease.
Vascular Diseases
Histone Deacetylase SIRT1, Smooth Muscle Cell Function, and Vascular Diseases.
Vascular Diseases
Splicing of Histone Deacetylase 7 Modulates Smooth Muscle Cell Proliferation and Neointima Formation Through Nuclear {beta}-Catenin Translocation.
Vascular System Injuries
Angiogenic Factor With G Patch and FHA Domains 1 Is a Novel Regulator of Vascular Injury.
Vascular System Injuries
HDAC6 inhibition prevents TNF-?-induced caspase 3 activation in lung endothelial cell and maintains cell-cell junctions.
Vasculitis
Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis.
Ventilator-Induced Lung Injury
Histone deacetylase inhibitors trichostatin A and suberoylanilide hydroxamic acid attenuate ventilator-induced lung injury.
Ventricular Dysfunction, Left
Calcium/calmodulin-dependent protein kinase II couples Wnt signaling with histone deacetylase 4 and mediates dishevelled-induced cardiomyopathy.
Vesicular Stomatitis
Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors.
Vesicular Stomatitis
Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4.
Vesicular Stomatitis
Histone deacetylase inhibitors potentiate vesicular stomatitis virus oncolysis in prostate cancer cells by modulating NF-?B-dependent autophagy.
Vesicular Stomatitis
Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone.
Viremia
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
Viremia
Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques.
Viremia
Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy.
Viremia
Hepatitis B Virus Replication Is Regulated by the Acetylation Status of Hepatitis B Virus cccDNA-Bound H3 and H4 Histones.
Virus Diseases
ATXN3 Positively Regulates Type I IFN Antiviral Response by Deubiquitinating and Stabilizing HDAC3.
Virus Diseases
Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection.
Virus Diseases
Corrigendum to "Inhibition of histone deacetylase 1 suppresses pseudorabies virus infection through cGAS-STING antiviral innate immunity" [Mol. Immunol. 136 (2021) 55-64].
Virus Diseases
Diverse roles of HDAC6 in viral infection: Implications for antiviral therapy.
Virus Diseases
HDAC6 controls innate immune and autophagy responses to TLR-mediated signalling by the intracellular bacteria Listeria monocytogenes.
Virus Diseases
HDAC6 Restricts Influenza A Virus by Deacetylation of the RNA Polymerase PA Subunit.
Virus Diseases
HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions.
Virus Diseases
Histone Deacetylase 1 and 2 are Phosphorylated at Novel Sites During Varicella Zoster Virus Infection.
Virus Diseases
Histone Deacetylase 6 Knockout Mice Exhibit Higher Susceptibility to Influenza A Virus Infection.
Virus Diseases
In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-X(L).
Virus Diseases
Influenza A virus dysregulates host histone deacetylase 1 that inhibits viral infection in lung epithelial cells.
Virus Diseases
Influenza A virus infection dysregulates the expression of microRNA-22 and its targets; CD147 and HDAC4, in epithelium of asthmatics.
Virus Diseases
Influenza A virus-induced caspase-3 cleaves the histone deacetylase 6 in infected epithelial cells.
Virus Diseases
Inhibition of histone deacetylase 1 suppresses pseudorabies virus infection through cGAS-STING antiviral innate immunity.
Virus Diseases
Overexpression of Hdac6 enhances resistance to virus infection in embryonic stem cells and in mice.
Virus Diseases
Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells.
Virus Diseases
PKC alpha regulates Sendai virus-mediated interferon induction through HDAC6 and ?-catenin.
Virus Diseases
Primary macrophages rely on histone deacetylase 1 and 2 expression to induce type I interferon in response to gammaherpesvirus infection.
Virus Diseases
Rabies Virus Infection Induces Microtubule Depolymerization to Facilitate Viral RNA Synthesis by Upregulating HDAC6.
Virus Diseases
Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.
Virus Diseases
Small RNA Profiling of Influenza A Virus-Infected Cells Identifies miR-449b as a Regulator of Histone Deacetylase 1 and Interferon Beta.
Virus Diseases
Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study.
Virus Diseases
The HDAC inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells with inhibition of STAT5/T-BET signaling and IFN? generation.
Virus Diseases
The Metabolic Regulator Histone Deacetylase 9 Contributes to Glucose Homeostasis Abnormality Induced by Hepatitis C Virus Infection.
Virus Diseases
Virus-induced differential expression of nuclear receptors and coregulators in dendritic cells: implication to interferon production.
Waldenstrom Macroglobulinemia
Epigenetic targeting of Waldenström macroglobulinemia cells with BET inhibitors synergizes with BCL2 or histone deacetylase inhibition.
Waldenstrom Macroglobulinemia
Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenström's Macroglobulinemia.
Waldenstrom Macroglobulinemia
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
Waldenstrom Macroglobulinemia
Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia.
Waldenstrom Macroglobulinemia
Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors.
West Nile Fever
Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection.
Williams Syndrome
A genome-wide screen for modifiers of transgene variegation identifies genes with critical roles in development.
Wilms Tumor
Histone deacetylase 5 promotes Wilms' tumor cell proliferation through the upregulation of c-Met.
Wilms Tumor
Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Wilms Tumor
Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
Wiskott-Aldrich Syndrome
Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.00228 - 0.0137
(1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide
0.00573
(2R)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.00595
(2S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-2-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.033
N-(4-amino-3'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, above, HDAC3 isozyme
0.0142
N-(4-amino-4'-chloro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.0259
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-1H-2-benzopyran-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.033
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3,4-dihydro-2H-1-benzopyran-3-carboxamide
Homo sapiens
pH 7.4, 22°C, above, HDAC3 isozyme
0.00149
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-3-oxabicyclo[3.1.0]hexane-6-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.00109
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.00385
N-(4-amino[1,1'-biphenyl]-3-yl)oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.0208
N-[2-amino-5-(pyridin-3-yl)phenyl]oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.033
N-[2-amino-5-(pyridin-4-yl)phenyl]oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, above, HDAC3 isozyme
0.033
N-[4-amino-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]oxane-4-carboxamide
Homo sapiens
pH 7.4, 22°C, above, HDAC3 isozyme
0.00228
(1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.0137
(1R,5S)-N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)-6-oxabicyclo[3.1.1]heptane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
0.00626
N-(4-amino-4'-fluoro[1,1'-biphenyl]-3-yl)oxane-3-carboxamide
Homo sapiens
pH 7.4, 22°C, HDAC3 isozyme
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). HDAC3_HUMAN
428
0
48848
Swiss-Prot
other Location (Reliability: 2)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Wagner, F.F.; Weiwer, M.; Steinbacher, S.; Schomburg, A.; Reinemer, P.; Gale, J.P.; Campbell, A.J.; Fisher, S.L.; Zhao, W.N.; Reis, S.A.; Hennig, K.M.; Thomas, M.; Mueller, P.; Jefson, M.R.; Fass, D.M.; Haggarty, S.J.; Zhang, Y.L.; Holson, E.B.
Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors
Bioorg. Med. Chem.
24
4008-4015
2016
Homo sapiens (O15379), Homo sapiens (Q13547), Homo sapiens (Q92769)
brenda
EXTERNAL LINKS (specific for EC-Number 3.5.1.98)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
